

University of Huddersfield Repository

Lewis, Ruth, Williams, Nefyn H, Matar, HE, Din, N, Fitzsimmons, D, Phillips, C, Jones, M., Sutton, A., Burton, A. Kim, Nafees, S, Hendry, Maggie, Rickard, I, Chakraverty, R and Wilkinson, Clare

The clinical effectiveness and cost effectiveness of management strategies for sciatica: systematic review and economic model

Original Citation

Lewis, Ruth, Williams, Nefyn H, Matar, HE, Din, N, Fitzsimmons, D, Phillips, C, Jones, M., Sutton, A., Burton, A. Kim, Nafees, S, Hendry, Maggie, Rickard, I, Chakraverty, R and Wilkinson, Clare (2011) The clinical effectiveness and cost effectiveness of management strategies for sciatica: systematic review and economic model. Health Technology Assessment, 15 (39). pp. 1-434. ISSN 1366-5278

This version is available at http://eprints.hud.ac.uk/id/eprint/12016/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/

Health Technology Assessment 2011; Vol. 15: No. 39 ISSN 1366-5278

The clinical effectiveness and costeffectiveness of management strategies for sciatica: systematic review and economic model

R Lewis, N Williams, HE Matar, N Din, D Fitzsimmons, C Phillips, M Jones, A Sutton, K Burton, S Nafees, M Hendry, I Rickard, R Chakraverty and C Wilkinson

November 2011 10.3310/hta15390

Health Technology Assessment NIHR HTA programme www.hta.ac.uk







How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:

- fax (with credit card details)
- post (with credit card details or cheque)
- phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:

Synergie UK (HTA Department)	Email: orders@hta.ac.uk
Digital House, The Loddon Centre Wade Road Basingstoke	Tel: 0845 812 4000 – ask for 'HTA Payment Services' (out-of-hours answer-phone service)
Hants RG24 8QW	Fax: 0845 812 4001 - put 'HTA Order' on the fax header

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in **pounds sterling**, made payable to *University of Southampton* and drawn on a bank with a UK address.

Paying by credit card

You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). *HTA on DVD* is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.

The clinical effectiveness and costeffectiveness of management strategies for sciatica: systematic review and economic model

R Lewis,^{1*} N Williams,¹ HE Matar,¹ N Din,¹ D Fitzsimmons,² C Phillips,² M Jones,¹ A Sutton,³ K Burton,⁴ S Nafees,¹ M Hendry,¹ I Rickard,⁵ R Chakraverty⁶ and C Wilkinson¹

 ¹Department of Primary Care and Public Health, Cardiff University, School of Medicine, North Wales Clinical School, Wrexham, UK
 ²School of Human and Health Sciences, Swansea University, Swansea, UK
 ³Department of Health Sciences, University of Leicester, Leicester, UK
 ⁴Spinal Research Institute, University of Huddersfield, Huddersfield, UK
 ⁵Patient representative, Betws-y-coed, UK
 ⁶The Spinal Unit, Royal Orthopaedic Hospital NHS Trust, Birmingham, UK

*Corresponding author

Declared competing interests of authors: none

Published November 2011 DOI: 10.3310/hta15390

This report should be referenced as follows:

Lewis R, Wiliams N, Matar HE, Din N, Fitzsimmons D, Philips C, *et al*. The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model. *Health Technol Assess* 2011;**15**(39).

Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.

The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 06/79/01. The contractual start date was in March 2008. The draft report began editorial review in July 2010 and was accepted for publication in February 2011. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief:	Professor Tom Walley CBE
Series Editors:	Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Tom Marshall, Professor John Powell,
	Dr Rob Riemsma and Professor Ken Stein
Associate Editor:	Dr Peter Davidson
Editorial Contact:	edit@southampton.ac.uk
ISSN 1366-5278 (Print)	
ISSN 2046-4924 (Online)	
100N1 0040 4000 (D) (D)	

ISSN 2046-4932 (DVD)

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www. publicationethics.org/).

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA. Printed on acid-free paper in the UK by the Charlesworth Group.

Abstract

The clinical effectiveness and cost-effectiveness of management strategies for sciatica: systematic review and economic model

R Lewis,^{1*} N Williams,¹ HE Matar,¹ N Din,¹ D Fitzsimmons,² C Phillips,² M Jones,¹ A Sutton,³ K Burton,⁴ S Nafees,¹ M Hendry,¹ I Rickard,⁵ R Chakraverty⁶ and C Wilkinson¹

¹Department of Primary Care and Public Health, Cardiff University, School of Medicine, North Wales Clinical School, Wrexham, UK

²School of Human and Health Sciences, Swansea University, Swansea, UK

³Department of Health Sciences, University of Leicester, Leicester, UK

⁴Spinal Research Institute, University of Huddersfield, Huddersfield, UK

⁵Patient representative, Betws-y-coed, UK

⁶The Spinal Unit, Royal Orthopaedic Hospital NHS Trust, Birmingham, UK

*Corresponding author

Background: Sciatica is a symptom characterised by well-localised leg pain with a sharp, shooting or burning quality that radiates down the back of the leg and normally to the foot or ankle. It is often associated with numbness or altered sensation in the leg. **Objectives:** To determine the clinical effectiveness and cost-effectiveness of different

management strategies for sciatica.

Data sources: Major electronic databases (e.g. MEDLINE, EMBASE and NHS Economic Evaluation Database) and several internet sites including trial registries were searched up to December 2009.

Review methods: Systematic reviews were undertaken of the clinical effectiveness and cost-effectiveness of different treatment strategies for sciatica. Effectiveness data were synthesised using both conventional meta-analyses and mixed treatment comparison (MTC) methods. An economic model was then developed to estimate costs per quality-adjusted life-year gained for each treatment strategy.

Results: The searches identified 33,590 references, of which 270 studies met the inclusion criteria and 12 included a full economic evaluation. A further 42 ongoing studies and 93 publications that could not be translated were identified. The interventions were grouped into 18 treatment categories. A larger number of studies evaluated invasive interventions and non-opioids than other non-invasive interventions. The proportion of good-quality studies for each treatment category ranged from 0% to 50%. Compared with studies of less invasive interventions, studies of invasive treatments were more likely to confirm disc herniation by imaging, to limit patients included to those with acute sciatica (<3 months' duration) and to include patients who had received previous treatment. The MTC analyses gave an indication of relative therapeutic effect. The statistically significant odds ratios of global effect compared with inactive control were as follows: disc surgery 2.8, epidural injection 3.1, chemonucleolysis 2.0 and non-opioids 2.6. Disc surgery and epidural injections were associated with more adverse effects than the inactive control. There was

some evidence for the effectiveness of biological agents and acupuncture. Opioid medication and activity restriction were found to be less effective than the comparator interventions and opioids were associated with more adverse effects than the inactive control. The full economic evaluations were of reasonable to good quality, but were not able to fully address our research question. Although individual studies raised a number of important issues, it was difficult to draw meaningful conclusions across studies because of their heterogeneity. The economic model demonstrated that stepped-care approaches to patient management were likely to be cost-effective, relative to strategies that involved direct referral to disc surgery.

Limitations: The limited number of studies for some comparisons, the high level of heterogeneity (within treatment comparisons) and the potential inconsistency (between treatment comparisons) weaken the interpretation of the MTC analyses.

Conclusions: These findings provide support for the effectiveness of currently used therapies for sciatica such as non-opioid medication, epidural corticosteroid injections and disc surgery, but also for chemonucleolysis, which is no longer used in the UK NHS. These findings do not provide support for the effectiveness of opioid analgesia, which is widely used in this patient group, or activity restriction. They also suggest that less frequently used treatments, such as acupuncture, and experimental treatments, such as anti-inflammatory biological agents, may be effective. Stepped-care approaches to treatment for patients with sciatica are cost-effective relative to direct referral for surgery. Future research should include randomised controlled trials with concurrent economic evaluation of biological agents. Development of alternative economic modelling approaches to assess relative cost-effectiveness of treatment regimes, based on the above trial data, would also be beneficial. **Funding:** The National Institute for Health Research Health Technology Assessment programme.

Contents

	List of abbreviations	ix
	Executive summary	xi
1.	Introduction	1
2.	Research objectives	3
3.	Background Definition of sciatica Epidemiology of sciatica Pathological mechanism Clinical diagnosis	5 5 5 5 6
	Treatments	6
4.	Evidence synthesis: methods Methods for reviewing clinical effectiveness and cost-effectiveness Literature search Management of references Inclusion and exclusion of studies Data extraction Quality assessment Methods of analysis/synthesis Standard pair-wise meta-analyses Mixed treatment comparison meta-analyses Analysis of covariates Publication bias Economic evaluations Economic model	9 9 10 10 13 14 14 16 16 17 17 17
5.	Results of searches	19
6.	Review of clinical effectiveness: results Disc surgery (including intraoperative interventions) Summary of overall findings for disc surgery compared with alternative interventions Epidural/intradiscal injection Summary of overall findings for epidural/intradiscal injections compared with alternative interventions Chemonucleolysis Summary of overall findings for chemonucleolysis compared with alternative interventions Non-opioids Summary of overall findings for non-opioids compared with alternative interventions	21 21 89 96 138 144 177 182 213
	Iraction	216

	Summary of overall findings for traction compared with alternative interventions Manipulation	233 237
	Summary of overall findings for manipulation compared with alternative interventions	246
	Alternative therapies	248
	Summary of overall findings for alternative interventions compared with	
	comparator interventions	250
	Active physical therapy/exercise therapy	258
	Summary of overall findings for active physical/exercise therapy compared with alternative interventions	271
	Passive physical therapy	280
	Summary of overall findings for passive physical therapy compared with	
	alternative interventions	288
	Biological agents	296
	Summary of overall findings for biological agent compared with alternative	
	Interventions	303
	Activity restriction	310
	Summary of overall findings for activity restriction compared with alternative	200
	Opioida	322
	Summary of overall findings for opioids compared with alternative interventions	320
	Education/advice	338
	Summary of overall findings for education/advice compared with alternative	000
	interventions	343
		• • •
7.	Mixed treatment comparisons: results	353
	Description of mixed treatment comparison models	353
	The results of the mixed treatment comparison of each intervention category with	
	inactive control	355
	Results of the mixed treatment comparison comparing all interventions that formed a	
	connected network	364
8		
0.	Review of existing economic evaluations: results	367
0.	Review of existing economic evaluations: results	367 367
υ.	Review of existing economic evaluations: results Introduction Summary of results	367 367 367
υ.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations	367 367 367 372
υ.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary	367 367 367 372 383
0.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary	367 367 367 372 383
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction	367 367 367 372 383 385 385
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model	367 367 367 372 383 385 385 385
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers	367 367 367 372 383 385 385 385 385 385
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description	367 367 372 383 385 385 385 385 386 387
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty	367 367 372 383 385 385 385 385 386 387 388
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty Data sources	367 367 372 383 385 385 385 385 386 387 388 389
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty Data sources Cost-effectiveness results	367 367 372 383 385 385 385 385 386 387 388 389 392
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty Data sources Cost-effectiveness results Sensitivity analysis	367 367 372 383 385 385 385 385 386 387 388 389 392 393
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty Data sources Cost-effectiveness results Sensitivity analysis Discussion	367 367 372 383 385 385 385 385 385 386 387 388 389 392 393 397
9.	Review of existing economic evaluations: results Introduction Summary of results Review of full economic evaluations Summary Economic evaluation Introduction Development of the economic model Telephone survey of service providers Model description Dealing with uncertainty Data sources Cost-effectiveness results Sensitivity analysis Discussion Conclusion	367 367 372 383 385 385 385 385 386 387 388 389 392 393 397 397

10.	Discussion Summary of clinical effectiveness review Summary of cost-effectiveness review Summary of economic evaluation Comparison with previous systematic reviews Assumptions, limitations and uncertainties Implications for further research	 399 399 407 407 408 409 411
11.	Conclusions	413
	Acknowledgements	415
	References	417
	Health Technology Assessment programme	435
	Appendix 1 Search strategies	441
	Appendix 2 Quality assessment checklist	463
	Appendix 3 WINBUGS code used for the mixed treatment comparison analyses	471
	Appendix 4 Ongoing or unpublished studies identified from search of trial registries	477
	Appendix 5 Quality assessment of included clinical effectiveness studies	491
	Appendix 6 Network diagrams	517
	Appendix 7 WINBUGS plots for the Gelman–Rubin statistic	523
	Appendix 8 Heterogeneity and model fit for the mixed treatment comparison analyses	527
	Appendix 9 Results of the mixed treatment comparison analyses	533
	Appendix 10 Full summary of economic evaluations	549
	Appendix 11 Study protocol	565

List of abbreviations

ANCOVA	analysis of covariance
AUC	area under the curve
CCS	concurrent cohort study
CEA	cost-effectiveness analysis
CI	confidence interval
CSOM	condition-specific outcome measure
CUA	cost-utility analysis
DRG	diagnostic-related group
EPHPP	Effective Public Health Practice Project
EQ-5D	European Quality of Life-5 Dimensions
ESI	epidural steroid injection
GP	general practitioner
GPE	global perceived effect
HCS	historical cohort study
НМО	health maintenance organisation
HRQoL	health-related quality of life
ICER	incremental cost-effectiveness ratio (e.g. incremental cost per QALY gained)
IQR	interquartile range
ITT	intention to treat
LRS	lumbar radicular syndrome
MANOVA	multivariate analysis of variance
MRI	magnetic resonance imaging
MTC	mixed treatment comparison
NICE	National Institute for Health and Clinical Excellence
NNT	number needed to treat
NSAID	non-steroidal anti-inflammatory drug
ODI	Oswestry Disability Index
OR	odds ratio
OTC	over the counter
PENS	percutaneous electrical nerve stimulation
РТ	physical therapy
OALY	quality-adjusted life-year
ODS	Quebec Back Pain Disability Scale
OoL	quality of life
Q-RCT	quasi-randomised controlled trial
RCT	randomised controlled trial
RMDO	Roland–Morris Disability Questionnaire
SD	standard deviation
SE	standard error
SF-36	Short Form questionnaire-36 items
SG	standard gamble
SLR	straight leg raise
SMD	standardised mean difference
SPORT	Spine Patient Outcomes Research Trial
TENS	transcutaneous electrical nerve stimulation
TNF-α	tumour necrosis factor-alpha
TTO	time trade-off
VAS	visual analogue scale

WHO	World Health Organization
WMD	weighted mean difference

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the notes at the end of the table.

Executive summary

Background

Previous systematic reviews have found evidence for the clinical effectiveness of invasive treatments such as epidural steroid injection, chemonucleolysis and lumbar discectomy in the treatment of sciatica, but found insufficient evidence for less invasive treatments. None of the reviews has made indirect comparisons across separate trials or has examined cost-effectiveness.

Objectives

To determine the clinical effectiveness and cost-effectiveness of different management strategies for sciatica by undertaking a systematic review and an economic evaluation.

Review methods

Major electronic databases (for example MEDLINE, EMBASE and the NHS Economic Evaluation Database) and several internet sites including trial registries were searched up to December 2009. No language restrictions were used. Studies examining clinical effectiveness and cost-effectiveness were reviewed separately. Any comparative study or full economic evaluation was considered for inclusion. Studies involving adults who had sciatica or lumbar nerve root pain diagnosed clinically or confirmed by imaging were eligible. The essential clinical criterion was leg pain worse than back pain. Studies that included participants with lower back pain were included only if the findings for patients with sciatica were reported separately. Any intervention or comparator used to treat sciatica was included. Data were extracted by one reviewer and checked by a second reviewer. Quality assessment was conducted independently by two reviewers. Disagreements were resolved by discussion and, when necessary, a third reviewer was consulted.

For the review of clinical effectiveness, interventions were grouped into 18 treatment categories. The analyses were limited to three patient-centred outcome domains – global effect (or overall improvement), reduction in pain intensity (on a continuous scale of 0–100) and improvement in condition-specific functional status – and any reported adverse effects. The data were analysed according to three follow-up intervals: short (≤ 6 weeks), medium (> 6 weeks to 6 months) and long term (> 6 months). The global effect was synthesised as binary data using odds ratios (ORs) and pain intensity and a composite condition-specific outcome measure (CSOM) as continuous data using weighted mean difference and standardised mean difference, respectively. Missing study-level outcome data, where feasible, were dealt with by deriving/imputing replacement values.

Mixed treatment comparison (MTC) meta-analyses were carried out to enable the simultaneous comparison of all treatment modalities for sciatica at a single follow-up interval (closest to 6 months). The analyses were conducted for the three main outcome domains, for all study designs and then after excluding observational studies and non-randomised trials.

The economic evaluation was based on a review of cost-effectiveness studies and a descriptive decision-analytic model, based on estimates of global effect (from the MTC analysis) and cost estimates derived from the literature following consultation with clinical experts.

Results of review

Searches

The searches identified 33,590 references, of which 270 studies that met the inclusion criteria were identified and 12 of these also included a full economic evaluation. A further 42 ongoing (or not yet reported) studies and 93 publications that could not be translated were identified.

Review of clinical effectiveness

The number of studies evaluating invasive interventions such as surgery, epidural and chemonucleolysis was greater than the number evaluating non-invasive interventions such as education/advice, alternative therapies, manipulation and opioid medication. The number of studies evaluating each treatment category ranged from two (manipulation and education/ advice) to 63 (disc surgery). The proportion of studies that were randomised control trials (RCTs) also varied, with the lowest being for disc surgery (51%), anti-inflammatory biological agents (50%) and chemonucleolysis (47%). The proportion that were deemed good quality ranged from 0% (chemonucleolysis, non-opioids, traction, alternative therapies, passive physical therapies, biological agents and education/advice) to 50% (manipulation, 1 out of 2); 14% of epidural studies and 3% of surgery studies were deemed to be good quality.

All but one study included patients with nerve root pain (or a combination of both nerve root and referred pain). The presence of disc herniation was confirmed by imaging in a greater proportion of studies evaluating invasive treatments than non-invasive interventions, as was the proportion of studies that did not limit inclusion to patients with acute sciatica (duration of symptoms being < 3 months), although this was not reported for many studies. Five treatment categories included a small number of studies that limited inclusion to patients experiencing their first episode (disc surgery, epidural injections, chemonucleolysis, non-opioid medication and biological agents). The proportion of studies that included patients who had received previous treatment were higher for invasive treatments compared with less invasive interventions, but the proportion was also fairly high for opioids and activity restriction and low for biological agents.

Results from the standard pair-wise meta-analyses were in broad agreement with those from the MTC analyses. The MTC provides an estimate of the relative treatment effects of the different management strategies at a single follow-up interval (closest to 6 months). We found a high level of between-study heterogeneity, so the results from the MTC analyses should be interpreted with caution.

Statistically significant findings were found for the following comparisons. Compared with inactive control, disc surgery [odds ratio (OR) 2.8], epidural injections (OR 3.1), chemonucleolysis (OR 2.0), non-opioids (OR 2.6) and alternative therapies (OR 4.7) resulted in greater overall improvement; epidural injections [weighted mean difference (WMD) –12.9], alternative therapies (WMD –26.1) and biological agents (WMD 21.8) resulted in better pain relief; and biological agents (SMD –0.7) resulted in better back specific function. When compared with usual care, disc surgery (OR 3.4), epidural injections (OR 3.8), chemonucleolysis (OR 2.4), non-opioids (OR 3.1) and alternative therapies (OR 5.7) resulted in better overall improvement. When compared with non-opioids, alternative therapies (WMD –22.1) and biological agents (WMD –17.8) were better for pain relief; and biological agents were better for improving functional status (standardised mean difference –0.8). When compared with opioids, epidural injections (WMD –22.2), alternative therapies (WMD –35.5) and biological agents (WMD –31.2) were better for pain relief; and when compared with activity restriction, alternative therapies (WMD –44.1) and biological agents (WMD –39.7) were also better for reducing pain. Biological agents were also better than passive physical therapy (PT) for pain relief (WMD –22.3).

Pair-wise meta-analyses were performed at short-, medium- and long-term follow-up and the statistically significant improvements were found for the following treatment groups. Disc surgery was superior to usual care (global effect, pain and CSOM at short-, medium- and longterm follow-up) and epidural injection (pain short-term follow-up), non-opioids (pain and CSOM at short-term follow-up), passive PT (global effect at medium- and long-term follow-up) and activity restriction (global effect at medium-term follow-up). Chemonucleolysis was superior to inactive control (pain at medium-term follow-up). Biological agents were superior to inactive control and non-opioid medication (global effect and pain at short-term follow-up). Non-opioid medication was superior to opioids (pain at short- and medium-term follow-up). Traction was superior to activity restriction (pain at short-term follow-up). Passive PT was superior to inactive therapy (pain at short-term follow-up). Spinal manipulation was superior to inactive control (global effect at medium-term follow-up).

Pair-wise analyses of adverse effects found that there was a statistically significant greater number of adverse effects in: disc surgery compared with usual care; epidural injection compared with education/advice, passive PT or usual care; non-opioids compared with inactive control; traction compared with activity restriction; manipulation compared with education/advice; and opioids compared with inactive control.

Review of economic evaluations

The full economic evaluations identified in the systematic review were of reasonable to good quality, but were not able to fully address our research question. Although individual studies raised a number of important issues, it was difficult to draw meaningful conclusions across these studies because of their heterogeneity. Although there was some indication of benefit, such as in the case of disc surgery, robust findings could not be reliably drawn. Although an evidence base is emerging, there remains a dearth of well-designed economic evaluations. In particular, there is a lack of published decision models. Furthermore, the relevance to the UK NHS setting of the studies that have been published is unclear.

Economic model

A decision-analytic model from the perspective of the UK NHS was constructed on the assumption that patients presenting with sciatica would be managed through one of three pathways, with alternative treatments within each of the pathways. The first pathway would involve management within primary care and revolve around what might be termed usual care, with the use of analgesics and other medications if considered appropriate, to attempt to secure symptom resolution. The second pathway would involve a stepped-care approach and include the use of intermediate treatments – offered in addition to the initial treatments provided within primary care – and provided in secondary care outpatients by multidisciplinary teams including physiotherapists, musculoskeletal physicians, etc.; the principle is one of ramping up the level of intervention if there is no timely symptom resolution following simpler, less invasive interventions. The third pathway would involve immediate referral for surgery to alleviate symptoms.

Each of the pathways and the treatment variations available were compared with 'inactive control' which, according to the findings from the MTC, has a non-zero probability of symptom resolution, but has been assumed to cost £0 in the baseline model.

A series of 100 independent scenarios were considered, with the utilities associated with success used to generate a utility score for each treatment regime and combined with costs to determine

relative incremental cost-effectiveness ratios and a series of sensitivity analyses were conducted on the baseline findings.

Results of economic evaluation

The treatment regimes that were shown to be the most cost-effective were inactive control; non-opioids followed by alternative/non-traditional treatments; non-opioids followed by alternative/non-traditional treatments followed by epidural; non-opioids followed by alternative/ non-traditional treatments followed by epidural followed by disc surgery; and non-opioids followed by biological therapies followed by epidural and followed by disc surgery. Although, this last regime would not be regarded as cost-effective when measured in terms of current costeffectiveness thresholds employed at national level in the UK NHS.

Conclusions

These findings provide support for the effectiveness of currently used therapies for sciatica, such as non-opioid medication, epidural corticosteroid injections and disc surgery, but also for chemonucleolysis, which is no longer used in the UK NHS. In addition, these findings do not provide support for the clinical effectiveness of opioid analgesia, which is widely used in this patient group. They also suggest that less frequently used treatments, such as acupuncture, and experimental treatments, such as anti-inflammatory biological agents, may be effective.

In terms of cost-effectiveness, the argument for stepped approaches based on an initial treatment with non-opioids, as opposed to direct referral for surgery, was apparent, although there are a number of limitations associated with the economic model.

Further research is needed to evaluate the use of biological agents and acupuncture compared with interventions that are currently being used such as non-opioids and epidural injections. Further research is also needed to compare the use of opioids with drugs used to treat neurogenic nerve pain or other treatments currently in use.

Recommendations for future research

The following areas are recommended for further investigation:

- RCTs with concurrent economic evaluation of biological agents compared either with placebo or with currently used treatments
- RCTs with concurrent economic evaluation of acupuncture compared with other currently used treatments
- RCTs with concurrent economic evaluation of opioids compared with drugs used to treat neurogenic nerve pain, such as tricyclic antidepressants and gabapentin (Neurontin[®], Pfizer)
- development of alternative economic modelling approaches to assess relative costeffectiveness of treatment regimes, based on the above trial data.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Introduction

Research is needed to identify the most clinically effective and cost-effective management strategies for sciatica. Many treatment modalities for sciatica have been evaluated in placebo-controlled trials (or usual care used as the comparator), and the evidence relating to the direct comparison of numerous treatment modalities is missing. Previous systematic reviews have found evidence for the clinical effectiveness of invasive treatments such as epidural steroid injection (ESI), chemonucleolysis and lumbar discectomy, but found insufficient evidence to advise bed rest, keeping active, analgesia, intramuscular steroid injection or traction. None of the reviews made indirect comparisons across separate trials or examined cost-effectiveness. Previous economic evaluations that have been conducted vary quite considerably, and their value is limited to the perspective and setting for which they were undertaken. We undertook a systematic review of the clinical effectiveness and cost-effectiveness of the different management strategies for sciatica, which tries to address some of these issues. We have also developed a decision-analytic model to assess the cost-effectiveness of different treatment modalities from the UK NHS perspective.

Research objectives

- To undertake a systematic review of the clinical effectiveness and cost-effectiveness of different management strategies for sciatica.
- To synthesise the results using meta-analyses and a mixed treatment comparison (MTC) method.
- To construct an appropriate decision-analytic model to estimate costs per quality-adjusted life-year (QALY) gained for each treatment strategy.

Background

Definition of sciatica

Sciatica is a symptom defined as unilateral, well-localised leg pain with a sharp, shooting or burning quality that approximates to the dermatomal distribution of the sciatic nerve down the posterior lateral aspect of the leg, and normally radiates to the foot or ankle. It is often associated with numbness or paraesthesia in the same distribution.^{1,2} The symptom of sciatica is used by clinicians in different ways. Some refer to any leg pain referred from the back as sciatica, others prefer to restrict its use to pain originating from the lumbar nerve root. Some authors prefer to use the term 'lumbar nerve root pain' to distinguish it from referred leg pain.³

Epidemiology of sciatica

The lack of clarity in the definition of sciatica persists in the epidemiological literature. In the UK, the prevalence of 'sciatica suggesting a herniated lumbar disc' has been reported as 3.1% in men and 1.3% in women.⁴ However, like most surveys, this study did not use strict criteria to diagnose sciatica. A large population survey in Finland which did found a lifetime prevalence of 5.3% in men and 3.7% in women.⁵ Sciatica accounts for < 5% of the cases of lower back pain presenting to primary care.³ Some cohort studies have found that most cases resolve spontaneously, with 30% of patients experiencing persistent troublesome symptoms at 1 year, 20% out of work and 5–15% requiring surgery.^{6,7} However, another cohort found that 55% still had symptoms of sciatica 2 years later, and 53% after 4 years (which included 25% who had recovered after 2 years, but had relapsed again by 4 years).⁸ As the sciatica becomes more chronic (>12 weeks), or with recurrent episodes, it becomes less responsive to treatment.⁹ Effective treatment for patients with acute or subacute sciatica is therefore important in order to prevent patients developing a more chronic condition that is resistant to treatment and likely to incur high health-care and socioeconomic costs. The cost of sciatica to society in the Netherlands in 1991 was estimated at US\$128M for hospital care, US\$730M for absenteeism and US\$708M for disablement.¹⁰

Pathological mechanism

Sciatica caused by lumbar nerve root pain usually arises from a prolapsed intervertebral disc, but also from spinal stenosis, or surgical scarring as well as other aetiologies such as trauma and tumours.⁶ It was initially thought to occur predominantly as a result of compression of the nerve root,¹¹ leading to neural ischaemia, oedema (which would, in turn, lead to chronic inflammation), scarring and perineural fibrosis. However, it is now known that symptoms can occur in the absence of direct nerve root compression, possibly as a result of release of proinflammatory factors from the damaged disc. Pain occurs because of chronic, repetitive firing of the inflamed nerve root.^{12,13} Referred leg pain occurs because pain fibres from paraspinal structures and from the leg converge on interneurons in the spinal cord and brain, so that nociceptive input from painful paraspinal tissues is perceived as leg pain.

Clinical diagnosis

It has been claimed that nerve root pain can be distinguished from referred leg pain because it is unilateral, radiates below the knee, results in leg pain that is worse than the back pain, can be aggravated by coughing or sneezing and has a segmental distribution. Important clinical signs include provocation tests for dural irritation, such as a limited straight leg raise (SLR) reproducing the leg pain, and compromised nerve root function leading to reduced power, sensation or reflexes in one nerve root.³ A systematic review of the diagnostic value of history and physical examination in nerve root pain found that pain distribution was the only useful item in the history. The SLR test was the only sensitive sign in the physical examination, but had poor specificity; the crossed SLR test was the only specific sign, but had poor sensitivity.¹⁴ However, another review found that there was no standard SLR procedure, no consensus on interpretation of results, no evidence of intra- and inter-observer reliability and its predictive value in lumbar intervertebral disc surgery was unknown.¹⁵

Treatments

A variety of surgical and non-surgical treatments have been used to treat sciatica and have been the subject of previous systematic reviews, the findings of which are summarised below. However, none of the reviews examined the cost-effectiveness of the various treatment modalities.

Bed rest and advice to stay active

Most cases resolve spontaneously and, traditionally, bed rest has been advised. A Cochrane systematic review of bed rest¹⁶ found that there was high-quality evidence of little or no difference in pain or functional status between bed rest and staying active; moderate-quality evidence of little or no difference in pain intensity between bed rest and physiotherapy, but small improvements in functional status with physiotherapy; and moderate-quality evidence of little or no difference in pain intensity or functional status between 2–3 and 7 days' bed rest. A Cochrane systematic review of advice to keep active reviewed the same trials comparing bed rest with activity and came to the same conclusions. Although there is no evidence to advise bed rest for sciatica, there is also very little evidence of any benefit of keeping active.¹⁶

Analgesia

Most patients will obtain analgesic medication either on prescription or purchased 'over the counter' from their pharmacist. A systematic review of the conservative treatment for sciatica identified three randomised controlled trials (RCTs) that compared non-steroidal anti-inflammatory drugs (NSAIDs) with a placebo tablet and found no evidence of efficacy.¹⁷

Intramuscular steroids

Part of the mechanism of production of nerve root pain is the release of proinflammatory factors from damaged discs, so administration of intramuscular corticosteroid steroid injections to reduce inflammation of the nerve root has a theoretical basis. The systematic review of conservative treatment for sciatica identified two RCTs comparing steroid injections with a placebo injection and found no evidence of efficacy.¹⁷

Traction

Traction is used relatively frequently to treat sciatica in North America, but less frequently in the UK, Ireland and the Netherlands.^{18,19} A Cochrane systematic review found strong evidence that there was no significant difference between either continuous or intermittent traction versus placebo, sham or other treatments.²⁰

Epidural steroids

Introduction of corticosteroids into the epidural space is a commonly used treatment for lumbar nerve root pain, with the rationale of reducing nerve root inflammation. It was performed on 47,665 occasions in the NHS in England in 2005–6.²¹ Systematic reviews of ESIs have reached conflicting conclusions with regard to their efficacy compared with placebo and their effectiveness compared with other treatments.^{17,22-24}

Spinal manipulation

The systematic review of conservative treatment for sciatica identified two RCTs of spinal manipulation. One found that manipulation was more effective than placebo, and another found no difference compared with manual traction, exercises or corset.¹⁷

Chemonucleolysis

Chemonucleolysis is a technique that is now rarely used. It attempts to decrease the volume of a disc herniation by reducing the amount of material contained within the nucleus pulposus by injecting the enzyme chymopapain. A systematic review of lumbar discectomy and percutaneous treatments identified three RCTs that compared chymopapain with placebo injection, and reported that symptom relief was greater in the group that received chymopapain.²⁵

Lumbar discectomy

Between 5% and 15% of patients with lumbar nerve root pain are treated with surgery,^{6,7} usually involving a lumbar discectomy. In 2005–6, 8683 lumbar discectomies were performed in the NHS in England.²¹ A Cochrane systematic review of surgery for lumbar disc prolapse²⁶ found 40 RCTs and two quasi-randomised controlled trials (Q-RCTs), but only four RCTs comparing discectomy with conservative management, which suggested a temporary benefit in clinical outcomes at 1 year, but no difference at longer-term follow-up. Meta-analyses showed that surgical discectomy produced better clinical outcomes than chemonucleolysis, which was better than placebo. The review concluded that there was considerable evidence of the clinical effectiveness of discectomy for carefully selected patients with sciatica caused by lumbar disc prolapse that fails to resolve with conservative management. Serious complications from lumbar disc surgery are uncommon, with one study²⁵ reporting a mortality rate of 0.3% an infection rate of 3% and 4% requiring an intraoperative transfusion. Surgery failed to relieve symptoms in 10–20% of the cases.²⁵

Other treatments

A number of other treatments that have not been included in previous systematic reviews, for example complementary therapies such as acupuncture, will be included in this review.

Pattern of treatments

Overall, there is no close correlation between symptom severity and pathology in sciatica. Increasing distance between onset and effective treatment has an unfavourable influence on symptoms and disability. Although there is reason to suppose that a stepped-care approach to sciatica could be helpful, the application of the various available treatments depends more on availability, clinician preference and socioeconomic variables than on patient needs. In practice, some patients will recover under an analgesic cocktail while on a waiting list, some will be offered surgery as a first-line intervention, and yet others will receive a combination of treatments in no particular order. With few exceptions, it would appear that the patients receiving differing treatments are clinically indistinguishable.

Evidence synthesis: methods

Methods for reviewing clinical effectiveness and costeffectiveness

The review was undertaken according to the methodology reported in the Centre for Reviews and Dissemination (CRD) report *Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews*²⁷ and the *Cochrane handbook for systematic reviews of interventions*.²⁸ Studies examining clinical effectiveness and those evaluating cost-effectiveness were reviewed separately. (The review protocol is presented in the appendices.)

Literature search

The following databases were searched for published, semi-published and grey literature. Full details of the search strategies are reported in *Appendix 1*. Initial searches took place in June 2008 and were then updated in December 2009, with databases searched from inception to the date of the search:

- MEDLINE
- MEDLINE In-Process & Other Non-Indexed Citations
- OLDMEDLINE
- EMBASE
- Cumulative Index to Nursing and Allied Health Literature (CINAHL)
- Allied and Complimentary Medicine Database (AMED)
- British Nursing Index
- Health Management Information Consortium (HMIC)
- PsychINFO
- Inspec
- Cochrane Central Register of Controlled Trials (CENTRAL)
- Database of Abstracts of Reviews of Effects (DARE)
- Cochrane Database of Systematic Reviews (CDSR)
- Health Technology Assessment (HTA) Database
- NHS Economic Evaluation Database (NHS EED)
- System for Information on Grey Literature In Europe (SIGLE)
- Science Citation Index
- Social Science Citation Index (SSCI)
- Index to Scientific & Technical Proceedings (ISTP)
- Physiotherapy Evidence Database (PEDro)
- BIOSIS
- National Research Register (NRR)
- National Institute for Health's ClinicalTrials.gov database
- CenterWatch Clinical Trials Listing Service
- Current Controlled Trials (CCT)
- World Health Organization's (WHO) International Clinical Trials Registry Platform (ICTRP) this collects weekly data from:

- Australian New Zealand Clinical Trials Registry
- ClinicalTrials.gov
- International Standard Randomised Controlled Trial Number Register (ISRCTN)
- and monthly data from:
- Chinese Clinical Trial Registry
- Clinical Trials Registry India
- German Clinical Trials Register
- Iranian Registry of Clinical Trials
- Japan Primary Registries Network
- Sri Lanka Clinical Trials Registry
- The Netherlands National Trial Register
- Australian New Zealand Clinical Trials Registry
- Clinical Trials Search.

The bibliographies of previous systematic reviews and included studies were screened to identify further relevant studies.

Management of references

The results of the searches were entered onto the reference management software ENDNOTE (Thomson Reuters, CA, USA) and duplicate records removed. Articles written in a language other than English were translated whenever possible. Multiple publications arising from the same study were identified, grouped together and represented by a single reference.

Inclusion and exclusion of studies

Selection criteria

Study design

Studies using any of the following study designs were considered for inclusion: RCTs, Q-RCTs, non-RCTs, cohort studies (with concurrent or historical controls), case–control studies, before and after studies and full economic evaluations as defined by Drummond *et al.*²⁹ and The Cochrane handbook.²⁸

Patient population

Studies involving adults with sciatica or lumbar nerve root pain diagnosed clinically or confirmed by imaging were eligible. The essential clinical criterion was leg pain worse than back pain. Other clinical criteria which support the diagnosis include unilateral leg pain, pain radiation below the knee, pain aggravated by coughs/sneezes, segmental distribution of pain, pain induced by provocation tests (e.g. impaired SLR) and reduced power, sensation or reflexes in one nerve root. Studies that included participants with low back pain were included only if the findings for patients with sciatica were reported separately; studies in which the results were not reported separately for sciatica were excluded. Studies of sciatica caused by specific conditions such as spinal stenosis or discogenic pain were only included if it was documented that leg pain was worse than back pain. If imaging was used it had to demonstrate evidence of nerve root irritation. Studies of sciatica caused by a tumour were excluded.

Interventions

Any intervention or comparator used to treat sciatica was included. Treatments were categorised using the system reported in *Table 1*. Inactive control represents placebo or sham treatment used within the study setting and could include sham traction or placebo epidural.

TABLE 1 Treatment categorisation

Level 1 Level 2		Level 3	
Invasiveness	Treatment category	Category code ^a	Type of treatment
Inactive control	Inactive control	А	Placebo
			Sham treatment
			No treatment
Non-invasive	Usual/conventional care	В	Usual care
			Conventional care
			Non-surgical treatment
			GP care
Invasive – surgical	Disc surgery	С	Discectomy
			Microdiscectomy
			Automated percutaneous discectomy
			Nucleoplasty
			Laser discectomy
			Disc sequestrectomy
			Laminectomy
			Surgical decompression
Invasive – non-surgical	Epidural/intradiscal injections	D	Caudal epidural
	(includes spinal nerve block)		Segmental epidural
			Intradiscal injections
			Facet joints injections
			Intraforaminal injections
			Spinal nerve root block
Invasive - non-surgical	Chemonucleolysis	E	Chymopapain
			Collagenase
			Ozone
Non-invasive	Non-opioids	F	Oral, i.v. or intramuscular
			Steroids
			COX-2 inhibitors
			NSAIDs
			Paracetamol
			Muscle relaxants
			Neuropathic pain treatment
Invasive – surgical	Intraoperative interventions	G	
Non-invasive	Traction	Н	Mechanical traction
Non-invasive	Manipulation	I	Manipulation
			Chiropractic
			Usteopathic
New transfer	Allerereller		
INON-INVASIVE	Alternative	J	Acupuncture
			Heiderikrais
			Muscle energy
			некі шегару
			waynets

continued

Level 1 Level 2		Level 3	
Invasiveness	Treatment category	Category code ^a	Type of treatment
Non-invasive	Active PT/exercise therapy	К	Flexibility
			Strengthening
			Conditioning
			Stabilisation
Non-invasive	Passive PT	L	Ultrasound/phonophoresis
			Iontophoresis
			Heat/ice
			Massage
			Therapeutic touch
			Interferential
			Electrical stimulation techniques (TENS/PENS)
			Laser
Non-invasive	Biological agents	М	Anti-TNFs (and other antibody related interventions)
Non-invasive	Activity restriction	Ν	Bed rest
Non-invasive	Opioids	0	Oral, i.v. or intramuscular opioids
Non-invasive	Education/advice	Р	Back school
			Home exercise instruction
			Coping skills training
			Vocational counselling
			Activities of daily living (ALD)
Invasive + non-invasive	Mixed treatments	Q	Combination of different physical therapies and advice, etc.
Invasive - non-surgical	Others	R	Peripheral nerve block
			Spinal cord stimulation (level 2, code Q)
			Radiofrequency lesioning (level 2, code S)

TABLE 1 Treatment categorisation (continued)

COX-2, cyclo-oxygenase-2; GP, general practitioner; i.v., intravenous; PENS, percutaneous electrical nerve stimulation; PT, physical therapy; TENS, transcutaneous electrical nerve stimulation; TNF, tumour necrosis factor.

a Interventions are summarised using these codes for displaying the results of the MTC analyses in Appendix 9.

Outcome measures

All relevant patient-based outcome measures such as pain, disability, functional status, adverse effects, health status, quality of life (QoL), analgesic use, operation rates, health utility, return to work, health-service use and costs were considered for inclusion in the review. Biochemical outcomes and biomechanical measurements (e.g. change in disc space) were excluded. Although all relevant outcome measures were extracted, because of the high volume of studies and time constraints, only those covered by the following important patient-centred outcome⁹ domains were included in the analysis of clinical effectiveness: global effect, pain intensity, condition-specific outcome measures (CSOMs) (*Table 2*) and adverse event data. This means that the outcomes health status, QoL, analgesic use, operation rates, health utility, return to work, health-service use and costs have not been analysed in the clinical effectiveness section of the review.

Assessing relevancy of included studies

Two reviewers independently screened the titles and abstracts identified by the electronic searches for relevance. Potentially relevant studies were ordered and assessed for inclusion, using the criteria reported above, by two independent reviewers. Disagreements during both stages were resolved by discussion or if necessary taken to a third reviewer.

TABLE 2 Sciatica outcome measures

Measure	Interpretation
Global effect	
MacNab criteria	Excellent, good, fair, poor
Global perceived effect (GPE)	Complete recovery to vastly worse
Patient perceived overall improvement	Various ordinal or dichotomous scales
Physician perceived overall improvement	Various ordinal or dichotomous scales
Proportion of patients below a threshold on a specific scale	
Proportion of patients free of pain	
Sciatica bothersomeness	Higher score indicates greater bothersomeness
Pain intensity outcomes	
Visual analogue scale (VAS)	Higher score indicates greater pain
Bergquist-Ullman and Larson, pain index (B-U&LPI)	Higher score indicates greater pain
Numerical rating scale (NRS)	Higher score indicates greater pain
Likert scale	Higher score indicates greater pain
Low back pain rating scale (LBRS) (pain subscale)	Higher score indicates greater pain
McGill Pain Questionnaire (subscales: VAS, present pain inventory)	Higher score indicates greater pain
Japanese Orthopaedic Association (JOA) score (pain subscale)	Lower score indicates greater pain
Roland–Morris annotated thermometer	Higher score indicates greater pain
Von Korff pain intensity	Higher score indicates greater pain
Pain diagram	Higher score indicates greater pain
CSOMs	
Roland–Morris Disability Questionnaire (RMDQ) (including modified versions)	Higher score indicates greater disability
Revised RMDQ	Lower score indicates greater disability
Oswestry Disability Index (ODI, also referred to as Oswestry Low Back Pain Disability Questionnaire) [including modified versions, e.g. Modified Oswestry Disability Index (MODEMS)]	Higher score indicates greater disability
Japanese Orthopaedic Association (JOA) score	Lower score indicates greater disability
Low back outcome score (LBOS)	Lower score indicates greater disability
Dallas Pain Questionnaire (subscales: daily activities, work and leisure activities, anxiety- depression and sociability)	Higher score indicates greater disability
Low back pain rating scale (LBRS) (subscales: pain, activity of daily living and physical function)	Higher score indicates greater disability
North American Spine Society (NASS) instrument score (subscales: neurogenic symptoms score and pain and disability score)	Lower score indicates greater disability
Symptom scoring system	Higher score indicates greater disability
Waddell Disability Index	Higher score indicates greater disability
Sciatica index	Higher score indicates greater disability
Funktionsfragebogen Hannover (FFbH)	Lower score indicates greater disability
Core Outcome Measures Index (COMI)	Higher score indicates greater disability
Quebec Back Pain Disability Scale (QDS)	Higher score indicates greater disability

Data extraction

Data were extracted using predefined forms developed on a Microsoft ACCESS database (Microsoft Corporation, Redmond, WA, USA). Separate forms were used for clinical effectiveness and cost-effectiveness studies. Data were extracted by one reviewer and checked for accuracy, against the original paper, by a second independent reviewer. Any disagreements were resolved by discussion or by a third reviewer if necessary. 13

Data extracted for clinical effectiveness studies included study location and setting, description of study population (including method of diagnosis and previous treatment), type of intervention and control used, how allocation was performed, outcome measures used and results (such as final means, change scores and proportions) with sufficient information, such as standard errors (SEs), significance levels and confidence intervals (CIs), in order to estimate missing standard deviations (SDs) wherever possible. When necessary, the results and the measures of dispersion were approximated from figures in the reports. Data for both continuous and binary outcomes were extracted based on the number of patients included in the analysis. Where possible, reported findings based on intention-to-treat (ITT) analysis were used. However, we did not recalculate findings based on the ITT principle, e.g. using worst- or best-case scenario for missing variables, as we believed we would be unlikely to have data on crossovers. For studies in which arm-level data were not available, but the mean difference between arms and associated SE had been reported, these were extracted and used in the synthesis instead. Additionally, if studies reported the mean difference between arms adjusted for baseline values, e.g. using analyses of covariates (ANCOVA), these were also extracted.

Data extraction for cost-effectiveness studies included the following: type of economic evaluation, specific details about the interventions being compared, study population, time period, measures of effectiveness, direct costs (medical and non-medical), productivity costs, resource use, currency, results and details of any decision modelling and sensitivity analysis.

Quality assessment

Quality assessment was undertaken by two independent reviewers with differences being resolved by consensus or by a third reviewer if necessary. Data relating to quality assessment were recorded in an Access database.

For clinical effectiveness studies, the quality of both trials and observational studies was assessed using the same checklist based on the one used by the 'Back Review Group' of the Cochrane Collaboration for RCTs³⁰ and the one developed by the Hamilton Effective Public Health Practice Project (EPHPP) team for quantitative studies (which includes both comparative observational studies and RCTs).³¹ The checklist is presented in *Appendix 2*. The criteria cover selection bias and confounding, detection bias, performance bias and attrition bias. Criteria relating to external validity have also been added.

The quality of the economic evaluations was assessed according to an updated version of the checklist developed by Drummond *et al.*²⁹ (see *Appendix 2*). The checklist reflects the criteria for economic evaluation detailed in the methodological guidance developed by the National Institute for Health and Clinical Excellence (NICE). For studies based on decision models, the critical appraisal was based on the checklist developed by Weinstein *et al.*³² (see *Appendix 2*).

Methods of analysis/synthesis

Treatments were categorised according to the system reported in *Table 1*. Pair-wise (standard) meta-analyses were initially conducted followed by MTC analysis. These were based on the three main outcome domains: global improvement (including absence of pain), reduction in pain intensity (measured using a continuous scale) and improvement in function based on a composite CSOM. Where feasible, the data were analysed according to chronicity of sciatica (acute ≤ 3 months; chronic > 3 months). The global effect was synthesised as binary data, pain intensity and the composite CSOM as continuous data.

Missing study-level outcome data, where feasible, were dealt with by deriving/imputing replacement values. Where mean values were unavailable but the medians were reported, the latter were used instead (i.e. medians were assumed to be equal to means). Where possible, SDs were estimated from SEs, 95% CIs or *p*-values, using methods reported in The Cochrane handbook,³³ and for median values, using the interquartile range (IQR). If SDs for baseline values were available, then these were substituted for missing SDs. Finally, for studies that did not report sufficient data to derive the SDs, these were imputed using the weighted mean,³⁴ which was calculated separately for each intervention category.

Global effect (including the absence of pain)

When this outcome was reported in an ordinal format, this was converted into binary data (e.g. improved, not improved, absence of pain, presence of pain). For studies that used ordinal scales, where little improvement (or similar terms) was a central category or grouped with unchanged, the data for patients in this group were classified as not improved. Where both treatment success and failure were reported, treatment success was used. Where treatment failure was reported on its own, the data were converted to treatment success. Where studies reported both overall improvement (sometimes based on a number of scales) and improvement in pain (categorical data), the data on overall improvement were used. For studies that reported both physician-and patient-perceived global effect, the data for patients' perceived effect were used, as this is considered to be the most useful; if the study reported only physician's assessment, then this was used.

Pain intensity (based on a continuous scale)

Most of the studies reporting pain intensity used a visual analogue scale (VAS) to measure pain, with a mixture of both final mean and change scores reported. Studies were pooled using weighted mean difference (WMD). Studies that measured pain intensity on a similar continuous scale were also included, with the data converted to a scale of 0–100. Other types of pain measures were excluded as their inclusion would have necessitated using standardised mean differences (SMDs), where both final and change scores could not be used. Multiple and different locations of the pain were assessed across the studies. We included a pain assessment from only one site from each study using the following preference hierarchy: leg pain (preferred), then overall pain, and then back pain.

Condition-specific outcome measures

The included studies used a number of different scales to measure condition-specific functional status. The Roland–Morris Disability Questionnaire (RMDQ)³⁵ and the Oswestry Disability Index (ODI)³⁶ are the most widely used CSOMs for sciatica studies,³⁷ and an expert panel has recommended the use of either in lower back pain research.³⁵ The RMDQ was designed, and is more widely used, in primary care settings; the ODI was designed, and is more widely used, in secondary care. Both show some evidence of criterion and construct validity. The RMDQ is the more frequently cited and is more responsive than the ODI, which in turn has better test–retest reliability.³⁶ The RMDQ has undergone Rasch analysis to examine item separation, which found that all but four of the items contributed to a single underlying construct, but several items in the middle of the disability hierarchy were too similar and there were insufficient items at the upper and lower extremes.³⁸ The ODI has not undergone Rasch analysis, but like the RMDQ shows evidence of ceiling and floor effects. There are also different versions of the ODI following its adaptation by different groups.³⁹

To enable synthesis, the data were combined using a SMD. We had initially intended using change scores. In order to impute change from baseline SDs for studies that report only baseline and final means, it is necessary to include an estimate of the correlation between baseline and follow-up values for individuals. This entails estimating the correlation coefficient from (other)

15

studies in the synthesis that reported SDs for baseline, final and change from baseline.⁴⁰ However, when doing this we found the average correlation to be ≤ 0.5 for most treatment categories, which means that there is little advantage over using final means. Some studies report findings for more than one CSOM scale, but results from only one scale from each study were used in the analyses, based on the following preference hierarchy: RMDQ,⁴¹ ODI,⁴² Quebec Back Pain Disability Scale (QDS), others.

Standard pair-wise meta-analyses

Data were analysed according to three follow-up periods: short (≤ 6 weeks), medium (6 weeks to 6 months) and long (>6 months). Where studies reported findings for multiple follow-up intervals within a single follow-up period, the data relating to the duration closest to the upper limit were used.

Results are presented in structured tables and forest plots, grouped according to the treatment category being evaluated (see *Table 1*). Studies were pooled using the random effects model⁴³ in STATA (StataCorp LP, College Station, TX, USA), with between-study heterogeneity examined using *I*² and chi-squared statistics. [There were insufficient studies to use individual treatments (level 3) as separate meta-analyses.]

Although studies comparing different interventions that fell into the same category were included in the review, their findings are not reported here, e.g. studies comparing different types of surgery or different types of epidural injections.

Mixed treatment comparison meta-analyses

Prior to performing the MTC we checked whether or not the included studies formed a closed network using level 2 treatment categorisations (see *Table 1*) [there were insufficient data to use individual (level 3) treatments as nodes]. Studies evaluating mixed treatments (or combination therapy) were excluded, because of the uncertainty regarding the extent of interaction between the combined interventions. For the MTC, only one time point was considered, with the findings from individual studies closest to 6 months' follow-up used in the analyses. Analyses were conducted for global effect, pain intensity and CSOMs, for all study designs and after excluding observational studies and non-RCTs.

The analyses were performed by the Multi-parameter Evidence Synthesis Research Group in the Bayesian framework and the modelling computed with Markov chain Monte Carlo stimulation methods using WINBUGS (MRC Biostatistics Unit, Cambridge, UK). The codes that were used are presented in the *Appendix 3* and are based on those used elsewhere.⁴⁴ An inactive control was used as the reference treatment. In all cases, an initial burn-in of at least 50,000 stimulations was discarded and all the results presented are based on a further sample of at least 50,000 stimulations. Convergence was assessed using the Brooks–Gelman–Rubin diagnostic tool in WINBUGS and the inspection of the auto-correlation and history plots. The model fit was checked by the global goodness of fit statistic, residual deviance. If the model is an adequate fit, it is expected that the residual deviance would be roughly equal to the number of unconditional data points.

The main parameters of interest in an MTC are the estimates of effects of treatments B, C, D, etc. relative to a baseline 'treatment' A (which is considered as a 'nuisance' variable). In our review, 'usual care' was a treatment category that we were interested in, and we therefore considered

inactive control to be the most appropriate 'baseline' comparator. We also included treatment categories such as non-opioids, which could similarly be used as a baseline comparator if considering the use of usual care.

Analysis of covariates

Where 10 or more studies were included in the pair-wise meta-analyses described in *Chapter 6*, it had been our intention to evaluate the effect of study-level covariates (e.g. symptom duration used and study quality criteria such as adequate randomisation procedure, adequate allocation concealment, > 80% followed up and blind outcome assessment) on between-study heterogeneity using metaregression, but only one comparison (disc surgery vs chemonucleolysis for global effect at long-term follow-up) included sufficient studies. The possible effect of covariates such as study design, study quality and duration of symptoms on pooled results has been discussed when summarising the findings.

Publication bias

For all comparisons for which there were more than eight studies, funnel plots together with associated statistical tests were used to assess the potential publication bias.

Economic evaluations

Given the nature and lack of homogeneity between included economic evaluations, we performed a narrative review of the included studies and made overall conclusions. Details of each published economic evaluation, together with a critical appraisal of its quality, are presented in structured tables with a narrative summary. Where appropriate and where the data permitted, indications of the uncertainty underlying the estimation of the differential cost and effects of the alternative treatment options were summarised.

Economic model

The methods and results of the economic model are reported separately in Chapter 9.

Results of searches

The electronic searches identified 33,560 references and a further 30 references were identified by hand searching. Of these, 777 references were ordered and, after collating multiple publications, 270 studies that met the inclusion criteria were identified. These included 12 economic evaluations performed as part of the clinical effectiveness studies, but reported separately.

A flow diagram showing the number of references identified, retrieved and included in the review is presented in *Figure 1*.

Forty-two ongoing or unpublished studies were identified while searching trial registries and are summarised in *Appendix 4*.

Seventeen (18%) out of 96 studies that reported data on CSOMs used more than one condition-specific outcome scale, five (5%) of which reported data on both RMDQ and ODI.


FIGURE 1 Flow diagram showing the number of references identified, documents/studies retrieved for assessment and included in the review.

Chapter 6

Review of clinical effectiveness: results

The results of clinical effectiveness are presented for each intervention category separately, according to the order that interventions are listed in *Table 1*. Findings relating to usual care and inactive control are not reported separately (only as comparators for other interventions). Studies that evaluated mixed treatments are also not reported separately. Studies that compared interventions that fell under the same treatment category were included in the review as a whole, but their findings are not presented here. However, information on the type of interventions that they examined is presented (see *Chapter 4*, *Standard pair-wise meta-analysis*).

The results are presented for overall recovery (global effect), pain intensity and back-specific functional status (CSOMs) at short-, medium- and long-term follow-up. The findings for any adverse effects that occurred during the study (overall follow-up) are also reported.

Details of the quality assessment of individual studies are presented in Appendix 5.

Disc surgery (including intraoperative interventions)

Intraoperative interventions have been considered as a separate intervention category to disc surgery in the MTC and are therefore treated the same here. Intraoperative interventions are supplemental procedures undertaken during surgery, such as the application of steroids or free fat grafts.

Description of disc surgery studies

Summary of interventions

A total of 97 studies evaluated disc surgery for sciatica.⁴⁵⁻¹⁴¹ Sixty-three of these studies compared disc surgery with an alternative type of intervention (including intraoperative).⁴⁵⁻¹⁰⁷ The type of interventions being compared are listed in *Table 3a*. One of theses studies,⁴⁶ which compared disc surgery with chemonucleolysis, did not include useable comparative data and reported only descriptive results for change from baseline for each group separately. One further study⁶¹ did not report any data on global effect, pain intensity or CSOMs.

Thirty-eight studies compared different types of disc surgery^{64,65,69,82,108–141} and five compared different intraoperative interventions^{64,65,69,82,141} (four of these studies were three-arm studies that also compared intraoperative interventions with disc surgery^{64,65,69,82}). The types of surgical procedures being compared are listed in *Table 3b*, but the findings of these studies are not considered any further than this.

One further study¹⁴² compared disc surgery plus epidural (mixed treatments) with conventional care given while waiting for surgery. However, the study only reported health-care utilisation and employment-related outcomes.

Summary of study participants for disc surgery

Summary data for included participants are presented in *Table 4*. The number of participants included in the 61 studies that reported outcome data for global effect, pain or CSOMs ranged from 10 to 2749 (median 103). A similar number of studies included patients with

TABLE 3a Summary of the interventions used when comparing disc surgery with alternative interventions (ordered by control group then author)

ID no.	Author, year	Study design	Treatment description	Control description
Disc s	urgery vs chemonucleolysi	s		
884	Alexander, 1989 ¹⁰³	CCS	Disc surgery (removal of protruding disc fragment only + free fat graft)	Chemonucleolysis with chymopapain (2000 U)
43	van Alphen, 198947	RCT	Discectomy with emptying of disc space	Chemonucleolysis with chymopapain (4000 U)
441	Bonafe, 1993 ⁷⁵ (French language)	CCS	Percutaneous automated nucleotomy	Chemonucleolysis with chymopapain (4000 U)
183	Bouillet, 198361	CCS	Conventional lumbar disc surgery	Chemonucleolysis with chymopapain injections
453	Brown, 198976	CCS	Disc surgery	Chemonucleolysis with chymopapain
453	Brown, 198976	CCS	Disc surgery	Collagenase chemonucleolysis
454	Buric, 200577	Non-RCT	Standard microdiscectomy	Chemonucleolysis with ozone-oxygen mixture
166	Crawshaw, 198460	RCT	Disc surgery	Chemonucleolysis with chymopapain (4000 U)
48	Dabezies, 197851	CCS	Laminectomy with or without fusion	Chemonucleolysis with chymopapain (2 ml)
471	Dei-Anang, 1990 ⁷⁹ (German language)	CCS	Percutaneous nucleotomy	Chemonucleolysis with chymopapain (4000 U) or collagenase (600 U)
727	Ejeskar, 198396	RCT	Discectomy with unilateral laminotomy and removal of disc hernia only	Chemonucleolysis with chymopapain (400 IU)
132	Hoogmartens, 197656	HCS	Discectomy	Chemonucleolysis with chymopapain
44	Javid, 1995 ⁴⁸	CCS	Partial hemilaminectomy using magnification and fat graft	Chemonucleolysis with chymopapain (3000 IU)
35	Krugluger, 200046	RCT	Automated percutaneous discectomy	Chemonucleolysis with chymodiactin (4000 U)
117	Lagarrigue, 1991 ⁵⁴ (French language)	CCS	Discectomy with minimal bony resection	Chemonucleolysis with chymopapain (2000– 5000 U)
129	Lavignolle, 1987 ⁵⁵ (French language)	RCT	Microscopic discectomy Unilateral limited interlaminar	Chemonucleolysis with chymopapain (4000 U)
889	Lee, 1996 ¹⁰⁴ (German language)	CCS	Automated percutaneous lumbar discectomy	Chemonucleolysis with chymopapain
889	Lee, 1996 ¹⁰⁴ (German language)	CCS	Percutaneous manual and laser discectomy	Chemonucleolysis with chymopapain
593	Muralikuttan, 1992 ⁸⁵	RCT	Standard discectomy with fenestration, disc space cleared	Chemonucleolysis with chymopapain (2000 U)
47	Norton, 198650	CCS	Conventional surgical discectomy	Chemonucleolysis with chymopapain
45	Postacchini, 198749	Non-RCT	Disc excision using unilateral laminotomy	Chemonucleolysis with chymopapain (2 ml)
617	Revel, 199388	RCT	Automated percutaneous lumbar discectomy	Chemonucleolysis
641	Steffen, 1999 ⁹⁰ (German language)	RCT	Laser disc decompression	Chemonucleolysis with chymodiactin (2 ml)
49	Stula, 1990 ⁵² (German language)	RCT	Conventional disc surgery	Chemonucleolysis with chymopapain (500 U)
61	Tregonning, 1991 ⁵³	CCS	Fenestration or partial laminectomy removing extruded disc material	Chemonucleolysis with chymopapain
893	Watters, 1988 ¹⁰⁵	Non-RCT	Microdiscectomy with free fat graft over exposed dura	Chemonucleolysis with chymopapain (4000 U)
160	Watts, 1975 ⁵⁹	CCS	Discectomy with laminotomy and foraminotomy	Chemonucleolysis with chymopapain (4 mg)
672	Weinstein, 198692	CCS	Discectomy	Chemonucleolysis with chymopapain
150	Zeiger, 1987 ⁵⁸	CCS	Microdiscectomy with intraoperative injection into intervertebral space with steroid 125 mg methylprednisolone + morphine 4 mg used to reduce postoperative pain and morbidity	Chemonucleolysis with chymodiactin (2.5 ml)

TABLE 3a Summary of the interventions used when comparing disc surgery with alternative interventions (ordered by control group then author) *(continued)*

ID no.	Author, year	Study design	Treatment description	Control description
Disc s	surgery vs epidural/intradis	cal injection		
725	Buttermann, 200495	RCT	Discectomy	Epidural injection of steroid betamethasone 10–15 mg up to three injections
Disc s	surgery vs exercise therapy	/		
300	Osterman, 200668	RCT	Microdiscectomy and exercise therapy	Exercise therapy
Disc s	surgery vs intraoperative in	terventions		
268	Aminmansour, 2006 ⁶⁴	Q-RCT	Discectomy with fenestration + distilled water injection	Discectomy with fenestration + 40 mg intravenous dexamethasone
268	Aminmansour, 200664	Q-RCT	Discectomy with fenestration + distilled water injection	Discectomy with fenestration + 80 mg intravenous dexamethasone
436	Bernsmann, 2001 ⁷⁴	RCT	Microdiscectomy with partial hemi- laminectomy, but no free fat graft	Microdiscectomy with partial hemi- laminectomy and free fat graft
470	Debi, 2002 ⁷⁸	RCT	Lumbar discectomy with saline applied to exposed nerve route on a collagen sponge	Lumbar discectomy with steroid methylprednisolone 80 mg applied to exposed nerve route on a collagen sponge
492	Gerszten, 2003 ⁸¹	RCT	Sham irradiation prior to repeat surgical decompression (control group)	Irradiation prior to repeat surgical decompression (treatment group)
497	Glasser, 1993 ⁸²	RCT	Microdiscectomy with partial hemilaminectomy and emptying of disc space only (group 3)	Microdiscectomy with partial hemilaminectomy, emptying of disc space and intraoperative steroid methylprednisolone 490 mg + local anaesthetic 30 ml bupivacaine (group 1)
497	Glasser, 1993 ⁸²	RCT	Microdiscectomy with partial hemilaminectomy and emptying of disc space only (group 3)	Microdiscectomy with partial hemilaminectomy, emptying of disc space and intraoperative local anaesthetic 30 ml bupivacaine (group 2)
520	Jensen, 1996 ⁸³	RCT	Flavectomy, partial laminectomy without free fat transplantation (group B)	Flavectomy, partial laminectomy with free fat transplantation (group A)
909	Jirarattanaphochai, 2007 ¹⁰⁶	RCT	Disc surgery + saline administered to nerve root + intramuscularly (placebo group)	Disc surgery + corticosteroid administration (80 mg of methylprednisolone sodium succinate) to nerve root + bupivacaine (30 ml 0.375%) intramuscularly (steroid group)
400	Kim, 2003 ⁷³	RCT	Discectomy without Oxiplex®/SP Gel (FzioMed, CA, USA)	Discectomy with anti-adhesion barrier Oxiplex [®] /SP Gel
551	Langmayr, 1995 ⁸⁴	RCT	Microdiscectomy plus intrathecal saline injection (placebo group)	Microdiscectomy with intrathecal steroid injection betamethasone (2 ml) (steroid group)
366	Lavyne, 199270	Q-RCT	Microdiscectomy followed with epidural irrigation of saline	Microdiscectomy followed with epidural irrigation of steroid methylprednisolone 40 mg
276	Lundin, 2003 ⁶⁶	RCT	Discectomy + saline (control group)	Discectomy + intramuscular, intravenous and fat graft soaked in steroids methylprednisolone 490 mg
270	MacKay, 199565	RCT	Standard hemilaminotomy, limited discectomy, dura left uncovered	Standard hemilaminotomy, limited discectomy, dura covered with free fat graft
270	MacKay, 199565	RCT	Standard hemilaminotomy, limited discectomy, dura left uncovered	Standard hemilaminotomy, limited discectomy, dura covered with gelfoam interposion membrane
854	Rasmussen, 2008 ¹⁰¹	RCT	Patients received disc surgery only	Local application of 40 mg methylprednisolone following disc excision
618	Richter, 200189	RCT	Microdiscectomy unilateral interlaminar without applying any gel	Microdiscectomy unilateral interlaminar with the application of ADCON-L gel (Gliatech Inc., OH, USA)

continued

. 15: No. 39

23

TABLE 3a Summary of the interventions used when comparing disc surgery with alternative interventions (ordered by control group then author) (continued)

ID no.	Author, year	Study design	Treatment description	Control description
856	Ronnberg, 2008 ¹⁰²	RCT	Partial discectomy with no gel applied prior to closure of the wound	Partial discectomy and ADCON-L gel applied around the nerve root, thecal sac and posterior longitudinal ligament
316	Cengiz, 200769	RCT	Disc surgery + no adhesion barrier	Disc surgery + anti-adhesion barrier ADCON-L
316	Cengiz, 200769	RCT	Disc surgery + no adhesion barrier	Disc surgery + anti-adhesion barrier Healon GV
915	de Tribolet, 1998 ¹⁰⁷	RCT	Decompression of the affected nerve root. Type of surgery: laminectomy 4, laminotomy 25, hemilaminectomy 53, hemilaminotomy 58, foraminotomy 1. Incision was closed in a routine fashion. No gel applied	Decompression of the affected nerve root. Type of surgery: laminectomy 2, laminotomy 22, hemilaminectomy 49, hemilaminotomy 55, foraminotomy 0. Before closure 3–5 g of ADCON-L gel applied to nerve root
Disc s	urgery vs mixed treatment	s		
734	Hoogland, 200697	Q-RCT	Endoscopic discectomy	(Surgery + chemonucleolysis)
				Endoscopic discectomy and chemonucleolysis with chymopapain (1000 U)
379	Prestar, 199571	RCT	Discectomy without preoperative,	(Surgery + non-opioids)
	(German language)		intraoperative or postoperative steroid	Discectomy with preoperative, intraoperative and postoperative steroid dexamethasone 4–40 mg for 7 days
705	Starkweather, 200693	RCT	Microdiscectomy and placebo medication	(Surgery + non-opioids)
				Microdiscectomy and antidepressant medication – amitriptyline 75 mg for 7 days prior
705	Starkweather, 200693	Non-RCT	(An additional non-randomised group)	(Surgery + non-opioids)
			Microdiscectomy with no intervention	Microdiscectomy and antidepressant medication – amitriptyline 75 mg for 7 days prior
263	Wang, 200063	RCT	Placebo acupuncture before and after surgery	(Surgery + alternative)
				Classical acupuncture before or after surgery
Disc s	urgery vs non-opioids			
475	Dubourg, 2002 ⁸⁰	CCS	Disc surgery (operative group) (various surgical techniques)	Non-operative intervention group. Some received steroids
144	Rossi, 1993 ⁵⁷ (Italian language)	Non-RCT	Percutaneous discectomy (groups la and lla)	Oral dexamethasone 8 mg for 9 days, naproxen 500–1000 mg for 5 days (group lb)
144	Rossi, 1993 ⁵⁷ (Italian language)	Non-RCT	Microdiscectomy (group 2b)	Oral dexamethasone 8 mg for 9 days, naproxen 500–1000 mg for 5 days (group lb)
Disc s	urgery vs others			
600	North, 200586	RCT	Re-operation with laminectomy, discectomy with our without fusion	Spinal cord stimulation group
Disc s	urgery vs usual/convention	nal care		
716	Alaranta, 199094	CCS	Discectomy with partial laminectomy	Conservative treatment
386	Atlas, 199672	CCS	Surgery most had open discectomy	Various non-surgical treatments
772	Hansson, 2007 ¹⁰⁰	CCS	Surgical treatment	Conservative non-surgical treatment. No further details
294	Koranda, 1995 ⁶⁷ (Czech language)	Q-RCT	Disc surgery	Conservative therapy
606	Peul, 200787	RCT	Microdiscectomy	Conventional care control
211	Shvartzman, 199262	HCS	Standard lumbar discectomy	Physical therapy at a local rehabilitation centre. No further details

TABLE 3a Summary of the interventions used when comparing disc surgery with alternative interventions (ordered by control group then author) (continued)

ID no.	Author, year	Study design	Treatment description	Control description
2	Thomas, 2007 ⁴⁵	CCS	Lumbar microdiscectomy with hemilaminotomy	Non-operative multidisciplinary care, no injections
664	Weber, 198391	RCT	Discectomy	Bed rest, physiotherapy, analgesia
750	Weinstein, 200698	CCS	Open or microdiscectomy (group S)	Non-operative treatment (usual care)
751	Weinstein, 200699	RCT	Standard open or microdiscectomy (group S)	Non-operative treatment (usual care)

CCS, concurrent cohort study; HCS, historical cohort study; IU, international units; U, units.

TABLE 3b Summary of the interventions used when comparing alternative forms of disc surgery (ordered by control group then author)

		a				
ID no.	Author, year	Study design	Intervention type	Treatment description	Control type	Control description
Bilate	eral vs unilateral					
21	Barlocher, 2000 ¹⁰⁸	CCS	Unilateral (microscope)	Unilateral fenestration with microdiscectomy	Bilateral (microscope)	Bilateral fenestration with microdiscectomy
502	Hagen, 1977 ¹²⁸	CCS	Bilateral	Discectomy with bilateral laminectomy and emptying of disc space (group1)	Unilateral	Discectomy with unilateral laminectomy and emptying of disc space (group 2)
Day c	ase vs inpatient					
219	Gonzalez- Castro, 2002 ¹¹⁷	Q-RCT	Day-case	Conventional discectomy (fenestration) day-case surgery – disc space cleared, no microscope	Inpatient	Conventional discectomy (fenestration) inpatient stay – disc space cleared, no microscope
Disc s	surgery + fusion v	rs disc surg	gery alone			
66	Takeshima, 2000 ¹⁰⁹	HCS	Disc surgery + fusion	Disc excision with posterolateral fusion (fusion group)	Disc surgery alone	Disc excision without fusion (non-fusion group)
653	Tria, 1987 ¹³⁶	HCS	Disc surgery + fusion	Laminectomy combined with spinal fusion	Disc surgery alone	Simple laminectomy
673	White, 1987 ¹³⁸	Non- RCT	Disc surgery + fusion	Discectomy with laminectomy plus fusion with internal fixation	Disc surgery alone	Simple laminectomy with no fusion
Disce	ctomy + endplate	curettage	vs disc surgery alone			
430	Balderston, 1991 ¹²⁴	CCS	Discectomy + endplate curettage	Lumbar discectomy combined with vertebral endplate curettage	Discectomy alone	Lumbar discectomy with laminectomy, but no endplate curettage
Endos	scopic discectom	y vs endos	copic discectomy			
680	Yang, 2005 ¹⁴⁰	HCS	Endoscopic discectomy (without laser)	Automated percutaneous lumbar discectomy	Endoscopic discectomy (laser decompression)	Percutaneous laser disc decompression
164	Righesso, 2007 ¹¹⁴	RCT	Open discectomy (no microscope)	Open discectomy using magnification	Endoscopic discectomy (microscope)	Microendoscopic discectomy

continued

TABLE 3b Summary of the interventions used when comparing alternative forms of disc surgery (ordered by control group then author) *(continued)*

ID no.	Author, year	Study design	Intervention type	Treatment description	Control type	Control description
402	Ruetten, 2008 ¹²¹	Q-RCT	Open discectomy (microscope)	Conventional microsurgical discectomy	Endoscopic discectomy (no microscope)	Full endoscopic interlaminar or transforaminal discectomy
403	Ryang, 2008 ¹²²	RCT	Open discectomy (microscope)	Standard open microdiscectomy	Endoscopic discectomy (microscope)	Minimal access trocar microdiscectomy
651	Toyone, 2004 ¹³⁵	Non- RCT	Open discectomy (no microscope)	Standard open microdiscectomy with removal of herniated material only	Endoscopic discectomy (microscope)	Microendoscopic discectomy
Endos	scopic discectom	y vs open d	liscectomy			
460	Chatterjee, 1995 ¹²⁷	RCT	Endoscopic discectomy	Automated percutaneous lumbar discectomy	Open discectomy	Microdiscectomy
536	Kim, 2007 ¹³⁰	CCS	Endoscopic discectomy (no microscope)	Targeted percutaneous transforaminal endoscopic discectomy	Open discectomy (no microscope)	Microscopic discectomy
582	Mayer, 1993131	RCT	Endoscopic discectomy (no microscope)	Percutaneous endoscopic discectomy	Open discectomy (no microscope)	Microdiscectomy
632	Schizas, 2005 ¹³²	Non- RCT	Endoscopic discectomy (no microscope)	Microendoscopic discectomy	Open discectomy (no microscope)	Microdiscectomy
327	Shin, 2008 ¹¹⁹	RCT	Endoscopic discectomy (microscope)	Microendoscopic discectomy with partial hemilaminectomy	Open discectomy (microscope)	Microscopic discectomy with partial hemilaminectomy
409	Wu, 2006 ¹²³	CCS	Endoscopic discectomy (microscope)	Microendoscopic discectomy	Open discectomy (no microscope)	Standard open posterior lumbar discectomy
459	Zhang, 2007 ¹²⁶	Non- RCT	Endoscopic discectomy (microscope)	Microendoscopic discectomy	Open discectomy (no microscope)	Open lumbar discectomy
Exten	sive disc surgery	vs limited	disc surgery			
391	Carragee, 2006 ¹²⁰	HCS	Open discectomy	Subtotal discectomy with removal of extruded fragments and emptying of disc space	Limited discectomy	Limited discectomy with removal of extruded fragments only
525	Kahanovitz, 1989 ¹²⁹	CCS	Extensive disc surgery (microscope)	Microdiscectomy (with an operating microscope)	Limited disc surgery (no microscope)	Limited unilateral discectomy without magnification
643	Striffeler, 1991 ¹³³	CCS	Limited discectomy (microscope)	Conservative microdiscectomy with removal of prolapsed disc, disc space irrigated	Extensive discectomy (microscope)	Standard microdiscectomy with emptying of disc space
647	Thome, 2005 ¹³⁴	RCT	Extensive discectomy (microscope)	Microdiscectomy with emptying of disc space	Limited discectomy (microscope)	Sequestrectomy with removal of herniated material only
Laser	discectomy vs of	pen discec	tomy			
116	Lee, 2006 ¹¹¹	CCS	Endoscopic discectomy (no microscope)	Percutaneous endoscopic lumbar discectomy	Open dicectomy (microscope)	Open lumbar microdiscectomy with partial hemilaminectomy
165	Tassi, 2006 ¹¹⁵	HCS	Laser decompression	Percutaneous laser disc decompression	(Microscope)	Standard surgical microdiscectomy

TABLE 3b Summary of the interventions used when comparing alternative forms of disc surgery (ordered by control group then author) (continued)

ID no.	Author, year	Study design	Intervention type	Treatment description	Control type	Control description
Ligam	entum flavum pro	eservation	vs ligamentum flavum excisi	ion		
69	Aydin, 2002 ¹¹⁰	HCS	Ligamentum flavum preservation (microscope)	Microdiscectomy with preservation of ligamentum flavum (group 1)	Ligamentum flavum excision (microscope)	Standard microdiscectomy with fenestration, foraminotomy, partial or total excision of ligamentum flavum (group 2)
Micros	scope vs no micro	oscope				
432	Barrios, 1990 ¹²⁵	CCS	Microscope	Standard discectomy with partial hemilaminectomy	No microscope	Microdiscectomy
167	Katayama, 2006 ¹¹⁶	RCT	Microscope	Microdiscectomy without laminectomy, disc space emptied (group B)	No microscope	Macrodiscectomy with partial laminectomy, no microscope, disc space emptied (group A)
143	Kho, 1986 ¹¹³ (German language)	HCS	Microscope	Microdiscectomy	No microscope	Lumbar discectomy without microscope
126	Lagarrigue, 1994 ¹¹² (French language)	RCT	Microscope	Microscopic lumbar discectomy	No microscope	Normal lumbar discectomy (without microscope)
232	Tullberg, 1993 ¹¹⁸	RCT	Microscope	Microscopic surgery (micro-group) – disc space cleared	No microscope	Standard macrodiscectomy (without microscope) – disc space cleared
654	Tureyen, 2003 ¹³⁷	RCT	Microscope	Microdiscectomy with emptying of disc space (group A)	No microscope	Macrodiscectomy with laminectomy and emptying of disc space, no microscope (group B)
674	Wilson, 1981 ¹³⁹	HCS	Microscope	Microdiscectomy with evacuation of disc space, but no curettage of end plates	No microscope	Standard open discectomy with evacuation of disc space, but no curettage of end plates

CCS, concurrent cohort study; HCS, historical cohort study.

chronic sciatica, or either chronic or acute sciatica, or did not report this information. Four studies^{62,68,80,87} included patients with acute sciatica, with a mean duration of symptoms ranging from 25.7 days⁸⁰ to 68.5 days.⁶⁸ Four studies^{54,67,69,83} included some patients with spinal stenosis and $10^{68,74,83,95,97,98,99,101,103,107}$ included patients with sequestered or extruded discs. The diagnosis of sciatica, or the presence of herniated disc, was confirmed by imaging in 52 (85%) studies. Six studies^{49,66,74,92,95,105} included patients who had sciatica for the first time and seven studies^{50,57,63,72,80,81,83,86} included only patients with recurrent sciatica. The remaining studies included patients with either first-episode or recurrent sciatica, or did not report this information. The majority of studies (n = 40) included patients who had received previous treatment for their current episode of sciatica. Ten studies^{45,56,59,63,71,80,81,86,88,95} included patients who had received previous disc surgery and 32 studies included patients who had not.

~
E
2
÷
Ľ
U
N
0
σ
Ð,
Ð
ō
Z
0
5
μ
⇇
Ļ
5
Ъ,
E.
č.
¥
8
0
≥.
σ
Ð
₽
2
2
<u>o</u>
~
ŝ
Z
ï≓
Ē
Ð
2
Ð
Ť
.∟
Φ
2
Ŧ
ğ
Ľ
Φ
≓
ω
Ļ
÷
3
>
2
ž
Ξ,
2
0)
Ú,
isc
disc
g disc
ng disc
ring disc
aring disc
paring disc
mparing disc
omparing disc
comparing disc
s comparing disc
es comparing disc
dies comparing disc
udies comparing disc
studies comparing disc
studies comparing disc
or studies comparing disc
for studies comparing disc
is for studies comparing disc
ails for studies comparing disc
tails for studies comparing disc
letails for studies comparing disc
details for studies comparing disc
n details for studies comparing disc
on details for studies comparing disc
tion details for studies comparing disc
lation details for studies comparing disc
ulation details for studies comparing disc
pulation details for studies comparing disc
population details for studies comparing disc
population details for studies comparing disc
ty population details for studies comparing disc
Idy population details for studies comparing disc
tudy population details for studies comparing disc
study population details for studies comparing disc
d study population details for studies comparing disc
nd study population details for studies comparing disc
and study population details for studies comparing disc
e and study population details for studies comparing disc
pe and study population details for studies comparing disc
type and study population details for studies comparing disc
type and study population details for studies comparing disc
ca type and study population details for studies comparing disc
tica type and study population details for studies comparing disc
atica type and study population details for studies comparing disc
ciatica type and study population details for studies comparing disc
sciatica type and study population details for studies comparing disc
f sciatica type and study population details for studies comparing disc
of sciatica type and study population details for studies comparing disc
y of sciatica type and study population details for studies comparing disc
ary of sciatica type and study population details for studies comparing disc
nary of sciatica type and study population details for studies comparing disc
imary of sciatica type and study population details for studies comparing disc
mmary of sciatica type and study population details for studies comparing disc
hummary of sciatica type and study population details for studies comparing disc
Summary of sciatica type and study population details for studies comparing disc
4 Summary of sciatica type and study population details for studies comparing disc
4 Summary of sciatica type and study population details for studies comparing disc
E4 Summary of sciatica type and study population details for studies comparing disc
ILE 4 Summary of sciatica type and study population details for studies comparing disc
NBLE 4 Summary of sciatica type and study population details for studies comparing disc
ABLE 4 Summary of sciatica type and study population details for studies comparing disc

<u>o</u> ë	Author, year	Study design	No. of patients	Mean age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis? ^a	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Disc s.	urgery vs chemonuch	eolysis											
884	Alexander, 1989 ¹⁰³	CCS	100	33.5 (range 18–65)	(06) 06	Mean 5.5 months	Nerve root pain	Yes	NR	No	Yes	Yes	No
43	van Alphen, 198947	RCT	151	34 (range 18–45)	(99) (<u>6</u> 6)	55% <6 months; 45% >6 months	Nerve root pain	Yes	NR	No	No	Yes	No
441	Bonafe, 1993 ⁷⁵ (French language)	CCS	40	46 (range 27–68)	28 (70)	Mean 3 months (range several days to 15 months)	Nerve root pain	Yes	NR	N	No	Yes	R
183	Bouillet, 1983 ⁶¹	CCS	2749	NR	NR	Ranged from weeks to months	Nerve root pain	Yes	NR	No	No	Yes	NR
453	Brown, 1989 ⁷⁶	CCS	85	37.6	59 (69)	At least 3 months	Nerve root pain	Yes	NR	No	No	Yes	No
454	Buric, 2005 ⁷⁷	Non- RCT	45	45 (SD 14.2; range 19–77)	23 (51)	Mean 203.9 days (SD 129.6; range 21 to > 365 days)	Nerve root pain	Yes	NR	No	No	Yes	No
166	Crawshaw, 198460	RCT	52	37	NR	NR	Nerve root pain	Yes	NR	No	No	Yes	No
48	Dabezies, 1978 ⁵¹	CCS	200	30	132 (66)	R	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	Yes	NR
471	Dei-Anang, 1990 ⁷⁹ (German language)	CCS	201	NR	NR	NR	Nerve root pain	NR	NR	No	No	NR	NR
727	Ejeskar, 1983 [%]	RCT	29	39.3	21 (72)	Mean 4.5 months (SD 3 months)	Nerve root pain	Yes	NR	No	No	NR	No
132	Hoogmartens, 1976 ⁵⁶	HCS	67	35.5	48 (49)	25–35 months	Nerve root pain	NR	Recurrent and first episode	No	No	Yes	Yes
44	Javid, 1995 ⁴⁸	CCS	200	39 (range 17–81)	134 (67)	Mean 7.2 months	Nerve root pain	Yes	NR	N	No	Yes	No

e ë	Author, year	Study design	No. of patients	Mean age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
35	Krugluger, 2000 ⁴⁶	RCT	22	40 (range 24–60)	16 (73)	Mean 7 months	Nerve root pain	Yes	NR	No	No	Yes	NR
117	Lagarrigue, 1991 ⁵⁴ (French language)	CCS	1085	42 (range 14–83)	682 (63)	Mean 13.4 months	Nerve root pain	No	NR	Yes	No	Yes	NR
129	Lavignolle, 1987 ⁵⁵ (French language)	RCT	358	41 (SD 12.03)	225 (63)	NR	Nerve root pain	NR	NR	No	No	NR	NR
889	Lee, 1996 ¹⁰⁴ (German language)	CCS	300	50% <30; 25% >40	213 (71)	NR	Nerve root pain	Yes	NR	No	No	Yes	NR
593	Muralikuttan, 1992 ⁸⁵	RCT	92	35 (range 19–60)	55 (60)	Mean 24 weeks	Nerve root pain	Yes	NR	No	No	Yes	NR
47	Norton, 1986 ⁵⁰	CCS	105	40 (range 20–67)	86 (82)	Mean 18.5 months (range 5 days-128 months)	Nerve root pain	Yes	Recurrent	No	No	Yes	No
45	Postacchini, 1987 ⁴⁸	Non- RCT	161	R	R	Mean 8.75 months (range 1.2–36.0 months)	Nerve root pain and referred pain	Yes	First episode	No	No	Yes	NR
617	Revel, 1993 ⁸⁸	RCT	165	39 (SD 9; range 21–65)	96 (68)	NR	Nerve root pain	Yes	NR	No	No	Yes	Yes
641	Steffen, 1999 ⁹⁰ (German language)	RCT	69	NR	NR	10.6 months	Nerve root pain	Yes	NR	No	No	Yes	NR
49	Stula, 1990 ⁵² (German language)	RCT	69	Range 22–54	57 (83)	<1 year	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	No
61	Tregonning, 1991 ⁵³	CCS	268	40.4 (range 20–65)	135 (68)	NR	Nerve root pain	Yes	NR	No	No	Yes	No
893	Watters,1988 ¹⁰⁵	Non- RCT	100	36.5	59 (59)	Mean 13 weeks	Nerve root pain	Yes	First episode	No	No	NR	NR
160	Watts, 1975 ⁵⁹	CCS	274	Range 24–62	55 (55)	R	Nerve root pain and referred pain	Yes	Recurrent and first episode	N	9N	Yes	Yes
													continued

б.	
auth	
by 8	
ed	
rder	
0 U	
the	
ator	
pan	
moc	
ĥ	
bed	
dno.	
s (gr	
ion	
/ent	
Iter	
íe ir	
וati∖	
terr	
th al	
, wit	
gery	
ùns	
lisc	
ng c	
pari	
lmo	
es c	
indi	
or st	
ls fo	
etai	
n d	
latic	
ndc	
y po	
stud	
nd S	
e a	
a typ	
ıtica	
scia	
/ of	
nary	
umr	
4 0	ed)
Ě	tinu
IAB	'con
	\sim

0 ë	Author, year	Study design	No. of patients	Mean age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis? ^a	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
672	Weinstein, 198692	ccs	159	41 (range 28–57)	64 (41)	Minimum period of 3 months	Nerve root pain	Yes	First episode	No	No	Yes	No
150	Zeiger, 1987 ⁵⁸	CCS	126	NR	NR	4 weeks or more	Nerve root pain	Yes	NR	No	No	Yes	No
Disc s	urgery vs epidural												
725	Buttermann, 2004 ⁹⁵	RCT	100	40.5 (SD 12)		Mean 3.55 months (SD 2.75 months)	Nerve root pain	Yes	First episode	No	Yes	Yes	Yes
Disc s	urgery vs exercise th	nerapy											
300	Osterman, 2006 ⁶⁸	RCT	57	38 (SD 7)	34 (61)	Mean 68.5 days (SD 27 days)	Nerve root pain	Yes	Recurrent and first episode	No	Yes	R	No
Disc s	urgery vs intraopera	tive interve	sntions										
268	Aminmansour, 2006 ⁶⁴	Q-RCT	61	38.5 (SD 10.4)	35 (57)	NR	Nerve root pain	Yes	NR	No	No	N	NR
436	Bernsmann, 2001 ⁷⁴	RCT	200	43 (range 22–75)	97 (52)	NR	Nerve root pain	Yes	First episode	No	Yes	N	NR
470	Debi, 2002 ⁷⁸	RCT	20	41 (range 18–60)	43 (70)	Mean 56 days (range 12-135 days)	Nerve root pain	NR	NR	No	No	Yes	No
492	Gerszten, 2003 ⁸¹	RCT	10	42	5 (50)	Mean 3.5 years (range 1.5–10.0 years)	Nerve root pain	Yes	Recurrent	No	No	Yes	Yes
497	Glasser, 1993 ⁸²	RCT	32	46.1 (SD 3.66)		Within 6 months	Nerve root pain	Yes	NR	No	No	Yes	No
520	Jensen, 1996 ⁸³	RCT	118	Median 46 (range 19–75)	53 (45)	Я	Nerve root pain	Yes	Recurrent	No central stenosis but some had lateral stenosis	Yes	NN	No

					No. of					Included patients	Included patients with sequestered	Any previous treatment	Any previous back
o é	Author, year	Study design	No. of patients	Mean age (years)	men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	with stenosis? ^a	disc (or extruded)?ª	for sciatica?	surgery for sciatica?
606	Jirarattanaphochai, 2007 ¹⁰⁶	RCT	103	52 (SD 11; range 21–79)	48 (47)	NR	Nerve root pain	R	NR	No	No	NR	NR
400	Kim, 2003 ⁷³	RCT	35	43.5 (range 28–65)	11 (31)	NR	Nerve root pain	Yes	NR	No	No	NR	No
551	Langmayr, 1995 ⁸⁴	RCT	26	42	20 (77)	Median 35 days (range 14–150 days)	Nerve root pain	Yes	NR	No	No	Yes	No
366	Lavyne, 1992 ⁷⁰	Q-RCT	84	40 (range 17-70)	57 (73)	Few days to several months	Nerve root pain	Yes	NR	No	No	Yes	NR
276	Lundin, 2003 ⁶⁶	RCT	80	41.7	44 (55)	Mean 4.5 months	Nerve root pain	Yes	First episode	No	No	NR	No
270	MacKay, 1995 ⁶⁵	RCT	190	39 (range 14–79)	106 (69)	NR	Nerve root pain	Yes	NR	No	No	Yes	NR
854	Rasmussen, 2008 ¹⁰¹	RCT	200	42.5 (range 18–66)	122 (61)	NR	Nerve root pain	Yes	NR	No	Yes	Yes	NR
618	Richter, 200189	RCT	398	43 (range 30–65)	221 (62)	NR	Nerve root pain	Yes	NR	No	No	NR	No
856	Ronnberg, 2008 ¹⁰²	RCT	128	39 (range 18–66)	68 (53)	NR	Nerve root pain	Yes	NR	No	No	Yes	No
316	Cengiz, 2007 ⁶⁹	RCT	60	44.2 (SD 10.2)	35 (58)	Mean 12.3 years (SD 9.2 years)	Nerve root pain	Yes	Recurrent and first episode	Yes	No	NR	No
915	de Tribolet, 1998 ¹⁰⁷	RCT	298	39.1 (SD 9.5)	167 (56)	Not stated	Nerve root pain	Yes	Recurrent and first episode	No	Yes extruded and sequestered discs	Yes	N
Disc s	urgery vs mixed treat	tments											
734	Hoogland, 2006 ⁹⁷	Q-RCT	280	40.5 (range 18–60)	186 (66)	NR	Nerve root pain	Yes	NR	No	Yes	Yes	No
379	Prestar, 1995 ⁷¹ (German language)	RCT	100	44.7 (range 26–76)	NR	NR	Nerve root pain	Yes	NN	N	No	Yes	Yes
													continued

uthor)	
d by a	
rdere	
then o	
rator 1	
ompa	
l by c	
onpec	
ns (gr	
/entio	
inter	
native	
n alter	
ry with	
surge	
g disc	
parinç	
s com	
studie	
ls for :	
detai	
llation	
/ popu	
study	
e and	
ca typ	
sciati	
ary of	
Summ	_
E 4 0	inued,
TABL	(cont

e é	Author, year	Study design	No. of patients	Mean age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis? ^a	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
705	Starkweather, 2006 ⁹³	RCT	70	45.5 (SD 11; range 21–65)	40 (57)	61% <1 year; 39% >1 year	Nerve root pain	Yes	NR	No	No	NR	NR
263	Wang, 2000 ⁶³	RCT	145	21–80	78 (59)	At least 6 months	Nerve root pain	Yes	Recurrent	No	No	Yes	Yes
Disc s.	urgery vs non-opioid	S											
475	Dubourg, 2002 ⁸⁰	ccs	67	48.8 (SD 13.9; range 28–81)	42 (63)	Mean 25.7 days (SD 28.7 days)	Nerve root pain	Yes	Recurrent and first episode	No	No	R	Yes
144	Rossi, 1993 ⁵⁷ (Italian language)	Non- RCT	40	42.5 (SD 10.5; range 20–65)	NR	<6 months	Nerve root pain	Yes	Recurrent	No	No	NR	NR
Disc s	urgery vs others												
600	North, 2005 ⁸⁶	RCT	60	50.2 (SD 13.3; range 26–76)	30 (50)	NR	Nerve root pain	Yes	Recurrent	No	No	Yes	Yes
Disc s.	urgery vs usual/conv	entional cé	ıre										
716	Alaranta, 1990 ⁹⁴	CCS	357 (322 partial rhizography)	39.6	179 (50)	Mean 3.6 months	Nerve root pain	No	R	No	No extrusion	R	No
386	Atlas, 1996 ⁷²	CCS	507	42 (range 18–85)	322 (64)	41% <1 year; 1–24% 5 years; 35% >5 years	Nerve root pain	No	Recurrent	No	No	Yes	No
772	Hansson, 2007 ¹⁰⁰	CCS	184	43 (range 22–59)	87 (47)	20% <1 week; 39% 1 week to 1 year; 42% >1 year	Nerve root pain	Yes	NR	No	No	N	No
294	Koranda, 1995 ⁶⁷ (Czech language)	Q-RCT	100	NR	NR	N	Nerve root pain	Yes	Recurrent and first episode	Yes	No	Yes	NR

Q		Study	No. of		No. of men		Type of	Confirmed	Recurrent	Included patients with	Included patients with sequestered disc (or	Any previous treatment for	Any previous back surgery for
u0.	Author, year	design	patients	Mean age (years)	(%)	Symptom duration	sciatica	by imaging?	episode	stenosis? ª	extruded)?ª	sciatica?	sciatica?
211	Shvartzman, 1992 ^{sz}	HCS	55	42.3 (SD 11.1; range 23-59)	55 (100)	Patients presented with acute episode of sciatica, actual duration NR	Nerve root pain	Yes	R	N	N	Yes	No
5	Thomas, 2007 ⁴⁵	CCS	623	42.9	291 (59)	Mean 191.5 days (SD 195 days)	Nerve root pain	Yes	Recurrent and first episode	No	No	NR	Yes
664	Weber, 1983 ⁹¹	RCT	126	41 (range 25–55)	68 (54)	At least 14 days	Nerve root pain	Yes	NR	No	No	NR	No
751	Weinstein, 2006 ⁹⁹	RCT	501	42 (SD 11.6)	278 (59)	79% <6 months	Nerve root pain	Yes	Recurrent and first episode	No	Yes	Yes	No
606	Peul, 2007 ⁸⁷	RCT	283	42.6 (SD 9.8)	186 (66)	Mean 9.5 weeks (range 6–12 weeks)	Nerve root pain	Yes	NR	No	No	NR	No
750	Weinstein, 2006 ⁹⁸	CCS	743	41.4 (SD 11.2)	406 (56)	77% <6 months	Nerve root pain	Yes	Recurrent and first episode	No	Yes	Yes	No
CCS, c a Ma	concurrent cohort study rked ves if patient pop	y; HCS, hist ulation or ir	corical cohort stu oclusion criteria	udy; NR, not reported; SC specifically reported tha), standard de t patient with	eviation. sequestered disc, extru-	ded disc or st	enosis were inclu	Ided; otherwise,	, reported as no			

DOI: 10.3310/hta15390

D no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Disc su	rgery vs chemonucleolysis			,						
884	Alexander, 1989 ¹⁰³	100	Mean 14 months; range 6–35 months	CCS	No	No	80-100	Unclear	Weak	Weak
43	van Alphen, 1989 ⁴⁷	151	12 months	RCT	Partial	Unclear	80-100	No	Moderate	Strong
441	Bonafe, 1993 ⁷⁵ (French language)	40	Mean 15 months; range 3–36 months	CCS	No	No	80-100	Unclear	Weak	Weak
453	Brown, 1989 ⁷⁶	85	3 months	CCS	No	No	80-100	Yes	Weak	Weak
454	Buric, 2005^{77}	45	18 months	Non-RCT	No	No	80-100	NA	Weak	Weak
166	Crawshaw, 198460	52	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate
48	Dabezies, 1978 ⁵¹	200	2 years	CCS	No	No	Can't tell	No	Weak	Moderate
471	Dei-Anang, 1990 ⁷⁹ (German language)	201	1 year	CCS	No	No	NA	Unclear	Weak	Weak
727	Ejeskar, 1983 ⁹⁶	29	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate
132	Hoogmartens, 1976 ⁵⁶	76	58 months for discectomy and 38 months for chemonucleolysis	HCS	No	No	NA	NA	Weak	Moderate
44	Javid, 1995 ⁴⁸	200	1 year	CCS	No	No	80-100	No	Weak	Moderate
35	Krugluger, 2000 ⁴⁶	22	2 years	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
117	Lagarrigue, 1991 ⁵⁴ (French language)	1085	Mean 17.2 months; range 12-4 months	CCS	No	No	80-100	Unclear	Weak	Moderate
129	Lavignolle, 1987 ⁵⁵ (French language)	358	Mean 25 months for surgery and 22 months for chemonucleolysis	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
889	Lee, 1996 ¹⁰⁴ (German language)	300	1 year	CCS	No	No	Can't tell	Unclear	Weak	Weak
593	Muralikuttan, 1992 ⁸⁵	92	1 year	RCT	Yes	Unclear	80-100	Unclear	Moderate	Moderate
47	Norton, 1986 ⁵⁰	105	At least 1 year	CCS	No	No	NA	Unclear	Weak	Weak
45	Postacchini, 1987 ⁴⁹	161	Mean 2.9 years; range 20–38 months in chemonucleolysis. Mean 2.8 years; range 21–42 months in surgery	Non-RCT	No	Q	80-100	N	Weak	Moderate

TABLE 5 Summary of the study details for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
617	Revel, 1993 ⁸⁸	165	1 year	RCT	Yes	Unclear	80-100	Unclear	Moderate	Weak
641	Steffen, 1999 ^{%)} (German language)	69	1 year	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
49	Stula, 1990 ⁵² (German language)	69	Postoperative	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
61	Tregonning, 199153	268	10 years	CCS	No	No	80-100	No	Weak	Moderate
893	Watters,1988 ¹⁰⁵	100	3 years	Non-RCT	No	No	80-100	No	Weak	Weak
160	Watts, 1975 ⁵⁹	274	2 years	CCS	No	No	80-100	Unclear	Weak	Weak
672	Weinstein, 1986 ⁹²	159	Mean 10.3 years; range 10.0–13.5 years	CCS	No	No	80-100	NA	Weak	Weak
150	Zeiger, 1987 ⁵⁸	126	Range 6–46 months; average time from treatment to follow- up 18 months	CCS	No	No	NA	Yes	Weak	Weak
Disc su	ırgery vs epidural									
725	Buttermann, 2004 ⁹⁵	100	23 years	RCT	Unclear	Unclear	80-100	No	Moderate	Moderate
Disc st	irgery vs exercise therapy									
300	Osterman, 2006 ⁶⁸	57	2 years	RCT	Yes	Yes	80-100	NA	Moderate	Weak
Disc st	ırgery vs intraoperative interver.	ntions								
268	Aminmansour, 2006 ⁶⁴	61	2 months	Q-RCT	No	No	80-100	Yes	Weak	Moderate
436	Bernsmann, 2001 ⁷⁴	200	Median of 24.2 months after surgery	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
470	Debi, 2002 ⁷⁸	70	1 year	RCT	Unclear	Partial	80-100	No	Weak	Weak
492	Gerszten, 200381	10	1 year	RCT	Yes	Unclear	80-100	NA	Moderate	Weak
497	Glasser, 199382	32	1 month	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
520	Jensen, 199683	118	Median 376 days; range 276–501 days	RCT	Unclear	Unclear	80-100	Yes	Moderate	Moderate
606	Jirarattanaphochai, 2007 ¹⁰⁶	103	3 months	RCT	Yes	Partial	80-100	Yes	Moderate	Moderate
400	Kim, 2003 ⁷³	35	6 months	RCT	Yes	Yes	80-100	NA	Moderate	Weak
551	Langmayr, 1995 ⁸⁴	26	6 months	RCT	Unclear	Unclear	80-100	Yes	Moderate	Moderate
										continued

Ď,
é
ž
Ę.
5
8
٢
E
ĕ
팥
ы
~
ف ا
σ
ē
ē
ō
ð
C
ē
근
F
5
Ŋ
g
P
Ĕ
8
Ξ.
á
0
ð
đ
DC
Ц
<u>0</u>
S
Z
. <u>ല</u>
Ē
é
Ś
te te
.⊆
Ð
<u> </u>
ati
č
P
Ĕ
ъ
÷
Ξ
2
≥
ē
2
2
~
S
÷
Š
ĉ
ij.
)a
ď
Ľ
5
ŝ
<u>ð</u>
ō
Ę
S
Z
¥
S
ai
et
σ
≥
g
ž
5
e E
Ŧ
Ť
<u> </u>
~
ary c
nary c
nmary c
ummary o
Summary o
Summary o
5 Summary o
.E 5 Summary o
3LE 5 Summary o
ABLE 5 Summary o
TABLE 5 Summary o

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
366	Lavyne, 1992 ⁷⁰	84	6 weeks	Q-RCT	No	No	80-100	Unclear	Weak	Weak
276	Lundin, 2003 ⁶⁶	80	2 years	RCT	Unclear	Unclear	80-100	Yes	Moderate	Moderate
270	MacKay, 1995 ⁶⁵	190	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
854	Rasmussen, 2008 ¹⁰¹	200	2 years	RCT	Yes	Unclear	80-100	Yes	Moderate	Weak
618	Richter, 200189	398	6 months	RCT	Yes	Yes	80-100	Yes	Moderate	Weak
856	Ronnberg, 2008 ¹⁰²	128	2 years	RCT	Unclear	Partial	80-100	Yes	Weak	Weak
316	Cengiz, 2007 ⁶⁹	60	12 months	RCT	Unclear	Yes	80-100	Unclear	Moderate	Weak
915	de Tribolet, 1998 ¹⁰⁷	298	6 months	RCT	Yes	Unclear	80-100	Yes	Moderate	Moderate
Disc sur	gery vs mixed treatments									
734	Hoogland, 2006^{97}	280	2 years	Q-RCT	No	No	80-100	Unclear	Weak	Weak
379	Prestar, 1995™ (German language)	100	1 year	RCT	Unclear	Unclear	6209	Unclear	Weak	Moderate
705	Starkweather, 200693	70	6 weeks	RCT	Unclear	Partial	80-100	Unclear	Weak	Weak
263	Wang, 2000 ⁶³	145	3 days	RCT	Unclear	Unclear	80-100	Unclear	Moderate	Moderate
Disc sur	gery vs non-opioids									
475	Dubourg, 2002 ⁸⁰	67	6 months	CCS	No	No	80-100	No	Weak	Weak
144	Rossi, 1993 ⁵⁷ (Italian language)	40	6 months	Non-RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
Disc sur	gery vs others									
600	North, 2005 ⁸⁶	60	2 years	RCT	Yes	Partial	6079	No	Weak	Moderate
Disc sur	gery vs usual/conventional care									
716	Alaranta, 1990⁰₄	357 (322 with partial rhizography)	1 year	CCS	No	No	80–100	No	Weak	Moderate
386	Atlas, 1996 ⁷²	507	10 years	CCS	No	No	60-79	NA	Moderate	Moderate
772	Hansson, 2007 ¹⁰⁰	184	2 years	CCS	No	No	80-100	NA	Weak	Moderate
294	Koranda, 1995 ⁶⁷ (Czech language)	100	3 months	Q-RCT	No	No	80-100	Unclear	Weak	Moderate

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
606	Peul, 2007 ⁸⁷	283	1 year (main follow-up visits at 8 weeks, 6 months and 1 year). 2 years' data reported later	RCT	Yes	Partial	80-100	NA	Strong	Strong
211	Shvartzman, 1992 ⁶²	55	2 years	HCS	No	No	NA	NA	Weak	Weak
2	Thomas, 2007 ⁴⁵	623	12 months	CCS	No	No	80-100	NA	Moderate	Strong
664	Weber, 1983 ⁹¹	126	10 years	RCT	Unclear	Partial	6079	No	Weak	Moderate
751	Weinstein, 200699	501	2 years	RCT	Yes	Yes	80-100	NA	Strong	Weak
750	Weinstein, 200698	743	2 years	CCS	No	No	80-100	NA	Moderate	Weak
CCS, co	ncurrent cohort study; HCS, historic	cal cohort study;	NA, not applicable.							

Summary of study design and quality for disc surgery studies

Summary information on study details are presented in *Table 5*. The full results of the quality assessment are presented in the *Appendix 5*. Just over half (33/62, 53%) of the disc surgery studies were RCTs, of which only two^{87,99} were good quality overall (comparing disc surgery with usual care). Four RCTs^{68,73,89,99} had used both adequate randomisation and allocation concealment (comparators included exercise therapy, intraoperative interventions and usual care). A further eight studies^{81,85-88,101,106,107} used adequate randomisation, but not allocation concealment (although two studies^{87,106} used sealed envelopes), and one study⁶⁹ used adequate allocation concealment, but not randomisation. Two studies^{91,93} used sealed envelopes, but gave no further details on method of randomisation. Three studies^{45,47,87} had strong external validity.

Disc surgery results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 6* and the accompanying forest plot (*Figure 2*). Disc surgery was compared with exercise therapy, chemonucleolysis (which is not widely used in the UK NHS) and intraoperative interventions. Most studies included patients with chronic sciatica.

One well-conducted RCT⁶⁸ compared disc surgery plus exercise therapy with exercise therapy alone for patients with acute sciatica owing to an intervertebral disc extrusion or sequester. Disc surgery plus exercise therapy was found to be superior to exercise therapy alone, but the findings were not statistically significant, probably owing to a lack of power as a result of the analysis of a small sample size (n = 57).

Six studies^{48,49,52,79,92,104} compared disc surgery with chemonucleolysis, for which there was no overall difference between the groups. Only one of these studies was an RCT,⁵² which was poorly reported with method of randomisation and allocation concealment not stated. Forty-four patients were randomised to each group, but 19 in the chemonucleolysis group received surgery and were analysed as surgery group patients. The results and methods of the remaining studies were also poorly reported.

Two RCTs^{71,82} compared surgery with intraoperative interventions and found no overall statistically significant difference.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 7* and the accompanying forest plot (*Figure 3*). Disc surgery was compared with usual care, intraoperative interventions, exercise therapy, mixed treatments and chemonucleolysis. Most studies included patients with chronic sciatica.

One study based in the Netherlands⁸⁷ compared early surgical intervention with usual care in patients with severe sciatica for 6–12 weeks. The study was well conducted with good external validity. Patients in the disc surgery group experienced a significantly greater reduction in pain intensity than those who received conventional care (WMD –15.70; 95% CI –20.98 to –10.42). Conventional care included rehabilitation at home supervised by a physiotherapist using a standardised exercise protocol, advice to resume work as soon as possible, pain medication and conservative treatment provided by general practitioners (GPs) (or neurologist where necessary). Microdiscectomy was offered if sciatica persisted for more than 6 months after randomisation. Patients with increasing leg pain not responsive to medication or progressive neurological deficits were offered surgery sooner.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Active	PT/exercise therapy						
300	Osterman, 200668	RCT	-	•		13.34 (0.70 to 253.89)	100.00
Chemo	nucleolysis						
471	Dei-Anang, 199079	CCS		+		0.72 (0.38 to 1.36)	21.31
44	Javid, 1995 ⁴⁸	CCS		_ . _		2.52 (1.04 to 6.11)	14.36
889	Lee, 1996 ¹⁰⁴	CCS	-	<u> </u>		1.00 (0.47 to 2.13)	17.65
45	Postacchini, 198749	Non-RCT	-	-		1.38 (0.73 to 2.61)	21.45
49	Stula, 1990 ⁵²	RCT		*		1.36 (0.28 to 6.65)	5.67
672	Weinstein, 198692	CCS		÷		0.64 (0.32 to 1.28)	19.56
Subtota	ll ($l^2 = 36.7\%$, $p = 0.162$	2)	<			1.06 (0.71 to 1.59)	100.00
Intraop	erative interventions						
497	Glasser, 1993 ⁸²	RCT				0.31 (0.02 to 4.41)	12.93
379	Prestar, 199571	RCT	-	•		1.00 (0.36 to 2.77)	87.07
Subtota	ll ($l^2 = 0.0\%$, $p = 0.422$)		<	\geq		0.86 (0.33 to 2.23)	100.00
		0.00	+)394 ·	1	254		
			Favours control	Favours surge	ery		

FIGURE 2 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing disc surgery with alternative interventions. CCS, concurrent cohort study; PT, physical therapy. Note: weights are from random effects analysis.

As with global effect, one well-conducted RCT⁶⁸ found disc surgery plus exercise therapy to be superior to exercise therapy alone for acute sciatica due to an intervertebral disc extrusion or sequestration, but the findings were not statistically significant.

Two studies,^{63,93} compared disc surgery with mixed treatments: acupuncture plus surgery⁶³ and disc surgery plus non-opioids.⁹³ Both found that the added intervention was significantly more effective than disc surgery alone for chronic sciatica. Both were poorly reported RCTs. For one study,⁶³ patients in the intervention group were divided into two non-random groups, with half receiving preoperative acupuncture and the other half postoperative acupuncture. The results were reported separately for preoperative and postoperative patients; thus, only those who had preoperative acupuncture are included in the meta-analysis.

Six RCTs^{66,73,78,84,89,106} compared surgery with intraoperative interventions and found no overall significant difference between treatment groups. Two studies^{78,84} included patients with either chronic or acute sciatica and one⁶⁶ included patients who had had sciatica for longer than 3 months; the chronicity of sciatica was not reported in three studies.^{73,89,106} Three studies^{73,89,106} were of moderate to good quality, with adequate randomisation in all three and allocation concealment in two.^{73,89}

Three studies compared disc surgery with chemonucleolysis: two were RCTs^{85,88} and one was a concurrent cohort study (CCS).⁷⁶ Overall, there was no statistically significant difference between the intervention groups. However, the results were heterogeneous, with the CCS favouring disc surgery and one of the RCTs⁸⁸ showing statistically significant findings in favour of chemonucleolysis. One study⁷⁶ included patients who had not received previous disc surgery,

to	
ara	
duc	
Š	
2 D D	
dnc	
) gr	
ons	
enti	
terv	
è in	
ativ	
terr	
th al	
/ wit	
gery	
ŝ	
lisc	
o Gu	
oarii	
ling	
es c	
tudi	
or st	
s) fc	
eek	
≷ 9	
_N ∩	
n-n	
ollo	
Ę	
t-tei	
hor	
ats	
fect	
ıl eft	
oba	
le gl	
ofth	
gs o	
din	
le fii	
of th	(Jo
ary (auth
nm	by ŝ
Sur	ð
	Ψ
ю Ш	ordere

then o	rdered by auti	or the Infat hor)		e giobal ellec	t at short-term 10110	w-up (≤) du-w	int (system)	studies co	Junparing uisc	sarger	v with alle		annons (group	ed by comparator
							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0r (95% CI)	Comments
Disc :	surgery vs chem	nonucleolysis												
471	Dei-Anang, 1990 ⁷⁹ (German language)	NR	ccs	42 days	Reported absence of pain	Patient	100	72	0	101	62	0	0.72 (0.38 to 1.36)	Data inferred from graphs, presented as percentages
44	Javid, 1995 ⁴⁸	O	CCS	6 weeks	Successful outcome: good or excellent (vs unsuccessful: slight or no improvement)	Patient	100	92	0	100	82	0	2.52 (1.04 to 6.11)	
888 880	Lee, 1996 ¹⁰⁴ (German language) (j) ^a (APLD)	N	CCS	6 weeks	Disappearance of back pain		100	16	¢.	100	16	~	1.00 (0.47 to 2.13)	Number randomised not stated, 300 included in analysis Excluded 29% chemonucleolysis and 14% surgery
888 880	Lee, 1996 ¹⁰⁴ (German language) (ij) ^a (PELD)	NR	CCS	6 weeks	Disappearance of back pain		100	29	¢.	100	16	~.	2.14 (4.08 to 4.26)	Number randomised not stated, 300 included in analysis Excluded 29% chemonucleolysis and 29% surgery
45	Postacchini, 1987 ⁴⁹	A + C	Non-RCT	1 month	Satisfactory outcome: good or excellent (vs unsuccessful: fair or poor)		84	52	0.03	72	õ	0.03	2.61) 2.61)	Data inferred from graphs. Five patients lost to follow-up were excluded. Patients who had surgery in chemonucleolysis group regarded as failure

							Interve	ntion		Control				
Ωġ	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	or (95% CI)	Comments
49	Stula, 1990 ⁵² (German language)	сı	RCT	Postoperative	Successful outcome: good (vs unsuccessful: unsatisfactory)	Physician	44	40	0.76	25	22	0.43	1.36 (0.28 to 6.65)	Nineteen patients in chemonucleolysis group received surgery and analysed as surgery group
672	Weinstein, 1986 ⁹²	C	CCS	< 6 weeks	Recovered within 2–6 weeks or immediate (vs no recovery, 5–12 weeks or 6–12 weeks)		63	0 8	0.11	85	61	0.03	0.64 (0.32 to 1.28)	Data presented as percentages
Disc s	urgery vs exerc	sise therapy												
300	Osterman, 2006 ⁶⁸	A	RCT	6 weeks	Reported full recovery	Patient	28	2	0.03	28	0	0	13.34 (0.70 to 253.89)	
Disc s	urgery vs intra	operative inte	rventions											
497	Glasser, 1993 ⁸² (j) ^b	S	RCT	1 month	Radicular pain: complete relief (vs partial or no relief)		2	Q	0.3	0	œ	0.25	0.31 (0.02 to 4.41)	
497	Glasser, 1993 ⁸² (ii) ^b	S	RCT	1 month	Radicular pain: complete relief (vs partial or no relief)		2	Ŋ	0.3	2	9	0.3	0.42 (0.03 to 6.06)	
379	Prestar, 1995″i (German Ianguage)	К	RCT	At discharge	Success: pain free, slight lumbar pain, slight radicular pain (vs failure: radicular pain considerably improved, complaint unchanged)		20	41	0.0	20	41	0.0	1.00 (0.36 to 2.77)	
2, uncl a Let me b Gla twid	ear; A, acute; AF ear; A, acute; AF et al. ¹⁰⁴ include ta-analysis (see sser et al. ⁸² inclu se, only the first (² LD, automated of three treatm. <i>Figure 2</i> . Juded three treat	d percutane ent groups: tment group nent groups	ous lumbar discec APLD (i), PELD (ii) s: surgery + corti have been incluc	thomy; C, chronic; A + C, and chemonucleolysis (costeroid and bupivicain ded in the meta-analysis	acute and chron iii). In order to pr e (i), surgery + br (see Figure 2).	iic; NR, n event usi upivicain	iot reported; C ing the same e (ii) and surg)R, odds ratio; PE comparator twice ery + no corticos;	EDL, pero e, only th teroid or	utaneous ma e first and th bupivicaine (i	tinual and laser d ird treatment gro iii). In order to pr	iscectomy. Jups have been in event using the se	cluded in the ame comparator

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 7 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

	rersion ^c		це це	u et	u e	om SE 55 ocation 69,				л Де
	Comment/conv		SD imputed fron weighted averag	SD imputed fron weighted averag	SD imputed fron weighted averac	SD estimated fr ITT not used Dropouts: 24/16 (15%), group all not stated plus further 11/141 (intervention = 7/72 control = 4/72				SD imputed fron weighted averag Data inferred fro graphs
	Mean difference (95% Cl) ^b		-19.00 (-30.70 to -7.30)	43.00 (-58.95 to -27.05)	0.0 (–3.52 to 9.52)	11.10 (0.79 to 21.41)		-13.00 (-25.45 to -0.55)		4.00 (-12.03 to 20.03)
je scores	Control									
Chanç (SD)	Intervention									
ean (SD)	Control		22 (25.48)	46 (25.48)	19 (25.48)	28.3 (27.21)		25 (27)		18 (37.61)
Final me	Intervention		3 (20.87)	3 (20.87)	19 (20.87)	39.4 (32.28)		12 (20)		22 (20.87)
le mean	Control		60	58	64	63.4 (24.6)		57 (21)		58
Baselir (SD)	Intervention		70	70	72	68.1 (21.6)		61 (20)		12
Ē	Control		51	15	46	68		28		26
Total	Intervention		19	19	46	62		28		35
	Scale (range) ^a		VAS (0-100)	VAS (0-100)	VAS (0-100)	VAS (0-100)		VAS (0-100)		VAS (0-10)
	Location		Leg	Leg	Leg	Leg		Leg		Leg
	Follow- up		6 weeks	6 weeks	6 weeks	1 month		6 weeks		14 days
	Study design		CCS	CCS	RCT	RCT		RCT	suc	RCT
	Chronicity	olysis	S	S	A+C	ĸ	rapy	A	re interventi	A+C
	Author, year	gery vs chemonucler	Brown, 1989 ⁷⁶ (j) ^d (chymopapain)	Brown, 1989 ⁷⁶ (ii) ^d (collagenase)	Muralikuttan, 1992 ⁸⁵	Revel, 1993 ⁸⁸	gery vs exercise ther	Osterman, 2006 ⁶⁸	gery vs intraoperativ	Debi, 2002 ⁷⁸
	ID no.	Disc sur	453	453	593	617	Disc sur	300	Disc sur	470

	Comment/conversion ^e	Median used as mean SD imputed from weighted average ITT using LOCF Dropouts 2/52 (4%): intraoperative 1/51, surgery 2/52	Pain scale 1–6 (also taking into account when patients had pain); six scores per patient combined into a single score (0–100) Dropouts 2/35 (6%): intervention = 1/23, control = 1/12	Data imputed from graph SD estimated from SE Small sample size ITT not used Dropouts 8%: intervention = 1/13, control = 1/13	continued
	Mean difference (95% Cl) ^b	0.00 (-11.78 to 11.78)	3.80 (–17.07 to 24.67)	5.00 (-3.24 to 13.24) Repeated measures analysis: between subjects – use of steroids p = 0.014; within subjects – time preoperative to 8 days postoperative p < 0.001; interaction between time and steroids p = 0.04	
scores	Control		-44.60 (29.7)		
Change (SD)	Intervention		-40.8 (30)		
an (SD)	Control	0 (37.61)	13.2 (18.8)	5 (4.5)	
Final me	Intervention	0 (20.87)	25 (28.2)	10 (13.86)	
mean	Control	80	57.8 (18.4)	54 (21.27)	
Baseline (SD)	Intervention	80	65.8 (16.7)	55 (11.54)	
(L)	Control	5	23	12	
Total	Intervention	52	12	12	
	Scale (range)ª	NRS (0-10)	Composite score (0–100)	VAS (0-100)	
	Location	Ceo	6a T	Overall	
	Follow- up	1 month	30 days	8 days	
	Study design	RCT	RCT	RCT	
	Chronicity	R	NA N	A + C	
	Author, year	Jirarattanaphochai, 2007 ¹⁰⁶	Kim, 2003 ⁷³	Langmayr, 1995 ⁸⁴	
	ID no.	606	400	551	

TABLE 7 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comment/conversion [€]	SD imputed from weighted average Mean inferred from graphs	SD estimated from IOR Dropouts 109 (27%): intervention = 57/199, control = 52/199		Data extracted from graphs. SD derived from SE	SD calculated from SE *Subgroup analysis of 64/145 (44%) patients who were given preoperative acupuncture IT not used 13/145 (9%) dropped out, group allocation not stated (intervention = 32/67), control = 32/65)
	Mean difference (95% Cl) ^b	5.00 (–8.52 to 18.52)	-2.00 (-7.10 to 3.10)		15.00 (2.61 to 27.39)	42.60 (32.36 to 52.84)
ge scores	Control					
Chan (SD)	Intervention					
ean (SD)	Control	9 (37.61)	22 (22)		6 (6.32)	29.8 (17.5)
Final m	Intervention	14 (20.87)	20 (22.2)		21 (26.83)	72.4 (23.8)
e mean	Control	54	78 (14.8)		66 (18.97)	71.5 (25.5)
Baselin (SD)	Intervention	48	75 (14.8)		70 (13.42)	75.9 (23.2)
<i>(u</i>)	Control	38	147		10	32
Total	Intervention	42	142		20	32
	Scale (range) ^a	VAS (0-100)	VAS (0-10)		VAS (0-100)	VAS (010)
	Location	Overall	Leg		Overall	6e1
	Follow- up	6 weeks	1 month		6 weeks	3 days
	Study design	RCT	RCT		RCT	RCT
	Chronicity	S	NR	ents	S	O
	5	99	88	d treatm	-	-
	Author, year	Lundin, 2003	Richter, 2001	gery vs mixeu	Starkweather, 2006 ⁹³ (surgery + nor opioids)	Wang, 2000 ⁶ (surgery + alternative)
	ID no.	276	618	Disc sur	705	263

	e Comment/conversion ^c		SD estimated from SE ITT based on LOCF used, but two patients lost to follow-up early on excluded (intervention = 1, control = 1)	re comparator twice, only incture and half had
	Mean difference (95% Cl)⁵		-15.70 (-20.98 to -10.42) Repeated measures analysis, difference between groups: 15.7 (95% Cl 11.7 to 19.7)	revent using the sam
ange scores)	Control). In order to pr :o two: half had
S CP	Intervention			n. Jery (iii
ean (SD)	Control		44.2 (22.64)	ard deviation nd disc surg up was divic
Final m	Intervention		28.5 (22.56)	;; SD, stand jenase (ii) a vention gro
ne mean	Control		64.4 (21.2)	rating scale ss. using collaç . Each inter
Baseli (SD)	Intervention		67.2 (27.7)	numerical udy in italic up. nucleolysis lisc surgery alyses.
Ξ	Control		141	NRS, by sti llow-u nemor nemor nemor ur ana
Total	Intervention		140	t reported; s reported s lost to fo apain (i), ch apuncture sluded in o
	Scale (range) ^a		VAS (0-100)	ard; NR, no ores); result and patient ng chymops see <i>Figure</i> 3 placebo acu ure were int
	Location		бөл	carried forw lility. - change sc exclusions exclusions usi eleolysis usi 1- analysis (a- acupuncti
	Follow- up		2 weeks	st observation (of comparate prence given to post-baseline post-baseline post-baseline post-baseline the met ded in the met true plus disc su ed preoperativ
	Study design		RCT	inic; LOCF, las alle of 0–101 (with a prefi missing data eatment grou e been inclu of acupuncti s who receiv
	Chronicity		A	the and chrouted to a scenes ange scores en used for inded three trued the used the used three trued the use only patient
	Author, year	urgery vs usual care	Peul, 2007 ⁸⁷	e; C, chronic; A + C, acuresults have been convertes ut the analysis of the convertes of
	ID no.	Disc s	606	A, acut a The b Bas c The c The d Brov the e War post

ID no.	Author, year	Study design		WMD (95% CI)	% weight
Mixed tr	reatments				
263	Wang, 200063	RCT	-	42.60 (32.36 to 52.84)	50.83
705	Starkweather, 200693	RCT		15.00 (2.61 to 27.39)	49.17
Subtotal	(<i>I</i> ² = 91.2%, <i>p</i> = 0.001)			29.03 (1.99 to 56.07)	100.00
Intraope	erative interventions				
276	Lundin, 200366	RCT		5.00 (-8.52 to 18.52)	7.59
400	Kim, 2003 ⁷³	RCT		3.80 (-17.07 to 24.67)	3.19
470	Debi, 2002 ⁷⁸	RCT		4.00 (-12.02 to 20.02)	5.40
551	Langmayr, 199584	RCT		5.00 (-3.24 to 13.24)	20.41
618	Richter, 2001 ⁸⁹	RCT		-2.00 (-7.10 to 3.10)	53.41
909	Jirarattanaphochai, 2007106	RCT		0.00 (-11.78 to 11.78)	10.00
Subtotal	$(l^2 = 0.0\%, p = 0.735)$		\diamond	0.67 (-3.06 to 4.39)	100.00
Active P	T/exercise therapy				
300	Osterman, 200668	RCT		-13.00 (-25.45 to -0.55)	100.00
Chemor	nucleolysis				
453	Brown, 1989 ⁷⁶	CCS		–19.00 (–30.70 to –7.30)	32.27
593	Muralikuttan, 199285	RCT	_ _	0.00 (-9.52 to 9.52)	34.21
617	Revel, 1993 ⁸⁸	RCT		11.10 (0.79 to 21.41)	33.52
Subtotal	(<i>l</i> ² = 86.1%, <i>p</i> = 0.001)			-2.41 (-18.65 to 13.83)	100.00
Usual/co	onventional care				
606	Peul, 2007 ⁸⁷	RCT	•	-15.70 (-20.98 to -10.42)	100.00
				56 1	
		Favo	urs surgery Favours contr	ol	

FIGURE 3 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for trials and observational studies comparing disc surgery with alternative interventions. PT, physical therapy. Note: weights are from random effects analysis.

whereas the other⁸⁸ included patients who had had previous surgery and also included a high proportion of men.

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 8* and the accompanying forest plot (*Figure 4*). Disc surgery was compared with usual care, exercise therapy, intraoperative interventions and chemonucleolysis. Most studies included patients with chronic sciatica.

One well-conducted RCT⁸⁷ compared early surgical intervention with conservative care in patients with severe sciatica for 6–12 weeks. Conservative care included exercise, pain medication and conservative treatment by their GP (or neurologist where necessary). Functional improvement was marginally, but statistically significantly, higher in patients in the conservative or usual care group than in those who received early surgery at 2 weeks. The findings reported by the authors based on repeated-measures analyses showed that patients in the control group had a greater improvement in functional status at 2 weeks (difference between groups for mean

TABLE 8 Summary of the findings of CSOMs at short-term follow-up for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered

by aut	nor)														
						Total ((L	Baseline n (SD)	nean	Final mea	n (SD)	Change s (SD)	cores		
e ë	Author, year	Chronicity	Study design	Follow- up	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ⁵	Comment/conversion ^c
Disc	surgery vs chen	nonucleolysis													
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	6 weeks	Part of Waddell Disability Index	46	46	6.7	6.2	2.8 (1.21)	3.5 (1.21)	3.9	-2.7	-0.58 (-1.00 to -0.16)	SD for final means calculated from <i>p</i> -values (Mann–Whitney <i>U</i> -test); most outcomes showed skewed distribution
617	Revel, 1993 ⁸⁸	R	RCT	1 month	Waddell Disability Index and Main Scale	62	69	6 (2.55)	4.9 (2.49)	1.5 (3.15)	1.5 (1.21)	-1.05	-3.4	0.00 (-0.34 to 0.34)	SD derived from SE Dropouts: $24/165$ (15%), group allocation not stated plus further 7/141 (5%); intervention = 7/69, control = 3/72
Disc	surgery vs exeru	cise therapy													
300	Osterman, 2006 ⁶⁸	A+C	RCT	6 weeks	ICIO	28	28	39 (15)	39 (14)	16 (16)	22 (16)	-23	-17	-0.38 (-0.90 to 0.15)	ITT (LOCF), but one patient who did not meet inclusion criteria was excluded from analysis
Disc	surgery vs intra	operative inte	rventions												
400	Kim, 2003 ⁷³	NR	RCT	30 days	Composite scale	12	23	52.3 (22.7)	46.9 (21.3)	32.8 (22.2)	19.7 (20.5)	-19.4 (25.2)	-27.2 (26)	0.62 (-0.09 to 1.34)	
															continued

dered	
en or	
tor th	
ıpara	
y con	
d bed	
group	
ions (
ervent	
e inte	
rnativ	
h alte	
ry wit	
surge	
disc	
aring	
comp	
Idies	
for stu	
v-up f	
follov	
-term	
short	
ds at	
csol	
gs of	
findin	
f the	
o vary o ∋d)	
Sumr ntinu€	
LE 8 (
TABL authc	

	Comment/conversion⁰	ITT not used Dropouts 6 (7%): intervention = 0/42, control = 6/42	SD calculated from weighted average SD for FFbH-R from long-term follow-up disc surgery studies ITT not used Dropouts 109 (27%): intervention = 52/199, control = 57/199		SD derived from SE
	Mean difference (95% Cl) ^b	1.12 (0.64 to 1.60)	-0.06 (-0.27 to 0.15)		0.24 (0.00 to 0.47) –1.6 (95% Cl –2.8 to –0.3), repeated- measures analysis of variance based on final means
scores	Control				က ကို
Change ((SD)	Intervention				-2.1
an (SD)	Control	7.3 (0.12)	28.7 (22.48)		13 (5.96)
Final me	Intervention	7.44 (0.13)	27.3 (22.48)		14.4 (5.92)
le mean	Control		49		16.3 (3.9)
Baselin (SD)	Intervention		20		16.5 (4.4)
(L)	Control	42	180		141
Total	Intervention	33	177		140
	Scale (range)ª	Scale based on analgesic use, functional status, hospital stay and return to work interval (max score 8)	FF bH-R		RMDQ
	Follow- up	6 weeks	1 month		2 weeks
	Study design	Q-RCT	RCT	al care	RCT
	Chronicity	A + C	К	al/convention&	٩
	Author, year	1992 ⁷⁰	Richter, 2001 ⁸⁹	rgery vs usua	Peul, 2007 ⁸⁷
	<u> </u>	366	618	Disc su	606

A, acute; C, chronic; A + C, acute and chronic; FFbH-R, Hanover functional ability questionnaire (Funktionsgragebogen Hannover); LOCF, last observation carried forward; NR, not reported; SD, standard deviation. a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores); results reported by study in italics. c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ð

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Active I	PT/exercise therapy						
300	Osterman, 200668	RCT		+		-0.38 (-0.90 to 0.15)	100.00
Chemo	nucleolysis						
593	Muralikuttan, 1992 ⁸⁵	RCT				–0.58 (–1.00 to –0.16)	47.80
617	Revel, 1993 ⁸⁸	RCT		-		0.00 (-0.34 to 0.34)	52.20
Subtota	l (<i>l</i> ² = 77.3%, <i>p</i> = 0.036)			\geq		-0.28 (-0.84 to 0.29)	100.00
Intraop	erative interventions						
400	Kim, 2003 ⁷³	RCT	-			0.62 (-0.09 to 1.34)	29.59
366	Lavyne, 199270	Q-RCT			\rightarrow	1.12 (0.64 to 1.60)	33.55
618	Richter, 2001 ⁸⁹	RCT		<u> </u>		-0.06 (-0.27 to 0.15)	36.86
Subtota	l (<i>l</i> ² = 90.7%, <i>p</i> = 0.000)					0.54 (-0.30 to 1.37)	100.00
Usual/c	onventional care						
606	Peul, 2007 ⁸⁷	RCT				0.24 (0.00 to 0.47)	100.00
		-1.6	(0	1.6		
			Favours surgery	Favours control			

FIGURE 4 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for trials comparing disc surgery with alternative interventions (grouped by comparator then ordered by author). PT, physical therapy. Note: weights are from random effects analysis.

RMDQ: -1.6; 95% CI -2.8 to -0.3), which then reversed to show a greater improvement among patients treated with surgery at 8 weeks (difference between groups for mean RMDQ 3.1; 95% CI 1.7 to 4.3). Mean scores plotted over time showed that the curves crossed at 4 weeks.

One well-conducted RCT⁶⁸ found disc surgery plus exercise therapy to be superior to exercise therapy alone for acute sciatica due to an intervertebral disc extrusion or sequester, but the findings were not statistically significant.

Three studies^{70,73,89} compared disc surgery with intraoperative interventions, for which the overall findings showed a greater improvement in functional status associated with disc surgery at 4–6 weeks, but the difference between the treatment groups was not statistically significant. The findings were heterogeneous. One study⁷⁰ included patients with either chronic or acute sciatica, but the chronicity of sciatica was not reported in the remaining two studies.^{73,89} Two studies^{73,89} were RCTs of moderate quality with adequate randomisation and allocation concealment, and the remaining study was a Q-RCT.⁷⁰

Two moderate quality RCTs^{85,88} compared disc surgery with chemonucleolysis. Pooled analysis showed a non-statistically significant difference between the intervention groups in favour of disc surgery.

Disc surgery results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 9* and the accompanying forest plot (*Figure 5*). Disc surgery was compared with usual care, non-opioids

TABLE 9 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

	Comments		Data reported as percentages	Data reported as percentages		Data reported as percentages	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 14%	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 29%
	OR (95% Cl)ª		5.13 (1.33 to 19.78)	3.56 (0.71 to 17.76)	0.77 (0.34 to 1.75)	3.58 (2.56 to 5.01)	1.73 to 2.39) (1.73 to 2.39)	0.21 (0.09 to 0.49)
	Withdrawal rate		0	0	0	0	<i>c</i>	<i>∽</i> .
_	Outcome (<i>n</i>)		26	J	88	238	29	29
Contro	Total (<i>n</i>)		51	15	100	334	100	100
	Withdrawal rate		0	0	0	0	¢.	<i>~</i>
ention	Outcome (<i>n</i>)		16	16	85	675	35	ω
Interv	Total (<i>n</i>)		19	19	100	751	100	100
	Perspective				Patient	Patient and physician		
	Outcome measure		Overall improvement: excellent or good (vs fair, poor or failed)	Overall improvement: excellent or good (vs fair, poor or failed)	Successful outcome: good or excellent (vs slight or no improvement)	MacNab criteria: excellent or good (vs mediocre, failure)	Disappearance of back pain	Disappearance of back pain
	Follow-up		3 months	3 months	6 months	2 months	2 months	2 months
	Study design		ccs	CCS	CCS	CCS	CCS	CCS
	Chronicity	cleolysis	C	O	C	O	RN	NN
	Author, year	gery vs chemonu	Brown, 1989 ⁷⁶ (j) ^b (chymopapain)	Brown, 1989 ⁷⁶ (ii) ^b (collagenase)	Javid, 1995 ⁴⁸	Lagarrigue, 1991 ⁵⁴ (French language)	Lee, 1996 ¹⁰⁴ (German language) (ĵ)⁰ (APLD)	Lee, 1996¹⁰₄ (German language) (ii)⁰ (PELD)
	D no.	Disc sur	453	453	44	117	889	889

DOI: 10.3310/hta15390		

	Comments	Data inferred from graphs. Five lost to follow-up were excluded. Patients who had surgery in chemonucleolysis group regarded as failure	ITT not used. 24/165 patients dropped out at beginning, group allocation not stated	Data reported as percentages	Data reported as percentages				continued
	0R (95% Cl)ª	1.41 (0.69 to 2.90)	0.49 (0.25 to 0.96)	4.13 (1.47 to 11.56)	1.05 (0.43 to 2.53)		1.30 (0.31 to 5.47)	0.15 (0.02 to 1.30)	
	Withdrawal rate	0.03	~	0.0	0.03		0	0.11	
-	Outcome (<i>n</i>)	51	44	32	71		4	24	
Contro	Total (<i>n</i>)	72	72	50	85		28	25	
	Withdrawal rate	0.03	<i>c.</i>	0.0	0.11		0.03	0.18	
ention	Outcome (<i>n</i>)	<u>.</u>	30	44	23		ъ	25	
Interv	Total (<i>n</i>)	84	69	50	63		28	32	
	Perspective		Patient	Physician			Patient		
	Outcome measure	Successful outcome: excellent or good (vs fair or poor)	Treatment success: good or very good (vs none or moderate)	Success of surgical results: excellent or good (vs fair or poor)	Recovered within 6–12 weeks, 2–6 weeks or immediate (vs no recovery or >12 weeks)		Reported full recovery	Recovery improvement (vs failure) according to change in VAS and muscle strength	
	Follow-up	3 months	6 months	Mean 46 days	3–6 months		6 months	6 months	
	Study design	Non-RCT	RCT	Non- RCT	CCS		RCT	CCS	
	Chronicity	A + C	N	A+C	C	therapy	∀ (}	٨	
	Author, year	Postacchini, 1987 ⁴⁹	Revel, 1993 ⁸⁸	Watters,1988 ¹⁰⁵	Weinstein, 1986 ²²	gery vs exercise i	Osterman, 2006 [®] gery vs non-opiol	Dubourg, 2002 ⁶⁰	
	D no.	45	617	893	672	Disc su	300 Disc sur	475	

TABLE 9 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

							Interv	rention		Contro	_			
D no.	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% Cl)ª	Comments
144	Rossi, 1993⁵7 (Italian language)	U	RCT	6 months		Patient	~	68%	с.	~	55%	с.		Data reported as percentages; 40 patients included, but not stated how many were in each group. The study included three intervention groups, but all surgery patients (two groups) were compared with conservative treatment
Disc su	gery vs usual care.													
294	Koranda, 1995 ⁶⁷ (Czech language)	O	Q-RCT	3 months	Effective results: excellent, very good, good (vs satisfactory, poor or worse)	Patient	54	42	0.0	46	27	0.0	2.46 (1.03 to 5.88)	Duration of follow-up not clear; both groups had 3 months' conservative group received surgery. Patients in control group who required surgery were classified as treatment failure. 28 patients in surgery group did not receive surgery as they got better during the conservative therapy period

			ited as 5. ITT reported kert	change cea uups 3/222 oup o chose gery and gery and gery and alysis atment atment tion
		Comments	Data presen percentages using LOCF for mean Lih score	Only mean percentage and differen between grc reported. 15 patients who to be in non operative gr to be in surg group did ne surgery. An based on tre received not group did ne surgery. An agroup did ne agroup did
		OR (95% Cl)ª	1.38 (0.81 to 2.37) Repeated measurements analysis adjusting for baseline values: 6.6% (95% CI -3.7% to 17.0%)	Treatment effect 11.3% (95% CI 1.6% to 20.9%)
		Withdrawal rate	0.01	0.18
		Outcome (<i>n</i>)	100	Change: 43% (SE 3.4)
	Contro	Total (<i>n</i>)	141	211
		Withdrawal rate	0.01	0.19
	ention	Outcome (<i>n</i>)	108	Change: 54% (SE 3.5) 3.5)
	Total (<i>n</i>)		140	198
		Perspective	Patient	Patient
		Outcome measure	Satisfaction with recovery: 'complete' or 'nearly recovery complete' on a seven-point Likert scale (other 5 scores = unsatisfactory recovery)	Satisfaction with current symptoms: very/somewhat satisfied
		Follow-up	26 weeks	3 months
		Study design	RCT	SC
		Chronicity	ح	A + C
		Author, year	Peul, 2007 ⁸⁷	Weinstein, 2006 [%] (a)
		D no.	606	750

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

continued

TABLE 9 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

	Comments	Only mean percentage change and difference between groups reported 472/501 included in ITT analysis using LOCF and longitudinal regression models Crossovers: intervention 117/232 (50%), control 71/240 (30%)
	0R (95% CI)ª	Treatment effect 38.7% (95% Cl 30.0% to 47.7%)
	Withdrawal rate	0.14
-	Outcome (<i>n</i>)	Change: 29% (SE 3.7)
Contro	Total (<i>n</i>)	190
	Withdrawal rate	0.11
/ention	Outcome (<i>n</i>)	Change: 68% (SE 2.3)
Interv	Total (<i>n</i>)	466
	Perspective	Patient
	Outcome measure	Satisfaction with current symptoms: very/somewhat satisfied
	Follow-up	3 months
	Study design	RCT
	Chronicity	A + C
	Author, year	Weinstein, 2006 ⁹⁹ (b)
	ID no.	751

2, unclear, A, acute; A + C, acute and chronic; APLD, automated percutaneous lumbar discectomy; C, chronic; LOCF, last observation carried forward; NR, not reported; OR, odds ratio; PELD, percutaneous manual and laser discectomy.

a Results reported by study in italics.

Brown and Tompkins⁷⁶ included three treatment groups: chemonucleolysis using chymopapain (i), chemonucleolysis using collagenase (ii) and disc surgery (iii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the meta-analysis (see Figure 5). q

c Lee et al.¹⁰⁴ included three treatment groups: APLD (i), PELD (ii) and chemonucleolysis (iii), In order to prevent using the same comparator twice, only the last two treatment groups have been included in the metaanalysis (see Figure 5).

ID no.	Author, year	Study design				OR (95% CI)	% weight
Active	PT/exercise therapy						
300	Osterman, 200668	RCT				1.30 (0.31 to 5.47)	100.00
Chemo	nucleolysis						
453	Brown, 1989 ⁷⁶	CCS		-	•	5.13 (1.33 to 19.78)	8.98
44	Javid, 1995 ⁴⁸	CCS		-	_	0.77 (0.34 to 1.75)	12.44
117	Lagarrigue, 199154	CCS				3.58 (2.56 to 5.01)	15.26
889	Lee, 1996 ¹⁰⁴	CCS				1.32 (0.73 to 2.39)	13.88
45	Postacchini, 198749	Non-RCT				1.41 (0.69 to 2.90)	13.08
617	Revel, 1993 ⁸⁸	RCT				0.49 (0.25 to 0.96)	13.40
893	Watters, 1988105	Non-RCT				4.13 (1.47 to 11.56)	10.99
672	Weinstein, 198692	CCS				1.05 (0.43 to 2.53)	11.97
Subtota	ll ($l^2 = 83.4\%$, $p = 0.000$))		<	>	1.58 (0.86 to 2.91)	100.00
Non-op	ioids						
475	Dubourg, 2002 ⁸⁰	CCS	•			0.15 (0.02 to 1.30)	100.00
Usual/c	conventional care						
294	Koranda, 199567	Q-RCT			•	2.46 (1.03 to 5.88)	31.66
606	Peul, 2007 ⁸⁷	RCT		-+•	-	1.38 (0.81 to 2.37)	68.34
Subtota	ll (l ² = 18.3%, p = 0.269	9)		<	>	1.66 (0.98 to 2.81)	100.00
			0.017	1		58.8	
			Favours co	ontrol	Favours surgery		

FIGURE 5 Summary of the findings of global effect at medium-term follow-up (>6 weeks to \leq 6months) for studies comparing disc surgery with alternative interventions. PT, physical therapy. Note: weights are from random effects analysis.

and chemonucleolysis. One further study⁶⁸ compared disc surgery plus exercise therapy with exercise therapy alone for patients with acute sciatica due to an intervertebral disc extrusion or sequestered disc. Duration of follow-up ranged from 2 to 3 months.

Four studies^{67,87,98,99} showed that disc surgery was superior to conservative treatment or usual care, but the meta-analysis of two studies^{67,87} was not statistically significant. One was a well-conducted RCT⁸⁷ that included patients with acute sciatica and the other was a poorly reported and conducted Q-RCT⁶⁷ that included patients with chronic sciatica. The remaining two studies^{98,99} could not be included in the meta-analysis because they only reported the percentage change and difference between groups. One was an RCT [the Spine Patient Outcomes Research Trial (SPORT)]⁹⁹ and the other a parallel observational cohort study. Both included patients with acute or chronic sciatica. The RCT was well conducted and rated strong for external validity, but recruitment rates were poor and may have been affected by the fact that all patients had already tried non-operative treatment for 6 weeks. Adherence to treatment protocols was also low, with 71/240 (30%) patients in the usual care group having had surgery at 3 months (44 patients at 6 weeks) and only 115/232 (50%) patients in the surgery group having undergone surgery during the same interval (74 patients at 6 weeks). The analyses in both studies were adjusted for a number of covariates including missing data. Both studies reported statistically significant findings in favour of disc surgery.
According to a well-conducted RCT,⁶⁸ there was no real difference between disc surgery plus exercise therapy and exercise therapy alone in terms of reported full recovery at 6 months in patients with acute sciatica.

One poorly reported CCS⁸⁰ found non-opioids to be more effective than disc surgery for recovery or improvement in patients with acute sciatica, but the findings were not statically significant. A second poorly conducted study⁵⁷ found that more patients in the surgery group were satisfied with cure than those in the non-opioids group, but results were only reported as percentages without stating how many patients were in each group.

Eight studies^{48,49,54,76,88,92,104,105} compared disc surgery with chemonucleolysis, for which there was no overall difference between the groups. Only one of these studies was an RCT,⁸⁸ of moderate quality, which found chemonucleolysis more effective than disc surgery. However, the withdrawal rate in the surgery group (at least 41%) was much greater than that of the chemonucleolysis group (at least 19%), with dropouts being given a poor outcome in the analysis. The duration, or chronicity of sciatica was not stated. The results and methods of the remaining studies were generally poorly reported. The funnel plot (*Figure 6*), for publication and other biases, does not appear to show asymmetry, but does not include many studies and demonstrates a lack of large studies.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 10* and the accompanying forest plot (*Figure 7*). Disc surgery was compared with usual care, non-opioids, exercise therapy, epidurals, chemonucleolysis and intraoperative interventions.

One well-conducted RCT⁸⁷ showed that early surgical intervention, compared with usual care, resulted in a statistically significantly greater reduction in pain intensity in patients with severe sciatica for 6-12 weeks. However, the size of the effect, or reduction in pain, at 6 months was less than that at 2 weeks (WMD -6.10; 95% CI -11.38 to -0.82).



FIGURE 6 Funnel plot with pseudo 95% CIs for studies comparing disc surgery with chemonucleolysis at medium-term follow-up (>6 weeks to \leq 6months).

continued

							Total (<i>n</i>		Baseline n (SD)	nean	Final mea	ın (SD)	Change s (SD)	cores		
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	Comment/ conversion [€]
Disc 5	surgery vs chemonuc	leolysis														
453	Brown, 1989 ⁷⁶ (j) ^d (chymopapain)	S	CCS	12 weeks	Leg	VAS (0-100)	19	51	02	60	4 (24.43)	14 (23.76)			–10.0 (–22.77 to 2.77)	SD imputed from weighted average
453	Brown, 1989 ⁷⁶ (ii) ^d (collagenase)	C	CCS	12 weeks	Leg	VAS (0-100)	19	15	20	58	4 (24.43)	22 (23.76)			–18.0 (–34.29 to –1.71)	SD imputed from weighted average
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	3 months	Leg	VAS (0-100)	46	46	72	64	14 (24.43)	20 (23.76)			—6.00 (15.85 to 3.85)	SD imputed from weighted average Most outcomes showed skewed distribution
617	Revel, 1993 [®]	NR	RCT	6 months	Ceg	VAS (0-100)	69	72	68.1 (21.6)	63.4 (24.61)	35.6 (34.89)	17.6 (23.76)		_	18.00 (8.11 to 27.89)	SD estimated from SE 24 patients excluded from analysis, group allocation not stated

TABLE 10 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

										_
	Comment/ conversionଂ		No data reported							Dropouts 7/67 (10%): intervention 4/39, control 3/28
	Mean difference (95% Cl) ^b		Significant less pain experienced by surgery group at 1–3 months' and 4–6 months' follow-up: p < 0.0001 and $p = 0.03$ respectively, Student's t-test		-9.00 (-22.05 to 4.05)		16.60 (4.13 to 29.07)	16.70 (3.88 to 29.52)		-1.60 (-11.39 to 8.19)
le scores	Control									
Chang (SD)	Intervention									
ean (SD)	Control				18 (29)		11.6 (12.4)	11.5 (14.4)		14.8 (20.6)
Final m	Intervention				9 (20)		28.2 (26.7)	28.2 (26.7)		13.2 (18.8)
e mean	Control				57 (21)		54.2 (15)	53 (13.4)		47.7 (34)
Baselin (SD)	Intervention				61 (20)		55.5 (14.3)	55.5 (14.3)		52.2 (28.5)
<i>(u)</i>	Control				28		19	20		28
Total	Intervention				28		22	22		36
	Scale (range) ^a		VAS (0-10)		VAS (0-100)		VAS (0-10)	VAS (0-10)		VAS (0-100)
	Location		6 0 - 1		Leg		Leg	Leg		Overall
	Follow-up		4-6 months		6 months		2 months	2 months		6 months
	Study design	ction	RCT		RCT	ions	Q-RCT	Q-RCT		CCS
	Chronicity	intradiscal inje	O	therapy	A	ative intervent	NR	RN	ids	A
	Author, year	irgery vs epidural/i	Buttermann, 2004 ^{ss}	irgery vs exercise	Osterman, 2006 ⁶⁸	ırgery vs intraoper.	Aminmansour, 2006 ⁶⁴ (i) ^e (40 mg dexamethasone)	Aminmansour, 2006 ⁶⁴ (ii) ^e (80 mg dexamethasone)	irgery vs non-opioi	Dubourg, 2002 ⁸⁰
	<u>ם</u> ë	Disc su	725	Disc su	300	Disc st	268	268	Disc su	475

							Total (<i>n</i>)		Baseline m (SD)	ıean	Final mea	n (SD)	Change ((SD)	scores		
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	Comment/ conversion ^e
606	Jirarattanaphochai, 2007 ¹⁰⁸	R	RCT	3 months	бөЛ	(0-10)	22	2	08	8	0 (24.43)	0 (19.98)		4.80	0.0 (-8.61 to 8.61)	Median used as mean SD imputed from weighted average ITT using LOCF Dropouts 2/52 (4%): intraoperative 1/51, surgery 2/52
400	Kim, 2003 ⁷³	Ř	RCT	6 months	Гед	Composite scale (0-100)	E	5	(16.7) ((16.7)	57.8 (18.4)	(29.4)	(16)	-44.2 (32.5)	-40.9 (27.8)	4.80 (13.82 to 23.42)	Pain scale 1–6 (also taking into account when patients had pain); six scores per patient combined into a single score (0–100) Change scores used for the meta-analysis. Dropouts 2/35 (6%): intervention 1/23, control 1/12
																continued

Health Technology Assessment 2011; Vol. 15: No. 39

TABLE 10 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comment/ conversion ^c	SD imputed from weighted average Small sample size Dropouts 8%: intervention 1/13, control 1/13	SD imputed from weighted average Mean inferred from graphs	Median used to represent mean SD imputed from weighted average Three separate pain measures using NRS (0–10) combined: pain now, worst, and average pain in the last 2 weeks, for back and leg pain separately
	Mean difference (95% Cl) ^b	1.00 (-16.86 to 18.86) Repeated- measures analysis: between subjects - use of steroids p = 0.014; within subjects - time preoperative to 8 days postoperative p < 0.001; interaction between time and steroids p = 0.04	2.00 (–7.74 to 11.74)	20.0 (13.81 to 26.19)
nge scores	Control			
Chai (SD)	Intervention			
lean (SD)	Control	4 (19.98)	8 (19.98)	23.3 (19.98)
Final m	Intervention	5 (24.43)	10 (24.43)	43.3 (24.43)
le mean	Control	54 (21.27)	54	20
Baselir (SD)	Intervention	55 (11.54)	48	68.3
(<i>u</i>)	Control	12	38	100
Total	Intervention	12	42	100
	Scale (range) ^a	VAS (0-100)	VAS (0-100)	Composite NRS (0-30)
	Location	Overall	Overall	D L
	Follow-up	6 months	26 weeks	2 months
	Study design	RCT	RCT	RCT
	Chronicity	A + C	O	Ϋ́Ν
	Author, year	Langmayr, 1995 ⁸⁴	Lundin, 2003 ⁶⁶	Rasmussen, 2008 ¹⁰¹
	e ë	551	276	854

		om %): 199,		<u>را</u>
	Comment/ conversionଂ	SD estimated fre IQR ITT not used Dropouts 42 (11 intervention 23/ control 19/199	SD estimated fro SE ITT based on LOCF used, but two patients lost to follow-up early on exclude (intervention = 1)	nparator twice, or ed water (iii). In
	Mean difference (95% Cl) ^b	3.00 (8.77 to 2.77)	-6.10 (-11.38 to -0.82) Repeated measures analysis, difference between groups: 6.1 (95% Cl 2.2 to 10.0)	ant using the same constration with i.v. distille
ange scores)	Control			In order to preve) and open fene
<u>ତ</u> ।	Intervention			ery (iii). Isone (i
lean (SD)	Control	23 (29.6)	14.5 (22.64	d deviation disc surg
Final n	Intervention	20 (25.9)	8.4 (22.56)	D, standar ase (ii) anc i.v. 80 mg
e mean	Control	78 (14.8)	64.4 (21.2)	ng scale; S ng collagen ration with nalysis (see
Baselin (SD)	Intervention	75 (14.8)	67.2 (27.7)	nerical rati in italics. solysis usir pen fenest
(u	Control	180	141	RS, nun ' study w-up. nonucle io (i), ol
Total (Intervention	176	140	ported; NI eported by ost to follo in (i), cher amethasor een incluc
	Scale (range) ^a	VAS (0-10)	VAS (0-100)	d; NR, not re es); results n nd patients lo i chymopapa e <i>Figure 7</i>). <i>i</i> . 40 mg dexi roups have b
	Location	Leg	6e1	carried forwar bility. change scor e exclusions a cleolysis using a-analysis (se stration with i.v
	Follow-up	6 months	26 weeks	st observation of or compara erence given tr post-baseline ups: chemonu ded in the met only the last tw
	Study design	RCT	RCT	ic; LOCF, la: ale of 0–10 (with a prefi inissing data nissing data atment grou thent grou thent grou ator twice, c
	Chronicity	R	A A	chronic; C, chror converted to a sc r change scores s been used for r included three tre nent groups have roluded three tres he same compar
	luthor, year	Richter, 2001 ⁸⁹	gery vs usual cå eul, 2007 ⁸⁷	A+C, acute and esults have been i on final means c erm 'dropouts' ha n and Tompkins ⁷⁶ st and third treatr mansour <i>et al.</i> ⁶⁴ ir to prevent using t
	⊡ ë	618 F	UISC SUIT 606 F	A, acute; A, acute; b Basec c The tt d Browr the fir e Aminr e Aminr

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Active	PT/exercise therapy					
300	Osterman, 200668	RCT	•		-9.00 (-22.05 to 4.05)	100.00
Chemo	nucleolysis					
453	Brown, 1989 ⁷⁶	CCS	•		-10.00 (-22.77 to 2.77)	31.79
593	Muralikuttan, 1992 ⁸⁵	RCT			-6.00 (-15.85 to 3.85)	34.12
617	Revel, 1993 ⁸⁸	RCT			18.00 (8.11 to 27.89)	34.09
Subtota	l (l ² = 87.5%, p = 0.000)				0.91 (-16.64 to 18.45)	100.00
Intraop	erative interventions					
268	Aminmansour, 200664	Q-RCT		\longrightarrow	16.70 (3.88 to 29.52)	13.68
909	Jirarattanaphochai, 2007106	RCT			0.00 (-8.61 to 8.61)	16.20
400	Kim, 2003 ⁷³	RCT ·			-3.30 (-25.75 to 19.15)	8.62
551	Langmayr, 1995 ⁸⁴	RCT			1.00 (-16.86 to 18.86)	10.80
276	Lundin, 200366	RCT			2.00 (-7.74 to 11.74)	15.54
854	Rasmussen, 2008 ¹⁰¹	RCT			20.00 (13.81 to 26.19)	17.48
618	Richter, 2001 ⁸⁹	RCT			-3.00 (-8.77 to 2.77)	17.68
Subtota	l (l ² = 82.9%, p = 0.000)		<		5.38 (-3.52 to 14.29)	100.00
Non-op	ioids					
475	Dubourg, 2002 ⁸⁰	CCS	+		-1.60 (-11.39 to 8.19)	100.00
Usual/c	conventional care					
606	Peul, 2007 ⁸⁷	RCT			-6.10 (-11.38 to -0.82)	100.00
		-29.5]29	5	
		20.0	avours surgery	Favours control	-	

FIGURE 7 Summary of the findings of pain at medium-term follow-up (>6 weeks to \leq 6months) for studies comparing disc surgery with alternative interventions. PT, physical therapy. Note: weights are from random effects analysis.

One poorly reported CCS⁸⁰ found no important difference between disc surgery and non-opioids in reduction in pain intensity at 6 months.

As with the global effect, one well-conducted RCT⁶⁸ found non-statistically significant findings in favour of disc surgery plus exercise therapy, compared with exercise therapy alone, in patients with acute sciatica at 6 months' follow-up.

One poorly reported RCT⁹⁵ compared the use of epidurals with disc surgery in patients with chronic sciatica [mean 3.55 months, standard deviation (SD) 2.75 months], and found that patients in the disc surgery group experienced significant less leg pain at 1–3 months' and 4–6 months' follow-up than those in the control group (p<0.0001 and p=0.03 respectively; Student's *t*-test). The methods of randomisation and allocation concealment were not reported.

Six RCTs^{66,73,84,89,101,106} and one Q-RCT⁶⁴ compared surgery with intraoperative interventions and found no overall statistically significant difference between treatment groups. The results were heterogeneous, with two studies^{64,101} reporting statistically significant findings in favour of intraoperative interventions. One study⁸⁴ included patients with acute and chronic sciatica

(median symptom duration 35 days, range 14–150 days) and one⁶⁶ included patients with chronic sciatica (mean 4.5 months); duration of symptoms was not stated in the remaining studies. Duration of follow-up ranged from 2 months to 6 months. Four studies^{73,89,101,106} were of moderate to good quality, with adequate randomisation in all four and allocation concealment in two.^{73,89}

As with pain at short-term follow-up, these studies compared disc surgery with chemonucleolysis; two were RCTs^{85,88} and one was a CCS.⁷⁶ Overall, there was no statistically significant difference between the intervention groups, but again the results were heterogeneous, with one study⁸⁸ showing statistically significant findings in favour of chemonucleolysis. This study included patients who had had previous surgery and also included a high proportion of men.

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 11* and the accompanying forest plot (*Figure 8*). Disc surgery was compared with usual care, exercise therapy, epidural, intraoperative interventions and chemonucleolysis.

Four studies^{72,87,98,99} compared disc surgery with usual care, for which the pooled findings showed no statistically significant difference between the intervention groups at 3–6 months. However, the findings were very heterogeneous, with one CCS reporting statistically significant findings in favour of surgery and another CCS reporting statistically significant findings in favour of usual care. Pooled analysis of the two well-conducted RCTs showed marginally statistically significant findings in favour of surgery (SMD –0.15; 95% CI –0.30 to –0.00; the findings were homogeneous $I^2 = 0\%$, p = 0.84).

One well-conducted RCT⁶⁸ found non-statistically significant findings in favour of disc surgery plus exercise therapy compared with exercise therapy alone in patients with acute sciatica at 6 months' follow-up.

One poorly reported RCT⁹⁵ compared the use of epidurals with disc surgery in patients with chronic sciatica. The methods of randomisation and allocation concealment were not stated and insufficient data were reported to estimate the mean difference between the intervention groups. The authors reported that there was a significantly greater decrease in disability in the discectomy group than in the epidural group at the 1–3 month follow-up interval (p<0.015, Student's *t*-test).

Four moderate RCTs^{73,89,106,107} compared disc surgery with intraoperative interventions. Pooled analysis for three RCTs^{73,89,107} showed no overall statistically significant difference between treatment groups at 6 months. The fourth RCT¹⁰⁶ did not report arm-level data, but also found no statistically significant difference between the intervention groups (at 3 months), based on repeated measures of analysis of variance using generalised estimating equation models (difference between groups –0.52, 95% CI –3.91 to 2.87, favouring intraoperative group; p = 0.763).

Three RCTs^{85,88,96} compared disc surgery with chemonucleolysis, for which pooled analyses showed no important difference between the intervention groups at 3–6 months. However, the findings were heterogeneous.

Results at long-term follow-up (>6 months)

Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 12* and the accompanying forest plot (*Figure 9*). Disc surgery was compared with usual care, active physical therapy (PT), intraoperative interventions, mixed treatments, chemonucleolysis and spinal cord

TABLE 11 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

						Total	<i>(u</i>)	Baselir (SD)	1e mean	Final me	an (SD)	Change scores (SD)			
а ё	Author, year	Chronicity	Study design	Follow-up	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion [€]
Disc sı	urgery vs chemonu	clysis													
727	Ejeskar, 1983 ⁹⁶	A+C	RCT	6 months	Composite score	14	15			9.71 (4.79)	9.27 (6.62)			0.08 (-0.65 to 0.80)	
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	3 months	Part of Waddell Disability index	46	46	6.7	6.2	2.3 (1.28)	3 (1.28)	-4.4	-3.2	-0.55 (-0.96 to -0.13)	SD for final means calculated from <i>p</i> -values (Mann–Whitney <i>U</i> -test); most outcomes showed skewed distribution
617	Revel, 1993 ⁸⁸	R	RCT	6 months	Waddell Disability Index and Main Scale	69	72	6 (3.9)	4.9 (2.55)	3.4 (3.32)	2.3 (4.65)	-2.6	-2.6	0.27 (-0.06 to 0.60)	SD calculated from SE Dropouts 24/165 (15%): group allocation not stated
Disc sı	urgery vs epidural														
725	Buttermann, 2004 ⁸⁶	A + C	RCT	1-3 months	IGO	20	20							Significantly greater decrease in disability in discectomy group compared with epidural; p < 0.015, Student's t-test	
Disc sı	urgery vs exercise t	herapy													
300	Osterman, 2006 [%]	A	RCT	6 months	IQO	28	28	39 (15)	39 (14)	8 (12)	12 (15)	-31	-27	-0.29 (-0.82 to 0.23)	ITT used LOCF, but one patient that did not meet inclusion criteria excluded from analysis

	Comment/conversion⁰		ITT used LOCF Dropouts 3/103 (3%):	III (1911) 2/32, COLITOL 1/31					SD calculated from weighted average SD for FFbH-R from	long-term follow-up disc surgery studies	III not used Dropouts 42 (11%): intervention 19/199, control 23/199		continued
	Mean difference (95% Cl) ^b		Repeated measures of	ariarysis or variance using	generalised estimating	equation models: -0.52 (95% Cl	-3.91 to 2.87), p = 0.763	0.09 (-0.64 to 0.81)	-0.07 (-0.27 to 0.14)			0.34 (0.09 to 0.59)	
	Control							-28.1 (21.7)					
Change scores (SD)	Intervention							–30.4 (25.8)					
an (SD)	Control							17.6 (19.8)	21.5 (22.48)			1.24 (1.02)	
Final me	Intervention							19.4 (23.3)	20 (22.48)			1.58 (0.99)	
le mean	Control		54 (15)					46.9 (21.3)	49				
Baselin (SD)	Intervention		49 (16)					52.3 (22.7)	50				
Ē	Control		51					22	180			128	
Total	Intervention		52					=	177			128	
	Scale (range) ^a		IOO					Composite scale	FFbH-R				
	Follow-up		3 months					6 months	6 months			6 months	
	Study design	suo	RCT					RCT	RCT			RCT	
	Chronicity	tive interventi	NR					NR	NR			NR	
	Author, year	urgery vs intraoperat	Jirarattanaphochai, 2007 ¹⁰⁶					Kim, 2003 ⁷³	Richter, 200189			de Tribolet, 1998 ¹⁰⁷	
	e ë	Disc s	606					400	618			915	

TABLE 11 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

1		
	Data inferred from graphs. No SDs reported. Baseline SD taken from 10-year follow-up data (see <i>Condition-specific</i> <i>outcome measures at long-</i> <i>term follow-up</i>), but this does not relate to same number of patients. Same SDs used for final means	ITT using LOCF, but two patients lost to follow-up early on were not included in analysis; Number randomised: intervention 141, control 142, baseline data based on all patients (sensitivity analysis showed no difference between ITT and non-ITT)
		-0.13 (-0.37 to 0.10)
	9. 0.	-115
	-10.8	-12.5
	9.7 (5.9)	4.8 (5.96)
	7 (4)	4 (5.94)
	13.6 (5.9)	16.3 (3.9)
	17.8 (4)	16.5 (4.4)
	181	141
	236	140
	Modified RMDQ	RMDQ
	6 months	26 weeks
	CCS	RCT
onventional care	o	ح
urgery vs usual/c	Atlas, 1996 ⁷²	Peul, 2007 ⁸⁷
Disc su	386	606
	Disc surgery vs usual/conventional care	Disc surgery vs usual/conventional care 386 Atlas, 1996 ⁷² C CS 6 months Modified 236 181 17.8 13.6 7 (4) 9.7 -10.8 -3.9 Data inferred from graphs. 386 Atlas, 1996 ⁷² C CS 6 months Modified 236 181 17.8 13.6 7 (4) 9.7 -10.8 -3.9 Data inferred from graphs. 386 Atlas, 1996 ⁷² C CS 6 months (4) (5.9) 7 (4) 9.7 -10.8 -3.9 Data inferred from graphs. NDQ Partients Partients

						Total	Ē	Baseline (SD)	mean	Final me	an (SD)	Change scores (SD)			
ē	Author, year	Chronicity	Study design	Follow-up	Scale (range) ^a	ntervention	Control	ntervention	Control	ntervention	Control	ntervention	Control	Mean difference (95% Cl)⁵	Comment/conversion [€]
751	Weinstein, 2006 ⁹⁹	A+ C	RCI	3 months	MODEMS version of ODI	198	211	47.5 (21.4)	(20.6) (20.6)	21.5 (21.4)	25 (20.6)	-26 (23.92)	-21.3 (23.24)	Adjusted difference between groups based on change scores: –4.7 (95% CI –9.3 to –0.2)	Baseline SD used for final mean ITT using LOCF and longitudinal mixed model controlling for covariates associated with missing values, but only included 472/501 patients with baseline data Dropouts: intervention 47/245 (19%), control 45/256 (18%) Crossovers: intervention 117/232 (50%), control 71/240 (30%)
750	Weinstein, 2006 ⁹⁶	A+ C	CCS	3 months	MODEMS version of ODI	466	190	56.7 (18.9)	35.9 (20.1)	(18.9)	15 (20.1)	-36.1 (18.78)	-20.9 (20.68)	Adjusted difference between groups based on change scores: –15.2 (95% CI–18.5 to –11.8)	Baseline SD used for final mean Dropouts 87/743 (12%): intervention 55/521, control 32/222. 19/222 patients who chose to be in the non- operative group received surgery and 44/521 who chose to be in the surgery for here surgery Analysis based on treatment received, not initial group allocation
A, acut LOCF, I. a The b Bas c The	3; A + C, acute and chills to observation carriec results have been cor 3d on final means or c term 'dropouts' has by	ronic; B-U&LPI, 1 forward; MOD werted to a sca thange scores (een used for m	Bergquist-I EMS, Modif le of 0-100 with a prefe issing data,	Jilman and Lar. led Oswestry D for comparabi rence given to post-baseline	son, pain index; isability Index (<i>i</i> lity. change scores) exclusions and	C, chro America ; results patients	nic; FFb 1 Acade reporte lost to f	H-R, Hano my of Orth d by study ollow-up.	ver functic lopaedic S in italics.	urgeons);	questionnal NR, not rep	ire (Funktion orted.	sfrageboger	i Hannover); LBPRS, I	wer back pain rating scale;

Health Technology Assessment 2011; Vol. 15: No. 39

Based on final means or change scores (with a preference given to change scores); results reported by study in italics. The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ID no.	Author, year	Study design		SMD (95% CI)	% weight
Active I	PT/exercise therapy				
300	Osterman, 200668	RCT	•	-0.29 (-0.82 to 0.23)	100.00
Chemo	nucleolysis				
727	Ejeskar, 1983 ⁹⁶	RCT		0.08 (-0.65 to 0.80)	25.77
593	Muralikuttan, 1992 ⁸⁵	RCT		-0.55 (-0.96 to -0.13)	35.79
617	Revel, 1993 ⁸⁸	RCT		• 0.27 (-0.06 to 0.60)	38.44
Subtota	l (<i>I</i> ² = 78.2%, <i>p</i> = 0.010))		-0.07 (-0.65 to 0.50)	100.00
Intraop	erative interventions				
400	Kim, 2003 ⁷³	RCT		0.09 (-0.64 to 0.81)	14.29
618	Richter, 200189	RCT		-0.07 (-0.27 to 0.14)	44.47
915	Tribolet, 1998 ¹⁰⁷	RCT		• 0.34 (0.09 to 0.59)	41.24
Subtota	l (<i>I</i> ² = 67.0%, <i>p</i> = 0.048	5)		>> 0.12 (-0.20 to 0.44)	100.00
Usual/c	conventional care				
386	Atlas, 199672	CCS		-0.55 (-0.75 to -0.35)	25.05
606	Peul, 2007 ⁸⁷	RCT		-0.13 (-0.37 to 0.10)	24.31
751	Weinstein, 2006 ⁹⁹	RCT		-0.17 (-0.36 to 0.03)	25.10
750	Weinstein, 200698	CCS		• 0.29 (0.12 to 0.46)	25.54
Subtota	l (l ² = 92.7%, p = 0.000))		-0.14 (-0.50 to 0.23)	100.00
			-0.963 0	0.963	

FIGURE 8 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to \leq 6months) for studies comparing disc surgery with alternative interventions. PT, physical therapy. Note: weights are from random effects analysis.

stimulation (others). Duration of follow-up ranged from 1 year to 10 years. Most studies included patients with chronic sciatica or a mixture of chronic and acute symptoms.

Six studies^{62,72,87,91,98,99} compared disc surgery with usual care; the overall findings for four^{62,72,87,91} included in the meta-analysis showed a statistically significant difference in favour of surgery. Two were RCTs, for which the duration of follow-up ranged from 1 year to 10 years.^{87,91} Only one RCT,⁹¹ which included patients with chronic sciatica, reported statistically significant findings. The overall quality rating for this study was poor, with the method of randomisation not stated and allocation concealment considered partial. The study was published in 1983 and surgical techniques are likely to have changed since then. The remaining RCT⁸⁷ was published in 2007. It was a well-conducted study that included patients with acute sciatica. Two further studies^{98,99} could not be included in the meta-analysis because they reported only the percentage change and difference between groups. One was a well-conducted RCT (SPORT)⁹⁹ and the other a parallel observational cohort study.⁹⁸ Both included patients with acute or chronic sciatica. The analyses in both studies were adjusted for a number of covariates including missing data. The treatment effect was much smaller in the RCT⁹⁹ than in the CCS⁹⁸ and the findings were not statistically significant. However, adherence to treatment protocols was low in the RCT, with 107/240 (45%) patients in the usual care group having surgery after 2 years and only 140/232 (60%) patients in the surgery group receiving surgery during the same 2-year period.

	Comments		Follow-up differed in each group: surgery mean 12 months (range 6–24 months), chemonucleolysis mean 16 months (range 6–35 months)					continued
	OR (95% Cl)ª		1.07 (0.41 to 2.81)	1.44 (0.68 to 3.06)	0.31 (0.07 to 1.25)	9.06 (2.13 to 38.49)	0.70 (0.38 to 1.26)	
	Withdrawal rate		0	0	0	0	0	
	Outcome (<i>n</i>)		40	53	16	1	71	
Cont	Total (<i>n</i>)		51	73	20	24	100	
	Withdrawal rate		0	0.01	0	0	0	
ention	Outcome (<i>n</i>)		30	61	,	23	63	
Interv	Total (<i>n</i>)		49	77	20	26	100	
	Perspective		Physician	Patient			Patient	
	Outcome measure		Satisfactory clinical outcome (vs unsatisfactory results)	Satisfied with final result of treatment: yes or largely (vs barely or no)	Overall treatment success using modified MacNab criteria: excellent or good (vs satisfactory or worse)	Overall outcome: excellent or good (vs poor)	Treatment outcome: excellent or good (vs unimproved)	
	Follow-up		Mean 14 (range 6-35) months	12 months	1 year	1 year	2 years	
	Study design		CCS	RCT	CCS	RCT	CCS	
	Chronicity	90lysis	O	0	A + C	NR	NR	
	Author, year	urgery vs chemonuch	Alexander, 1989' ¹⁰³	van Alphen, 1989⁴7	Bonafe, 1993 ⁷⁵ (French language)	Crawshaw, 198460	Dabezies, 1978 ⁵¹	
	D no.	Disc s	884	43	441	166	48	

TABLE 12 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comments	Data inferred from percentages Follow-up differed for the two groups: surgery mean 58 months, chemonucleolysis mean 38 months			Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 29%	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 14%
	OR (95% Cl) ^a	1.93 (0.84 to 4.44)	0.68 (0.31 to 1.48)	1.16 (0.68 to 1.98)	1.74 (0.98 to 3.09)	0.76 (0.43 to 1.32)
	Withdrawal rate	0	0	0	с.	∽-
이	Outcome (<i>n</i>)	24	87	141	55	55
Contr	Total (<i>n</i>)	44	100	176	100	100
	Withdrawal rate	0	0	0	~	ç.
ention	Outcome (<i>n</i>)	37	82	150	48	68
Interv	Total (<i>n</i>)	23	100	182	100	100
	Perspective		Patient		Patient	Patient
	Outcome measure	Satisfactory result for radicular pain: excellent or good (vs fair or poor)	Successful outcome: good or excellent (vs slight or no improvement)	Overall success: MacNab type scores: good or medium (vs mediocre or bad)	Results of treatment: very good or good; (vs moderate or bad)	Results of treatment: very good or good; (vs moderate or bad)
	Follow-up	Mean 49 months	1 year	Mean: surgery 24 months, chemonucleolysis 2 months	1 year	1 year
	Study design	HCS	CCS	RCT	CCS	CCS
	Chronicity	O	S	NR	R	NN
	Author, year	Hoogmartens, 1976 ⁵⁶	Javid, 1995 ⁴⁸	Lavignolle, 1987 ⁵⁵ (French language)	Lee, 1996 ¹⁰⁴ (German language) (j) ^b (APLD)	Lee, 1996 ¹⁰⁴ (German language) (ii) ^b (PELD)
	ID no.	132	44	129	889	889

							Interve	ention		Control				
D no.	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% Cl)ª	Comments
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	1 year	Completely pain free (vs residual back pain only or residual back and referred pain)		46	14	0	46	ω	0	2.08 (0.77 to 5.58)	Reported as percentages One patient crossed over to surgery
47	Norton, 1986 ⁵⁰	A+C	CCS	≥1 year	Treatment success: satisfactory (vs unsatisfactory) based on patient and physician report	Patient + physician	44	26	0	61	17	0	3.74 (1.64 to 8.50)	
45	Postacchini, 1987 ⁴⁸	A+C	Non- RCT	> 20 months	Treatment success: excellent or good (vs fair or poor)	Patient + physician	84	02	0.03	72	54	0.03	1.67 (0.76 to 3.65)	Data inferred from graphs Five lost to follow-up were excluded
617	Revel, 1993 ⁸⁸	щ	RCT	1 year	Overall success rate	Patient	69	2 ²	>0.41	72	48	>0.19	0.28 (0.14 to 0.57)	High dropout rate 24/165 excluded patients dropped out at beginning, group allocation not stated A further 30% dropped out (surgery 28/69; chemonucleolysis 14/72), but included in analysis (given poor outcome)
641	Steffen, 1999 [%] (German language)	C	RCT	1 year	MacNab criteria: good or very good (vs satisfactory or poor)		36	=	0	33	17	0	0.41 (0.15 to 1.11)	Reported as percentages only
61	Tregonning, 1991 ⁵³	C	CCS	10 years	MacNab criteria: excellent or good (vs fair or poor)		91	51	0.13	145	47	0.12	2.66 (1.55 to 4.56)	
														continued

TABLE 12 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

	Comments			Results included seven surgery patients who had had reoperation; five with good results				
	OR (95% Cl) ^a	2.33 (1.37 to 3.96)	0.83 (0.28 to 2.43)	5.33 (2.14 to 13.31)		1.53 (0.42 to 5.58)		0.57 (0.28 to 1.17)
	Withdrawal rate	0	0.03	0		0		0.08
lo.	Outcome (<i>n</i>)	59	22	27		ى ك		22
Contr	Total (<i>n</i>)	100	88	45		28		92
	Withdrawal rate	0	0.11	0		0.03		0.06
ention	Outcome (<i>n</i>)	134	56	72		2		20
Interv	Total (<i>n</i>)	174	63	81		28		9
	Perspective			Patient		Patient		Patient
	Outcome measure	Overall outcome: successful (vs failure)	Recovered within >12 weeks, 6–12 weeks, 2–6 weeks or immediate (vs no recovery)	Current level of discomfort: pain free or improvement (vs no better or worse)		Full recovery		Permanently free of complaints or permanent improvement (vs initially free of complaints then just improvement, same complaints, initially improvement then same complaints, initially improvement then worse or no effect)
	Follow-up	2 years	> 1 year	Mean 18 months (range 6–46 months)		2 years		Median 24.2 months
	Study design	CCS	CCS	CCS		RCT	ions	RCT
	Chronicity	O	C	A+C	erapy	A	ive intervent	Ë
	Author, year	Watts, 1975 ⁵⁹	Weinstein, 1986 ⁹²	Zeiger, 1987 ⁵⁸	rgery vs exercise thu	Osterman, 2006 ⁶⁸	ırgery vs intraoperati	Bernsmann, 2001 ⁷⁴
	ID no.	160	672	150	Disc su	300	Disc su	436

	Comments		19/118 (16%) dropped out; group allocation not stated	36/190 excluded from analysis, group allocation not stated (three intervention groups)	36/190 excluded from analysis, group allocation not stated (three intervention groups)
	OR (95% Cl) ^a	0.13 (0.00 to 3.52)	0.97 (0.40 to 2.38)	0.70 (0.25 to 1.93)	1.14 (0.25 to 1.93)
	Withdrawal rate	0	Ċ	<u>~</u>	~
ol	Outcome (<i>n</i>)	Ω	37	46	42
Contr	Total (<i>n</i>)	ນ	50	54	20
	Withdrawal rate	0	Ċ	~	÷
/ention	Outcome (<i>n</i>)	ო	36	40	40
Interv	Total (<i>n</i>)	Ŋ	49	50	20
	Perspective		Patient		
	Outcome measure	Pain free or improvement (vs no improvement). Improvement = increases of ≥ 7 points on SF-36	Overall assessment: very satisfied or satisfied little discomfort (vs acceptable some discomfort, unchanged or aggravated)	Overall outcome: excellent or good (vs fair or poor)	Overall outcome: excellent or good (vs fair or poor)
	Follow-up	1 year	1 year	1 year	1 year
	Study design	RCT	RCT	RCT	RCT
	Chronicity	S	NR	O	υ
	Author, year	Gerszten, 2003 ⁸¹	Jensen, 1996 ⁸³	MacKay, 1995 ⁶⁵ (i)° (gelfoam)	MacKay, 1995 ⁶⁵ (ii)° (free fat graft)
	D no.	492	520	270	270

continued

TABLE 12 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comments	Interim analysis based on first 40/61 patients (65%) to complete 12 months' follow- up (grup allocation of remainder not stated) Dropouts at 6 months 10/61 (16%): intervention 5/20, control 5/20 All included in ITT analysis				
	OR (95% Cl)ª	0.77 (0.44 to 2.94)		0.88 (0.28 to 2.80)		1.42 (0.93 to 2.17)
	Withdrawal rate	~		0.2		0.25
0	Outcome (<i>n</i>)	41		တ		107
Contr	Total (<i>n</i>)	09		24		175
	Withdrawal rate	~		0.13		0.25
ention	Outcome (<i>n</i>)	30		S		143
Interv	Total (<i>n</i>)	48		26		207
	Perspective	Physician		Patient + physician		Patient
	Outcome measure	MacNab criteria: excellent or good (vs fair or poor)		Success: ≥ 50% pain relief and patient satisfaction with treatment rated as success (vs failure)		Improvement in predominant symptom: completely gone, much better or better (vs not improved or worse)
	Follow-up	24 months		2 years		10 years
	Study design	RCT		RCT		CCS
	Chronicity	н Н Н		O		O
	Author, year	Romberg, 2008 ¹⁰²	urgery vs other	North, 2005 [%] (spinal cord stimulation)	urgery vs usual care	Atlas, 1996 ⁷²
	D no.	856	Disc sı	600	Disc sı	386

							Interve	ention		Contro	_			
ID no.	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% CI) ^a	Comments
606	Peul, 2007 ⁸⁷	<	RCT	52 weeks	Satisfaction with recovery: 'complete' or 'nearly recovery complete' on seven-point Likert scale (other 5 scores = unsatisfactory recovery)	Patient	130	106	0.08	130	103	0.08	 1.16 (0.63 to 2.14) Repeated measurements analysis adjusting for baseline values: 2.4% (95% Cf: -7.2% to 12.0%) 	Data presented as percentages ITT using LOCF reported for mean Likert score
211	Shvartzman, 1992 ⁸²	ح	HCS	2 years	Results categorised as good (vs satisfactory; poor) using composite scale based on functional (work-related) and perceptual (subjective- opinion) criteria	Patient	25	16	0	30	4	0	2.03 (0.69 to 6.02)	
664	Weber, 1983 ⁹¹	Ϋ́Ν.	RCT	10 years	Overall outcome: good or fair (vs poor or bad)	Physician	22	34	0.0	66	27	0	2.34 (1.12 to 4.87)	17 from control group received surgery, but analysed according to randomised group Seven patients registered as permanently incapacitated were categorised as 'fair' in final analysis
														continued

TABLE 12 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (*continued*)

							Interv	ention		Contro				
											-			
								Out	Withdra		Out	Withdra		
ID no.	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	tcome (<i>n</i>)	awal rate	Total (<i>n</i>)	tcome (<i>n</i>)	awal rate	0R (95% CI) ^a	Comments
220	Weinstein, 2006 ⁹⁸ (a)	С + Ч	S	2 years	Satisfaction with current symptoms: very/ somewhat satisfied	Patient	456	Change: 72% (SE 2.2)	0.12	1021	Change: 49% (SE 4.3)	0.26	Adjusted treatment effect 22. 4% (95% Cl 12.8% to 32.0%)	Only mean percentage change and difference between groups reported 48/222 patients who chose to be in non-operative group received surgery and 40/521 who chose to be in surgery group did not have surgery Analysis based on treatment received not initial group allocation Sensitivity analyses used to determine the impact of
														missing data

							Interve	ntion		Control				
D no.	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% Cl)⁵	Comments
751	Weinstein, 2006 ⁹⁹ (b)	A + C	RCT	2 years	Satisfaction with current symptoms: very/ somewhat satisfied		186	Change: 68% (SE 3.4)	0.24	187	Change: 64% (SE 3.5)	0.37	Adjusted treatment effect 4.0% (95% CI –5.6% to 13.5%)	Only mean percentage change and difference between groups reported ITT included 472/501 using LOCF and longitudinal mixed model controlling for covariates associated with missed visits Crossovers: intervention 92/232 (40%), control 107/240 (45%)
Disc su	rgery vs mixed treat	ments												
734	Hoogland, 2006 ⁹⁷ (discectomy + chemonucleolysis)	0	Q-RCT	2 years	Satisfaction with results classified as excellent or good (vs fair or not satisfied)	Patient	119	101	0.16	116	108	0.16	0.42 (0.17 to 1.00)	Reported as percentages only
379	Prestar, 1995 ⁷¹ (German language) (discectomy + non- opioids)	RN	RCT	1 year	Treatment success: very good or good (vs inadequate or poor).		34	o	0.32	34	5	0.32	0.58 (0.21 to 1.63)	
?, uncle not repc a Resu b Lee (meta c Mach comp	ar; A, acute; A + C, aci inted; PELD, percutane litts reported by study i <i>et al.</i> ¹⁰⁴ included three <i>r</i> -analysis (see <i>Figure</i> . (ay <i>et al.</i> ⁶⁵ included th parator twice, only the	ute and chroo cous manual n italics. treatment gr 9. rree treatmer first and thir	nic; APLD, and laser i roups: APL t groups: (d treatmer	automated percutant discectomy; SF-36, S D (i), PELD (ii) and ch surgery + dura cover t groups have been	eous lumbar discectomy; BVCi hort Form questionnaire-36 it iemonucleolysis (iii). In order t ad with gelfoam (i), surgery + c included in the meta-analysis	; baseline value ems. p prevent using th lura covered with (see Figure 9).	carried for	ward; C, chr omparator tr ıraft (ii) and s	onic; HCS vice, only surgery + c	, historic: the first a dura left u	al cohort stu and third tre incovered (i	ldy; LOCF atment gr ii). In orde	; last observation c roups have been ir er to prevent using	arried forward; NR, cluded in the the same

Health Technology Assessment 2011; Vol. 15: No. 39

ID no.	Author, year	Study design	OR (95% CI)	% weight
Active P	T/exercise therapy			
300	Osterman 200668	RCT	1.53 (0.42 to 5.58)	100.00
Chemor	nucleolvsis			
884	Alexander 1989 ¹⁰³	CCS	1.07 (0.41 to 2.81)	5.10
43	Alphen 198947	RCT	1.44 (0.68 to 3.06)	5.87
441	Bonafe 1993 ⁷⁵	CCS	0.31 (0.07 to 1.25)	3.69
166	Crawshaw 198460	RCT	9.06 (2.13 to 38.49	3.58
48	Dabezies 1978 ⁵¹	CCS	0.70 (0.38 to 1.26)	6.45
132	Hoogmartens 1976 ⁵⁶	HCS	1.93 (0.84 to 4.44)	5.57
44	Javid 1995 ⁴⁸	CCS	0.68 (0.31 to 1.48)	5.79
129	Lavignolle 1987 ⁵⁵	BCT	1.16 (0.68 to 1.98)	6.66
889	Lee 1996 ¹⁰⁴	CCS	1 74 (0 98 to 3 09)	6.51
593	Muralikuttan 1992 ⁸⁵	BCT	2 08 (0 77 to 5 58)	5.01
47	Norton 1986 ⁵⁰	CCS	→ 374 (1.64 to 8.50)	5.62
45	Postacchini 198749	Non-BCT	1 67 (0 76 to 3 65)	5.76
617	Bevel 1993 ⁸⁸	BCT		6.09
641	Steffen 1999 ⁹⁰	BCT	0.20 (0.14 to 0.07)	5.02
61	Tregonning 199153	CCS	2 66 (1 55 to 4 56)	6.63
160	Watts 1975 ⁵⁹	CCS	→ 2.33 (1.37 to 3.96)	6.66
672	Weinstein 1986 ⁹²	CCS	0.83 (0.28 to 2.43)	4 72
150	Zeiger 1987 ⁵⁸	HCS	5 33 (2 14 to 13 31	5.27
Subtotal	$(l^2 = 76.4\%, p = 0.000)$	100	> 1.37 (0.94 to 2.00)	100.00
Intraopo	vrativa interventions			
136	Bornsmann 2001 ⁷⁴	PCT	0.57 (0.28 to 1.17)	22.10
400		PCT	0.37 (0.28 to 1.17)	1 57
492 520	Jonson 1006 ⁸³		0.13 (0.00 to 3.32)	21.57
320 270	MacKay 100565	PCT		16.56
270	Bopphorg 2008 ¹⁰²	PCT	0.70 (0.23 to 1.33)	27.12
Subtatal	$(l^2 - 0.0\% - 0.751)$	nui		100.00
Subiolai	(l = 0.0%, p = 0.751)		0.70 (0.40 10 1.00)	100.00
Mixed tr	reatments	0.007		57.00
734	Hoogland 2006	Q-RCT	0.42 (0.17 to 1.00)	57.99
379	Prestar 1995	RGT		42.01
Subtotal	$(l^2 = 0.0\%, p = 0.626)$		0.48 (0.25 to 0.93)	100.00
Others				
600	North 2005®	RCT	• 0.88 (0.28 to 2.80)	100.00
Usual/co	onventional care			
386	Atlas 1996 ⁷²	CCS	→ 1.42 (0.93 to 2.17)	50.95
606	Peul 2007 ⁸⁷	RCT	1.16 (0.63 to 2.14)	24.30
211	Shvartzman 199262	HCS	• 2.03 (0.69 to 6.02)	7.73
664	Weber 1983 ⁹¹	RCT	2.34 (1.12 to 4.87)	17.02
Subtotal	(<i>l</i> ² = 0.0%, <i>p</i> = 0.483)			100.00
		0.00461	1 017	
		0.00461 F	Favours control Favours surgery	

FIGURE 9 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions. HCS, historical cohort study; PT, physical therapy. Note: weights are from random effects analysis.

According to a well-conducted RCT,⁶⁸ there was no real difference between disc surgery plus exercise therapy and exercise therapy alone in terms of reported full recovery at 2 years in patients with acute sciatica.

Intraoperative interventions were found to be superior to disc surgery alone in five RCTs, 65,74,81,83,102 but the overall findings were not statistically significant. One study⁸¹ reported a large effect size, but had a very wide CI owing to a small sample size (n = 10).

Two studies^{71,97} compared disc surgery with mixed treatments: chemonucleolysis plus surgery⁹⁷ and disc surgery plus non-opioids.⁷¹ Both found non-statistically significant findings in favour of the combined interventions. One was a Q-RCT⁹⁷ and the other a poor-quality and poorly reported RCT,⁷¹ for which the method of randomisation and allocation concealment were unclear. The withdrawal rate in this study was also high (32% in both intervention groups).

Eighteen studies^{47,48–51,53,55,56,58–60,75,85,88,90,92,103,104} compared disc surgery and chemonucleolysis, for which the findings were very heterogeneous, giving a pooled result that was borderline statistically significant in favour of surgery. There was a mixture of study designs. The duration of follow-up ranged from 1 year to 10 years and duration of sciatica varied between studies. If only the six RCTs^{47,55,60,85,88,90} were considered, the findings were still heterogeneous, although most reported findings in favour of disc surgery [pooled analysis: odds ratio (OR) 1.12; 95% CI 0.51 to 2.49]. One moderate-quality RCT⁸⁸ found chemonucleolysis to be more effective than disc surgery, but the study had a high withdrawal rate in the surgery group (at least 41%) compared with chemonucleolysis (at least 19%), with dropouts being given a poor outcome in the analysis. The funnel plot (*Figure 10*), for publication and other biases, does not appear to show asymmetry, but does indicate a lack of large studies.

According to one RCT,⁸⁶ there was no important difference between repeat disc surgery and spinal cord stimulation (others) in terms of treatment success for chronic sciatica following previous disc surgery.

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 13* and the accompanying forest plot (*Figure 11*). Disc surgery was compared with usual care, exercise therapy, epidural, intraoperative interventions, chemonucleolysis and mixed treatments.



FIGURE 10 Funnel plot with pseudo 95% CIs for studies comparing disc surgery with chemonucleolysis at long-term follow-up (>6 months).

TABLE 13 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

							Total (e (u	Baselir mean (le SD)	Final m (SD)	ean	Change scores ((QS		
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI) ^b	Comment/conversion⁰
Disc s	urgery vs chemon	ucleolysis														
454	Buric, 2005 ⁷⁷	A+C	Non- RCT	18 months	Overall	VAS (0-10)	15	30	61 (31)	53 ; (22) (20 13)	22 (13)	-41	40	7.0 (–1.72 to 15.72)	Two patients crossed over to surgery, classed as treatment failures
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	3 months	Leg	VAS (0-100)	46	46	72	64	14 24.43)	20 (23.76)			-2.00 (-10.49 to 6.49)	SD imputed from weighted average Most outcomes showed skewed distribution
Disc s	urgery vs epidural	_														
725	Buttermann, 2004 ⁹⁵	A+C	RCT	2–3 years	Back	VAS (0-10)									No significant differences between groups, Student's t-test (p-value not given)	No summary estimates reported
Disc s	urgery vs exercise	therapy														
300	Osterman, 2006 ⁶	β	RCT	2 years	Leg	VAS (0-100)	28	28	61 (20)	57 ((21) (3 (11)	15 (24)		- 0	-9.00 —18.78 to 0.78)	ITT using LOCF Dropouts: surgery 2/29, exercise 4/28
Disc s	urgery vs intraope.	rative interventio	su													
470	Debi, 2002 ⁷⁸	A+C	RCT	1 year	Leg	VAS (0-10)	35	26	71	28	13 (20.31)	13 (8.68)			0.0 (-7.51 to 7.51)	SD imputed from weighted average Mean inferred from graphs Dropouts 9/70 (13%): intervention 9/35, control 0/35

							Total (Ē	Baseline mean (Sl	D)	inal mea 3D)	2 2	nange ores (SD)		
⊆ ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control		Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion [€]
276	Lundin, 200366	0	RCT	104 weeks	Overall	VAS (0-100)	42	38 4	2	4 14 (20	8).31) (8.	68)		6.00 (-0.73 to 12.73)	SD imputed from weighted average Mean inferred from graphs
854	Rasmussen, 2008 ¹⁰¹	Я	RCT	2 years	69 T	Composite NRS (0-30)	100	100 €	20.33	0 (2(68)		5.54 (1.21 to 9.87)	Median used to represent mean SD imputed from weighted average Three separate pain measures using NRS (0–10) combined: pain now, worst, and average pain in the last 2 weeks, for back and leg pain separately ITT using LOCF. Dropouts 2/200 (1%): group allocation not stated
316	Cengiz, 2007 ⁶⁹ (i) ^c (anti-adhesion barrier ADCON-L)	C	RCT	12 months	Overall	VAS (0-10)	18	21 1 ((00 (1. 1) (0.0	2.8 46 0.5) (12	.6 44 2.3) (9.	.7 8)		1.90 (-5.16 to 8.96)	
316	Cengiz, 2007 ⁶⁹ (ii) ^d (anti-adhesion barrier Healon GV)	O	RCT	12 months	Overall	VAS (0-10)	10	21 ((.6 0.0 0.0	7.1 46 9.5) (12	.6 46 2.3) (7.	(4)		-1.40 (-7.90 to 5.10)	
Disc s	urgery vs usual care														
716	Alaranta, 1990 ⁹⁴	A + C	CCS	12 months		B-U&LPI (0-30)	235	122						Surgery group had greatest decrease in pain indices Pain index: surgery vs control p < 0.001; surgery vs control not significant, Student's t-test	Patients in control group had no disc herniation on rhizography or did not meet criteria for surgery Data presented in unusable graphical form
															continued

TABLE 13 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

							Total	(1)	Basel	ine (SD)	Final r (SD)	nean	Chang	e (SD)		
ම පි	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	Comment/conversion⁰
772	Hansson, 2007 ¹⁰⁰	A+C	CCS	2 years	Overall	Von Korff – pain scale (0–10)	92	92	71	70	45	59	-26 (34)	-11 (73.3)	–15 (–31.51 to 1.51)	SD for change score derived from <i>p</i> -value of <i>t</i> -test (individual group) converted to 0–100
606	Peul, 2007 ⁸⁷	Þ	RCT	104 weeks	Ceo 1	VAS (0-100)	130	130	67.2 (27.7)	64.4 (21.2)	11 (21.66)	9 (21.66)			2.0 (-3.27 to 7.27) Repeated measures analysis, analysis, afference between groups: -2.0 (95% Cl -6.0 to 2.0)	Final SD based on SE Dropouts 23 (8%): intervention 11/141, control 12/142 ITT not done because no difference between ITT and non-ITT at 1-year follow-up
Disc s	surgery vs mixed tre	atments														
734	Hoogland, 2006 ⁹⁷ (surgery + chemonucleolysis)	O	Q-RCT	2 years	feg	VAS (0-10)	119	116	80.5	82.2	20.2 (20.31)	18.5 (21.22)			1.70 (–3.61 to 7.01)	SD imputed from weighted average ITT not used Dropouts 45 (16%): intervention 23/142, control 22/138
A, acu a Thé b Dag	te; A + C, acute and cl eresults have been cc	hronic; B-U&LPI, onverted to a sca	, Bergquist-Ul ile of 0–100 t	Ilman and Lars for comparabili	on, pain inde ty.	x; C, chronic;	LOCF, Is	ast obse	rvation c	arried fc	nward; N	IR, not rej	oorted; NI	3S, num(erical rating scale.	

based on tinal means or change scores (with a preference given to change scores); results reported by study in italics. The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ουρ

Cengiz and Baysefer^{es} included three treatment groups: surgery + anti-adhesion barrier ADCON-L (i), surgery + anti-adhesion barrier Healon GV (ii) and surgery + no adhesion barrier (ii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the meta-analysis (see *Figure 11*).

ID no.	Author, year	Study design					WMD (95% CI)	% weight
Active I	PT/Exercise therapy							
300	Osterman, 200668	RCT			•	+	-9.00 (-18.78 to 0.78)	100.00
Chemo	nucleolysis							
454	Buric, 2005 ⁷⁷	Non-RCT			-	•	7.00 (-1.72 to 15.72)	49.36
593	Muralikuttan, 1992 ⁸⁵	RCT				+	-2.00 (-10.49 to 6.49)	50.64
Subtota	ll (l ² = 52.4%, p = 0.147)				<		2.44 (-6.38 to 11.26)	100.00
Intraop	erative interventions							
470	Debi, 2002 ⁷⁸	RCT				*	0.00 (-7.51 to 7.51)	15.66
276	Lundin, 200366	RCT				• • • • • • • • • • • • • • • • • • •	6.00 (-0.73 to 12.73)	19.48
854	Rasmussen, 2008101	RCT					5.54 (1.21 to 9.87)	47.14
316	Cengiz, 200769	RCT				•	1.90 (-5.16 to 8.96)	17.72
Subtota	l ($l^2 = 0.0\%$, $p = 0.522$)					\diamond	4.12 (1.14 to 7.09)	100.00
Mixed t	reatments							
734	Hoogland, 200697	Q-RCT			_	•	1.70 (-3.61 to 7.01)	100.00
Usual/c	conventional care							
772	Hansson, 2007100	CCS		٠		+	–15.00 (–31.51 to 1.51)	38.97
606	Peul, 2007 ⁸⁷	RCT			_	•	2.00 (-3.27 to 7.27)	61.03
Subtota	l (l ² = 72.9%, p = 0.055)						-4.63 (-20.87 to 11.62)	100.00
			-31.5			0	31.5	
				Favours	surgery	Favours co	ontrol	

FIGURE 11 Summary of the findings of pain intensity at long-term follow-up studies (>6 months) comparing disc surgery with alternative interventions. Note: weights are from random effects analysis.

Three studies^{87,94,100} compared disc surgery with usual care. One well-conducted RCT⁸⁷ included patients with severe sciatica for 6–12 weeks. The study did not find any important differences between the interventions groups for pain intensity at 104 weeks. The other two studies were CCSs that included patients with acute and chronic sciatica. Neither study used VAS as their pain scale. Only one study⁹⁴ found statistically significant findings in favour of surgery, but the data were reported in an unusable graphical format and could not be included in the meta-analysis. The study was poorly reported in general and had obvious selection bias, with patients in the comparator group including those with no disc herniation on rhizography or who were not eligible for disc surgery.

As with the global effect, one well-conducted RCT⁶⁸ found non-statistically significant findings in favour of disc surgery plus exercise therapy compared with exercise therapy alone in patients with acute sciatica at 2 years' follow-up.

One poorly reported study⁹⁵ compared the use of epidurals with disc surgery in patients with chronic sciatica [mean 3.55 months (SD 2.75 months)], and found no statistically significant difference between the intervention groups for back pain intensity at follow-up intervals of 7–12 months, 1–2 years or 2–3 years (Student's *t*-test). Results of leg pain were not reported beyond 6 months.

The pooled analysis of four RCTs^{66,69,78,101} found a statistically significant improvement following intraoperative interventions compared with disc surgery alone. One study⁷⁸ included patients with acute and chronic sciatica (mean symptom duration 56 days, range 12–135 days), two studies^{66,69} included patients with chronic sciatica, and duration of symptoms was not stated in the remaining study.¹⁰¹ Duration of follow-up ranged from 1 year to 2 years. Overall study quality was moderate^{66,69,101} or poor.⁷⁸

Two studies^{77,85} compared disc surgery with chemonucleolysis: one was an RCT⁸⁵ and the other a non-RCT.⁷⁷ Overall, there was no statistically significant difference between the intervention groups.

A Q-RCT⁹⁷ evaluated the use of chemonucleolysis plus surgery versus surgery alone in patients with chromic sciatica. There was no statistically significant difference between the intervention groups.

Condition-specific outcome measures at long-term follow-up

The results for CSOMs at long-term follow-up are presented in *Table 14* and the accompanying forest plot (*Figure 12*). Disc surgery was compared with usual care, exercise therapy, intraoperative interventions and chemonucleolysis.

Six studies^{45,72,87,98–100} compared disc surgery with usual care, for which the pooled findings showed no statistically significant difference between the intervention groups at 1 year to 10 years^{45,72} (median 2 years). Two studies^{87,99} were well-conducted RCTs and the remaining four^{45,72,98,100} were CCSs. Pooled analysis of the RCTs also showed no important differences between the intervention groups (SMD –0.01; 95% CI –0.16 to 0.15).

One well-conducted RCT⁶⁸ found non-statistically significant findings in favour of disc surgery plus exercise therapy compared with exercise therapy alone in patients with acute sciatica at 2 years' follow-up.

The pooled analysis of four RCTs^{69,74,81,83} showed no important difference between disc surgery and intraoperative interventions for CSOMs at 1 year's^{69,81,83} follow-up or a median of 2 years' follow-up.⁷⁴

Four studies^{77,85,92,96} compared disc surgery and chemonucleolysis: two were RCTs,^{85,96} one was a non-RCT⁷⁷ and one was a CCS.⁹² The CCS⁹² reported insufficient data to be included in the meta-analysis. The results of six pain and disability outcome measures were analysed in a one-way multivariate analysis of variance (MANOVA), the results of which showed no significant relationship between pain outcome measures and treatment type (Wilks' criterion F(6,54) = 1.18; p < 0.34). Pooled analysis of the remaining three studies^{77,85,96} showed no statistically significant difference between the intervention groups.

						Total	2	Baseliné (SD)	e mean	Final me	an (SD)	Change (SD)	scores		
Ωë	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CJ)ª	Comment/conversion ^b
Disc :	surgery vs chem	nonucleolysis													
454	Buric, 2005 ⁷⁷	A+C	Non- RCT	18 months	RMDQ	15	30	12.4 (4.3)	9.1 (3.5)	2.1 (1.9)	2.2 (3.2)	-10.3	-6.9	-0.04 (-0.66 to 0.58)	ITT used but method not stated Dropouts: two, considered as treatment failure
727	Ejeskar, 1983 ⁹⁶	A+C	RCT	12 months	Composite score	14	15			8.79 (6.02)	9.4 (6.88)			-0.08 (-0.3 to 0.21)	
593	Muralikuttan, 1992 ^{es}	A + C	RCT	1 year	Part of the Waddell Disability Index	46	46	6.7	6.2	2.8 (1.21)	2.6 (1.21)	ဝ. ဗ ၂	-3.6	0.17 (–0.24 to 0.57)	SD for final means calculated from <i>p</i> -values (Mann–Whitney <i>U</i> -test); most outcomes showed skewed distribution ITT not used, but all patients included in analysis except one for psychological outcomes
672	Weinstein, 1986 ⁹²	O	SS	Mean 10.3 years	Composite score	71	85							Results of MANOVA showed no significant relationship between pain outcome measures and treatment type [Wilks' criterion: F(6,54) = 1.18, p < 0.34]	Pain + disability measured in six different scales Actual data not presented Dropouts: 3/159 (2%) (chemonucleolysis group)
Disc :	surgery vs exerc	sise therapy													
300	Osterman, 2006 ⁶⁸	¢	RCT	2 years	IQO	28	28	39 (15)	39 (14)	6 (9)	11 (16)	-33	-28	0.39 (0.91 to 0.14)	ITT using LOCF, but one patient who did not meet inclusion criteria excluded from analysis
															continued

/e interventions (grouped by comparator then

TABLE 14 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

	Control Intervention Control Intervention	Control Intervention Control Intervention
	94 92	Aedian FFbH-R 94 92 :4.2 months
<i>(</i>) <i>-</i>	5 5 31.4 32.6 (5.5) (7.8)	year 0DI 5 5 31.4 32.6 (5.5) (7.8)
10	49 50 57.0 54.5	year LBPRS 49 50 57.0 54.5
	18 21	2 months ODI 18 21
10.0	188 152 17.7 13.5 (4) (5.9)) years Modified 188 152 17.7 13.5 RMDQ (4) (5.9)

						Total	(1)	Baselir (SD)	ne mean	Final me	an (SD)	Change (SD)	scores		
e ë	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
772	Hansson, 2007 ¹⁰⁰	A+C	CCS	2 years	FFbH-R	92	92	47	58	35 (13.09)	36 (13.09)	18	9	-0.08 (-0.37 to 0.21)	Final SD imputed from weighted means of FFbH-R for usual care
606	Peul, 2007 ⁸⁷	ح	RCT	2 years	RMDQ	130	130	16.5 (4.4)	16.3 (3.9)	3.1 (5.7)	2.6 (5.7)	-13.4	-13.7	0.09 (-0.16 to 0.33) Adjusted mean difference 0.5 (95% CI -0.8 to 1.8), repeated-measures analysis of variance; difference between groups based on AUC also reported	SDs calculated from SE ITT not used because sensitivity analysis showed no difference between ITT and non-ITT at 1-year follow-up; 23 (8%) patients lost to follow-up; no randomised intervention 141, control 142
2	Thomas, 2007 ⁴⁵	O	CCS	Intervention: 6 months; control: 12 months	NASS Lumbar Spine Q subscale – pain and disability	333	164	21.4 (10)	29 (10)	58.3 (10)	57.7 (10)	20.2	13.3	0.06 (-0.13 to 0.25) Adjusted mean difference 3.46 (95% CI 0.17 to 6.75) p = 0.04	ITT used (method of dealing with missing values not reported) Dropouts 126 (20%): intervention 84/417, control 42/206
750	Weinstein, 2006 ⁹⁸	A + C	CCS	2 years	MODEMS version of ODI	456	165	56.7 (18.9)	35.9 (20.1)	19.1 (18.9)	11.7 (20.1)	-37.6 (18.15)	-24.2 (21.84)	0.38 (0.21 to 0.56) Adjusted mean difference -13.4 (95% CI - 17.0 to -9.7); n = 6207743	Final score calculated from change score No final SD so baseline SD used, adjusted difference between groups based on change scores Missed visits adjusted for in analysis. 48/222 patients who chose to be in non-operative group received surgery and 40/521 who chose to be in surgery group did not have surgery group did not have surgery and halysis based on treatment received not initial group allocation
															continued

TABLE 14 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

	Comment/conversion ^b	Final score calculated from change score No final SD so baseline SD used, adjusted difference between groups based on change scores ITT analysis included 472/501 patients using LOCF (longitudinal mixed model controlling for covariates associated with missing values) Dropouts: intraoperative 59/245 (24%), chemonucleolysis 69/256 (27%) Crossovers: intervention 92/232 (40%), control 107/240 (45%)
	Mean difference (95% Cl) ^a	-0.07 (-0.27 to 0.13) Adjusted mean difference -2.7 (95% CI -7.4 to 1.9); n = 472/501
scores	Control	-28.7
Change (SD)	Intervention	-31.4
ean (SD)	Control	17.6 (20.6)
Final m	Intervention	(21.4) (21.4)
le mean	Control	46.3 (20.6)
Baselir (SD)	Intervention	47.5 (21.4)
(<i>u</i>)	Control	187
Tota	Intervention	186
	Scale	MODEMS version of ODI
	Follow-up	2 years
	Study design	RCT
	Chronicity	A + C
	Author, year	Weinstein, 2006 ⁹⁹
	ē.	751

A, acute; AUC, area under the curve; A + C, acute and chronic; C, chronic; FFbH-R, Hanover functional ability questionnaire (Funktionsgragebogen Hannover); LBPRS, lower back pain rating scale; LOCF, last observation carried forward; MODEMS, Modified Oswestry Disability Index (American Academy of Orthopaedic Surgeons); NASS, North American Spine Society; NR, not reported.

a Based on final means or change scores (with a preference given to change scores); results reported by study in italics. b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ID no.	Author, year	Study design		SMD (95% CI)	% weight
Active I	PT/exercise therapy				
300	Osterman, 200668	RCT		-0.39 (-0.91 to 0.14)	100.00
Chemo	nucleolysis				
454	Buric, 2005 ⁷⁷	Non-RCT		–0.04 (–0.66 to 0.58)	24.90
727	Ejeskar, 198396	RCT		-0.09 (-0.82 to 0.63)	18.01
593	Muralikuttan, 199285	RCT		0.17 (-0.24 to 0.57)	57.08
Subtota	$I(l^2 = 0.0\%, p = 0.774)$			0.07 (-0.24 to 0.38)	100.00
Intraop	erative interventions				
436	Bernsmann, 200174	RCT	• _	-0.02 (-0.31 to 0.26)	55.80
492	Gerszten, 2003 ⁸¹	RCT	*	0.08 (-1.16 to 1.32)	3.00
520	Jensen, 1996 ⁸³	RCT		–0.05 (–0.44 to 0.35)	29.70
316	Cengiz, 2007 ⁶⁹	RCT		–0.29 (–0.93 to 0.34)	11.50
Subtota	$I(l^2 = 0.0\%, p = 0.886)$		\Leftrightarrow	-0.06 (-0.27 to 0.16)	100.00
Usual/c	conventional care				
386	Atlas, 199672	CCS		-0.23 (-0.44 to -0.01)	16.84
772	Hansson, 2007 ¹⁰⁰	CCS		-0.08 (-0.37 to 0.21)	14.19
606	Peul, 2007 ⁸⁷	RCT		0.09 (–0.16 to 0.33)	15.81
2	Thomas, 200745	CCS		0.06 (-0.13 to 0.25)	17.82
750	Weinstein, 200698	CCS		0.38 (0.21 to 0.56)	18.09
751	Weinstein, 200699	RCT		–0.07 (–0.27 to 0.13)	17.25
Subtota	l (l ² = 77.3%, p = 0.001)		\diamond	0.03 (-0.15 to 0.22)	100.00
		t			
		-1.3	2 0 1.3 Favours surgery Favours control	32	

FIGURE 12 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing disc surgery with alternative interventions. Note: weights are from random effects analysis.

Analysis of adverse effects for disc surgery

Adverse events were very poorly reported in most studies. *Table 15* and *Figure 13* present the overall number of any adverse event that occurred.

There was a statistically significant greater number of adverse effects with disc surgery compared with usual care. Overall there was no statistically significant difference in the number of adverse effects following disc surgery compared with: epidural and exercise therapy, chemonucleolysis, epidural, intraoperative interventions, mixed treatments, non-opioids or others.

SUMMARY OF OVERALL FINDINGS FOR DISC SURGERY COMPARED WITH ALTERNATIVE INTERVENTIONS

Most disc surgery studies included patients with chronic sciatica or both acute and chronic sciatica. Four studies^{62,68,80,87} included acute sciatica, for which the comparator included exercise

 TABLE 15
 Summary of the findings of any adverse effect for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Disc s	surgery vs chemonucleolys	sis					
884	Alexander, 1989103	CCS	8	49	8	51	1.05 (0.36 to 3.06)
43	van Alphen, 198947	RCT	3	78	3	73	0.93 (0.18 to 4.78)
441	Bonafe, 199375	CCS	1	20	10	20	0.05 (0.01 to 0.47)
183	Bouillet, 198361	CCS	91	613	152	2136	2.28 (1.72 to 3.00)
453	Brown, 1989 ⁷⁶ (chemopapain)	CCS	NR	NR	NR	NR	
453	Brown, 1989 ⁷⁶ (collagenase)	CCS	NR	NR	NR	NR	
454	Buric, 200577	Non-RCT	NR	NR	NR	NR	
166	Crawshaw, 198460	RCT	0	27	1	25	0.30 (0.01 to 7.63)
48	Dabezies, 197851	CCS	0	100	2	100	0.20 (0.01 to 4.14)
471	Dei-Anang, 1990 ⁷⁹ (German language)	CCS	NR	NR	NR	NR	
727	Ejeskar, 198396	RCT	1	14	1	15	1.08 (0.06 to 19.05)
132	Hoogmartens, 197656	HCS	19	53	3	44	7.64 (2.08 to 28.02)
44	Javid, 199548	CCS	4	100	6	100	0.65 (0.18 to 2.39)
35	Krugluger, 200046	RCT	1	10	5	12	0.16 (0.01 to 1.65)
117	Lagarrigue, 1991 ⁵⁴ (French language)	CCS	30	751	5	334	2.74 (1.05 to 7.12)
129	Lavignolle, 1987 ⁵⁵ (French language)	RCT	7	182	7	176	0.97 (0.33 to 2.81)
889	Lee, 1996104 (APLD)	CCS	3	100	73	100	0.01 (0.00 to 0.04)
889	Lee, 1996104 (PELD)	CCS	4	100	73	100	0.02 (0.01 to 0.05)
593	Muralikuttan, 199285	RCT	0	46	1	46	0.33 (0.01 to 8.22)
47	Norton, 198650	CCS	2	44	12	61	0.19 (0.04 to 0.92)
45	Postacchini, 198749	Non-RCT	20	84	2	72	10.94 (2.46 to 48.65)
617	Revel, 199388	RCT	15	69	35	72	0.29 (0.14 to 0.61)
641	Steffen, 199990	RCT	NR	NR	NR	NR	
49	Stula, 1990 ⁵² (German language)	RCT	NR	NR	NR	NR	
61	Tregonning, 1991 ⁵³	CCS	4	145	5	91	0.49 (0.13 to 1.87)
893	Watters, 1988105	Non-RCT	1	50	2	50	0.49 (0.04 to 5.58)
160	Watts, 197559	CCS	2	174	3	100	0.38 (0.06 to 2.29)
672	Weinstein, 198692	CCS	NR	NR	NR	NR	
150	Zeiger, 198758	CCS	5	81	16	45	0.12 (0.04 to 0.36)
Disc s	surgery vs epidural/intradis	scal injection					
725	Buttermann, 200495	RCT	7	77	5	50	0.90 (0.27 to 3.01)
Disc s	surgery vs active PT/exerci	ise therapy					
300	Osterman, 200668	RCT	1	28	0	28	3.11 (0.12 to 79.64)
Disc s	surgery vs intraoperative ir	nterventions					
268	Aminmansour, 2006^{64} (control = 40 mg)	Q-RCT	1	22	0	19	3.46 (0.13 to 89.95)

TABLE 15 Summary of the findings of any adverse effect for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) *(continued)*

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% Cl)
268	Aminmansour, 2006^{64}	Q-RCT	1	22	0	20	2.72 (0.10 to 70.79)
436	Bernsmann, 2001 ⁷⁴	BCT	0	94	0	92	
470	Debi, 2002 ⁷⁸	RCT	0	26	0	35	
492	Gerszten, 2003 ⁸¹	RCT	1	5	1	5	1.00 (0.05 to 22.18)
497	Glasser, 1993 ⁸² (control = LA)	RCT	NR	NR	NR	NR	х <i>г</i>
497	Glasser, 1993 ⁸² (control = steroid + LA)	RCT	NR	NR	NR	NR	
520	Jensen, 199683	RCT	NR	NR	NR	NR	
909	Jirarattanaphochai, 2007106	RCT	2	51	1	52	2.08 (0.18 to 23.70)
400	Kim, 200373	RCT	NR	NR	NR	NR	
551	Langmayr, 1995 ⁸⁴	RCT	NR	NR	NR	NR	
366	Lavyne, 1992 ⁷⁰	Q-RCT	0	42	0	42	
276	Lundin, 200366	RCT	1	42	0	38	2.78 (0.11 to 70.39)
270	MacKay, 1995 ⁶⁵ (control = free fat graft)	RCT	NR	NR	NR	NR	
270	MacKay, 1995 ⁶⁵ (control = gelfoam membrane)	RCT	NR	NR	NR	NR	
379	Prestar, 1995 ⁷¹ (German language)	RCT	6	34	0	34	15.74 (0.85, 291.46)
854	Rasmussen, 2008101	RCT	NR	NR	NR	NR	
618	Richter, 200189	RCT	3	177	3	180	1.02 (0.20 to 5.11)
856	Ronnberg, 2008102	RCT	NR	NR	NR	NR	
316	Cengiz, 2007 ⁶⁹ (control = Adcon-L)	RCT	1	18	0	21	3.69 (0.14 to 96.22)
316	Cengiz, 2007 ⁶⁹ (control = Healon GV)	RCT	1	18	0	21	3.69 (0.14 to 96.22)
705	Starkweather, 200693	RCT	NR	NR	NR	NR	
915	de Tribolet, 1998107	RCT	81	141	65	128	1.31 (0.81 to 2.12)
Disc s	urgery vs mixed treatments						
734	Hoogland, 200697	Q-RCT	3	119	2	116	1.47 (0.24 to 8.99)
600	North, 2005 ⁸⁶	RCT	0	26	1	19	0.23 (0.01 to 6.03)
263	Wang, 200063	RCT	NR	NR	NR	NR	
Disc s	urgery vs non-opioids						
475	Dubourg, 2002 ⁸⁰	CCS	1	39	0	28	2.22 (0.09 to 56.54)
144	Rossi, 1993 ⁵⁷ (surgery = microdiscectomy)	Non-RCT	0	NR	1	NR	х <i>У</i>
144	Rossi, 1993 ⁵⁷ (surgery = percutaneous discectomy)	Non-RCT	0	NR	1	NR	
Disc s	urgery vs usual/conventiona	l care					
716	Alaranta, 199094	CCS	NR	NR	NR	NR	
386	Atlas, 199672	CCS	16	275	0	232	29.57 (1.76 to 495.56)

continued
ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
772	Hansson, 2007 ¹⁰⁰	CCS	NR	NR	NR	NR	
294	Koranda, 199567	Q-RCT	NR	NR	NR	NR	
606	Peul, 200787	RCT	NR	NR	NR	NR	
211	Shvartzman, 199262	HCS	NR	NR	NR	NR	
2	Thomas, 200745	CCS	NR	NR	NR	NR	
664	Weber, 198391	RCT	NR	NR	NR	NR	
750	Weinstein, 200698	CCS	2	538	0	216	2.02 (0.10 to 42.20)
751	Weinstein, 200699	RCT	24	232	0	240	56.52 (3.42 to 935.13)

TABLE 15 Summary of the findings of any adverse effect for studies comparing disc surgery with alternative interventions (grouped by comparator then ordered by author) (continued)

APLD, automated percutaneous lumbar discectomy; HCS, historical cohort study; LA, local anaesthetic; NR, not reported; PELD, percutaneous manual and laser discectomy.

therapy,⁶⁸ non-opioids⁸⁰ and usual care.^{62,87} Just over half of the disc surgery studies were RCTs. There were only a small number of good-quality studies, two of which compared disc surgery with usual care (*Table 16*).

One well-conducted RCT⁸⁷ found that early disc surgery resulted in a statistically significant improvement in pain at short- and medium-term follow-up compared with usual care, with a greater reduction at short-term follow-up. The same RCT found that functional status after disc surgery was significantly worse than usual care for the first 4 weeks, but significantly better after 4 weeks. However, there was no statistically significant difference between the treatment groups at medium-term follow-up. Pooled data from two RCTs^{67,87} showed a small improvement, which was not statistically significant, in favour of surgery for the global effect at medium-term follow-up. One further RCT⁹⁹ (that could not be included in the meta-analysis) showed a small but statistically significant effect in favour of surgery for satisfaction with symptoms. Pooled data showed disc surgery to be better than usual care for the global effect at long-term follow-up [two RCTs,^{87,91} one CCS,⁷² one historical cohort study (HCS)⁶²]. There were no statistically significant differences between intervention groups for pain intensity^{87,100} or CSOMs at long-term follow-up.^{45,72,87,98-100} The number of adverse effects was statistically significantly higher following disc surgery than after usual care (one RCT,⁹⁹ two CCSs^{72,98}).

Disc surgery was significantly better than epidural at reducing pain intensity at medium-term follow-up but not at long-term follow-up (one poor-quality RCT⁹⁵). There was no statistically significant difference between the intervention groups for adverse effects.

There was no statistically significant difference between disc surgery and non-opioids for global effect (one non-RCT,⁵⁷ one CCS⁸⁰) and pain intensity (one CCS⁸⁰) at medium-term follow-up, or for adverse effects, according to two poor-quality studies.^{57,80} Disc surgery in combination with non-opioids led to a greater reduction in pain intensity than disc surgery alone at short-term follow-up (one poor-quality RCT⁹³), but there was no statistically significant difference between similar comparisons at long-term follow-up for global effect (one poor-quality RCT⁷¹).

There was no statistically significant difference between disc surgery plus exercise therapy and exercise therapy alone in terms of reported full recovery, pain intensity or functional status

	Author year	Study			% woight
	Autior, year	design			weight
Active P	T/exercise therapy				
300	Osterman 200668	RCT	•	3.11 (0.12 to 79.64)	100.00
Chemon	ucleolysis				
43	Alphen 198947	RCT		0.93 (0.18 to 4.78)	4.88
166	Crawshaw 1984 ⁶⁰	RCT		0.30 (0.01 to 7.63)	2.87
48	Dabezies 1978 ⁵¹	CCS		0.20 (0.01 to 4.14)	3.07
727	Ejeskar 198396	RCT	.	1.08 (0.06 to 19.05)	3.26
132	Hoogmartens 1976 ⁵⁶	HCS		7.64 (2.08 to 28.02)	5.35
44	Javid 199548	CCS	.	0.65 (0.18 to 2.39)	5.35
35	Krugluger 200046	RCT		0.16 (0.01 to 1.65)	3.88
129	Lavignolle 198755	RCT		0.97 (0.33 to 2.81)	5.65
889	Lee 1996 ¹⁰⁴	CCS -		0.01 (0.00 to 0.04)	5.44
593	Muralikuttan 199285	RCT		0.33 (0.01 to 8.22)	2.89
617	Revel 1993 ⁸⁸	RCT		0.29 (0.14 to 0.61)	6.03
61	Tregonning 1991 ⁵³	CCS		0.49 (0.13 to 1.87)	5.29
160	Watts 1975 ⁵⁹	CCS	• •	0.38 (0.06 to 2.29)	4.64
150	Zeiger 1987 ⁵⁸	CCS		0.12 (0.04 to 0.36)	5.62
884	Alexander 1989 ¹⁰³	CCS	_ . _	1.05 (0.36 to 3.06)	5.65
441	Bonafe 199375	CCS		0.05 (0.01 to 0.47)	4.10
183	Bouillet 1983 ⁶¹	CCS	-	2.28 (1.72 to 3.00)	6.35
117	Lagarrigue 199154	CCS		2.74 (1.05 to 7.12)	5.79
47	Norton 1986 ⁵⁰	CCS		0.19 (0.04 to 0.92)	5.00
45	Postacchini 198749	Non-RCT		10.94 (2.46 to 48.65)	5.08
893	Watters 1988 ¹⁰⁵	Non-RCT		0.49 (0.04 to 5.58)	3.79
Subtotal	(<i>l</i> ² = 87.2%, <i>p</i> = 0.000)		\sim	0.54 (0.26 to 1.13)	100.00
Epidural	/intradiscal injection	DOT			100.00
725	Buttermann 2004 ⁹⁵	RCI		0.90 (0.27 to 3.01)	100.00
Intraope	erative interventions				
268	Aminmansour 200664	Q-RCT		2.72 (0.10 to 70.79)	1.75
492	Gerszten 2003 ⁸¹	RCT		1.00 (0.05 to 22.18)	1.94
276	Lundin 200366	RCT		2.78 (0.11 to 70.39)	1.78
379	Prestar 199571	RCT		- 15.74 (0.85 to 291.46)	2.18
618	Richter 2001 ⁸⁹	RCT		1.02 (0.20 to 5.11)	7.14
316	Cengiz 2007 ⁶⁹	RCT		3.69 (0.14 to 96.22)	1.75
909	Jirarattanaphochai 2007 ¹⁰⁶	RCT		2.08 (0.18 to 23.70)	3.14
915	Tribolet 1998 ¹⁰⁷	RCT		1.31 (0.81 to 2.12)	80.32
Subtotal	$(l^2 = 0.0\%, p = 0.806)$		\diamond	1.43 (0.93 to 2.20)	100.00
Mixed to	raatmanta				
734	Hoodand 200697	O-BCT		1 47 (0 24 to 8 99)	100.00
704	10091010 2000	Q-HOT		1.47 (0.24 10 0.33)	100.00
Non-opi	oids				
475	Dubourg 2002 ⁸⁰	CCS		2.22 (0.09 to 56.54)	100.00
011-01-0					
600	North 2005 ⁸⁶	BCT		0.23 (0.01 to 6.03)	100.00
000	North 2005	noi		0.23 (0.01 10 0.03)	100.00
Usual/co	onventional care				
386	Atlas 1996 ⁷²	CCS	•	– 29.57 (1.76 to 495.56)	34.38
750	Weinstein 200698	CCS		2.02 (0.10 to 42.20)	31.02
751	Weinstein 200699	RCT		→ 56.52 (3.42 to 935.13)	34.59
Subtotal	$(l^2 = 32.6\%, p = 0.227)$			16.09 (2.11 to 122.40)	100.00
		0 00107	· · · · · · · · · · · · · · · · · · ·	935	
		Favoure	disc surgery Favours cont	rol	

FIGURE 13 Summary of the findings of any adverse effect for studies comparing disc surgery with alternative interventions. Note: weights are from random effects analysis.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs (%)	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Disc surgery vs chemonucleolysis	27 (29)	29–1085 (126)	8/27 (30)	0/27 (0)	0/27 (0)	27/27 (100)	22/27 (81)	1/27 (4)	1/27 (4)	3/27 (11)	22/27 (81)	3/27 (11)
Disc surgery vs epidural/ Intradiscal injection	1 (1)	100 (100)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)
Disc surgery vs exercise therapy	1 (1)	57 (57)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	1/1 (100)	0/1 (0)	1/1 (100)	(0) 1/0	0/1 (0)	0/1 (0)
Disc surgery vs intraoprative interventions	17 (17)	10–398 (84)	15/17 (88)	0/17 (0)	0/17 (0)	17/17 (100)	15/17 (88)	1/17 (6)	4/17 (24)	2/17 (12)	9/17 (53)	1/17 (6)
Disc surgery vs mixed treatments	4 (5)	70–280 (123)	3/4 (75)	0/4 (0)	0/4 (0)	4/4 (100)	4/4 (100)	0/4 (0)	1/4 (24)	0/4 (0)	3/4 (75)	2/4 (50)
Disc surgery vs non- opioids	2 (3)	40–67 (54)	0/2 (0)	0/2 (0)	1/2 (50)	2/2 (100)	2/2 (100)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)
Disc surgery vs others	1 (1)	60 (60)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)
Disc surgery vs usual/ conventional care	10 (10)	55–743 (320)	3/10 (30)	2/10 (20)	2/10 (20)	10/10 (100)	8/10 (80)	1/10 (10)	2/10 (20)	0/10 (0)	5/10 (50)	1/10 (10)
Total (for disc surgery studies)	62 (65)	10–1085 (105)	32/62 (52)	2/62 (3)	4/62 (6)	62/62 (100)	53/62 (85)	3/62 (5)	10/62 (16)	6/62 (10)	41/62 (62)	10/62 (16)

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs.

TABLE 16 Summary of the disc surgery studies

at short-, medium- or long-term follow-up in patients with acute sciatica (one small, wellconducted RCT⁶⁸). There was also no significant difference between the intervention groups in terms of adverse effects.

One poorly reported RCT⁶³ (moderate quality) found that disc surgery in combination with acupuncture led to a greater reduction in pain intensity than disc surgery alone at short-term follow-up.

Intraoperative interventions led to a greater reduction in pain intensity at long-term follow-up than did disc surgery alone (four moderate- to poor-quality RCTs^{66,69,78,101}). However, there was no statistically significant difference between the intervention groups for global effect (at short-^{71,82} and long-term^{65,74,81,83,102} follow-up), pain intensity (at short-^{66,73,78,84,89,106} and medium-term^{64,66,73,84,89,101,106} follow-up), CSOMs (at short-^{70,73,89} and medium-term^{73,89,107} follow-up) and adverse effects (according to a number of studies, ranging from good to poor quality^{64,66,69,71,81,89,106,107}).

Pooled analysis of 18 studies^{47-51,53,55,56,58-60,75,85,88,90,92,103,104} showed marginally statistically significant findings in favour of disc surgery, compared with chemonucleolysis, for the global effect at long-term follow-up (see *Figure 9*). However, there was no statistically significant difference between the intervention groups for the global effect at short-^{48,49,52,79,92,104} and medium-term^{48,49,54,76,88,92,104,105} follow-up; pain intensity at short-,^{76,85,88} medium-^{76,85,88} and long-term^{77,85} follow-up; CSOMs at short-,^{85,88} medium-^{85,88,96} and long-term^{77,85,96} follow-up; or adverse effects^{46–51,53–56,58–61,75,85,88,96,103–105} (according to a number of studies, ranging from good to poor quality). There was no statistically significant difference between disc surgery in combination with chemonucleolysis and disc surgery alone, at long-term follow-up, for global effect, pain, or for adverse effects (one poor-quality Q-RCT⁹⁷).

There was no statistically significant difference between repeat disc surgery and spinal cord stimulation for the global effect at long-term follow-up or adverse effects of patients with chronic sciatica following previous disc surgery (one RCT⁸⁶).

Epidural/intradiscal injection

This category includes the use of epidural (injection into the epidural space) or intradiscal (injection into disc) injection of steroid and/or local anaesthetic in various combinations, as well as spinal nerve block using local anaesthetic. Studies that evaluate the use of an alternative class of medication via epidural or intradiscal injection have been classified according to the medication used. The use of a peripheral nerve block is not included in this section.

Description of epidural/intradiscal injection studies Summary of interventions

Sixty-three studies evaluated the use of epidural/intradiscal injection for sciatica^{95,143–204} (eight studies had more than two treatment arms^{146,149,161,163,167,169,183,197}), of which 35^{95,143–176} compared epidural/intradiscal injection with alternative interventions; the type of interventions being compared are listed in *Table 17a*. Five of these did not report usable data for pain, global or CSOMs,^{146,161,164,169,172} but three^{146,161,169} provided data on adverse effects. (Two studies^{161,169} were pilot studies that reported only baseline data for main outcome measures and follow-up data for adverse effects and cost.)

Thirty studies^{149,167,177-204} compared different types (in terms of content) of epidural/intradiscal injections, 10 studies^{181,183-185,187,193,194,197,200,202} (two studies had more than two treatment arms^{183,197}) compared different modes of administering epidural/intradiscal injections and 20 studies^{149,167,177-180,182,186,188-192,195,196,198,199,203,204,207} compared the use of different epidural/intradiscal injections. Details of the interventions are summarised in *Table 17b*, but the findings of these studies are not considered any further here.

Two further studies^{142,166} evaluated mixed treatments which included epidural. One study¹⁶⁶ compared the use of epidural plus traction and exercise therapy with traction and exercise therapy without epidural.

One further study¹⁴² compared disc surgery plus epidural (mixed treatments) with conventional care given while waiting for surgery. However, the study reported only health-care utilisation and employment-related outcomes.

Summary of study participants for epidural/intradiscal injections

Summary data for included participants are presented in Table 18. The number of participants included in the 28 studies that reported outcome data for global, pain or CSOMs ranged from 23 to 278 (median 74). Most epidural studies included patients with either acute or chronic sciatica. Only two studies^{145,176} included patients with acute sciatica (one epidural vs activity restriction and one epidural vs inactive control), with a mean of 34 days¹⁴⁵ or a median 4 weeks¹⁷⁶ for symptom duration of the current episode. One study⁹⁴ only included patients with the first episode of sciatica (epidural vs disc surgery) and one study¹⁵⁴ only included patients with recurrent symptoms (epidural vs usual care). The remaining studies included first and recurrent episodes or more usually did not report this information. Fifteen studies included patients who had received previous treatment for their current episode of sciatica; this information was not stated for the remaining studies. Two studies included patients who had previously received an epidural for their current episode, but this information was not reported for most studies. Three studies^{94,156,169} included patients who had had previous disc surgery, one of which¹⁶⁹ did not report data on global effect, pain or CSOMs. (One study⁹⁵ compared the use of epidural with disc surgery.) Two studies^{156,166} (comparator included non-opioids) included some patients with spinal stenosis and one study⁹⁴ (epidural vs disc surgery) included patients with sequestered discs.

TABLE 17a Summary of the interventions used when comparing epidural/intradiscal injection with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	Treatment description	Control description
Epidu	ral vs activity resi	triction		
140	Coomes, 1961 ¹⁴⁵	Non-RCT	Sacral epidural injection local anaesthetic 50–60 ml procaine	Bed rest at home on fracture-boards
Epidu	ral vs alternative/	non-traditional		
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	Nerve root blockade with local anaesthetic 5 ml mepivacaine twice a week for 5 weeks	Acupuncture and herbal medication
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	Nerve root blockade with steroid triamcinolone 20 mg + local anaesthetic 5 ml mepivacaine twice a week for 5 weeks	Acupuncture and herbal medication
Epidu	ral vs biological a	gents		
321	Becker, 2007 ¹⁴⁹	RCT	Epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (group 2)	Epidural injection of autologous conditioned serum (group 1)
321	Becker, 2007 ¹⁴⁹	RCT	Epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (group 3)	Epidural injection of autologous conditioned serum (group 1)
Epidu	ral vs chemonucl	eolysis		
720	Bontoux, 1990 ¹⁶⁸ (French language)	RCT	Intradiscal injection of triamcinolone 70 mg	Chemonucleolysis with chymopapain 4000 U
447	Bourgeois, 1988 ¹⁶⁰ (French language)	RCT	Intradiscal injection of triamcinolone 80 mg	Chemonucleolysis with chymopapain 4000 U
729	Gallucci, 2007 ¹⁷⁰	RCT	Intraforaminal and intradiscal injections of steroid triamcinolone 80 mg + local anaesthetic 2–4 ml ropivacaine (group A)	Intraforaminal and intradiscal injections of steroid triamcinolone 80 mg + local anaesthetic 2–4 ml ropivacaine plus ozone– oxygen (group B)
50	Graham, 1976 ¹⁴⁴	Non-RCT	Intradiscal hydrocortisone injection (dose not stated)	Chemonucleolysis with chymopapain (dose not stated)
Epidu	ral vs disc surger	y		
725	Buttermann, 2004 ⁹⁵	RCT	Epidural injection of steroid betamethasone 10–15 mg up to three injections	Discectomy
Epidu	ral vs education/a	advice		
722	Bronfort, 2004 ¹⁶⁹	RCT	Three ESIs over 12 weeks	Self-care education
Epidu	ral vs inactive cor	ntrol		
203	Bush, 1991 ¹⁴⁷	RCT	Caudal epidural injection of steroid (80 mg of triamcinolone acetonide) + local anaesthetic (0.5% procaine hydrochloride)	Caudal injection of 25 ml normal saline
350	Carette, 1997 ¹⁵²	RCT	Epidural injection of steroid methylprednisolone 80 mg, 1–3 injections	Normal saline epidural injections
383	Dilke, 1973 ¹⁵⁷	RCT	Lumbar epidural injection of steroid methylprednisolone 80 mg	Injection of saline into interspinous ligament
512	Helliwell, 1985 ¹⁶²	RCT	Epidural injection of steroid methylprednisolone 80 mg (EDI)	Interspinous saline injections (control)

continued

Interve	entions (groupe	d by comparato	or then ordered by author) (continued)	
ID no.	Author, year	Study design	Treatment description	Control description
739	Karppinen, 2001 ¹⁷¹	RCT	Periradicular injection of steroid methylprednisolone 40 mg + local anaesthetic bupivacaine	Periradicular saline injection
539	Klenerman, 1984 ¹⁶³	RCT	Epidural injection of steroid methylprednisolone 80 mg	Epidural injection of saline
539	Klenerman, 1984 ¹⁶³	RCT	Epidural injection of local anaesthetic 20 ml bupivacaine	Epidural injection of saline
905	Mathews,	RCT	Caudal epidural injection	Control injection
	1987 ¹⁷⁶		Injections of 20 ml of 0.125% bupivacaine and 2 ml (80 mg) methylprednisolone acetate given at fortnightly intervals, up to three times as needed	Injection of 2 ml lidocaine over the sacral hiatus or into a tender spot
778	Price, 2005 ¹⁷³	RCT	Epidural injection of steroid triamcinolone 80 mg and local anaesthetic 10 ml bupivacaine	Saline injection into interspinous ligament (placebo)
620	Ridley, 1988 ¹⁶⁵	RCT	Epidural injection of steroid methylprednisolone 80 mg	Saline injection into interspinous ligament (placebo)
240	Snoek, 1977148	RCT	Epidural injection of steroid methylprednisolone 80 mg	Epidural injection of saline
406	Vad, 2002 ¹⁵⁸	RCT	Transforaminal epidural steroid injections with betamethasone 9 mg and 1.5 ml xylocaine, 1–3 injections	Trigger-point saline injections epidural steroid injections, 1–2 injections
351	Valat, 2003 ¹⁵³	RCT	Three interlaminar epidural injections of steroid methylprednisolone 50 mg at two day intervals	Three interlaminar epidural injections of saline at 2-day intervals
175	Yates, 1978146	RCT (crossover)	Caudal epidural injections of steroid	Caudal epidural injections of saline
175	Yates, 1978146	RCT (crossover)	Caudal epidural injections of local anaesthetic	Caudal epidural injections of saline
175	Yates, 1978 ¹⁴⁶	RCT (crossover)	Caudal epidural injections of steroid + local anaesthetic	Caudal epidural injections of saline
Epidu	ral vs manipulatio	on		
451	Bronfort, 2000 ¹⁶¹	RCT	Epidural injection of steroid injections, 1–3 injections	Chiropractic spinal manipulation
722	Bronfort, 2004 ¹⁶⁹	RCT	Three epidural steroid injections over 12 weeks	Chiropractic spinal manipulation
Epidu	ral vs mixed treat	ment		
439	Blonna,	RCT	Epidural steroid + local anaesthetic injections (4 mg	(Epidural + non-opioids)
	2004 ¹⁵⁹ (Italian language)		betamethasone + 3 ml ropovicaine 0.2%)	Epidural steroid + local anaesthetic injections (4 mg betamethasone + 3 ml ropovicaine 0.2%) and oral gabapentin (Neurontin [®] , Pfizer) (up to 900 mg daily)
348	Pirbudak,	RCT	Epidural injection of steroid betamethasone 14 mg	(Epidural + non-opioids)
	2003150		and local anaesthetic bupivacaine + oral placebo for 9 months	Epidural injection of steroid betamethasone 14 mg and local anaesthetic bupivacaine + oral amitriptyline 10 mg daily for 9 months
Epidu	ral vs non-opioids	5		
451	Bronfort, 2000 ¹⁶¹	RCT	Epidural injection of steroid injections, 1–3 injections	Paracetamol, NSAIDs, activity modification
20	Dincer, 2007 ¹⁴³	RCT	Caudal epidural injection 40 mg methylprednisolone acetate, 8 mg dexamethasone phosphate, 7 ml of 2% prilocaine	Oral diclofenac 75 mg for 14 days (NSAID)
771	Lafuma, 1997 ¹⁷²	RCT	Epidural steroid (125 mg prednisolone) injections at admission	Usual care (rest + NSAIDs) without epidural injections during hospital admission

TABLE 17a Summary of the interventions used when comparing epidural/intradiscal injection with alternative interventions (grouped by comparator then ordered by author) (continued)

TABLE 17a Summary of the interventions used when comparing epidural/intradiscal injection with alternative interventions (grouped by comparator then ordered by author) (continued)

ID				
no.	Author, year	Study design	Treatment description	Control description
362	Wilson- MacDonald, 2005 ¹⁵⁶	RCT	Epidural injection of steroid methylprednisolone 80 mg and local anaesthetic 8 ml bupivacaine	Intramuscular injections of steroid methylprednisolone 80 mg and local anaesthetic 8 ml bupivacaine
846	Murata, 2009 ¹⁷⁵	RCT	L2 nerve block using steroid (3.3 mg dexamethasone sodium phosphate) and local anaesthetic (2 ml of 1% lidocaine)	Injection of steroid (3.3 mg dexamethasone sodium phosphate) and local anaesthetic (7 ml of 1% lidocaine) in the back muscles of L2 area (control block)
Epidu	ral vs passive PT			
9	Veihelmann, 2006 ¹⁵⁵	RCT	Epidural injection via epidural catheter (neuroplasty) of steroid triamcinolone 40 mg and ropivacaine	Conservative physiotherapy
Epidu	ral vs usual/conve	entional care		
349	Buchner, 2000 ¹⁵¹	RCT	Three epidural injections of steroid methylprednisolone 100 mg and 10 ml bupivacaine plus conservative therapy and graded rehabilitation	Conservative therapy and graded rehabilitation without epidural injections
828	Laiq, 2009 ¹⁷⁴	Q-RCT	Epidural steroid (80 mg methylprednisolone) + local anaesthetic (3 ml of 2% plain xylocaine) + 3 ml normal saline (steroid group)	Bed rest, NSAIDs, muscle relaxants and opioids (Conservative group)
581	Matyjek, 1986 ¹⁶⁴ (Polish language)	CCS	Caudal epidural injection. Seven doses of hydrocortisone acetate 0.025 g and a final injection of methylprednisolone 0.04 g	Control group treated by various other methods which were not stated
358	Popiolek, 1991 ¹⁵⁴ (Polish language)	Non-RCT	Epidural injection of steroid and local anaesthetic. Injected with separate syringes of 5 ml of 0.5% bupivacaine then 40 mg methylprednisolone (n =15) or 40 mg triamcinolone (n =15). Repeated after 14 days if necessary	No epidural injection
Mixed	l treatment incorp	orating epidural v	vs mixed treatment without epidural	
644	Styczynski, 1997 ¹⁶⁶ (Polish language)	Non-RCT	Epidural, traction and therapeutic exercises	Traction and therapeutic exercises

U, units.

TABLE 17b Summary of the interventions used when comparing alternative forms of epidural (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	Treatment category	Treatment description	Control category	Control description
Сотр	arison of different	modes of	administration	1		
326	Acherman, 2007 ¹⁸³	RCT	Epidural/ intradiscal injection	Intralaminar epidural injections of steroid triamcinolone 40 mg	Epidural/ intradiscal injection	Caudal epidural injections of steroid triamcinolone 40 mg
326	Acherman, 2007 ¹⁸³	RCT	Epidural/ intradiscal injection	Transforaminal epidural injection of steroid triamcinolone 40 mg	Epidural/ intradiscal injection	Caudal epidural injections of steroid triamcinolone 40 mg
389	Candido, 2008 ¹⁸⁷	RCT	Epidural/ intradiscal injection	Epidural steroid injection (80 mg prednisolone with lidocaine) using parasagittal interlaminar approach	Epidural/ intradiscal injection	ESIs (80 mg prednisolone with lidocaine) using transforaminal approach

continued

99

TABLE 17b Summary of the interventions used when comparing alternative forms of epidural (grouped by comparator then ordered by author) (continued)

ID no.	Author, vear	Study desian	Treatment category	Treatment description	Control category	Control description
302	Jeong, 2007 ¹⁸¹	RCT	Epidural/ intradiscal injection	Transforaminal epidural steroid injection (ganglionic group)	Epidural/ intradiscal injection	Transforaminal epidural steroid injection (preganglionic group)
328	Kolsi, 2000 ¹⁸⁴	RCT	Epidural/ intradiscal injection	Nerve root injections of steroid cortivazol 3.75 mg + local anaesthetic 2 ml lidocaine	Epidural/ intradiscal injection	Interspinous epidural injection of steroid cortivazol 3.75 mg + local anaesthetic 2 ml lidocaine
556	Lee, 2006 ¹⁹³	HCS	Epidural/ intradiscal injection	Preganglionic epidural injection of steroid triamcinolone 40 mg and 0.5 ml bupivacaine (preganglionic)	Epidural/ intradiscal injection	Interlaminar or caudal epidural injection of steroid triamcinolone 40 mg and 0.5 ml bupivacaine (conventional)
830	Lee, 2009 ¹⁹⁷	CCS	Epidural/ intradiscal injection	Translaminar epidural steroid (40 mg triamcinolone) and local anaesthetic (8 ml of 0.5% lidocaine) injection	Epidural/ intradiscal injection	Caudal epidural steroid (40 mg triamcinolone) and local anaesthetic (15 ml of 0.5% lidocaine) injection
830	Lee, 2009 ¹⁹⁷	CCS	Epidural/ intradiscal injection	Translaminar epidural steroid (40 mg triamcinolone) and local anaesthetic (8 ml of 0.5% lidocaine) injection	Epidural/ intradiscal injection	Transforaminal epidural steroid (40 mg triamcinolone) and local anaesthetic (2 ml of 0.5% lidocaine) injection; small volume group
830	Lee, 2009 ¹⁹⁷	CCS	Epidural/ Intradiscal injection	Translaminar epidural steroid (40 mg triamcinolone) and local anaesthetic (8 ml of 0.5% lidocaine) injection	Epidural/ intradiscal injection	Transforaminal epidural steroid (40 mg triamcinolone) and local anaesthetic (2 ml of 0.5% lidocaine) injection; large volume group
842	Mendoza- Lattes ²⁰⁰	CCS	Epidural/ intradiscal injection	Caudal epidural steroid (either 2 ml of 80 mg methylprednisolone or 3 ml of 18 mg betamethasone) injection	Epidural/ intradiscal injection	Transforaminal epidural injection of steroid [methylprednisolone (40 mg/ ml) or betamethasone (6 mg/ml)] and local anaesthetic (1.5–2.0 cc 1 : 1 solution of bupivacaine 0.25%) injections
630	Schaufele, 2006 ¹⁹⁴	CCS	Epidural/ intradiscal injection	Interlaminar epidural injection of steroid methylprednisolone 80 mg + 3 ml lidocaine	Epidural/ intradiscal injection	Transforaminal epidural injection of steroid methylprednisolone 80 mg + 2 ml lidocaine
330	Thomas, 2003 ¹⁸⁵	RCT	Epidural/ intradiscal injection	Interspinous epidural injection of steroid dexamethasone 5 mg	Epidural/ intradiscal injection	Transforaminal epidural injection of steroid dexamethasone 5 mg
895	Winnie, 1972 ²⁰²	RCT	Epidural/ intradiscal injection	Epidural corticosteroid (80 mg of methylprednisolone). Average of 2.1 injections	Epidural/ intradiscal injection	Intrathecal corticosteroid (80 mg of methylprednisolone). Average of 2.1 injections
Сотр	arison of different	type of ep	idurals (conte	nt)		
896	Anwar, 2005 ²⁰³	RCT	Epidural/ intradiscal injection	Caudal epidural steroid injection with triamcinolone (40 mg) and local anaesthetic (5 ml of 1% lignocaine)	Epidural/ intradiscal injection	Caudal epidural steroid injection with methylprednisolone (40 mg) and local anaesthetic (5 ml of 1% lignocaine)
321	Becker, 2007 ¹⁴⁹	RCT	Epidural/ intradiscal injection	Epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (group 2)	Epidural/ intradiscal injection	Epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (group 3)
141	Beliveau, 1971 ¹⁷⁷	Q-RCT	Epidural/ intradiscal injection	Epidural injection of steroid 80 mg methylprednisolone + local anaesthetic 40 ml procaine	Epidural/ intradiscal injection	Epidural injection of 42 ml procaine
437	Blankenbaker, 2005 ¹⁸⁹	HCS	Epidural/ intradiscal injection	Selective lumbar nerve root block with triamcinolone 40 mg	Epidural/ intradiscal injection	Selective lumbar nerve root block with betamethasone 6 mg
450	Breivik, 1976 ¹⁹⁰	RCT	Epidural/ intradiscal injection	Epidural steroid + local anaesthetic injections (80 mg depot methylprednisolone + 20 ml bupivacaine 0.25%)	Epidural/ intradiscal injection	Epidural bupivacaine injections 20 ml
803	Cocelli, 2009 ¹⁹⁵	RCT	Epidural/ intradiscal injection	Epidural injection of betamethasone (10 mg) and bupivacaine (0.125% in 20 ml), 1–3 injections (group 1)	Epidural/ intradiscal injection	Epidural injection of triamcinolone (80 mg) and bupivacaine (0.125% in 20 ml), 1–3 injections (group 2)

TABLE 17b Summary of the interventions used when comparing alternative forms of epidural (grouped by comparator then ordered by author) (continued)

ID no.	Author, year	Study design	Treatment category	Treatment description	Control category	Control description
413	Cuckler, 1985 ¹⁸⁸	RCT	Epidural/ intradiscal injection	Epidural injection of steroid methylprednisolone 80 mg and local anaesthetic 5 ml procaine	Epidural/ intradiscal injection	Epidural injection of saline and local anaesthetic 5 ml procaine
149	Dashfield, 2005 ¹⁷⁸	RCT	Epidural/ intradiscal injection	Targeted injection during spinal endoscopy of steroid 40 mg triamcinolone + 10 ml lidocaine	Epidural/ intradiscal injection	Caudal epidural injection of steroid 40 mg triamcinolone + local anaesthetic 10 ml lidocaine
483	Faraj, 2006 ¹⁹¹	RCT	Epidural/ intradiscal injection	Nerve root infiltration using steroid + local anaesthetic (40 mg + 0.5 ml of 0.5% bupivacaine) with the aid of nerve stimulator	Epidural/ intradiscal injection	Nerve root infiltration using steroid + local anaesthetic (40 mg + 0.5 ml bupivacaine 0.5%) without the aid of nerve stimulator
500	Gronemeyer, 1995 ¹⁹² (German language)	RCT	Epidural/ intradiscal injection	Epidural injection of steroid triamcinolone 40 mg. 2–11 treatments over 3–8 weeks	Epidural/ intradiscal injection	Epidural injection of steroid triamcinolone 10 mg. 2–11 treatments over 3–8 weeks
814	Hagihara, 2009 ¹⁹⁶	Q-RCT	Epidural/ intradiscal injection	Selective nerve root block with steroid (4 mg in 1 ml betamethasone) and local anaesthetic (2 ml of lidocaine hydrochloride)	Epidural/ intradiscal injection	Selective nerve root block of local anaesthetic only (3 ml of lidocaine hydrochloride)
838	Manchikanti, 2008 ¹⁹⁸	RCT	Epidural/ intradiscal injection	Caudal epidural steroid (either 6 mg of betamethasone or 40 mg of methylprednisolone) and local anaesthetic (9 ml of 0.5% lidocaine) injections (steroid group)	Epidural/ intradiscal injection	Caudal epidural local anaesthetic (10 ml of lidocaine 0.5%) injections (local anaesthetic group)
908	Manchikanti, 2009 ²⁰⁴	RCT	Epidural/ intradiscal injection	Caudal epidural steroid (either 6 mg of betamethasone or 40 mg of methylprednisolone) and local anaesthetic (9 ml of 0.5% lidocaine) injections (steroid group)	Epidural/ intradiscal injection	Caudal epidural injections of local anaesthetic (0.5% lidocaine 9 ml) (local anaesthetic group)
839	Manchikanti, 2009 ¹⁹⁹	RCT	Epidural/ intradiscal injection	Caudal epidural steroid (either 6 mg of betamethasone or 40 mg of methylprednisolone) and local anaesthetic (9 ml of 0.5% lidocaine) injections (steroid group)	Epidural/ intradiscal injection	Caudal epidural local anaesthetic (10 ml of lidocaine 0.5%) injections (local anaesthetic group)
318	Ng, 2005 ¹⁸²	RCT	Epidural/ intradiscal injection	Periradicular injection of steroid methylprednisolone 40 mg + local anaesthetic 2 ml bupivacaine	Epidural/ intradiscal injection	Periradicular injection of local anaesthetic 2 ml bupivacaine
176	Owlia, 2007 ¹⁷⁹	RCT	Epidural/ intradiscal injection	Epidural injection of 80 mg methylprednisolone acetate (80 mg steroid group)	Epidural/ intradiscal injection	Epidural injection of 40 mg methylprednisolone acetate (40 mg steroid group)
273	Riew, 2000 ¹⁸⁰	RCT	Epidural/ intradiscal injection	Nerve root injection of steroid betamethasone 6 mg + local anaesthetic 1 ml bupivacaine up to four injections	Epidural/ intradiscal injection	Nerve root injection of local anaesthetic 1 ml bupivacaine up to four injections
365	Rogers, 1992 ¹⁸⁶	RCT	Epidural/ intradiscal injection	Epidural injection of steroid methylprednisolone 80 mg and local anaesthetic 14 ml lidocaine	Epidural/ intradiscal injection	Epidural injection of local anaesthetic 14 ml lidocaine
866	Tafazal, 2009 ²⁰¹	RCT	Epidural/ intradiscal injection	Periradicular infiltration of steroid (40 mg methylprednisolone) and bupivacaine (2 ml of 0.25%) injection	Epidural/ intradiscal injection	Periradicular infiltration bupivacaine (2 ml of 0.25%)
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	Epidural/ intradiscal injection	Nerve root blockade with steroid triamcinolone 20 mg + local anaesthetic 5 ml mepivacaine, twice a week for 5 weeks	Epidural/ intradiscal injection	Nerve root blockade with local anaesthetic 5 ml mepivacaine, twice a week for 5 weeks

en	
or th	
arato	
dm	
y co	
q þé	
edno	
(gro	
ions	
vent	
nter	
ive i	
rnat	
alte	
with	
, suc	
ectic	
al inj	
disca	
ntrac	
ral/ir	
oidu	
ig ep	
oarir	
omp	
es c	
studi	
for s	
ails	
det	
ation	
pula	
y po	
stud	
and 3	
be a	
ca ty	
siatic	
of sc	
ary c	÷
ШШ	thor
Su	y au
Е 18	ğ
BLI	dere

TABLE ordere	18 Summe d by author)	ary of sciat	ica type ar	nd study popu	ulation det	ails for studies com	ıparing epidı	ıral/intradisc:	al injections	with alterna	itive interventi	ons (grouped	d by compar	ator then
<u>م</u> ع	Author, vear	Study	No. of patients	Ade (vears)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent enisode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)?ª	Any previous treatment for sciatica?	Any previous back surgery for sciatica?	Any previous enidural?
Epidu	ral vs activity i	restriction	-					5	-					
140	Coomes, 1961 ¹⁴⁵	Non- RCT	40	Mean 43 (range 16–70)	26 (65)	Mean 34 days	Nerve root pain	No	RN	No	N	Yes	R	NR
Epidu	ral vs alternati	ive/non-trad	itional											
667	Wehling, 1997 ¹⁶⁷ (German Ianguage)	CCS	278	NR	ĸ	At least 3 months	Nerve root pain and referred pain	No	N	N	N	NR	NR	Yes
Epidu	ral vs biologic:	al agents												
321	Becker, 2007 ¹⁴⁹	RCT	06	Mean 53.9 (range 29–81)	52 (62)	At least 6 weeks	Nerve root pain	Yes	N	0 N	N	NR	RN	No epidural in last 3 months
Epidu.	ral vs chemon	ucleolysis												
720	Bontoux, 1990 ¹⁶⁸ (French language)	RCT	80	Mean 40	50 (63)	At least 2 months; >6 months 34%	Nerve root pain	Yes	RN	N	N	Yes	NR	Yes
447	Bourgeois, 1988 ¹⁶⁰ (French language)	RCT	60	Mean 37 (range 26–62)	40 (67)	Mean 178 (range 50–700) days	Nerve root pain	Yes	Recurrent and first episode	N	N	Yes	N	Yes
729	Gallucci, 2007 ¹⁷⁰	RCT	159	Mean 41.5 (range 18–71)	86 (54)	Mean 15 weeks	Nerve root pain	Yes	NR	No	No	Yes		

e ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)?ª	Any previous for sciatica?	Any previous back surgery for sciatica?	Any previous epidural?
20	Graham, 1976 ¹⁴⁴	RCT-RCT	40 (23 with sciatica)	Mean 42 Sciatica patients: mean 41 (range 24–66)	25 (63). Sciatica patients: 13 (57)	Mean back pain or sciatica for whole group 5.35 years. Sciatica patients median 1 year (range 12 weeks-25 years)	Nerve root pain and referred pain	Yes	R	N	R	Yes	R	ЯN
Epidu	ral vs disc sur _t	<i>jery</i>												
725	Buttermann, 2004 ⁹⁵	RCT	100	Mean 40.5 (SD 12)		Mean 3.55 months (SD 2.75 months)	Nerve root pain	Yes	First episode	No	Yes	Yes	Yes	NR
Epidu	ral vs educatio	n/advice												
722	Bronfort, 2004 ¹⁶⁹	RCT	32	Mean 49.0 (SD 9.1)	18 (56)	1–3 months 19%, 4–6 months 6%, 7–12 months 9%, >12 months 66%	Nerve root pain and referred pain	N	Recurrent and first episode	No	No	NN	Yes	R
Epidu	ral vs inactive	control												
203	Bush, 1991 ¹⁴⁷	RCT	23	Mean 37.8 (range 23-71)	15 (65)	Mean 4.7 months (range 1–13 months)	Nerve root pain	No	NR	No	No	NR	NR	NR
350	Carette, 1997 ¹⁵²	RCT	158	Mean 39.8 (SD 10.2)	103 (65)	Median 13 weeks	Nerve root pain	Yes	Recurrent and first episode	No	No	NR	No	No epidural in last year
383	Dilke, 1973 ¹⁵⁷	RCT	100	Mean 40.4 (range 18-75)	55 (56)	1-4 weeks 10%, 4 weeks-3 months 27%, 3-6 months 33%, 6-12 months 17%, 1-2 years 10%, > 2 years 2%	Nerve root pain	No	Recurrent and first episode	No	8	N	Q	R
														continued

parator then	
ouped by con	
erventions (gr	
ı alternative in	
injections with	
ral/intradiscal	
nparing epidu	
for studies co	
ulation details	
nd study popu	
sciatica type a nued)	
Summary of s author) <i>(contii</i>	
TABLE 18 ordered by	

Any previous epidural?	R	No	NR	NR	No	None for current episode	NR	No	No spinal injection in last month	R
Any previous back surgery for sciatica?	No	N	No	NR	No	No	N	No	NO	NR
Any previous treatment for sciatica?	NR	NR	NR	NR	Yes	R	NR	Yes	NR	NR
Included patients with sequestered disc (or extruded)?ª	No	No	No	NR	No	No	No	No	No	No
Included patients with stenosis?ª	Q	No	No	NR	No	No	No	No	N	N
Recurrent episode	R	Recurrent and first episode	NR	NR	Recurrent and first episode	Recurrent and first episode	NR	NR	Recurrent and first episode	NR
Confirmed by imaging?	N	Yes	No	No	No	No	Yes	Yes	NO	No
Type of sciatica	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain and refereed pain	Nerve root pain and referred pain
Symptom duration	Mean 10.7 months (range 2.5–48 months)	2.5 months (SD 1.5 months)	< 6 months	Median 4 weeks (range 3 days–3 months)	< 4 months 37%, 4-18 months 63%	Mean 8.2 months (SD 6.8 months)	Mean 11.2 weeks (range 12 days-36 weeks)	> 6 weeks	> 15 days and < 180 days	R
No. of men (%)	9 (23)	115 (72)	NR	43 (75)	121 (53)	15 (43)	26 (51)	NR	46 (54)	N
Age (years)	Mean 46 (range 20–69)	Mean 43.8 (SD 13)	N	Median 40 (range 18–59)	Mean 43.5 (SD 12)	Mean 39 (SD 10)	Mean 45 (range 26–67)	Mean 41.5	Mean 41 (SD 10.4)	N
No. of patients	39	160	74	57	228	30	51	50	85	20
Study design	RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT	RCT
Author, year	Helliwell, 1985 ¹⁶²	Karppinen, 2001 ¹⁷¹	Klenerman, 1984 ¹⁶³	Mathews, 1987 ¹⁷⁶	Price, 2005 ¹⁷³	Ridley, 1988 ¹⁶⁵	Snoek, 1977 ¹⁴⁸	Vad, 2002 ¹⁵⁸	Valat, 2003 ¹⁵³	Yates, 1978 ¹⁴⁶
₽ Ê	512	739	539	905	778	620	240	406	351	175

ny evious ack Any	urgery for previous statica? epidural?		No	o No epidural in last year		NR	0 NR	R	ss Partial (seven patients had previous epidural)	No
Any Ar previous pr treatment ba	for su sciatica? so		Yes No	Yes No		Yes No	NR	Yes NF	Yes	Yes No
Included patients with sequestered	disc (or extruded)?ª		NR	No		No	No	NR	No	NR
Included	with stenosis? ^a		Yes	N		No	No	No	Yes	NR
	Recurrent episode		NN	RN		NN	NR	Recurrent and first episode	R	NR
Confirmed	by imaging?		Yes	Yes		N	Yes	N	Yes	No
	Type of sciatica		Nerve root pain	Nerve root pain		Nerve root pain and refereed pain	Nerve root pain and refereed pain	Nerve root pain	Nerve root pain	Nerve root pain
	Symptom duration		Mean 84 days (SD 48 days)	Median 16.5 months (range 6–48 months)		≤3 weeks <i>n</i> =6, 4–12 weeks <i>n</i> =14	1-12 months	Mean 56 days (range 1–854 days)	> 6 weeks, exact duration NR	Median 31 months (SD 52 months)
No. of	men (%)		NN	30 (33)		12 (60)	46 (72)	66 (61)	37 (40)	90 (37)
	Age (years)		Mean 61 (SD 15)	Mean 49 (SD 12.1)		Mean 44.5 (SD 10.6)	Mean 28 (SD 5)	Mean 42.1 (SD 10.6)	Mean 49 (range 23–79)	Mean 68 (SD 12, range 27–90)
	No. of patients		50	92		20	64	108	93	246 (136 radicular pain)
	Study design	9atment	RCT	RCT	ids	RCT	RCT	RCT	RCT	RCT
	Author, year	al vs mixed tre	Blonna, 2004 ¹⁵⁹ (Italian language)	Pirbudak, 2003 ¹⁵⁰	al vs non-opio	Bronfort, 2000 ¹⁶¹	Dincer, 2007 ¹⁴³	Lafuma, 1997¹ ⁷²	Wilson- MacDonald, 2005 ¹⁵⁶	Murata, 2009 ¹⁷⁵
	Ωġ	Epidur.	439	348	Epidur	451	20	771	362	846

len	
r th	
rato	
pa	
τος	
ο λ	
ed l	
dn	
(grc	
su	
Jtio	
IVel	
nte	
vei	
nati	
ter	
ha	
wit	
suc	
ctic	
inje	
cal	
dis	
Jtra	
al/ir	
qup	
epi	
ing	
par	
Eo	
o se	
ipr	
r sti	
s foi	
tails	
det	
ion	
ulat	
doc	
Å ₽	
stu	
pu	
ое а	
tyr	
d)	
scia	
of s ntir	
ary (cc	
nm; hor)	
Sur autl	
by <mark>1</mark>	
red F	
rde	
	1

Any previous	epidurais		NR		NR	No	NN	NR		NR
Any previous back surgery for	scialica?		NR		No	NR	NR	NR		No
Any previous treatment for	scialica?		Yes		R	NR	NR	NR		NR
Included patients with sequestered disc (or	exiruaeu) :"		No		No	NR	NR	NR		R
Included patients with	SIGIIOSIS		No		No	No	NR	NR		Yes
Recurrent	episone		NR		R	NR	NR	Recurrent		NR
Confirmed by	imaging <i>:</i>		Yes		Yes	Yes	No	Yes		Yes
Type of	scialica		Nerve root pain		Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain		Nerve root pain
Sumation duration	symptom auranon		NR		Median 8 weeks (range 1–150 weeks)	> 2 weeks	NR	Mean 1.95 months	dural	Mean 4 weeks one group; 5 months
No. of men	(%)		45 (45)		23 (64)	32 (62)	R	39 (65)	t without epi	57 (55)
And (under)	Age (years)		Mean 44.5 (SD 24)		Mean 34.3 (range 20–50)	Mean 40.5 (SD 2.3)	NR	Mean 41.3 (range 27–63)	nixed treatmen	Range 27–85
No. of	pallents		66	care	36	52	629	60	epidural vs n	103
Study	nesign	Ы	RCT	nventional u	RCT	Q-RCT	CCS	Non- RCT	orporating e	Non- RCT
Author,	year	al vs passive	Veihelmann, 2006 ¹⁵⁵	al vs usual/co	Buchner, 2000 ¹⁵¹	Laiq, 2009 ¹⁷⁴	Matyjek, 1986 ¹⁶⁴ (Polish language)	Popiolek, 1991 ¹⁵⁴ (Polish language)	treatment inc	Styczynski, 1997 ¹⁶⁶ (Polish Ianguage)
<u>و</u>	2 I	Epidura	359	Epidurč	349	828	581	358	Mixed	644

NR, not reported. a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included otherwise reported as no.

Summary of study design and quality for epidural/intradiscal injection studies

Summary information on study details is presented in *Table 19*, excluding studies^{146,161,164,169,172} that did not report outcome data for global effect, pain intensity or CSOMs. Most included epidural studies were RCTs (24/29, 83%); however, the proportion that were deemed good quality was very low (4/29, 14%), all of which compared epidural with inactive control. Although 10 studies^{149,152,153,156,160,163,165,168,171,173} used and adequate method for generating a random number sequence, eight of these used sealed envelopes to conceal allocation, which is a partially adequate method. Only one study had good external validity.¹⁷¹

Epidural/intradiscal injection results at short-term follow-up (≤6 weeks) Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 20* and the accompanying forest plot (*Figure 14*). Epidural/intradiscal injections were compared with inactive control, usual care and chemonucleolysis (not widely used in the UK NHS). One study¹⁷⁶ included only patients with acute sciatica, and the remaining studies included patients with either acute or chronic sciatica. The duration of follow-up ranged from 24 hours¹⁴⁸ to 6 weeks.¹⁷³

Six RCTs^{148,152,153,165,173,176} compared epidural injections with inactive control; the overall findings were found to be in favour of epidural, but were not statistically significant. Three RCTs^{152,153,173} were good quality. The study that had the largest effect size in favour of epidural injections,¹⁶⁵ and the only study to have statistically significant results, was of poor quality.

One poorly reported non-RCT¹⁵⁴ found that epidural injections were much better than usual care, in terms of the global effect at 21 days, in patients who had had sciatica for a mean of 2 months.

One moderate-quality RCT¹⁷⁰ found no statistically significant difference between intraforaminal and intradiscal injections of steroid plus local anaesthetic (categorised as epidural) compared with intraforaminal and intradiscal injections of steroid, local anaesthetic and ozone–oxygen (categorised as chemonucleolysis). The study included patients with both acute and chronic sciatica, with a mean duration of symptoms of 15 weeks.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 21* and the accompanying forest plot (*Figure 15*). Epidural injections/nerve block were compared with inactive control, usual care, non-opioids, alternative therapy and mixed treatments. Three studies^{150,167,175} included patients with chronic sciatica, one study¹⁷⁴ did not report the duration of symptoms, and the remaining studies included patients with either acute or chronic sciatica. The duration of follow-up ranged from post treatment to 6 weeks.^{158,173}

The overall findings from seven RCTs^{147,152,153,158,162,171,173} found a statistically significant reduction in pain intensity for epidural injections compared with inactive control. Four of these RCTs^{152,153,171,173} were good quality; three were moderate quality. One study¹⁷¹ was also considered as having good external validity, whereas four^{147,153,158,162} of the seven were rated as poor. One further RCT¹⁶⁵ found epidural injection to be superior to inactive control, but reported data only for median percentage improvement.

One moderate-quality RCT¹⁵¹ and one Q-RCT¹⁷⁴ compared epidural injections with usual care. The Q-RCT¹⁷⁴ reported a statistically significant improvement in favour of epidural injection; the RCT¹⁵¹ reported a smaller improvement which was not statistically significant. When the results were combined in a meta-analysis, there was no statistically significant difference.
 TABLE 19
 Summary of the study details for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow- up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Epidu	ral vs activity restric	tion								
140	Coomes, 1961 ¹⁴⁵	40	9 weeks	Non- RCT	No	No	80–100	No	Weak	Weak
Epidu	ral vs alternative/no	n-traditiona	1							
667	Wehling, 1997 ¹⁶⁷ (German language)	278	5 weeks	CCS	No	No	80–100	No	Weak	Weak
Epidu	ral vs biological age	nts								
321	Becker, 2007149	90	22 weeks	RCT	Yes	Partial	80–100	Yes	Moderate	Weak
Fnidu	ral vs chemonucleol	vsis								
720	Bontoux, 1990 ¹⁶⁸ (French language)	80	3 months	RCT	Yes	Unclear	80–100	Yes	Moderate	Weak
447	Bourgeois, 1988 ¹⁶⁰ (French language)	60	6 months	RCT	Yes	Partial	80–100	Yes	Moderate	Weak
729	Gallucci, 2007170	159	6 months	RCT	Unclear	Unclear	80–100	Yes	Moderate	Weak
50	Graham, 1976 ¹⁴⁴	40 (23 with sciatica)	2 years	Non- RCT	No	No	80–100	Yes	Weak	Weak
Epidu	ral vs disc surgery									
725	Buttermann, 2004 ⁹⁵	100	2–3 years	RCT	Unclear	Unclear	80–100	No	Moderate	Moderate
Epidu	ral vs education/adv	ice								
722	Bronfort, 2004 ¹⁶⁹	32	52 weeks	RCT	Unclear	Partial	80–100	Unclear	Weak	Weak
Fnidu	ral vs inactive contro	nl								
203	Bush 1991 ¹⁴⁷	23	1 vear	BCT	Unclear	Unclear	60-79	Yes	Moderate	Weak
350	Carette, 1997 ¹⁵²	158	3 months	BCT	Yes	Partial	60-79	Yes	Strong	Moderate
383	Dilke. 1973 ¹⁵⁷	100	3 months	RCT	Unclear	Unclear	60-79	Yes	Moderate	Weak
512	Helliwell, 1985 ¹⁶²	39	3 months	RCT	Unclear	Unclear	80–100	Unclear	Moderate	Weak
739	Karppinen, 2001 ¹⁷¹	160	1 year	RCT	Yes	Partial	80–100	Yes	Strong	Strong
539	Klenerman, 1984 ¹⁶³	74	2 months	RCT	Yes	Partial	80–100	Yes	Weak	Weak
905	Mathews, 1987176	57	12 months	RCT	Partial	Unclear	60–79	Yes	Moderate	Moderate
778	Price, 2005173	228	12 months	RCT	Yes	Partial	80–100	Yes	Strong	Moderate
620	Ridley, 1988165	39	6 months	RCT	Yes	Unclear	80–100	Yes	Moderate	Weak
240	Snoek, 1977 ¹⁴⁸	51	Ranged from 8 to 20 months	RCT	Unclear	Unclear	80–100	Yes	Weak	Weak

TABLE 19 Summary of the study details for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (continued)

					rand	8				
ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate lomisation?	Allocation ncealment?	Follow- up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
406	Vad, 2002 ¹⁵⁸	50	Mean 16 months (range 12–21 months)	RCT	Unclear	Unclear	80–100	Yes	Moderate	Weak
351	Valat, 2003 ¹⁵³	85	35 days	RCT	Yes	Partial	80–100	Yes	Strong	Weak
175	Yates, 1978 ¹⁴⁶	20	1 month	RCT	Unclear	Unclear	Cannot tell	Unclear	Weak	Weak
Epidura	al vs mixed treatme	nt								
439	Blonna, 2004 ¹⁵⁹ (Italian language)	50	60 days	RCT	Unclear	Partial	80–100	Unclear	Weak	Moderate
348	Pirbudak, 2003 ¹⁵⁰	92	9 months	RCT	Partial	No	80–100	Yes	Moderate	Weak
Epidura	al vs non-opioids									
451	Bronfort, 2000 ¹⁶¹	20	12 weeks	RCT	Unclear	Partial	80–100	NA	Moderate	Weak
20	Dincer, 2007 ¹⁴³	64	3 months, assessment at day 15, first month and third month	RCT	Unclear	Unclear	80–100	Yes	Moderate	Moderate
771	Lafuma, 1997 ¹⁷²	108	3 months	RCT	Unclear	Unclear	80–100	No	Weak	Weak
362	Wilson- MacDonald, 2005 ¹⁵⁶	93	35 days	RCT	Yes	Partial	80–100	Unclear	Moderate	Moderate
846	Murata, 2009 ¹⁷⁵	246 (136 radicular pain)	7 days	RCT	Unclear	Partial	80–100	Unclear	Weak	Weak
Epidura	al vs passive PT									
359	Veihelmann, 2006 ¹⁵⁵	99	12 months	RCT	Partial	Yes	<60	Yes	Moderate	Weak
Epidura	al vs usual/conventi	ional care								
349	Buchner, 2000 ¹⁵¹	36	6 months	RCT	Partial	Partial	80–100	Unclear	Moderate	Weak
828	Laiq, 2009174	52	6 months	Q-RCT	No	No	80–100	No	Weak	Weak
581	Matyjek, 1986 ¹⁶⁴ (Polish language)	629	Not stated	CCS	No	No	80–100	No	Weak	Weak
358	Popiolek, 1991 ¹⁵⁴ (Polish language)	60	21 days	Non- RCT	Unclear	Unclear	80–100	Unclear	Weak	Weak
Mixed	treatment incorpora	ting epidur	al vs mixed trea	atment wit	hout epidu	ral				
644	Styczynski, 1997 ¹⁶⁶ (Polish language)	103	10 days	Non- RCT	No	No	80–100	No	Weak	Weak

NA, not applicable.

TABLE 20 Summary of the findings of the global effect at short-term follow-up (≤6 weeks) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

	Comments				Data reported as percentages. ITT reported for study using LOCF, but data missing for three patients for global outcome; not stated how missing data handled for binary outcomes	Number of dropouts reported were different to the number missing from the analysis						
	0R (95% CI)		0.83 (0.31 to 2.24)		1.15 (0.58 to 2.27)	1.56 (0.50 to 4.89)	1.15 (0.56 to 2.35)	36.83 (5.35 to 253.62)	2.45 (0.56 to 10.81)	1.05 (0.45 to 2.46)		38.50 (7.42 to 199.87)
	Withdrawal rate		0		0.03	0.06	0	5	0	0		0
lol	Outcome (<i>n</i>)		69		44	18	16	ო	ო	20		ω
Conti	Total (<i>n</i>)		77		78	32	108	16	24	42		30
	Withdrawal rate		0		0.04	0.09	0	0.10	0	0		0
ention	Outcome (<i>n</i>)		72		42	14	20	17	7	21		28
Interv	Total (<i>n</i>)		82		75	21	120	19	27	43		30
	Perspective							Patient		Patient		
	Outcome measure		Treatment success: 0DI ≤ 20%		Marked or very marked improvement	Recovered: pain score of 5 or 6 (vs not recovered: scores of 1–4)	Global improvement: 75% improvement in ODI	Reported some improvement	Improvement in radiating pain	Overall success		Overall improvement: large improvement or moderate improvement (vs no improvement)
	Follow- up		2 weeks		3 weeks	1 month	6 weeks	2 weeks	24 hours	35 days		21 days
	Study design		RCT		RCT	RCT	RCT	RCT	RCT	RCT		Non- RCT
	Chronicity	olysis	A+C	trol	A+C	A	A+C	A+C	A+C	A+C	ntional care	A+C
	Author, year	ral vs chemonuclev	Gallucci, 2007 ¹⁷⁰	ral vs inactive com	Carette, 1997 ¹⁵²	Mathews, 1987 ¹⁷⁶	Price, 2005 ¹⁷³	Ridley, 1988 ¹⁶⁵	Snoek, 1977 ¹⁴⁸	Valat, 2003 ¹⁵³	ral vs usual/convei	Popiolek, 1991 ¹⁵⁴ (Polish language)
	⊡ ë	Epidu	729	Epidu	350	905	778	620	240	351	Epidu	358

ID no.	Author, year	Study design					OR (95% CI)	% weight
Chemo	nucleolysis							
729	Gallucci, 2007170	RCT	•	-			0.83 (0.31 to 2.24)	100.00
Inactive	e control							
350	Carette, 1997152	RCT		•			1.15 (0.58 to 2.27)	22.51
905	Mathews, 1987176	RCT		•			1.56 (0.50 to 4.89)	15.60
778	Price, 2005 ¹⁷³	RCT		•			1.15 (0.56 to 2.35)	21.96
620	Ridley, 1988 ¹⁶⁵	RCT		-		•	36.83 (5.35 to 253.62)	8.33
240	Snoek, 1977 ¹⁴⁸	RCT		•			2.45 (0.56 to 10.81)	11.79
351	Valat, 2003153	RCT		•			1.05 (0.45 to 2.46)	19.82
Subtota	al ($l^2 = 60.8\%$, $p = 0.02$	26)		\diamond			1.73 (0.90 to 3.33)	100.00
Usual/o	conventional care							
358	Popiolek, 1991 ¹⁵⁴	Non-RCT			-	•	38.50 (7.42 to 199.87)	100.00
							+	
	0.00394			1		2	54	
		Favours	s control	Favours	epidural			

FIGURE 14 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing epidural/interdiscal injection with alternative interventions. Note: weights are from random effects analysis.

Epidural injections were found to be significantly better than non-opioids at reducing pain at 1 week to 1 month, according to two poorly reported RCTs of weak to moderate quality.^{143,175} One further poorly reported RCT,¹⁵⁶ of moderate quality, found epidural to be significantly better than non-opioids for pain relief at 35 days (p < 0.004, statistical test not stated), but did not report any summary statistics.

Two RCTs^{150,159} compared the use of epidural injection with epidural injection plus non-opioids (mixed treatments) at 2–6 weeks, and found no overall benefit. One RCT¹⁵⁰ was of moderate quality, and included blinding of participants, clinicians and outcome assessors. Patients were randomly assigned to the two groups by one of the authors by drawing sealed envelopes from a box. The second RCT¹⁵⁹ was poorly reported and of poor quality. The SDs for this study were not reported and have been imputed using the weighted mean.

One CCS¹⁶⁷ found no important difference between nerve root block and acupuncture plus herbal medicine for pain relief at 5 weeks in patients with chronic sciatica.

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 22* and the accompanying forest plot (*Figure 16*). Epidural injections were compared with inactive control, usual care, biological agents and mixed treatments. One study¹⁵⁰ included patients with chronic sciatica, and the remaining studies included patients with either acute or chronic symptoms. The duration of follow-up ranged from post treatment to 6 weeks.^{149–151,158,173}

The overall findings from five RCTs^{152,153,158,171,173} showed epidural injections to be significantly better than inactive control for improving function. The findings were heterogeneous, with one poor-quality RCT¹⁵⁸ reporting a large effect size in favour of epidural injection. The quality of the

TABLE 21 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

	Comment/conversion ^b	Besults renorted as nercentarie	improvement reported to purchase improvement = no pain; 0% pain reduction = pain the same as before treatment)	Results reported as percentage improvement (100% improvement = no pain; 0% pain reduction = pain the same as before treatment)		SD imputed from weighted average Dropouts 22%: intervention 1/12, control 4/11 ITT analysis based on LOCF		Summary statistics derived from graphs
	Mean difference (95% Cl) ^a	0 4 1	(-18.18 to 10.18)	14.0 (-2.84 to 30.84)		-29.00 (-50.71 to -7.29)	-8.60 (-17.48 to 0.28)	20.00 (31.15 to 8.85)
scores	Control	-62	(28)	-62 (28)			-12.4 (27.3)	-7 (14)
Change (SD)	Intervention	yy I	(24)	48 (24)			–21 (29.2)	27.0 (21.0)
ean (SD)	Control					45.0 (23.67)	49.1	
Final me	Intervention					16.0 (22.48)	44.9	
e mean	Control					49.2	61.5 (21.4)	
Baselin (SD)	Intervention					38.5	65.6 (21.6)	
(<i>u</i>)	Control	230		230		1	79	19
Total	Intervention	26	2	26		12	27	20
	Scale	Percentarie	(0-100)	Percentage improvement (0–100)		VAS (0-100)	VAS (0-100)	VAS (0-10)
	Location	Overall		Overall		Overall	Overall	Overall
	Follow-up	syber S		5 weeks		4 weeks	3 weeks	1 month
	Study design	SUC		CCS		RCT	RCT	RCT
	Chronicity		2	O	ntrol	A + C	A+C	S
	Author, year	al vs alternative	(German, 1997 ¹⁶⁷ (j)c (German language) (steroid + local anaesthetic)	Wehling, 1997 ¹⁶⁷ (ij) ^c (German language)	il vs inactive co	Bush, 1991 ¹⁴⁷	Carette, 1997 ¹⁵²	Helliwell, 1985 ¹⁶²
	ÐË	Epidur: 667		667	Epidura	203	350	512

							Total (<i>r</i>	(Baseline (SD)	mean	Final me	an (SD)	Change (SD)	scores		
Ωë	Author, year	Chronicity	Study design	Follow-up	Location	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^a	Comment/conversion ^b
739	Karppinen, 2001 ¹⁷¹	A + C	RCT	4 weeks	бө	VAS (0-100)	8	80	71.0 (18)	75.2 (19)	36.9 (35.66)	43.9 (35.66)			-2.80 (-13.76 to 8.16) Multivariate analysis (adjusted change from baseline): 2.3 (95% C1-8.7 to 13.4)	SDs (and SEs) for change estimated from 95% Cl of difference between treatment groups Two patients lost to follow-up from steroid group
778	Price, 2005 ¹⁷³	A+C	RCT	6 weeks	Leg	VAS (0-100)	120	108	52 (23)				-15 (32)	-15 (32)	0.00 (8.32 to 8.32)	
620	Ridley, 1988 ¹⁶⁵	A+C	RCT	2 weeks	Overall	VAS (0-100)	19	16					-46	0	-46	Only median percentage improvement and range reported
406	Vad, 2002 ¹⁵⁸	A+C	Non-RCT	Post- treatment	Overall	VAS (0-10)	25	25	88 (14)	94 (14)	16 (8)	36 (11)			-2.70 (-12.52 to 7.12)	
351	Valat, 2003 ¹⁵³	A+C	RCT	35 days	Overall	VAS (0-100)	43	42	57.5 (16.3)	58 (16.6)	22.1 (20.1)	24.8 (25.7)			-10.73 (-18.47 to -2.99)	
Epidu 439	<i>iral vs mixed trea</i> Blonna, 2004 ¹⁵⁸ (Italian language)	tments A + C	RCT	14 days	Overall	VAS (0-10)	24	26	80.4 (10.0)	83.5 (12.6)	34.3 (22.48)	35.6 (22.86)			-1.30 (-22.07 to 19.47)	SD imputed from weighted average ITT using LOCF, dropouts 3 (6%): intervention 3/26, control 0/24
348	Pirbudak, 2003 ¹⁵⁰	C	RCT	6 weeks	Overall	VAS (0-10)	46	46	84.0 (17.0)	78.1 (40.0)	40	11.0	-44.0 (22.0)	-49.0 (10.0)	5.00 (–1.98 to 11.98)	
																continued

TABLE 21 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (continued)

Ores	Mean difference (95% Cl) ^a Comment/conversion ^b		-12.00 (-17.94 to -6.06)	 -24.00 SD imputed from weighted (-31.63 to average -16.37) Subgroup analysis based on 136/246 (55%) with radicular pain; intervention 71/122, control 65/124. Dropouts: 8/246 (3%), no further details 	Significant Summary statistics not difference reported in pain relief Dropouts 14/93 (15%): group between allocation not stated groups, in favour of
hange sc SD)	Control				
5) (G	Intervention		(13)	86)	
nean (S	Control) 44 (67 (22.	
Final r	Intervention		32 (11	43 (22.48	
ne mean	Control) 68 (10)		
Baselii (SD)	Intervention		69 (10)		
(<i>u</i>)	Control		30	65	
Total	Intervention		34	00	
	Scale		VAS (0-10)	VAS (0-100)	Oxford pain chart
	Location		Overall	бөл	Overall
	Follow-up		1 month	7 days	35 days
	Study design		RCT	RCT	RCT
	Chronicity	sp	A+C	U	ЖN
	Author, year	ıral vs non-opioı	Dincer, 2007 ¹⁴³	Murata, 2009 ¹⁷⁵	Wilson- MacDonald, 2005 ^{1 ss}
	e ë	Epidt	20	846	362

							Total	(u)	Baseline (SD)	mean	Final mea	an (SD)	Change sc (SD)	ores	
⊡ ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Mean differen (95% Cl	ce comment/conversion ^b
Epidu	ral vs usual/com	ventional care													
349	Buchner, 2000 ¹⁵¹	A+C	RCT	2 weeks	Overall	VAS (0-100)	17	19	84.4	81	30.8 (12.47)	37.1 (12.47)		-6.30 (-14.46 1.86)	2-week data used instead of 6-weeks because <i>p</i> -value for one-sided <i>t</i> -test available to calculate SD
															Dropouts 9/31 (29%): intervention 4/16, control 5/15
828	Laiq, 2009 ¹⁷⁴	NR	Q-RCT	1 month	Overall	VAS (0-10)	25	25			20 (15)	45 (14.8)		-15.64 (-33.96 2.69)	Dropouts 2/52 (4%): to intervention 1/26, control 1/26
Mixeu	1 treatment incor	rporating epidurs	al vs mixed ti	reatment with	out epidural										
644	Styczynski, 1997 ¹⁶⁶ (Polish language)	A+ C	Non-RCT	10 days	Overall	VAS (1-100)	58	45	100	100	39.8	53.8		14	Pain scale used was not stated SD not reported and no statistical analysis undertaken
A+C, b Th c Wf	acute and chronic sed on final mean e term 'dropouts' I shling and Reineck	c; C, chronic; LOC is or change score has been used for ce ¹⁶⁷ included thre r twice, only the is	F, last observerses (with a pref s (with a pref r missing data be treatment g	ation carried fo ference given to a, post-baseline froups: epidural	rward; NR, nc o change scor exclusions a. I injection of lo	it reported. es); results repo nd patients lost t ocal anaesthetic	ted by ; o follow (i), epid	study in -up. ural injec (see <i>Fi</i> r	italics. ction of ste	eroid + loc	al anaesth	letic (ii), an	d acupunct	ure + herbal mec	icine (iii). In order to prevent using

ID no.	Author, year	Study design		WMD (95% CI)	% weight
Alternat	live				
667	Wehling, 1997 ¹⁶⁷	CCS		-4.00 (-18.18 to 10.18)	100.00
Inactive	control				
203	Bush, 1991 ¹⁴⁷	RCT —	•	-29.00 (-47.91 to -10.09)	8.97
350	Carette, 1997152	RCT	•	-8.60 (-17.48 to 0.28)	15.35
512	Helliwell, 1985 ¹⁶²	RCT		–20.00 (–31.15 to –8.85)	13.75
739	Karppinen, 2001171	RCT		-2.80 (-13.76 to 8.16)	13.88
778	Price, 2005173	RCT		0.00 (-8.32 to 8.32)	15.74
406	Vad, 2002 ¹⁵⁸	RCT		-20.00 (-25.33 to -14.67)	17.61
351	Valat, 2003153	RCT		-2.70 (-12.52 to 7.12)	14.69
Subtota	$l^2 = 78.9\%, p = 0.000$))	\sim	-10.98 (-18.74 to -3.22)	100.00
Mixed t	reatments				
348	Pirbudak, 2003 ¹⁵⁰	RCT	+•	5.00 (-1.98 to 11.98)	76.42
439	Blonna, 2004 ¹⁵⁹	RCT		-1.30 (-13.87 to 11.27)	23.58
Subtota	(<i>l</i> ² = 0.0%, <i>p</i> = 0.391)		$\langle \rangle$	3.51 (-2.59 to 9.62)	100.00
Non-op	ioids				
20	Dincer, 2007 ¹⁴³	RCT		-12.00 (-17.94 to -6.06)	52.07
846	Murata, 2009175	RCT		-24.00 (-31.63 to -16.37)	47.93
Subtota	$(l^2 = 83.1\%, p = 0.015)$	5)		-17.75 (-29.50 to -6.00)	100.00
Usual/c	onventional care				
349	Buchner, 2000 ¹⁵¹	RCT	•	-6.30 (-14.46 to 1.86)	50.06
828	Laiq, 2009 ¹⁷⁴	Q-RCT		-25.00 (-33.26 to -16.74)	49.94
Subtota	(<i>l</i> ² = 90.0%, <i>p</i> = 0.002	2)		-15.64 (-33.96 to 2.69)	100.00
		-47.9	0	47.9	
			Favours epidural Favo	ours control	

FIGURE 15 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing epidural/intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

remaining $RCTs^{152,153,171,173}$ was good, and pooled analysis showed a significant difference in favour of epidural (SMD -0.19; 95% CI -0.34 to -0.03).

One moderate-quality RCT¹⁵¹ found epidural to be significantly better than usual care for improving functional status at 6 weeks' follow-up.

One moderate-quality RCT¹⁴³ found epidural to be significantly better than non-opioids for improving functional status at 4 weeks' follow-up. The methods of randomisation and allocation concealment were not stated.

One moderate-quality RCT¹⁵⁰ found no statistically significant difference between epidural injection in combination with non-opioids (mixed treatments) and epidural injection alone for improving functional status for patients with chronic sciatica at 6 weeks' follow-up.

						Total (<i>n</i>)		Baseline (SD)	mean	Final me	an (SD)	Change s (SD)	cores		
ID no.	Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI) ^a	Comment/conversion ^b
Epidur	al vs biological age.	nts													
321	Becker, 2007¹⁴9 (i)⁰ (5 mg)	A+C	RCT	6 weeks	IDO	27	32	20.6 (8.1)	22.0 (8.3)	12.1 (9.0)	13.8 (9.8)			-0.18 (-0.69 to 0.33)	
321	Becker, 2007 ¹⁴⁹ (ii) ^c (10mg)	A+C	RCT	6 weeks	IDO	25	32	19.4 (9.9)	22.0 (8.3)	11.0 (9.5)	13.8 (9.8)			0.29 (0.82 to 0.24)	
Epidur	al vs inactive contr	ol													
350	Carette, 1997 ¹⁵²	A+C	RCT	3 weeks	Modified ODI	77	80	49.6 (15.7)	50 (15.5)	41.6 (15.7)	44.5 (15.5)	—8 (15.3)	-5.5 (14.3)	-0.19 (-0.50 to 0.13)	Final SD missing, so baseline SD used ITT using LOCF: one dropout excluded Analysis of variance results not reported
739	Karppinen, 2001 ¹⁷¹	A+C	RCT	4 weeks	IDO	80	80	42.9 (16)	43.5 (15)	26.8 (16)	29.1 (15)	-16.1 (18.88)	-14.4 (18.88)	-0.15 (-0.46 to 0.16)	Final SD missing, so baseline SD used
														Adjusted change from baseline -0.4 (95% Cl -7.0 to 6.2)	
778	Price, 2005 ¹⁷³	A+C	RCT	6 weeks	IQO	120	108	44 (15)	45 (18)	31 (15)	35 (18)	-13 (17)	-10 (18)	-0.24 (-0.50 to 0.02)	Final mean calculated from change scores Baseline SD used ITT using LOCF
406	Vad, 2002 ¹⁵⁸	A+C	RCT	Post- treatment	RMDQ	25	25	8.8 (1.2)	9.6 (1.3)	0.9 (1.6)	4.7 (2.1)	13.3	8.7	-2.04 (-2.72 to -1.35)	

4 ÷ ÷ ÷ -1/1 3 . ÷ 4 _ 6 = .

TABLE 22 Summary of the findings of CSOMs at short-term follow-up (≤6 weeks) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	nce Comment/conversion ⁵	ITT using LOCF Dropouts 22/85 (26%): intervention 9/43, control 13/42		15)		Final SD missing, so 7) baseline SD used		2-week data used instead of 6-week data because <i>p</i> -value for one-sided <i>t</i> -test available to calculate SD	
	Mean differei (95% Cl)ª	-0.11 (-0.54 to 0.3 ⁻		-0.66 (-1.16 to -0.1		0.26 (-0.15 to 0.67		-1.03 (-1.73 to -0.3	
scores	Control	-5.1		-12.2		—21.8 (24.5)			
Change (SD)	Intervention	-9.6		-18.8		-17.6 (20.5)			
ean (SD)	Control) 9.1 (5.4)		22.2 (8.6)		28 (15.2)		42.5 (6.01)	
Final m	Intervention	8.5 (5.4		17 (7.3)		32 (15.5)		36.3 (6.01)	
e mean	Control	14.2 (4.2)		34.4 (6.7)		50.2 (15.2)		39.9	
Baselin (SD)	Intervention	15.1 (4.7)		35.8 (6.7)		49.6 (15.5)		38.5	
(Control	42		30		46		19	
Total (r	Intervention	43		34		46		17	
	Scale	RMDQ		IQO		IQO		Hannover Functional Ability	forward.
	Follow- up	35 days		1 month		6 weeks		6 weeks	ation carried
	Study design	RCT		RCT		RCT		RCT	- last observ
	Chronicity	A+C		A+C	ents	C	ntional care	A+C	chronic: 1.00F
	Author, year	Valat, 2003 ¹⁵³	al vs non-opioids	Dincer, 2007 ¹⁴³	al vs mixed treatm	Pirbudak, 2003 ¹⁵⁰	al vs usual/conven	Buchner, 2000 ¹⁵¹	cute and chronic: C
	ID no.	351	Epidura	20	Epidura	348	Epidura	349	A+C. ar

based on final means of change scores (with a preference given to change scores); results reported by study in italics.

The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. പറ

Becker et at^{11,40} included three treatment groups: epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (ii), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of autologous conditioned serum (iii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the meta-analysis (see Figure 16).

ID no.	Author, year	Study design					SMD (95% CI)	% weight
Biologi	cal agents							
321	Becker, 2007 ¹⁴⁹	RCT			•	+-	-0.29 (-0.82 to 0.24)	100.00
Inactive	e control							
350	Carette, 1997152	RCT			•	+	-0.19 (-0.50 to 0.13)	21.59
739	Karppinen, 2001 ¹⁷¹	RCT				+-	-0.15 (-0.46 to 0.16)	21.65
778	Price, 2005 ¹⁷³	RCT			•	+	-0.24 (-0.50 to 0.02)	22.43
406	Vad, 2002 ¹⁵⁸	RCT					-2.04 (-2.72 to -1.35)	14.74
351	Valat, 2003 ¹⁵³	RCT				-	-0.11 (-0.54 to 0.31)	19.58
Subtota	l (<i>l</i> ² = 85.0%, <i>p</i> = 0.00	0)			\bigcirc	>	-0.45 (-0.87 to -0.03)	100.00
Non-op	ioids							
20	Dincer, 2007 ¹⁴³	RCT		-	•		-0.66 (-1.16 to -0.15)	100.00
Mixed t	reatments							
348	Pirbudak, 2003150	RCT			-	•	0.26 (-0.15 to 0.67)	100.00
Usual/c	conventional care							
349	Buchner, 2000 ¹⁵¹	RCT			•		-1.03 (-1.73 to -0.33)	100.00
			-2.72			0	2.72	
				Favours	epidural	Favours co	ntrol	

FIGURE 16 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing epidural/ intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

One moderate-quality RCT¹⁴⁹ compared epidural using two different dosages of steroid with an epidural injection of autologous conditioned serum (biological agent). There was no statistically significant difference between either dose of epidural steroid and the biological agent at 6 weeks.

One poorly conducted non-RCT,¹⁶⁶ reported a greater decrease in pain intensity for patients treated with epidural, traction and exercise therapy than those treated with traction and exercise therapy without epidural.

Epidural/intradiscal injections results at medium-term follow-up (>6 weeks to \leq 6 months)

Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 23* and the accompanying forest plot (*Figure 17*). Epidural/intradiscal/nerve block injections were compared with inactive intervention, usual care, activity restriction, non-opioids, passive PT and chemonucleolysis. One study¹⁴⁵ included only patients with acute sciatica, whereas five studies^{155,160,162,168,175} included only patients with chronic symptoms. The remaining studies included patients with either acute or chronic sciatica, or did not state the duration of symptoms.¹⁷⁴ The duration of follow-up ranged from 2 months^{163,175} to 6 months.^{151,155,160,170,174}

Five RCTs^{152,157,162,163,173} compared epidural injections with inactive control; the overall findings were in favour of epidural at 2–3 months, but the difference was not statistically significant. Two of these RCTs^{152,173} were good quality and two^{157,162} were of moderate quality.

TABLE 23 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

							Interve	intion		Control				
<u>o</u> e	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (1)	Outcome (n)	Withdrawal rate	0R (95% CI)ª	Comments
Epidur	al vs activity restri	iction												
140	Coomes, 1961 ¹⁴⁵	A	Non- RCT	9 weeks	Neurological state: completely relieved or improved (vs not changed or worse)	Physician	20	12	0	20	Ŋ	0	4.50 (1.17 to 17.37)	
Epidur	al vs chemonuclec	sisylu												
720	Bontoux, 1990 ¹⁶⁸ (French language)	C	RCT	3 months	Overall improvement: very good or good (vs mediocre or bad; other cases)		40	27	0	40	26	0	1.12 (0.44 to 2.83)	
447	Bourgeois, 1988 ¹⁶⁰ (French language)	C	RCT	6 months	Overall pain relief: very good or good (vs failure)		30	16	0	30	20	0	0.57 (0.20 to 1.62)	
729	Gallucci, 2007 ¹⁷⁰	A+C	RCT	6 months	Treatment success: 0DI ≤ 20%		17	36	0	82	61	0	3.31 (1.70 to 6.45)	
Epidur.	al vs inactive cont.	rol												
350	Carette, 1997' ⁵²	A + C	RCT	3 weeks	Marked or very marked improvement		12	25	0.01	78	53	0.03	0.98 (0.52 to 1.86) <i>Treatment</i> <i>effect</i> -0.4% (95% Cl -16.5% to 15.7%); not clear not clear for baseline for baseline	Data reported as percentages ITT reported for study using LOCF, but data missing for five patients for global outcome; not stated how missing data handled for binary outcomes
383	Dilke, 1973 ¹⁵⁷	A+C	RCT	3 months	Pain: not severe or none (vs severe and unknown)	Patient	44	40	0.14	38	28	0.21	3.57 (1.02 to 12.54)	

							Intervei	ntion		Control				
е ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% CI)ª	Comments
512	Helliwell, 1985 ¹⁶²	сı	RCT	3 months	Definitive improvement	Patient	20	14	0	19	a	0	6.53 (1.61 to 26.47)	
539	Klenerman, 1984 ¹⁶³ (j) ^b (steroid)	A+C	RCT	2 months	Treatment success based on overall pain (VAS) and physical examination: not failed, i.e. improved or curred (vs failed)	Physician	19	-1 5	~	16	1	~	1.70 (0.37 to 7.85)	Number randomised unclear
539	Klenerman, 1984 ¹⁶³ (jj) ^b (anaestheticd)	A+C	RCT	2 months	Treatment success based on overall pain (VAS) and physical examination: not failed, i.e. improved or cured (vs failed)	Physician	16	.	¢.	16		~	1.00 (0.22 to 4.46)	Number randomised unclear
778 Enidur	Price, 2005 ¹⁷³	A+C	RCT	12 weeks	Global improvement: ≥ 75% improvement in ODI		120	22	0	108	26	0	0.71 (0.37 to 1.34)	Data inferred from graphs reporting percentages ITT using LOCF
846	Murata, 2009 ¹⁷⁵	O	RCT	24 weeks	Adequate recovery from leg pain		71	=	€.	0 0	ى	~	2.20 (0.72 to 6.72)	Subgroup analysis of 136/246 (55%) patients with radicular pain: intervention 71/122, control 65/124 8/246 patients dropped out, group allocation or radicular pain not stated
														continued

TABLE 23 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (continued)

							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)ª	Comments
Epidu	al vs passive PT													
359	Veihelmann, 2006 ¹⁵⁵	C	RCT	6 months	Gerbershagen score (chronification index), GHS I (vs GHS II, III)		46	31	0.02	27	ω	0.48	4.91 (1.75 to 13.76)	
Epidui	'al vs usual/conven	tional care												
349	Buchner, 2000 ¹⁵¹	A+C	RCT	6 months	Overall assessment: very good or good based on VAS, SLR and functional status		17	-1 57	0	19	14	0	2.68 (0.45 to 16.11)	ITT used
828	Laiq, 2009 ¹⁷⁴	NR	Q-RCT	6 months	Successfully treated: ≥ 50% reduction in pain using VAS		25	21	0.04	25	19	0.04	1.66 (0.41 to 6.78)	Findings reported in terms of treatment failure
2, uncl	ear; A, acute; A + C, .	acute and chro	nic; C, chro	nic; LOCF, lasi	t observation carried forw	vard; NR, not rep	oorted.							

a resuns reported by study in narks. b Klenerman *et al.*¹⁶³ included three treatment groups: epidural steroid injection (i), epidural anaesthetic injection (ii) and epidural saline injection (ii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the meta-analysis (see forest plot).

ID no.	Author, year	Study design			OR (95% CI)	% weight
Activity	restriction					
140	Coomes, 1961 ¹⁴⁵	Non-RCT		•	4.50 (1.17 to 17.37)	100.00
Chemo	nucleolysis					
720	Bontoux, 1990 ¹⁶⁸	RCT		•	1.12 (0.44 to 2.83)	32.53
447	Bourgeois, 1988 ¹⁶⁰	RCT	•		0.57 (0.20 to 1.62)	30.47
729	Gallucci, 2007170	RCT			3.31 (1.70 to 6.45)	37.00
Subtota	l (<i>l</i> ² = 77.2%, <i>p</i> = 0.012)	<		1.36 (0.47 to 3.91)	100.00
Inactive	e control					
350	Carette, 1997152	RCT		•	0.98 (0.52 to 1.86)	26.66
383	Dilke, 1973 ¹⁵⁷	RCT		• • •	3.57 (1.02 to 12.54)	17.22
512	Helliwell, 1985 ¹⁶²	RCT			6.53 (1.61 to 26.47)	15.45
539	Klenerman, 1984163	RCT			1.70 (0.37 to 7.85)	14.01
778	Price, 2005 ¹⁷³	RCT		-	0.71 (0.37 to 1.34)	26.66
Subtota	ll (l ² = 65.9%, p = 0.019)	-		1.63 (0.77 to 3.46)	100.00
Non-op	ioids					
846	Murata, 2009 ¹⁷⁵	RCT	-	•	2.20 (0.72 to 6.72)	100.00
Passive	e PT					
359	Veihelmann, 2006 ¹⁵⁵	RCT		•	4.91 (1.75 to 13.76)	100.00
Usual/c	conventional care					
349	Buchner, 2000 ¹⁵¹	RCT		•	2.68 (0.45 to 16.11)	38.15
828	Laiq, 2009 ¹⁷⁴	Q-RCT		•	1.66 (0.41 to 6.78)	61.85
Subtota	l ($l^2 = 0.0\%$, $p = 0.680$)		<		1.99 (0.66 to 6.03)	100.00
		I	0.1 0.5	1 2 10		
		Fav	ours control	Favours epidural		

FIGURE 17 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing epidural/intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

Two moderate- or poor-quality RCTs^{151,174} compared epidural injection with usual care; the overall finding was in favour of epidural at 6 months, but the difference was not statistically significantt.

Epidural injection was found to be significantly better than activity restriction for overall improvement in neurological state for patients with acute sciatica (mean duration of symptoms 34 days) at 9 weeks. But these findings are based on a poor-quality non-RCT,¹⁴⁵ which also had poor external validity.

One poor-quality RCT¹⁷⁵ reported non-statistically significant findings in favour of epidural, compared with non-opioids, for adequate recovery from leg pain at 24 weeks. The findings were based on a subgroup analysis of 136/246 (55%) patients with radicular pain.

One moderate-quality RCT¹⁵⁵ found epidural injections to be significantly better than passive PT in terms of the number for patients with Gerbershagen pain chronicity score I (vs II or III; pain staging system) at 6 months. However, the withdrawal rate was very high in the control group

(48%) compared with the intervention group (2%). Patients in the control group had the choice to cross over to the epidural group after 3 months of unsatisfactory treatment with PT. These patients were then excluded from analysis (n = 12/52).

Two moderate-quality RCTs^{160,168} compared intradiscal injection with chemonucleolysis using chymopapain for chronic sciatica, and one poorly reported but moderate-quality RCT¹⁷⁰ compared intraforaminal/intradiscal injections of steroid plus local anaesthetic (epidural) with intraforaminal/intradiscal injections of steroid, local anaesthetic and ozone–oxygen (chemonucleolysis). The first RCTs^{160,168} found no statistically significant difference between the intervention groups, while the third RCT¹⁷⁰ found statistically significant findings in favour of the epidural group for patients who had had symptoms for a mean of 15 weeks.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 24* and the accompanying forest plot (*Figure 18*). Epidural injections were compared with inactive control, usual care, passive PT, mixed treatments, disc surgery and biological agents. Three studies^{150,155,162} included only patients with chronic sciatica, one study¹⁷⁴ did not report the duration of symptoms, and the remaining studies included patients with either acute or chronic sciatica. The duration of follow-up ranged from 60 days¹⁵⁹ to 6 months.^{150,151,155,171,174}

Four RCTs^{152,162,171,173} compared epidural injections with inactive control, for which pooled analyses showed no important difference between the groups at $3^{152,162,173}$ and 6^{171} months. However, the findings were heterogeneous. The overall quality for three trials^{152,171,173} was good. The fourth study¹⁶² was small (n = 39), poorly reported and of moderate quality, and, unlike the remaining studies, found statistically significant findings in favour of epidural. One RCT¹⁷¹ also reported findings based on ANCOVA, adjusted for baseline values, which favoured inactive control for leg pain at 3 months (-12.2; 95% CI -23.5 to -1.0, p = 0.003; negative values indicate a negative effect). The same analyses showed no statistically significant difference between the groups at 12 months.

Two studies^{151,174} compared epidural injections with usual care; the overall findings at 6 months were in favour of epidural, but were not statistically significant. One was a moderate-quality RCT and the other a Q-RCT.

One moderate-quality RCT¹⁵⁵ reported a non-statistically significant reduction in pain intensity at 6 months in favour of epidural, compared with passive PT. The withdrawal rate was much higher in the control group (48%) than in the intervention group (2%). Patients in the control group had the choice to cross over to the epidural group after 3 months of unsatisfactory treatment with PT. These patients were then excluded from the analysis (n = 12/52).

Two RCTs^{150,159} compared the use of epidural injection with epidural injection plus non-opioids (mixed treatments) at 2 months¹⁵⁹ or 6 months.¹⁵⁰ Overall, there was a non-statistically significant finding in favour of the mixed treatments. A much greater (and statistically significant) reduction in pain was achieved by the better-quality RCT¹⁵⁰ than by the poor-quality and poorly reported study.¹⁵⁹

One poorly reported RCT⁹⁵ of moderate quality compared epidural with disc surgery. The method of randomisation and allocation concealment were not reported. The level of leg pain experienced by the epidural group was significantly more than that of the disc surgery group at 4–6 months' follow-up (p = 0.03, Student's *t*-test). No summary statistics were reported and, therefore, the study is not presented in *Figure 18*.

							Total (r	-	Baselin (SD)	e mean	Final m	ean (SD)	Change (SD)	scores		
e é	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion ^c
Epidu	ıral vs biologica	l agents														
321	Becker, 2007 ¹⁴⁹ (j) ^d (5 mg)	A + C	RCT	22 weeks	Overall	VAS (0-100)	27	32	82	78					-13.5 (95% Cl -27.4 to O.4); repeated measures analysis of variance	Summary statistics not reported
321	Becker, 2007 ¹⁴⁹ (ii) ^c (10 mg)	A + C	RCT	22 weeks	Overall	VAS (0-100)	24	32	85	78					-9.3 (95% CI -23.5 to 4. 9); repeated measures analysis of variance	Summary statistics not reported One patient in epidural group dropped out
Epidu	ıral vs disc surg	lery														
725	Buttermann, 2004 ⁹⁵	A + C	RCT	4-6 months	Leg	VAS (0-10)	20	20							Statistically significant greater pain experienced by epidural group (b < 0.03, Student's t- test)	Summary statistics not reported
Epidu	ıral vs inactive u	control														
350	Carette, 1997 ¹⁵²	A+C	RCT	3 months	Overall	VAS (0-100)	77	79	65.6 (21.6)	61.5 (21.4)	38.9	39.5	-26.5 (36)	-22.5 (34.4)	-4.00 (-15.05 to 7.05)	ITT analysis used
512	Helliwell, 1985 ¹⁶²	C	RCT	3 months	Overall	VAS (0-100)	20	19					-27 (21)	-4 (21)	-23.00 (-36.19 to -9.81)	

TABLE 24 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comment/conversion ⁶	SDs (and SEs) for change estimated from 95% Cl of difference between treatment groups ITT not used Two patients lost to follow- up from steroid group			SD derived from SE 26 (26%) dropped out: intervention 1/47, control 25/52		SD imputed from weighted average from non-opioids for intervention ITT using LOCF Dropouts: intervention 3/26, control 0/24	
	Mean difference (95% CI) ^b	13.30 (2.78 to 23.82) Multivariate analysis (adjusted change from baseline): -16.2 (95% Cl -26.8 to -5.6)	5.00 (-3.58 to 13.58)		–35.00 (–94.60 to 24.60)		6.70 (–1.91 to 15.31)	28.00 (22.88 to 33.12)
scores	Control		-18 (33)					-70.0 (5.0)
Change (SD)	Intervention		-13 (33)					-42.0 (17.0)
an (SD)	Control	21.6 (33.99)			58 (114.3)		10.2 (18.0)	8.0
Final me	Intervention	30.7 (33.99)			23 (142.4)		16.9 (12.8)	42
mean	Control	75.2 (19)	56 (22)		67 (103.9)		83.5 (12.6)	78.1 (40.0)
Baseline (SD)	Intervention	71 (18)	52 (23)		72 (135.6)		80.4 (10.0)	84 (17)
	Control	80	108		27		26	46
Total (<i>n</i>)	Intervention	78	120		46		24	46
	Scale (range) ^a	VAS (0-100)	VAS (0-100)		VAS (0-10)		VAS (0-10)	VAS (0-10)
	Location	ſeġ	Leg		Leg		Overall	Overall
	Follow-up	6 months	12 weeks		6 months		60 days	6 months
	Study design	RCT	RCT		RCT		RCT	RCT
	Chronicity	A+ C	A+C	T	O	atments	A + C	O
	Author, year	2001 ¹⁷¹	Price, 2005 ¹⁷³	Il vs passive Pi	Veihelmann, 2006 ¹⁵⁵	ıl vs mixed tre:	Blonna, 2004 ¹⁵⁹ (Italian Ianguage)	Pirbudak, 2003 ¹⁵⁰
	<u>n</u> e	739	778	Epidura	359	Epidura	439	348

	version		st al means) tte SD	(4%): 26, control	Jural
	Comment/con		One-sided <i>t</i> -te (comparing fin: used to calcula	ITT not used Dropouts 2/52 intervention 1/: 1/26	c 1ml (ii) and epic
	Mean difference (95% Cl) ^b		-6.30 (-19.62 to 7.02)	-5.00 (-12.63 to 2.63)	mg + local anaesthetic
je scores	Control				cinolone 10
Chanç (SD)	Intervention		-	-	oid triamc
ean (SD)	Control		39.2 (20.35)	65 (13)	ion of ster
Final me	Intervention		32.9 (20.35)	60 (14.5)	pidural injecti
ne mean	Control		81		ics. 1ml (i), e
Baselii (SD)	Intervention		84.4		tudy in ital up. naesthetic
(L	Control		19	25	orted by s t to follow- g + local a
Total (Intervention		17	25	orted. ssults rep ients lost olone 5 m
	Scale (range) ^a		VAS (0-100)	VAS (0-10)	NR, not rep scores); re ons and pat id triamcinc
	Location		Overall	Overall	ation carried; nparability. ven to change seline exclusi ection of stero
	Follow-up		6 months	6 months	CF, last observ D-100 for com preference gi data, post-ba s: epidural inje
	Study design		RCT	Q-RCT	chronic; LO a scale of (cores (with a for missing
	Chronicity	ventional care	A+C	NR	und chronic; C, i en converted to is or change sc has been used ided three treat
	Author, year	I vs usual/con	Buchner, 2000 ¹⁵¹	Laiq, 2009 ¹⁷⁴	; $A + C$, acute <i>z</i> results have be- id on final mear term 'dropouts' er <i>et al.</i> ¹⁴⁹ inclu
	<u>n</u> e	Epidura	349	828	A, acutt a The b Bast c The d Beck

The term "tropours" has been used for missing data, post-baseline exclusions and patients lost to follow-up. Becker *et al.*¹⁴⁸ included three treatment groups: epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (i), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of autologous conditioned serum (iii).
ID no.	Author, year	Study design					WMD (95% CI)	% weight
Inactive	e control							
350	Carette, 1997152	RCT				_	-4.00 (-15.05 to 7.05)	24.87
512	Helliwell, 1985 ¹⁶²	RCT		_	•		-23.00 (-36.19 to -9.81)	23.26
739	Karppinen, 2001171	RCT			-		13.30 (2.78 to 23.82)	25.26
778	Price, 2005 ¹⁷³	RCT			+	•	5.00 (-3.58 to 13.58)	26.60
Subtota	$l (l^2 = 84.7\%, p = 0.000)$)			\langle	>	-1.66 (-15.29 to 11.98)	100.00
Mixed t	reatments							
439	Blonna, 2004159	RCT			+		6.70 (-1.91 to 15.31)	48.63
348	Pirbudak, 2003150	RCT				-	28.00 (22.88 to 33.12)	51.37
Subtota	$I (I^2 = 94.2\%, p = 0.000)$)			<	\bigcirc	17.64 (-3.22 to 38.51)	100.00
Passive	e PT							
359	Veihelmann, 2006 ¹⁵⁵	RCT		•			-35.00 (-94.60 to 24.60)	100.00
Usual/	Conventional care							
349	Buchner, 2000 ¹⁵¹	RCT				_	-6.30 (-19.62 to 7.02)	24.74
828	Laiq, 2009 ¹⁷⁴	Q-RCT			-•-		-5.00 (-12.63 to 2.63)	75.26
Subtota	al ($l^2 = 0.0\%$, $p = 0.868$)				\diamond		-5.32 (-11.94 to 1.30)	100.00
			04.6					
			-34.0	Favours epi	dural	Favours co	ontrol	

FIGURE 18 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing epidural/intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

One moderate-quality RCT¹⁴⁹ compared two types of epidural (containing local anaesthetic plus triamcinolone at a dose of either 5 mg or 10 mg) with biological agents (epidural injection of autologous conditioned serum). Insufficient data were reported to include the study in *Figure 18*. Pair-wise analysis showed a non-statistically significant difference in favour of the biological agent for pain reduction at 22 weeks.

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 25* and the accompanying forest plot (*Figure 19*). Epidural injections were compared with inactive control, usual care, non-opioids, passive PT, biological agents and mixed treatments. Two studies^{150,155} only included patients with chronic sciatica, and the remaining studies^{143,149,151,152,171,173} included patients with either acute or chronic sciatica. The duration of follow-up ranged from 3⁹⁵ to 6 months.^{150,151,155,171}

There was no overall statistically significant difference between epidural and inactive control for improving functional status, according to three good-quality RCTs.^{152,171,173} The duration of follow-up ranged from 3 months^{152,173} to 6 months.¹⁷¹ All three studies included patients with either acute or chronic sciatica.

One moderate-quality RCT¹⁵¹ reported non-statistically significant findings in favour of epidural compared with usual care for improving functional status at 6 months' follow-up.

ernative	
with alte	
jections	
discal in	
ural/intra	
ing epidu	
compari	
· studies	
inths) for	
:o ≤6 mc	
i weeks t	
v-up (> 6	
irm follov	5
edium-te	oy autho
∕ls at me	ordered b
of CSO	or then c
findings	omparat
ry of the	oed by co
Summai	ns (group
BLE 25	erventio
₽.	Ē

						Total	(I)	Baseline (SD)	mean	Final me	an (SD)	Changé (SD)	scores		
D no.	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
Epidura	Il vs biological age	nts													
321	Becker, 2007 ¹⁴⁹ (i) ^c (5 mg)	A+C	RCT	22 weeks	IQO	27	32	20.6 (8.1)	22.0 (8.3)	11.1 (7.1)	11.7 (9.2)			-0.07 (-0.58 to 0.044)	Dropouts 7 (8%): Number originally randomised to each group not stated
321	Becker, 2007 ¹⁴⁹ (ii) ^c (10 mg)	A+C	RCT	22 weeks	IOO	25	32	19.4 (9.9)	22.0 (8.3)	11.0 (9.5)	11.7 (9.2)			-0.08 (-0.60 to 0.45)	Dropouts 7 (8%): Number originally randomised to each group not stated
Epidura	il vs disc surgery														
725	Buttermann, 2004 ^{ss}	A + C	RCT	1–3 months	Q									There was a significantly greater decreasing in disability in the discectomy group compared with the epidural group at the 1–3 month follow-up interval; p < 0.015, Student's t-test	
Epidura	ll vs inactive contro	la													
350	Carette, 1997 ¹⁵²	A + C	RCT	3 months	Modified ODI	12	62	49.6 (15.7)	50 (15.5)	32.2 (15.7)	34.6 (15.5)	-17.3 (20.6)	-15.4 (25.5)	-0.15 (-0.47 to 0.16)	Final SD missing so baseline SD used ITT used LOCF Two patient dropouts excluded Analysis of variance, but results not reported
739	Karppinen, 2001 ¹⁷¹	A + C	RCT	6 months	IGO	78	80	42.9 (16)	43.5 (15)	18.9 (16)	15.8 (15)	-24 (21.0)	-27.7 (21.0)	0.20 (-0.11 to 0.51) Adjusted change from baseline -5.9 (95% Cl -12.4 to 7.0)	Final SD missing, so baseline SD used ITT not used; two patients lost to follow-up from steroid group
															continued

TABLE 25 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (continued)

						Total (/	(Baseline (SD)	mean	Final me	an (SD)	Change (SD)	scores		
D no.	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
778	Price, 2005 ¹⁷³	A+C	RCT	12 weeks	ā	120	108	44 (15)	45 (18)	32 (15)	27 (18)	-12 (19)	-12 (21)	0.30 (0.04 to 0.56)	Final score calculated from change score Final SD missing so baseline SD used ITT used LOCF
Epidur 20	al <i>vs non-opioids</i> Dincer, 2007 ¹⁴³	A+C	RCT	3 months	IQO	34	30	35.8 (6.7)	28.4 (5.4)	16.2 (9.4)	20.3 (10.1)	-19.6	-8.1	-0.42 (-0.92 to 0.08)	
Epidura	al vs mixed treatm	ents													
348	Pirbudak, 2003 ¹⁵⁰	C	RCT	6 months	IQO	46	46	49.6 (15.5)	50.2 (15.2)	45 (15.5)	25 (15.2)	-7.6 (15.3)	-13.2 (15.5)	1.30 (0.85 to 1.75)	
Epidura	al vs passive PT														
359	Veihelmann, 2006 ¹⁵⁵	0	RCT	6 months	IQO	46	27	23.1	21.4	10.8 (50.19)	22.5 (55.58)			-0.22 (-0.70 to 0.25)	SD based on weighted average Dropouts 26 (26%): intervention 1/47, control 25/52
Epidura	al vs usual/conven	vtional care													
349	Buchner, 2000 ¹⁵¹	A+C	RCT	6 months	Hannover Functional Ability (0–100)	17	17	38.5	39.9	38.2 (13.09)	42.8 (13.09)			-0.35 (-1.03 to 0.33)	SD calculated from SE Dropouts 26 (26%): intervention 1/47, control 25/52
A + C, a	cute and chronic; C	;, chronic; LOCF,	last observ	ation carried fo.	rward.	1.002									

a based on tinal means or change scores (with a preference given to change scores); results reported by study in italics. b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. c Becker *et al.*¹⁴⁶ included three treatment arouns: epidirral injection of starnid triaminations. From a hord to the treatment arouns:

Becker *et al.*¹⁴⁹ included three treatment groups: epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (i), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of autologous conditioned serum (iii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the meta-analysis (see *Figure 19*.

ID no.	Author, year	Study design					SMD (95% CI)	% weight
Biologic	al agents							
321	Becker, 2007 ¹⁴⁹	RCT	+				-0.08 (-0.60 to 0.45)	100.00
Inactive	control							
350	Carette, 1997 ¹⁵²	RCT		_			-0.15 (-0.47 to 0.16)	31.67
739	Karppinen, 2001 ¹⁷¹	RCT	-				0.20 (-0.11 to 0.51)	31.81
778	Price, 2005 ¹⁷³	RCT					0.30 (0.04 to 0.56)	36.52
Subtota	$(l^2 = 60.0\%, p = 0.082)$		<	\sim			0.13 (-0.14 to 0.40)	100.00
Non-op	ioids							
20	Dincer, 2007 ¹⁴³	RCT	•	-			-0.42 (-0.92 to 0.08)	100.00
Mixed t	reatments							
348	Pirbudak, 2003 ¹⁵⁰	RCT			•		1.30 (0.85 to 1.75)	100.00
Passive	РТ							
359	Veihelmann, 2006 ¹⁵⁵	RCT					-0.22 (-0.70 to 0.25)	100.00
Usual/c	onventional care							
349	Buchner, 2000 ¹⁵¹	RCT					-0.35 (-1.03 to 0.33)	100.00
		I				1		
		-1.75	() D		1.75		
			Favours epidural	Favou	rs control			

FIGURE 19 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing epidural/intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

One moderate-quality RCT¹⁴³ reported non-statistically significant findings in favour of epidural compared with non-opioids for improving functional status at 3 months' follow-up. The methods of randomisation and allocation concealment were not stated.

One moderate-quality RCT¹⁵⁰ found epidural used in combination with non-opioids (mixed treatments) to be significantly better than epidural used alone for improving functional status at 6 months' follow-up. The study included patients with duration of symptoms ranging from 1 month to 12 months.

There was no statistically significant difference between epidural and passive PT in terms of improvement in functional status for chronic sciatica at 6 months. This was according to one moderate-quality study¹⁵⁵ with a differential dropout rate in favour of epidural.

There was no important difference between epidural using either a low- or high-dose steroid and biological agents, in terms of functional status at 22 weeks. This was according to one moderatequality RCT¹⁴⁹ that included patients with chronic or acute sciatica.

One poorly reported RCT⁹⁵ of moderate quality compared epidural with disc surgery. The method of randomisation and allocation concealment were not reported. There was a significantly greater decreasing in disability in the discectomy group compared with the epidural group at the 1–3 month follow-up interval (p < 0.015, Student's *t*-test). No summary statistics were reported and, therefore, the study is not presented in *Figure 19*.

Results at long-term follow-up for epidural/intradiscal injections (>6 months) Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 26* and the accompanying forest plot (*Figure 20*). Epidural/intradiscal injections were compared with inactive control, passive PT and chemonucleolysis. One study¹⁵⁸ only included patients with acute sciatica, two studies^{144,155} only included patients with chronic sciatica and the remaining two studies^{158,173} included patients with either acute or chronic sciatica. The duration of follow-up ranged from 1 year^{155,173} to 2 years.¹⁴⁴

Two studies^{158,173} compared epidural injections with inactive control in patients with either acute or chronic sciatica, for which there was a non-statistically significant overall findings in favour of epidural. One study was a good-quality RCT,¹⁷³ whereas the other was a poorly reported non-RCT.¹⁵⁸

As with medium-term follow-up, one RCT,¹⁵⁵ of moderate quality, found epidural injections to be significantly better than passive PT at 12 months. However, the withdrawal rate was very high in the control group (48%) compared with the intervention group (2%). Patients in the PT group were able to cross over to an epidural injection after 3 months of unsatisfactory treatment, but were then excluded from the analysis (n = 12/52).

One poorly reported non-RCT¹⁴⁴ found chemonucleolysis to be significantly more effective than epidural injection in terms of overall recovery according to the physician, for patients with chronic sciatica at 2 years. All patients had been treated by the author. The findings were based on a subgroup of included patients with sciatica, for whom symptom duration ranged from 12 weeks to 25 years (median 1 year). All patients had already tried various treatments for at least 3 months.

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 27* and the accompanying forest plot (*Figure 21*). Epidural injections were compared with inactive control, passive PT, mixed treatments and disc surgery. Two studies^{150,155} included patients with chronic

ID no.	Author, year	Study design				OR (95% CI)	% weight
Chemo	nucleolysis						
50	Graham, 1976 ¹⁴⁴	Non-RCT —	•			0.12 (0.02 to 0.87)	100.00
Inactive	e control						
778	Price, 2005 ¹⁷³	RCT			*	1.14 (0.65 to 2.01)	57.49
406	Vad, 2002 ¹⁵⁸	Non-RCT				5.73 (1.49 to 22.01)	42.51
Subtota	$I (I^2 = 78.7\%, p = 0.030)$)		<		2.27 (0.48 to 10.82)	100.00
Passive	PT						
359	Veihelmann, 2006 ¹⁵⁵	RCT				5.36 (1.87 to 15.36)	100.00
		0.0169	9	1	1	59	
			Favours co	ntrol	Favours epidural		

FIGURE 20 Summary of the findings of global effect at long-term follow-up (>6 months) for studies comparing epidural/ intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

native interventions	
injections with alter	
epidural/intradiscal	
studies comparing	
ip (>6 months) for s	
t long-term follow-u	
the global effect at	by author)
y of the findings of	rator then ordered
TABLE 26 Summar	(grouped by compa

no in														
							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0r (95% CI)	Comments
Epid	ural vs chemo.	nucleolysis												
50	Graham, 1976 ¹⁴⁴	S	Non- RCT	2 years	Perceived effect: good (vs fair or unimproved)	Physician	13	N	0	10	9	0	0.12 (0.02 to 0.87)	Only sciatica patients included here (23/40)
Epid	ural vs inactiv.	e control												
778	Price, 2005 ¹⁷³	A+C	RCT	52 weeks	Global improvement: ≥ 75% improvement in ODI		120	39	0	108	32	0	1.14 (0.65 to 2.01)	Data inferred from graphs reporting percentages ITT using LOCF
406	Vad, 2002' ¹⁵⁸	A+C	Non- RCT	Mean 1.4 years (range 12–21 months)	Successful outcome: patient satisfaction (score of 2 or 3), improvement on the RMDQ (\geq 5), and pain reduction (\geq 50%)	Patient + physician	25	21	0	53	=	60.0	5.73 (1.49 to 22.01)	2
Epid	'ural vs passivı	9 PT												
359	Veihelmann, 2006 ¹⁵⁵	O	RCT	12 months	Gerbershagen score (chronification index), GHS I (vs GHS II, III)		46	30	0.02	27	2	0.48	2.52 (1.87 to 15.36)	Almost half of patients in control group missing ITT not used
A+C), acute and chr	onic; C, chroni	c; LOCF, la:	st observation carrie	d forward.									

TABLE 27 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

	Comment/conversion		Summary statistics not reported Dropouts 4/100 (4%): intervention 3/50, control 1/50		SD imputed from weighted average Dropouts 22%: intervention 1/12, control 4/11 ITT analysis based on LOCF	SDs (and SEs) for change estimated from 95% Cl of difference between treatment groups Two patients lost to follow-up from steroid group ITT not used	
	Mean difference (95% CI) [®]		There were no significant differences between intervention groups (Student's t-test)		-15.40 (-32.04 to 1.24)	3.90 (–6.37 to 14.17) Multivariate analysis (adjusted change from baseline) –5.3 (95% Cl –15.7 to 5.0)	3.00 (–6.09 to 12.09)
e scores	Control						-20 (34)
Change (SD)	Intervention						-17 (36)
an (SD)	Control				29.6 (23.67)	24.2 (17.15)	
Final me	Intervention				14.2 (15.94)	23.9 (17.15)	
e mean	Control				49.2	75.2 (19)	56 (22)
Baselin (SD)	Intervention				38.5	71 (18)	52 (23)
(<i>u</i>)	Control		50		,	80	108
Total	Intervention		20		12	78	120
	Scale (range) ^a		VAS (0-10)		VAS (0-100)	VAS (0-100)	VAS (0-100)
	Location		Back		Overall	De l	Leg
	Follow-up		23 years		52 weeks	12 months	52 weeks
	Study design		RCT		RCT	RCT	RCT
	Chronicity	hery	A + C	control	U	A + C	A+C
	Author, year	al vs disc sur _i	Buttermann, 2004 ⁹⁵	al vs inactive	Bush, 1991 ¹⁴⁷	Karppinen, 2001' ⁷⁷	Price, 2005 ¹⁷³
	<u>ם</u> פ	Epidura	725	Epidura	203	739	778

Health Technolo	av Assessment 2	011: Vol. 15: No. 39

	Comment/conversion [©]		SD estimated from SE Dropouts 26%: intervention 1/47, control 25/52 Almost half of control group dropped out			
	Mean difference (95% CI) ^b		—31.00 (—102.02 to 40.02)		53.00 (47.31 to 58.69)	
e scores	Control				-62.0 (8.0)	
Chang (SD)	Intervention				9 (18)	
n (SD)	Control		59 (119.51)		16	
Final mea	Intervention		28 (189.91)		75	
mean	Control		67 (103.92)		78.1 (40.0)	talics.
Baseline (SD)	Intervention		72 (135.6)		84 (17)	oy study in i ow-up.
(<i>u</i>)	Control		27		46	eported ost to foll
Total	Intervention		46		46	esults r atients lo
	Scale (range) ^a		VAS (0-10)		VAS (0-10)	ge scores); sions and p
	Location		De T		Overall	ried forward. mparability. jiven to chan aseline exclu
	Follow-up		12 months		9 months	sservation car 0–100 for co a preference ç g data, post-b
	Study design		RCT		RCT	-OCF, last ol o a scale of cores (with a for missing
	Chronicity	Ч	S	etments	O	nic; C, chronic; I een converted ti uns or change s has been used
	Author, year	I vs passive i	Veihelmann, 2006 ¹⁵⁵	łl vs mixed tr	Pirbudak, 2003 ¹⁵⁰	cute and chror results have build on final mea term 'dropouts
	D e	Epidura	359	Epidura	348	A+C,a a The b Base c The



FIGURE 21 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing epidural/intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

sciatica and the remaining studies included patients with either acute or chronic sciatica. The duration of follow-up ranged from 9 months¹⁵⁰ to 2–3 years.⁹⁵

Three RCTs^{147,171,173} compared epidural injections with inactive control, for which pooled analyses showed no important difference between the groups at 12 months. The overall quality of two trials^{171,173} was good. The third study¹⁴⁷ was small (n = 23), poorly reported and of moderate quality. The method of randomisation and allocation concealment were not stated, but the study included blind outcome assessment. SDs for final mean were not reported, so were imputed using the weighted mean. Unlike the remaining studies, the WMD for this study was statistically significant in favour of epidural. One of the RCTs¹⁷¹ also reported findings based on ANCOVA, adjusted for baseline values, which favoured inactive control for leg pain at 6 months (-16.2; 95% CI -26.8 to -5.6, p = 0.003; negative values indicate a negative effect). The same analysis showed no statistically significant difference between the groups at 12 months.

One moderate-quality RCT¹⁵⁵ found epidural injection to be significantly better than passive PT in terms of pain reduction in chronic sciatica at 12 months. The withdrawal rate was much higher in the control group (48%) than the intervention group (2%).

One moderate-quality RCT¹⁵⁰ found epidural injection in combination with non-opioids (mixed treatments) to be significantly better than epidural injection alone in terms of pain reduction in chronic sciatica at 9 months' follow-up.

One poorly reported RCT⁹⁴ of moderate quality, compared epidural injection with disc surgery. The method of randomisation and allocation concealment were not reported. There were no significant differences between the epidural injection and disc surgery groups at 2–3 years follow-up for low back pain (Student's *t*-test). No summary statistics were reported and, therefore, the study is not presented in *Figure 21*.

Condition-specific outcome measures at long-term follow-up

The results for CSOMs at long-term follow-up are presented in *Table 28* and the accompanying forest plot (*Figure 22*). Epidural injections were compared with inactive control, passive PT and

TABLE 28 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing epidural/intradiscal injections with alternative interventions (grouped by

						Total (<i>n</i>)		Baseline I (SD)	mean	Final me	an (SD)	Change s (SD)	scores		
ÐË	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI)ª	Comment/conversion ^b
Epidu	iral vs inactive	control													
739	Karppinen, 2001 ¹⁷¹	A + C	RCT	12 months	IQO	78	80	42.9 (16)	43.5 (15)	15.9 (16)	16.3 (15)	-27 (21.16)	-27.2 (21.16)	−0.3 (−0.34 to 0.29) Adjusted change from baseline −0.4 (95% Cl −7.0 to 6.2)	No final SD so baseline SD used Two patients lost to follow-up from steroid group
778	Price, 2005 ¹⁷³	A + C	RCT	52 weeks	IQO	120	108	44 (15)	45 (18)	28 (15)	27 (18)	-16 (23)	-14 (24)	0.06 (-0.20 to 0.32)	Final score calculated from change score No final SD, so baseline SD used ITT used LOCF
Epidu	ıral vs mixed trı	eatment													
348	Pirbudak, 2003 ¹⁵⁰	O	RCT	9 months	IQO	46	46	49.6 (15.5)	50.2 (15.2)	46 (15.5)	26 (15.2)	-7.6 (15.3)	-13.2 (15.5)	1.30 (0.85 to 1.75)	No final SD, so baseline SD used
Epidu	iral vs passive i	РТ													
359	Veihelmann, 2006 ¹⁵⁵	C	RCT	12 months	IOO	46	27	23.1	21.4	11.6 (13.04)	21.6 (13.04)			-0.77 (-1.26 to -0.28)	Final SD imputed from weighted mean of SDs of ODI for epidural Dropouts 26 (26%): intervention 1/47, control 25/52
A+C, a Ba; b The	acute and chror sed on final mes e term 'dropouts	nic; C, chronic; ans or change s 3' has been use	LOCF, last ok scores (with a d for missing	servation carri a preference giv 1 data, post-bas	ed forward 'en to char eline exclu	I. 1ge scores 1sions and); results patients	reported by lost to follo	y study in it wv-up.	talics.					

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.



FIGURE 22 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing epidural/ intradiscal injections with alternative interventions. Note: weights are from random effects analysis.

mixed treatments. Two studies^{150,155} included patients with chronic sciatica and the remaining studies included patients with either acute or chronic sciatica. The duration of follow-up ranged from 9 months¹⁵⁰ to 12 months.^{155,171,173}

Two good-quality RCTs^{171,173} compared epidural injections with inactive control; the pooled analyses showed no statistically significant difference between the groups at 12 months.

One moderate-quality RCT¹⁵⁵ found epidural injections to be significantly better than passive PT for improving functional status for patients with chronic sciatica at 12 months. However, the withdrawal rate was much higher in the control group (48%) than in the intervention group (2%).

One moderate-quality RCT¹⁵⁰ found epidural injection in combination with non-opioids (mixed treatments) to be significantly better than epidural injection alone for improving functional status in patients with chronic sciatica at 9 months' follow-up.

Analysis of adverse effects for epidural/intradiscal injections

The results for the occurrence of any reported adverse effects are presented in *Table 29* and the accompanying forest plot (*Figure 23*). The incidence of adverse effects were significantly greater for epidural injections compared with either education/advice, passive PT or usual care. Overall there was no statistically significant difference in the number of adverse effects when comparing epidural injections with either activity restriction, biological agents, chemonucleolysis, disc surgery, manipulation, mixed treatments, non-opioids or inactive control.

SUMMARY OF OVERALL FINDINGS FOR EPIDURAL/INTRADISCAL INJECTIONS COMPARED WITH ALTERNATIVE INTERVENTIONS

Most epidural injection studies included patients with chronic sciatica or both acute and chronic sciatica. One study included acute sciatica.¹⁴⁵ Less than half of the studies were RCTs. Apart from studies comparing epidural with inactive control, the quality of studies was poor (*Table 30*).

TABLE 29 Summary of the findings of any adverse effect for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author)

			No. of events in	No. of participants in	No. of events	No. of participants	
ID no.	Author, year	Study design	intervention group	intervention group	in control group	in control group	OR (95% CI)
Epidui	ral vs activity restriction						
140	Coomes, 1961 ¹⁴⁵	Non-RCT	1	20	0	20	3.15 (0.12 to 82.16)
Epidui	ral vs alternative						
667	Wehling, 1997 ¹⁶⁷ (epidural = steroid + LA)	CCS	NR	NR	NR	NR	
667	Wehling, 1997 ¹⁶⁷ (epidural = LA)	CCS	NR	NR	NR	NR	
Epidui	ral vs biological agents						
321	Becker, 2007 ¹⁴⁹ (epidural = 10 mg steroid)	RCT	1	27	1	32	1.19 (0.07 to 20.01)
321	Becker, 2007 ¹⁴⁹ (epidural = 5 mg steroid)	RCT	1	25	1	32	1.29 (0.08 to 21.73)
Epidui	ral vs chemonucleolysis						
720	Bontoux, 1990 ¹⁶⁸	RCT	NR	NR	NR	NR	
447	Bourgeois, 1988 ¹⁶⁰	RCT	0	30	3	30	0.13 (0.01 to 2.61)
729	Gallucci, 2007170	RCT	0	82	0	77	
50	Graham, 1976144	Non-RCT	NR	NR	NR	NR	
Epidui	ral vs disc surgery						
725	Buttermann, 200495	RCT	5	50	7	77	1.11 (0.33 to 3.72)
Epidui	ral vs education/advice						
722	Bronfort, 2004 ¹⁶⁹	RCT	10	10	0	10	441.00 (7.98 to 24,372.70)
Epidui	ral vs inactive control						
203	Bush, 1991 ¹⁴⁷	RCT	1	12	0	11	3.00 (0.11 to 81.61)
350	Carette, 1997152	RCT	22	77	17	79	1.46 (0.70 to 3.03)
383	Dilke, 1973157	RCT	6	51	0	48	13.86 (0.76 to 253.00)
512	Helliwell, 1985162	RCT	0	20	0	19	
739	Karppinen, 2001 ¹⁷¹	RCT	1	80	0	80	3.04 (0.12 to 75.69)
539	Klenerman, 1984 ¹⁶³ (epidural = LA)	RCT	0	16	0	16	
539	Klenerman, 1984 ¹⁶³ (epidural = steroid)	RCT	1	19	0	16	2.68 (0.10 to 70.31)
905	Matthews, 1987176	RCT	NR	NR	NR	NR	
778	Price, 2005173	RCT	12	120	11	108	0.98 (0.41 to 2.32)
620	Ridley, 1988165	RCT	2	21	0	18	4.74 (0.21 to 106.00)
240	Snoek, 1977 ¹⁴⁸	RCT	0	27	0	24	
406	Vad, 2002 ¹⁵⁸	Non-RCT	0	25	0	25	
351	Valat, 2003 ¹⁵³	RCT	2	42	3	42	0.65 (0.10 to 4.10)

continued

TABLE 29 Summary of the findings of any adverse effect for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author) (continued)

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
175	Yates, 1978 ¹⁴⁶ (epidural = LA)	RCT (crossover)	0	20	0	20	
175	Yates, 1978 ¹⁴⁶ (epidural = steroid)	RCT (crossover)	0	20	0	20	
175	Yates, 1978 ¹⁴⁶ (epidural = steroid + LA)	RCT (crossover)	0	20	0	20	
Epidur	al vs manipulation						
451	Bronfort, 2000 ¹⁶¹	RCT	6	6	3	7	16.71 (0.68 to 409.09)
722	Bronfort, 2004 ¹⁶⁹	RCT	10	10	6	11	17.77 (0.84 to 377.00)
Epidur	al vs mixed treatment						
439	Blonna, 2004159	RCT	0	24	3	26	0.14 (0.01 to 2.80)
348	Pirbudak, 2003 ¹⁵⁰	RCT	0	46	0	46	
Epidur	al vs non-opioids						
451	Bronfort, 2000161	RCT	6	6	4	6	7.22 (0.28 to 189.19)
20	Dincer, 2007143	RCT	2	34	0	30	4.69 (0.22 to 102.00)
771	Lafuma, 1997 ¹⁷²	RCT	NR	NR	NR	NR	
362	Wilson-MacDonald, 2005 ¹⁵⁶	RCT	NR	NR	NR	NR	
846	Murata, 2009 ¹⁷⁵	RCT	NR	NR	NR	NR	
Epidur	al vs passive PT						
359	Veihelmann, 2006 ¹⁵⁵	RCT	16	46	0	39	42.74 (2.47 to 741.00)
Epidur	al vs usual care						
349	Buchner, 2000151	RCT	NR	NR	NR	NR	
828	Laiq, 2009174	Q-RCT	8	52	0	52	24.77 (1.34 to 458.00)
581	Matyjek, 1986164	CCS	NR	NR	NR	NR	
358	Popiolek, 1991 ¹⁵⁴	Non-RCT	NR	NR	NR	NR	
Mixed	treatments including epi	dural vs mixe	d treatments with	out epidural			
913	Saberski, 2000142	RCT	NR	NR	NR	NR	
644	Styczynski, 1997 ¹⁶⁶	Non-RCT	NR	NR	NR	NR	

LA, local anaesthetic; NR, not reported.

Meta-analysis of the mainly good-quality RCTs (up to seven studies) showed epidural injections to be significantly better than the inactive control at short-term follow-up for reducing pain^{147,152,153,158,162,171,173} and improving functional status.^{152,153,158,171,173} However, there was no statistically significant difference between intervention groups for the global effect.^{148,152,153,165,173,176} Furthermore, there was no statistically significant difference between epidural injection and inactive control for global effect,^{152,157,162,163,173} pain intensity^{152,162,171,173} or CSOMs^{152,171,173} at medium-term follow-up or global effect,^{158,173} pain intensity^{147,171,173} or CSOMs^{171,173} at long-term follow-up, or in terms of the number of adverse effects.^{146-148,152,153,157,158,162,163,165,171,173} A similar pattern was found for epidural injection compared with usual care. There was a statistically significant difference in favour of epidural for overall recovery (one non-RCT¹⁵⁴) and functional

ID no.	Author, year	Study design				OR (95% CI)	% weight
Activity	restriction						
140	Coomes, 1961 ¹⁴⁵	Non-RCT		•		3.15 (0.12 to 82.16)	100.00
Biologic	cal agents						
321	Becker, 2007 ¹⁴⁹	RCT		•		1.19 (0.07 to 20.01)	100.00
Chemor	nucleolysis						
447	Bourgeois, 1988 ¹⁶⁰	RCT		<u> </u>		0.13 (0.01 to 2.61)	100.00
Disc su	rgery						
725	Buttermann, 200495	RCT	-	•		1.11 (0.33 to 3.72)	100.00
Educati	on/advice						
722	Bronfort, 2004 ¹⁶⁹	RCT			>	441.00 (7.98 to 24,372.70)	100.00
Inactive	control						
203	Bush, 1991 ¹⁴⁷	RCT				3.00 (0.11 to 81.61)	2.28
350	Carette, 1997152	RCT		- • -		1.46 (0.70 to 3.03)	46.72
383	Dilke, 1973 ¹⁵⁷	RCT		— •—		13.86 (0.76 to 253.04)	2.95
739	Karppinen, 2001 ¹⁷¹	RCT		•		3.04 (0.12 to 75.69)	2.41
539	Klenerman, 1984163	RCT		•		2.68 (0.10 to 70.31)	2.33
778	Price, 2005 ¹⁷³	RCT		•		0.98 (0.41 to 2.32)	33.41
620	Ridley, 1988 ¹⁶⁵	RCT		•		4.74 (0.21 to 105.54)	2.58
351	Valat, 2003 ¹⁵³	RCT		·		0.65 (0.10 to 4.10)	7.32
Subtotal	l (l ² = 0.0%, p = 0.656)			\diamond		1.39 (0.85 to 2.29)	100.00
Manipul	lation						
451	Bronfort, 2000 ¹⁶¹	RCT		•		16.71 (0.68 to 409.09)	47.73
722	Bronfort, 2004 ¹⁶⁹	RCT		•		17.77 (0.84 to 377.40)	52.27
Subtotal	l (l ² = 0.0%, p = 0.978)					17.26 (1.89 to 157.20)	100.00
Mixed t	reatments						
439	Blonna, 2004 ¹⁵⁹	RCT				0.14 (0.01 to 2.80)	100.00
Non-op	ioids						
451	Bronfort, 2000 ¹⁶¹	RCT	_	•		7.22 (0.28 to 189.19)	47.02
20	Dincer, 2007 ¹⁴³	RCT	_	•		4.69 (0.22 to 101.72)	52.98
Subtotal	l (l ² = 0.0%, p = 0.850)					5.75 (0.61 to 53.94)	100.00
Passive	PT						
359	Veihelmann, 2006 ¹⁵⁵	RCT				42.74 (2.47 to 740.97)	100.00
Usual/c	onventional care						
828	Laiq, 2009 ¹⁷⁴	Q-RCT		•		24.77 (1.34 to 457.61)	100.00
	0.	000041		1	24,373		
		Favo	urs epidural	⊢avours control			

FIGURE 23 Summary of the findings of any adverse effect for studies comparing epidural/intradiscal injections with alternative interventions (grouped by comparator then ordered by author). Note: weights are from random effects analysis.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs (%)	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Epidural vs activity restriction	1 (1)	40 (40)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)
Epidural vs alternative/non- traditional	1 (2)	278 (278)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0
Epidural vs biological agents	1 (1)	(06) 06	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Epidural vs chemonucleolysis	4 (4)	40–159 (70)	3/4 (75)	0/4 (0)	0/4 (0)	4/4 (100)	4/4 (100)	0/4 (0)	0/4 (0)	0/4 (0)	4/4 (100)	0/4 (0)
Epidural vs disc surgery	1 (1)	100 (100)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)
Epidural vs inactive control	12 (13)	23–288 (67)	12/12 (100)	4/12 (33)	1/12 (8)	12/12 (100)	4/12 (33)	0/12 (0)	0/12 (0)	0/12 (0)	2/12 (17)	0/12 (0)
Epidural vs mixed treatment	2 (2)	50–92 (71)	2/2 (100)	0/2 (0)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	2/2 (100)	0/2 (0)
Epidural vs non-opioids	3 (3)	64–246 (93)	3/3 (100)	0/3 (0)	0/3 (0)	3/3 (100)	2/3 (67)	1/3 (33)	0/3 (0)	0/3 (0)	2/3 (67)	1/3 (33)
Epidural vs passive PT	1 (1)	(66) 66	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)
Epidural vs usual/ conventional care	3 (3)	36–60 (52)	1/3 (33)	0/3 (0)	0/3 (0)	3/3 (100)	3/3 (100)	0/3 (0)	0/3 (0)	0/3 (0)	0/3 (0)	0/3 (0)
Total (results for epidural studies)	29 (31)	23–278 (74)	24/29 (83)	4/29 (14)	2/29 (7)	29/29 (100)	18/29 (62)	2/29 (7)	1/29 (3)	1/29 (3)	13/29 (45)	2/29 (7)

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs.

TABLE 30 Summary of epidural studies

status (one RCT¹⁵¹) at short-term follow-up, but not for pain intensity (one RCT,¹⁵¹ one Q-RCT¹⁷⁴). There were no statistically significant difference between epidural injection and usual care at medium-term follow-up for global effect,^{151,174} pain intensity^{151,174} or CSOMs.¹⁵¹ However, usual care was associated with significantly fewer adverse effects than epidural injection (one Q-RCT¹⁷⁴).

Epidural injections were found to be better than non-opioids for reducing pain and improving functional status at short-term follow-up according to three poorly reported RCTs.^{143,156,175} There was no statistically significant difference between epidural and non-opioids for global effect (one RCT¹⁷⁵) or CSOMs (one RCT¹⁴³) at medium-term follow-up or adverse effects (two RCTs^{143,161}). One poorly reported RCT found that epidural injection in combination with non-opioids was better than epidural injection alone for reducing pain and improving functional status at long-term follow-up.¹⁵⁰ However, there was no statistically significant difference between the intervention groups at short- and medium-term follow-up for pain (two poorly reported RCTs^{150,159}) and CSOMs (RCT¹⁵⁰) or in terms of the number of adverse effects.^{150,159}

Chemonucleolysis using chymopapain was found to be better than epidural injection for the global effect at long-term follow-up (one poor-quality non-RCT¹⁴⁴). There was no statistically significant difference between epidural injection and chemonucleolysis for the global effect at short-term (one poorly reported RCT¹⁷⁰ using ozone–oxygen) or medium-term follow-up (three RCTs;^{160,168,170} one RCT¹⁷⁰ used ozone–oxygen). There was no statistically significant difference in the number of adverse effects experienced with epidural than with chemonucleolysis (one RCT¹⁶⁰).

Statistically significant findings in favour of epidural injection were found when compared with passive PT for global effect (at medium-¹⁵⁵ and long-term¹⁵⁵ follow-up) and activity restriction for global effect (medium-term follow-up¹⁴⁵), but these findings were reported by a single RCT¹⁵⁵ or non-RCT.¹⁴⁵ Disc surgery was found to be significantly better than epidural injection at reducing pain intensity at medium-term follow-up, but not at long-term follow-up (one poor-quality RCT⁹⁵). There was also no statistically significant difference in pain intensity between epidural injection and acupuncture (CCS¹⁶⁷ at short-term follow-up) and biological agents (poorly reported RCT¹⁴⁹ at medium-term follow-up).

Chemonucleolysis

Description of chemonucleolysis studies Summary of interventions

Forty studies evaluated chemonucleolysis for sciatica,^{46–56,58–61,75–77,79,85,88,90,92,96,103–105,144,160,168,170,205–213} 37^{46–56,58–61,75–77,79,85,88,90,92,96,103–105,144,160,168,170,205–210} of which compared chemonucleolysis with alternative interventions. The type of interventions evaluated by these latter studies are listed in *Table 31a*. One of these studies,⁴⁶ which compared disc surgery with chemonucleolysis, did not include comparative data and reported only descriptive results for change from baseline for each group.⁴⁶ One further study⁶¹ did not report any global effect, pain intensity or CSOM data.⁶¹

Three studies compared different types of chemonucleolysis²¹¹⁻²¹³ and one study²¹³ included three intervention arms. The types of chemonucleolysis being compared are listed in *Table 31b*, but the findings of these studies are not considered any further than this.

Summary of study participants for chemonucleolysis

The summary data for included participants are presented in *Table 32*. The number of participants included in the 36 studies that reported outcome data for global effect, pain or CSOMs ranged from 22 to 1085 participants (median 100 participants). A similar number of studies included patients with chronic sciatica or included patients with either chronic or acute sciatica. One study (comparing chemonucleolysis with disc surgery),¹⁰³ included some patients with spinal stenosis and none included patients with sequestered or extruded discs. The diagnosis of sciatica, or the presence of herniated disc, was confirmed by imaging in 31 (84%) studies. Two studies^{49,105} compared the use of chemonucleolysis with disc surgery in only patients who had sciatica for the first time, and one study⁵⁰ compared the same intervention in patients who had recurrent sciatica or, more usually, did not report this information. The majority of studies included patients who had received previous treatment for their current episode of sciatica, with this information not being stated in the remaining studies. Three studies^{56,59,88} that compared chemonucleolysis with disc surgery, included patients who had received previous disc surgery.

Summary of study design and quality for chemonucleolysis studies

Summary information on study details are presented in *Table 33*. Fewer than half (17/36, 47%) of chemonucleolysis studies were RCTs, and only one of these²⁰⁶ was good quality (comparator was inactive control). Eleven studies^{47,85,88,160,168,170,205,207–210} were of moderate quality. One study²⁰⁶ used both adequate randomisation and allocation concealment (comparator included inactive control). A further five studies^{85,88,160,205,210} used adequate randomisation, but not allocation concealment (although two studies^{160,210} used sealed envelopes), and one study⁶⁹ used adequate allocation concealment but not randomisation. One multicentre study²⁰⁹ reported that separate randomisation sequences were provided for each participating institute, but gave no details on how these sequences were generated. One study⁴⁷ had strong external validity (comparator included inactive control).

Chemonucleolysis results at short-term follow-up (≤6 weeks) Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 34* and the accompanying forest plot (*Figure 24*). Chemonucleolysis was compared with inactive control, disc surgery and epidural. Five studies^{46,48,52,92,205} included only patients with chronic sciatica, four studies^{49,170,206,207} included patients with either acute or chronic sciatica and the remaining studies did not report the duration of symptoms. The duration of follow-up ranged from 72 hours²⁰⁶ to 6 weeks.^{46,48,79,104,205,209}

TABLE 31a Summary of the interventions used when comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	Chemonucleolysis description	Control description
Chem	onucleolysis vs disc surg	gery		
884	Alexander, 1989 ¹⁰³	CCS	Chymopapain chemonucleolysis (2000 U)	Disc surgery (removal of protruding disc fragment only + free fat graft)
43	van Alphen, 198947	RCT	Chemonucleolysis with 4000 U chymopapain	Discectomy with emptying of disc space
441	Bonafe, 1993 ⁷⁵ (French language)	CCS	Nucleolysis using chymopapain (4000 U)	Percutaneous automated nucleotomy
183	Bouillet, 198361	CCS	Chemonucleolysis by chymopapain injections	Conventional lumbar disc surgery
453	Brown, 198976	CCS	Chemonucleolysis with chymopapain	Disc surgery
453	Brown, 1989 ⁷⁶	CCS	Collagenase chemonucleolysis	Disc surgery
454	Buric, 200577	Non-RCT	Chemonucleolysis with ozone-oxygen mixture	Standard microdiscectomy
166	Crawshaw, 198460	RCT	Chemonucleolysis with 4000 U chymopapain	Disc surgery
48	Dabezies, 197851	CCS	Chemonucleolysis using 2 ml chymopapain	Laminectomy with or without fusion
471	Dei-Anang, 1990 ⁷⁹ (German language)	CCS	Chemonucleolysis with 4000 U chymopapain or 600 units collagenase	Percutaneous nucleotomy
727	Ejeskar, 198396	RCT	Chemonucleolysis with chymopapain 400 IU	Discectomy with unilateral laminotomy and removal of disc hernia only
132	Hoogmartens, 197656	HCS	Chymopapain chemonucleolysis	Discectomy
44	Javid, 199548	CCS	Chemonucleolysis with 3000 IU chymopapain	Partial hemilaminectomy using magnification and fat graft
35	Krugluger, 200046	RCT	Chemonucleolysis using 4000 U chymodiactin	Automated percutaneous discectomy
117	Lagarrigue, 1991 ⁵⁴ (French language)	CCS	Chemonucleolysis with 2000–5000 U chymopapain	Discectomy with minimal bony resection
129	Lavignolle, 1987 ⁵⁵ (French language)	RCT	Chemonucleolysis with 4000 U chymopapain	Microscopic discectomy. Unilateral limited interlaminar
889	Lee, 1996 ¹⁰⁴ (German language)	CCS	Chemonucleolysis with chymopapain	Percutaneous manual and laser discectomy
889	Lee, 1996 ¹⁰⁴ (German language)	CCS	Chemonucleolysis with chymopapain	Automated percutaneous lumbar discectomy
593	Muralikuttan, 1992 ⁸⁵	RCT	Chemonucleolysis with chymopapain 2000 U	Standard discectomy with fenestration, disc space cleared
47	Norton, 198650	CCS	Chymopapain chemonucleolysis	Conventional surgical discectomy
45	Postacchini, 198749	Non-RCT	2 ml chymopapain chemonucleolysis	Disc excision using unilateral laminotomy
617	Revel, 199388	RCT	Chemonucleolysis	Automated percutaneous lumbar discectomy
641	Steffen, 1999 ⁹⁰ (German language)	RCT	Chemonucleolysis with 2 ml chymodiactin	Laser disc decompression
49	Stula, 1990 ⁵² (German language)	RCT	Chemonucleolysis with 500 U chymopapain	Conventional disc surgery
61	Tregonning, 1991 ⁵³	CCS	Chemonucleolysis with chymopapain	Fenestration or partial laminectomy removing extruded disc material
893	Watters, 1988 ¹⁰⁵	Non-RCT	Chemonucleolysis using chymopapain (4000 U)	Microdiscectomy with free fat graft over exposed dura
160	Watts, 197559	CCS	Chemonucleolysis with chymopapain 4 mg	Discectomy with laminotomy and foraminotomy
672	Weinstein, 198692	CCS	Chemonucleolysis with chymopapain	Discectomy
150	Zeiger, 1987 ⁵⁸	CCS	Chemonucleolysis with 2.5 ml chymodiactin	Microdiscectomy with intraoperative injection into intervertebral space with steroid 125 mg methylprednisolone + morphine 4 mg used to reduce postoperative pain and morbidity

continued

TABLE 31a Summary of the interventions used when comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author) (continued)

ID no.	Author, year	Study design	Chemonucleolysis description	Control description
Chemo	nucleolysis vs epidural			
720	Bontoux, 1990 ¹⁶⁸ (French language)	RCT	Chemonucleolysis with chymopapain 4000 U	Intradiscal injection of triamcinolone 70 mg
447	Bourgeois, 1988 ¹⁶⁰ (French language)	RCT	Chemonucleolysis with chymopapain 4000 U	Intradiscal injection of triamcinolone 80 mg
729	Gallucci, 2007 ¹⁷⁰	RCT	Intraforaminal and intradiscal injections of steroid triamcinolone 80 mg + local anaesthetic 2–4 ml ropivacaine plus ozone–oxygen (group B)	Intraforaminal and intradiscal injections of steroid triamcinolone 80 mg + local anaesthetic 2–4 ml ropivacaine (group A)
50	Graham, 1976 ¹⁴⁴	Non-RCT	Chemonucleolysis with chymopapain (dose not stated)	Intradiscal hydrocortisone injection (dose not stated)
Chemo	nucleolysis vs inactive c	ontrol		
726	Dabezies, 1988209	RCT	Chemonucleolysis using 8 mg chymopapain	Placebo injections
244	Feldman, 1986 ²⁰⁷ (French language)	RCT	Chemonucleolysis with 4000 U chymopapain	Intradiscal injection of distilled water
55	Gogan, 1992 ²⁰⁵	RCT	Chemonucleolysis with 8 mg chymopapain	Intradiscal injection of normal saline 2 ml
738	Javid, 1983 ²¹⁰	RCT	Chymopapain injections of 3.0 ml (3000 U/ 1.5 ml)	Placebo group (3 ml of sterile pyrogen-free saline solution)
236	Schwetschenau, 1976 ²⁰⁶	RCT	Chemonucleolysis by 4 mg chymopapain	Intradiscal injection of inactive control (placebo group)
Chemo	nucleolysis vs manipula	tion		
723	Burton, 2000 ²⁰⁸	RCT	Chemonucleolysis with 400 U chymopapain	Osteopathic spinal manipulation for up to 12 weeks

IU, international units; U, units

TABLE 31b Summary of the interventions used when comparing alternative forms of chemonucleolysis (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	Chemonucleolysis description	Control description
Chemo	nucleolysis vs chemonu	ıcleolysis		
435	Benoist, 1993 ²¹²	RCT	Chemonucleolysis using low-dose chymopapain 2000 U	Chemonucleolysis using standard-dose chymopapain 4000 U
453	Brown, 198976	CCS	Chemonucleolysis with chymopapain	Collagenase chemonucleolysis
511	Hedtmann, 1987 ²¹³	Q-RCT	Chemonucleolysis with collagenase 600 ABC U (high dose)	Chemonucleolysis with chymopapain 400 ABC U
511	Hedtmann, 1987 ²¹³	Q-RCT	Chemonucleolysis with collagenase 400 ABC U (low dose)	Chemonucleolysis with chymopapain 400 ABC U
407	Wittenberg, 2001 ²¹¹	RCT	Chemonucleolysis with 4000 IU chymopapain	Chemonucleolysis with 400 ABC U collagenase

IU, international units; U, units.

Chemonucleolysis was compared with an inactive control in four RCTs,^{205–207,209} for which the pooled analysis showed a non-statistically significant difference in favour of the chemonucleolysis group. One RCT²⁰⁶ was good quality and the remaining three were of moderate quality, with most using adequate randomisation. Unlike the remaining RCTs, this study²⁰⁶ reported non-statistically significant findings in favour of the inactive control.

~	
8	
E C	
ð	
ð	
c	
e	
누	
۲	
Ĕ	
ē.	
g	
Ĕ	
5	
ŏ	
≥	
Δ	
ğ	
۳.	
5	
2	
ē	
S	
E	
£	
Ē	
é	
ŝ	
Ĕ	
-∟	
ð	
£	
<u>a</u>	
E	
te	
ਯ	
È	
÷	
3	
<u>.</u> 0	
Ś	
6	
ð	
$\overline{\mathbf{O}}$	
Z	
Ъ	
Ĕ	
ē	
운	
Š	
2	
_	
Ŀ,	
oarir	
nparir	
omparir	
comparir	
es comparir	
lies comparir	
udies comparir	
studies comparir	
r studies comparir	
for studies comparir	
s for studies comparir	
ails for studies comparir	
stails for studies comparir	
details for studies comparir	
ו details for studies comparir	
on details for studies comparir	
tion details for studies comparin	
Ilation details for studies comparin	
oulation details for studies comparir	
opulation details for studies comparir	
population details for studies comparin	
by population details for studies comparin	
udy population details for studies comparii	
study population details for studies comparir	
d study population details for studies comparir	
ind study population details for studies comparin	
and study population details for studies comparit	
se and study population details for studies comparir	
ype and study population details for studies comparir	
a type and study population details for studies comparir	
ca type and study population details for studies comparii	
itica type and study population details for studies comparir	
iatica type and study population details for studies comparin	
sciatica type and study population details for studies comparii	
of sciatica type and study population details for studies compari	
of sciatica type and study population details for studies comparir	
iry of sciatica type and study population details for studies comparii	
nary of sciatica type and study population details for studies comparir	
mary of sciatica type and study population details for studies compari	
immary of sciatica type and study population details for studies comparir	
Summary of sciatica type and study population details for studies comparir	
Summary of sciatica type and study population details for studies comparing	
32 Summary of sciatica type and study population details for studies comparit	(JC
32 Summary of sciatica type and study population details for studies comparit	hor)
LE 32 Summary of sciatica type and study population details for studies comparit	uthor)
BLE 32 Summary of sciatica type and study population details for studies comparir	author)
ABLE 32 Summary of sciatica type and study population details for studies comparit	ly author)

											Included	Included patients with sequestered	Any previous	Any previous hack
Chemonecleopysis relace surgery Chemonecleopysis relace surgery 864 Alexandler CCS 100 Mean 33.5 90 (60) Mean 5.5 months Nev Yes Ne No Yes 41 anolybien CCS 100 Mean 34.5 90 (60) Alean 5.5 months Nev Yes Ne No Yes 411 Bondie, 1993* CCS 400 Mean 4.6 26 (70) Mean 3.7 months Neve Yes NR No Ne 431 Bondie, 1993* CCS 20 Mean 4.6 26 (70) Mean 3.7 Months Neve Yes NR No NR 433 Bouliet, 1983* CCS 23 Mean 37.6 59 (50) At least 3 months Neve Yes NR No No 433 Bunic, 2005* Non-Fic1 45 Mean 37.6 59 (50) At least 3 months Yes Nn No No 434 Bunic, 2005* Non-Fic1 45 </th <th>₽ë</th> <th>Author, year</th> <th>Study design</th> <th>No. of patients</th> <th>Age (years)</th> <th>No. of men (%)</th> <th>Symptom duration</th> <th>Type of sciatica</th> <th>Confirmed by imaging?</th> <th>Recurrent episode</th> <th>patients with stenosis?^a</th> <th>disc (or extruded)?ª</th> <th>treatment for sciatica?</th> <th>surgery for sciatica?</th>	₽ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	patients with stenosis? ^a	disc (or extruded)?ª	treatment for sciatica?	surgery for sciatica?
864 Hazarder, 1989 ^w CS 100 Mara 35, (ange) 18-6); (ange) 18-6); (ange) 18-5); 90 (6) Mara 55 months (or pain) Neve Yes Neve Yes Neve	Chem	onucleolysis vs di	isc surgery											
43 van Alphen, FC1 151 Mean 34, (ange 18-45) 90 (6) < 6 months 55%, in orbinal being 1983* CS 40 No No No 41 Bondie, 1993* CS 40 Mean 44, (ange 27-68) 28 (70) Mean 345%, in orbinal dang several in noupely No No No No No 138 Bouliet, 1983* CS 20 Nem 45, (ange 27-68) 28 (70) Mean 37,6 50 (70) No No No No 13 Bouliet, 1983* CS 273 Nn Nn Rege several dans to to copial No	884	Alexander, 1989 ¹⁰³	ccs	100	Mean 33.5 (range 18–65)	(06) 06	Mean 5.5 months	Nerve root pain	Yes	NR	No	Yes	Yes	No
411Bonate, 1993"CS40Mean 4628 (70)Mean 3 monthsNeveNeveNeNeNeNeNe15Bouillet, 1983"CS2249NNNNNNNNN453Bouillet, 1983"CS2249NNNNNNNNN454Bouillet, 1983"CS2349NNNNNNNNN454Burit, 2005"NNNNNNNNNNN454Burit, 2005"NNNNNNNNNN454Burit, 2005"NNNNNNNNNN454Burit, 2005"NNNNNNNNNN454Burit, 2005"NNNNNNNNNN45Burit, 2005"NNNNNNNNNN45DeleteredS0142.6.6.monNNNNNNNN45DeleteredS0142.6.6NNNNNNNN45DeleteredS0142.6.6NNNNNNNN46DeleteredS0142.6.6NNNN <td>43</td> <td>van Alphen, 1989⁴7</td> <td>RCT</td> <td>151</td> <td>Mean 34 (range 18–45)</td> <td>(99) (<u>6</u>6)</td> <td>< 6 months 55%; > 6 months 45%</td> <td>Nerve root pain</td> <td>Yes</td> <td>NR</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td>	43	van Alphen, 1989⁴7	RCT	151	Mean 34 (range 18–45)	(99) (<u>6</u> 6)	< 6 months 55%; > 6 months 45%	Nerve root pain	Yes	NR	No	No	Yes	No
183 Bouliet, 1983 ⁶ CCS 2749 NR NR Range (weeks to months) Nerve to topain Verve toot pain Verve toot pain Verve toot pain NR No NN 453 Brown, 1989 ⁶ CCS 85 Maan 37.6 59 (69) At least 3 months) Norve to pain No No No 454 Buric. 2005 ⁷ Non-RCT 45 Maan 37.6 59 (63) At least 3 months Norve 1 No No No 454 Buric. 2005 ⁷ Non-RCT 45 Norve 1 Norve 1 No No No No No 16 Total and and total and and total and total and	441	Bonafe, 1993 ⁷⁵ (French language)	CCS	40	Mean 46 (range 27–68)	28 (70)	Mean 3 months (range several days to 15 months)	Nerve root pain	Yes	NR	N	NR	Yes	NR
453 Brown, 1989" CCS 85 Mean 37.6 59 (6) At least 3 months in the cot pain out pain out pain out pain out pain in the cot pain out pain out pain in the cot pain out pain	183	Bouillet, 198361	CCS	2749	NR	R	Range (weeks to months)	Nerve root pain	Yes	R	No	NR	Yes	R
454 Burk. 2005 ⁷ Non-RCT 45 Mean 45 23 (51) Mean 2039 days Neve Yes NR No No No 166 Crawshaw, 1984 ⁹⁶ RCT 52 Mean 37 NR NR No No No No 48 Dabezies, 1984 ⁹⁶ CCS 200 Mean 39 132 (66) NR No	453	Brown, 1989 ⁷⁶	CCS	85	Mean 37.6	59 (69)	At least 3 months	Nerve root pain	Yes	NR	No	No	Yes	No
166Cawshaw, 1984°RCT52Mean 37NRNerve not painVes not painNRNoNo48Dabezies, 1978°CCS200Mean 39132 (66)NRNerveClinicalRecurrentNoNo47Dabezies, 1978°CCS200Mean 39132 (66)NRNerveClinicalRecurrentNoNo471Dei-Anang, 1990°CCS201NRNRNervePainNRNoNo471Dei-Anang, 1990°CCS201NRNRNRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNR471Dei-Anang, 1990°CCS201NRNRNRNR472Ejeskar, 1983°RCT29Mean 39.321 (72)Mean 4.5 months)NRNRNR727Ejeskar, 1983°RCT29Mean 39.321 (72)Mean 4.5 months)NRNRNR	454	Buric, 2005 π	Non-RCT	45	Mean 45 (SD 14.2, range 19–77)	23 (51)	Mean 203.9 days (SD 129.6, range 21 to > 365 days)	Nerve root pain	Yes	NR	No	N	Yes	No
48Dabezies, 1978 ⁵¹ CS200Mean 39132 (66)NRNerveClinicalRecurrentNoNo471Dei-Anang, 1990 ⁷³ CS201NRNRNRNRNRNRNR471Dei-Anang, 1990 ⁷³ CS201NRNRNRNRNRNR727Ejeskar, 1983 ⁹⁸ RCT29Mean 39.321 (72)Mean 4.5 monthsNRNRNRNR727Ejeskar, 1983 ⁹⁸ RCT29Mean 39.321 (72)Mean 4.5 monthsNRNRNRNR	166	Crawshaw, 1984 ⁶⁰	RCT	52	Mean 37	R	NR	Nerve root pain	Yes	R	No	No	Yes	No
471 Dei-Anang, CCS 201 NR NR NR verve NR No No 1990 ⁷⁸ German root pain root pain root pain (German Ianguage) R 20 Mean 39.3 21 (72) Mean 4.5 months Nrve Yes No No 727 Ejeskar, 1983 ⁵⁸ RCT 29 Mean 39.3 21 (72) Mean 4.5 months Nrve Yes No No 727 Ejeskar, 1983 ⁵⁶ RCT 29 Mean 39.3 21 (72) Mean 4.5 months root pain	48	Dabezies, 1978 ^{si1}	CCS	200	Mean 39	132 (66)	NR	Nerve root pain and referred pain	Clinical	Recurrent and first episode	ON	ON	Yes	N
727 Ejeskar, 1983 ^{se} RCT 29 Mean 39.3 21 (72) Mean 4.5 months Nerve Yes NR No No No (SD 3 months) root pain	471	Dei-Anang, 1990 ⁷⁹ (German language)	CCS	201	R	NN	NR	Nerve root pain	NN	NN	No	No	NN	RN
	727	Ejeskar, 1983%	RCT	29	Mean 39.3	21 (72)	Mean 4.5 months (SD 3 months)	Nerve root pain	Yes	NR	No	No	NR	No

rdered by
ttor then o
y compara
grouped b
rventions (
native inte
s with alter
nucleolysi
ing chemo
es compar
ls for studi
ation detai
udy popul
ype and st
f sciatica t
summary o 'inued)
ABLE 32 { Lthor) (coni
а –

بابع previous back ment surgery for itatica? sciatica?	Yes	No	NR	NN	NR	NR	NR	No	No	Yes
Any p treati for so	Yes	Yes	Yes	Yes	NR	Yes	Yes	Yes	Yes	Yes
Included patients with sequestered disc (or extruded)? ^a	N	No	No	No extrusion	No	No	No	R	QN	No
Included patients with stenosis?ª	N	No	No	Yes	No	No	No	R	N	No
Recurrent episode	Recurrent and first episode	NR	NR	NR	NR	NN	NR	Recurrent	First episode	NR
Confirmed by imaging?	R	Yes	Yes	Clinical	NR	Yes	Yes	Yes	Yes	Yes
Type of sciatica	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain	Nerve root pain and referred pain	Nerve root pain
Symptom duration	25-35 months	Mean 7.2 months	Mean 7 months	Mean 13.4 months	NR	NR	Mean 24 weeks	Mean 18.5 months (range 5 days– 128 months)	Mean 8.75 months (range 1.2–36.0 months)	NR
No. of men (%)	48 (49)	134 (67)	16 (73)	682 (63)	225 (63)	213 (71)	55 (60)	86 (82)	NN	96 (68)
Age (years)	Mean 35.5	Mean 39 (range 17–81)	Mean 40 (range 24–60)	Mean 42 (range 14–83)	Mean 41 (SD 12.03)	<30 50%; >40 25%	Mean 35 (range 19–60)	Mean 40 (range 20–67)	NR	Mean 39 (SD 9, range 21–65)
No. of patients	97	200	22	1085	358	300	92	105	161	165
Study design	HCS	CCS	RCT	CCS	RCT	CCS	RCT	CCS	Non-RCT	RCT
Author, year	Hoogmartens, 1976 ⁵⁶	Javid, 1995 ⁴⁸	Krugluger, 2000 ⁴⁶	Lagarrigue, 1991 (French language) ⁵⁴	Lavignolle, 1987 ⁵⁵ (French language)	Lee, 1996 ¹⁰⁴ (German language)	Muralikuttan, 1992 ⁸⁵	Norton, 1986 ⁵⁰	Postacchini, 1987⁴9	Revel, 1993 ⁸⁸
- Ó	32	4	5	17	29	89	93	2	Ω.	17

⊡ ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)?ª	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
641	Steffen, 1999 ⁹⁰ (German language)	RCT	69	К	NR	10.6 months	Nerve root pain	Yes	R	N	N	Yes	No
49	Stula, 1990 ⁵² (German language)	RCT	69	Range 22–54	57 (83)	<1 year	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	No
61	Tregonning, 1991 ⁵³	CCS	268	Mean 40.4 (range 20–65)	135 (68)	NR	Nerve root pain	Yes	NR	No	No	Yes	No
893	Watters, 1988 ¹⁰⁵	Non-RCT	100	Mean 36.5	59 (59)	Mean 13 weeks	Nerve root pain	Yes	First episode	No	NR	NR	NR
160	Watts, 197559	CCS	274	Range 24–62	55 (55)	N	Nerve root pain and referred pain	Yes	Recurrent and first episode	No	Unclear	Yes	Yes
672	Weinstein, 1986 ⁹²	CCS	159	Mean 41 (range 28–57)	64 (41)	Minimum period of 3 months	Nerve root pain	Yes	First episode	No	No	Yes	No
150	Zeiger, 1987 ⁵⁸	CCS	126	R	NR	≥4 weeks	Nerve root pain	Yes	R	No	No	Yes	No
Chem	ronucleolysis vs ep	nidural											
720	Bontoux, 1990 (French language) ¹⁶⁸	RCT	80	Mean 40	50 (63)	At least 2 months, >6 months 34%	Nerve root pain	Yes	RN	No	No	Yes	NR
447	Bourgeois, 1988 ¹⁶⁰ (French Language)	RCT	60	Mean 37 (range 26–62)	40 (67)	Mean 178 (range 50–700) days	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	R
729	Gallucci, 2007 ¹⁷⁰	RCT	159	Mean 41.5 (range 18–71)	86 (54)	Mean 15 weeks	Nerve root pain	Yes	NR	No	No	Yes	No
													continued

by	
ered	
orde	
len	
or th	
ratc	
npa	
So	
ą	
peq	
rou	
0) SI	
itior	
ven	
nter	
ve j	
nati	
llter	
th	
s Vi	
lysi	
clec	
nuc	
em	
g ch	
arin	
du	
Ö	
dies	
stu	
for	
tails	
i de:	
tion	
oula	
bod	
udy	
d st	
an	
iype	
ca t	
ciati	
of sc	
ary c	_
лт	ued
Sur	ntin
32	(co
3LE	hor)
TAE	auti

Ðġ	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis? ^a	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
50	Graham, 1976 ¹⁴⁴	Non-RCT	40 (23 with sciatica)	Mean 42 Sciatica patients: mean 41 (range 24–66)	25 (63) Sciatica patients: 13 (57%)	Mean whole group 5.35 years Sciatica patients median 1 year (range 12 weeks- 25 years)	Nerve root pain and referred pain	Yes	R	2	^o Z	Yes	R
Chem	onucleolysis vs inč	active contru	10										
726	Dabezies, 1988 ²⁰⁹	RCT	173	RN	NR	NR	Nerve root pain	Yes	Recurrent and first episode	N	NR	Yes	No
244	Feldman, 1986 ²⁰⁷ (French language)	RCT	39	Mean 42.5 (range 21–77)	19 (49)	Mean 6.6 months (range 1–18 months)	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	R
55	Gogan, 1992 ²⁰⁵	RCT	60	Mean 37 (range 19–69)	39 (65)	< 6 weeks 10%, 6 weeks to 6 month 75%, >6 months 15%	Nerve root pain	Yes	NR	No	No	Yes	N
738	Javid, 1983 ²¹⁰	RCT	108	NR	NR	Mean 26 weeks	Nerve root pain	Yes	NR	No	NR	Yes	No
236	Schwetschenau, 1976 ²⁰⁶	RCT	66	Mean 36.2 (SE 1.9)	44 (67)	Mean 11.6 weeks (SE 1.9 weeks)	Nerve root pain	Yes	NR	N	NR	Yes	No
Chem	onucleolysis vs m	anipulation											
723	Burton, 2000 ²⁰⁸	RCT	40	Mean 41.9 (SD 10.6)	19 (48)	Mean 31 weeks (SD 35 weeks)	Nerve root pain	Yes	Recurrent and first episode	No	No	NR	No
NR, nc a Ma	ot reported. Irked yes if patient p	opulation or i	inclusion crit	teria specifically report	ed that patient v	with sequestered disc,	, extruded dis	ic or stenosis wer	e included; oth	erwise reported as	no.		

<u> </u>	
0	
ē	
÷	
Ъ	
~	
6	
-	
ð	
ž	
ő	
ž	
2	
Ř	
Ĕ	
₽	
7	
Ĕ	
ē	
ğ	
얻	
8	
~	
6	
-	
8	
ă	
Ž	
2	
୍ଟି	
<u>~</u>	
ñ	
ō	
Ξ	
E C	
ž	
ይ	
Ĕ	
.∟	
Ð	
.≥	
at	
ĉ	
ይ	
ž	
б	
Ļ	
÷	
>	
S	
ίΩ.	
≥	
Ő.	
<u><u></u></u>	
Q	
7	
<u> </u>	
ъ	
nor	
emor	
chemor	
chemor	
ig chemor	
ring chemor	
aring chemor	
paring chemor	
mparing chemor	
omparing chemor	
comparing chemor	
s comparing chemor	
lies comparing chemor	
udies comparing chemor	
studies comparing chemor	
 studies comparing chemor 	
or studies comparing chemor	
for studies comparing chemor	
Is for studies comparing chemor	
ails for studies comparing chemor	
etails for studies comparing chemor	
details for studies comparing chemor	
y details for studies comparing chemor	
idy details for studies comparing chemor	
tudy details for studies comparing chemor	
study details for studies comparing chemor	
e study details for studies comparing chemor	
the study details for studies comparing chemor	
f the study details for studies comparing chemor	
of the study details for studies comparing chemor	
y of the study details for studies comparing chemor	
ary of the study details for studies comparing chemor	
mary of the study details for studies comparing chemor	
mmary of the study details for studies comparing chemor	
ummary of the study details for studies comparing chemor	
Summary of the study details for studies comparing chemor	
Summary of the study details for studies comparing chemor	
33 Summary of the study details for studies comparing chemor	
33 Summary of the study details for studies comparing chemor	
.E 33 Summary of the study details for studies comparing chemor	
3LE 33 Summary of the study details for studies comparing chemor	
ABLE 33 Summary of the study details for studies comparing chemor	

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Chemo.	nucleolysis vs disc surgery									
884	Alexander, 1989 ¹⁰³	100	Mean 14 (range 6–35) months	CCS	No	No	80-100	Unclear	Weak	Weak
43	van Alphen, 1989 ⁴⁷	151	12 months	RCT	Partial	Unclear	80-100	No	Moderate	Strong
441	Bonafe, 1993 ⁷⁵ (French language)	40	Mean 15 (range 3–36) months	CCS	No	No	80-100	Unclear	Weak	Weak
183	Bouillet, 198361	2749	NR	CCS	No	No	NA	No	Weak	Moderate
453	Brown, 1989 ⁷⁶	85	3 months	CCS	No	No	80-100	Yes	Weak	Weak
454	Buric, 2005 $^{\prime\prime}$	45	18 months	Non-RCT	No	No	80-100	NA	Weak	Weak
166	Crawshaw, 198460	52	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate
48	Dabezies, 1978 ⁵¹	200	2 years	CCS	No	No	Cannot tell	No	Weak	Moderate
471	Dei-Anang, 1990 ^{7⊚} (German language)	201	1 year	CCS	No	No	NA	Unclear	Weak	Weak
727	Ejeskar, 1983 ⁹⁶	29	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate
132	Hoogmartens, 1976 ⁵⁶	26	58 months for discectomy and 38 months for chemonucleolysis	HCS	No	No	NA	NA	Weak	Moderate
44	Javid, 1995 ⁴⁸	200	1 year	ccs	No	No	80-100	No	Weak	Moderate
35	Krugluger, 2000 ⁴⁶	22	2 years	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
117	Lagarrigue, 1991 ⁵⁴ (French language)	1085	Mean 17.2 (range 12–84) months	CCS	No	No	80-100	Unclear	Weak	Moderate
129	Lavignolle, 1987 ⁵⁵ (French language)	358	Mean 25 months for surgery and 22 months for chemonucleolysis	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
889	Lee, 1996 ¹⁰⁴ (German language)	300	1 year	CCS	No	No	Cannot tell	Unclear	Weak	Weak
593	Muralikuttan, 1992 ⁸⁵	92	1 year	RCT	Yes	Unclear	80-100	Unclear	Moderate	Moderate
47	Norton, 1986 ⁵⁰	105	At least 1 year	CCS	No	No	NA	Unclear	Weak	Weak
45	Postacchini, 1987 ⁴⁹	161	Mean 2.9 years (range 20–38 months) in chemonucleolysis group Mean 2.8 years (range 21–42 months in surgery) group	Non-RCT	N	No	80-100	No	Weak	Moderate
										continued

R	
ĕ	
5	
.5	
Ę	
õ	
Q	
-	
ð	
Ē.	
Ħ	
ສົ	
>	
ف ا	
σ	
Ð	
P	
ŏ	
5	
2	
5	
Ĕ	
₽	
۲ ۲	
Ĕ	
ē	
ğ	
ğ	
F	
<u> </u>	
0	
≳	
2	
Ö	
ě	
막	
ັດ	
Ĭ	
9	
S	
É	
<u>o</u> .	
Ħ	
ē	
>	
ē	
Ť	
·=	
Ð	
.≥	
at	
Ë	
P	
Ĕ	
g	
2	
÷	
≥	
S	
. <u>0</u>	
<u> </u>	
0	
<u>e</u>	
<u>ں</u>	
2	
2	
Ĕ	
5	
Ĕ	
Ö	
D	
Ē	
Ľ.	
g	
Ř	
Ĕ	
8	
~	
ő	
÷≓	
ĭ	
5	
ž	
ō	
÷	
5	
ai.	
et.	
ð	
>	
ð	
:udy	
study	
e study	
he study	
the study	
of the study	
/ of the study	
try of the study	
nary of the study	
imary of the study	
mmary of the study	
lummary of the study	
Summary of the study	
3 Summary of the study	
33 Summary of the study	
E 33 Summary of the study	
LE 33 Summary of the study	
BLE 33 Summary of the study	
ABLE 33 Summary of the study	

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
617	Revel, 1993 ⁸⁸	165	1 year	RCT	Yes	Unclear	80-100	Unclear	Moderate	Weak
641	Steffen, 1999 ⁹⁰ (German language)	69	1 year	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
49	Stula, 1990 ⁵² (German language)	69	Postoperative	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
61	Tregonning, 199153	268	10 years	CCS	No	No	80-100	No	Weak	Moderate
893	Watters,1988 ¹⁰⁵	100	3 years	Non-RCT	No	No	80-100	No	Weak	Weak
160	Watts, 1975 ⁵⁹	274	2 years	CCS	No	No	80-100	Unclear	Weak	Weak
672	Weinstein, 1986 ⁹²	159	Mean 10.3 (range 10.0-13.5) years	CCS	No	No	80-100	NA	Weak	Weak
150	Zeiger, 1987 ⁵⁸	126	Range 6–46 months, with an average time from treatment procedure to follow-up evaluation of 18 months	CCS	No	No	NA	Yes	Weak	Weak
Chemor	ucleolysis vs epidural									
720	Bontoux, 1990 ¹⁶⁸ (French language)	80	3 months	RCT	Yes	Unclear	80-100	Yes	Moderate	Weak
447	Bourgeois, 1988 ¹⁶⁰ (French language)	60	6 months	RCT	Yes	Partial	80-100	Yes	Moderate	Weak
729	Gallucci, 2007170	159	6 months	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
50	Graham, 1976 ¹⁴⁴	40 (23 with sciatica)	2 years	Non-RCT	No	No	80-100	Yes	Weak	Weak

ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Chemo.	nucleolysis vs inactive contr	rol								
726	Dabezies, 1988 ²⁰⁹	173	6 months	RCT	Partial	Yes	60-79	Yes	Moderate	Weak
244	Feldman, 1986 ²⁰⁷ (French language)	39	3 months	RCT	Unclear	Unclear	80-100	Unclear	Moderate	Moderate
55	Gogan, 1992 ²⁰⁵	60	10 Years	RCT	Yes	Unclear	80-100	Yes	Moderate	Moderate
738	Javid, 1983 ²¹⁰	108	6 months	RCT	Yes	Partial	80-100	Yes	Moderate	Weak
236	Schwetschenau, 1976 ²⁰⁶	66	1 year	RCT	Yes	Yes	80-100	Yes	Strong	Moderate
Chemo	nucleolysis vs manipulation									
723	Burton, 2000 ²⁰⁸	40	12 months	RCT	No	No	60-79	Yes	Moderate	Weak
Chemo	nucleolysis vs mixed treatm	ents								
534	Khoromi, 2007 ²¹⁴	55	36 weeks	RCT (crossover)	Yes	Yes	<60	Yes	Moderate	Strong
NA, not	applicable; NR, not reported.									

Health Technology Assessment 2011; Vol. 15: No. 39

trouped by	
rventions (c	
rnative inte	
sis with alte	
nonucleoly	
oaring cher	
tudies com	
/eeks) for st	
w-up (≤6 w	
t-term follo	
fect at shor	
ie global eff	
ndings of th	author)
try of the fir	rdered by a
34 Summa	ator then o
TABLE	compar

							Interventio	5		Control				
⊡ ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	or (95% CI)	Comments
Chen	nonucleolysis vs	disc surgery												
471	Dei-Anang, 1990 ⁷⁹ (German language)	NR	ccs	42 days	Reported absence of pain	Patient	101	62	0	100	72	0	1.40 (0.73 to 2.66)	Data inferred from percentages reported in graphs
44	Javid, 1995 ⁴⁸	O	CCS	6 weeks	Successful outcome: good or excellent (vs slight or no improvement)	Patient	100	82	0	100	92	0	0.40 (0.16 to 0.96)	
889	Lee, 1996 ¹⁰⁴ (German language) (j) ^a (APLD)	NR	CCS	6 weeks	Disappearance of back pain		100	16	~	100	16	~	1.00 (0.47 to 2.13)	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 14%
889	Lee, 1996 ¹⁰⁴ (German language) (ii) ^a (PELD)	NR	CCS	6 weeks	Disappearance of back pain		100	16	~	100	29	~	0.47 (0.23 to 0.93)	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 29%
45	Postacchini, 1987 ⁴⁸	A + C	Non- RCT	1 month	Treatment success: excellent or good (vs fair or poor)		72	30	0.03	84	52	0.03	0.40 (0.16 to 0.96)	Data inferred from graphs Five lost to follow-up were excluded Patients in chemonucleolysis group who had surgery regarded as failure
49	Stula, 1990 ⁵² (German language)	ы	RCT	Postoperative	Therapeutic success: good (vs unsatisfactory)	Physician	25	22	0.43	44	40	0.76	0.73 (0.38 to 1.38)	Per protocol analysis with 19 crossed over to surgery

						Interventi	и		Control				
ID no. Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	or (95% CI)	Comments
672 Weinstein, 1986 ^{se}	C	CCS	< 6 weeks	Recovered within 2–6 weeks or immediate (vs no recovery, 6–12 weeks recovery or > 12 weeks recovery)	Patient	88	61	0.04	71	30	0.13	1.56 (0.78 to 3.13)	
Chemonucleolysis v:	s epidural/intra	adiscal inje.	ction										
729 Gallucci, 2007 ¹ .	⁷⁰ A+C	RCT	2 weeks	Treatment success: 0DI ≤ 20%		82	72	0	77	69	0	1.20 (0.45 to 3.21	
Chemonucleolysis v:	s inactive cont	trol											
726 Dabezies, 1988 ²⁰⁹	NR	RCT	6 weeks	Treatment success: pain free or moderate improvement (vs unimproved or worse)		22	56	0.11	81	42	0.06	2.48 (1.27 to 4.81)	
244 Feldman, 1986 ²⁰⁷ (French language)	A+C	RCT	1 month	Favourable results – based on VAS pain assessment: very good or good (vs mediocre, bad or failures)	Patient	20		0	19	വ	0	3.42 (0.89 to 13.18)	
55 Gogan, 1992 ²⁰⁵	C	RCT	6 weeks	Treatment success (yes or no)	Patient	30	22	0	30	Ħ	0	4.45 (1.58 to 14.25)	Data inferred from graphs
236 Schwetschenau 1976 ²⁰⁶	, A+C	RCT	72 hours	Symptom improvement: excellent or good (vs fair)		31	ω	ō	35	13	0	0.59 (0.20 to 1.69)	
7, unclear; A + C, acut a Lee <i>et al</i> . ¹⁰⁴ include meta-analysis (see	e and chronic; <i>i</i> ed three treatm <i>Figure 24</i> 0.	APLD, autor ent groups: /	ated percutaneo APLD (j), PELD (ii;	us lumbar discectomy; (and chemonucleolysis	C, chronic; NA, n (iii). In order to p	lot applicabl revent using	e; NR, not rep g the same co	orted; PELD, per mparator twice, .	cutaneous only the fi	s manual and st and third t	laser discectomy reatment groups	/. have been i	ncluded in the



FIGURE 24 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

Six studies^{48,49,52,79,92,104} compared chemonucleolysis with disc surgery, for which there was no overall statistically significant difference between the groups. Only one of these studies was a RCT,⁵² which was poorly reported with method of randomisation and allocation concealment not stated. Nineteen patients in the chemonucleolysis group crossed over to receive surgery and were analysed accordingly. The results and methods of the remaining studies were also poorly reported.

One poorly reported RCT,¹⁷⁰ of moderate quality, compared intraforaminal and intradiscal injections of steroid, local anaesthetic and ozone–oxygen (categorised as chemonucleolysis) with intraforaminal and intradiscal injections of steroid plus local anaesthetic (epidural), for which there was no overall difference between the groups. The study included patients with mainly acute sciatica (mean duration of symptoms of 15 weeks).

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 35* and the accompanying forest plot (*Figure 25*). Chemonucleolysis was compared with inactive control, disc surgery and manipulation. One study⁷⁶ included patients with chronic sciatica, three studies^{85,207,208} included patients with either acute or chronic sciatica, and the remaining study⁸⁸ did not report the duration of symptoms. The duration of follow-up ranged from 4 weeks^{88,207} to 6 weeks.^{76,85,208}

þ	
ed	
dno	
(gr	
suo	
enti	
erv	
e int	
ttive	
erne	
alte	
vith	
is v	
olys	
icle	
onu	
em	
д с <mark>н</mark>	
ring	
npa	
co	
lies	
stuc	
õ	
Ks) 1	
veel	
2 0 2	
) ⊇	
n-w	
ollo	
Ē	
-ter	
jort	
it sh	
₹	
ensi	
inte	
ain	
of p	
sgr	(Jor
ndir	auth
le fi	by ;
of th	red
JLY C	rdei
лпе	o u
Sun	. the
35	ator
ÿ	par
B	E
	Ϋ́

							Total (<i>n</i>		Baseline (SD)	e mean	Final mea (SD)	5	Change scores (S	6	
Ðë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Control Intervention	Mean difference (95% Cl) ^b	Comment/conversion ^c
Chem	onucleolysis vs	disc surgery													
453	Brown, 1989 ⁷⁶ (j) ^d (chymopapain)	C	CCS	6 weeks	Leg	VAS (0-100)	51	19	60	20	22 (25.48)	3 (20.87)		19.00 (7.30 to 30.70)	SD imputed from weighted average
453	Brown, 1989 ⁷⁶ (ii) ^d (collagenase)	S	CCS	6 weeks	Leg	VAS (0-100)	15	19	58	20	46 (25.48)	3 (20.87)		43.00 (27.05 to 58.95)	SD imputed from weighted average
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	6 weeks	Leg	VAS (0-100)	46	46	9	72	19 (25.48)	19 (20.87)		0.00 (-9.52 to 9.52)	SD imputed from weighted average (one study)
617	Revel, 1993 ⁸⁸	NN	RCT	1 month	бөл	VAS (0-100)	68	62	63.4 (24.6)	68.1 (21.6)	28.3 (27.21)	39.4 (32.28)		-11.10 (-21.41 to -0.79)	SD derived from SE Dropouts 24/165 (15%): intervention 4/72, control 7/69 A further 24 patients were also excluded from the analysis, group allocation not stated

continued

TABLE 35 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author) *(continued)*

							Total (<i>n</i>	0	Baseline (SD)	emean	Final mea (SD)	ц	Change scores (S	(0	
<u> </u>	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Control	Mean difference (95% CI) ^b	Comment/conversion ^c
Chen	nonucleolysis vs	inactive contru	91												
244	Feldman, 1986 ²⁰⁷ (French language)	A+C	RCT	28 days	feg	VAS (0-100)	20	19	64.0	54.1	30.3 (25.48)	40.2 (23.67)		-9.90 (-25.33 to 5.53)	SD imputed from weighted average (one study)
Chen	nonucleolysis vs	manipulation													
723	Burton, 2000 ²⁰⁸	A+C	RCT	6 weeks	Leg	Annotated thermometer (0–6)	18	19	60.8 (26.5)	66.7 (14.7)	45.3 (17.0)	44.7 (26.7)		0.63 (-13.72 to 14.98)	Missing data: intervention 2/20, control 1/20
A + C, a Th	acute and chroni e results have be	ic; C, chronic; N en converted to	R, not repol a scale of (rted.)–100 for co	omnarabilitv.										

b Based on final means or change scores (with a preference given to change scores).

c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. the first and third treatment groups have been included in the meta-analysis (see Figure 25).



FIGURE 25 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

One poorly reported RCT,²⁰⁷ of moderate quality, showed non-statistically significant findings in favour of chemonucleolysis compared with inactive control, for reduction in leg pain at 28 days.

Three studies^{76,85,88} compared chemonucleolysis with disc surgery, for which there was no overall statistically significant difference between the intervention groups. However, the results were heterogeneous. One CCS⁷⁶ reported findings in favour of disc surgery and one RCT⁸⁸ reported findings in favour of chemonucleolysis, whereas the remaining RCT⁸⁵ reported no statistically significant difference between the interventions. One study⁷⁶ included patients who had not received previous disc surgery, whereas the other⁸⁸ included patients who had had previous surgery and also had a high proportion of men.

According to one RCT,²⁰⁸ there was no important difference between chemonucleolysis and osteopathic manipulation at 6 weeks in terms of pain reduction. However, although the randomisation sequence was generated by computer and treatment allocated using envelopes, some patients were not randomised according to the predetermined order because of administrative problems.

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 36* and the accompanying forest plot (*Figure 26*). Chemonucleolysis was compared with disc surgery and manipulation. Two studies^{46,92} included patients with chronic sciatica, two studies^{85,208} included patients with either acute or chronic symptoms, and the remaining study⁸⁸ did not report this information. The duration of follow-up ranged from 1 month⁸⁸ to 6 weeks.^{46,85,208}

Two studies compared chemonucleolysis with disc surgery; one was an RCT⁸⁵ and one was a non-RCT.⁷⁷ Overall, there was a non-statistically significant difference between the intervention groups in favour of disc surgery.

One moderate-quality RCT²⁰⁸ showed a non-statistically significant improvement in function in favour of manipulation, compared with chemonucleolysis, at 6 weeks. The study experienced problems with the randomisation process.

TABLE 36 Summary of the findings of CSOMs at short-term follow-up (≤6 weeks) for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

	Comment/conversion ^b		SD imputed from weighted average Most outcomes showed skewed distribution	Final SDs derived from SEs 24 patients were excluded from analysis, group allocation not stated, plus further 10/141 (7%): intervention 3/72, control 7/69		
	Mean difference (95% Cl) ^a		0.58 (0.16 to 1.00)	-0.00 (-0.34 to 0.34)		
scores	Control		3.0	-1.05		-4.11
Change (SD)	Intervention		-2.7	-3.4		-0.95
an	Control		2.8 (1.21)	1.5 (3.15)		7.79 (6.65)
Final me (SD)	Intervention		3.5 (1.21)	1.5 (2.55)		11 (5.69)
mean	Control		6.7	6 (2.55)		11.9 (5.48)
Baseline (SD)	Intervention		6.2	4.9 (2.49)		11.95 (5.83)
ſ	Control		46	62		19
Total (r	Intervention		46	69		18
	Scale		Part of Waddell Disability Index	Waddell Disability Index and Main Scale		RMDQ
	Follow- up		6 weeks	1 month		6 weeks
	Study design		RCT	RCT		RCT
	Chronicity	sc surgery	A+C	Ϋ́	anipulation	A+C
	Author, year	nucleolysis vs di:	Muralikuttan, 1992 ⁸⁵	Revel, 1993 ⁸⁸	nucleolysis vs mi	Burton, 2000 ²⁰⁸
	D e	Chemor	593	617	Chemor	723

A + C, acute and chronic; NR, not reported.
 a Based on final means or change scores (with a preference given to change scores).
 b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Disc su	irgery						
593	Muralikuttan, 1992 ⁸⁵	RCT				0.58 (0.16 to 1.00)	47.80
617	Revel, 1993 ⁸⁸	RCT		*		0.00 (-0.34 to 0.34)	52.20
Subtota	$I (l^2 = 77.3\%, p = 0.036)$)	<			0.28 (-0.29 to 0.84)	100.00
Manipu	lation						
723	Burton, 2000 ²⁰⁸	RCT				0.52 (-0.14 to 1.17)	100.00
		-1.17		0	1.17		
		Favours che	monucleolysis	Favours control			

FIGURE 26 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

Chemonucleolysis results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 37* and the accompanying forest plot (*Figure 27*). Chemonucleolysis was compared with inactive intervention, disc surgery, and epidural. Eight studies^{48,54,76,92,160,168,205,210} only included patients with chronic symptoms. The remaining studies included patients with either acute or chronic sciatica^{49,105,170,206,207} or did not state the duration of symptoms.^{88,104,209} The duration of follow-up ranged from 2 to 6 months, or mean 13¹⁰⁵ to 23 weeks.²⁰⁶

Pooled analysis of five RCTs²⁰⁵⁻²¹⁰ showed chemonucleolysis to be significantly better than inactive control for overall recovery at 3–6 months^{205,207,209,210} or mean 23 weeks.²⁰⁶

Eight studies^{48,49,54,76,88,92,104,105} compared chemonucleolysis and disc surgery, for which there was no overall difference between the groups. One moderate-quality RCT⁸⁸ found chemonucleolysis to be more effective than disc surgery. However, the withdrawal rate in the surgery group (at least 41%) was much greater than that in the chemonucleolysis group (at least 19%), with dropouts being given a poor outcome in the analysis. The remaining studies were observational or non-RCTs, the results and methods of which were generally poorly reported.

Three RCTs^{160,168,170} compared chemonucleolysis with epidural, two of which used chymopapain^{160,168} and one¹⁷⁰ used injections of steroid, local anaesthetic, and ozone–oxygen. The first two RCTs found no important difference between the intervention groups for chronic sciatica, whereas the third RCT¹⁷⁰ found statistically significant findings in favour of the epidural group for patients who had had symptoms for a mean of 15 weeks. However, the study was poorly reported (with method of randomisation not stated) and of moderate quality. The first two studies were also of moderate quality overall, but used an adequate method of randomisation.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 38* and the accompanying forest plot (*Figure 28*). Chemonucleolysis was compared with inactive control and disc surgery. One study⁷⁶ only included patients with chronic sciatica, one study⁸⁸ did not report the duration of symptoms and the remaining studies^{207,85} included patients with either acute or chronic sciatica. The duration of follow-up ranged from 60 days¹⁵⁹ to 6 months.^{150,151,155,171,174}

ntions	
interve	
native	
th alter	
lysis wi	
nucleo	
chemo	
paring	
es com	
r studie	
nths) fo	
≤6 mo	
eks to	
(>6 w∈	
dn-wol	
erm fol	
edium-1	
ct at m	
oal effe)) J
the glol	oy autho
ngs of	dered b
he findi	then or
ary of t	barator
Summ	y comp
SLE 37	uped b
TAE	(gro

		nments		a reported as entages	a reported as entages		a reported as :entages	bber tomised ded in ysis uded: nonucleolysis , surgery	nber Iomised stated, 300 Joed in vsis uded: nonucleolysis , surgery
		Co		Data	Data		Data	Num ranc inclu Excl Excl 14%	Num ranc inclu Excl 29% 29%
		or (95% CI)		0.19 (0.05 to 0.75)	0.28 (0.06 to 1.41)	1.29 (0.57 to 2.93)	0.28 (0.20 to 0.39)	0.76 (0.42 to 1.38)	4.70 (2.02 to 10.90)
	Withdrawal	rate		0	0	0	0	¢.	~
	Outcome	(I)		16	16	85	675	35	ω
Contro	Total	<u>(</u> 2)		19	19	100	751	100	100
	Withdrawal	rate		0	0	0	0	29	29
ention	Outcome	(u)		26	J	8	238	с.	~
Interve	Total	<u>(</u> 2)		51	15	100	334	100	100
	:	Perspective		NR	NR	Patient	Patient + physician		
		Outcome measure		Final outcome: excellent or good (vs fair, poor or failed)	Final outcome: excellent or good (vs fair, poor or failed)	Successful outcome: good or excellent (vs slight or no improvement)	MacNab criteria: excellent or good (vs mediocre or failure)	Disappearance of back pain	Disappearance of back pain
	:	Follow-up		3 months	3 months	6 months	2 months	2 months	2 months
	Study	design		CCS	CCS	CCS	CCS	CCS	S
	: ;	Chronicity	sc surgery	C	0	C	C	К	R
	:	Author, year	onucleolysis vs dix	Brown, 1989 ⁷⁶ (j) ^a (chymopapain)	Brown, 1989 ⁷⁶ (ii) ^a (collagenase)	Javid, 1995 ⁴⁸	Lagarrigue, 1991 ⁵⁴ (French language)	Lee, 1996 ¹⁰⁴ (German language) (j) ^b (APLD)	Lee, 1996 ¹⁰⁴ (German language) (ij) ^b (PELD)
	₽	Ö	Chem	453	453	44	117	889	888

	-						Interve	ention		Control				
Stud Author, year Chronicity desi	Stud Chronicity desig	Stud	~ 뚭	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	or (95% CI)	Comments
Postacchini, A+C Non- 1987 ⁴⁹ RCT	A+C Non-RCT	Non - RCT		3 months	Treatment success: excellent or good (vs fair or poor)		72	51	0.03	84	65	0.03	0.71 (0.35 to 1.46)	Data inferred from graphs Five lost to follow- up were excluded Patients who had surgery in chemonucleolysis group regarded as failure
Revel, 1993 ⁸⁸ NR RCT	NR	RCT		6 months	Treatment success categorised as: very good or good (vs none or moderate)	Patient	72	44	~	69	30	۰.	2.04 (1.04 to 4.00)	ITT not used. 24/165 (15%) patients excluded from analysis, group allocation not stated
Watters,1988 ¹⁰⁵ A+C Non-RCT	A+C Non- RCT	Non- RCT		Mean 46 days	Success of surgical results: excellent or good (vs fair or poor)	Physician	50	32	0	50	44	0	0.24 (0.09 to 0.68)	Reported as percentages only
Weinstein, C CCS 1986 ^{%2}	000	CCS		3–6 months	Recovered within 2–6 weeks, 6–12 weeks or immediate (vs no recovery, >12 weeks)	Patient	85	71	0.03	63	53	0.11	0.96 (0.39 to 2.32)	Data reported as percentages
onucleolysis vs epidural/intradiscal injec	idural/intradiscal injec	iscal injec	3	ion										
Bontoux, C RCT 1990 ¹⁶⁸ (French language)	C RCT	RCT		3 months	Overall improvement: very good or good (vs mediocre or bad)		40	26	0	40	27	0	0.89 (0.35 to 2.26)	
Bourgeois, C RCT 1988 ¹⁶⁰ (French language)	C RCT	RCT		6 months	Overall pain relief: very good or good (vs failure)		30	20	0	30	16	0	1.75 (0.62 to 4.97)	
Gallucci, A+C RCT 2007 ¹⁷⁰	A+C RCT	RCT		6 months	Treatment success: 0DI ≤ 20%		82	61	0	77	36	0	0.30 (0.15 to 0.59)	
			1											continued
ouped by comparator then ordered by author) (continued)														
---	--													
	(grouped by comparator then ordered by author) (continued)													

							Interve	Intion		Control				
<u>e</u> 2	Author vear	Chronicity	Study design	Follow-m	Outcome measure	Persnective	Total	Outcome	Withdrawal	Total	Outcome	Withdrawal	OR (95% CI)	Comments
Chem	onucleolysis vs in	active control												
726	Dabezies, 1988 ²⁰⁹	R	RCT	6 months	Treatment success: pain free or moderate improvement (vs unimproved or worse)		62	44	0.29	74	33	0.14	3.04 (1.49 to 6.21)	
244	Feldman, 1986 ²⁰⁷ (French language)	A+C	RCT	3 months	Favourable results – based on VAS pain assessment: very good or good (vs mediocre, bad or failures)		20	13	0	19	ω	O	2.55 (0.70 to 9.31)	
55	Gogan, 1992 ²⁰⁵	C	RCT	6 months	Treatment success (yes or no)	Patient	30	24	0	30	17	0	3.06 (0.97 to 9.66)	Data inferred from graphs
738	Javid, 1983 ²¹⁰	C	RCT	6 months	Success (vs failure)		55	40	0	53	22	0	3.76 (1.68 to 8.42)	
236	Schwetschenau, 1976 ²⁰⁶	A+C	RCT	Mean 23 weeks	Symptom improvement: excellent or good (vs fair)		31	Q	0	35	[0	0.89 (0.31 to 2.56)	
2, unc a Bro	lear; APLD, automal with a second structures and Tompkins ⁷⁶	ted percutanec included three	ous lumbar e treatment	discectomy; A + groups: chemor	 C, acute and chronic; C, c nucleolysis using chymopa 	chronic; NR, not i apain (i), chemon	reported; iucleolysis	PELD, percuta s using collage	aneous manual a enase (ii) and dis	and laser	discectomy. / (iii). In order	to prevent usin	ig the same comp	varator twice, only

the first and third treatment groups have been included in the meta-analysis (see *Figure 27*). b Lee *et al.*¹⁰⁴ included three treatment groups: APLD (ii), PELD (ii) and chemonucleolysis (iii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the

meta-analysis (see Figure 27).

ID no.	Author, year	Study design		OR (95% CI)	% weight
Disc su	irgery				
453	Brown, 1989 ⁷⁶	CCS	· · · · · · · · · · · · · · · · · · ·	0.19 (0.05 to 0.75)	8.98
44	Javid, 199548	CCS		1.29 (0.57 to 2.93)	12.44
117	Lagarrigue, 199154	CCS		0.28 (0.20 to 0.39)	15.26
889	Lee, 1996 ¹⁰⁴	CCS		0.76 (0.42 to 1.38)	13.88
45	Postacchini, 198749	Non-RCT		0.71 (0.35 to 1.46)	13.08
617	Revel, 1993 ⁸⁸	RCT	•	2.04 (1.04 to 4.00)	13.40
893	Watters, 1988105	Non-RCT		0.24 (0.09 to 0.68)	10.99
672	Weinstein, 198692	CCS		0.96 (0.39 to 2.32)	11.97
Subtota	al ($l^2 = 83.4\%$, $p = 0.000$)		\sim	0.63 (0.34 to 1.16)	100.00
Epidura	al/intradiscal injection				
720	Bontoux, 1990 ¹⁶⁸	RCT		0.89 (0.35 to 2.26)	32.53
447	Bourgeois, 1988 ¹⁶⁰	RCT		1.75 (0.62 to 4.97)	30.47
729	Gallucci, 2007170	RCT		0.30 (0.15 to 0.59)	37.00
Subtota	ll (<i>I</i> ² = 77.2%, <i>p</i> = 0.012)			0.73 (0.26 to 2.11)	100.00
Inactiv	e control				
726	Dabezies, 1988 ²⁰⁹	RCT		— 3.04 (1.49 to 6.21)	30.65
244	Feldman, 1986 ²⁰⁷	RCT		2.55 (0.70 to 9.31)	11.95
55	Gogan, 1992 ²⁰⁵	RCT		3.06 (0.97 to 9.66)	14.65
738	Javid, 1983 ²¹⁰	RCT		3.76 (1.68 to 8.42)	25.79
236	Schwetschenau, 1976206	RCT		0.89 (0.31 to 2.56)	16.96
Subtota	al ($l^2 = 20.2\%$, $p = 0.286$)		\diamond	2.56 (1.59 to 4.12)	100.00
		0	.0506 1	19.8	

FIGURE 27 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design							WMD (95% CI)	% weight
Disc su	rgery									
453	Brown, 1989 ⁷⁶	CCS			_		•		10.00 (-2.77 to 22.77)	31.79
593	Muralikuttan, 199285	RCT				_	•		6.00 (-3.85 to 15.85)	34.12
617	Revel, 1993 ⁸⁸	RCT	\leftarrow		_				–18.00 (–27.89 to –8.11)	34.09
Subtota	l (l ² = 87.5%, p = 0.000)	1		\sim		\vdash			-0.91 (-18.45 to 16.64)	100.00
Inactive	e control									
244	Feldman, 1986 ²⁰⁷	RCT			•	_			-5.40 (-27.83 to 17.03)	100.00
			-27.9			0		27.9		
		Favo	ours cher	monucleo	lysis		Favours control			

FIGURE 28 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

TABLE 38 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

nonicity ratioState (asign)State (asign)Late (asign)State (asign)Late (asign)State (asign)Late (asign)State (asign)Late (asign)Construction <i>upprint</i> <i>upprint</i> CS12 weeksLegWS010010,00 <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>Total (</th> <th>(L</th> <th>Baseline (SD) –</th> <th>mean</th> <th>Final mea</th> <th>an (SD)</th> <th>Change scores (SD) —</th> <th></th> <th></th>								Total ((L	Baseline (SD) –	mean	Final mea	an (SD)	Change scores (SD) —		
CCS 12 weeks Leg WS 10 0 0.00 S0 imputed from weighted CS 12 weeks Leg WS 15 19 60 70 14 10 0 aerage CS 12 weeks Leg WS 15 19 58 70 22 4 18 10 00 30 imputed from weighted CS 12 weeks Leg WS 15 19 58 70 22 4 18 10 00 30 imputed from weighted CS 12 woeths Leg WS 16 64 72 20 14 53.65 30 imputed from weighted CS 3 months Leg WS 16 72 20 14 53.65 30 imputed from weighted Rot 3 months Leg WS 12 20 24.43 36.443 90 imputed from weighted Rot 3 months Leg WS 17 23.85 04 04.05 010.00 0 010.00 010.00 010.00 010.00	ear Chro	Chro	nicity	Study design	Follow- up	Location	Scale (range) ^a	ntervention	Control	ntervention	Control	ntervention	Control	Control ntervention	Mean difference (95% CI) ^b	Comment/conversion ⁰
CCS 12 weeks Leg WS 51 19 50 70 14 4 1000 S0 imputed from weighted average C 12 weeks Leg WS 15 19 58 70 23.76 (24.43) (1.71 to 24.29) S0 imputed from weighted average C RCT 3 months Leg WS 15 19 58 70 23.76 (24.43) (1.71 to 24.29) S0 imputed from weighted average C RCT 3 months Leg WS 16 6.00 50 imputed from weighted average RCT 3 months Leg WS 14 72 20 14 365 15.85 S0 imputed from weighted average RCT 8 months Leg WS 14 72 20 14 365 15.85 S0 imputed from weighted average RCT 6 months Leg WS 17.6 23.75 (24.43) (17.1 to 24.29) S0 imputed from weighted istrintoweigrand	sis vs disc sur	uns s	gery													
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$) ^d C 1pain)	0		CCS	12 weeks	Leg	VAS (0-100)	51	19	60	70	14 (23.76)	4 (24.43)		10.00 (-2.77 to 22.77)	SD imputed from weighted average
$ + C \text{RCT} 3 \text{ months} \text{Leg} \frac{\text{VAS}}{(0-100)} \frac{46}{(0-100)} \frac{72}{(23.76)} \frac{20}{(23.76)} \frac{14}{(24.43)} \frac{6.00}{(-3.865 \text{ to} 15.85)} \frac{\text{Subtrically}}{\text{wast outcomes showed skewed}} \\ \frac{1}{(0-100)} \frac{1}{($	989 ⁷⁶ C Jenase)	0		ccs	12 weeks	Leg	VAS (0-100)	15	19	58	20	22 (23.76)	4 (24.43)		18.00 (1.71 to 34.29)	SD imputed from weighted average
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	tan, A	4	O +	RCT	3 months	Гед	VAS (0-100)	46	46	64	72	20 (23.76)	14 (24.43)		6.00 (−3.85 to 15.85) Statistically significant difference between groups, p < 0.05, Mann–Mhrimev	SD imputed from weighted average Most outcomes showed skewed distribution
<i>e control</i> +C RCT 90 days Leg VAS 14 10 64.0 54.1 8.7 14.1 -5.40 SD imputed from weighted (0-100) (23.76) (30.1) (-27.83 to 17.03) average Missing data: intervention 6/20, control 9/19	193 ⁸⁸	2	범	RCT	6 months	feg	VAS (0-100)	72	69	63.4 (24.61)	68.1 (21.6)	17.6 (23.76)	35.6 (34.89)		U-test -18.00 (-27.89 to -8.11)	SDs derived from SEs 24 patients were excluded from the analysis, group allocation not stated
+C RCT 90 days Leg VAS 14 10 64.0 54.1 8.7 14.1 -5.40 SD imputed from weighted (0-100) (0-100) (23.76) (30.1) (-27.83 to 17.03) average Missing data: intervention 6/20, 0.10 (-27.83 to 17.03) (0.10 (-27.83 to 17.03) (0.10 (-27.83 to 17.03)) (0.10	sis vs inactiv	cti	<i>ie control</i>													
	4	4	0 +	RCT	90 days	Leg	VAS (0-100)	14	10	64.0	54.1	8.7 (23.76)	14.1 (30.1)		-5.40 (-27.83 to 17.03)	SD imputed from weighted average Missing data: intervention 6/20, control 9/19

The results have been converted to a scale of 0-100 for comparability. q

മ

Based on final means or change scores (with a preference given to change scores); results reported by study in italics.

The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. Brown and Tompkins⁷⁶ included three treatment groups: chemonucleolysis using chemonucleolysis using collagenase (ii) and disc surgery (iii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the meta-analysis (see Figure 28). υσ

One small, poorly reported RCT of moderate quality, showed a non-statistically significant findings in favour of chemonucleolysis, compared with inactive control, at 90 days. The number of dropouts for the study was quite high, and more patients were lost to follow-up in the control group (47%) than in the intervention group (30%).

Three studies^{76,85,88} compared chemonucleolysis with disc surgery; two were RCTs^{85,88} and one was a CCS.⁷⁶ Overall, there was no statistically significant difference between the intervention groups, but the results were heterogeneous, with one RCT⁸⁸ showing statistically significant findings in favour of chemonucleolysis. This study included patients who had had previous surgery and also included a high proportion of men.

Condition-specific outcome measures at medium-term follow-up

The results for the CSOMs at medium-term follow-up are presented in *Table 39* and the accompanying forest plot (*Figure 29*). Chemonucleolysis was compared with disc surgery.

Three RCTs^{85,88,96} compared chemonucleolysis with disc surgery; the pooled analysis showed no statistically significant difference between the intervention groups at 3–6 months. However, the findings were heterogeneous.

Results at long-term follow-up (>6 months) Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 40* and the accompanying forest plot (*Figure 30*). Chemonucleolysis was compared with inactive control, disc surgery and epidural. Ten studies^{47,48,53,56,59,90,92,103,144,205} included patients with chronic sciatica and six studies included patients with either acute or chronic sciatica,^{49,50,58,75,85,206} although the remaining five studies did not report this information.^{51,55,60,88,104} The duration of follow-up ranged from <1 year⁹² to 10 years.^{53,205}

Two RCTs, which were good to moderate quality,^{205,206} compared chemonucleolysis with inactive control. Pooled analysis showed no statistically significant difference between the intervention groups, but there was some degree of heterogeneity between the studies. The duration of follow-up ranged from 1 year²⁰⁶ to 10 years.²⁰⁵ The mean duration of symptoms was 11.6 weeks in one study,²⁰⁶ whereas in the second study²⁰⁵ 75% of participants had symptoms for between 6 weeks and 6 months and a further 15% had symptoms for > 6 months. The second study²⁰⁵ reported statistically significant better outcomes in patients treated with chemonucleolysis than in those who received inactive control.

Eighteen studies^{47-51,53,55,56,58-60,75,85,88,90,92,103,104} compared chemonucleolysis with disc surgery, the findings of which were very heterogeneous. The pooled result were borderline statistically significant in favour of surgery. There was a mixture of study designs. The duration of follow-up ranged from 1 year to 10 years and duration of sciatica varied between studies. Even when considering the six RCTs on their own,^{47,55,60,85,88,90} the findings were still heterogeneous, although most reported findings in favour of disc surgery (pooled analysis: OR 1.12; 95% CI 0.51 to 2.49). One moderate-quality RCT⁸⁸ found chemonucleolysis to be more effective than disc surgery. But the study had a high withdrawal rate in the surgery group (at least 41%), compared with chemonucleolysis (at least 19%), with dropouts being given a poor outcome in the analysis.

One poorly reported non-RCT¹⁴⁴ found chemonucleolysis to be significantly better than epidural in terms of overall recovery, according to the physician, among patients with chronic sciatica at 2 years. All patients had been treated by the author. The study included patients with long-term back pain or sciatica, and these findings are based on a subgroup of patients with sciatica (23/40), among whom symptom duration ranged from 12 weeks to 25 years (median 1 year). All patients had already tried various treatments for at least 3 months.

TABLE 39 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing chemonucleolysis with alternative interventions (ordered by author)

Change scores (SD)

Final mean (SD)

Baseline mean (SD)

Total (*n*)

•		
·		
•		
	author)	

Comment/ conversion ^b			SD for final means calculated from <i>p</i> -values (Mann– Whitney <i>U</i> -test); most outcomes showed skewed distribution	SD calculated from SE Dropouts 24/165 (15%): group allocation not stated
Mean difference (95% Cl)⁴		-0.08 (-0.80 to 0.65)	0.55 (0.13 to 0.96)	-0.27 (-0.60 to 0.06)
Control			-4.4	-2.6
Intervention			-3.2	-2.6
Control		9.71 (4.79)	2.3 (1.28)	3.4 (3.32)
Intervention		9.27 (6.62)	3 (1.28)	2.3 (4.65)
Control			6.7	6 (3.9)
Intervention			6.2	4.9 (2.55)
Control		14	46	69
Intervention		15	46	72
Scale		Composite score	Part of Waddell Disability Index	Waddell Disability Index and Main Scale
Follow- up		6 months	3 months	6 months
Study design		RCT	RCT	RCT
Chronicity	c surgery	A+C	A + C	R
Author, year	ucleolysis vs dis	Ejeskar, 1983 ⁹⁶	Muralikuttan, 1992 ⁸⁵	Revel, 1993 ⁸⁸
ID no.	Chemor	727	593	617

A + C, acute and chronic; NR, not reported.

a Based on final means or change scores (with a preference given to change scores). b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Disc su	rgery						
727	Ejeskar, 1983 ⁹⁶	RCT				-0.08 (-0.80 to 0.65)	25.77
593	Muralikuttan, 1992 ⁸⁵	RCT				0.55 (0.13 to 0.96)	35.79
617	Revel, 1993 ⁸⁸	RCT		+		-0.27 (-0.60 to 0.06)	38.44
Subtota	l (l ² = 78.2%, p = 0.010))				0.07 (-0.50 to 0.65)	100.00
		-0.96	3	0	0.963		
		Favours o	hemonucleolysis	Favours contro	l		

FIGURE 29 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

	•	Study			%
ID no.	Author, year	design		OR (95% CI)	weight
Disc su	rgery				
884	Alexander 1989 ¹⁰³	CCS	_	0.93 (0.36 to 2.44)	5.11
43	Alphen 198947	RCT		0.70 (0.33 to 1.48)	5.86
441	Bonafe 199375	CCS		3.27 (0.80 to 13.35)	3.74
166	Crawshaw 198460	RCT -		0.11 (0.03 to 0.47)	3.63
48	Dabezies 1978 ⁵¹	CCS		1.44 (0.79 to 2.60)	6.42
132	Hoogmartens 197656	HCS		0.52 (0.23 to 1.20)	5.57
44	Javid 199548	CCS		1.47 (0.68 to 3.19)	5.78
129	Lavignolle 198755	RCT	.	0.86 (0.51 to 1.46)	6.62
889	Lee 1996 ¹⁰⁴	CCS		1.32 (0.76 to 2.31)	6.54
593	Muralikuttan 199285	RCT		0.48 (0.18 to 1.29)	5.03
47	Norton 1986 ⁵⁰	CCS		0.27 (0.12 to 0.61)	5.62
45	Postacchini 198749	Non-RCT		0.60 (0.27 to 1.31)	5.75
617	Revel 1993 ⁸⁸	RCT		3.52 (1.76 to 7.04)	6.07
641	Steffen 199990	RCT		2.41 (0.90 to 6.46)	5.04
61	Tregonning 1991 ⁵³	CCS		0.38 (0.22 to 0.65)	6.59
160	Watts 197559	CCS		0.43 (0.25 to 0.73)	6.61
672	Weinstein 198692	CCS		1.20 (0.41 to 3.51)	4.75
150	Zeiger 1987 ⁵⁸	HCS	•	0.19 (0.08 to 0.47)	5.29
Subtota	(<i>l</i> ² = 77.4%, <i>p</i> = 0.000)		\diamond	0.77 (0.53 to 1.13)	100.00
Epidura	l/intradiscal injection				
50	Graham 1976 ¹⁴⁴	Non-RCT		- 8.25 (1.15 to 59.00)	100.00
Inactive	control				
55	Gogan 1992 ²⁰⁵	RCT		7.56 (2.26 to 25.22)	49.13
236	Schwetschenau 1976 ²⁰⁶	RCT		0.69 (0.25 to 1.95)	50.87
Subtota	(<i>l</i> ² = 88.5%, <i>p</i> = 0.003)			2.24 (0.22 to 23.30)	100.00
				+	
		0.0169	9 1	59	
		F	avours control Favours chemor	nucleolysis	

FIGURE 30 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

TABLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

							Intervent	ion		Control				
Ξë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	0R (95% CI)	Comments
Chem	nonucleolysis vs a	isc surgery												
884	Alexander, 1989 ¹⁰³	O	CCS	Mean 14 (range 6–35) months	Satisfactory clinical outcome (vs unsatisfactory results)	Physician	5	40	0	49	60	0	0.93 (0.36 to 2.44)	Follow-up differed in each groups: chemonucleolysis mean 16 (range 6–35) months, surgery mean 12 (range 6–24) months
43	van Alphen, 1989⁴7	S	RCT	12 months	Satisfaction with final result of treatment: yes or largely; (vs barely or no)	Patient	73	23	0	22	61	-	0.70 (0.33 to 1.48)	
441	Bonafe, 1993 ⁷⁵ (French language)	A + C	SOCS	1 year	Overall treatment success using modified MacNab criteria: excellent or good (vs satisfactory or worse)		20	16	0	20	-	0	3.27 (0.80 to 13.35)	
166	Crawshaw, 1984⁰	NR	RCT	1 year	Overall outcome: excellent or good (vs poor)		24	=	0. 04	26	23	0.04	0.11 (0.03 to 0.47)	
48	Dabezies, 1978 ⁵¹	R	CCS	2 years	Results categorised as excellent or good (vs unimproved)	Patient	100	71	0	100	63	0	1.44 (0.79 to 2.60)	

							Interventi	on		Control				
₽ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
132	Hoogmartens, 1976 ⁵⁶	U	SH	Mean 49 months	Satisfactory result for amount of radicular pain: excellent or good (vs fair or poor)		44	24	0	53	37	0	0.52 (0.23 to 1.20)	Data inferred from percentages Follow-up differed for the two groups: surgery mean 58 months, chemonucleolysis mean 38 months
44	Javid, 1995 ⁴⁸	O	CCS	1 year	Success categorised as: good or excellent (vs slight or no improvement)	Patient	100	87	0	100	82	0	1.47 (0.68 to 3.19)	
129	Lavignolle, 1987 ⁵⁵ (French language)	NN	RCT	Mean: surgery 25 months; chemonucleolysis 22 months	Overall success using MacNab type score: good or medium (vs mediocre or bad)	Patient	176	141	0	182	150	0	0.86 (0.51 to 1.46)	
889	Lee, 1996 ¹⁰⁴ (German language) (j ^a (APLD)	Ч	CCS	1 year	Results of treatment: very good or good; (vs moderate or bad)	Patient	100	22	~	100	48	~.	1.32 (0.76 to 2.31)	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 29%
889	Lee, 1996 ¹⁰⁴ (German language) (ii) ^a (PELD)	R	CCS	1 year	Results of treatment: very good or good (vs moderate or bad)	Patient	100	22	ç.	100	68	<i>c</i> .	0.58 (0.32 to 1.02)	Number randomised not stated, 300 included in analysis Excluded: chemonucleolysis 29%, surgery 14%
593	Muralikuttan, 1992 ⁸⁵	A + C	RCT	1 year	Completely pain free (vs residual back pain only, residual back and referred pain)		46	ω	0	46	14	0	0.48 (0.18 to 1.29)	Reported as percentages One patient crossed over to surgery
														continued

ILE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions (grouped parator then ordered by author) (continued)	þ	
ILE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions (group parator then ordered by author) (continued)	eq	
iLE 40 Summary of the findings of the global effect at long-term follow-up (> 6 months) for studies comparing chemonucleolysis with alternative interventions (griparator then ordered by author) (continued)	dnc	
iLE 40 Summary of the findings of the global effect at long-term follow-up (> 6 months) for studies comparing chemonucleolysis with alternative interventions iparator then ordered by author) (continued)	(gr	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventic iparator then ordered by author) (continued)	suc	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interve (continued)	ntio	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative inte iparator then ordered by author) (continued)	ev.	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative iparator then ordered by author) (continued)	inte	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternati parator then ordered by author) (continued)	Ne Ve	
iLE 40 Summary of the findings of the global effect at long-term follow-up (> 6 months) for studies comparing chemonucleolysis with alteriparator then ordered by author) (continued)	nati	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis with a parator then ordered by author) (continued)	lteri	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis wit iparator then ordered by author) (continued)	hа	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleolysis iparator then ordered by author) (<i>continued</i>)	wit	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemonucleoly iparator then ordered by author) (<i>continued</i>)	'sis	
iLE 40 Summary of the findings of the global effect at long-term follow-up (> 6 months) for studies comparing chemonucle iparator then ordered by author) (continued)	soly	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chemon iparator then ordered by author) (continued)	ncle	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing chen iparator then ordered by author) (continued)	UOL	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing cl iparator then ordered by author) (<i>continued</i>)	лег	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparin, iparator then ordered by author) (continued)	g c	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies compaparator then ordered by author) (<i>continued</i>)	arinç	
iLE 40 Summary of the findings of the global effect at long-term follow-up (> 6 months) for studies con iparator then ordered by author) (continued)	npa	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies iparator then ordered by author) (continued)	con	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studi iparator then ordered by author) (continued)	es	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for siparator then ordered by author) (continued)	tudi	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) fo iparator then ordered by author) (<i>continued</i>)	or st	
LE 40 Summary of the findings of the global effect at long-term follow-up (> 6 month: parator then ordered by author) (continued)	s) fc	
iLE 40 Summary of the findings of the global effect at long-term follow-up (>6 mo iparator then ordered by author) (continued)	nth	
LE 40 Summary of the findings of the global effect at long-term follow-up (>6 iparator then ordered by author) <i>(continued)</i>	ĪŌ	
LE 40 Summary of the findings of the global effect at long-term follow-up (iparator then ordered by author) (<i>continued</i>)	0 ^	
LE 40 Summary of the findings of the global effect at long-term follow-uparator then ordered by author) (continued))) dr	
LE 40 Summary of the findings of the global effect at long-term follo parator then ordered by author) (<i>continued</i>)	-M-L	
LE 40 Summary of the findings of the global effect at long-term fiparator then ordered by author) <i>(continued)</i>	ollo	
LE 40 Summary of the findings of the global effect at long-ter parator then ordered by author) (<i>continued</i>)	Ę	
LE 40 Summary of the findings of the global effect at long- iparator then ordered by author) <i>(continued)</i>	-ter	
LE 40 Summary of the findings of the global effect at lo parator then ordered by author) <i>(continued)</i>	-bu	
LE 40 Summary of the findings of the global effect a parator then ordered by author) (<i>continued</i>)	at Ic	
LE 40 Summary of the findings of the global effe parator then ordered by author) (<i>continued</i>)	ct 8	
LE 40 Summary of the findings of the global iparator then ordered by author) (continued)	effe	
LE 40 Summary of the findings of the glot parator then ordered by author) (<i>continue</i>	a) al	
LE 40 Summary of the findings of the iparator then ordered by author) (<i>contin</i>	glot	
LE 40 Summary of the findings of t parator then ordered by author) (cor	he	
LE 40 Summary of the findings parator then ordered by author)	of t (co/	
LE 40 Summary of the findin parator then ordered by auth	or) i	
LE 40 Summary of the fir parator then ordered by a	uth.	
LE 40 Summary of the parator then ordered t	e fir vy a	
LE 40 Summary of parator then ordere	žd b	
LE 40 Summar parator then orc	y of Jere	
ILE 40 Sumr parator then	orc	
t LE 40 Suparator the	ner	
LE 40	rt S	
ba	40 ratc	
mr		

							into the	ion.		Control				
₽			Study		Outcome		Total	Outcome	Withdrawal	Total	Outcome	Withdrawal	OR	
uo.	Author, year	Chronicity	design	Follow-up	measure	Perspective	(u)	(<i>u</i>)	rate	(<i>u</i>)	(<i>u</i>)	rate	(95% CI)	Comments
47	Norton, 1986 ⁵⁰	A + C	CCS	≥1 year	Treatment success: satisfactory (vs unsatisfactory) based on patient and physician report	Patient + physician	61	17	0	44	26	0	0.27 (0.12 to 0.61)	
45	Postacchini, 1987 ⁴⁹	A+C	Non- RCT	> 20 months	Treatment success: excellent or good (vs fair or poor)	Patient + physician	72	54	0.03	84	02	0.03	0.60 (0.27 to 1.31)	Data inferred from graphs Five lost to follow- up were excluded
617	Revel, 1993 ⁸⁸	К	RCT	1 year	Treatment success	Patient	23	8	~	41	25	~	3.52 (1.76 to 7.04)	24/165 (15%) patients dropped out at beginning, group allocation not stated A further 30% dropped out (surgery: 28/69; chemonucleolysis 14/72), but included in analysis (given poor outcome)
641	Steffen, 1999 ^{so} (German language)	U	RCT	1 year	MacNab criteria: good or very good (vs satisfactory or poor)		33	17	0	36	1	0	2.41 (0.90 to 6.46)	Reported as percentages only
61	Tregonning, 1991 ⁵³	C	CCS	10 years	MacNab criteria: excellent or good (vs fair or poor)		145	47	0.12	91	51	0.13	0.38 (0.22 to 0.65)	
160	Watts, 1975 ⁵⁹	υ	CCS	2 years	Overall outcome: success (vs failure)		100	59	0	174	134	0	0.43 (0.25 to 0.73)	

							Interventi	и		Control				
₽ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
672	Weinstein, 1986 ⁹²	G	CCS	> 1 year	Recovered within 2–6 weeks, 6–12 weeks, > 12 weeks or immediate (vs no recovery)	Patient	88	77	с	71	20	ω	1.20 (0.41 to 3.51)	
150	Zeiger, 1987 ⁵⁸	A + C	CCS	Mean 18 (range 6-46) months	Current level of discomfort: pain free or improvement (vs no better or worse)		45	27	0	81	72	0	0.19 (0.08 to 0.47)	Results included seven surgery patients who had had reoperation; five with good results
Chem	onucleolysis vs ep	hidural/intrad	'iscal inject	tion										
50	Graham, 1976 ¹⁴⁴	C	Non- RCT	2 years	Results categorised as good (vs fair or unimproved)	Physician	10 sciatica patients	Q	0	1	5	0	8.25 (1.15 to 59.00)	
Chem	onucleolysis vs in	active contro	1											
55	Gogan, 1992 ²⁰⁵	S	RCT	10 years	Treatment success (yes or no)	Patient	30	24	0	26	D	4	7.56 (2.26 to 25.22)	Data inferred from graphs
236	Schwetschenau, 1976 ²⁰⁶	A + C	RCT	1 year	Symptom improvement: excellent or good (vs fair)		31	O	0	35	13	0	2.24 (0.22 to 23.30)	
?, unc a Let me	ear; APLD, automa e <i>et al.</i> ¹⁰⁴ included ti ta-analysis (see <i>Fig</i>	ted percutanec hree treatmeni ure 30.	ous lumbar t groups: Af	discectomy; A + C, at PLD (i), PELD (ii) and t	cute and chronic; C, ch chemonucleolysis (iii).	rronic; NR, not r In order to prew	eported; PE ent using th	ELD, percutan le same comp	eous manual an parator twice, on	d laser dis ly the firs	scectomy. t and third ti	eatment groups	have been in	cluded in the

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 41* and the accompanying forest plot (*Figure 31*). Chemonucleolysis was compared with disc surgery and manipulation. Three studies^{77,85,208} included patients with either acute or chronic symptoms. The duration of follow-up ranged from 12^{85,208} to 18 months.⁷⁷

Two studies compared chemonucleolysis with disc surgery; one was a moderate-quality RCT⁸⁵ and one was a non-RCT.⁷⁷ Overall, there was a non-statistically significant difference between the intervention groups, in favour of chemonucleolysis.

One moderate-quality RCT²⁰⁸ showed a non-statistically significant reduction in pain intensity in favour of manipulation, compared with chemonucleolysis, at 12 months. As previously stated the study experienced problems with the randomisation process.

Condition-specific outcome measures at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 42* and the accompanying forest plot (*Figure 32*). Chemonucleolysis was compared with disc surgery and



FIGURE 31 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design	SMD	(95% CI)	% weight
Disc su	irgery				
454	Buric, 200577	Non-RCT		1 (–0.58 to 0.66)	24.90
727	Ejeskar, 1983 ⁹⁶	RCT		9 (–0.63 to 0.82)	18.01
593	Muralikuttan, 1992 ⁸⁵	RCT	-0.17	7 (-0.57 to 0.24)	57.08
Subtota	ll ($l^2 = 0.0\%$, $p = 0.774$)		-0.07	7 (-0.38 to 0.24)	100.00
Manipu	lation				
723	Burton, 2003 ²⁰⁸	RCT	• 0.22	? (-0.50 to 0.94)	100.00
		-0.94	0 0.94		
		Favours o	emonucleolysis Eavours control		

FIGURE 32 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

ped by	
s (grout	
vention	
ve inter	
ternativ	
with a	
leolysis	
monuc	
ing che	
compar	
tudies o	
is) for s	
month	
9<) dn-	
n follow	
ng-tern	
ity at lo	
intens	
of pair	
indings	author)
of the f	ered by
mmary	ien orde
41 Su	rator th
TABLE	compai

-		•														
							Total ((u	Baseline n (SD)	nean	Final mea	ın (SD)	Change s((SD)	cores		
<u> </u>	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/ conversion ^c
Chen	onucleolysis vs t	disc surgery														
454	Buric, 200577	A+C	Non-RCT	18 months	Overall	VAS (0-10)	30	15	53 (22)	61 (31)	13 (16)	20 (13)	-40.0	-41	-7.00 (-15.7 to 1.72)	Two patients crossed over to surgery, classed as treatment failures
593	Muralikuttan, 1992 ⁸⁵	A+C	RCT	1 year	Leg	VAS (0-100)	46	46	64	72	18 (21.22)	16 (20.31)			2.00 (–6.49 to 10.49)	SD imputed from weighted average Most outcomes showed skewed distribution
Chen.	onucleolysis vs ı	manipulation														
723	Burton, 2000 ²⁰⁸	A+C	RCT	12 months	Leg	Annotated thermometer (0–6)	15	15	60.8 (26.5)	66.7 (14.2)	37.8 (29.2)	35.5 (32)			2.30 (-19.62 to 24.22)	Missing data: intervention 5/20, control 5/20
A+C, a Th b Ba c Th	acute and chronic e results have bee sed on final means term 'dropouts' h	: In converted to a s or change scol has been used fi	a scale of 0–1 res (with a pr or missing da	100 for compau eference given tta, post-baselli	rability. I to change s ine exclusion:	icores). s and patients lo	st to foll	ow-up.								

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 42 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

						Total (Ē	Baseline (SD)	; mean	Final m((SD)	ean	Change : (SD)	scores		
D. G.	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^a	Comment/conversion ^b
Chem	onucleolysis vs	disc surgery													
454	Buric, 2005 ⁷⁷	A+C	Non- RCT	18 months	RMDQ	30	15	9.1 (3.5)	12.4 (4.3)	2.2 (3.2)	2.1 (1.9)	-6.9	-10.3	0.04 (-0.58 to 0.66)	ITT used but method not stated Dropouts: two, considered as treatment failure
727	Ejeskar, 1983 ⁹⁶	A+C	Non- RCT	12 months	Composite score	15	14			9.4 (6.88)	8.79 (6.02)			-0.07 (-0.38 to 0.24)	
593	Muralikuttan, 1992 ⁸⁵	A + C	RCT	1 year	Part of Waddell Disability Index	46	46	6.2	6.7	2.6 (1.21)	2.8 (1.21)		6. 	-0.17 (-0.57 to 0.24)	SD for final means calculated from ρ -values (Mann–Whitney U -test); most outcomes showed skewed distribution ITT not used, but all patients included in analysis except one for psychological outcomes
672	Weinstein, 1986 ⁹²	O	CCS	Mean 10.3 years	Composite score	81	71	1						Results of MANOVA showed no significant relationship between pain outcome measures and treatment type, Wilks' criterion F(6, 54) = 1.18, p < 0.34	Pain + disability measured on six different scales Actual data not presented Dropouts 3/159 (2%): (chemonucleolysis group)
Chem 723	ionucleolysis vs Burton, 2000 ²⁰⁸	<i>manipulation</i> A+C	SOO	12 months	RMDQ	15	15	11.95 (5.83)	11.9 (5.48)	7.27 (6.65)	5.87 (5.96)	-4.68	-6.03	0.22 (-0.50 to 0.94)	
A+C, a Ba b The	acute and chroni sed on final mear e term 'dropouts'	ic; C, chronic. Is or change scc has been used t	bres (with a provided in the second se	preference give data, post-base	in to change s line exclusion:	cores); r s and pa	esults rep tients los	oorted by s t to follow-	tudy in ita up.	lics.					

manipulation. Three studies^{77,85,208} included patients with either acute or chronic symptoms. The duration of follow-up ranged from 12^{85,208} to 18 months.⁷⁷

Four studies^{77,85,92,96} compared chemonucleolysis with disc surgery. Pooled analysis of three weakto-moderate quality studies^{77,85,96} showed a non-statistically significant difference between the intervention groups in favour of chemonucleolysis. One CCS⁸⁸ reported insufficient data to be included in the meta-analysis. The study followed patients for a mean of 10.3 years. The results of six pain and disability outcome measures were analysed in a one-way MANOVA, the results of which showed no significant relationship between pain outcome measures and treatment type (Wilks' criterion F(6,54) = 1.18; p < 0.34).

One moderate-quality RCT²⁰⁸ showed a non-statistically significant reduction in functional status in favour of manipulation, compared with chemonucleolysis, at 12 months. As previously stated, the study experienced problems with the randomisation process.

Analysis of adverse effects for chemonucleolysis

The results for the occurrence of any reported adverse effects are presented in *Table 43* and the accompanying forest plot (*Figure 33*).

The number of adverse effects were significantly less with chemonucleolysis compared with epidural injection. Pooled analyses showed no statistically significant differences between the intervention groups in the number of adverse effects when comparing chemonucleolysis with disc surgery, manipulation or inactive control.

Serious adverse effects (as considered by the review team) reported by patients receiving chemonucleolysis included nerve root injury, dural defect with subsequent leakage of cerebrospinal fluid, phlebitis, disc space infection, discitis, pulmonary embolus and deep-vein thrombosis plus pulmonary embolism.^{47,48,51,56,205} However, these were experienced by only one or two participants within each study (that compared chemonucleolysis with another types of treatment). One study²¹¹ that compared two types of chemonucleolysis (with 5 years' follow-up data) reported slightly higher levels of serious adverse effects. When combining data from both treatment arms (n = 50), 12 participants experienced severe pain and 11 experienced neurological deficit.

SUMMARY OF OVERALL FINDINGS FOR CHEMONUCLEOLYSIS COMPARED WITH ALTERNATIVE INTERVENTIONS

Most of the chemonucleolysis studies included patients with chronic sciatica or both acute and chronic sciatica. Almost half (47%) of the studies were RCTs. One study was deemed to be of good quality (comparator was inactive control²⁰⁶) and 12 studies^{47,85,88,160,168,170,205,207-210,214} (36%) were of moderate quality, most of which compared chemonucleolysis with an inactive control or epidural. One study had good external validity (comparator was disc surgery⁴⁷) (*Table 44*).

Meta-analysis of five RCTs^{205-207,209,210} deemed to be moderately or well conducted showed chemonucleolysis to be significantly better than the inactive control, in terms of improved global effect, at medium-term follow-up. However, there was no significant difference between the intervention groups in terms of global effect (four RCTs^{205-207,209}) or pain intensity (one small RCT²⁰⁷) at short-term follow-up; in terms of pain intensity at medium term (one small RCT with fairly high dropout rate²⁰⁷); global effect (two good- to moderate-quality RCTs^{205,206}) at long-term follow-up for; or for overall adverse effects.^{205,207,209,210}

 TABLE 43
 Summary of the findings of any adverse effect for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Chemo	nucleolysis vs disc surgery						
884	Alexander, 1989 ¹⁰³	CCS	8	51	8	49	1.64 (0.50 to 5.40)
43	van Alphen, 198947	RCT	3	73	3	78	1.07 (0.21 to 4.57)
441	Bonafe, 199375	CCS	0	20	1	20	0.32 (0.01 to 8.26)
183	Bouillet, 198361	CCS	152	2136	91	613	0.44 (0.33 to 0.58)
453	Brown, 1989 ⁷⁶ (chymopapain)	CCS	NR	NR	NR	NR	
453	Brown, 1989 ⁷⁶ (collagenase)	CCS	NR	NR	NR	NR	
454	Buric, 200577	Non-RCT	NR	NR	NR	NR	
166	Crawshaw, 198460	RCT	1	25	0	27	3.37 (0.13 to 86.55)
48	Dabezies, 197851	CCS	2	100	0	100	5.10 (0.24 to 107.62)
471	Dei-Anang, 199079	CCS	NR	NR	NR	NR	
727	Ejeskar, 198396	RCT	1	15	1	14	0.93 (0.05 to 16.42)
132	Hoogmartens, 197656	HCS	3	44	19	53	0.13 (0.04 to 0.48)
44	Javid, 199548	CCS	4	100	6	100	0.65 (0.18 to 2.39)
35	Krugluger, 200046	RCT	5	12	1	10	6.43 (0.60 to 68.31)
117	Lagarrigue, 199154	CCS	5	334	30	751	0.37 (0.14 to 0.95)
129	Lavignolle, 198755	RCT	7	176	7	182	1.04 (0.36 to 3.02)
889	Lee, 1996 ¹⁰⁴ (control = APLD)	CCS	73	100	3	100	87.42 (25.53 to 299.34)
889	Lee, 1996 ¹⁰⁴ (control = PELD)	CCS	73	100	4	100	64.89 (21.75 to 193.63)
593	Muralikuttan, 199285	RCT	1	46	0	46	3.07 (0.12 to 77.24)
47	Norton, 198650	CCS	12	61	2	44	5.14 (1.09 to 24.29)
45	Postacchini, 198749	Non-RCT	2	72	0	84	5.99 (0.28 to 126.89)
617	Revel, 199388	RCT	35	72	15	69	3.41 (1.63 to 7.10)
641	Steffen, 199990	RCT	NR	NR	NR	NR	
49	Stula, 199052	RCT	NR	NR	NR	NR	
61	Tregonning, 199153	CCS	4	145	5	91	0.49 (0.13 to 1.87)
893	Watters, 1988105	Non-RCT	2	50	1	50	2.04 (0.18 to 23.27)
160	Watts, 197559	CCS	3	100	32	174	0.14 (0.04 to 0.46)
672	Weinstein, 198692	CCS	NR	NR	NR	NR	
150	Zeiger, 1987 ⁵⁸	CCS	16	45	5	81	8.39 (2.82 to 24.98)
Chemo	nucleolysis vs epidural						
447	Bourgeois, 1988160	RCT	3	30	30	30	0.00 (0.00 to 0.04)
720	Bontoux, 1990168	RCT	NR	NR	NR	NR	
729	Gallucci, 2007170	RCT	0	82	0	77	
50	Graham, 1976 ¹⁴⁴	Non-RCT	NR	NR	NR	NR	
Chemo	nucleolysis vs inactive contr	ol					
726	Dabezies, 1988 ²⁰⁹	RCT	14	87	1	86	16.3 (2.09 to 126.97)
244	Feldman, 1986 ²⁰⁷	RCT	0	14	2	10	0.12 (0.01 to 2.74)
55	Gogan, 1992 ²⁰⁵	RCT	2	30	2	26	2.07 (0.18 to 24.15)
738	Javid, 1983 ²¹⁰	RCT	28	55	7	53	6.81 (2.62 to 17.71)
236	Schwetschenau, 1976206	RCT	0	31	0	35	

TABLE 43 Summary of the findings of any adverse effect for studies comparing chemonucleolysis with alternative interventions (grouped by comparator then ordered by author) (continued)

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Chemor	nucleolysis vs manipulation						
723	Burton, 2000 ²⁰⁸	RCT	4	15	5	15	0.73 (0.15 to 3.49)

APLD, automated percutaneous lumbar discectomy; NR, not reported; PELD, percutaneous manual and laser discectomy.

		Study		%
ID no.	Author, year	design	OR (95% CI)	weight
Disc su	rgery			
884	Alexander 1989 ¹⁰³	CCS	1.64 (0.50 to 5.40)	5.66
43	Alphen 198947	RCT	1.07 (0.21 to 5.49)	5.01
441	Bonafe 199375	CCS		2.89
183	Bouillet 198361	CCS	• 0.44 (0.33 to 0.58)	6.58
48	Dabezies 1978 ⁵¹	CCS	5.10 (0.24 to 107.62)	3.11
727	Ejeskar 1983 ⁹⁶	RCT	0.93 (0.05 to 16.42)	3.31
44	Javid 199548	CCS	0.65 (0.18 to 2.39)	5.51
117	Lagarrigue 199154	CCS	0.37 (0.14 to 0.95)	5.98
593	Muralikuttan 199285	RCT		2.93
47	Norton 1986 ⁵⁰	CCS	5.14 (1.09 to 24.29)	5.13
45	Postacchini 198749	Non-RCT	5.99 (0.28 to 126.89)	3.11
61	Tregonning 199153	CCS	0.49 (0.13 to 1.87)	5.45
893	Watters 1988 ¹⁰⁵	Non-RCT	2.04 (0.18 to 23.27)	3.86
150	Zeiger 1987 ⁵⁸	CCS		5.80
166	Crawshaw 1984 ⁶⁰	RCT		2.91
132	Hoogmartens 1976 ⁵⁶	HCS	0.13 (0.04 to 0.48)	5.51
35	Krugluger 2000 ⁴⁶	RCT	6.43 (0.60 to 68.31)	3.95
129	Lavignolle 1987 ⁵⁵	RCT		5.83
889	Lee 1996 ¹⁰⁴	CCS) 5.61
617	Bevel 1993 ⁸⁸	BCT		6.23
160	Watts 1975 ⁵⁹	CCS	0 14 (0.04 to 0.46)	5.63
641	Steffen 1999 ⁹⁰	BCT	(Excluded)	0.00
Subtotal	$(l^2 = 86.4\%, p = 0.000)$		(1.50 (0.72 to 3.14)	100.00
Epidura	l/intradiscal injection	_		
447	Bourgeois 1988 ¹⁶⁰	BCT	0.00 (0.00 to 0.04)	100.00
729	Gallucci 2007 ¹⁷⁰	RCT	(Excluded)	0.00
0				0.00
Inactive	control			
726	Dabezies 1988 ²⁰⁹	RCT	→ 16.30 (2.09 to 126.97)	25.17
244	Feldman 1986 ²⁰⁷	RCT	• 0.12 (0.01 to 2.74)	16.05
55	Gogan 1992 ²⁰⁵	RCT	2.07 (0.18 to 24.15)	21.32
738	Javid 1983 ²¹⁰	RCT	6.81 (2.62 to 17.71)	37.46
Subtotal	l (<i>I</i> ² = 60.7%, <i>p</i> = 0.054)		3.43 (0.70 to 16.86)	100.00
Manipul	ation			
723	Burton 2000 ²⁰⁸	RCT	0.73 (0.15 to 3.49)	100.00
		0.0001	1 9701	
		Envoure chor		
		ravours chem	ionucleolysis Favours control	

FIGURE 33 Summary of the findings of any adverse effect for studies comparing chemonucleolysis with alternative interventions. Note: weights are from random effects analysis.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Chemonucleolysis vs disc surgery	26 (29)	29–1085 (116)	8/26 (31)	0/26 (0)	0/26 (0)	26/26 (100)	21/26 (81)	1/26 (4)	1/26 (4)	3/26 (12)	21/26 (81)	3/26 (12)
Chemonucleolysis vs epidural/intradiscal injection	4 (4)	40–159 (70)	3/4 (75)	0/4 (0)	0/4 (0)	4/4 (100)	4/4 (100)	0/4 (0)	0/4 (0)	0/4 (0)	4/4 (100)	0/4 (0)
Chemonucleolysis vs inactive control	5 (5)	39–173 (66)	5/5 (100)	1/5 (20)	0/2 (0)	5/5 (100)	5/5 (100)	0/5 (0)	0/5 (0)	0/2 (0)	5/5 (100)	0/5 (0)
Chemonucleolysis vs manipulation	1 (1)	40 (40)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Total (for chemonucleolysis results)	36 (39)	29–1085 (100)	17/36 (47)	1/36 (3)	0/36 (0)	36/36 (100)	31/36 (86)	1/36 (3)	1/36 (3)	3/36 (8)	30/36 (83)	3/36 (8)

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs.

TABLE 44 Summary of chemonucleolysis studies

Pooled analysis of 18 studies^{47–51,53,55,56,58–60,75,85,88,90,92,103,104} showed marginally statistically significant findings in favour of disc surgery, compared with chemonucleolysis, for the global effect at long-term follow-up (see *Figure 30*). However, there was no statistically significant difference between the intervention groups for the global effect at short-^{48,49,52,79,92,104} and medium-term^{48,49,54,76,88,92,104,105} follow-up; pain intensity at short-,^{76,85,88} medium-^{76,85,88} and long-term^{77,85} follow-up; CSOMs at short-,^{85,88} medium-^{85,88,96} and long-term^{77,85,96} follow-up; or adverse effects^{46–51,53–56,58–61,75,85,88,96,103–105} (according to a number of studies, ranging from good to poor quality). There was no statistically significant difference between disc surgery in combination with chemonucleolysis and disc surgery alone, at long-term follow-up, for global effect, pain, or for adverse effects (one poor-quality Q-RCT⁹⁷).

Chemonucleolysis using steroid plus ozone–oxygen was found to be better than epidural for overall recovery at short-term follow-up (one poorly reported RCT¹⁷⁰) and chemonucleolysis using chymopapain better than epidural at long-term follow-up (one poor-quality non-RCT¹⁴⁴). There was no statistically significant difference between epidural and chemonucleolysis for overall recovery at medium-term follow-up (three RCTs,^{160,168,170} one of which used ozone–oxygen¹⁷⁰). There were more adverse effects experienced with epidural injections than with chemonucleolysis (one RCT¹⁶⁰).

There was no statistically significant difference between chemonucleolysis and osteopathic manipulation, in terms of pain intensity and functional status, at short- or medium-term follow-up (one RCT²⁰⁸).

Non-opioids

Description of non-opioids studies Summary of interventions

Thirty-six studies evaluated the use of non-opioids for sciatica,^{6,57,80,143,156,161,172,175,214–241} 25 of which compared non-opioids with alternative interventions.^{6,57,80,143,156,162,173,176,214–230} (Two studies were reported in a single publication;²²³ studies 696 and 99999.) Seven studies included more than two arms.^{57,166,214,215,223,227,229} The types of intervention being evaluated by the studies are presented in *Table 45a*. Three studies^{161,172,226} did not report any pain, global or CSOM data.^{161,172,226}

Fifteen studies compared different types of non-opioids^{223,227,229,231-241} (seven of which were three-arm studies^{57,215,223,227,229} and two studies of which were reported in a single publication²²³). The types of non-opioids being compared are presented in *Table 45b* but the findings are not considered further.

Summary of study participants for non-opioids

Summary data for included participants are presented in Table 46. The number of participants included in the 22 studies that reported outcome data for global effect, pain or CSOMs ranged from 10 to 532 participants (median 65 participants). Nine studies (41%) included patients with acute sciatica and six studies (27%) included patients with chronic sciatica, whereas the majority of the remaining studies included patients with either acute or chronic sciatica (one study did not report this information). Two studies (one in which the comparator was epidural¹⁵⁶ and one in which the comparator was opioids²²⁹) included some patients with spinal stenosis and none included patients with sequestered or extruded discs. The diagnosis of sciatica, or the presence of herniated disc, was confirmed by imaging in eight studies (38%). One study⁵⁷ compared the use of non-opioids with disc surgery in patients who had recurrent sciatica. The remaining studies included a mixture of patients with either first-episode or recurrent sciatica or, more likely, did not report this information. One study (comparator was inactive control)6 included patients who had not received any previous treatment for their current episode of sciatica. Eleven studies (50%) included patients who had received previous treatment for their current episode of sciatica and this information was not stated in the remaining studies. Two studies that compared non-opioids with disc surgery⁸⁰ or epidural¹⁵⁶ included patients who had received previous disc surgery.

Summary of study quality for non-opioids studies

Summary information on study details is presented in *Table 47*. Most of the non-opioid studies were RCTs (17/21, 81%), but none was good quality. Ten studies^{6,143,161,214,218,220,223,224,227,228} were of moderate quality, most of which compared non-opioids with inactive control. Two of these studies^{214,227} used adequate methods for random sequence generation and allocation concealment (comparators included inactive control, opioids and mixed treatment). A further two studies^{156,224} used adequate randomisation, but not allocation concealment, although both used sealed envelopes. Two studies^{218,222} used adequate allocation concealment, but the method of randomisation was unclear. Only one study²¹⁴ had strong external validity, although it had a high attrition rate.

Non-opioids results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 48* and the accompanying forest plot (*Figure 34*). Non-opioids were compared with inactive control and opioids. One study²²¹ included only patients with chronic sciatica, five studies^{218,220,223,224,227}

TABLE 45a Summary of the interventions used when comparing non-opioids with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author. vear	Study desian	Treatment description	Control description
Non-opi	oids vs alternat	ive/non-tradi	tional	
801	Chen, 2009 ²¹⁵	RCT	Western medicine – oral nimesolide (NSAIDs) 2 g daily for 10 days (WMG)	Warming acupuncture by burning moxa daily for 10 days (WAG)
801	Chen, 2009 ²¹⁵	RCT	Western medicine – oral nimesolide (NSAIDs) 2 g daily for 10 days (WMG)	Anisodamine (2 mg) point injections into acupoints daily for 10 days (PIG)
Non-opi	oids vs biologic	al agents		
323	Genevay, 2004 ²¹⁶	HCS	Three intravenous injections of methylprednisolone 250 mg	Three subcutaneous injections of etanercept (Enbrel®, Wyeth Pharmaceuticals) 25 mg (anti-TNF- α)
Non-opi	ioids vs disc sui	rgery		
475	Dubourg, 2002 ⁸⁰	CCS	Non-operative intervention group. Some received steroids	Disc surgery (operative group) (various surgical techniques)
144	Rossi, 1993 ⁵⁷ (Italian Ianguage)	RCT	Oral dexamethasone 8 mg for 9 days, naproxen 500–1000 mg for 5 days (group lb)	Percutaneous discectomy (groups la and lla)
144	Rossi, 1993 ⁵⁷ (Italian language)	RCT	Oral dexamethasone 8 mg for 9 days, naproxen 500–1000 mg for 5 days (group lb)	Microdiscectomy (group IIb)
Non-opi	ioids vs epidura	l/intradiscal il	njection	
451	Bronfort, 2000 ¹⁶¹	RCT	Paracetamol, NSAIDs, activity modification	Epidural injection of steroid injections, 1–3 injections
20	Dincer, 2007 ¹⁴³	RCT	Oral diclofenac 75 mg for 14 days (NSAID)	Caudal epidural injection 40 mg methylprednisolone acetate, 8 mg dexamethasone phosphate, 7 ml of 2% prilocaine
771	Lafuma, 1997 ¹⁷²	RCT	Usual care (rest + NSAIDs) without epidural injections during hospital admission	Epidural steroid (125 mg prednisolone) injections at admission
362	Wilson- MacDonald, 2005 ¹⁵⁶	RCT	Intramuscular injections of steroid methylprednisolone 80 mg and local anaesthetic 8 ml bupivacaine	Epidural injection of steroid methylprednisolone 80 mg and local anaesthetic 8 ml bupivacaine
846	Murata, 2009 ¹⁷⁵	RCT	Injection of steroid (3.3 mg dexamethasone sodium phosphate) and local anaesthetic (7 ml 1% lidocaine) in the back muscles of L2 area (control block)	L2 nerve block using steroid (3.3 mg dexamethasone sodium phosphate) and local anaesthetic (2 ml of 1% lidocaine)
Non-opi	ioids vs inactive	control		
696	Dreiser, 2001 ²²³	RCT	Oral meloxicam (NSAID) 7.5 mg for 7 days (M I)	Oral placebo for 7 days
696	Dreiser, 2001 ²²³	RCT	Oral meloxicam (NSAID) 15 mg for 7 days (M II)	Oral placebo for 7 days
334	El-Zahaar, 1995 ²²¹	RCT	Intravenous injections of colchicine 1 mg twice weekly for 3 weeks	Intravenous injections of saline twice weekly for 3 weeks
728	Finckh, 2006 ²²⁴	RCT	Intravenous steroid methylprednisolone 500 mg	Intravenous saline infusion (placebo)
62	Gibson, 1975 ²¹⁷	Non-RCT	Chymoral tablets (proteolytic enzymes) for 7 days	Placebo tablets for 7 days

continued

TABLE 45a Summary of the interventions used when comparing non-opioids with alternative interventions (grouped by comparator then ordered by author) (continued)

ID no.	Author, year	Study design	Treatment description	Control description
97	Goldie, 1968 ²¹⁸	RCT	Oral indomethacin 75 mg daily	Oral placebo
732	Grevsten, 1975 ²²⁵	RCT	Phenylbutazone (NSAID) 300–600 mg for 15 days	Intramuscular and oral placebo
312	Hedeboe, 1982 ²²⁰	RCT	Intramuscular injection dexamethasone (8–64 mg) for 7 days	Intramuscular injection of saline
816	Herrmann, 2009 ²²⁷	RCT	Lornoxicam 8 mg	Placebo
816	Herrmann, 2009 ²²⁷	RCT	Diclofenac 50 mg	Placebo
817	Holve, 2008 ²²⁸	Q-RCT	Steroid oral tablets (prednisolone decreasing dose from 60 mg to 20 mg every 3 days) + standard medical + PT	Placebo tablets + standard medical + PT
736	Jacobs, 1968 ²²⁶	Q-RCT	Oral indomethacin (NSAID) 75–100 mg for 7 days	Oral placebo for 7 days
534	Khoromi 2007 ²¹⁴	RCT (crossover)	Oral nortriptyline (Allegron [®] , King Pharmaceuticals) plus inert placebo (up to 100 mg/day for 7.5 weeks)	Oral benztropine (active placebo) plus inert placebo (0.25–1 mg/day for 8.5 weeks)
611	Porsman, 1979 ²²²	RCT	Intramuscular dexamethasone 8-64 mg for 7 days	Intramuscular saline for 7 days (placebo)
665	Weber, 1993 ⁶	RCT	Oral pirixicam (NSAID) 20–40 mg for 14 days	Oral placebo for 14 days
297	Yildirim, 2003 ²¹⁹	RCT	Oral gabapentin 900–3600 mg for 2 months	Oral placebo for 2 months
Non-op	ioids vs manipu	lation		
451	Bronfort, 2000 ¹⁶¹	RCT	Paracetamol, NSAIDs, activity modification	Chiropractic spinal manipulation
Non-op	ioids vs mixed t	reatment		
534	Khoromi 2007 ²¹⁴	RCT (crossover)	Oral nortriptyline plus inert placebo (up to 100 mg/day for 7.5 weeks)	(Opioids + non-opioids). Morphine plus nortriptyline (oral morphine up to 90 mg/day for 8.5 weeks; oral nortriptyline up to 100 mg/day for 7.5 weeks)
Non-op	ioids vs opioids			
534	Khoromi 2007 ²¹⁴	RCT (crossover)	Oral nortriptyline plus inert placebo (up to 100 mg/day for 7 weeks)	Sustained-release morphine (oral) plus inert placebo (up to 90 mg/day for 7 weeks)
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	Fluvoxamine (10 mg oral)	Tramadol (100 mg intramuscular injection)
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	Imipramine (25 mg oral)	Tramadol (100 mg intramuscular injection)
547	Kwasucki, 1993 ²³⁰ (Polish language)	RCT	Dexamethasone. First and second days 24 mg (16 mg at 7 AM, 8 mg at 7 PM); third day 8 mg twice daily; fourth and fifth days 4 mg twice daily; sixth and seventh days 4 mg once daily	Tramadol. First 5 days 100 mg twice daily; sixth and seventh days 100 mg once daily

M, meloxican; PIG, point injection group; TNF-α, tumour necrosis factor-alpha; WAG, warming acupuncture group; WMG, western medicine group.

ID no.	Author, year	Study design	Treatment description	Control description
238	Andersen, 1978235	RCT	Oral proquazone (NSAID)	Oral naproxen (NSAID)
122	Blazek, 1986232	RCT	Oral proquazone	Oral diclofenac
159	Borms, 1988 ²³⁴	RCT	Intramuscular tiaprofenic acid	Intramuscular ketoprofen
721	Braun, 1982 ²³⁸ (German language)	RCT	Intramuscular injection of ketoprofen	Intramuscular injection of corticosteroid containing antirheumatic combination preparation (sodium phenylbutazone, dexamethasone, lidocaine, cyanocobalamin)
136	Desnuelle, 1986 ⁵⁶ (French language)	RCT	Intramuscular indomethacin injections	Intramuscular diclofenac injections
696	Dreiser, 2001223	RCT	Oral meloxicam (NSAID) 7.5 mg for 7 days (M I)	Oral meloxicam (NSAID) 15 mg for 7 days (M II)
9999	Dreiser, 2001 ²²³	RCT	NSAID (low-dose meloxicam, M I)	Traditional NSAID (diclofenac)
9999	Dreiser, 2001 ²²³	RCT	NSAID (high-dose meloxicam, M II)	Traditional NSAID (diclofenac)
810	Friedman, 2008 ²³⁹	RCT	Steroid intramuscular injection (160 mg of methylprednisolone acetate) + oral naproxen + oral oxycodone/acetaminophen	Placebo intramuscular injection + oral naproxen + oral oxycodone/acetaminophen
816	Herrmann, 2009 ²²⁷	RCT	Lornoxicam 8 mg	Diclofenac 50 mg
527	Kanayama, 2005 ²³⁷	RCT	5-HT _{2A} receptor inhibitor. Sarpogrelate hydroxychloride 300 mg orally for 2 weeks	NSAID. Sodium diclofenac 75 mg orally for 2 weeks
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	Fluvoxamine (10 mg oral)	Imipramine (25 mg oral)
841	Memeo, 2008 ²⁴⁰	Q-RCT	Acetyl-∟-carnitine 1180 mg/day	Thiotic acid 600 mg/day
109	Schuermans, 1988 ²³¹	RCT	Intramuscular tiaprofenic acid	Intramuscular alclofenac
241	Stevanovic, 1986236	RCT	Intramuscular injection of tenoxicam	Intramuscular injection of piroxicam
871	Toroudi, 2009 ²⁴¹	RCT	500 mg of oral ibuprofen prescribed three times a day for 9 days	400 mg of oral mesalamine prescribed three times a day for 9 days

TABLE 45b Summary of the interventions used when comparing alternative forms of non-opioids (ordered by author)

5-HT₂₄, 5-hydroxytryptamine₂₄; M, meloxican.

included only patients with acute sciatica and the remainder included patients with either acute or chronic sciatica. The duration of follow-up ranged from 1 day²²⁴ to 19 days.²³⁰

Pooled analysis of nine studies^{217,218,220-226} showed non-opioids to be significantly better than inactive control at 1 day²²⁴ to 21 days.²²¹ Eight studies were RCTs and one was a non-RCT. There was much heterogeneity between studies (I^2 = 82.6%), with one RCT, which evaluated the use of intravenous injections of colchicine for patients with chronic sciatica, having a larger effect size than the other studies. Excluding this study reduced the effect size to an OR of 1.63 (95% CI 1.03 to 2.59) and improved homogeneity (I^2 = 44.3%); follow-up ranged from 1 day²²⁴ to 14 days.^{218,225}

Non-opioids were compared with opioids in two RCTs;^{229,230} the pooled analysis showed a non-statistically significant difference in favour of non-opioids. Both studies were poorly reported and conducted. Follow-up ranged from 14²²⁹ to 19 days.²³⁰

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 49* and the accompanying forest plot (*Figure 35*). Non-opioids were compared with inactive control, opioids, epidural, alternative therapy and biological agents. Five studies^{216,223,224,227,228} included only patients with acute sciatica, three^{175,215,219} included only patients with chronic sciatica, one¹⁵⁶ did not report the duration of symptoms and the remaining studies included patients with acute or chronic sciatica. The duration of follow-up ranged from 8 hours²²⁷ to 36 days.²¹⁵

hor)	
Å	
~	
-	
а	
Ş	
Р	
σ	
ē	
٦.	
ň	
Ĕ	
0	
Ð	
긒	
τ	
ō	
Ť	
5	
ğ	
g	
E	
ō	
Ö	
\geq	
р	
ă	
ă	
0	
Ľ	
9	
S	
<u>0</u> .	
Ę	
٣	
ž	
5	
μ	
-	
Ψ	
÷	
ົອ	
Ē	
ይ	
Ť	
a	
, с	
È	
Ň	
5	
<u>9</u> .	
<u>0</u>	
ā	
ō	
Ĺ	
۲	
ž	
7	
ō	
⊒.	
ž	
õ	
_	
C	
E	
moc	
com	
s com	
ies com	
idies com	
tudies com	
studies com	
r studies com	
or studies com	
for studies com	
ils for studies com	
ails for studies com	
stails for studies com	
letails for studies com	
details for studies com	
on details for studies com	
ion details for studies com	
ation details for studies com	
llation details for studies com	
vulation details for studies com	
pulation details for studies com	
oppulation details for studies com	
' population details for studies com	
ty population details for studies com	
udy population details for studies com	
tudy population details for studies com	
study population details for studies com	
d study population details for studies com	
nd study population details for studies com	
and study population details for studies com	
e and study population details for studies com	
pe and study population details for studies com	
type and study population details for studies com	
ι type and study population details for studies com	
ca type and study population details for studies com	
ica type and study population details for studies com	
atica type and study population details for studies com	
ciatica type and study population details for studies com	
sciatica type and study population details for studies com	
f sciatica type and study population details for studies com	
of sciatica type and study population details for studies com	
y of sciatica type and study population details for studies com	
ary of sciatica type and study population details for studies com	
nary of sciatica type and study population details for studies com	
mary of sciatica type and study population details for studies com	
mmary of sciatica type and study population details for studies com	
ummary of sciatica type and study population details for studies com	
Summary of sciatica type and study population details for studies com	
Summary of sciatica type and study population details for studies com	
16 Summary of sciatica type and study population details for studies com	
46 Summary of sciatica type and study population details for studies com	
E 46 Summary of sciatica type and study population details for studies com	
LE 46 Summary of sciatica type and study population details for studies com	
BLE 46 Summary of sciatica type and study population details for studies com	
ABLE 46 Summary of sciatica type and study population details for studies com	

ID no.	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Non-op	ioids vs alterna	tive/non-tr.	aditional										
801	Chen, 2009 ²¹⁵	RCT	06	Mean 34.5 (SD 7.7)	63 (70)	Mean 5.3 years (SD 4.14 years)	Nerve root pain	No	R	No	No	NR	NR
do-uoN	ioids vs biologic	al agents:											
323	Genevay, 2004 ²¹⁶	HCS	10	Mean 47.3 (SD 13.3, range 1 to >18)	10 (50)	Mean 3.2 weeks (SD 3.7 weeks)	Nerve root pain	No	NR	No	No	NR	R
do-uoN	ioids vs disc su	rgery											
475	Dubourg, 2002 ⁸⁰	CCS	67	Mean 48.8 (SD 13.9, range 28–81)	42 (63)	Mean 25.7 days (SD 28.7 days)	Nerve root pain	Yes	Recurrent and first episode	No	No	R	Yes
144	Rossi, 1993 ⁵⁷ (Italian language)	RCT	40	Mean 42.5 (SD 10.5, range 20–65)	R	< 6 months	Nerve root pain	Yes	Recurrent	No	No	NR	R
do-uoN	vioids vs epidura	\/intradisc.	al injection										
451	Bronfort, 2000 ¹⁶¹	RCT	20	Mean 44.5 (SD 10.6)	12 (60)	\leq 3 weeks $n=6$; 4-12 weeks $n=14$	Nerve root pain and refereed pain	No	RN	No	No	Yes	No
20	Dincer, 2007 ¹⁴³	RCT	64	Mean 28 (SD 5)	46 (72)	1-12 months	Nerve root pain and refereed pain	Yes	NR	No	N	NR	No
771	Lafuma, 1997 ¹⁷²	RCT	108	Mean 42.1 (SD 10.6)	66 (61)	Mean 56 days (range 1–854 days)	Nerve root pain	NR	Recurrent and first episode	No	No	Yes	NR
362	Wilson- MacDonald, 2005 ¹⁵⁶	RCT	93	Mean 49 (range 23–79)	37 (40)	> 6 weeks, exact duration NR	Nerve root pain	Yes	R	Yes	No	Some had	Yes
846	Murata, 2009 ¹⁷⁵	RCT	246 (136 radicular pain)	Mean 68 (SD 12, range 27–90)	90 (37)	Median 31 months (SD 52 months)	Nerve root pain	No	NR	N	No	Yes	No

		Study	No. of		No. of		Type of	Confirmed	Recurrent	Included patients with	Included patients with sequestered disc (or	Any previous treatment for	Any previous back surgery for
ID no.	Author, year	design	patients	Age (years)	men (%)	Symptom duration	sciatica	by imaging?	episode	stenosis?ª	extruded)? ^a	sciatica?	sciatica?
Non-op	nioids vs inactivu	e control											
696	Dreiser, 2001 ²²³	RCT	532	Mean 47 years	234 (44)	93% within 3 days	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	NR	No
334	El-Zahaar, 1995 ²²¹	RCT	100	Mean 38.7 (range 26–58)	NR	R	Nerve root pain and referred pain	Yes	Recurrent and first episode	No	No	Yes	R
728	Finckh, 2006 ²²⁴	RCT	65	Mean 47.2 (SD 15.2)	29(48)	Median 15 days	Nerve root pain	Yes	Recurrent and first episode	No	No	NR	No
62	Gibson, 1975 ²¹⁷	Non- RCT	93	Mean 40 (range 19–67)	55 (59)	< 1–6 months	Nerve root pain and referred pain	No	NR	No	No	NR	No
97	Goldie, 1968 ²¹⁸	RCT	50	Range 15–65	26 (52)	1 week 34%; 2 weeks 56%; 3 weeks 10%	Nerve root pain and referred pain	No	NR	No	No	NR	NR
732	Grevsten, 1975 ²²⁵	RCT	36	Range 23–62	17 (47)	Days to years	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	NR	NR
312	Hedeboe, 1982 ²²⁰	RCT	39	Mean 41.8 (range 24–63)	25 (64)	< 2 weeks 36%, 2–8 weeks 28%, > 2 months 36%	Nerve root pain and referred pain	No	NR	No	No	Yes	R
816	Herrmann, 2009 ²²⁷	RCT	171	Mean 50.2 (SD12.6)	76 (44)	<72 hours	Nerve root pain	No	Recurrent and first episode	No	No	No	NR
817	Holve, 2008 ²²⁸	Q-RCT	29	Mean 43.7	17 (59)	<1 week	Nerve root pain	No	First episode	No	No	NR	NR
736	Jacobs, 1968 ²²⁶	Q-RCT	110 (50 sciatica)	NR	NR	Inclusion criteria acute and chronic	Nerve root pain	No	NR	No	No	NR	NR
534	Khoromi, 2007 ²¹⁴	RCT (cross- over)	55	Median 53 (range 19–65)	30 (55)	Median 5 years (range 0.3–37.0 years)	Nerve root pain	Yes	Recurrent and first episode	NN	R	Yes	R
													continued

Ъ	
ţ	
/ al	
β	
rec	
rde	
Ō	
the	
ort	
arat	
npê	
noc	
Ś	
∋d k	
npe	
Jroi	
5) S	
ion	
ent	
Ъ	
int	
<u>v</u> e	
lati	
terr	
ı alt	
vith	
s <	
ioic	
ġ	
-uo	
ũ ŋ	
rin	
ра	
no	
S C	
idie	
stu	
٩	
ilsi	
eta	
٦d	
tio	
ula	
doc	
ΎΓ	
tuo	
d s	
an	
/pe	
a ty	
ttic	
<u>m</u>	
ő	
of sc	
iry of sc	
mary of sc	
ummary of sc	
Summary of sc	J)
: 46 Summary of sc	(pan
3LE 46 Summary of sc	ntinued)
TABLE 46 Summary of sc	continued)

ous ry for ca?											
Any previc back surge sciati	NR	NR	No		No		NR		NR	NR	NR
Any previous treatment for sciatica?	Yes	No	Yes		Yes		Yes		Yes	Yes	R
Included patients with sequestered disc (or extruded)?ª	No	No	N		N		NN		N	No	ON
Included patients with stenosis?ª	No	No	No		No		NR		NR	Yes	9 N
Recurrent episode	Recurrent and first episode	NR	NR		Not reported		Recurrent and first episode		Recurrent and first episode	Recurrent and first episode	Recurrent and first episode
Confirmed by imaging?	No	No	Yes		No		Yes		Yes	Yes	Q
Type of sciatica	Nerve root pain	Nerve root pain	Nerve root pain		Nerve root pain and refereed pain		Nerve root pain		Nerve root pain	Nerve root pain	Nerve root pain and referred pain
Symptom duration	Range few days–6 months	Recruited at onset sciatica	Mean 68.5 months (SD 60.2, range 3–240 months)		≤3 weeks <i>n</i> =6; 4–12 weeks <i>n</i> =14		Median 5 years (range 0.3–37.0 years)		Median 5 years (range 0.3–37.0 years)	Range 1 week–8 months	Mean 6.3 weeks (range 1 week-8 months)
No. of men (%)	33 (67)	NR	18 (36)		12 (60)		30 (55)		30 (55)	51 (73)	37 (86)
Age (years)	Mean 44.8 (range 21–67)	Mean 48	Mean 39.3 (SD 8.2, range 25–60)		Mean 44.5 (SD 10.6)		Median 53 (range 19–65)		Median 53 (range 19–65)	Mean 42.8 (range 23–68)	Mean 43.2 (range 27–69)
No. of patients	52	214	50		20		55		55	70	43
Study design	RCT	RCT	RCT	lation	RCT	reatment	RCT (cross- over)		RCT (cross- over)	RCT	RCT
Author, year	Porsman, 1979 ²²²	Weber, 19936	Yildirim, 2003 ²¹⁹	ioids vs manipul	Bronfort, 2000 ¹⁶¹	ioids vs mixed t	Khoromi, 2007 ²¹⁴	ioids vs opioids	Khoromi, 2007 ²¹⁴	Kwasucki, 2002 ²²⁹ (Polish language)	Kwasucki, 1993 ²³⁰ (Polish language)
ID no.	611	665	297	Non-op.	451	Non-op	534	Non-op.	534	368	547

0	
금	
Ē	
σ	
2	
8	
Ĕ,	
Å	
Ĕ	
0	
ñ	
é	
÷	
۲	
Ĕ	
ē	
ğ	
g	
F	
8	
Š	
_∩	
-	
8	
ă	
_ت	
2	
<u>D</u>	
6	
č	
ō	
Ē	
Ъ	
٣	
ę	
Ť	
.=	
ð	
.≥	
ਯ	
Ę.	
ē	
Ë	
ω	
근	
. <u> </u>	
~	
8	
oids	
ioids	
pioids	
-opioids	
opioids	
non-opioids	
g non-opioids	
ng non-opioids	
ring non-opioids	
oaring non-opioids	
nparing non-opioids	
omparing non-opioids	
comparing non-opioids	
s comparing non-opioids	
es comparing non-opioids	
dies comparing non-opioids	
udies comparing non-opioids:	
studies comparing non-opioids	
or studies comparing non-opioids	
for studies comparing non-opioids	
s for studies comparing non-opioids	
ails for studies comparing non-opioids	
stails for studies comparing non-opioids	
details for studies comparing non-opioids	
/ details for studies comparing non-opioids	
dy details for studies comparing non-opioids	
udy details for studies comparing non-opioids	
study details for studies comparing non-opioids	
e study details for studies comparing non-opioids	
he study details for studies comparing non-opioids	
f the study details for studies comparing non-opioids	
of the study details for studies comparing non-opioids	
y of the study details for studies comparing non-opioids	
ary of the study details for studies comparing non-opioids	
mary of the study details for studies comparing non-opioids	
nmary of the study details for studies comparing non-opioids	
ummary of the study details for studies comparing non-opioids	
Summary of the study details for studies comparing non-opioids	
Summary of the study details for studies comparing non-opioids	
47 Summary of the study details for studies comparing non-opioids	
: 47 Summary of the study details for studies comparing non-opioids	
LE 47 Summary of the study details for studies comparing non-opioids	
BLE 47 Summary of the study details for studies comparing non-opioids	
ABLE 47 Summary of the study details for studies comparing non-opioids	

TABLE 4	47 Summary of the s	tudy details i	for studies comparing	non-opioi	ds with alternativ	e interventions (g	rouped by compa	rator then ordered	by author)	
ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Non-opi	ioids vs alternative/non	traditional								
801	Chen, 2009 ²¹⁵	06	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate
Non-opi	ioids vs biological agent:	S								
323	Genevay, 2004 ²¹⁶	10	6 weeks	HCS	No	No	80-100	No	Weak	Moderate
Non-opi	ioids vs disc surgery									
144	Rossi, 1993 ⁵⁷ (Italian language)	40	6 months	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
475	Dubourg, 2002 ⁸⁰	67	6 months	CCS	No	No	80-100	No	Weak	Weak
Non-opi	ioids vs epidural/intradis	cal injection								
451	Bronfort, 2000 ¹⁶¹	20	12 weeks	RCT	Unclear	Partial	80–100	NA	Moderate	Weak
20	Dincer, 2007 ¹⁴³	64	3 months Assessment at day 15, first month and third month	RCT	Unclear	Unclear	80-100	Yes	Moderate	Moderate
771	Lafuma, 1997 ¹⁷²	108	3 months	RCT	Unclear	Unclear	80–100	No	Weak	Weak
362	Wilson-MacDonald, 2005 ¹⁵⁶	93	35 days	RCT	Yes	Partial	80-100	Unclear	Moderate	Weak
846	Murata, 2009 ¹⁷⁵	246 (136 RP)	7 days	RCT	Unclear	Partial	80–100	Unclear	Weak	Weak
Non-opi	ioids vs inactive control									
696	Dreiser, 2001 ²²³	532	7 days	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
334	El-Zahaar, 1995 ²²¹	100	3 weeks	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
728	Finckh, 2006 ²²⁴	65	30 days	RCT	Yes	Partial	80-100	Yes	Moderate	Weak
62	Gibson, 1975 ²¹⁷	93	3 months	Non- RCT	No	No	80-100	Unclear	Weak	Weak
97	Goldie, 1968 ²¹⁸	20	14 days	RCT	Unclear	Yes	80-100	Yes	Moderate	Weak
732	Grevsten, 1975 ²²⁵	36	2 weeks	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
312	Hedeboe, 1982 ²²⁰	39	3 months	RCT	Partial	Partial	80-100	Unclear	Moderate	Moderate
										continued

_	
R	
ğ	
Ĵ	
5	
Ħ	
õ	
Q	
Ĵ	
ō	
÷	
Ŧ	
ъ	
>	
Р	
σ	
ē	
Ð	
ō	
5	
Ĕ	
2	
Ĕ	
÷-	
5	
Ĕ	
6	
ğ	
2	
Ĕ	
õ	
0	
≥	
-	
ŏ	
ě	
4	
ŏ	
Ъ	
9	
S	
ç	
.0	
Ħ	
ē	
~	
Ð	
Ħ	
.=	
Ð	
.≥	
ਯੋ	
<u>_</u>	
5	
ž	
ъ	
Ļ	
÷	
~	
S	
<u>ס</u> .	
0	
ā	
Ō	
ō	
È	
D	
Ē	
Ĩ	
0 0 0	
겉	
Ĕ	
8	
~	
ä	
÷Ē	
ĭ	
st	
Ľ	
ō	
4	
ŝ	
(O)	
eta	
deta	
y deta	
dy deta	
tudy deta	
study deta	
e study deta	
the study deta	
f the study deta	
of the study deta	
y of the study deta	
ary of the study deta	
nary of the study deta	
nmary of the study deta	
immary of the study deta	
Summary of the study deta	
Summary of the study deta	
7 Summary of the study deta	
47 Summary of the study deta	
E 47 Summary of the study deta	
LE 47 Summary of the study deta	

TABLE 4	47 Summary of the stu	idy details	for studies comparing	j non-opioi	ids with alternative	e interventions (g	ouped by compa	rator then ordered	by author) <i>(contir</i>	ued)
ID 10.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
816	Herrmann, 2009 ²²⁷	171	5 days	RCT	Yes	Yes	80-100	Unclear	Moderate	Weak
817	Holve, 2008 ²²⁸	29	6 months	Q-RCT	No	Partial	80-100	Yes	Moderate	Weak
736	Jacobs, 1968 ²²⁶	110 (50 NRP, 60 BP)	1 week	Q-RCT	No	Unclear	80-100	Yes	Weak	Weak
534	Khoromi, 2007 ²¹⁴	55	36 weeks	RCT (cross- over)	Yes	Yes	< 60	Yes	Moderate	Strong
611	Porsman, 1979 ²²²	52	9 days	RCT	Unclear	Yes	80-100	Yes	Weak	Moderate
665	Weber, 19936	214	4 weeks	RCT	Unclear	Unclear	80-100	No	Moderate	Weak
297	Yildirim, 2003 ²¹⁹	50	2 months	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Non-op	ioids vs manipulation									
451	Bronfort, 2000 ¹⁶¹	20	12 weeks	RCT	Unclear	Partial	80-100	NA	Moderate	Weak
Non-op	ioids vs mixed treatment									
534	Khoromi, 2007 ²¹⁴	55	36 weeks	RCT (cross- over)	Yes	Yes	< 60	Yes	Moderate	Strong
Non-op	ioids vs opioids									
534	Khoromi, 2007 ²¹⁴	55	36 weeks	RCT (cross- over)	Yes	Yes	< 60	Yes	Moderate	Strong
368	Kwasucki, 2002 ²²⁹ (Polish language)	20	19 days	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
547	Kwasucki, 1993 ²³⁰ (Polish language)	43	2 weeks	RCT	Unclear	Unclear	80100	Unclear	Weak	Weak
BP, back	k pain; NRP, nerve root pain; l	RP, radicular p	Jain.							

TABLE 48 Summary of the findings of the global effect at short-term follow-up (≤6 weeks) for studies comparing non-opioids with alternative interventions (grouped by

							Interve	ention		Contro
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)
Non-c	pioid vs inactive	control								
696	Dreiser, 2001 ²²³ (j) ^a (7.5 mg)	A	RCT	7 days	Global efficacy: good or satisfactory (vs not satisfactory or bad)	Patient	171	130	0	180
696	Dreiser, 2001 ²²³ (ii) ^a (15 mg)	A	RCT	7 days	Global efficacy: good or satisfactory (vs not satisfactory or bad)	Patient	181	138	0	180
334	El-Zahaar, 1995 ²²¹	O	RCT	3 weeks	Number of patients with pain improvement for sciatica, low back pain and sciatica, and low back pain		49	46	0.02	48
728	Finckh, 2006 ²²⁴	ح	RCT	1 day	Responders: decrease in VAS > 20 mm		5	с Ю	~	29
62	Gibson, 1975^{217}	A+C	Non- RCT	7 days	Fully recovered	Physician	45	7	0.02	44
97	Goldie, 1968 ²¹⁸	A	RCT	14 days	Relief from pain: complete (vs fair or none)	Patient	25	14	0	25

ITT using worst-

(56.27 to 2210.11) 352.00

0.04

 \sim

Data inferred from

1.71 (1.07 to 2.72)

0

117

Comments

OR (95% CI)

Withdrawal rate

Outcome

Ξ

graphs reporting

ITT using worst-

percentages

case analysis

Data inferred from

graphs reporting

1.73 (1.09 to 2.74)

0

117

percentages

case analysis

regression model

0.63 (0.21 to 1.83)

0.06

10

0.72 (0.23 to 2.23)

0

16

longitudinal

stated ITT where missing

Dropouts 5/65

2.46 (0.84 to 7.22)

<u></u>~-

 ∞

(8%): group allocation not

values assumed to be missing

at random and imputed using

continued

ò	
edl	
dno	
g,	
ons	
enti	
terv	
e in	
ativ	
tern	
h ali	
wit	
oids	
opic	
-uo	
n gr	
arir	
dmc	
s CC	
Jdie	
r sti	
s) fo	
seks	
× C	
<u>v</u>	
dn-/	
Nollo	
nfo	
terr	
lort-	
it sh	
cta	
effe	
bal	ק
glo	nue
the	ontii
s of	č (
ling	thor
find	/ au
the	d b
, of	erec
nary	ord
uшr	nen
പ്	or tł
148 148	arat
BL	mp

TABLI comp	E 48 Summar arator then orc	y of the finc dered by au	lings of th thor) <i>(con</i>	he global e ntinued)	ffect at short-term fc	llow-up (≤6	weeks)	for studies	s comparing	ido-uou	oids with a	lternative inte	erventions (grou	ped by
							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
732	Grevsten, 1975 ²⁵	A+C	RCT	2 weeks	Overall improvement (vs uncertain or not improved)		18	15	0	13	ω	0	6.25 (1.33 to 29.43)	
312	Hedeboe, 1982 ²²⁰	A	RCT	9 days	Overall pain improvement: better (vs unchanged or worst)	Patient	10	13	0	20	2	0	4.02 (1.06 to 15.28)	
816	Herrmann, 2009 ²²⁷ (j) ^b (lornoxicam)	¢	RCT	5 days	Overall assessment of efficacy and tolerability: very good or good (vs fair or poor)	Patient	57	38	0	57	32	0	1.56 (0.73 to 3.34)	ITT reported; seven patients dropped out: lornoxicam 4/57, diclofenac 2/57, placebo 1/57
816	Herrmann, 2009 ²²⁷ (ii) ^b (diclofenac)	A	RCT	5 days	Overall assessment of efficacy and tolerability: very good or good (vs fair or poor)	Patient	57	42	0	57	32	0	2.19 (0.99 to 4.81)	ITT reported; seven patients dropped out: lornoxicam 4/57, diclofenac 2/57, placebo 1/57
611	Porsman, 1979 ²²²	A+C	RCT	9 days	Treatment effective (vs not effective)		25	13	0.07	24	14	0.04	0.77 (0.25 to 2.39)	

							Interve	ntion		Control				
а ё	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
Non-	spioid vs opioids													
547	Kwasucki, 1993 ²³⁰ (Polish language)	A+C	RCT	2 weeks	Improvement in pain: cessation of symptoms or clear improvement (vs no improvement) improvement)		21	16	0	22	ω	0	5.60 (1.48 to 21.13)	Data extracted from histograms of raw pain scores
368	Kwasucki, 2002 ²²⁹ (Polish language) (I) ^c (fluvoksamine)	A + C	RCT	19 days (end of treatment)	Overall improvement: complete relief or improvement (vs no improvement)	Patient	24	1	0	22	17	0	0.88 (0.23 to 3.44)	
368	Kwasucki, 2002 ²²⁹ (Polish language) (ii) [©] (imipramine)	A+C	RCT	19 days (end of treatment)	Overall improvement: complete relief or improvement (vs no improvement)	Patient	24	90	0	22	17	0	0.59 (0.16 to 2.18)	
,, unc a Dr b He ha	elear; A, acute; A + eiser <i>et al.</i> ²²³ inclu t two treatment gr rrmann and Geert <i>v</i> e been included ii	C, acute and ded three trea oups have be sen ²²⁷ included	chronic; C, (thent group in included three treat alysis (see /	chronic. ss: oral melox. in the meta-a ment groups: <i>Figure 34</i>).	cam (NSAID) 7.5 mg (M nalysis (see <i>Figure 34</i>). Iornoxicam (LNX) 8 mg (l) (i), oral meloxi i), diclofenac 50	cam (NSA mg (ii) an	JD) 15 mg (M	ll) (ii) and oral I	olacebo (P event usin) (iii). In order g the same cc	to prevent usinç omparator twice,	g the same comparat , only the last two tre	or twice, only the atment groups

Kwasucki *et al.*²²⁸ included three treatment groups: fluvoksamine (10 mg oral) (i), impramine (25 mg oral) (ii) and tramadol (100 mg intramuscular injection) (iii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the meta-analysis (see *Figure 34*). c

ID no.	Author, year	Study design				OR (95% CI)	% weight
Inactive	e control						
696	Dreiser, 2001 ²²³	RCT				1.73 (1.09 to 2.74)	13.76
334	El-Zahaar, 1995 ²²¹	RCT			•	352.67 (56.27 to 2210.11)	8.29
728	Finckh, 2006 ²²⁴	RCT				2.46 (0.84 to 7.22)	11.48
62	Gibson, 1975 ²¹⁷	Non-RCT		+		0.63 (0.21 to 1.83)	11.51
97	Goldie, 1968 ²¹⁸	RCT		-		0.72 (0.23 to 2.23)	11.23
732	Grevsten, 1975 ²²⁵	RCT				6.25 (1.33 to 29.43)	9.44
312	Hedeboe, 1982220	RCT				4.02 (1.06 to 15.28)	10.36
816	Herrmann, 2009 ²²⁷	RCT				2.19 (0.99 to 4.81)	12.67
611	Porsman, 1979222	RCT		•		0.77 (0.25 to 2.39)	11.26
Subtota	$l (l^2 = 82.6\%, p = 0.00)$)0)		\diamond		2.61 (1.16 to 5.88)	100.00
Opioids	6						
547	Kwasucki, 1993 ²³⁰	RCT				5.60 (1.48 to 21.13)	49.88
368	Kwasucki, 2002 ²²⁹	RCT		+		0.59 (0.16 to 2.18)	50.12
Subtota	l (<i>I</i> ² = 82.2%, <i>p</i> = 0.01	8)	<			1.81 (0.20 to 16.47)	100.00
	0.0004	5		1	2210		
		Favours	control	Favours non-opi	iods		

FIGURE 34 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing nonopioids with alternative interventions. Note: weights are from random effects analysis.

The overall findings from five studies^{219,223,224,227,228} showed non-opioids to be significantly better than inactive control for reducing pain. Four studies included patients with acute sciatica, and one poorly reported and poorly conducted RCT²¹⁹ included patients with chronic sciatica (evaluating the use of oral gabapentin). As with the global effect, excluding the study with chronic sciatica improved homogeneity (I^2 = 0%), giving a pooled WMD for four studies of -6.45 (95% CI –10.60 to –2.30). Three of the four studies were moderate-quality RCTs;^{223,224,227} the remaining study²²⁸ was a Q-RCT.

Pooled analysis from two RCTs^{229,230} showed non-opioids to be significantly better than opioids for reducing pain. Both studies were poorly reported and conducted. Follow-up ranged from 14²²⁹ to 19 days.²³⁰

According to two RCTs, ^{143,175} non-opioids were significantly less effective than epidural at reducing pain at 1 week¹⁷⁵ to 1 month.¹⁴³ Both were poorly reported and of weak to moderate quality. One further poorly reported RCT¹⁵⁶ of moderate quality also found non-opioids to be statistically significantly less effective than epidural for pain relief at 35 days (p < 0.004; statistical test not stated), but did not report any summary statistics.

One poorly reported and poorly conducted RCT²¹⁵ found non-opioids to be significantly better than warming acupuncture (alternative therapy) for reducing pain in patients with chronic sciatica at the end of a 35-day treatment period.

A small HCS (323, n = 20) found biological agents to be significantly better than non-opioids for reducing pain intensity in patients with acute severe sciatica.

							Total (Ē	Baseline (SD)	mean	Final me	an (SD)	Change so (SD)	ores		
e ë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	(95% C)	h fference	Comment/conversion [€]
Non-G	pioids vs altern	native														
801	Chen, 2009 ²¹⁵ (j) ^d (WAG)	O	RCT	36 days (end of treatment)	6 9 T	Not stated	30	8	1.42 (0.37)	1.56 (0.35)	2.42 (0.33)	5.74 (0.25)		-3.32 (-3.47 tt	-3.17)	Outcome = improvement in clinical symptoms (scale and range not stated) Reported separately for: sciatica, lumbago, aggravated pain on sneezing, aggravated pain on sneezing, aggravated
801	Chen, 2009²¹⁵ (ij) ^d (PIG)	U	RCT	36 days (end of treatment)	Feg	Not stated	30	90	1.42 (0.37)	1.75 (0.32)	2.42 (0.33)	2.75 (0.32)		-0.33 (-0.49 tt	0.17)	pain on deraecation Outcome = improvement in clinical symptoms (scale and range not stated) Reported separately for: sciatica, lumbago, aggravated pain on coughing, aggravated pain on sneezing, aggravated pain on defecation
лоп-с	pioids vs biolog	tical agents														
323	Genevay, 2004 ²¹⁶	A	HCS	6 weeks	Leg	VAS (0-100)	10	10	75.1 (14.2)	74.4 (12.9)	52.9 (25.1)	12.4 (13.2)		40.50 (22.92 to	0 58.08)	
лоп-с	npioids vs epidu	'ral/intradiscal	injection													
20	Dincer, 2007 ¹⁴³	A+C	RCT	1 month	Overall	VAS (0-100)	30	34	68 (10)	69 (10)	44 (13)	32 (11)		12.00 (6.06 to	17.94)	
																po nuitado

TABLE 49 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author) (*continued*)

	Comment/conversion [©]	SD imputed from weighted average Subgroup analysis based on 136/246 (55%) with radicular pain: intervention 71/122, control 65/124 Dropouts 8/246 (3%): no further details	No data other than <i>p</i> -values presented Dropouts 23%: non- opioids 12/44, epidural 8/44		SD estimated from SE ITT using LOCF Dropouts 32/532 (6%): low dose 6/171, placebo 12/180	SD estimated from SE ITT using LOCF Dropouts 32/532 (6%): high dose 14/181, placebo 12/180
	Mean difference (95% Cl) ^b	24.00 (16.37 to 31.63)	There was a significant difference in pain relief between the two groups with the epidural group being better (p < 0.004)		-6.00 (-11.54 to -0.46)	-5.00 (-10.54 to 0.54)
cores	Control				40 (26.83)	-40 (26.83)
Change s (SD)	Intervention				-46 (26.15)	–45 (26.91)
ın (SD)	Control	43 (22.48)				
Final mea	Intervention	67 (22.86)				
e mean	Control	69			76 (10.7)	76 (10.7)
Baselin (SD)	Intervention	74			75.6 (11.4)	75.4 (10.6)
(1)	Control	71	36		180	180
Total	Intervention	65	36		171	181
	Scale (range) ^a	VAS (0-100)	Oxford pain chart		VAS (0-100)	VAS (0-100)
	Location	бел	Overall		Overall	Overall
	Follow- up	7 days	35 days		7 days	7 days
	Study design	RCT	RCT		RCT	RCT
	Chronicity	o	Ϋ́Ν.	ive control	A	<
	Author, year	Murata, 2009 ¹⁷⁵	Wilson- MacDonald, 2005 ¹⁵⁶	oioids vs inacti	Dreiser, 2001 ²²³	Dreiser, 2001 ²²³
	Ωġ	846	362	Non-o	696	696

Image: Second								Total ((U	Baselin (SD)	e mean	Final me	an (SD)	Change (SD)	scores		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	thor, year Chronicity design up Location (range)	Study Follow- Scale Chronicity design up Location (range)	Study Follow- Scale design up Location (range)	Follow- Scale up Location (range)	Scale Location (range)	Scale (range)	3	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion [©]
57 57 84.9 83.2 62.9 69.5 -22.0 -13.7 -6.60 Final mean derived from weighted from weighted average (7.5) (7.0) (22.86) (23.67) (23.67) (-15.14 to 1.94) imputed from weighted average Reading (7.5) (7.0) (22.86) (23.67) (23.67) -6.60 imputed from weighted average Reading (7.5) (7.0) (22.86) (23.67) -13.7 -6.60 imputed from weighted average Reading (7.5) (7.0) (22.86) (23.67) -13.7 -6.60 imputed from weighted average Reading (7.6) (22.86) (23.67) -13.7 -6.60 imputed from weighted average Reading (7.6) (22.86) (23.67) -13.7 -6.60 imputed from weighted average Reading (7.6) (7.6) (22.86) (23.67) -14.9 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60<	106 ²²⁴ A RCT 30 days Leg VAS 06 ²²⁴ (0-100	A RCT 30 days Leg VAS (0-100	RCT 30 days Leg VAS (0-100	30 days Leg VAS (0-10)	Leg VAS (0-10)	(0-100)		31	29	67.1 (22.1)	63.3 (20.7)	36.1 (22.1)	45.3 (20.7)	- 33		-9.20 (-20.03 to 1.63) Significantly greater pain reduction in steroid group during the first 3 days (p = 0.04), but both groups similar after 3 days (p = 0.22); linear spline regression model	Final mean calculated using change score and baseline SD used Dropouts 5/65 (8%): group allocation not stated ITT where missing values assumed to be missing at random and imputed using longitudinal regression model
	rmann, A RCT 8 hours Overall VAS 09 ²²⁷ (0–10	A RCT 8 hours Overall VAS (0-10)	RCT 8 hours Overall VAS (0-10)	8 hours Overall VAS (0-10	Overall VAS (0-10	VAS (0-10)	Ô	22	57	84.9 (7.5)	83.2 (7.0)	62.9 (22.86)	69.5 (23.67)	-22.0	-13.7	-6.60 (-15.14 to 1.94)	Final mean derived from change scores and SD imputed from weighted average Treatment administered over 4 days (with an optional 5 days), but PID was measured at day 1 and therefore only evaluates the effectiveness of the loading dose Mean PID using VAS (0–100) compared with baseline

TABLE 49 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author) (continued)

	e Comment/conversion⁰	Data derived from histograms of pain scores	Data derived from histograms of pain scores	ouncture group; WMG, nd western medicine – oral (see <i>Figure 35</i>). :ame comparator twice, only
	Mean differencı (95% Cl) ⁶	-20.00 (-33.16 to -6.84)	-12.50 (-26.96 to 1.96)	WAG, warming acur ng moxa (WAG) (i) ar n the meta-analysis p prevent using the s
e scores	Control			ions group; ied by burni n included ir). In order to
Chang (SD)	Intervention			point inject edles warm s have beei njection) (iii
an (SD)	Control	50.0 (25)	50.0 (25)	ence; PIG, up with nee nent groups muscular ir
Final me	Intervention	30 (20)	37.5 (25)	ansity differ ancture gro third treatn 00 mg intra
mean	Control	70.0 (17.5)	70.0 (17.5)	ID, pain intr alics. ming acupu e first and ramadol (1
Baseline (SD)	Intervention	67.5 (15)	75 (25)	ng scale; P y study in it w-up. P(G) (ii), war vice, only th (ii); and t
<i>(u</i>)	Control	52	53	rrical rati ported b st to follc points (F arator tv 5 mg ora
Total	Intervention	24	24	S, nume ssults rel tients los into acu ne comp amine (2
	Scale (range) ^a	NRS (0-4)	NRS (0-4)	forward; NR le scores); re sions and pa' mine (2 mg) tsing the sar ral) (i), imipre ee Figure 35
	Location	Overall	Overall	ation carried Iparability. ven to chang selline exclus is of anisoda to prevent u ine (10 mg o a-analysis (s
	Follow- up	19 days	19 days	F, last observ -100 for com preference gi data, post-ba point injectior in) (iii). In order ups: fluvoxam
	Study design	RCT	RCT	chronic; LOC chronic; LOC cores (with a 1 for missing nent groups: 3 days (WMG been include
	Chronicity	A+C	A+C	nd chronic; C, an converted tr is or change sr has been used ad three treatm 2 g daily for 10 cluded three tr it groups have
	Author, year	Kwasucki, 2002 ²²⁹ (Polish language) (i) ^e (fluvoxamine)	Kwasucki, 2002 ²²⁹ (Polish language) (ii) ^e (imipramine)	3; A + C, acute a i medicine grout results have be ad on final mear term 'dropouts' a r al. ²¹⁵ includ ssolide (NSAIDs) scucki et al. ²²⁹ in ast two treatmei ast two treatmei
	ם ë	368	368	A, acutt westerr westerr a The b Base c The c The d Cher d Cher e Kwa e Kwa

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.


FIGURE 35 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing nonopioids with alternative interventions. Note: weights are from random effects analysis.

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 50* and the accompanying forest plot (*Figure 36*). Epidural injections were compared with inactive control, epidural injections and biological agents. Three studies^{6,216,228} included only patients with acute sciatica and the remaining study¹⁴³ included patients with either acute or chronic symptoms. The duration of follow-up ranged from 4^{6,143,228} to 6 weeks.²¹⁶

Two studies^{6,228} compared non-opioids with inactive control; there was an overall non-statistically significant finding in favour of inactive control at 4 weeks. One was a moderate-quality RCT⁶ that did not report the methods of randomisation and allocation concealment and the other was a Q-RCT.²²⁸

One moderate-quality RCT¹⁴³ found epidural to be significantly better than non-opioids for improving functional status in patients with acute or chronic sciatica. The methods of randomisation and allocation concealment were not stated.

A small (n = 20) historical cohort study²¹⁶ found biological agents to be significantly better than non-opioids for improving functional status in patients with acute severe sciatica at 6 weeks.

or then	
nparato	
by con	
ouped	
ions (gi	
tervent	
ative in	
altern	
ids with	
oido-no	
aring nc	
compa	
studies	
eks) for	
(≤6 wee	
) dn-mo	
erm foll	
short-te	
DMs at	
of CSC	
indings	
of the f	
mmary	thor)
50 Su	d by au
TABLE	orderec

						Total (n		Baseline (SD)	mean	Final mea	л (SD)	Change ((SD)	scores		
Ωë	Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% C)ª	Comment/ conversion ^b
Non- 323	<i>opioids vs biologic.</i> Genevay, 2004 ²¹⁶	al agents A	HCS	6 weeks	RMDQ	10	10	15.5 (2.9)	17.8 (3.3)	11.1 (4.6)	5.8 (5.5)			1.05 (0.10 to 1.99)	
Non- 20	<i>opioids vs epidura</i> Dincer, 2007 ¹⁴³	<i>l/intradiscal in</i> A+C	<i>ijection</i> RCT	1 month	IQO	30	34	34.4 (6.7)	35.8 (6.7)	22.2 (8.6)	17 (7.3)	-12.2	-18.8	0.66 (0.15 to 1.16)	
Non- 817	<i>opioids vs inactive</i> Holve, 2008 ²²⁸	control A	Q-RCT	4 weeks	RMDQ	13	14	16	16	8 (4.6)	9.2 (4.47)			-0.26 (-1.02 to 0.49)	Final SD imputed from weighted mean of SDs from other studies
665	Weber, 1993 ⁶	A	RCT	4 weeks	Disability, Roland's Functional Test (0–17)	120	94	55 (14)	54 (12)	22 (14)	16 (14)	- 33	- 38	0.43 (0.16 to 0.70)	ITT not used Dropouts 2/29 (7%): intervention 2/15, control 0/14
A, act a Bé b Th	tte; A + C, acute and tsed on final means term 'dropouts' ha	l chronic. or change scori	es (with a pre r missing dat	sference giver ta, post-baseli	1 to change scol	res). Ind patient	ts lost to	follow-up.							

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.



FIGURE 36 Summary of the findings of CSOMs at short-term follow-up (≤6 weeks) for studies comparing non-opioids with alternative interventions. Note: weights are from random effects analysis.

Non-opioid results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 51* and the accompanying forest plot (*Figure 37*). Non-opioids were compared with inactive intervention, epidural injections, disc surgery, opioids and mixed treatment. Two studies^{220,80} included only patients with acute sciatica and the remaining three studies^{175,214,220} included only patients with chronic sciatica. The duration of follow-up ranged from 9 weeks²¹⁴ to 6 months.^{57,175}

Two moderate-quality RCTs^{214,220} compared non-opioids with inactive control; there was a non-statistically significant finding in favour of non-opioids, for both acute and chronic sciatica. One study²¹⁴ was a four-arm crossover RCT with a high dropout rate; only 44% of patients who completed the study were included in the analysis.

One poor-quality RCT¹⁷⁵ reported non-statistically significant findings in favour of epidural, compared with non-opioids, for adequate recovery from leg pain at 24 weeks. The findings were based on a subgroup analysis of 136/246 (55%) patients with chronic radicular pain.

Two studies compared disc surgery with non-opioids. One poorly reported CCS⁸⁰ found nonopioids to be more effective than disc surgery for recovery or improvement in patients with acute sciatica, but the findings were not statistically significant. A second poorly conducted study⁵⁷ found that more patients in the surgery group (68%) than in the non-opioids group (55%) were satisfied with cure, but the findings were reported only as percentages, and the number of patients in each treatment group was not stated. The study was essentially two studies that were very poorly reported, and which included the comparison of two surgical procedures (percutaneous discectomy and microdiscectomy) with medical treatment. Patients (n = 40) were initially divided into two groups according to the type of disc herniation they had, with patients in one group randomised to one of two surgical procedures; the other group does not appear to have been randomised.

A moderate-quality crossover RCT²¹⁴ compared non-opioids with opioids or a combination of both opioids and non-opioids (mixed treatments). There was no statistically significant difference between non-opioids and opioids, but combination therapy (mixed treatments) resulted in

D Autor, year Study Buy Currents Test and test a								Intervei	ntion		Control				
Monopolies redictanget Reduction of pain Patient 2 55 55 51 54 56 54 56 56 56 56 56 56 56 56 56 56 </th <th>₽ë</th> <th>Author, year</th> <th>Chronicity</th> <th>Study design</th> <th>Follow- up</th> <th>Outcome measure</th> <th>Perspective</th> <th>Total (<i>n</i>)</th> <th>Outcome (<i>n</i>)</th> <th>Withdrawal rate</th> <th>Total (<i>n</i>)</th> <th>Outcome (<i>n</i>)</th> <th>Withdrawal rate</th> <th>0r (95% CI)</th> <th>Comments</th>	₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0r (95% CI)	Comments
14 Resi, 1303* C Norld Falcender free Statinative detections Instantion Resi, 1303* C Norld Falcender free Statinative detections Instantion Resi, 1303* C Norld Resi, 1303* Statinative detections Statinative detections Instantion Resi, 1303* C Norld Resi, 1303* Statinative detections Statin	Non-c	pioids vs disc s	urgery												
475 Duburg, A CS 6 months Recovery improvement (s)	144	Rossi, 1993 ⁵⁷ (Italian language)	U	Non-RCT	6 months	Reduction of pain	Patient	<	89 S		~	ß			Study included three comparative groups, but the two surgical groups were combined for the analysis of global effect Total number of participants was 40, but number in each group not stated and results reported only as percentages, therefore could not include in the meta-analysis
Mon-opioids vs epidural/intradiscal injection B46 Murata, C RCT 24 weeks Satisfactory Physician 65 5 7 1 1 7 0.45 Subgroup analysis of vith radicular pain: intervention 846 Murata, C RCT 24 weeks Satisfactory Physician 65 5 7 1 1 7 0.45 Subgroup analysis of vith radicular pain: intervention 11.39 with radicular pain: intervention 11.39 with radicular pain: intervention 11.39 with radicular pain: intervention 11.31 2001/152, control 65/124 2016/163/124 2016/163/124 2016/163/124 20110 201110 201110	475	Dubourg, 2002 ⁸⁰	A	CCS	6 months	Recovery improvement (vs failure) according to change in VAS and muscle strength		25	24	0.11	32	25	0.18	6.72 (0.77 to 58.79)	
846 Murata, C RCT 24 weeks Satisfactory Physician 65 5 7 71 11 ? 0.45 Subgroup analysis of clinical outcome clinical outcome (0.15 to 136/246 (55%) patients (0.15 to 136/246 (55%) patients (vs unsatisfactory results) control 65/124 Eight patients dropped out, group allocation or and group and stated of group and stated outcome out, group allocation or additional patients dropped out group and stated outcome out group and stated outcome out group and stated outcome (vs unsatisfactory results) control 65/124 Eight patients dropped out, group allocation or additional patients dropped out group allocation or additional patients dropped ou	Non-G	upioids vs epidu	ral/intradiscal	injection											
	846	Murata, 2009 ¹⁷⁵	U	RCT	24 weeks	Satisfactory clinical outcome (vs unsatisfactory results)	Physician	<u>9</u> 2	a	℃.	71		с.	0.45 (0.15 to 1.39)	Subgroup analysis of 136/246 (55%) patients with radicular pain: intervention 71/122, control 65/124 Eight patients dropped out, group allocation or radicular pain not stated

DOI: 10.3310/hta15390

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 51 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author) (*continued*)

•			,		、 、									
							Interver	ıtion		Control				
ē	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0r (95% CI)	Comments
Non-G	pioids vs inactiv	ive control												
312	Hedeboe, 1982 ²²⁰	A	RCT	3 months	Overall pain improvement: better (vs unchanged or worst)	Patient	19	Q	0	20	Ŋ	0	1.38 (0.34 to 5.62)	
534	Khoromi, 2007 ²¹⁴	C	RCT (crossover)	9 weeks (end of treatment)	Global pain relief (GPR): worse pain or no pain relief		33	.	0.40	32	13	0.42	1.26 (0.45 to 3.51)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Non-G	npioids vs mixea	1 treatment												
534	Khoromi, 2007 ²¹⁴ (opioids + non- opioids)	C	RCT (crossover)	9 weeks (end of treatment)	Global pain relief (GPR): worse pain or no pain relief		28	18	0.49	32	13	0.42	0.35 (0.12 to 1.01)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Non-G	npioids vs opioia	ls												
534	Khoromi, 2007 ²¹⁴	O	RCT (crossover)	9 weeks (end of treatment)	Global pain relief (GPR): worse pain or no pain relief		31	12	0.44	32	13	0.42	0.92 (0.34 to 2.53)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)

?, unclear; A, acute; C, chronic

ID no.	Author, year	Study design				OR (95% CI)	% weight
Disc su	irgery						
475	Dubourg, 2002 ⁸⁰	CCS	+	•		6.72 (0.77 to 58.79)	100.00
Epidura	al/intradiscal injectio	on					
846	Murata, 2009175	RCT	•	_		0.45 (0.15 to 1.39)	100.00
Inactive	e control						
312	Hedeboe, 1982 ²²⁰	RCT		•		1.38 (0.34 to 5.62)	34.80
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		•		1.26 (0.45 to 3.51)	65.20
Subtota	$l (l^2 = 0.0\%, p = 0.91)$	7)	<	>		1.30 (0.57 to 2.98)	100.00
Mixed t	reatment						
534	Khoromi, 2007 ²¹⁴	RCT (crossover)				0.35 (0.12 to 1.01)	100.00
Opioids	6						
534	Khoromi, 2007 ²¹⁴	RCT (crossover)				0.92 (0.34 to 2.53)	100.00
					1		
		0.017	1		58.8		
		Fa	vours control	Favours non-opiod	ls		

FIGURE 37 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing non-opioids with alternative interventions. Note: weights are from random effects analysis.

marginally statistically significant better outcomes than non-opioids used alone. Only 28 patients (44%) who completed the study were included in the analysis.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 52* and the accompanying forest plot (*Figure 38*). Non-opioids were compared with inactive control and disc surgery, opioids and mixed treatments. Two studies^{80,228} included patients with acute sciatica and two studies^{214,219} included patients with chronic sciatica. The duration of follow-up ranged from 2²¹⁹ to 6 months.^{80,228}

Pooled analysis from three studies^{214,219,228} showed non-opioids to be significantly better than the inactive control for reducing the overall pain of acute²²⁸ or chronic^{214,219} sciatica. One was a fourarm crossover RCT, one was a Q-RCT²²⁸ and the other a poor-quality RCT.²¹⁹ Follow-up ranged from 2²¹⁹ to 6 months.²²⁸ Two studies were of moderate quality.^{214,228}

One poorly reported CCS⁸⁰ found no important difference between non-opioids and disc surgery for reducing pain intensity of acute sciatica at 6 months.

One moderate-quality crossover RCT²¹⁴ compared non-opioids with opioids or a combination of both opioids and non-opioids (mixed treatments) for reducing pain intensity at 9 weeks. There was a non-statistically significant difference between the intervention groups in favour of non-opioids for both comparators. Only 28 patients (44%) who completed the study were included in the analysis.

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 53* and the accompanying forest plot (*Figure 39*). Non-opioids were compared with the inactive control,

TABLE 52 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author)

	Comment/conversion ^c		Dropouts 7/67 (10%): intervention 4/39, control 3/28		SD imputed from weighted average	ITT not used Dropouts 2/29 (7%): intervention 2/15, control 0/14	Dropouts: intervention 2/25, control 5/25	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
	Mean difference (95% Cl)⁵		1.60 (–8.19 to 11.39)		-24.00 (-44.04 to	-3.96)	-26.66 (-38.35 to -14.97)	–7.00 (–21.14 to 5.38)
inge scores)	Control							
Cha (SD	Intervention							
ean (SD)	Control		13.2 (18.8)		32 (30.1)		45.33 (19.67)	37.0 (27)
Final m	Intervention		14.8 (20.6)		8 (22.76)		18.67 (19.33)	30.0 (27)
mean	Control		52.2 (28.5)		62		56 (22.33)	49 (24.3)
Baseline (SD)	Intervention		47.7 (34)		76		53.33 (31.33)	49 (24.3)
5	Control		36		14		20	28
Total (r	Intervention		28		13		23	28
	Scale (range) ^a		VAS (0-100)		RMDQ subscale	(0-2)	NRS (03)	NRS (0-10)
	Location		Overall		Overall		Overall	Leg
	Follow-up		6 months		6 months		2 months	9 weeks (end of treatment)
	Study design		CCS		Q-RCT		RCT	RCT (crossover)
	Chronicity	; surgery	A	stive control	A		O	S
	Author, year	nioids vs disc	Dubourg, 2002 ⁸⁰	nioids vs inau	Holve, 2008 ²²⁸		Yildirim, 2003 ²¹⁹	Khoromi, 2007 ²¹⁴
	<u> </u>	lo-uoN	475	lo-uoN	817		297	534
		1	-	-				

							Total (<i>n</i>)		Baseline m (SD)	ean	Final mea	ın (SD)	Change scol (SD)	es	
<u>o</u> ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Control Intervention	Mean difference (95% CI) ^b	Comment/conversion ^c
Non-t	ipioids vs m	ixed treatment													
534	Khoromi, 2007 ²¹⁴	O	RCT (crossover)	9 weeks (end of treatment)	Leg	NRS (0-10)	28	28	49 (24.3)	49 (24.3)	30.0 (27)	38.0 (24)		-8.00 (-21.38 to 5.38)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Non-	do sv sbioidc	ioids													
534	Khoromi, 2007 ²¹⁴	C	RCT (crossover)	9 weeks (end of treatment)	Leg	NRS (0-10)	28	28	49 (24.3)	49 (24.3)	30.0 (27)	34 (28)		-4.00 (-18.41 to 10.41)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
A, act a Th	te; C, chronic 9 results have	; NRS, numerical been converted t	rating scale. o a scale of 0-	100 for compa	rability.										

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

Based on final means or change scores (with a preference given to change scores). The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. c b a A

ID no.	Author, year	Study design		WMD ((95% CI)	% weight
Disc su	rgery					
475	Dubourg, 2002 ⁸⁰	CCS		1.60	(–8.19 to 11.39)	100.00
Inactive	e control					
817	Holve, 2008 ²²⁸	Q-RCT	•	-24.00	(–44.04 to –3.96)	24.80
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		-7.00	(–21.14 to 7.14)	35.00
297	Yildirim, 2003 ²¹⁹	RCT		-26.66	(-38.35 to -14.97)	40.20
Subtota	l (<i>l</i> ² = 56.8%, <i>p</i> = 0.0	099)		-19.12	(-32.22 to -6.02)	100.00
Mixed t	reatment					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)			(–21.38 to 5.38)	100.00
Opioids	;					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		-4.00	(–18.41 to 10.41)	100.00
Note: w	eights are from rand	om effects analysis			I	
		-	-44 0	4	4	
			Favours non-opiods	Favours control		

FIGURE 38 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing non-opioids with alternative interventions. Note: weights are from random effects analysis.

and epidural injections, opioids and mixed treatments. One study²²⁸ included patients with acute sciatica and two studies^{143,214} included patients with either acute or chronic sciatica. The duration of follow-up ranged from 9 weeks²¹⁴ to 6 months.²²⁸

Pooled analysis of two studies showed a non-statistically significant finding in favour of nonopioids at 2²¹⁴–6²²⁸ months, when compared with inactive control. One study was a moderatequality, four-arm crossover RCT²¹⁴ with adequate randomisation and allocation concealment but only 44% of patients were included in the analysis. The second study was a Q-RCT.²²⁸ Patients were sequentially entered into the study by the pharmacy department, with odd-numbered patients given prednisone and even-numbered patients given the placebo. The principal investigator and research nurse were blind to the specific group allocation and to the methods used to make that assignment.

One moderate-quality RCT¹⁴³ reported non-statistically significant findings in favour of epidural compared with non-opioids for improving functional status at 3 months' follow-up. The methods of randomisation and allocation concealment were not stated.

A moderate-quality, crossover RCT²¹⁴ compared non-opioids with opioids or a combination of opioids and non-opioids (mixed treatments). There was no statistically significant difference between the intervention groups for either comparison.

Results at long-term follow-up (>6 months)

Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 54* and the accompanying forest plot (*Figure 40*).

One study²¹⁵ compared the overall success of the use of non-opioids or warming acupuncture in patients with chronic sciatic at 1 year's follow-up. The study was a poorly conducted RCT

þ	
ed	
dnc	
Jb)	
su	
ntio	
Vel	
ntei	
/e ii	
ati∖	
em	
alt	
vith	
s S	
ioi	
do	
-Lo	
дD	
arin	
npa	
Sor	
es	
indi	
rst	
) fo	
ths	
DO	
6 п	
VI	
sto	
sek	
Š	
Ś	
dņ	
-MC	
<u>o</u>	
ц	
-ter	
Ė	
edii	
Ĕ	
sat	
Š	
ğ	
of	
gs	٩.
din	ţ
fin	y aı
the	à T
ę	ere
ary	orde
ШШ	en (
Sur	Ę
ŝ	ator
щ	Jari
BL	mp
-	

						Total (/	Ē	Baseline (SD)	mean	Final mea	n (SD)	Change s (SD)	scores		
В	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^a	Comment/conversion ^b
-uoN	opioids vs et	pidural/intradis	scal injection												
20	Dincer, 2007 ¹⁴³	A + C	RCT	3 months	IQO	30	34	28.4 (5.4)	35.8 (6.7)	20.3 (10.1)	16.2 (9.4)	-8-	-19.6	0.42 (0.08 to 0.92)	Final SD imputed from weighted mean of SDs for RMDQ at short-term follow-up Dropouts 2/29 (7%): intervention 2/15, control 0/14
-uoN	opioids vs in	active control													
817	Holve, 2008 ²²⁸	A	Q-RCT	6 months	RMDQ	13	14	16	16	1.1 (4.6)	2.1 (4.47)			-0.22 (-0.98 to 0.54)	
534	Khoromi, 2007 ²¹⁴	S	RCT (crossover)	9 weeks (end of treatment)	IOO	28	28	30 (15)	30 (15)	27.5 (16.7)	30.5 (15.9)			0.18 (-0.71 to 0.34)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
-uoN	opioids vs m	nixed treatmen	t												
534	Khoromi, 2007 ²¹⁴	S	RCT (crossover)	9-weeks (end of treatment)	IOO	28	28	30 (15)	30 (15)	27.5 (16.7)	27.4 (15.4)			0.01 (-0.52 to 0.53)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Non-	to sn spioids	pioids													
534	Khoromi, 2007 ²¹⁴	C	RCT (crossover)	9 weeks (end of treatment)	IOO	28	28	30 (15)	30 (15)	27.5 (16.7)	25.7 (16.5)			0.11 (-0.42 to 0.63)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
A, acı a Ba b Th	ute; A + C, act ised on final r e term 'dropo	ute and chronic; means or chang uts' has been u	; C, chronic. Je scores (with a used for missing	a preference gi j data, post-ba	ven to chang seline exclus	je scores). sions and p	patients lo	st to follow-L	ġ						

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Epidura	al/intradiscal injection	on				
20	Dincer, 2007 ¹⁴³	RCT			- 0.42 (-0.08 to 0.92)	100.00
Inactive	e control					
817	Holve, 2008 ²²⁸	Q-RCT			-0.22 (-0.98 to 0.54)	32.45
534	Khoromi, 2007 ²¹⁴	RCT (crossover)			-0.18 (-0.71 to 0.34)	67.55
Subtota	al ($l^2 = 0.0\%$, $p = 0.93$	38)			-0.20 (-0.63 to 0.24)	100.00
Opioids	3					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		•	0.11 (-0.42 to 0.63)	100.00
Mixed	treatment					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		*	0.01 (-0.52 to 0.53)	100.00
			-0.978	0	0.978	
			Favours non-opiods	Favours contro	1	

FIGURE 39 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing non-opioids with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Alterna	tive						
801	Chen, 2009 ²¹⁵	RCT		•		– 0.31 (0.07 to 1.29)	100.00
			0.0723		1	13.8	
				Favours control		Favours non-opiods	

FIGURE 40 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing nonopioids with alternative interventions. Note: weights are from random effects analysis.

and found a non-statistically significant difference between the intervention groups, in favour of acupuncture.

Pain intensity at long-term follow-up

No study reported long-term outcome in terms of pain intensity.

Condition-specific outcome measures at long-term follow-up

No study reported long-term outcome in terms of CSOMs.

Analysis of adverse effects for non-opioids

The results for the occurrence of any reported adverse effects are presented in *Table 55* and the accompanying forest plot (*Figure 41*).

The incidence of adverse effects associated with non-opioids was statistically significantly greater than the incidence of adverse events associated with inactive control and significantly lower than the incidence of adverse events associated with mixed treatments (opioids plus non-opioids). Pooled analyses showed no statistically significant differences between the intervention groups for the number of adverse effects when comparing non-opioids with disc surgery, epidural, mixed treatments (morphine plus nortriptyline) or opioids.

S
S
₽
ĥ
ž
ē
E
Ð
<u>Š</u> .
at
Ξ
te
a
0
5 U
Ö
<u>0</u> .
g
ž
Ъ
Č
p
÷E
g
Ĭ
ъ
Õ
ŝ
i,≝
Ĕ
S
5
Ť
)S
È
ъ
E
9
$^{\wedge}$
d
_
7
-∧-I
llow-l
follow-i
n follow-ı
erm follow-u
-term follow-ı
g-term follow-u
ong-term follow-u
t long-term follow-ı
at long-term follow-u
ct at long-term follow-ı
fect at long-term follow-u
effect at long-term follow-u
al effect at long-term follow-u
bal effect at long-term follow-u
jlobal effect at long-term follow-u
global effect at long-term follow-u
he global effect at long-term follow-
f the global effect at long-term follow-
of the global effect at long-term follow-r
gs of the global effect at long-term follow-
ings of the global effect at long-term follow-
idings of the global effect at long-term follow-i
findings of the global effect at long-term follow-
e findings of the global effect at long-term follow-
the findings of the global effect at long-term follow-
of the findings of the global effect at long-term follow-
y of the findings of the global effect at long-term follow-
ary of the findings of the global effect at long-term follow-
mary of the findings of the global effect at long-term follow-
mmary of the findings of the global effect at long-term follow-u
Summary of the findings of the global effect at long-term follow-
Summary of the findings of the global effect at long-term follow-u
54 Summary of the findings of the global effect at long-term follow-
E 54 Summary of the findings of the global effect at long-term follow-u
ILE 54 Summary of the findings of the global effect at long-term follow-u
ABLE 54 Summary of the findings of the global effect at long-term follow-u

							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	or (95% CI)	Comments
-non	opioid vs alterni	ative												
801	Chen, 2009 ²¹⁵ (j) ^a (WAG)	O	RCT	1 year	Success: cured or improved (vs no improvement)	Patient	30	22	0	30	27	0	0.31 (0.07 to 1.29)	Data inferred from graphs reporting percentages ITT using worst-case analysis (with non-opioids
801	Chen, 2009 ²¹⁵ (ii) ^a (PIG)	C	RCT	1 year	Success: cured or improved (vs no improvement)	Patient	30	22	0	30	19	0	1.59 (0.53 to 4.77)	as the control group) Data inferred from graphs reporting percentages ITT using worst-case analysis (with non-opioids
ي م ت م م	ronic. Tonic. Ton <i>et al.</i> ²¹⁵ incluc oup) (1) and weste sluded in the met	ded three treatme srn medicine – or a-analysis (see F	ant groups: r al nimesolid ioure 40.	oint injectiou le (NSAIDs) 2	ns of anisodamine (2 2 g daily for 10 days	2 mg) into acupoin (western medicin	its (point i	njection groul	p) (ii), warming (acupunctu the same	ire group wit comparator 1	h needles warm. wice, only the fil	ed by burning mo	as the control group) wa (warming acupuncture ment groups have been

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

 TABLE 55
 Summary of the findings of any adverse effect for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Non-o	opioids vs alternative tr	eatment					
801	Chen, 2009 ²¹⁵ (warming acupuncture)	RCT	NR	NR	NR	NR	
801	Chen, 2009 ²¹⁵ [anisodamine (2 mg) point injections]	RCT	NR	NR	NR	NR	
Non-o	opioids vs biological ag	ent					
323	Genevay, 2004 ²¹⁶	HCS	NR	NR	NR	NR	
Non-o	opioids vs disc surgery						
475	Dubourg, 2002 ⁸⁰	CCS	0	28	1	39	0.45 (0.02 to 11.46)
144	Rossi, 1993 ⁵⁷ (microdiscectomy)	RCT	1	NR	0	NR	, , , , , , , , , , , , , , , , , , ,
144	Rossi, 1993 ⁵⁷ (percutaneous discectomy)	RCT	1	NR	0	NR	
Non-o	opioids vs epidural						
451	Bronfort, 2000 ¹⁶¹	RCT	4	6	6	6	0.14 (0.01 to 3.63)
20	Dincer, 2007143	RCT	0	30	2	34	0.21 (0.01 to 4.62)
771	Lafuma, 1997172	RCT	NR	NR	NR	NR	
362	Wilson-MacDonald, 2005 ¹⁵⁶	RCT	NR	NR	NR	NR	
846	Murata, 2009 ¹⁷⁵	RCT	NR	NR	NR	NR	
Non-o	opioids vs inactive cont	rol					
696	Dreiser, 2001 ²²³ (low dose)	RCT	10	171	9	180	1.18 (0.47 to 2.98)
696	Dreiser, 2001 ²²³ (high dose)	RCT	13	181	9	180	1.47 (0.61 to 3.53)
334	El-Zahaar, 1995 ²²¹	RCT	3	50	0	50	7.44 (0.37 to 148.00)
728	Finckh, 2006224	RCT	3	31	0	29	7.25 (0.36 to 147.00)
62	Gibson, 1975 ²¹⁷	Non-RCT	NR	NR	NR	NR	
97	Goldie, 1968 ²¹⁸	RCT	8	25	5	25	1.88 (0.52 to 6.84)
732	Grevsten, 1975225	RCT	3	18	4	18	0.70 (0.13 to 3.70)
312	Hedeboe, 1982220	RCT	6	19	1	20	8.77 (0.94 to 81.70)
816	Herrmann, 2009 ²²⁷	RCT	11	57	7	57	1.71 (0.61 to 4.78)
816	Herrmann, 2009 ²²⁷ (diclofenac)	RCT	6	57	7	57	0.84 (0.26 to 2.68)
817	Holve, 2008 ²²⁸	Q-RCT	0	15	0	14	
736	Jacobs, 1968226	Q-RCT	28	55	20	55	1.81 (0.85 to 3.89)
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	37	55	28	55	1.98 (0.92 to 4.29)
611	Porsman, 1979222	RCT	1	25	1	24	0.96 (0.06 to 16.24)
665	Weber, 19936	RCT	22	120	13	94	1.4 (0.66 to 2.95)
297	Yildirim, 2003 ²¹⁹	RCT	2	23	0	20	4.77 (0.22 to 105.00)

TABLE 55 Summary of the findings of any adverse effect for studies comparing non-opioids with alternative interventions (grouped by comparator then ordered by author) (continued)

ID		Study	No. of events in intervention	No. of participants in intervention	No. of events in control	No. of participants in control	
no.	Author, year	design	group	group	group	group	OR (95% CI)
Non-o	pioids vs manipulation						
451	Bronfort, 2000 ¹⁶¹	RCT	4	6	3	7	2.67 (0.28 to 25.64)
Non-o	pioids vs opioids						
534	Khoromi, 2007 ²¹⁴	RCT	37	55	51	55	0.16 (0.05 to 0.52)
		(crossover)					
368	Kwasucki, 2002 ²²⁹ (fluvoxamine)	RCT	2	24	1	22	1.91 (0.16 to 22.66)
368	Kwasucki, 2002 ²²⁹ (imipramine)	RCT	12	24	1	22	21.00 (2.42 to 182.00)
547	Kwasucki, 1993230	RCT	NR	NR	NR	NR	NR
Non-o	pioids vs mixed treatm	ent					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	37	55	49	55	0.25 (0.09 to 0.70)

NR, not reported.

SUMMARY OF OVERALL FINDINGS FOR NON-OPIOIDS COMPARED WITH ALTERNATIVE INTERVENTIONS

Almost half (9/22,^{6,80,216,218,220,223,224,227,228} 41%) of the non-opioid studies included patients with acute sciatica; 27% (6/22^{57,175,214,215,219,221}) included patients with chronic sciatica. Most of the non-opioid studies (77%) were RCTs. None of the studies was deemed good quality overall; although two^{214,227} included adequate randomisation and allocation concealment, one²¹⁴ of these studies had a high dropout rate. Both compared non-opioids with inactive control (one also included comparisons with opioids and mixed treatments²¹⁴) (*Table 56*).

Non-opioids resulted in a statistically significant greater proportion of patients who recovered at short term follow-up than inactive control (eight RCTs^{218,220–225,227} and one non-RCT²¹⁷). Non-opioids were also significantly better than inactive control for reducing pain intensity of acute (three RCTs^{223,224,227} and one Q-RCT,²²⁸ all moderate quality) and chronic sciatica (one poor-quality RCT²¹⁹) at short-term follow-up. However, there were no statistically significant difference between the intervention groups in terms of functional status (one RCT⁶ and one Q-RCT²²⁸) during the same follow-up period. Non-opioids were significantly better than inactive control for reducing pain intensity of acute (one moderate-quality Q-RCT²²⁸) and chronic sciatica (one poor-quality RCT²¹⁹ and one moderate-quality crossover RCT²¹⁴) at medium-term follow-up. There was no statistically significant difference between the intervention groups in terms of the proportion of patients who recovered (two moderate-quality RCTs^{214,220}) or functional status (one moderate-quality Q-RCT²²⁸ and one moderate-quality crossover RCT²¹⁴) at medium-term follow-up. Non-opioids resulted in significantly more adverse effects than inactive control.^{6,214,217-227}

There was no statistically significant difference between non-opioids and disc surgery for global effect (one non-RCT⁵⁷ and one CCS⁸⁰) and pain intensity (one CCS⁸⁰) at medium-term follow-up or for adverse effects, according to two poor-quality studies.^{57,80}

ID no.	Author, year	Study design		OR (95% CI)	% weight
Disc sur	gery				
475	Dubourg, 2002 ⁸⁰	CCS		0.45 (0.02 to 11.46)	100.00
Epidural	injections				
451	Bronfort, 2000 ¹⁶¹	RCT –	•	0.14 (0.01 to 3.63)	100.00
Epidural	/intradiscal injection				
20	Dincer, 2007 ¹⁴³	RCT		0.21 (0.01 to 4.62)	100.00
Inactive	control				
696	Dreiser, 2001 ²²³	RCT		1.47 (0.61 to 3.53)	14.71
334	El-Zahaar, 1995 ²²¹	RCT		7.44 (0.37 to 147.92)	1.26
728	Finckh, 2006 ²²⁴	RCT		7.25 (0.36 to 146.64)	1.25
97	Goldie, 1968 ²¹⁸	RCT		1.88 (0.52 to 6.84)	6.78
732	Grevsten, 1975 ²²⁵	RCT		0.70 (0.13 to 3.70)	4.08
312	Hedeboe, 1982 ²²⁰	RCT		— 8.77 (0.94 to 81.67)	2.27
816	Herrmann, 2009 ²²⁷	RCT		0.84 (0.26 to 2.68)	8.42
736	Jacobs, 1968 ²²⁶	Q-RCT		1.81 (0.85 to 3.89)	19.43
534	Khoromi, 2007 ²¹⁴	RCT crossover	•	1.98 (0.92 to 4.29)	18.93
611	Porsman, 1979 ²²²	RCT		0.96 (0.06 to 16.24)	1.41
665	Weber, 1993 ⁶	RCT	_	1.40 (0.66 to 2.95)	20.29
297	Yildirim, 2003 ²¹⁹	RCT			1.18
62	Gibson, 1975 ²¹⁷	Non-RCT		(Excluded)	0.00
Subtotal	$(l^2 = 0.0\%, p = 0.749)$		\$	1.65 (1.18 to 2.31)	100.00
Manipula	ation				
451	Bronfort, 2000 ¹⁶¹	RCT		2.67 (0.28 to 25.64)	100.00
Mixed tr	eatment				
534	Khoromi, 2007 ²¹⁴	RCT crossover		0.25 (0.09 to 0.70)	100.00
Opioids					
534	Khoromi, 2007 ²¹⁴	RCT crossover	+	0.16 (0.05 to 0.52)	51.71
368	Kwasucki, 2002 ²²⁹	RCT		21.00 (2.42 to 182.05)	48.29
Subtotal	$(l^2 = 93.8\%, p = 0.000)$			1.69 (0.01 to 229.65)	100.00
		0.004	35 1	230	
		Favours	non-opioids Favours	control	

FIGURE 41 Summary of the findings of any adverse effect for studies comparing non-opioids with alternative interventions. Note: weights are from random effects analysis.

Non-opioids were less effective than epidural for reducing pain^{143,156,175} and improving functional status¹⁴³ at short-term follow-up according to three poorly reported RCTs. There was no statistically significant difference between non-opioids and epidural for functional status at medium-term follow-up (RCT¹⁴³).

Non-opioids were found to be statistically significantly better than opioids for reducing pain intensity at short-term follow-up,^{229,230} but there was no significant difference between the intervention groups for global effect^{229,230} or adverse effects (two poor-quality RCTs^{214,229}).

One poor-quality RCT²¹⁵ found non-opioids to be significantly better than warming acupuncture for reducing pain intensity of chronic sciatica at short-term follow-up, but there was no significant difference between the intervention groups for the global effect at long-term follow-up.

One small historical CCS²¹⁶ found biological agents to be to be significantly better than nonopioids for reducing pain intensity and functional status at short-term follow-up.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment	Proportion of studies that included patients who had received previous surgery (%)
Non-opioids vs alternative/non- traditional	1 (2)	(06) 06	1/1 (100)	0/1 (0)	(0) 1/0	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Non-opioids vs biological agents	1 (1)	10 (10)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0
Non-opioids vs disc surgery	2 (3)	4067 (54)	1/2 (50)	0/2 (0)	0/2 (0)	2/2 (100)	2/2 (100)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)
Non-opioids vs intradiscal intection	3 (3)	64–246 (93)	3/3 (100)	0/3 (0)	0/3 (0)	3/3 (100)	2/3 (67)	1/3 (33)	0/3 (0)	0/3 (0)	1/3 (33)	1/3 (33)

ut has been counted only once here).	
s three comparators, bu	
.g. study 534 ²¹⁴ include	SOMe
r of arms as above (e	iant main intensity or (
studies not the numbe	intromes for alabal af
based on number of s	"undies that renorted or
hese numbers are	table shows only si

6

2/22 (

8/22 (36)

1/22 (5)

0/22 (0)

2/22 (9)

9/22 (41)

22/22 (100)

9/22 (41)

0/22 (0)

17/22 (77)

10–532 (38)

22 (29)

0/13 (0)

5/13 (38)

1/13 (8)

0/13 (0)

0/13 (0)

4/13 (31)

13/13 (100)

8/13 (62)

1/13 (8)

10/13 (77)

29-532 (55)

13 (14)

0/1 (0)

1/1 (100)

0 1/0

0/1 (0)

0/1 (0)

1/1 (100)

1/1 (100)

0/1 (0)

0/1 (0)

0 170

55 (55)

1 (1)

0/3 (0)

2/3 (67)

0/3 (0)

0/3 (0)

1/3 (33)

2/3 (67)

3/3 (100)

0/3 (0)

0/3 (0)

2/3 (67)

43-70 (55)

3 (4)

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

Traction

Description of traction studies

Summary of interventions

Twelve studies evaluated traction for sciatica.^{176,242-252} Ten of these studies compared traction to an alternative intervention (three were multiple-arm studies).^{176,242-250} One further study compared mixed treatment that included traction, with mixed treatments or with other comparators without traction (*Table 57a*).²⁵³⁻²⁵⁶

Three studies compared different types of traction (Table 57b).^{248,251,252}

Summary of study participants for traction

Summary data for included participants are presented in *Table 58.* The number of participants included in the 10 studies that reported outcome data for global, pain or CSOMs ranged from 16 to 157 (median 60 participants). Five studies^{176,243,245,246,249} (45%) included patients with acute sciatica, one study²⁴² (9%) included patients with chronic sciatica, one study²⁴⁷ included patients with either acute or chronic sciatica and the remaining three studies^{244,248,250} did not report this information. None of the studies included patients with spinal stenosis or sequestered or extruded discs. The diagnosis of sciatica, or the presence of herniated disc, was confirmed by imaging in four studies (40%). Two studies^{243,246} included a mixture of patients with either recurrent or first episode of sciatica, whereas the remaining studies did not report this information. Two studies (one in which the comparator was activity restriction²⁴³ and one in which the comparator was inactive control²⁴⁷) included patients who had already received previous treatment for their current episode of sciatica. This information was not stated for the remaining studies. One study,²⁴³ which compared traction with activity restriction, included patients who had received previous disc surgery.

Summary of study quality for traction studies

Summary information on study details are presented in *Table 59*. Most of the traction studies were RCTs (9/10, 90%), but none was deemed to be good quality overall. Seven studies^{176,242,243,245,246,248,249} were of moderate quality. Three studies^{243,245,248} used adequate randomisation, but not allocation concealment, although two^{243,245} used sealed envelopes. One study²⁴³ had strong external validity.

Traction results at short-term follow-up (≤ 6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 60* and the accompanying forest plot (*Figure 42*). Traction was compared with inactive control, usual care/ conservative treatment, activity restriction, exercise therapy and passive PT. Only one study²⁴² included patients with chronic sciatica; four studies^{176,243,245,246} included patients with acute sciatica and the remaining study²⁵⁰ did not report this information. The duration of follow-up ranged from 1 week²⁴² to 4 weeks.²⁴⁵ Three further studies^{254–256} combined the use of mixed treatments that incorporated traction with an alternative treatment.

Pooled analysis of two moderate-quality RCTs^{245,246} showed non-statistically significant difference in favour of traction, compared with inactive control, for overall recovery from acute sciatica at 3 weeks²⁴⁶ to 4 weeks.²⁴⁵

One poorly reported non-RCT²⁵⁰ found a non-statistically significant difference in favour of pulse traction, compared with conservative treatment without traction, for overall improvement at 3 weeks. All patients were in bed for at least 18 hours a day in a position taking the strain off

TABLE 57a Summary of the interventions used when comparing traction with alternative interventions (grouped by comparator then ordered by author)

ID no.	Author, year	Study design	Treatment description	Control description
Tractio	on vs activity restriction	on		
222	Moret, 1998 ²⁴³	RCT	Bed rest and traction (vertical traction using patient weight), 180 minutes daily for 1–2 weeks	Bed rest
Tractio	on vs exercise therapy	/		
2	Ljunggren, 1992 ²⁴²	RCT	Manual traction	Isometric exercises
Tractio	on vs inactive control			
553	Larsson, 1980 ²⁴⁶	RCT	Auto-traction, three treatments	Inactive corset
579	Mathews, 1975 ²⁴⁷	RCT	Traction (full traction) 5 days per week for 3 weeks	Sham traction (minimal traction) 5 days per week for 3 weeks
206	Pal, 1986 ²⁴⁴	RCT	Weighted traction: continuous lumbar traction of 5.5–8.2 kg according to body weight	Sham traction: continuous lumbar traction of 1.4–1.8 kg according to body weight
299	Rattanatharn, 2004 ²⁴⁵	RCT	Traction three times per week Traction force of 35–50% of the body weight performed intermittently	Sham traction three times per week Traction force of < 20% of body weight performed intermittently
746	Reust, 1988 ²⁴⁸ (French language)	RCT	Normal traction (50 kg)	Placebo traction (5 kg)
746	Reust, 1988 ²⁴⁸ (French language)	RCT	Light traction (15 kg)	Placebo traction (5 kg)
Tractio	on vs passive PT			
9059	Mathews, 1987 ¹⁷⁶	RCT	Lumbar traction of at least 45 kg, but sufficient to relieve pain sustained for 30 minutes	Control treatment. Infrared heat treatment to the low back area at 60 cm for 15 minutes, three times per week
148	Unlu, 2008 ²⁴⁹	RCT	Lumbar traction	Ultrasound treatment
148	Unlu, 2008 ²⁴⁹	RCT	Lumbar traction	Low-power laser
Tractio	on vs usual/conventio	nal care		
77	Styczynski, 1991 ²⁵⁰ (Polish language)	Non- RCT	Antigravitational traction. Up to 15 treatments, mean 12.3	Conservative treatment without traction Up to 15 treatment sessions, mean 12.0
77	Styczynski, 1991 ²⁵⁷ (Polish language)	Non- RCT	Chair traction. Up to 15 treatments, mean 11.7	Conservative treatment without traction Up to 15 treatment sessions, mean 12.0
77	Styczynski, 1991 ²⁵⁷ (Polish language)	Non- RCT	Pulse traction. Up to 15 treatments, mean 11.3	Conservative treatment without traction Up to 15 treatment sessions, mean 12.0
Mixed	treatment including t	traction vs	mixed treatment without traction	
301	Harte, 2007 ²⁵⁴	RCT	Traction and/or manual therapy, exercise and/or advice to stay active	Manual therapy, exercise and/or advice to stay active

TABLE 57b Summary of the interventions used when comparing alternative forms of traction

ID no.	Author, year	Study design	Treatment description	Control description
161	Guvenol, 2000 ²⁵¹	RCT	Conventional traction	Inverted traction
569	Ljunggren, 1984 ²⁵²	RCT	Autotraction	Manual traction
746	Reust, 1988 ²⁴⁸ (French language)	RCT	Normal traction (50 kg)	Light traction (15 kg)

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

e ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Tractic	m vs activity restrict	tion											
222	Moret, 1998 ²⁴³	RCT	16	Mean 41.9 (SD 8.7)	12 (75)	Acute symptoms 50%	Nerve root pain	No	Recurrent and first episode	No	NR	Yes	Yes
Tractic	m vs exercise thera	Ла											
570	Ljunggren, 1992 ²⁴²	RCT	50	Mean 41.6 (range 19–62)	27 (54)	Mean 5 months	Nerve root pain	Yes	NR	No	No	NR	No
Tractic	m vs inactive contro	-											
553	Larsson, 1980 ²⁴⁶	RCT	84	Mean 37 (range 20–55)	51 (62)	Mean 6.7 weeks (range 2-14 weeks)	Nerve root pain	No	Recurrent and first episode	No	No	NR	NN
579	Mathews, 1975 ²⁴⁷	RCT	27	Range 20–60	NR	Mean 13 weeks	Nerve root pain and refereed pain	No	NR	No	No	Yes	NR
206	Pal, 1986 ²⁴⁴	RCT	41	Mean 39	23 (59)	Median 49 days	Nerve root pain and referred pain	NR	R	No	No	NR	NR
299	Rattanatharn, 2004 ²⁴⁵	RCT	120	Mean 37.3	47 (46)	< 3 months	Nerve root pain	No	NR	No	No	Yes	No
746	Reust, 1988 ²⁴⁸ (French language)	RCT	60	Mean 50.8 (SD 12.5)	35 (58)	NR	Nerve root pain and referred pain	No	NR	No	No	NR	NR

TABLE 58 Summary of sciatica type and study population details for studies comparing traction with alternative interventions (grouped by comparator then ordered by author)

e ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Tractic	n vs passive PT												
9059	Mathews, 1987 ¹⁷⁶	RCT	143	Median 40 (range 20–60)	80 (56)	Median 3.5 weeks (range 0 days– 3 months)	Nerve root pain	ON	NR	NR	NR	N	NN
148	Unlu, 2008 ²⁴⁹	RCT	60	Mean 44.5 (range 20–60)	18 (30)	< 3 months	Nerve root pain	Yes	NR	No	No	R	No
Tractic	n vs usual/conven	tional care											
77	Styczynski, 1991 ²⁵⁰ (Polish language)	Non- RCT	157	Range 18–67	84 (54)	RN	Nerve root pain	Yes	NR	RN	NR	NR	NR
Mixed	treatment includin	ig traction vs	mixed treat	tment without tract	ion								
301	Harte, 2007 ²⁵⁴	RCT	64	Mean 41.1 (SD 9.8)	28 (44)	Median 47.5 days (range 2–671 days)	Nerve root pain	N	Recurrent and first episode	No	N	Yes	Yes
NR, not a Mar	t reported. ked yes if patient po	ipulation or in	clusion criteri	ia specifically reporte	id that patient wi	th sequestered di	sc, extruded disc or	stenosis were in	cluded; otherwis	se reported as n	0.		

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 5	9 Summary of the stu	ldy details fo	or studies compar	ring traction with	alternative interve	entions (grouped	by comparator th	nen ordered by au	thor)	
ID no.	Author, year	Study size	Overall follow- up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Traction	vs activity restriction									
222	Moret, 1998 ²⁴³	16	3 weeks	RCT	Yes	Partial	80-100	No	Moderate	Strong
Traction	vs active PT/exercise the	rapy								
570	Ljunggren, 1992 ²⁴²	50	1 week	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
Traction	vs inactive control									
553	Larsson, 1980 ²⁴⁶	84	3 months	RCT	Unclear	Unclear	80-100	Unclear	Moderate	Weak
579	Mathews, 1975 ²⁴⁷	27	3 months	RCT	Unclear	Unclear	Cannot tell	Unclear	Weak	Weak
206	Pal, 1986 ²⁴⁴	41	2 years	RCT	Unclear	Unclear	80-100	Yes	Weak	Weak
299	Rattanatharn, 2004 ²⁴⁵	120	4 weeks	RCT	Yes	Partial	60-79	NA	Moderate	Weak
746	Reust, 1988 ²⁴⁸ (French language)	60	12 days	RCT	Yes	Unclear	< 60	Yes	Moderate	Weak
Traction	vs passive PT									
9059	Mathews, 1987 ¹⁷⁶	143	12 months	RCT	Partial	Unclear	<60	Yes	Moderate	Moderate
148	Unlu, 2008 ²⁴⁹	60	3 months	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
Traction	vs usual/conventional cai	æ								
77	Styczynski, 1991 ²⁵⁰ (Polish language)	157	After treatment	Non-RCT	No	No	80-100	Unclear	Weak	Weak
Mixed tr	eatment including traction	ר vs mixed tre	atment without trac	tion						
301	Harte, 2007 ²⁵⁴	30	6 months	RCT	Yes	Partial	62-09	Yes	Moderate	Strong

							Interver	ıtion		Control				
а ё	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (n)	Outcome (n)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	or (95% CI)	Comments
Tractio	n vs activity rest	riction												
222	Moret, 1998 ²⁴³	A	RCT	3 weeks	Leg pain: recovered or strongly improved (vs little improved, no change, little worse, much worse or worse than ever)	Patient	ω	4	0	ω	4	0	1.00 (0.14 to 7.10)	
Tractio	n vs exercise the	irapy												
570	Ljunggren, 1992 ²⁴²	O	RCT	1 week	Global evaluation: symptom-free or satisfactory improvement (vs unsatisfactory improvement or unchanged)	Physician	24	10	0	26	10	0	1.14 (0.37 to 3.55)	
Tractio	ר א inactive cor	itrol												
553	Larsson, 1980 ²⁴⁶	A	RCT	3 weeks	Completely recovered: free from back or leg pain (vs partially recovered 1 = no leg pain, partially recovered 2 = no back pain or no recovery)		4	~	0.05	41	ო	0	2.61 (0.62 to 10.89)	
299	Rattanatharn, 2004 ²⁴⁵	¢	RCT	4 weeks	Global improvement: complete recovery or much improved (vs little improved/unchanged or little/much worse)	Patient	54	88	0.10	48	34	0.20	0.98 (0.42 to 2.30)	

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

continued

TABLE 60 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing traction with alternative interventions (grouped by comparator then ordered by author) (continued)

							Interve	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	or (95% CI)	Comments
Tractic	n vs passive PT													
9059	Mathews, 1987 ¹⁷⁶	¢	RCT	2 weeks	Recovered: pain score of 5 or 6 (vs not recovered=scores of 1–4)		22	40	20.0	54	27	0.10	1.08 (0.54 to 2.17)	Number of dropouts reported was different from the number missing from the analysis
Tractic	n vs usual/conve	entional care												
77	Styczynski, 1991 ²⁵⁰ (i) (antigravity) ^a	N	Non- RCT	3 weeks	Overall improvement		38	26	0.10	29	17	0.03	1.53 (0.56 to 4.19)	
77	Styczynski, 1991 ²⁵⁰ (ii) (chair) ^a	NR	Non- RCT	3 weeks	Overall improvement		41	28	0.05	29	17	0.03	1.52 (0.57 to 4.09)	
77	Styczynski, 1991 ²⁵⁰ (iii) (pulse) ^a	R	Non- RCT	3 weeks	Overall improvement		41	28	0.02	29	17	0.03	1.52 (0.57 to 4.09)	
Mixed	treatment incluc	ling traction v	s mixed tre	atment with	out traction									
301	Harte, 2007 ²⁵⁴	ح	RCT	Post- treatment	Median percentage overall improvement	Patient	16	Median 90% (IQR 24)	0.13	4	Median 90% (IQR 22.5) LT	0.14		ITT not used for dichotomous outcome Percentage improvement reported, not number of patients who improved
A, acut	∋; A+C, acute anα	I chronic; C, chi	ronic; NR, n	iot reported.										

a Styczynski *et al.*²²⁰ included four treatment groups: antigravitational traction (i), chair traction (ii), pulse traction (iii) and conservative treatment without traction (iv). In order to prevent using the same comparator twice, only the first (i) and last (iv) treatment groups have been included in the meta-analysis (see *Figure* 42).

ID no.	Author, year	Study design				OR (95% CI)	% weight
Active	PT/exercise therapy						
570	Ljunggren, 1992 ²⁴²	RCT		•		1.14 (0.37 to 3.55)	100.00
Activity	restriction						
222	Moret, 1998 ²⁴³	RCT		•	-	1.00 (0.14 to 7.10)	100.00
Inactive	e control						
553	Larsson, 1980 ²⁴⁶	RCT				2.61 (0.62 to 10.89)	32.24
299	Rattanatharn, 2004245	RCT				0.98 (0.42 to 2.30)	67.76
Subtota	l ($l^2 = 25.1\%$, $p = 0.248$)					1.34 (0.55 to 3.30)	100.00
Passive	PT						
9059	Mathews, 1987 ¹⁷⁶	RCT		•		1.08 (0.54 to 2.17)	100.00
Usual/c	conventional care						
77	Styczynski, 1991 ²⁵⁰	Non-RCT		•		1.53 (0.56 to 4.19)	100.00
		0.0918		1	10.9		
			Favours control	Favours traction			

FIGURE 42 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

with legs bent at hips and knees for 3 weeks, and undertaking isometric exercises to strengthen muscles around the spine, hips, abdomen and limbs.

One small (n = 16), moderate-quality RCT²⁴³ found no statistically significant difference between vertical traction using patient weight plus bed rest and bed rest alone (activity restriction) in terms of the proportion of patients with improvement in leg pain for acute sciatica at 3 weeks. Twelve patients (75%) were hospitalised.

One RCT²⁴² found no statistically significant difference between manual traction and isometric exercise (active PT) for overall improvement of chronic sciatica at 1 week. All patients were hospital inpatients and used crutches and elastic lumbar supports for any necessary out-of-bed activities. The study was of moderate quality, but the method of randomisation and allocation concealment was not stated.

One moderate-quality RCT¹⁷⁶ found no important difference between traction and infrared heat treatment (passive PT) for overall recovery from acute sciatica at 2 weeks. Patients were also given paracetamol to take when necessary and offered a corset. All patients attended a special outpatients clinic.

One small, moderate-quality, pilot RCT²⁵⁴ reported the same median percentage improvement, as perceived by the patient, for mixed treatment (manual therapy, exercise and advice) with or without traction.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 61* and the accompanying forest plot (*Figure 43*). Traction was compared with inactive control, activity

TABLE 61 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing traction with alternative interventions (grouped by comparator then ordered by author)

	_ ۲						pe	SD om verade	OCF	ו 3/18, cebo)	OCF	1 3/22, cebo)
	Comment						Median use	for mean; S imputed fro weighted a	ITT using L	Dropouts: interventior control (pla 2/31	ITT using L Dropouts:	interventior control (pla 2/31
	Mean difference (95% Cl) ^b		-5.00 (-15.58 to 5.58)	-3.80	(-15.25 to 7.65)		2.00	(–11.68 to 15.68)	3.36	(—14.49 to 21.21)	-0.43 (-15.63 to	16.49)
je scores	Control											
Chanç (SD)	Intervention											
an (SD)	Control		26.8 (18.36)	25.6	(21.1)		ю		30.25	(26.23)	30.25 (26.23)	
Final me	Intervention		21.8 (15.4)	21.8	(15.4)		5		33.61	(29.55)	30.68 (26.83)	
mean (SD)	Control		56 (15.3)	53.1	(25.9)		50		61.5	(23.63)	61.5 (23.63)	
Baseline	Intervention		59.6 (15.4)	59.6	(15.4)		50		75.28	(23.85)	67.27 (23.74)	
(u)	Control		20	20			15		20		20	
Total (Intervention		20	20			24		18		22	
	Scale (range) ^a		VAS (0-100)	VAS	(0-100)		VAS	(0—1 00)	VAS	(0-100)	VAS (0-100)	
	Location		Leg	Leg			Overall		Overall		Overall	
	Follow- up		1 month	1 month			3 weeks		12 davs	`	12 days	
	Study design		RCT	RCT			RCT		RCT		RCT	
	Chronicity		A	A		lo	NR		NR		NR	
	Author, year	n vs passive PT	Unlu, 2008 ²⁴⁹ (j) ^d (ultrasound)	Unlu, 2008 ²⁴⁹ (ii) ^d	(laser)	n vs inactive contr	Pal, 1986 ²⁴⁴		Reust. 1988 ²⁴⁸	(i)ª (French language) (50 kg)	Reust, 1988 ²⁴⁸ (ii) ^e (French	language) (1 ö kg)
	<u> </u>	Tractic	148	148		Tractic	206		746		746	

							Total (с Г	Baseline n	nean (SD)	Final mea	an (SD)	Change s (SD)	scores		
⊡ ë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ⁵	Comment/ conversion ^c
Tracti	m vs activity restr	riction														
222	Moret, 1998 ²⁴³	۲	RCT	3 weeks	Leg	NRS (0-10)	ω	∞	74 (12.0)	73 (10.0)	44 (12)	63 (10)	-30	-10	19.00 (29.82 to 8.18)	Final mean calculated from change score and baseline SD used
Mixea	treatment includ	ing traction vs I	nixed trea	tment withou	ıt traction											
301	Harte, 2007 ²⁵⁴	ح	RCT	Post treatment	Overall	McGill	16	14	20.5 (6.67)	29 (14.81)	4 (11.33)	12 (12.22)	17.5 (9.48)	15.5 (19.11)	—8.00 (—16.47 to 0.47)	Small sample sizes Mean and SDs derived from median and IQR values ITT use LOCF Dropouts 3/30 (10%): intervention 2/16, control 1/14
A, acu b Ba; c Th d Unl e Reu gro	e; LOCF, last obser t results have been ed on final means term 'dropouts' hs <i>a et al.</i> ²⁴⁸ included e been included in ist <i>et al.</i> ²⁴⁸ included in ts have been inclu	vation carried fo converted to a s or change score as been used for three treatment three treatment of three treatment ded in the meta	rward; NR, ccale of 0–1 s (with a pru missing da groups: uttr: is (see <i>Figu</i> groups: lig -analysis (s	not reported; 00 for compa eference giver. ita, post-baseli asound treatm <i>ire 43</i>). iht traction (15 see <i>Figure 43</i>).	NRS, numeric trability. T to change sc ine exclusions nent (i), low-pc 5kg) (ii), norm:	al rating scale cores). s and patients ower laser (ii) al traction (50	lost to fo and lumb kg) (į) an	illow-up ar tract d place	ion (ii). In orc bo traction (5	der to preven ökg) (iii). In or	t using the	same comps ent using the	arator twice	, only the fir	st (i) and last (iii) trea	tment groups hird treatment

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.



FIGURE 43 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

restriction and passive PT. Two studies^{243,249} included patients with acute sciatica; the remaining two studies^{244,248} did not report the duration of symptoms. The duration of follow-up ranged from 12 days²⁴⁸ to 3 weeks.^{243,244} Three further studies^{253–255} compared the use of mixed treatments that incorporated traction with alternative interventions.

Two RCTs^{247,248} compared the use of traction with inactive control; the pooled analysis showed a non-statistically significant difference in favour of inactive control for overall pain at 2 weeks²⁴⁸ to 3 weeks.²⁴⁴ The quality of the studies was poor in one case²⁴⁴ and moderate in the other.²⁴⁸ Only one of these used an adequate method of randomisation.²⁴⁸ The method of randomisation was not stated in the second study and allocation concealment was not reported for either study. Inactive treatment included sham traction in both studies (1.4–1.8 kg according to body weight²⁴⁴ or 20% of body weight²⁴⁸).

One small (n = 16), moderate-quality RCT²⁴³ found vertical traction plus bed rest to be significantly better than bed rest alone (activity restriction) for reducing leg pain in patients with acute sciatica at 3 weeks. Twelve patients (75%) were hospitalised.

One moderate-quality RCT²⁴⁹ compared the use of standard motorised traction with ultrasound (passive PT); there was an overall non-statistically significant finding in favour of ultrasound, for acute sciatica at 1 month. The method of randomisation and allocation concealment was not reported.

One small, moderate-quality pilot RCT²⁵⁴ that compared manual exercise therapy, exercise and advice found that the traction combination resulted in a non-statistically significantly greater reduction in overall pain intensity that the control intervention.

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 62* and the accompanying forest plot (*Figure 44*). Traction was compared with inactive control, activity restriction and passive PT. All three studies^{243,245,249} included patients with acute sciatica. The duration of

tor then	
compara	
uped by	
ons (groi	
Iterventi	
mative ir	
with alter	
traction	
nparing	
udies cor	
<s) for="" sti<="" td=""><td></td></s)>	
(≤6 weel	
Ilow-up	
t-term fo	
s at shor	
f CSOM	
ndings o	
/ of the fi	
Summary	author)
3LE 62 {	sred by ¿
IAE	ord

					Total ((E	Baseline (SD)	mean	Final mea	n (SD)	Change s (SD)	cores		
ID No. Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
Traction vs activity	restriction													
222 Moret, 1998 ²⁴³	A	RCT	3 weeks	RMDQ	ω	ω	18.1 (1.8)	18.5 (2.1)	14.5 (3.87)	17.1 (6.2)	-3.6	-1.4	-0.50 (-1.50 to 0.49)	Final mean calculated from change scores, final SD imputed from weighted mean of SDs from other studies
Traction vs inactive	control													
299 Rattanatharn 2004 ²⁴⁵	Α	RCT	4 weeks	IQO	54	48	47.97 (15.32)	40.61 (13.94)	22.72 (18.61)	21.36 (17.27)	-25.25 (16.68)	-19.25 (15.9)	ANCOVA for change scores showed no statistically significant difference, p = 0.301 0.08 (-0.31 to 0.46)	ITT not reported, no dropouts
Traction vs passive	РТ													
148 Unlu, 2008 ²⁴ (i) ^c	A	RCT	1 month	RMDQ	20	20	14.2 (4.3)	12.5 (5)	8.5 (3.5)	7.3 (4.3)	-5.7	-5.2	0.31 (–0.32 to 0.93)	
148 Unlu, 2008 ²⁴ (ii) ^c	6 6	RCT	1 month	RMDQ	20	20	14.2 (4.3)	13.4 (4.5)	8.5 (3.5)	8.2 (6)	-5.7	-5.2	0.06 (–0.56 to 0.68)	
Mixed treatment in	corporatin	g traction v	vs mixed trea	ttment wit	hout trac	tion								
301 Harte, 2007 ²	A	RCT	Post- treatment	RMDQ	16	14	10 (3.33)	11.5 (6.3)	4 (4.3)	4 (7.63)	-4.5 (5.41)	3 (5.93)	0.0 (-0.72 to 0.72)	Medians used for means and SDs calculated from IQRs Small sample sizes – likely to be skewed ITT using LOCF
A, acute. a Based on final me b The term 'dropou: c Unlu <i>et al.</i> ²⁴⁹ inclu hean incluided in +	ans or cha s' has bee ided three t	Inge scores n used for n treatment gr	(with a preference) nissing data, p roups: ultrasou Finure 44	ence given oost-baselir. und treatme	to chang ne exclusi ent (i), low	e score: ions anc v-power	s); results re d patients lo r laser (ii) an	sported by st st to follow-1 id lumbar tra	udy in italics up. iction (iii). In c	order to prev	/ent using th	le same col	mparator twice, only the fi	rst and third treatment groups have

Health Technology Assessment 2011; Vol. 15: No. 39

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Activity	restriction						
222	Moret, 1998 ²⁴³	RCT	×	*		-0.50 (-1.50 to 0.49)	100.00
Inactive	e control						
299	Rattanatharn, 2004245	RCT				0.08 (-0.31 to 0.46)	100.00
Passive	PT						
148	Unlu, 2008 ²⁴⁹	RCT				0.31 (-0.32 to 0.93)	100.00
			-1.5	Eavours traction	0 Eavours control	1.5	

FIGURE 44 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

follow-up ranged from 12 days²⁴⁸ to 3 weeks.^{243,244} Two further studies^{254,255} compared the use of mixed treatments that incorporated traction with alternative treatments.

One RCT,²⁴⁵ of moderate quality, compared traction with inactive control and found a nonstatistically significant difference, in favour of inactive control, in improved function in patients with acute sciatica at 4 weeks.

One small RCT,²⁴³ of moderate quality, compared traction plus bed rest with bed rest alone (activity restriction) and found a non-statistically significant difference, in favour of traction, for improved function in patients with acute sciatica at 3 weeks.

One moderate-quality RCT²⁴⁹ compared traction with ultrasound (passive PT); at 1 month, there was an overall non-statistically significant finding in favour of ultrasound for the treatment of acute sciatica. The methods of randomisation and allocation concealment were not reported.

One small, moderate-quality study²⁵⁴ found no important difference between traction or no traction, with manual exercise therapy, exercise and advice for acute sciatica at treatment completion.

Traction results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 63* and the accompanying forest plot (*Figure 45*).

One moderate-quality RCT²⁴⁶ compared the use of auto-traction with inactive control (inactive corset) in terms of the proportion of patients with acute sciatica who were symptom free at 3 months' follow-up. The methods of randomisation and allocation concealment used were not reported. There was a non-statistically significant difference between the groups in favour of inactive control. Most patients were treated as outpatients [20/84 (24%) were hospitalised] and patients in both groups were were supplied with a corset and advised to rest.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 64* and the accompanying forest plot (*Figure 46*). Traction was compared with inactive control and passive

~
ĉ
<u>9</u> .
Ĕ
Š
ъ
Ľ
- -
.≚
ati
Ê
Ē
ы.
÷
Ę
2
p
Ξ
ğ
Ξ
g
3ri.
b
E
8
6
<u>ĕ</u>
ð
ž
5
ę
d
Ļ
Š
≅
ę
٦
ЯĽ
Ť.
Ε
<u>i</u>
80
Ĕ
÷
ц 0
õ
₩
e
al
5
ē
Ð
ቲ
£
ŝ
ğ
÷⊨
ĕ
Ę
he
Ę
Ö
≥
Ja
Ľ
F
S
ო
0
щ
B
A
E -

							Intervei	ntion		Control				
Ωë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	or (95% CI)	Comments
Tract	ion vs inactive con	trol												
553	Larsson, 1980 ²⁴⁶	A	RCT	3 months	Symptom free (vs persisting symptoms)		40	19	0.07	41	17	0	1.28 (0.53 to 3.07)	
A, act	ute.													



FIGURE 45 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				WMD (95% CI)	% weight
Passive	PT						
148	Unlu, 2008 ²⁴⁹	RCT		*	\rightarrow	4.30 (-5.22 to 13.82)	100.00
		-13.8	Favours traction	0 Favours control	13.8		

FIGURE 46 Summary of the findings of pain at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

PT. One further study²⁵⁴ compared the use of mixed treatments that incorporated traction with mixed treatments without traction for acute sciatica.

One small (n = 27), poor-quality and poorly reported RCT²⁴⁷ compared traction with inactive control (sham traction using a maximum force of 9 kg). The study was published in 1975 and carried out by single physiotherapist. Patients were asked to judge by what percentage their pain had changed, assuming the level of pain at baseline to be 100%. The average improvement at 6 weeks was 28.8% in the traction group compared with 18.9% in the control group.

One moderate-quality RCT²⁴⁹ compared traction with ultrasound (passive PT); at 3 months, there was a non-statistically significant improvement in acute sciatica, in favour of ultrasound. The methods of randomisation and allocation concealment were not reported.

One moderate-quality pilot study²⁵⁴ compared the use of motorised lumbar traction combined with manual therapy, exercise and/or advice to stay active compared with manual therapy, exercise and/or advice to stay active without traction. There was no statistically significant difference between the intervention groups at 6 months' follow-up, but this may be due to the small sample size (n = 30).

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 65* and the accompanying forest plot (*Figure 47*). Traction was compared with passive PT for acute sciatica. One further study²⁵⁴ compared the use of mixed treatments that incorporated traction with mixed treatments without traction for acute sciatica.

One moderate-quality RCT²⁴⁹ compared traction with ultrasound (passive PT); at 3 months, there was an overall non-statistically significant improvement in acute sciatica, in favour of ultrasound.

							Total ((r	Baseline (SD)	mean	Final me	an (SD)	Change (SD)	scores		
ΞË	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion [€]
Tracti	on vs passive P1	-														
148	Unlu, 2008 ²⁴⁹ (i) ^d (ultrasound)	A	RCT	3 months	Leg	VAS (0-100)	20	20	59.6 (15.4)	56 (15.3)	29.5 (16.7)	25.2 (13.9)			4.30 (–5.22 to 13.82)	
148	Unlu, 2008 ²⁴⁹ (ii) ^d (laser)	A	RCT	3 months	Leg	VAS (0-100)	20	20	59.6 (15.4)	53.1 (25.9)	29.5 (16.7)	23.6 (17.7)			5.90 (-4.76 to 16.56)	
Tracti	on vs inactive co	ontrol														
579	Mathews, 1975 ²⁴⁷	A + C	RCT	3 months	Overall	Improvement (0–100)	13	14					28.80	18.90		Average percentage improvement in pain since starting treatment All patients asked to judge by what percentage pain had changed assuming the level on entry to the trial to be 100%
Міхе	l treatment incol	rporating tract	tion vs mixe	sd treatment	without tra	stion										
301	Harte, 2007 ²⁵⁴	4	RCT	6 months	Overall	McGill	16	14	20.5 (6.67)	29 (14.8)	10 (15.9)	6.5 (15.56)	15.5 (12.81)	16.5 (22.81)	3.50 (-7.54 to 14.54)	Mean and SDs derived from median and IQR values
A, act b Ba c Th d Un	te; A + C, acute al e results have bee sed on final mean e term 'dropouts'	nd chronic. an converted to is or change sc has been used	a scale of 0 ores (with a for missing)-100 for con preference gi data, post-ba	iparability. Ven to chang seline exclus	e scores). ions and patients	lost to fo	llow-up.		-	-			-		-

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

þ	
В	
đņ	
gro	
)s(
tior	
.u.	
erv	
int	
Ne.	
lati	
ter	
aj.	
Ę	
~	
ger	
ŝŭ	
ő	
<u>i</u>	
ng	
ari	
цр	
S	
ies	
nd	
rst	
þ	
(hs)	
out	
Е	
VI	
þ	
sks	
veeks	
6 weeks	
o (>6 weeks	
-up (>6 weeks	
ow-up (>6 weeks	
follow-up (>6 weeks	
m follow-up (>6 weeks	
-term follow-up (>6 weeks	
Im-term follow-up (>6 weeks	
<pre>sdium-term follow-up (>6 weeks</pre>	
medium-term follow-up (>6 weeks	
at medium-term follow-up (>6 weeks	
Ms at medium-term follow-up (>6 weeks	
SOMs at medium-term follow-up (>6 weeks	
f CSOMs at medium-term follow-up (>6 weeks	
s of CSOMs at medium-term follow-up (>6 weeks	(
ngs of CSOMs at medium-term follow-up (>6 weeks	hor)
ndings of CSOMs at medium-term follow-up (>6 weeks	author)
e findings of CSOMs at medium-term follow-up (>6 weeks	oy author)
the findings of CSOMs at medium-term follow-up (>6 weeks	d by author)
of the findings of CSOMs at medium-term follow-up (>6 weeks	ered by author)
ary of the findings of CSOMs at medium-term follow-up (>6 weeks	ordered by author)
mmary of the findings of CSOMs at medium-term follow-up (>6 weeks	en ordered by author)
Summary of the findings of CSOMs at medium-term follow-up (>6 weeks	then ordered by author)
Summary of the findings of CSOMs at medium-term follow-up (>6 weeks	ttor then ordered by author)
E 65 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks	arator then ordered by author)
BLE 65 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks	mparator then ordered by author)

	onversion ^b					calculate SD, mple sizes – kewed 3F	
	Comment/c					IQR used to but small sa likely to be s ITT used LO	
	Mean difference (95% Cl) ^a		0.52 (-0.11 to 1.15)	0.06 (-0.56 to 0.68)		-0.75 (-1.49 to -0.01)	
cores (SD)	Control		-5.8	-4.8		-3 (9.11)	
Change s	Intervention		-5.3	- 5.3		-4 (9.11)	
n (SD)	Control		6.7 (4.5)	8.6 (6)		11.5 (6.3)	
Final mea	Intervention		8.9 (4)	8.9 (4)		4.5 (11.33)	
ie mean	Control		12.5 (5)	13.4 (4.5)		11.5 (6.3)	
Baselir (SD)	Intervention		14.2 (4.3)	14.2 (4.3)		10 (3.33)	
(<i>u</i>)	Control		20	20	ation	14	
Total	Intervention		20	20	ıt manipul	16	
	Scale		RMDQ	RMDQ	ent withou	RMDQ	
	Follow- up		3 months	3 months	mixed treatm	6 months	
	Study design		RCT	RCT	ulation vs	RCT	forward.
	Chronicity	passive PT	A	A	orating manip	A	vation carried
	Author, year	(ultrasound) vs	Unlu, 2008 ²⁴⁹ (i)° (ultrasound)	Unlu, 2008²⁴9 (ii)⁰ (laser)	eatment incorp	Harte, 2007 ²⁵⁴	LOCF, last obser
	ÐË	Traction	148	148	Mixed tr	301	A, acute;

a Based on final means or change scores (with a preference given to change scores). b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up. c Unlu *et al.*²⁴⁹ included three treatment groups: ultrasound treatment (i), low-power laser (ii) and lumbar traction (iii). In order to prevent using the same comparator twice only the first and last treatment groups have been included in the meta-analysis (see Figure 47).

	0.52 (-0.11 to 1.15)	100.00
1.15		
	 1.15	0.52 (-0.11 to 1.15)



One moderate-quality pilot study²⁵⁴ compared the use of motorised lumbar traction combined with manual therapy, exercise and/or advice to stay active with manual therapy, exercise and/or advice to stay active without traction. Improvement in functional status at 6 months' follow-up was marginally higher in the traction group and the difference was statistically significant.

Results at long-term follow-up (>6 months)

No long-term outcomes were reported for traction.

Analysis of adverse effects for traction

The results for the occurrence of any reported adverse effects are presented in *Table 66* and the accompanying forest plot (*Figure 48*).

The number of adverse effects associated with traction was significantly greater than the number associated with activity restriction. Pooled analyses showed no statistically significant differences for the number of adverse effects when comparing traction with inactive control, usual care or exercise therapy.

SUMMARY OF OVERALL FINDINGS FOR TRACTION COMPARED WITH ALTERNATIVE INTERVENTIONS

Half (5/10,^{176,243,245,246,249} 50%) of the traction studies included patients with acute sciatica; 10% (1/10²⁴²) included patients with chronic sciatica. Most of the traction studies (90%) were RCTs,^{176,242-249} but none was of a good quality (*Table 67*). One small, moderate-quality, pilot study evaluated mixed treatment (manual therapy, exercise and advice) with and without traction for patients with acute sciatica.²⁵⁴

There was no statistically significant difference between traction and inactive control for the treatment of acute sciatica in terms of the global effect (two moderate-quality RCTs^{245,246}), reduction in pain intensity (two moderate-quality RCTs^{244,248}) and improvement in functional status (one moderate-quality RCT²⁴⁵) at short-term follow-up, or in terms of the global effect at medium-term follow-up (one moderate-quality RCT²⁴⁶), or in adverse effects.²⁴⁵

One poorly reported non-RCT²⁵⁰ found no statistically significant difference between traction and usual care in terms of the global effect at short-term follow-up or for adverse effects.

One small RCT²⁴³ (moderate quality) found traction plus bed rest to be significantly better than bed rest alone (activity restriction) for reducing leg pain in patients with acute sciatica at short-term follow-up. Patients who received traction experienced significantly more adverse effects than those in the control group. There was no statistically significant difference TABLE 66 Summary of the findings of any adverse effect for studies comparing traction with alternative interventions (grouped by comparator then ordered by author)

ID		Study	No. of events in intervention	No. of participants in intervention	No. of events in control	No. of participants in	
no.	Author, year	design	group	group	group	control group	OR (95% CI)
Tracti	on vs active PT/exercise t	therapy					
570	Ljunggren, 1992 ²⁴²	RCT	8	24	8	26	1.13 (0.34 to 3.69)
Tracti	on vs activity restriction						
222	Moret, 1998 ²⁴³	RCT	6	8	0	8	44.2 (1.8 to 1088.0)
Tracti	on vs inactive control						
206	Pal, 1986 ²⁴⁴	RCT	NR	NR	NR	NR	
299	Rattanatharn, 2004245	RCT	4	54	2	48	1.84 (0.32 to 10.52)
553	Larsson, 1980 ²⁴⁶	RCT	NR	NR	NR	NR	
579	Mathews, 1975247	RCT	NR	NR	NR	NR	
746	Reust, 1988 ²⁴⁸ (French language)	RCT	NR	NR	NR	NR	
746	Reust, 1988 ²⁴⁸ (French language)	RCT	NR	NR	NR	NR	
Tracti	on vs passive PT						
148	Unlu, 2008 ²⁴⁹	RCT	NR	NR	NR	NR	
148	Unlu, 2008 ²⁴⁹	RCT	NR	NR	NR	NR	
Tracti	on vs usual care						
77	Styczynski, 1991 ²⁵⁰	Non- RCT	7	38	1	29	6.32 (0.73 to 54.64)
Mixea	l treatment including trac	tion vs mixe	ed treatment witho	ut traction			
301	Harte, 2007 ²⁵⁴	RCT	NR	NR	NR	NR	

NR, not reported.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Active	PT/exercise therapy						
570	Ljunggren, 1992 ²⁴²	RCT				1.13 (0.34 to 3.69)	100.00
Activity	restriction						
222	Moret, 1998 ²⁴³	RCT				44.20 (1.80 to 1088.14)	100.00
Inactive	e control						
299	Rattanatharn, 2004245	RCT		*		1.84 (0.32 to 10.52)	100.00
Usual/c	conventional care						
77	Styczynski, 1991 ²⁵⁰	Non-RCT	+	*		6.32 (0.73 to 54.64)	100.00
	0.00092		1		1088		
		Favours tractior	ר	Favours control			

FIGURE 48 Summary of the findings of any adverse effect for studies comparing traction with alternative interventions. Note: weights are from random effects analysis.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs (%)	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous (%)	Proportion of studies that included patients who had received previous surgery (%)
Traction vs activity restriction	1 (1)	16 (16)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0	1/1 (100)	1/1 (100)
Traction vs exercise therapy	1 (1)	50 (50)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Traction vs inactive control	5 (6)	27–120 (60)	5/5 (100)	0/2 (0)	2/5 (40)	5/5 (100)	0/2 (0)	0/2 (0)	0/5 (0)	0/2 (0)	2/5 (40)	0/2 (0)
Traction vs passive PT	2 (3)	60–143 (102)	2/2 (100)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)
Traction vs usual/ conventional care	1 (3)	157 (157)	0/1 (0)	0/1 (0)	(0) 1/0	1/1 (100)	1/1 (100)	(0) 1/0	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0
Total (for traction studies)	10 (14)	16–157 (60)	9/10 (90)	0/10 (0)	5/10 (50)	10/10 (100)	3/10 (30)	0/10 (0)	0/10 (0)	0/10 (0)	3/10 (30)	1/10 (10)

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs.

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 67 Summary of traction studies
between the treatment groups for global effect and CSOMs at short-term follow-up (one small, moderate-quality RCT²⁴³).

There was no statistically significant difference between traction and exercise therapy for the treatment of chronic sciatica in terms of the global effect at short-term follow-up or for adverse effects, according to one moderate-quality RCT.²⁴²

According to two moderate-quality RCTs,^{176,249} there were no statistically significant difference between traction and passive PT for the treatment of acute sciatica in terms of global effect,¹⁷⁶ reduction in pain intensity²⁴⁹ and improvement in functional status²⁴⁹ at short-term follow-up, global effect²⁴⁹ and functional status²⁴⁹ at medium-term follow-up, or adverse effects.²⁴⁹ There were no important differences between mixed treatments with or without traction for overall improvement, pain intensity or functional status at the end of the treatment (pilot RCT²⁵⁴).

Description of manipulation studies

Summary of interventions

Four studies compared spinal manipulation with an alternative type of intervention for sciatica.^{169,208,258,259} Summary data of the interventions used are presented in *Table 68*. One RCT²⁵⁸ compared chiropractic spinal manipulation with sham manipulation. One RCT²⁰⁸ compared osteopathic spinal manipulation with chemonucleolysis. Two three-armed pilot RCTs compared chiropractic spinal manipulation with epidural corticosteroid injections, and also with either self-care education¹⁶⁹ or paracetamol, NSAIDs and activity modification.¹⁶¹ Neither of these pilot RCTs reported outcomes at follow-up apart from adverse effects and cost data. One further non-RCT compared massage, traction and spinal manipulation (mixed treatment) with digital stimulation of acupuncture points and traction.²⁶⁰

Summary of study participants for manipulation

Summary data on the included participants are presented in *Table 69*. The two RCTs comparing manipulation with alternative interventions that reported follow-up results included 142 participants with mean ages between 42 and 43 years (48–63% men): one with acute symptom duration and one with chronic symptoms. One study included patients with recurrent episodes. Sciatica was confirmed by imaging in both. There were no patients with spinal stenosis or previous back surgery or sequestered discs.

Summary of study quality for manipulation studies

Study details are summarised in *Table 70*. All of the studies comparing manipulation with alternative interventions were RCTs and one was of good quality,²⁵⁸ which was the only RCT with

ID no.	Author, year	Study design	Treatment description	Control description
Manipula	ation vs chemonucled	olysis		
723	Burton, 2000 ²⁰⁸	RCT	Osteopathic spinal manipulation for up to 12 weeks	Chemonucleolysis with 400 U chymopapain
Manipula	ation vs education/ad	vice		
722	Bronfort, 2004 ¹⁶⁹	RCT	Chiropractic spinal manipulation	Self-care education
Manipula	ation vs epidural			
451	Bronfort, 2000 ¹⁶¹	RCT	Chiropractic spinal manipulation	Epidural corticosteroid injection (one to three times)
722	Bronfort, 2004 ¹⁶⁹	RCT	Chiropractic spinal manipulation	Epidural corticosteroid injection (three times)
Manipula	ation vs inactive cont	rol		
52	Santilli, 2006258	RCT	Chiropractic manipulation up to 20 sessions	Sham manipulation up to 20 sessions
Manipula	ation vs non-opioids			
451	Bronfort, 2000 ¹⁶¹	RCT	Chiropractic spinal manipulation	Paracetamol, NSAIDs, activity modification
Mixed tr	eatment including ma	anipulation vs i	nixed treatment without manipulation	
687	Zhang, 2005 ²⁶⁰	Non-RCT	Massage, traction and spinal manipulation	Digital stimulation of acupuncture points and traction

TABLE 68 Summary of the interventions used when comparing manipulation with alternative interventions

U, units.

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

<u>ے چ</u>	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Mani	oulation vs chemo	nucleolysis											
723	Burton, 2000 ²⁰⁸	RCT	40	Mean 41.9 (SD 10.6)	19 (48)	Mean 31 (SD 35) weeks	Nerve root pain	Yes	Recurrent and first episode	No	No	RN	No
Manij	oulation vs educat	tion/advice											
722	Bronfort, 2004 ¹⁶⁹	RCT	32	Mean 49.0 (SD 9.1)	18 (56)	1-3 months 19%; 4-6 months 6%; 7-12 months 9%; >12 months 66%	Nerve root pain and referred pain	No	Recurrent and first episode	0N	No	NN	No previous spinal fusion
Mani,	oulation vs epidura	al											
451	Bronfort, 2000 ¹⁶¹	RCT	20	Mean 44.5 (SD 10.6)	12 (60)	\leq 3 weeks n =6; 4-12 weeks n =14	Nerve root pain and referred pain	No	NR	No	No	Yes	No
722	Bronfort, 2004 ¹⁶⁹	RCT	32	Mean 49.0 (SD 9.1)	18 (56)	1–3 months 19%; 4–6 months 6%; 7–12 months 9%; >12 months 66%	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	NR	No previous spinal fusion
Manij	oulation vs inactiv	e control											
52	Santilli, 2006 ²⁵⁸	RCT	102	Mean 43.1 (range 19–63)	64 (63)	<10 days	Nerve root pain and referred pain	Yes	NR	No	No	NR	No
Mani,	oulation vs non-op	vioids											
451	Bronfort, 2000 ¹⁶¹	RCT	20	Mean 44.5 (SD 10.6)	12 (60)	≤ 3 weeks $n=6$; 4-12 weeks $n=14$	Nerve root pain and referred pain	No	NR	No	No	Yes	No
Mixeu	1 treatment includ	ing manipul	'ation vs mi)	xed treatment wit	hout manipul	ation							
687	Zhang, 2005 ²⁶⁰	Non-RCT	210	Mean 41.8	112 (53)	NR	Nerve root pain	Yes	NR	No	No	NR	NR

TABLE 69 Summary of sciatica type and study population details for studies comparing spinal manipulation with alternative interventions

238

NR, not reported. a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included; otherwise reported as no.

~
tions
ven.
inter
tive
erna
h alt
ı witl
atior
ipuli
man
ring
mpa
s co
udie
or st
ails fo
deta
tudy
ne si
of tł
nary
Sumr
20
E
IAE

	ourningry or the study	/ Uelalis IUI SI	uales comparing n	iariipuiatiori witt	ו מונפרוזמנועפ ורונפר	VELLIOUIS				
ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Manipulat	tion vs chemonucleolysis								1	
723	Burton, 2000 ²⁰⁸	40	12 months	RCT	No	No	60-79	Yes	Moderate	Weak
Manipulat	tion vs education/advice									
722	Bronfort, 2004 ¹⁶⁹	32	52 weeks	RCT	Unclear	Partial	80–100	Unclear	Weak	Weak
Manipulat	tion vs epidural									
451	Bronfort, 2000 ¹⁶¹	20	12 weeks	RCT	Unclear	Partial	80-100	NA	Moderate	Weak
722	Bronfort, 2004 ¹⁶⁹	32	52 weeks	RCT	Unclear	Partial	80-100	Unclear	Weak	Weak
Manipulat	tion vs inactive control									
52	Santilli, 2006 ²⁵⁸	102	6 months	RCT	Yes	Yes	80-100	Yes	Strong	Strong
Manipulat	tion vs non-opioids									
451	Bronfort, 2000 ¹⁶¹	20	12 weeks	RCT	Unclear	Partial	80-100	NA	Moderate	Weak
Mixed tre	atment including spinal ma	mipulation vs m	ixed treatment withou	ıt						
687	Zhang, 2005 ²⁶⁰	210	1 day	Non-RCT	No	No	80-100	Unclear	Weak	Weak
NA, not ap	plicable.									

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

an adequate method of random number generation, a secure method of allocation concealment and good external validity.

Manipulation results at short-term follow-up (≤6 weeks) Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 71* and the accompanying forest plot (*Figure 49*). There was no significant difference in the global effect in one good-quality RCT comparing chiropractic spinal manipulation with sham manipulation.²⁵⁸ There was a significant improvement in global effect in one poor-quality non-RCT of massage, traction and spinal manipulation compared with digital stimulation of acupuncture points and traction.²⁶⁰

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 72* and the accompanying forest plot (*Figure 50*). There was no significant difference in pain intensity in one moderate-quality RCT comparing osteopathic spinal manipulation with chemonucleolysis.²⁰⁸

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 73* and the accompanying forest plot (*Figure 51*). There was no significant difference in CSOMs in one moderate-quality RCT comparing osteopathic spinal manipulation with chemonucleolysis.²⁰⁸

Manipulation results at medium-term follow-up (>6 weeks to \leq 6 months)

Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 74* and the accompanying forest plot (*Figure 52*). There was significant improvement in global effect in one good-quality RCT comparing chiropractic spinal manipulation with sham manipulation.²⁵⁸



FIGURE 49 Summary of the findings of the global effect short-term follow-up (≤ 6 weeks) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.



FIGURE 50 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.

								Interventio	5		Cont	rol				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspi	ective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawa rate	al Tota	() () () ()	utcome	Withdrawal rate	0R (95% CI)	Comments
Mani	oulation vs	inactive control	_													
52	Santilli, 2006 ²⁵⁸	A	RCT	30 days	Becominç free – rad leg pain	j pain liating		53	12	0	49		(0	0	2.10 (0.72 to 6.11)	Number randomised used as denominators by authors (two dropped out and four discontinued treatment)
Mixe	d treatment	including spiné	ıl manipuli	ation vs mix	ked treatmen.	t without										
687	Zhang, 2005 ²⁶⁰	C	Non-RCT	1 day	Remarkat on pain, S analgesia	ole effect SLR and score		108	56	0	102	Ř	10	0	0.40 (0.20 to 0.78)	
A, acı TABLI	ite; C, chron Ξ 72 Sum	ic; SLR, straight mary of the fi	leg raise. ndings o	f pain inte	insity at sho	ort-term follow	9≥) dn-	weeks) fo	or studies	comparinç	g manipı	ulation v	vith alter	native interv	entions	
							Total (<i>n</i>	Ē	Baseline m (SD)	lean	Final mea	n (SD)	Change (SD)	scores		
ΞË	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	≥ ⊕ ⊕ Control	lean ifference 5% Cl)⁵	Comment/conversion [€]
Mani	oulation vs	chemonucleoly.	sis													
723	Burton, 2000 ²⁰⁸	A+C	RCT	6 weeks	Leg	RMDQ annotated thermometer (0–6)	19	18	66.67 (14.1 <i>7</i>)	60.83 (26.5)	44.67 (26.7)	45.3 (17)		ΥUΥ	0.63 -14.98 to 3.72)	3/40 (8%) dropped out: intervention 1/20, control 2/20
A + C a Tr b Ba c Th	acute and c e results hav sed on final e term 'dropo	hronic. he been converte means or chang outs' has been u	d to a scale e scores (w sed for mis	e of 0–100 fi ith a prefere sing data, po	or comparabili ince given to c ost-baseline e.	ity. :hange scores). xclusions and pati	ents lost t	o follow-up								

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 73 Summary of the findings of CSOMs at short-term follow-up (≤6 weeks) for studies comparing manipulation with alternative interventions

						Total (<i>n</i>)		Baseline	mean (SD)	Final mea	an (SD)	Change s	cores (SD)	
ID no.	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª
Manipul	ation vs chemon	ucleolysis												
723	Burton, 2000 ²⁰⁸	A+C	RCT	6 weeks	RMDQ	19	18	11.9 (5.48)	11.95 (5.83)	7.79 (6.65)	11 (5.69)	-4.11	-0.95	-0.52 (-1.17 to 0.14)
<														

A+C, acute and chronic. a Based on final means or change scores (with a preference given to change scores.

TABLE 74 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing manipulation with alternative interventions

A, acute.

ID no.	Author, year	Study design					SMD (95% CI)	% weight
Chemo	nucleolysis							
723	Burton, 2000 ²⁰⁸	RCT		*	+	_	-0.52 (-1.17 to 0.14)	100.00
							1	
			-1.17		0		1.17	
				Favours epidural		Favours control		

FIGURE 51 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Inactive	control						
52	Santilli, 2006 ²⁵⁸	RCT		*	_	4.71 (1.95 to 11.37)	100.00
		0.088		1	1.4		
		0.000	Favours control	Favours manipulation			

FIGURE 52 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.

Pain intensity at medium-term follow-up

No study reported medium-term outcomes for pain intensity.

Condition-specific outcome measures at medium-term follow-up No study reported medium-term outcomes for CSOMs.

Results at long-term follow-up (>6 months)

Global effect at long-term follow-up

No study reported long-term outcomes for the global effect.

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 75* and the accompanying forest plot (*Figure 53*). There was no significant difference in pain intensity in one moderate-quality RCT comparing osteopathic spinal manipulation with chemonucleolysis.²⁰⁸

Condition-specific outcome measures at long-term

The results for CSOMs at long-term follow-up are presented in *Table 76* and the accompanying forest plot (*Figure 54*). There was no significant difference in CSOMs in one moderate-quality RCT comparing osteopathic spinal manipulation with chemonucleolysis.²⁰⁸

Analysis of adverse effects for spinal manipulation

The total number of adverse effects is presented in *Table 77* and the accompanying forest plot (*Figure 55*). Significantly more adverse effects were associated with manipulation than with self-care education,¹⁶⁹ but there was no significant difference compared with inactive control,²⁵⁸ epidural injections¹⁶⁹ or chemonucleolysis.²⁰⁸

TABLE 75 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing manipulation with alternative interventions

			oped 5/20,	
	Comment/ conversion⁰		10/40 (25%) droj out: intervention (control 5/20	
	Mean difference (95% Cl) ^b		-2.30 (-24.22 to 19.62)	
je scores	Control			
Chan((SD)	Intervention			
iean (SD)	Control		37.8 (29.2)	
Final m	Intervention		35.5 (32)	
nean (SD)	Control		60.83 (26.5)	
Baseline r	Intervention		66.67 (14.17)	
(<i>u</i>)	Control		15	
Total	Intervention		10	
	Scale (range) ^ª		RMDQ annotated thermometer (0–6)	nde scores).
	Location		Leg	omparability. aiven to cha
	Follow-up		12 months	of 0–100 for c
	Study design	sis	RCT	d to a scale c scores (with
	Chronicity	hemonucleolys	A + C	ronic. been converted
	Author, year	lation vs c.	Burton, 2000 ²⁰⁸	cute and ch results have d on final m
	ID no.	Manipu	723	A+C, a a The i b Base

c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

TABLE 76 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing manipulation with alternative interventions

	Mean difference (95% Cl) ^a		0.22 (0.94 to 0.50)	
e scores (SD)	Control			
Chanç	Intervention			
ean (SD)	Control		11 (5.69)	
Final m	Intervention		7.79 (6.65)	
e mean (SD)	Control		7.27 (6.65)	
Baselin	Intervention		5.87 (5.96)	
(Control		15	
Total (r	Intervention		15	
	Scale		RMDQ	
	Follow-up		6 weeks	
	Study design		RCT	
	Chronicity	lysis	A+C	
	Author, year	tion vs chemonucleo	Burton, 2000 ²⁰⁸	
	ID no.	Manipula	723	

A+C, acute and chronic. a Based on final means or change scores (with a preference given to change scores).

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Chemo	nucleolysis					
723	Burton, 2000 ²⁰⁸	RCT	<*		— –2.30 (–24.22 to 19.62)	100.00
				0	24.2	

FIGURE 53 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Chemo	nucleolysis						
723	Burton, 2000 ²⁰⁸	RCT				-0.22 (-0.94 to 0.50)	100.00
			-0.94 Favours mar	0 Nipulation	Favours control	0.94	

FIGURE 54 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing manipulation with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Chemo	nucleolysis						
723	Burton, 2000 ²⁰⁸	RCT		*		1.38 (0.29 to 6.60)	100.00
Educat	ion/advice						
722	Bronfort, 2004 ¹⁶⁹	RCT		*	\rightarrow	24.82 (1.17 to 527.12)	100.00
Epidura	al injections						
451	Bronfort, 2000 ¹⁶¹	RCT -	•	+		0.06 (0.00 to 1.46)	100.00
Epidura	al/intradiscal injecti	on					
722	Bronfort, 2004 ¹⁶⁹	RCT -		+		0.06 (0.00 to 1.20)	100.00
Inactive	e control						
52	Santilli, 2006258	RCT				(Excluded)	0.00
Non-op	bioids						
451	Bronfort, 2000 ¹⁶¹	RCT		<u> </u>		0.38 (0.04 to 3.61)	100.00
					1		
		0.001	9	1	527		
		1	Favours manipulation	Favours control			

FIGURE 55 Summary of the findings of any adverse effect for studies comparing spinal manipulation with alternative interventions. Note: weights are from random effects analysis.

TABLE 77 Summary of the findings of any adverse effect for studies comparing spinal manipulation with alternative interventions

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Manip	ulation vs chemonucle	olysis					
723	Burton, 2000 ²⁰⁸	RCT	5	15	4	15	1.38 (0.29 to 6.60)
Manip	ulation vs education/ad	lvice					
722	Bronfort, 2004 ¹⁶⁹	RCT	6	11	0	10	24.82 (1.17 to 527.00)
Manip	ulation vs epidural inje	ction					
451	Bronfort, 2000 ²⁰⁸	RCT	3	7	6	6	0.60 (0.00 to 1.46)
722	Bronfort, 2004 ¹⁶⁹	RCT	6	11	10	10	0.06 (0.00 to 1.20)
Manip	ulation vs inactive cont	trol					
52	Santilli, 2006 ²⁵⁸	RCT	0	53	0	49	
Manip	ulation vs non-opioids						
451	Bronfort, 2000 ²⁰⁸	RCT	3	7	4	6	0.38 (0.04 to 3.61)
Mixed	treatment including sp	inal manip	ulation vs mixed tr	reatment without			
687	Zhang, 2005 ²⁶⁰	Non- RCT	NR	NR	NR	NR	

NR, not reported.

SUMMARY OF OVERALL FINDINGS FOR MANIPULATION COMPARED WITH ALTERNATIVE INTERVENTIONS

Two RCTs^{208,258} compared the use of manipulation with other interventions, one of which restricted inclusion to patients with acute sciatica (*Table 78*).

There was a statistically significant improvement in medium-term (but not short-term) global effect in a good-quality RCT²⁵⁸ of chiropractic manipulation compared with sham manipulation. There was no significant difference in short- or long-term pain intensity, or in short-term CSOMs, in a moderate-quality RCT²⁰⁸ comparing osteopathic manipulation with chemonucleolysis.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Manipulation vs chemonucleolysis	1 (1)	40 (40)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0) 1/0
Manipulation vs inactive control	1 (1)	102 (102)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)	0/1 (0)	(0) 1/0	(0) 1/0	(0) 1/0	(0) 1/0
Total (for manipulation studies)	2 (2)	40–102 (71)	2/2 (100)	1/2 (50)	1/2 (50)	2/2 (100)	2/2 (100)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs.

TABLE 78 Summary of manipulation studies

Alternative therapies

Description of alternative therapy studies

Summary of interventions

Five studies evaluated alternative therapies for sciatica.^{167,215,261-263} Three of these studies compared alternative therapy with an alternative intervention.^{167,215,261} The types of interventions being compared are presented in *Table 79a*. One RCT compared acupuncture in correct acupuncture points with acupuncture in non-acupuncture points. One three-armed RCT²¹⁵ compared warming acupuncture by burning moxa with injections of an herbal preparation anisodamine, and with an oral NSAID nimesolide. One three-armed CCS¹⁶⁷ compared acupuncture and herbal medication with epidural injection of corticosteroid and local anaesthetic, and with epidural injection.

Two studies compared different types of alternative therapy.^{262,263} The types of alternative therapy compared are listed in *Table 79b*, but the findings of these studies are not considered any further.

Summary of study participants for alternative therapy

Summary data on the included participants are presented in *Table 80*. The three studies that compared alternative therapies with comparator treatments included 398 participants with

ID no.	Author, year	Study design	Treatment description	Control description
Altern	ative vs epidural			
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	Acupuncture and herbal medication	Nerve root blockade with local anaesthetic 5 ml mepivacaine twice a week for 5 weeks
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	Acupuncture and herbal medication	Nerve root blockade with steroid triamcinolone 20 mg + local anaesthetic 5 ml mepivacaine twice a week for 5 weeks
Altern	ative vs inactive conti	rol		
476	Duplan, 1983 ²⁶¹ (French language)	RCT	Acupuncture	Placebo (same acupuncture procedure but in non-acupuncture points)
Altern	ative vs non-opioids			
801	Chen, 2009 ²¹⁵	RCT	Warming acupuncture by burning moxa daily for 10 days (WAG)	Western medicine – oral nimesolide (NSAIDs) 2 g daily for 10 days (WMG)
801	Chen, 2009 ²¹⁵	RCT	Anisodamine (2 mg) point injections into acupoints daily for 10 days (PIG)	Western medicine – oral nimesolide (NSAIDs) 2 g daily for 10 days (WMG)

TABLE 79a Summary of the interventions used when comparing alternative therapies with alternative interventions

PIG, point injection group; WAG, warming acupuncture group; WMG, western medicine group.

ID no.	Author, year	Study design	Treatment description	Control description
533	Khoromi, 2007 ²⁶²	RCT (crossover)	Use of 200-g magnets in belts	Use of 50-g magnets in belts
72	Zhi, 1995 ²⁶³	Non-RCT	Scalp acupuncture combined with single body acupoint using scalp needles	Body acupuncture alone using stainless steel needles

ම දි	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Altern	ative vs epidura	al/intradiscal	' injection										
667	Wehling, 1997 ¹⁶⁷ (German language)	CCS	278	N	NR	≤3 months	Nerve root pain and referred pain	Clinical	NR	oN	No	NR	NR
Altern	ative vs inactive	e control											
476	Duplan, 1983 ²⁶¹ (French language)	RCT	30	Mean 40 (SD 10)	21 (70)	Mean 34 days (SD 15 days)	Nerve root pain and referred pain	Clinical	NR	oN	No	Yes	No
Altern	ative vs non-op	ioids											
801	Chen, 2009 ²¹⁵	RCT	06	Mean 34.5 (SD 7.7)	63 (70)	Mean 5.3 years (SD 4.14 years)	Nerve root pain	Clinical	NR	RN	NR	NR	NR

TABLE 80 Summary of sciatica type and study population details for studies comparing alternative therapies with alternative interventions

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

NR, not reported; PIG, point injection group; WAG, warming acupuncture group; WMG, western medicine group. a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included; otherwise reported as no.

mean ages between 35 and 40 years (70% men): two with acute symptom duration and one with chronic symptoms. Recurrent episodes were not reported. Sciatica was not confirmed by imaging in any of the studies. There were no patients with spinal stenosis or previous back surgery or sequestered discs.

Summary of study quality for alternative therapy studies

Study details are summarised in *Table 81*. Two of the studies were RCTs^{215,261} and none was of good quality. Neither an adequate method of random number generation nor a secure method of allocation concealment was recorded. No studies had good external validity.

Alternative therapy results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

No study reported short-term outcomes for global effect.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 82* and the accompanying forest plot (*Figure 56*). There was a significant improvement in pain intensity in a moderate-quality RCT of true acupuncture compared with needling non-acupuncture points²⁶¹ and in a poor-quality RCT of oral NSAID compared with warming acupuncture by burning moxa.²¹⁵ There was no significant difference in pain intensity in a poor-quality CCS of acupuncture and herbal medication compared with epidural injection.²⁶⁴

Condition-specific outcome measures at short-term follow-up

No study reported short-term CSOMs.

Alternative therapy results at medium-term follow-up (>6 weeks to \leq 6 months)

No study reported medium-term outcomes for global effect, pain intensity or CSOMs.

Alternative therapy results at long-term follow-up (>6 months)

Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 83* and the accompanying forest plot (*Figure 57*). There was no significant difference in the global effect in one poor-quality RCT comparing warming acupuncture by burning moxa, or injections of an herbal preparation anisodamine, with an oral NSAID.²¹⁵

Pain intensity at long-term follow-up

No study reported long-term outcomes for pain intensity.

Condition-specific outcome measures at long-term follow-up No study reported short-term CSOMs.

Analysis of adverse effects for alternative therapies

No adverse effects were reported in any of the studies (Table 84).

	Overall qualit
	Blind outcome
ns	100
ative interventio	Allocation
apies with altern	Adequate
Iternative thera	
udies comparing a	1.1
tudy details for stu	ł
Summary of the st	
TABLE 81	ŝ

D no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Alternativ	ve vs epidural/intradiscal in	jection								
667	Wehling, 1997 ¹⁶⁷ (German language)	278	5 weeks	CCS	No	No	80-100	No	Weak	Weak
Alternativ	e vs inactive control									
476	Duplan, 1983 ²⁶¹ (French language)	30	5 days	RCT	Unclear	Unclear	80-100	Yes	Moderate	Moderate
Alternativ	e vs non-opioids									
801	Chen, 2009 ²¹⁵	06	1 year	RCT	Unclear	Unclear	80-100	Unclear	Weak	Moderate

TABLE 82 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing alternative therapies with alternative interventions (grouped by comparator then ordered by author)

	rsion		ts vernent ant = no ie same it)	ts vement ant = no nt) nt)		VAS score weighted 3d		(ement in (scale and sly ago, n ted pain ggravated
	Comment/conve		Results reported a percentage impro (100% improvem, pain; 0% pain reduction = pain tl as before treatme	Results reported a percentage impro (100% improvemi pain; 0% pain reduction = pain th reduction = pain th		Mean percentage SD imputed from a average Dropouts not state		Outcome = improv clinical symptoms range not stated) Reported separate for: sciatica, lumb aggravated pain o aggravated pain o aggravated and a on sneezing and a
	Mean difference (95% Cl) ^b		4.0 (10.18 to 18.18)	14.00 (27.45 to 0.55)		-25.00 (-41.19 to -8.81)		3.32 (3.17 to 3.47)
e : (SD)	Control		-66 (24)	-48 (31)				
Chang scores	Intervention		-62 (28)	-62 (28)				
nean (SD)	Control					44 (23.67)		2.42 (0.33)
Final r	Intervention					19 (21.51)		5.74 (0.25)
e mean	Control					45		1.42 (0.37)
Baseline (SD)	Intervention					48		1.56 (0.35)
u)	Control		26	22		15		30
Total (Intervention		230	230		15		30
	Scale (range) ^a		VAS (0-100)	VAS (0-100)		VAS (0-100)		Not stated
	Location					Overall		Leg
	Follow- up		5 weeks	5 weeks		5 days		36 days (end of treatment)
	Study design	ions	CCS	CCS		RCT		RCT
	Chronicity	adiscal inject	O	U	trol	A		U
	Author, year	ive vs epidural/intr	Wehling, 1997 ¹⁶⁷ (German language) (j) ^d (steroid + LA)	Wehling, 1997' ⁶⁷ German Ianguage) (ii) ^a (LA)	ive vs inactive con	Duplan, 1983 ²⁶¹ (French language)	ive vs non-opioids	Chen, 2009²¹₅ (j) ^e (WAG)
	e ë	Alternat	667	667	Alternat	476	Alternat	801
		1						

							Total (<i>n</i>)		Baseline I (SD)	nean	Final me	an (SD)	Change scores	(D)		
ම දි	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	Comment/conversion ^c
801	Chen, 2009 ²¹⁵ (ii) ^e (PIG)	υ	RCT	36 days (end of treatment)	6a 1	stated	0e	30	1.75 (0.32)	1.42 (0.37)	2.75 (0.32)	2.42 (0.33)			0.33 (0.17 to 0.49)	Outcome = improvement in clinical symptoms (scale and range not stated) Reported separately for: sciatica, lumbago, aggravated pain on coughing, aggravated pain on sneezing and aggravated pain on defecation
A, acu A, acu b Bat c The c The d We her c Che	e; C, chronic; LΔ, loc. results have been cc ed on final means or term 'dropouts' has ling and Reinecke ¹⁶⁷ bal medication (iii). In n <i>et al.</i> ²¹⁵ included th esolide (NSAIDs) 2 g c	al anaesthetic; inverted to a so change scores been used for included three order to prevel ree treatment, daily for 10 day	PIG, point ir sale of 0–10 (with a pref missing data treatment of treatment of treatment of so (WMG) (iii	ijection group; 0 for compara (erence given tr , post-baseline groups: nerve r same compara ming acupunct), In order to pr	WAG, warmir bility. change sco exclusions (exclusions (tor twice, on ture group wit event using 1	ng acupunctu rres). and patients li with steroid (ly the first an th needles wa the same com	e group; V bst to follor triamcinolo 1 third tree rmed by b parator tw	VMG, wes w-up. one) + LA (utrning mc vice, only t	tern medici (mepivacair oups have b oxa (WAG) (the first and	ine group ie) (i), ner een inclu), point in 1 third trea	ve root blc ded in the jections of atment gro	ockade with meta-anal f anisodam oups have t	n local ana ysis (see F ine (2 mg)	esthetic (r <i>igure 56</i>), into acup	mepivacaine) (ii) oints (PIG) (ii) ar meta-analysis (and acupuncture and id western medicine – oral see <i>Figure 56</i>).

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design				WMD (95% CI)	% weight
Epidura	al/intradiscal injecti	on					
667	Wehling, 1997 ¹⁶⁷	CCS			•		100.00
Inactive	e control						
476	Duplan, 1983 ²⁶¹	RCT		•		-25.00 (-41.19 to -8.81)	100.00
Non-op	ioids						
801	Chen, 2009 ²¹⁵	RCT			٠	3.32 (3.17 to 3.47)	100.00
		_4	1.2		0	41.2	
			Favo	ours alternative	Favo	urs control	

FIGURE 56 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing alternative therapies with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study desigr	1			OR (95% CI)	% weight
Non-op	ioids						
801	Chen, 2009 ²¹⁵	RCT		*		3.27 (0.77 to 13.83)	100.00
		0.0723	1 Favours control	Favours alternative	13.8		

FIGURE 57 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing alternative therapies with alternative interventions. Note: weights are from random effects analysis.

SUMMARY OF OVERALL FINDINGS FOR ALTERNATIVE INTERVENTIONS COMPARED WITH COMPARATOR INTERVENTIONS

Three studies,^{167,215,261} two of which were RCTs,^{215,261} compared the use of acupuncture with other interventions (*Table 85*).

There was a significant improvement in pain intensity in a moderate-quality RCT of true acupuncture compared with needling non-acupuncture points,²⁶¹ but pain intensity was significantly worse in another poor-quality RCT²¹⁵ comparing warming acupuncture by burning moxa, or injecting a herbal preparation into acupuncture points, with an oral NSAID. There was no significant difference in pain intensity in a poor-quality CCS¹⁶⁷ of acupuncture and herbal medication compared with epidural injection.

ative interventions
e therapies with altern
comparing alternative
6 months) for studies
ng-term follow-up (>
the global effect at lc
ary of the findings of
TABLE 83 Summ

Secretary of State for Health.

		Chr					Interve	ntion		Contro	_			
₽ë	Author, year	onicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0r (95% CI)	Comments
Altern	ative vs non-c	spioids												
801	Chen,	U	RCT	1 year	Success: cured or	Patient	30	27	0	30	22	0	3.27	Data inferred from graphs
	2009 ²¹⁵ (j) ^a				improved (vs no								(0.77 to	reporting percentages
	(WAG)				improvement)								13.83)	ITT using worst-case analysis
														(with non-opioids as the control
														group)
801	Chen,	ပ	RCT	1 year	Success: cured or	Patient	30	19	0	30	22	0	0.63	Data inferred from graphs
	2009 ²¹⁵ (ii) ^a				improved (vs no								(0.21 to	reporting percentages
	(PIG)				improvement)								1.88)	ITT using worst-case analysis
														(with non-opioids as the control
														group)
C, chro	nic; PIG, point	injection g	froup; WAG	, warming a	cupuncture group; WMG	a, western medic	ine group							

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the

Chen *et al.*²¹⁵ included three treatment groups: point injections of anisodamine (2 mg) into acupoints (PIG) (ii), warming acupuncture group with needles warmed by burning moxa (WAG) (i) and western medicine – oral nimesolide (NSAIDS) 2 g daily for 10 days (WMG) (iii). In order to prevent using the same comparator twice, only the first and third treatment groups have been included in the meta-analysis (see *Figure 57*). പ

 TABLE 84
 Summary of the findings of any adverse effect for studies comparing alternative therapies with alternative interventions

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group
Altern	native vs epidural inje	ctions				
667	Wehling, 1997167	RCT	NR	NR	NR	NR
667	Wehling, 1997 ¹⁶⁷	RCT	NR	NR	NR	NR
Altern	native vs inactive com	trol				
476	Duplan, 1983 ²⁶¹	RCT	NR	NR	NR	NR
Altern	native vs non-opioid					
801	Chen, 2009 ²¹⁵	RCT	NR	NR	NR	NR
801	Chen, 2009 ²¹⁵	RCT	NR	NR	NR	NR

NR, not reported.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Alternative vs epidural/intradiscal injection	1 (2)	278 (278)	0/1 (0)	0/1 (0)	(0) 1/0	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0) 1/0	0/1 (0)
Alternative vs inactive control	1 (1)	30 (30)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	(0) 1/0	0/1 (0)	1/1 (100)	(0) 1/0
Alternative vs non- opioids	1 (2)	60 (06)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0	(0) 1/0	(0) 1/0
Total (for alternative therapies)	3 (4)	30–278 (90)	2/3 (67)	0/3 (0)	1/3 (33)	3/3 (100)	0/3 (0)	0/3 (0)	0/3 (0)	0/3 (0)	1/3 (33)	0/3 (0)
This table shows only s	tudies that rep	sorted outcomes	tor global effect	, pain intensity or (CSOMs.							

TABLE 85 Summary of alternative therapies

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

Active physical therapy/exercise therapy

Description of exercise therapy studies

Summary of interventions

Six studies compared active physical/exercise therapy with an alternative type of intervention for sciatica.^{68,242,255,256,264,265} Summary data of the interventions used are presented in *Table 86*. One crossover RCT²⁶⁵ compared a 4-week course of lumbar-stabilising exercise with no exercise. One three-arm RCT²⁵⁶ compared massage, hot packs and exercise with hot packs and rest or with pelvic traction and strengthening exercises. One RCT⁶⁸ compared exercise therapy alone with disc surgery plus exercise therapy. One RCT²⁵⁵ compared an extension-orientated treatment including exercise, mobilisation and education with lumbar traction plus the extension-orientated treatment approach. One RCT²⁴² compared isometric exercises with manual traction. One RCT²⁶⁶ compared physiotherapy plus GP care with GP care alone.

Summary of study participants for active physical therapy/exercise therapy

Summary data on the included participants are presented in *Table 87*. The six trials included 305 participants with mean ages between 32 and 42 years; between 44% and 61% were men; and, three with acute and chronic symptom duration and three with chronic symptoms. Two RCTs included participants with first and recurrent episodes of sciatica, but this was not reported in the remainder. Sciatica was confirmed by imaging in three trials. There were no patients with spinal stenosis, or previous back surgery, and one RCT included patients with sequestered discs.

Summary of study quality for active physical therapy/exercise therapy

Study details are summarised in *Table 88*. All of the studies were RCTs and one was of good quality.²⁶⁶ Four had an adequate method of random number generation and two documented a secure method of allocation concealment. One study had good external validity.²⁶⁶

Active physical therapy/exercise therapy results at short-term follow-up (<6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 89* and the accompanying forest plot (*Figure 58*). There was no significant difference in global effect in a moderate-quality RCT comparing isometric exercises with manual traction;²⁴² a moderate-quality RCT comparing exercise therapy alone with disc surgery plus exercise therapy;⁶⁸ a poor-quality RCT comparing massage, hot packs and exercise with hot packs and rest;²⁵⁶ a moderate-quality RCT comparing exercise, mobilisation and education with extension-orientated approach and traction;²⁵⁵ and a good-quality RCT comparing general practitioner care and PT with GP care.²⁶⁶ In a poor-quality RCT, there was a significant improvement in global effect with pelvic traction and strengthening exercises compared with massage, hot packs and exercise.²⁵⁶

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 90* and the accompanying forest plot (*Figure 59*). There was a significant improvement in pain intensity in a moderate-quality crossover RCT of exercise therapy compared with inactive control,²⁶⁵ and in a moderate-quality RCT of disc surgery plus exercise therapy compared with exercise therapy alone.⁶⁸ In a good-quality RCT there was no significant difference in pain intensity with GP care and PT compared with GP care alone,²⁶⁶ or in a moderate-quality RCT of exercise, mobilisation and education compared with extension-orientated approach and traction.²⁵⁵

TABLE 86 Summary of the interventions used when comparing exercise therapy with alternative interventions (ordered by control group then author)

ID no.	Author, year	Study design	Treatment description	Control description
Exerci	se therapy vs activity rest	triction		
564	Lidstrom, 1970 ²⁵⁶	RCT	Massage, hot packs and exercise (conventional treatment)	Hot packs and rest (control group)
Exerci	se therapy vs disc surger	v		
300	Osterman, 200668	RCT	Exercise therapy (conservative treatment)	Microdiscectomy and exercise therapy (surgery)
Exerci	se therapy vs inactive cor	ntrol		
429	Bakhtiary, 2005 ²⁶⁵	RCT (crossover)	4 weeks of lumbar-stabilising exercise followed by a 4 weeks of no exercise (group A)	4 weeks of no exercise followed by 4 weeks of lumbar-stabilising exercise (group B)
			Only 4-week outcomes used	Only 4-week outcomes used
Exerci	se therapy vs mixed treat	ment		
395	Fritz, 2007 ²⁵⁵	RCT	Extension-oriented treatment approach (exercises, mobilisation and education) only	Traction and extension-oriented treatment approach
564	Lidstrom, 1970 ²⁵⁶	RCT	Hot packs, massage, mobilising exercise and strengthening exercises	Traction and strengthening exercises
Exerci	se therapy vs traction			
570	Ljunggren, 1992242	RCT	Isometric exercises	Manual traction
Exerci	se therapy vs usual/conve	entional care		
742	Luijsterburg, 2008 ²⁶⁴	RCT	General practitioner care plus PT	General practitioner care

Condition-specific outcomes at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 91* and the accompanying forest plot (*Figure 60*). There was no significant difference in CSOMs in a moderate-quality RCT of exercise therapy alone compared with disc surgery plus exercise therapy⁶⁸ or in a moderate-quality RCT of exercise, mobilisation and education compared with extension-orientated approach and traction.²⁵⁵ There was a marginal statistically significant improvement in a good-quality RCT of pain intensity for GP care alone compared with PT and GP care.²⁶⁶

Active physical therapy/exercise therapy results at medium-term follow-up (>6 weeks to ≤ 6 months)

Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 92* and the accompanying forest plot (*Figure 61*). In a moderate-quality RCT there was no significant difference in global effect with exercise therapy alone compared with disc surgery plus exercise therapy,⁶⁸ or in a good-quality RCT of GP care and PT compared with GP care alone.²⁶⁶

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 93* and the accompanying forest plot (*Figure 62*). There was no significant difference in pain intensity in a moderate-quality RCT of exercise therapy alone compared with disc surgery plus exercise therapy⁶⁸ or in a good-quality RCT of GP care and PT compared with GP care alone.²⁶⁶

259

ns	
ç	
_	
<u>.o</u>	
Ħ	
Ð	
ž	
5	
Ĕ	
d)	
ž	
Ξ	
g	
F	
Ð	
브	
ω	
Ч	
÷	
>	
>	
D.	
g	
ð	
ž	
4	
ð	
<u>.o</u>	
Q	
ē	
×	
Φ	
D	
Ĉ,	
g	
얻	
F	
0	
0	
S	
Ð	
5	
Ē	
ъ	
č	
ō	
÷	
<u>0</u>	
ы.	
÷	
8	
Ξ.	
Ē	
ion	
ation (
lation (
oulation (
opulation (
population	
/ population	
dy population	
udy population	
study population	
study population	
id study population	
and study population	
and study population	
te and study population	
/pe and study population	
type and study population	
a type and study population	
ca type and study population	
ttica type and study population	
iatica type and study population	
sciatica type and study population	
^c sciatica type and study population	
of sciatica type and study population	
/ of sciatica type and study population	
iry of sciatica type and study population	
lary of sciatica type and study population	
mary of sciatica type and study population	
mmary of sciatica type and study population	
ummary of sciatica type and study population	
Summary of sciatica type and study population	
Summary of sciatica type and study population	
37 Summary of sciatica type and study population	
87 Summary of sciatica type and study population	
.E 87 Summary of sciatica type and study population	
3LE 87 Summary of sciatica type and study population	
\BLE 87 Summary of sciatica type and study population	
ABLE 87 Summary of sciatica type and study population	

e ë	Author, vear	Study design	No. of patients	Age (vears)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)?ª	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Exerci	ise therapy vs ac	stivity restrictio	uc Ic										
564	Lidstrom, 1970 ²⁵⁶	RCT	62	Range 21–61	29 (47)	>1 year 52%	Nerve root pain and referred pain	No	N	No	No	NR	R
Exerci	ise therapy vs di.	isc surgery											
300	Osterman, 2006 ⁶⁸	RCT	57	Mean 38 (SD 7)	34 (61)	Mean 68.5 days (SD 27 days)	Nerve root pain	Yes	Recurrent and First episode	No	Yes	NR	No
Exerci	ise therapy vs in	active control											
429	Bakhtiary, 2005 ²⁶⁵	RCT (crossover)	60	Mean 32 (SD 5.79)	Not reported	Mean 3.95 months (SD 1.30 months)	NR	Yes	NR	No	No	NR	R
Exerci	ise therapy vs m	vixed treatmen	t										
395	Fritz, 2007 ²⁵⁵	RCT	64	Mean 41.1 (SD 9.8; range 18–60)	28 (44)	Median 47.5 days (range 2–761 days)	Nerve root pain	No	49 (77%) had prior history of low back pain	No	No	NR	No
564	Lidstrom, 1970 ²⁵⁶	RCT	62	Range 21–61	29 (47)	>1 year 52%	Nerve root pain and referred pain	No	NR	No	No	NR	R
Exerci	ise therapy vs tra	action											
570	Ljunggren, 1992 ²⁴²	RCT	50	Mean 41.6 (range 19–62)	27 (54)	Mean 5 months	Nerve root pain	Yes	NR	No	No	NR	No
Exerci	ise therapy vs us	sual/conventio	nal care										
742	Luijsterburg, 2008 ²⁶⁴	RCT	135	Mean 43 (SD 11)	70 (52)	>6 weeks	Nerve root pain	No	NR	No	No	NR	No
	totooot t												

NR, not reported. a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included; otherwise reported as no.

vith alternative interventions	
exercise therapy v	
udies comparing e	
ly details for st	
nary of the stud	
LE 88 Sumr	

© Queen	's Printer and Controller of HMSO 2011.	This work was produced by	Lewis et al. u	inder the terms of	a commissioning contra	act issued by the
Secretary	of State for Health.					

TABLE 8	8 Summary of the study	details for stuc	lies comparing ex	xercise therapy w	vith alternative int	erventions				
ID no.	Author, year	Study size	Overall follow- up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Exercise	therapy vs activity restriction	-								
564	Lidstrom, 1970 ²⁵⁶	62	1 month	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Exercise	therapy vs disc surgery									
300	Osterman, 2006 ⁶⁸	57	2 years	RCT	Yes	Yes	80-100	NA	Moderate	Weak
Exercise	therapy vs inactive control									
429	Bakhtiary, 2005 ²⁶⁵	60	8 weeks	RCT	Yes	Partial	80-100	Yes	Moderate	Weak
Exercise	therapy vs mixed treatments									
395	Fritz, 2007 ²⁵⁵	64	6 weeks	RCT	Yes	Partial	80-100	Partial	Moderate	Weak
564	Lidstrom, 1970 ²⁵⁶	62	1 month	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Exercise	therapy vs traction									
570	Ljunggren, 1992 ²⁴²	50	1 week	RCT	Unclear	Unclear	80-100	Yes	Moderate	Weak
Exercise	therapy vs usual/convention.	al care								
742	Luijsterburg, 2008 ²⁶⁴	135	12 months	RCT	Yes	Yes	80-100	NA	Strong	Strong
NA, not ap	pplicable.									

ed by	
groupe	
ions (
ervent	
ve inte	
ernati	
vith alt	
rapy v	
se the	
exerci	
baring	
s com	
studies	
s) for s	
week	
9≥) dn	
-wollo	
term fo	
short-	
ect at	
bal eff	
he glo	
gs of t). J
finding	/ autho
of the	sred by
Jmary	n orde
9 Sun	tor the
BLE 8	mparat

TABLE compe	89 Summary of t trator then ordered	the findings by author)	of the glc	obal effeci	t at short-term follow-u	p (≤6 weeks)	for stu	dies comp	aring exercis	e thera	oy with alt	ernative inter	rventions (g	Irouped by
							Intervei	rtion		Control				
₽ë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
Exerc	ise therapy vs activity	restriction												
564	Lidstrom, 1970 ²⁵⁶ (ii) ^a (Rest)	A+C	RCT	1 month	Noticeable improvement (vs no change or worse)	Patient	21	10	0	21	14	0	0.45 (0.13 to 1.58)	
Exerc	ise therapy vs disc su	rgery												
300	Osterman, 2006 ⁶⁸	A	RCT	6 weeks	Full recovery	Patient	28	0	0	28	2	0.03	0.07 (0.00 to 1.43)	
Exerc	ise therapy vs mixed	treatments												
395	Fritz, 2007 ²³⁵	A	RCT	6 weeks	Improved: Likert- type scale rating >2 (scale range -7 to + 7: worsened <-2; unchanged -2 to +2)	Patient	33	21	0	31	21	0	0.83 (0.30 to 2.34)	ITT using LOCF Dropouts 13%: intervention 3/33, control 5/31
564	Lidstrom, 1970 ²⁵⁶ (i) ^a (traction + excercise)	A+C	RCT	1 month	Noticeable improvement (vs no change or worse)	Patient	21	10	0	20	18	0	0.10 (0.02 to 0.55)	

							Intervei	ntion		Control				
₽			Study	Follow-			Total	Outcome	Withdrawal	Total	Outcome	Withdrawal	OR	
цо.	Author, year	Chronicity	design	dn	Outcome measure	Perspective	(II)	(<i>u</i>)	rate	(<i>u</i>)	(<i>u</i>)	rate	(95% CI)	Comments
Exerci	se therapy vs trac	tion												
570	Ljunggren, 1992 ²⁴²	C	RCT	1 week	Global evaluation: symptom-free or satisfactory improvement (vs unsatisfactory improvement or unchanged)	Patient	26	10	0	24	-	0	0.88 (0.28 to 2.72)	
Exerci	se therapy vs usu	al/conventional c	care											
742	Luijsterburg, 2008 ²⁶⁴	٩	RCT	6 weeks	Improved (on seven-point Likert scale): 'completely recovered' and 'much improved' (vs 'slightly improved', 'not changed', 'slightly worsened', 'much worsened' and 'worse than ever')	Patient	67	38	0	68	30	0	1.66 (0.84 to 3.28)	ITT using LOCF Dropouts 4%: intervention 2/67, control 4/68
A, acut a Lid	e; A + C, acute and strom and Zachriss	chronic; C, chron. on ²⁵⁶ included thre	ic; LOCF, la: se treatmen	st observatio t groups: tra	on carried forward. (ction + strengthening exercis	ies (i), rest + hot p	oacks (ii)	and massage	, mobilising exe	rcises, st	rengthening (exercises + hot p	oacks (iii).	

DOI: 10.3310/hta15390

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Tractio	n						
570	Ljunggren, 1992 ²⁴²	RCT			•	0.88 (0.28 to 2.72)	100.00
Disc su	irgery						
300	Osterman, 200668	RCT		•		0.07 (0.00 to 1.43)	100.00
Activity	restriction						
564	Lidstrom, 1970 ²⁵⁶	RCT			<u> </u>	0.45 (0.13 to 1.58)	100.00
Mixed	reatments						
564	Lidstrom, 1970 ²⁵⁶	RCT				0.10 (0.02 to 0.55)	44.79
395	Fritz, 2007 ²⁵⁵	RCT				0.83 (0.30 to 2.34)	55.21
Subtota	ll (<i>l</i> ² = 77.2%, <i>p</i> = 0.036)					0.32 (0.04 to 2.56)	100.00
Usual/c	conventional care						
742	Luijsterburg, 2008 ²⁶⁴	RCT				1.66 (0.84 to 3.28)	100.00
						1	
			0.00394		1	254	
				Favours control	Favours exercise the	rapy	

FIGURE 58 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design	I			WMD (95% CI)	% weight
Disc su	irgery						
300	Osterman, 200668	RCT				13.00 (0.55 to 25.45)	100.00
Inactive	e control						
429	Bakhtiary, 2005 ²⁶⁵	RCT				-27.00 (-33.72 to -20.28)	100.00
Mixed t	treatment						
395	Fritz, 2007 ²⁵⁵	RCT				-2.00 (-14.02 to 10.02)	100.00
Usual/c	conventional care						
742	Luijsterburg, 2008 ²⁶⁴	RCT			•	3.00 (-6.28 to 12.28)	100.00
		-3	3.7		0	33.7	
		F	avours exerci	se therapy	Favours control		

FIGURE 59 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

							Total (Ē	Baseline (SD)	mean	Final me	an (SD)	Change (SD)	scores		
e ë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion ^c
Exerci	ise therapy vs d	lisc surgery														
300	Osterman, 2006 ⁸⁸	4	RCT	6 weeks	Leg	VAS (0-100)	28	28	57 (21)	61 (20)	25 (27)	12 (20)			13.00 (0.55 to 25.45)	Dropouts 2%: surgery 1/29 (did not meet inclusion criteria, excluded from analysis), exercise 0/28
Exerci	ise therapy vs in	nactive contro	-													
429	Bakhtiary, 2005 ²⁸⁵	A + C	(crossover)	4 weeks	Overall	VAS (0-10)	30	08	42.9 (9)	45 (11)			-32 (14.7)	-5 (11.7)	-27.00 (-33.72 to -20.28) Mean difference -2.7 (-3.5 to -1.9), p < 0.0001 (two- way ANOVA)	ITT, method not stated Dropouts 1%: intervention 3/30, control 3/30 This was a crossover study, where all patients received LSE or no exercise; however, the authors compared the outcomes of group A (LSE followed by no exercise followed by LSE) not LSE vs no exercise
Exerci	ise therapy vs m	nixed treatmen	nts													
395	Fritz, 2007 ²⁸⁵	ح	RCT	6 weeks	Overall	NRS (0-10)	33	31	53.0 (15.0)	50.0 (18.0)	30.0 (24.0)	32.0 (25.0)			-2.00 (-14.02 to 10.02) Adjusted mean difference, AMCOUA -0.17 (95% CI -1.4 to 1.1)	ITT using LOCF Dropouts 13%: intervention 3/33, control 5/31
																continued

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 90 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing exercise therapy with alternative interventions (continued)

	Comment/conversion [©]		ITT using LOCF Dropouts 4%:	intervention 2/67, control 4/68
	Mean difference (95% CI) ^b		3.00 (-6.28 to 12.28)	Unadjusted mean difference 3 (95% CI –6 to 12)
e scores	Control		-33 (28)	
Chang (SD)	Intervention		-30 (27)	
nean (SD)	Control			
Final r	Intervention			
mean	Control		63 (22)	
Baseline (SD)	Intervention		63 (22)	
(<i>u</i>)	Control		68	
Total	Intervention		67	
	Scale (range) ^a		NRS (0-10)	
	Location		Leg	
	Follow- up		6 weeks	
	Study design	onal care	RCT	
	Chronicity	ual/conventi	A	
	Author, year	therapy vs usu	Luijsterburg, 2008 ²⁶⁴	
	<u> </u>	Exercise	742	

A, acute; A + C, acute and chronic; LOCF, last observation carried forward; LSF, lumbar stabilising exercise; NRS, numerical rating scale.

a The results have been converted to a scale of U-TUU ror comparation. b Based on final means or change scores (with a preference given to change scores); results reported by study in italics. c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

TABLE	91 Summar	y of the findir	ngs of CSC	OMs at sho	rt-term follc	≂) dn-wo	6 weeks)	for studie	s compa	tring exer	cise ther	apy with	alternat	ive interventions	
						Total (n		Baseline (SD)	mean	Final mea	an (SD)	Change (SD)	scores		
e ë	Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI)ª	Comment/conversion ^b
Active	PT/exercise the	stapy vs disc s	urgery												
300	Osterman, 2006 ^{ss}	A	RCT	6 weeks	IQO	28	28	39 (14)	39 (15)	22 (16)	16 (16)	-17	23	0.38 (-0.15 to 0.90)	ITT used LOCF, but one patient that did not meet inclusion criteria excluded from analysis
Active	PT/exercise the	srapy vs mixed	l treatment												
395	Fritz, 2007 ²⁵⁵	ح	RCT	6 weeks	Modified ODI	33	31	41.5 (10.7)	46.1 (14.9)	25.6 (19.9)	28.3 (19.3)			-0.14 (-0.63 to 0.35) Adjusted mean difference, ANCOVA: 1.8 (95% CI -6.4 to 10.1)	ITT used LOCF Dropouts 13%: intervention 3/33, control 5/31
Active	PT/exercise the	srapy vs usual/	/conventiona	al care											
742	Luijsterburg, 2008 ²⁶⁴	4	RCT	6 weeks	RMDQ	67	68	15.9 (4.1)	15.4 (5)	10.6 (4.1)	8.8 (6.1)	-5.3	-6.6 (6.1)	0.35 (0.01 to 0.69)	Final mean calculated from change score, final SD missing so baseline SD used
A, acui a Bas b The	te; LOCF, last obs sed on final mean term 'dropouts'	servation carried Is or change scc has been used 1	l forward. ores (with a pi for missing da	reference give ata, post-base	en to change si eline exclusion:	cores); res s and patie	ults reporte ints lost to f	d by study ir ollow-up.	n italics.						

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design		SMD (95% CI)	% weight
Disc su	irgery				
300	Osterman, 200668	RCT —	*	0.38 (-0.15 to 0.90)	100.00
Mixed t	reatments				
395	Fritz, 2007 ²⁵⁵	RCT		-0.14 (-0.63 to 0.35)	100.00
Usual/c	conventional care				
742	Luijsterburg, 2008 ²⁶⁴	RCT		0.35 (0.01 to 0.69)	100.00
				1	
		-0.904	0	0.904	
		Favours exercise therapy	Favours control		

FIGURE 60 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.



FIGURE 61 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 94* and the accompanying forest plot (*Figure 63*). There was no significant difference in CSOMs in a moderate-quality RCT of exercise therapy alone compared with disc surgery plus exercise therapy⁶⁸ or in a good-quality RCT of GP care and PT compared with GP care alone.²⁶⁶

Active physical therapy results at long-term follow-up (>6 months) Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 95* and the accompanying forest plot (*Figure 64*). There was no significant difference in CSOMs in a moderate-quality RCT of exercise therapy alone compared with disc surgery plus exercise therapy.⁶⁸ There was a significant improvement for the global effect in a good-quality RCT of GP care and PT compared with GP care alone.²⁶⁶

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 96* and the accompanying forest plot (*Figure 65*). There was no significant difference in pain intensity with exercise therapy alone compared with disc surgery plus exercise therapy⁶⁸ or with GP care and PT compared with GP care alone.²⁶⁶

							Interver	ntion		Control				
е ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	or (95% CI)	Comments
Exercis	se therapy vs d	isc surgery												
300	Osterman, 2006≋	ح	RCT	6 months	Full recovery	Patient	58	4	0	58	പ	0	0.77 (0.18 to 3.22)	ITT using LOCF Dropouts 12%: surgery 3/29 (one patient did not meet inclusion criteria, excluded from analysis), exercise 4/28
Exercis	se therapy vs u.	sual/conventio	nal care											
742	Luijsterburg, 2008 ²⁸⁴	ح	RCT	12 weeks	Improved (seven- point Likert scale): 'completely recovered' and 'much improved' (vs 'slightly improved', 'not changed', 'slightly worsened' and 'worse than ever')	Patient	67	47	o	68	42	0	1.45 (0.71 to 2.98)	ITT using LOCF Dropouts 7%: intervention 3/67, control 6/68

A, acute; LOCF, last observation carried forward.

TABLE 92 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing exercise therapy with alternative interventions

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 93 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing exercise therapy with alternative interventions

	Comment/conversion [€]		ITT using LOCF Dropouts 12%: surgery 3/29 (one patient did not meet inclusion criteria, excluded from analysis), exercise 4/28		ITT using LOCF Dropouts 7%: intervention 3/67, control 6/68
	Mean difference (95% Cl)		9.00 (-4.05 to 22.05)		-2.00 (-11.96 to 7.96) Mean difference -0.2 (95% Cl -1.2 to 0.8)
e scores	Control				-37 (31)
Chang (SD)	Intervention				39 (28)
1ean (SD)	Control		9 (20)		
Final n	Intervention		18 (29)		
mean	Control		61 (20)		63 (22)
Baseline (SD)	Intervention		57 (21)		63 (22)
<i>(u</i>)	Control		28		68
Total	Intervention		28		67
	Scale (range) ^a		VAS (0-100)		NRS (0-10)
	Location		Leg		Leg
	Follow- up		6 months		12 weeks
	Study design		RCT	onal care	RCT
	Chronicity	lisc surgery	ح	sual/conventi	A
	Author, year	se therapy vs o	Osterman, 2006 ⁶⁸	se therapy vs u	Luijsterburg, 2008 ²⁶⁴
	e ë	Exercis	300	Exercis	742

A, acute; LOCF, last observation carried forward; NRS, numerical rating scale.

The results have been converted to a scale of 0-100 for comparability.

മ

b Based on final means or change scores (with a preference given to change scores); results reported by study in italics.

c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

Bakhtiary et al²⁶⁵ also reported 8-week outcome data, but these data do not represent exercise therapy vs atternative and therefore are not included here. The intervention was 4 weeks of lumbar-stabilising exercise

followed by a 4 weeks of no exercise (group A) compared with 4 weeks of no exercise followed by 4 weeks of lumbar-stabilising exercise (group B).

ID no.	Author, year	Study design				WMD (95% CI)	% weight
Disc su	rgery						
300	Osterman, 200668	RCT		*		9.00 (-4.05 to 22.05)	100.00
Usual/c	conventional care						
742	Luijsterburg, 2008 ²⁶⁴	RCT				-2.00 (-11.96 to 7.96)	100.00
		1					
	-	22	()	22		
		Favours ex	ercise therapy	Favours control			

FIGURE 62 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to \leq 6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Disc su	rgery					
300	Osterman, 200668	RCT ——			0.29 (-0.23 to 0.82)	100.00
Usual/c	conventional care					
742	Luijsterburg, 2008 ²⁶⁴	RCT –	*		0.28 (-0.05 to 0.62)	100.00
	-0.821		0	0.821		
	Fa	avours exercise therapy	Favours control			

FIGURE 63 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

Condition-specific outcome measures at long-term follow-up

The results for CSOMs at long-term follow-up are presented in *Table 97* and the accompanying forest plot (*Figure 66*). There was no significant difference in CSOMs in a moderate-quality RCT of exercise therapy alone compared with disc surgery plus exercise therapy,⁶⁸ or in a good-quality RCT of GP care and PT compared with GP care alone.²⁶⁶

Adverse effects

The total number of adverse effects is presented in *Table 98* and the accompanying forest plot (*Figure 67*). There was no significant difference between exercise therapy and disc surgery with exercise therapy,⁶⁸ or between isometric exercises and manual traction.²⁴²

SUMMARY OF OVERALL FINDINGS FOR ACTIVE PHYSICAL/EXERCISE THERAPY COMPARED WITH ALTERNATIVE INTERVENTIONS

Six RCTs,^{68,242,255,256,264,265} one of which was a crossover trial,²⁶⁵ compared the use of active physical therapy with other interventions (*Table 99*).

One moderate-quality crossover RCT²⁶⁵ found that lumbar-stabilising exercises, compared with no exercise, resulted in a significant improvement in pain intensity in the short term. However, in another poor-quality RCT,²⁵⁶ massage, hot packs and exercise resulted in no significant difference in short-term global effect compared with hot packs and rest. In this same RCT, short-term

271
TABLE 94 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing exercise therapy with alternative interventions

	Comment/conversion ^b		ITT used LOCF, but one patient that did not meet inclusion criteria excluded from analysis		Baseline SD used for final mean SD ITT used LOCF	
	Mean difference (95% Cl)ª		0.29 (-0.23 to 0.82)		0.28 (-0.05 to 0.62)	
res (SD)	Control		-31		-8.5 (6.7)	
Change sco	Intervention		-27		-7.7 (7.3)	
(SD)	Control		8 (12)		6.9 (5)	
Final mean	Intervention		12 (15)		8.2 (4.10)	
nean	Control		39 (15)		15.4 (5)	
Baseline r (SD)	Intervention		39 (14)		15.9 (4.1)	
(u	Control		28		68	
Total (Intervention		28		67	
	Scale		IOO		RMDQ	
	Follow- up		6 months		12 weeks	
	Study design		RCT	al care	RCT	
	Chronicity	surgery	A	al/conventior.	A	
	Author, year	e therapy vs disc	Osterman, 2006 [%]	e therapy vs usu:	Luijsterburg, 2008 ²⁶⁴	
	D e	Exercis	300	Exercis	742	

A, acute; LOCF, last observation carried forward. a Based on final means or change scores (with a preference given to change scores). b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

S
P
nti
Ą
Ę
.⊆
۷e
ati
Ë
lte
a
Ē
3
đ
era
Ĕ
ė.
Cis:
ē
ě
p
arir
d
E C
ö
es
īġ
stl
Ъ
Ĵ.
Ë
Ū
Ĕ
9
$\overline{\nabla}$
<) dn
<) dn-m
<) dn-woll
follow-up (>
rm follow-up (>
term follow-up (>
ng-term follow-up (>
ong-term follow-up (>
at long-term follow-up (>
st at long-term follow-up (>
fect at long-term follow-up (>
effect at long-term follow-up (>
oal effect at long-term follow-up (>
lobal effect at long-term follow-up (>
s global effect at long-term follow-up (>
the global effect at long-term follow-up (>
of the global effect at long-term follow-up (>
s of the global effect at long-term follow-up (>
ings of the global effect at long-term follow-up (>
ndings of the global effect at long-term follow-up (>
\circ findings of the global effect at long-term follow-up (>
the findings of the global effect at long-term follow-up (>
of the findings of the global effect at long-term follow-up (>
y of the findings of the global effect at long-term follow-up (>
hary of the findings of the global effect at long-term follow-up (>
nmary of the findings of the global effect at long-term follow-up (>
summary of the findings of the global effect at long-term follow-up (>
Summary of the findings of the global effect at long-term follow-up (>
95 Summary of the findings of the global effect at long-term follow-up (>
.E 95 Summary of the findings of the global effect at long-term follow-up (>
ABLE 95 Summary of the findings of the global effect at long-term follow-up (>

							Intervei	ntion		Control				
Ξë	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
Exerc	ise therapy vs c	tisc surgery												
300	Osterman, 2006 ⁸⁸	A	RCT	2 years	Full recovery	Patient	28	D	0	28	~	0.03	0.66 (0.18 to 2.37)	ITT using LOCF Dropouts 12%: surgery 3/29 (one patient did not meet inclusion criteria, excluded from analysis), exercise 4/28
Exerc	ise therapy vs u	isual/conventi	onal care											
742	Luijsterburg, 2008 ²⁸⁴	ح	RCT	52 weeks	Improved (seven- point Likert scale): 'completely recovered' or 'much improved' (vs 'slightly improved', 'inot changed', 'slightly worsened', 'much worsened' or 'worse than ever')	Patient	67	23	0	68	88	0	2.99 (1.40 to 6.38)	ITT using LOCF Dropouts 13%: intervention 7/67, control 11/68
A, acu	te; LOCF, last ob:	servation carrie	d forward.											



FIGURE 64 Summary of the findings of the global effect at long-term follow-up (>6 months) for studies comparing exercise therapy to alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				WMD (95% CI)	% weight
Disc su	rgery						
300	Osterman, 200668	RCT	-		\longrightarrow	9.00 (-0.78 to 18.78)	100.00
Usual/c	conventional care						
742	Luijsterburg, 2008 ²⁶⁴	RCT -	*	<u> </u>		-7.00 (-16.11 to 2.11)	100.00
		-18.8		0	18	.8	
		Favor	urs exercise therapy	Favours cont	trol		

FIGURE 65 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

global effect of massage, hot packs and exercise were worse than those of pelvic traction and strengthening exercises, but two other moderate-quality RCTs^{242,255} found no significant difference in short-term global effect between isometric exercises and traction, and no significant difference in short-term global effect, pain intensity or CSOMs between an extension-orientated treatment approach consisting of exercise, mobilisation and exercises and the extensionorientated treatment approach plus traction. In one good-quality RCT,²⁶⁶ PT plus GP care, compared with GP care alone, resulted in significantly worse short-term CSOMs and significantly better long-term global effect, but there was no significant difference at other follow-up periods or in pain intensity at any of the three follow-up periods. In one moderate-quality RCT,⁶⁸ shortterm pain intensity was significantly worse in the group that received exercise therapy than in the group treated with exercise therapy plus microdiscectomy, but there was no significant difference in pain intensity at medium- and long-term follow-up, or in the global effect or CSOMs at any of the three follow-up periods.

S	
0	
Ξ	
5	
3	
5	
Ψ.	
^d	
~	
÷	
g	
5	
ē	
÷	
σ	
÷	
÷	
>	
\geq	
<u>o</u>	
Ŋ	
ē	
Ĩ	
÷	
ő	
.99	
2	
Ð	
×	
Ψ	
g	
⊒.	
L.	
8	
¥	
Ē	
<u> </u>	
0	
ŝ	
<u>e</u> .	
σ	
St	
ĩ	
ō	
÷	
ŝ	
<u> </u>	
Ę	
ō	
Ē	
-	
G	
Λ,	
<u>^</u>	
<) dr	
<) dn-	
<) dn-w	
<) dn-mo	
<) dn-woll	
<) dn-wollo	
<) dn-wollot (>	
-<) dn-wollow	
erm follow-up (>	
-term follow-up (>	
g-term follow-up (>	
ng-term follow-up (>	
long-term follow-up (>	
t long-term follow-up (>	
at long-term follow-up (>	
y at long-term follow-up (>	
ity at long-term follow-up (>	
sity at long-term follow-up (>	
ensity at long-term follow-up (>	
itensity at long-term follow-up (>	
intensity at long-term follow-up (>	
n intensity at long-term follow-up (>	
ain intensity at long-term follow-up (>	
pain intensity at long-term follow-up (>	
f pain intensity at long-term follow-up (>	
of pain intensity at long-term follow-up (>	
s of pain intensity at long-term follow-up (>	
gs of pain intensity at long-term follow-up (>	
ings of pain intensity at long-term follow-up (>	
dings of pain intensity at long-term follow-up (>	
indings of pain intensity at long-term follow-up (>	
findings of pain intensity at long-term follow-up (>	
e findings of pain intensity at long-term follow-up (>	
the findings of pain intensity at long-term follow-up (>	
f the findings of pain intensity at long-term follow-up (>	
of the findings of pain intensity at long-term follow-up (>	
y of the findings of pain intensity at long-term follow-up (>	
ary of the findings of pain intensity at long-term follow-up (>	
nary of the findings of pain intensity at long-term follow-up (>	
imary of the findings of pain intensity at long-term follow-up (>	
mmary of the findings of pain intensity at long-term follow-up (>	
ummary of the findings of pain intensity at long-term follow-up (>	
Summary of the findings of pain intensity at long-term follow-up (>	
Summary of the findings of pain intensity at long-term follow-up (>	
36 Summary of the findings of pain intensity at long-term follow-up (>	
: 96 Summary of the findings of pain intensity at long-term follow-up (>	
.E 96 Summary of the findings of pain intensity at long-term follow-up (>	
3LE 96 Summary of the findings of pain intensity at long-term follow-up (>	
ABLE 96 Summary of the findings of pain intensity at long-term follow-up (>	
TABLE 96 Summary of the findings of pain intensity at long-term follow-up (>	

						Total (n		Baseline r (SD)	nean	Final me	an (SD)	Change : (SD)	scores		
ID no. Author, yea	r Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	Comment/ conversion⁰
Exercise therapy vs	disc surgery														
300 Osterman, 2006≋	ح	RCT	2 years	Feg	VAS (0-100)	28	58	57 (21)	61 (20)	15 (24)	6 (11)			9.00 (-0.78 to 18.78)	ITT using LOCF Dropouts 12%: surgery 4/29 (one patient did not meet inclusion criteria, excluded from analysis), exercise 4/28
Exercise therapy vs	s usual/convention	nal care													
742 Luijsterburg 2008 ²⁸⁴	٩	RCT	52 weeks	6e T	NRS (0-10)	67	8	63 (22)	63 (22)			44 (27)	-37 (27)	-7.00 (-16.11 to 2.11) Mean difference -0.7 (95% C/ -1.7 to 0.2)	ITT using LOCF Dropouts 13%: intervention 7/67, control 11/68
A, acute; LOCF, last c a The results have I b Based on final me c The term 'dropout	bbservation carried 1 been converted to a sans or change scor s' has been used fc	forward; NR t scale of 0- res (with a p or missing d	S, numerical r. -100 for comp reference give 'ata, post-base	ating scale. arability. In to change	scores. s and patient	is lost to fc	ollow-up.								

TABLE 97 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing exercise therapy to alternative interventions

	Comment/ conversion ^b		ITT used LOCF, but one patient that did not meet inclusion criteria excluded from analysis		Final score calculated from change score No final SD, so baseline SD used ITT used LOCF
	Mean difference (95% Cl)ª		0.39 (-0.14 to 0.91)		0.09 (-0.42 to 0.25)
scores	Control		- 33		-9.1 (6.1)
Change (SD)	Intervention		-28		-10 (6.5)
ın (SD)	Control		6 (9)		6.3 (5)
Final mea	Intervention		11 (16)		5.9 (4.1)
nean (SD)	Control		39 (15)		15.4 (5)
Baseline n	Intervention		39 (14)		15.9 (4.1)
(<i>u</i>)	Control		28		68
Total	Intervention		28		67
	Scale		IQO		RMDQ
	Follow- up		2 years		52 weeks
	Study design		RCT	l care	RCT
	Chronicity	; surgery	¢	al/conventiona	ح
	Author, year	therapy vs disc	Osterman, 2006 ⁶⁸	therapy vs usu.	Luijsterburg, 2008 ²⁶⁴
	Ωë	Exercise	300	Exercise	742

A, acute; LOCF, last observation carried forward.
 a Based on final means or change scores (with a preference given to change scores).
 b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Disc su	rgery					
300	Osterman, 200668	RCT —	*		0.39 (-0.14 to 0.91)	100.00
Usual/c	conventional care					
742	Luijsterburg, 2008 ²⁶⁴	RCT*			-0.09 (-0.42 to 0.25)	100.00
		ł				
	-0	.914	0 Eavours control	0.914		
		i avours exercise therapy	r avours control			

FIGURE 66 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			OR (95% CI)	% weight
Tractio	n					
570	Ljunggren, 1992 ²⁴²	RCT	*		0.89 (0.27 to 2.92)	100.00
Disc su	rgery					
300	Osterman, 200668	RCT			0.32 (0.01 to 8.24)	100.00
Mixed t	reatment vs activity	restriction				
713	Hofstee, 2002 ²⁶⁷	RCT			0.20 (0.01 to 4.18)	100.00
			0.00934 1		107	
			Favours exercise therapy	Favours control		

FIGURE 67 Summary of the findings of any adverse effect for studies comparing active PT with alternative interventions. Note: weights are from random effects analysis.

No. of participants in No. of events No. of events No. of ID in intervention intervention in control participants in control group OR (95% CI) Author, year Study design group group group no. Exercise therapy vs activity restriction Bakhtiary, 2005265 NR NR 429 RCT (crossover) NR NR NR 564 Lidstrom, 1970256 RCT NR NR NR Exercise therapy vs activity restriction Hofstee, 2002267 2 5.00 (0.24 to 713 RCT 0 83 84 100.00) Exercise therapy vs disc surgery 300 Osterman, 200668 RCT 0 28 28 0.32 (0.01 to 1 8.24) Exercise therapy vs mixed treatment 564 Lidstrom, 1970256 RCT NR NR NR NR Exercise therapy vs traction Ljunggren, 1992242 570 RCT 8 26 8 24 0.89 (0.27 to 2.92) Exercise therapy vs usual care 742 Luijsterburg, 2008²⁶⁴ RCT NR NR NR NR

TABLE 98 Summary of the findings of any adverse effects for studies comparing active PT with alternative interventions

NR, not reported.

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients with nerve root pain (%)	Proportion of studies that reported diagnosis confirmed by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs (%)	Proportion of studies that only included patients with first episode %)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Exercise therapy vs activity restriction	1 (1)	62 (62)	1/1 (100)	0) 1/0	0/1 (0)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Exercise therapy vs disc surgery	1 (1)	57 (57)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	1/1 (100)	(0) 1/0	1/1 (100)	0)1 (0)	0/1 (0)	0/1 (0)
Exercise therapy vs inactive control	1 (1)	60 (60)	1/1 (0)	(0) 1/0	(0) 1/0	0/1 (0)	1/1 (100)	0/1 (0)	(0) 1/0	(0) 1/0	0/1 (0)	0/1 (0)
Exercise therapy vs mixed treatment	1 (1)	62 (63)	1/1 (100)	0/1 (0)	(0) 1/0	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0	0/1 (0)	0/1 (0)
Exercise therapy vs traction	1 (1)	50 (50)	1/1 (100)	(0) 1/0	(0) 1/0	1/1 (100)	1/1 (100)	0/1 (0)	(0) 1/0	0) 1/0	0/1 (0)	0/1 (0)
Exercise therapy vs usual/ conventional care	1 (1)	135 (135)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)	(0) 1/0	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)	0/1 (0)
Total (for exercise therapy studies)	(6) (7)	50–135 (62)	6/6 (100)	1/6 (17)	3/6 (50)	5/6 (83)	3/6 (50)	0/6 (0)	1/6 (17)	0/6 (0)	0/6 (0)	0/6 (0)
This table shows on	Ily studies the	at reported out	comes for global (effect, pain intensi	ity or CSOMs.							

TABLE 99 Summary of exercise therapy studies

Passive physical therapy

Description of passive physical therapy studies

Summary of interventions

Six studies compared passive PT with an alternative type of intervention for sciatica.^{155,176,249,253,268,269} Summary data of the interventions used are presented in *Table 100a*. Two of these studies also included more than two arms and both compared different types of passive PT (*Table 100b*).^{249,268} One three-armed crossover RCT²⁶⁸ compared transcutaneous electrical nerve stimulation (TENS) with percutaneous electrical nerve stimulation (PENS) and with sham PENS. One three-armed RCT²⁴⁹ compared ultrasound treatment with a low-power laser and with lumbar traction. One RCT²⁵³ compared a PT programme (consisting of hot packs, ultrasound and diadynamic electric currents) with the PT programme and traction. One RCT¹⁷⁶ compared infrared heat treatment with lumbar traction. One RCT¹⁵⁵ compared conservative physiotherapy (no further details given) with epidural steroid and local anaesthetic injection. One non-RCT²⁶⁹ compared physiotherapy (no further details given) with ESI and active or passive PT.

TABLE 100a Summary of the interventions used when comparing passive PT with alternative interventions (grouped by comparator then ordered by author)

ID				
no	. Author, year	Study desig	n Treatment description	Control description
Pa	nssive PT vs epidura	al/intradiscal injection		
35	9 Veihelmann, 2	006 ¹⁵⁵ RCT	Conservative physiotherapy	Epidural injection via epidural catheter (neuroplasty) of steroid triamcinolone 40 mg and ropivacaine
Pa	ssive PT vs inactiv	e control		
49	6 Ghoname, 19	99 ²⁶⁸ RCT (crossov	ver) PENS	Sham PENS
49	Ghoname, 199	P9 ²⁶⁸ RCT (crossov	ver) TENS	Sham PENS
Pa	assive PT vs mixed	treatment		
35	4 Bokonjic, 197 (German langi	5 ²⁶⁹ Non-RCT Jage)	Physiotherapy alone	Three epidural injection of steroid dexa- neurobion every 4 days + active or passive PT
26	6 Ozturk, 2006 ² (traction vs pa	⁵³ RCT ssive PT)	PT programme (control group)	Traction and PT programme (traction group)
Pa	ssive PT vs traction	1		
90	59 Mathews, 198	7 ¹⁷⁶ RCT	Infrared heat treatment	Lumbar traction
14	8 Unlu, 2008 ²⁴⁹	RCT	Ultrasound treatment	Lumbar traction
14	8 Unlu, 2008 ²⁴⁹	RCT	Low-power laser	Lumbar traction

PENS, percutaneous electrical nerve stimulation; TENS, transcutaneous electrical nerve stimulation.

....

TABLE 100b Summary of the interventions used when comparing alternative forms of passive PT

id no.	Author, year	Study design	Treatment description	Control description
496	Ghoname, 1999 ²⁶⁸	RCT (crossover)	TENS	Sham PENS
148	Unlu, 2008 ²⁴⁹	RCT	Low-power laser	Ultrasound treatment
496 148	Ghoname, 1999 ²⁶⁸ Unlu, 2008 ²⁴⁹	RCT (crossover) RCT	TENS Low-power laser	Sham PENS Ultrasound treatment

PENS, percutaneous electrical nerve stimulation; TENS, transcutaneous electrical nerve stimulation.

Summary of study participants in passive physical therapy studies

Summary data on the included participants are presented in *Table 101*. The six trials included 468 participants with mean ages between 31 and 46 years (30–60% men): one with acute symptom duration, three with chronic symptoms and two that did not report length of symptoms. One non-RCT included participants with first and recurrent episodes of sciatica, but this was not reported in the remainder. Sciatica was confirmed by imaging in five trials. There were no patients with spinal stenosis or sequestered discs and previous back surgery was excluded in two trials.

Summary of study quality for passive physical therapy

Study details are summarised in *Table 102*. Five of the studies were RCTs (5/6, 83%) and none was of good quality. None had an adequate method of random number generation and only one documented a secure method of allocation concealment.¹⁵⁵ No studies had good external validity.

Passive physical therapy results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 103* and the accompanying forest plot (*Figure 68*). There was a significant improvement in the global effect in the TENS or PENS group compared with inactive control in one poor-quality crossover RCT.²⁶⁸ However, one poor-quality non-RCT found a significant improvement in the global effect when ESI was combined with active or passive PT compared with physiotherapy alone.²⁶⁹ There was no significant difference in the global effect in one moderate-quality RCT comparing heat treatment with traction.¹⁷⁶

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 104* and the accompanying forest plot (*Figure 69*). There was a significant improvement in pain intensity in the groups receiving TENS or PENS compared with inactive control in one poor-quality non-RCT.²⁶⁸ There was no significant difference in pain intensity in two moderate- or poor-quality RCTs comparing ultrasound or laser with traction²⁴⁹ or unspecified PT with PT and traction.²⁵³

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 105* and the accompanying forest plot (*Figure 70*). There was no significant difference in CSOMs in one moderate-quality RCT comparing ultrasound or laser with traction.²⁴⁹

Passive physical therapy results at medium-term follow-up (>6 weeks to ≤ 6 months)

Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 106* and the accompanying forest plot (*Figure 71*). In one moderate-quality RCT there was a significant improvement in global effect in a group receiving epidural steroids compared with conservative physiotherapy.¹⁵⁵

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 107* and the accompanying forest plot (*Figure 72*). There was no significant difference in pain intensity in one moderate-quality RCT comparing ultrasound or laser with traction²⁴⁹ or in another moderate-quality RCT that compared epidural steroids with conservative physiotherapy.¹⁵⁵

	ັດ
	Ĕ
	Ħ
	ສັ
	≥
	Ο
-	õ
	Ψ
	ð
	2
	0
	Ç
	é
1	₽
	≻
	¥
	ā
	ğ
	9
	Ĕ
	8
	ζ.
	6
	~
	ð
	ā
	Z
	2
	0
	ŝ
	č
	⁰
-	Ë
	Ð
	Ś
	Ð
	Ħ
	=
	é
	≓
	g
	Ξ
	Ð
-	¥
	0
	글
1	⋝
	>
ļ	5
1	-
	ŝ
	ŝ
	ő
	đ
	2
	õ
	ğ
	nng p
	aring p
	paring p
	mparing p
	comparing po
	comparing p
	es comparing pa
	lies comparing pa
:	idies comparing pa
-	studies comparing pa
:	studies comparing p
:	or studies comparing p
:	for studies comparing p
	Is for studies comparing po
-	ails for studies comparing po
-	etails for studies comparing po
-	details for studies comparing p
	n details for studies comparing p
-	on details for studies comparing p
	ition details for studies comparing p
	lation details for studies comparing p
	oulation details for studies comparing p
-	opulation details for studies comparing part
-	population details for studies comparing p
	y population details for studies comparing p
	dy population details for studies comparing pa
-	udy population details for studies comparing part
-	study population details for studies comparing pa
	d study population details for studies comparing p
	nd study population details for studies comparing pa
	and study population details for studies comparing part
	e and study population details for studies comparing pa
-	/pe and study population details for studies comparing pa
	type and study population details for studies comparing pa
	a type and study population details for studies comparing pa
	ica type and study population details for studies comparing pa
	atica type and study population details for studies comparing p
	statica type and study population details for studies comparing partic
	sciatica type and study population details for studies comparing p
	if sciatica type and study population details for studies comparing p
-	of sciatica type and study population details for studies comparing pi
	y of sciatica type and study population details for studies comparing pi
	ary of sciatica type and study population details for studies comparing p.
	mary of sciatica type and study population details for studies comparing pi
	mmary of sciatica type and study population details for studies comparing pi
-	ummary of sciatica type and study population details for studies comparing pi
	Summary of sciatica type and study population details for studies comparing p.
	Summary of sciatica type and study population details for studies comparing pu
	31 Summary of sciatica type and study population details for studies comparing p.
	101 Summary of sciatica type and study population details for studies comparing pu
	101 Summary of sciatica type and study population details for studies comparing p.
	LE 101 Summary of sciatica type and study population details for studies comparing p.
	BLE 101 Summary of sciatica type and study population details for studies comparing p.
	ABLE 101 Summary of sciatica type and study population details for studies comparing p.

vious k jery for tica?											
Any prev bac surt scia		Yes		Yes		NR	No		NR	No	
Any previous treatment for sciatica'		Yes		Yes		RN	NR		NR	NR	
Included patients with sequestered disc (or extruded)?ª		No		No		No	N		No	No	
Included patients with stenosis?ª		No		No		NO	No		No	No	
Recurrent episode		NR		NR		Recurrent and first episode	RN		R	NR	
Confirmed by imaging?		Yes		Yes		Yes	Yes		No	Yes	
Type of sciatica		Nerve root pain		Nerve root pain and referred pain		Nerve root pain and referred pain	Nerve root pain		Nerve root pain	Nerve root pain	
Symptom duration		NR		Mean 21 months (SD 9; range 6–28 months)		R	Inclusion criteria ≥ 6 months		Median 3.5 weeks (range 0 days–3 months)	> 3 months	
No. of men (%)		45 (45)		30 (47)		23 (64)	22 (48)		80 (56)	18 (30)	
Age (years)		Mean 44.5 (SD 24)		Mean 43 (range ±19)		Mean 31.1	Mean 46.2 (SD 10.2); range 16–70)		Median 40 (range 20–60)	Mean 44.5 (range 20–60)	
No. of patients	ection	66		64		56	46		143	60	
Study design	lintradiscal inj	RCT	control	RCT (crossover)	eatments	Non-RCT	RCT		RCT	RCT	
Author, year	PT vs epidural,	Veihelmann, 2006 ¹⁵⁵	PT vs inactive	Ghoname, 1999 ²⁶⁸	PT vs mixed tr	Bokonjic, 1975 ²⁶⁹ (German language)	Ozturk, 2005 ²⁵³	PT vs traction	Mathews, 1987 ¹⁷⁶	Unlu, 2008 ²⁴⁹	eported.
⊡ ë	Passive	359	Passive	496	Passive	354	266	Passive	9059	148	NR, not r

Ψ
۵ ک
Ľ
. <u> </u>
.š
lat
Ľ,
lfe
g
Ë
≥
F
0
.≚
SS
Зa
5
Ĩ.
ar
ę
Б
Õ
es
ö
Ę
ŝ
ę
<u>s</u>
aj.
e
2
Ę,
ŭ
0)
Ē
Ť
~
a,
Ĩ
E
Su
0
8
۳
Ξ

TABLE 10	2 Summary of the study c	details for stu	dies comparing	t passive PT wit	th alternative int	erventions				
ID no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Passive P	'T vs epidural/intradiscal injecti	ion								
359	Veihelmann, 2006 ¹⁵⁵	66	12 months	RCT	Partial	Yes	<60	Yes	Moderate	Weak
Passive P	'T vs inactive control									
496	Ghoname, 1999 ²⁶⁸	64	11 weeks	RCT	Unclear	Unclear	Can't tell	NA	Weak	Weak
Passive P	'T vs mixed treatments									
354	Bokonjic, 1975 ²⁶⁹ (German Janni Janni	56	12 days	Non-RCT	No	No	80-100	Unclear	Weak	Weak
266	Ozturk, 2006 ²⁵³	46	2 weeks	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Passive P	'T vs traction									
9059	Mathews, 1987 ¹⁷⁶	143	12 months	RCT	Partial	Unclear	<60	Yes	Moderate	Moderate
148	Unlu, 2008 ²⁴⁹	60	3 months	RCT	Unclear	Unclear	80–100	Yes	Moderate	Weak

	Comments							Number of dropouts reported were different to the number missing from the analysis
	0r (95% CI)		22.53 (7.89 to 64.28)	4.27 (1.47 to 12.42)		0.25 (0.07 to 0.90)		0.93 (0.46 to 1.86)
	Withdrawal rate		0	0		0.06		0.07
_	Outcome (<i>n</i>)		Ω.	Q		17		40
Contro	Total (<i>n</i>)		64	64		34		22
	Withdrawal rate		0	0		0		0.10
ention	Outcome (<i>n</i>)		42	17		4		27
Interv	Total (<i>n</i>)		64	64		20		54
	Perspective		Patient	Patient				
	Outcome measure		'Improved sense of well being' selected out of four subheadings (asked about treatment preference in crossover trial)	'Improved sense of well being' selected out of four subheadings (asked about treatment preference in crossover trial)		Improved = excellent or good (vs no change = moderate or poor)		Number of patients recovered (percentage). Pain score of 5 or 6 represented definite improvement and designated 'recovered', scores of 1–4 designated 'not recovered'
	Follow- up		72 hours	72 hours		12 days		2 weeks
	Study design		RCT (crossover)	RCT (crossover)		Non-RCT		RCT
	Chronicity	control	A + C	A + C	reatments	R	-	4
	Author, year	PT vs inactive	Ghoname, 1 999 ²⁶⁸ (j) ^a (PENS)	Ghoname, 1999² ⁸⁸ (ij)ª (TENS)	PT vs mixed t	Bokonjic, 1975 ²⁶⁹ (German language)	PT vs traction	Mathews, 1987 ¹⁷⁶
	ID no.	Passive	496	496	Passive	354	Passive	9059

TABLE 103 Summary of the findings of the global effect at short-term follow-up (≤6 weeks) for studies comparing passive PT with alternative interventions

A, acute; A+C, acute and chronic; NR, not reported. a Ghoname *et al.*²⁶⁸ included three treatment groups: PENS (i), TENS (ii) and sham PENS (ii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the meta-analysis (see *Figure 63*).

ID no.	Author, year	Study design		OR (95% CI)	% weight
Inactive 496	control Ghoname, 1999 ²⁶⁸	RCT (crossover)		4.27 (1.47 to 12.42)	100.00
Mixed tro 354	eatments Bokonjic, 1975 ²⁶⁹	Non-RCT+		0.25 (0.07 to 0.90)	100.00
Traction 9059	Mathews, 1987 ¹⁷⁶	RCT		0.93 (0.46 to 1.86)	100.00
		0.0691	1	14.5	
		Favours co	ntrol Favou	rs passive PT	

FIGURE 68 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.



FIGURE 69 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 108* and the accompanying forest plot (*Figure 73*). There was no significant difference in CSOMs in one moderate-quality RCT comparing ultrasound or laser with traction,²⁴⁹ or in another moderate-quality RCT that compared epidural steroids with conservative physiotherapy.¹⁵⁵

Passive physical therapy results at long-term follow-up (>6 months) Global effect at long-term follow-up

The results for the global effect at long-term follow-up are presented in *Table 109* and the accompanying forest plot (*Figure 74*). In one moderate-quality RCT, there was a significant improvement in global effect in a group receiving epidural steroids compared with a group

receiving conservative physiotherapy.155

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 110* and the accompanying forest plot (*Figure 75*). There was no significant difference in pain intensity in one moderate-quality RCT that compared conservative physiotherapy with epidural steroids.¹⁵⁵

Condition-specific outcome measures at long-term follow-up

The results for CSOMs at long-term follow-up are presented in *Table 111* and the accompanying forest plot (*Figure 76*). In one moderate-quality RCT, there was a significant improvement in CSOMs in a group receiving epidural steroids compared with conservative physiotherapy.¹⁵⁵

SL
tio
eu
еZ
ij
٨e
lati
ern
alte
국
Ň
РТ
٨ ٩
ssi
pa
þ
arir
ğu
ő
ŝ
die
stu
٩.
s) fe
ek.
Š
6
<u>vi</u>
d'-
×
Ы
ц Ц
terr
Ŧ
P0
it s
S S
lsit
ter
.⊑
air
бp
s
ing
na
еfi
ţ
of
ary
Ĩ
μ
S
8
μ
BL
I

							Total (n		Baseline n	ıean (SD)	Final mea	n (SD)	Chang scores	e s (SD)	
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI)⁵
Pass	ive PT vs inactive control														
496	Ghoname, 1999 ²⁶⁸ (j) ^c (PENS)	A+C	RCT (crossover)	72 hours		VAS (0-10)	64	64	72 (18)	66 (19)	41 (14)	61 (19)			-20.00 (-25.78 to -14.22)
496	Ghoname, 1999 ²⁶⁸ (ii) ^c (TENS)	A+C	RCT (crossover)	72 hours	Leg	VAS (0-10)	28	28	70 (19)	66 (19)	54 (19)	61 (19)			-7.00 (-13.58 to -0.42)
Pass	ive PT vs traction														
148	Unlu, 2008 ²⁴⁹ (j) ^d (ultrasound)	A	RCT	1 month	Leg	VAS (0-100)	20	20	56.0 (15.3)	59.6 (15.4)	26.8 (18.6)	21.8 (15.4)			5.00 (–5.58 to 15.58)
148	Unlu, 2008 ²⁴⁹ (ii) ^d (laser)	٩	RCT	1 month	Leg	VAS (0-100)	20	20	53.1 (25.9)	59.6 (15.4)	25.6 (21.1)	21.8 (15.4)			3.80 (–7.65 to 15.25)
Pass	ive PT vs mixed treatmen	ts													
266	Ozturk, 2006 ²⁵³ (traction + PT vs PT)	NR	RCT	15 days	Overall	VAS (0-10)	22	24	68 (11)	63 (14)	36 (27)	24 (17)			12.00 (–1.17 to 25.17)
A, acı	te; A+C, acute and chronic	ic; NR, not report	ed.												

a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores). c Ghoname *et al.*²⁰⁶ included three treatment groups: PENS (i), TENS (ii) and sham PENS (ii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the metaanalysis (see Figure 69).

Unlu *et al.*²⁴⁹ included three treatment groups: ultrasound treatment (i), low-power laser (ii) and lumbar traction (iii). In order to prevent using the same comparator twice, only the first and last treatment groups have been included in the meta-analysis (see *Figure 69*. ρ

TABLE	: 105 Summary	of the finding:	s of CSOMs	at short-teri	m follow-up	(≤6 weeks	s) for studie	s compar	ing passive	PT with al	ternative i	nterventic	su	
						ē	tal (<i>n</i>)	Baseline	mean (SD)	Final mear	I (SD)	Change s	cores (SD)	
<u> </u>	Author, year	Chronicity	Study desi	'gn Follow	v-up Sc	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^a
Passi	ve PT vs traction													
148	Unlu, 2008 ²⁴⁹ (i) ^b (ultrasound)	٨	RCT	1 mon	ith RM	DQ 20	20	13.4 (4.5)	14.2 (4.3)	8.2 (6)	8.5 (3.5)	-5.2	-5.7	-0.06 (-0.68 to 0.56)
148	Unlu, 2008²⁴9 (ii)⁵ (laser)	A	RCT	1 mon	nth RM	DQ 20	20	12.5 (5)	14.2 (4.3)	7.3 (4.3)	8.5 (3.5)	-5.2	-5.7	-0.31 (-0.93 to 0.32)
A, acu a Ba c Un bei TABLE	te. sed on final means i u <i>et al.</i> ²⁴⁹ included i included in the m included in the m 106 Summary	or change scores (three treatment gr leta-analysis (see of the findings	(with a preferent oups: ultrasount <i>Figure 70</i>). s of the globs	ce given to cha d treatment (i), al effect at n	ange scores). Iow-power lası medium-tern	er (ii) and lum n follow-up	bar traction (ii o (> 6 week:	ii). In order tt s to ≤6 m	o prevent usin,	g the same co tudies corr	mparator tw	ice, only the ssive ther	first and last apy with al	reatment groups have ternative interventions
								Interve	ention		CO	ntrol		
⊡ °	Author, year	Chronicity	Study design	Follow-up	Outcome m	leasure	Perspectiv	re (n)	Outcome (<i>n</i>)	Withdr rate	awal Tot	al Outco (<i>n</i>)	me Withd rate	awal 0R (95% CI)
Passi	ve PT vs epidural/i.	ntradiscal injecti	ion											
359	Veihelmann, 2006 ¹⁵⁵	U	RCT	6 months	Gerbershagi (Chronificati GHS I (vs GF	en score on Index), +S II, III)		27	ω	0.48	46	31	0.02	0.19 (0.07 to 0.54)
C, chr	nic.													

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Tractio	n						
148	Unlu, 2008 ²⁴⁹	RCT		*		-0.31 (-0.93 to 0.32)	100.00
			-0.93	Favours passive PT) Favours control	0.93	

FIGURE 70 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Epidura	I/intradiscal injection						
359	Veihelmann, 2006 ¹⁵⁵	RCT	<u> </u>			0.20 (0.07 to 0.57)	100.00
			0.0727	Favours control	1	13.8 Favours passive PT	

FIGURE 71 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing passive therapy with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Epidura	I/intradiscal injection					
359	Veihelmann, 2006155	RCT —	*		35.00 (-24.60 to 94.60)	100.00
Tractio	n					
148	Unlu, 2008 ²⁴⁹	RCT	+		-4.30 (-13.82 to 5.22)	100.00
	-94.6	6	0	94.6		
	-94.6	Favours passive PT	U Favours control	94.6		

FIGURE 72 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.

Adverse effects

The total number of adverse effects is presented in *Table 112* and the accompanying forest plot (*Figure 77*). Adverse effects were reported in only one RCT, which found significantly more adverse events in the group receiving epidural steroids than in the group receiving conservative physiotherapy.¹⁵⁵

SUMMARY OF OVERALL FINDINGS FOR PASSIVE PHYSICAL THERAPY COMPARED WITH ALTERNATIVE INTERVENTIONS

Six studies, five of which were RCTs^{155,176,249,253,269} (one was a crossover trial²⁶⁸), compared the use of passive physical therapy with other interventions. Two RCTs^{176,249} restricted inclusion to patients with acute sciatica (*Table 113*).

							Total (<i>i</i>	<i>(</i> د	Baseline (SD)	mean	Final me	an (SD)	Change scol (SD)	Sa	
e ë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Control	Mean difference (95% Cl) ^b	Comment/ conversion⁰
Pass	ive PT vs epidural														
359	Veihelmann, 2006 ¹⁵⁵	S	RCT	6 months	Leg	VAS (0-10)	27	46	67 (103.9)	72 (135.6)	58 (114.3)	23 (142.4)		35.00 (-24.60 to 94.60)	SD derived from SE
Pass	ive PT vs traction														
148	Unlu, 2008 ²⁴⁹ (j) ^d (ultrasound)	A	RCT	3 months	Leg	VAS (0-100)	20	20	56.0 (15.3)	59.6 (15.4)	25.2 (13.9)	29.5 (16.7)		-4.30 (-13.82 to 5.22)	
148	, Unlu, 2008 ²⁴⁹ (ii) ^d (laser)	A	RCT	3 months	Leg	VAS (0-100)	20	20	53.1 (25.9)	59.6 (15.4)	23.6 (17.7)	29.5 (16.7)		-5.90 (-16.56 to 4.76)	
т В I a gc	ute; C, chronic. In results have been c tsed on final means of the term 'dropouts' has	onverted to a s change score been used for	scale of 0–1 s (with a pre missing dat	00 for compara sference given	ability. to change sc e exclusions	ores). and patients	lost to fol	low-up.						condocad do citado	

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ŝ UDIU et al. ---- Included titlee ureautient groups, un as been included in the meta-analysis (see Figure 72). 0

TABLE 108 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing passive PT with alternative interventions

	rence Comment/conversion ^b		SD based on weighted average 25) Dropouts 26 (26%): control (epidural) 1/47, intervention (PT) 25/52		56)	(11)	ast two treatment groups have been
	Mean differ (95% Cl) ^a		-0.22 (-0.70 to 0.		-0.06 (-0.68 to 0.	-0.52 (-1.15 to 0.	vice, only the Is
e scores	Control				-5.3	-5.3	nparator t
Chang (SD)	Intervention				-4.8	-5.8	same cor
an (SD)	Control		10.8 (50.19)		8.94 (4)	8.9 (4)	ent using the
Final me	Intervention		22.5 (46.25)		8.6 (6)	6.7 (4.5)	order to preve
mean	Control		21.4		14.2 (4.3)	14.2 (4.3)	on (iii). In c
Baseline (SD)	Intervention		23.1		13.4 (4.5)	12.5 (5)	to follow-up. Iumbar tracti
(u)	Control		46		20	20	ients lost er (ii) and
Total	Intervention		27		20	20	cores). s and pat ower lase
	Scale		IQO		RMDQ	RMDQ	change sc exclusions (i), low-po
	Follow-up		6 months		3 months	3 months	rence given to post-baseline (ound treatment
	Study design		RCT		RCT	RCT	(with a prefe nissing data, oups: ultrasc
	Chronicity		C		A	A	r change scores been used for n iree treatment gr alysis (see Figure
	Author, year	e PT vs epidural	Veihelmann, 2006 ¹⁵⁵	e PT vs traction	Unlu, 2008 ²⁴⁹ (i) ^c (laser)	Unlu, 2008 ²⁴⁹ (ii) ^c (ultrasound)	<i>s</i> ; C, chronic. ed on final means or term 'dropouts' has I <i>et al.</i> ²⁴⁹ included th ided in the meta-ani
	ÐË	Passivu	359	Passivu	148	148	A, acutt a Bast b The c Unlu inclu

Review of clinical effectiveness: results

290

ID no.	Author, year	Study design					SMD (95% CI)	% weight
Epidura	Il/intradiscal injection							
359	Veihelmann, 2006155	RCT		_		•	0.22 (-0.25 to 0.70)	100.00
Traction	n							
148	Unlu, 2008 ²⁴⁹	RCT		•		_	-0.52 (-1.15 to 0.11)	100.00
			-1.15		Ó		1.15	
				Favours passive F	T	Favours control		

FIGURE 73 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			OR (95% CI)	% weight
Epidura	I/intradiscal injection					
359	Veihelmann, 2006 ¹⁵⁵	RCT	<u> </u>		0.19 (0.07 to 0.54)	100.00
			0.0651	1	15.4	
				Favours control	Favours passive PT	

FIGURE 74 Summary of the findings of the global effect at long-term (>6 months) follow-up for studies comparing passive PT with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Epidura	I/intradiscal injection					
359	Veihelmann, 2006 ¹⁵⁵	RCT ———	*		31.00 (-40.02 to 102.02)	100.00
	-102	>	 	102		
		- Favours passive PT	Favours control			

FIGURE 75 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

In one poor-quality crossover RCT²⁶⁸ there was a significant improvement in global effect and pain intensity in the short term with TENS or PENS compared with inactive control. There was no significant difference in terms of global effect, pain intensity or CSOMs at short-, medium-or long-term follow-up in three moderate- or poor-quality RCTs^{176,249,253} that compared heat, ultrasound, laser or an unspecified PT programme with traction. Physiotherapy programmes were less effective than epidural corticosteroid injections in terms of short-term global effect in one poor-quality non-RCT²⁶⁹ and in terms of medium- and long-term global effect, pain intensity and CSOMs in one moderate-quality RCT.¹⁵⁵ Adverse effects were less common with physiotherapy than with epidural injection of corticosteroid in this latter RCT.

TABLE 109 Summary of the findings of the global effect at long-term (>6 months) follow-up for studies comparing passive PT with alternative interventions

							Interver	ntion		Control				
0 9 9	luthor, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Out come <i>(n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (n)	Withdrawal rate	or (95% ci)	Comments
Passive	PT vs epidur:	al/intradiscal i	injection											
359 1	/eihelmann, 2006 ¹⁵⁵	U	RCT	12 months	Gerbershagen score (Chronification Index), GHS I (vs GHS II, III)	I	27	2	0.48	46	30	0.02	0.20 (0.07 to 0.57)	Twelve patients moved over to epidural group and excluded from analysis
C, chroni														

TABLE 110 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions

				ervention ural) 1/47) moved over om analysis
	Comment/conversion		SD derived from SE	Dropouts 26/99 (26%): int 22/52 (48%), control (epid (2%) Twelve patients in PT groul to epidural and excluded fr
	Mean difference (95% Cl) ^b		35.00	(24.60 to 94.60)
ige es (SD)	Control			
Chan score	Intervention			
an (SD)	Control		28	(189.91)
Final me	Intervention		59	(119.51)
mean	Control		72	(135.6)
Baseline (SD)	Intervention		67	(103.9)
<i>(u)</i>	Control		46	
Tota	Intervention		27	
	Scale (range) ^a		VAS	(0-10)
	Location		Leg	
	Follow-up	u	12 months	
	Study design	scal injectio	RCT	
	Chronicity	Vintradi.	S	
	Author, year	e PT vs epidura.	Veihelmann,	2006 ¹⁵⁵
	e ë	Passiv	359	

C, chronic.

a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores). c The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.

TABLE 111 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions

	Comment/conversion ^b		SD based on weighted average Dropouts 26/99 (26%): intervention 22/52 (48%), control (epidural) 1/47 (2%) Twelve patients in PT group moved over to epidural and excluded from analysis	
	Mean difference (95% Cl)ª		-0.77 (-1.26 to -0.28)	
scores	Control			
Change (SD)	Intervention			
ean (SD)	Control		11.6 (67.82)	
Final me	Intervention		21.6 (54.2)	
ie mean	Control		21.4	
Baselir (SD)	Intervention		23.1	
(<i>u</i>) I	Control		46	:ores). J.
Tota	Intervention		27	ange sc ollow-up
	Scale		IQO	en to ch lost to f
	Follow-up		12 months	preference give vell as patients
	Study design	injection	RCT	scores (with a sing data as v
	Chronicity	Nintradiscal	C	is or change s used for miss
	Author, year	PT vs epidurá	Veihelmann, 2006 ¹⁵⁵	lic. d on final mear outs have been
	e ë	Passive	359	C, chror a Base b Drop

ID no.	Author, year	Study desigr	I			SMD (95% CI)	% weight
Epidura	I/intradiscal injection						
359	Veihelmann, 2006 ¹⁵⁵	RCT				0.77 (0.28 to 1.26)	100.00
		-1.26	(Favours passive PT	Favours control	1.26		

FIGURE 76 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing exercise therapy with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			OR (95% CI)	% weight
Epidura	I/intradiscal injection					
359	Veihelmann, 2006 ¹⁵⁵	RCT	*		0.02 (0.00 to 0.41)	100.00
		0.00)135	1	741	
		Favours	s passive PT	Favours control		

FIGURE 77 Summary of the findings of any adverse effect for studies comparing passive PT with alternative treatment. Note: weights are from random effects analysis.

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Passiv	e PT vs epidural						
359	Veihelmann, 2006 ¹⁵⁵	RCT	0	39	16	46	0.02 (0.00 to 0.40)
Passiv	e PT vs inactive control						
496	Ghoname, 1999 ²⁶⁸ (PENS)	RCT	NR	NR	NR	NR	
496	Ghoname, 1999 ²⁶⁸ (TENS)	RCT	NR	NR	NR	NR	
Passiv	e PT vs mixed treatment						
354	Bokonjic, 1975 ²⁶⁹	Non-RCT	NR	NR	NR	NR	
266	Ozturk, 2006 ²⁵³ (traction vs passive PT)	RCT	NR	NR	NR	NR	
Passiv	e PT vs traction						
9059	Mathews, 1987176	RCT	NR	NR	NR	NR	
148	Unlu, 2008 ²⁴⁹ (laser)	RCT	NR	NR	NR	NR	
148	Unlu, 2008 ²⁴⁹ (ultrasound)	RCT	NR	NR	NR	NR	

TABLE 112 Summary of the findings of any adverse effect for studies comparing passive PT with alternative treatment

NR, not reported.

DOI: 10.3310/hta15390

											Proportion	Proportion
									Proportion of		of studies	of studies
						Proportion	Proportion	Proportion	studies that	Proportion	that	that
					Proportion	of studies	of studies	of studies	included	of studies	included	included
				Proportion	of studies	that	that	that	patients	that only	patients	patients
				of studies	that only	included	reported	included	with	included	who had	who had
			Proportion of	that were	included	patients	diagnosis	patients	extruded/	patients	received	received
	No. of	Sample	studies that	deemed	acute	with nerve	confirmed	with	sequestered	with first	previous	previous
Control category	studies (arms)	size range (median)	were RCIS (%)	good quality (%)	sciatica (%)	root paın (%)	by imaging (%)	stenosis (%)	discs (%)	episode (%)	treatment (%)	surgery (%)
Passive PT vs epidural/ intradiscal injection	1 (1)	(66) 66	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)
Passive PT vs inactive control	1 (2)	64 (64)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)
Passive PT vs mixed treatment	2 (2)	46–56 (51)	1/2 (50)	0/2 (0)	0/2 (0)	2/2 (100)	2/2 (100)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)
Passive PT vs traction	2 (2)	60–143 (102)	2/2 (100)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)
Total (for passive PT studies)	6 (6)	46–143 (62)	5/6 (83)	0/0 (0)	2/6 (33)	6/6 (100)	5/6 (83)	0/6 (0)	0/6 (0)	0/9 (0)	2/6 (33)	2/6 (33)
This table shows only studie	s that reporte	ed outcomes for	global effect, pain	intensity or CSO	Ms.							

TABLE 113 Summary of passive PT studies

Biological agents

Biological agents are derived from living material and have a highly complex chemical structure. They are being used increasingly in rheumatological practice to control inflammatory disease. Tumour necrosis factor-alpha (TNF- α) is one of the proinflammatory factors released from prolapsed intervertebral discs that is responsible for inflammation of the affected nerve root in sciatica and may be amenable to treatment by these biological therapies. Biological agents that inhibit TNF- α include etanercept, infliximab (Remicade[®], Schering-Plough Ltd) and adalimumab (Humira[®], Abbott).

Description of biological agents studies

Summary of interventions

Five studies evaluated biological agents for sciatica.^{149,216,270-272} Four of these studies compared biological agents with an alternative type of intervention.^{149,216,270,271} Summary data of the interventions used are presented in *Table 114a*. Two RCTs,^{149,271} one non-RCT²⁷⁰ and one HCS²¹⁶ compared biological agents with alternative treatments. One RCT²⁷⁰ and one non-RCT²⁷¹ compared intravenous infusions of infliximab with placebo injections of saline. One RCT¹⁴⁹ compared epidural injections of autologous conditioned serum, rich in anti-inflammatory cytokines, with epidural injections of corticosteroid and local anaesthetic. One CCS²¹⁶ compared subcutaneous injections of etanercept with intravenous injections of corticosteroid.

One three-armed study compared different doses of the same biological agent with each other.²⁷² The doses and biological agent being compared are presented in *Table 114b*, but this study is not considered any further.

TABLE 114a Summary of the interventions used when comparing biological agents with alternative intervention	าร
---	----

ID no.	Author, year	Study design	Treatment description	Control description
Biolog	ical agents vs epidura	l/intradisca	al injection	
321	Becker, 2007149	RCT	Epidural injection of autologous conditioned serum (group 1)	Epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (group 3)
321	Becker, 2007 ¹⁴⁹	RCT	Epidural injection of autologous conditioned serum (group 1)	Epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (group 2)
Biolog	ical agents vs inactive	e control		
398	Karppinen, 2003270	Non- RCT	Intravenous infusion of infliximab 3 mg/kg (anti-TNF- α)	Periradicular saline injection
741	Korhonen, 2005271	RCT	Intravenous infliximab 5 mg/kg	Intravenous saline (placebo)
Biolog	ical agents vs non-op	ioids		
323	Genevay, 2004 ²¹⁶	HCS	Three subcutaneous injections of etanercept 25 mg (anti-TNF- α)	Three intravenous injection of methylprednisolone 250 mg

TABLE 114b Summary of the interventions used when comparing alternative forms of biological agents

ID no.	Author, year	Study design	Treatment description	Control description
804	Cohen, 2009 ²⁷²	RCT	Transforaminal epidural injections of etanercept (4 mg)	Transforaminal epidural injections of etanercept (2 mg)
804	Cohen, 2009 ²⁷²	RCT	Transforaminal epidural injections of etanercept (6 mg)	Transforaminal epidural injections of etanercept (2 mg)

Summary of study participants in biological agent studies

Summary data on the included participants are presented in *Table 115*. The four studies that compared biological agents with alternative treatments included 213 participants with mean ages between 39 and 54 years (50–80% men), all with acute symptom duration. One non-RCT included only participants with the first episode of sciatica, one RCT also included recurrent symptoms, but symptom duration was not reported in two studies. Sciatica was confirmed by imaging in three trials. There were no patients with spinal stenosis or sequestered discs and previous back surgery was excluded in two trials.^{270,271}

Summary of study quality for biological agents

Study details are summarised in *Table 116*. Half of the studies were RCTs (2/4, 50%) and none was of good quality. Only two had an adequate method of random number generation,^{149,271} and none documented a secure method of allocation concealment. No studies had good external validity.

Biological agent results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

No studies reported global effect data at short-term follow-up.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 117* and the accompanying forest plot (*Figure 78*). There was a significant improvement in pain intensity in the infliximab group compared with the inactive control group in one poor-quality non-RCT,²⁷⁰ and also in the etanercept group compared with the intravenous corticosteroid injection group in a poor-quality HCS.²¹⁶

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 118* and the accompanying forest plot (*Figure 79*). There was a significant improvement in CSOMs with infliximab compared with placebo injection in one poor-quality non-RCT,²⁷⁰ and also with etanercept compared with intravenous corticosteroid in one poor-quality HCS.²¹⁶ There was no significant difference in CSOMs in the group receiving an epidural injection of autologous conditioned serum compared with epidural injection of corticosteroid and local anaesthetic in one moderate-quality RCT.¹⁴⁹

Biological agents results at medium-term follow-up (>6 weeks to ≤6 months)

Global effect at medium-term follow-up

No studies reported global effect data at long-term follow-up.

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 119* and the accompanying forest plot (*Figure 80*). There was a significant improvement in pain intensity in one poor-quality non-RCT of infliximab compared with placebo injection,²⁷⁰ but not in another moderate-quality RCT,²⁷¹ and there was no significant difference when these results were combined in a meta-analysis. There was no significant difference in pain intensity in a group receiving an epidural injection of autologous conditioned serum compared with epidural injection of corticosteroid and local anaesthetic in one moderate-quality RCT.¹⁴⁹

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 120* and the accompanying forest plot (*Figure 81*). There was a significant improvement in CSOMs in one poor-quality non-RCT of infliximab compared with placebo injection.²⁷⁰ There was no significant difference in CSOMs in a group receiving an epidural injection of autologous conditioned

TABLE 115 Summary of sciatica and study population details for studies comparing biological agents with alternative interventions

⊡ ë	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging	Recurrent episode	Included patients with stenosis? ^a	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Biolo	gical agents vs epidu	ural/intrao	liscal injectic	uo									
321	Becker, 2007 ¹⁴⁹	RCT	06	Mean 53.9 (range 29–81)	52 (62)	At least 6 weeks	Nerve root pain	Yes	NR	No	No	NR	NR
Biolo	gical agents vs inact	tive contro	7										
398	Karppinen, 2003 ²⁷⁰	Non- RCT	72	TNF-α group: mean 38.5	TNF-α group: 8 (80)	TNF-α group: mean 7.2 weeks (range 2–12 weeks); no data for saline group	Nerve root pain	Yes	First episode	No	No	NR	No
741	Korhonen, 2005 ²⁷¹	RCT	41	Mean 40.7 (SD 8.4)	24 (60)	Median 61 days (range 20–102 days)	Nerve root pain	Yes	Recurrent and first episode	No	N	Yes	No
Biolo	gical agents vs non-,	opioids											
323	Genevay, 2004 ²¹⁶	HCS	10	Mean 47.3 (SD 13.3, range > 18)	10 (50)	Mean 3.2 weeks (SD 3.7 weeks)	Nerve root pain	No	NR	No	No	NR	NR
NR, nt	ot reported.												

a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included; otherwise reported as no.

ID no.	Author, year	Stud	C ty size fr)verall ollow-up	Stud	y design	Adequi randorr	ate nisation?	Alloca conce:	ttion alment?	Follow-	(%) dn	Blind ou assessm	itcome nent?	Overall quality rating	Overall external validity rating
Biologic	al agents vs epidur	al/intradisc	al injection													
321	Becker, 200714	606	N	2 weeks	RCT		Yes		Partial		80-100	6	Yes		Moderate	Weak
Biologic	al agents vs inactiv	re control														
398	Karppinen, 200	13270 72	ĉ) months	Non-	RCT	No		No		Cannot	tell	No		Weak	Weak
741	Korhonen, 200	5 ²⁷¹ 41	-	year	RCT		Yes		Unclea	JL	80-100		Unclear		Moderate	Weak
Biologic	al agents vs non-o	oioids														
323	Genevay, 2004	216 10	9) weeks	HCS		No		No		80-100	_	No		Weak	Moderate
							Total (<i>n</i>)	-	Baseline n (SD)	nean	Final mea	ın (SD)	Change (SD)	scores		
			Study	Follow-		Scala	nterven	Con	nterven	Con	nterven	Con	nterven	Con	Mean difference	Comment/
ID no.	Author, year C	hronicity	design	dn	Location	(range) ^a	tion	trol	tion	trol	tion	trol	tion	trol	(95% CI) ^b	conversion
Biologic	al agents vs inactiv	re control														
398	Karppinen, A 2003 ²⁷⁰		Non-RCT	1 month	Leg	VAS (0-100)	10	62 {	80 (18)	76 (19)	18 (19)	47 (32)	-62	-29	-40.50 (-43.22 to -14.78)	Change scores presented as percentages
Biologic	al agents vs non-ol:	oioids														
323	Genevay, A 2004 ²¹⁶		HCS	6 weeks	Leg	VAS (0-100)	10	10	74.4 (12.9)	75.1 (14.2)	12.4 (13.2)	52.9 (25.1)			-40.50 (-58.08 to -22.92)	
A, acute. a The ri h Baser	esults have been cor on final means or c	werted to a (scale of 0–10)0 for compa	rability.	COTES)										
c The te	erm 'dropouts' has b	een used for	r missing data	a, post-baseli	ine exclusion	is and patient.	s lost to fol-	low-up.								

ID no.	Author, year	Study design		WMD (95%	CI)	% weight
Inactive	e control					
398	Karppinen, 2003 ²⁷⁰	Non-RCT		-29.00 (-43.2	22 to -14.78)	100.00
Non-op	ioids					
323	Genevay, 2004 ²¹⁶	HCS		-40.50 (-58.0	08 to -22.92)	100.00
			-58.1 (0	58.1	
			Favours biological agents	Favours control		

FIGURE 78 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design					SMD (95%	i CI)	% weight
Epidura	al/intradiscal injection	1							
321	Becker, 2007 ¹⁴⁹	RCT			-	•	0.29 (-0.2	24 to 0.82)	100.00
Inactive	e control								
398	Karppinen, 2003 ²⁷⁰	Non-RCT		•			-0.93 (-1.6	61 to –0.24)	100.00
Non-op	ioids								
323	Genevay, 2004 ²¹⁶	HCS	\leftarrow	•			-1.05 (-1.9	99 to –0.10)	100.00
			-1.99		Ó		1.9	9	
			Favor	irs biological ac	ients	Favours con	trol		

FIGURE 79 Summary of the findings of CSOMs at short-term follow-up (<6 weeks) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

serum compared with epidural injection of corticosteroid and local anaesthetic in one moderate-quality RCT.¹⁴⁹

Biological agent results at long-term follow-up (>6 months)

Global effect at long-term follow-up

No studies reported the global effect data at long-term follow-up.

Pain intensity at long-term follow-up

The results for pain intensity at long-term follow-up are presented in *Table 121* and the accompanying forest plot (*Figure 82*). There was no significant difference in pain intensity in one moderate-quality RCT of infliximab compared with placebo injection.²⁷¹

Condition-specific outcome measures at long-term follow-up

The results for CSOMs at long-term follow-up are presented in *Table 122* and the accompanying forest plot (*Figure 83*). There was no significant difference in CSOMs in one moderate-quality RCT of infliximab compared with placebo injection.²⁷¹

Adverse effects

The total number of adverse effects are presented in *Table 123* and the accompanying forest plot (*Figure 84*). There was no significant difference in the number of adverse events between

						Total (<i>n</i>	(Baseline ı (SD)	mean	Final me	an (SD)	Change (SD)	scores		
еë	Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI)ª	Comment/conversion ^b
Biolo	țical agents vs epidură	ચા													
321	Becker, 2007 ¹⁴⁹ (j)° (5 mg)	A+C	RCT	6 weeks	IOO	32	27	22.0 (8.3)	20.6 (8.1)	13.8 (9.8)	12.1 (9.0)			0.18 (-0.33 to 0.69)	ITT not used Dropouts 6 (7%); number originally randomised to each oroun ond started
321	Becker, 2007 ¹⁴⁹ (ii) ^c (10mg)	A + C	RCT	6 weeks	IOO	32	25	22.0 (8.3)	19.4 (9.9)	13.8 (9.8)	11.0 (9.5)			0.29 (-0.24 to 0.82)	TT not used Dropouts 6 (7%); number originally randomised to each group not stated
Biolo	țical agents vs inactivi	e control													
398	Karppinen, 2003 ²⁷⁰	A	Non-RCT	1 month	IQO	10	62	43 (21)	44 (15)	15 (9)	30 (17)	-28	14	-0.93 (-1.61 to -0.24)	Percentage change scores from baseline and adjusted difference between groups Percentage change converted
Biolo	tical agents vs non-op	ioids													
323	Genevay, 2004 ²¹⁶	A	HCS	6 weeks	RMDQ	10	10	17.8 (3.3)	15.5 (2.9)	5.8 (5.5)	11.1 (4.6)			-1.05 (-1.99 to -0.10)	
A, acu a Ba b Th c Be	te; A + C, acute and chr sed on final means or ch e term 'dropouts' has be cker <i>et al.</i> ¹⁴⁹ included thu	onic. nange scores (v ten used for mix ree treatment g	vith a preferen ssing data, pc Iroups: epidur	nce given to st-baseline (al injection o	change score exclusions an	ss). Id patients conditione	lost to fol d serum (llow-up. (i), epidural i	injection of	steroid tria	mcinolone 10) ma + loca	l anaesthe	tic 1 ml (ii) and epidural i	injection of steroid

TABLE 118 Summary of the findings of CSOMs at short-term follow-up (< 6 weeks) for studies comparing biological agents with alternative interventions

triamcinolone 5 mg + local anaesthetic 1 ml (iii). In order to prevent using the same comparator twice, only the first and last treatment groups have been included in the meta-analysis.

TABLE 119 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing biological agents with alternative interventions

	٩					eq	ain ns nted
	iversion		ants (8% umber omised ti t stated	ants (8% umber omised tu t stated t		present	ed for stion in p orm mea derived m weigh
	ient/cor		particips ed out; n Ily rando Iroup no	particips ed out; n illy rando iroup noi		e scores centage:	n reporte ne, reduce nge n used fa lal score hange outed frc
	Comr		Seven droppe origina each g	Seven droppe origina each g		Chang as per	Medial baselir Medial and fir form c SD im averag
	e		een i): 23.5	een iii): –27.4 d sis of		.80)	a
	liffereno (1) ^a		d mean ce betw (j) and (i 5% Cl –	d mean ce betw (j) and ((95% Cl repeate es analy e) to -13	to 22.04
	Mean c (95% C		Adjuste differen groups -9.3 (9 to 4.9)	Adjuste differen groups –13.5 (to 0.4); measur varianc		-27.00 (-40.20	7.00 (-8.04
scores	Control					-39	-20
Change (SD)	Intervention					-70	-43
an (SD)	Control					37 (35)	23 (30.1)
Final me	Intervention					10 (16)	30 (15.31)
mean	Control		85	82		76 (19)	73
Baseline (SD)	Intervention		28	78		80 (18)	73
Ē	Control		24	27		62	19
Total (<i>r</i>	Intervention		32	32		10	21
	Scale (range)		VAS (0-100)	VAS (0-100)		VAS (0-100)	VAS (0-100)
	Location		Overall	Overall		Leg	Ceo
	Follow-up		22 weeks	22 weeks		3 months	12 weeks
	Study design		RCT	RCT	rol	Non- RCT	RCT
	Chronicity	spidural	A + C	A + C	nactive cont	A	A + C
	יסר, (igents vs e	ker, 7¹₄9 g)	7 ¹⁴⁹ mg)	igents vs i	opinen, 3 ²⁷⁰	5 ²⁷¹
	Auth year	'ogical á	°Bec 200 (5 m	°Bec 200 (101)	ogical á	Karp 200	Kort 200
	₽ë	Biol	321	321	Biol	398	741

A, acute; A + C, acute and chronic.

^a Based on final means or change scores (with a preference given to change scores); results reported by study in italics.
 ^b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.
 ^c Becker *et al.*¹⁴⁶ included three treatment groups: epidural injection of autologous conditioned serum (i), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (ii). In order to prevent using the same comparator twice, only the first and second treatment groups have been included in the meta-analysis.

ID no.	Author, year	Study design					WMD (95% CI)	% weight
Inactive	control							
398	Karppinen, 2003 ²⁷⁰	Non-RCT					-27.00 (-40.20 to -13.80)	50.58
741	Korhonen, 2005 ²⁷¹	RCT		_			7.00 (-8.04 to 22.04)	49.42
Subtota	l (l ² = 91.0%, p = 0.00	1)	\sim				-10.20 (-43.52 to 23.12)	100.00
			43.5				43.5	
		-	Favours biolo	gical agents	s	Favours cont	43.5 rol	

FIGURE 80 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			S	MD (95% CI)	% weight
Epidura	Il/intradiscal injectior	ı					
321	Becker, 2007 ¹⁴⁹	RCT				0.08 (–0.45 to 0.60)	100.00
Inactive	e control						
398	Karppinen, 2003 ²⁷⁰	Non-RCT			-	0.90 (–1.59 to –0.22)	100.00
			-1.59	0		1.59	
			Favours biologica	al agents	Favours control		

FIGURE 81 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

infliximab and placebo in two RCTs,^{270,271} or between epidural injections of autologous conditioned serum compared with corticosteroid and local anaesthetic in one RCT.¹⁴⁹

SUMMARY OF OVERALL FINDINGS FOR BIOLOGICAL AGENT COMPARED WITH ALTERNATIVE INTERVENTIONS

Four studies,^{149,216,270,271} three of which were RCTs,^{149,216,271} compared the use of biological agents with other interventions (*Table 124*).

There was conflicting evidence for the efficacy of intravenous infliximab as one poor-quality non-RCT found significant improvement in global effect and pain intensity at short- and medium-term follow-up,²⁷⁰ but one moderate-quality RCT did not.²⁷¹ A poor-quality HCS found significant improvement in short-term pain intensity and CSOMs with etanercept compared with intravenous corticosteroids.²¹⁶ There was no significant difference in pain intensity or CSOMs in the short or medium term with epidural injection of autologous conditioned serum compared with epidural injection of corticosteroid and local anaesthetic in one moderate-quality RCT.¹⁴⁹ There was no difference in the number of adverse effects.

TABLE 120 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing biological agents with alternative interventions

						Total (e	Baseline I (SD)	mean	Final me (SD)	an	Change (SD)	scores		
Ξë	Author, year	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
Biolo	ogical agents v	ıs epidural													
321	Becker, 2007 ¹⁴⁹ (j)⁰ (5 mg)	A+C	RCT	6 weeks	IOO	32	27	22.0 (8.3)	11.1 (7.1)	11.7 (9.2)	11.1 (7.1)			0.07 (-0.44 to 0.58)	ITT not used Dropouts: 7 (8%) Number originally randomised to each group not stated
321	Becker, 2007 ¹⁴⁹ (ii) ^c (10mg)	A+C	RCT	6 weeks	IQO	32	25	22.0 (8.3)	11.0 (9.5)	11.7 (9.2)	11.0 (9.5)			0.08 (-0.45 to 0.60)	ITT not used Dropouts: 7 (8%) Number originally randomised to each group not stated
Biolo	ogical agents v	vs inactive con	trol												
398	Karppinen, 2003 ²⁷⁰	×	Non- RCT	1 month	IQO	10	62	43 (21)	24 (20)	7 (6)	24 (20)	-36	-20	-0.90 (-1.59 to -0.22) Adjusted mean difference 13% (95% Cl 4 to 22); ANOVA (poor- quality study)	Percentage change scores from baseline and adjusted difference between groups – not based on summary score (repeated ANCOVA)
741	Korhonen, 2005 ²⁷¹	A+C	RCT	12 weeks	0DI (%)	21	19								Only medians reported; p -values reported based on Mann–Whitney U -test or Fisher's exact-test ITT not used but all patients included in analysis except one who did not meet including criteria
A, ac B	ute; A + C, acut ased on final me	te and chronic. eans or change	scores (wit	l a preference	aiven to chai	nde scol	es): re;	sults report	ed by sti	ldv in itali	CS.				

b The term 'dropouts' has been used for missing data, post-baseline exclusions and patients lost to follow-up.
 c Becker *et al.*¹⁴⁹ included three treatment another animal intention.

Becker *et al.*¹⁴⁶ included three treatment groups: epidural injection of autologous conditioned serum (i), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (iii). In order to prevent using the same comparator twice, only the first and second treatment groups have been included in the meta-analysis.

TABLE 121 Summary of the findings of pain intensity at long-term follow-up (> 6 months) for studies comparing biological agents with alternative interventions

							Total (<i>i</i>	6	Baseline m (SD)	lean Final (SD)	mean	Change (SD)	scores		
e ë	Author, year	Chronicity	Study design	Follow- up	Location	Scale (range) ^a	Intervention	Control	Intervention	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁰	Comment/conversion ^c
Biolog	ical agents v	's inactive co.	introl												
741	Korhonen, 2005 ²⁷¹	A + C	RCT	12 weeks	Ceg	VAS (0-100)	51	0	73 7	3 23 (15.3	12 (23.67)	-43	-20	11.00 (-1.50 to 23.50)	Median reported for baseline, reduction in pain and range Median used form means and final score derived form change SD imputed from weighted average Dropouts 1/41 (2%): group allocation not stated
A + C, a The b Bas c The	acute and chr results have ed on final me term 'dropou'	onic. been converte eans or chang ts' has been u	ad to a scale le scores (w used for mis	e of 0–100 fo //ith a preferen //sing data, po	r comparabili ice given to cl st-baseline ex	ty. hange score: (clusions and	s). 1 patient:	s lost to fc	llow-up.						



FIGURE 82 Summary of the findings of pain intensity at long-term follow-up (>6 months) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Inactive	control					
741	Korhonen, 2005 ²⁷¹	RCT	*		-0.06 (-0.68 to 0.56)	100.00
		-().684 Favours biological agents	0 Favours control	0.684	

FIGURE 83 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

TABLE 122 Summary of the findings of CSOMs at long-term follow-up (>6 months) for studies comparing biological agents with alternative interventions

	Mean difference (95% Cl)ª Comment/conversion ^b		 -0.06 Only median reported – used as mean (-0.68 to <i>p</i>-values reported based on Mann–Whitney 0.56) <i>U</i>-test or Fisher's exact test Final SD imputed from WMD of SDs for ODI medium-term follow-up IT not used, but all patients included in analysis except one who did not meet inclusion criteria 	
e scores	Control		-23	
Chang (SD)	Intervention		-28	
(SD)	Control		10 (20)	
Final mean	Intervention		9 (10.71)	
e mean	Control		48	st to follow-
Baselin (SD)	Intervention		45). patients lo
(<i>u</i>)	Control		6	ige scores) isions and
Total	Intervention		21	to chan ne exclu
	Scale		0DI (%)	ence giver oost-baseli
	Follow-up		12 months	s (with a prefer missing data, p
Study design			RCT	nge scores 1 used for
	Chronicity	nactive	A + C	ic. Is or chai has beer
	Author, year	ical agents vs i.	Korhonen, 2005 ²⁷¹	acute and chroni ed on final mear term 'dropouts'
	ם ë	Biologi	741	A+C, <i>ɛ</i> a Bası b The
TABLE 123 Summary of the findings of any adverse effects for studies comparing biological agents with alternative interventions

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Biolog	ical agent vs epidural						
321	Becker, 2007 ¹⁴⁹ (i) ^a (5 mg)	RCT	1	32	1	27	0.84 (0.05 to 14.08)
321	Becker, 2007 ¹⁴⁹ (ii)ª (10 mg)	RCT	1	32	1	25	0.77 (0.05 to 13.02)
Biolog	ical agent vs inactive co	ontrol					
398	Karppinen, 2003 ²⁷⁰	Non-RCT	0	10	0	62	
741	Korhonen, 2005271	RCT	0	21	0	19	
Biolog	ical agent vs non-opioid	ls					
323	Genevay, 2004 ²¹⁶	HCS	NR	NR	NR	NR	

NR, not reported.

a Becker *et al.*¹⁴⁹ included three treatment groups: epidural injection of autologous conditioned serum (i), epidural injection of steroid triamcinolone 10 mg + local anaesthetic 1 ml (ii) and epidural injection of steroid triamcinolone 5 mg + local anaesthetic 1 ml (iii). In order to prevent using the same comparator twice, only the first and second treatment groups have been included in *Figure 84*.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Epidura	I						
321	Becker, 2007 ¹⁴⁹	RCT	•			0.77 (0.05 to 13.02)	100.00
			0.046 Favours biological agents	1 Favours control	2	+ I.7	

FIGURE 84 Summary of the findings of any adverse effects for studies comparing biological agents with alternative interventions. Note: weights are from random effects analysis.

Health Technology Assessment 2011; \

0/4 (0)

1/4 (25)

1/4 (25)

0/4 (0)

0

5

0/1 (0)

0/1 (0)

0

5

0/1 (0)

0/1 (0)

1/1 (100)

1/1 (100)

0/1 (0)

0/1 (0)

10 (10)

1 (1

0/2 (0)

1/2 (50)

1/2 (50)

0

0/2 (

0/2 (0)

2/2 (100)

2/2 (100)

1/2 (50)

0/2 (0)

1/2 (50)

41–72

2 (2)

(57)

TABLE 124 Summary of biological agent studies Biological agents vs non-Biological agents vs Biological agents vs epidural/intradiscal **Control category** inactive control injection opioids © Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.



Proportion of studies

Proportion of studies

patients received previous

patients who had

that only included patients with first episode

patients with extruded/ that included

sequestered

with

confirmed

with nerve

root pain

sciatica

good quality

RCTs

Sample size range (median) 06) 06

No. of studies (arms) 1 (2)

acute

discs

surgery

treatment

received previous

(%) 5

%

%

%

%

(%)

(%

%

(%)

(%)

by imaging

0

0/1 (0)

0/1 (0)

0/1 (0)

0/1 (0)

1/1 (100)

1/1 (100)

0/1 (0)

0/1 (0)

1/1 (100)

included who had

that

that included

Proportion of studies

Proportion of studies

Proportion of studies included patients stenosis

Proportion of studies

roportion

of studies

that

that reported diagnosis

included

hat

of studies Proportion that only included

> Proportion of studies that were deemed

> > Proportion of studies that were

patients

15: No. 39

Activity restriction

Description of activity restriction studies

Summary of interventions

Five studies compared passive PT with an alternative type of intervention.^{14,145,243,256,267} Summary data of the interventions used are presented in *Table 125*. Two RCTs compared bed rest for 1 or 2 weeks with advice to keep active,¹⁴ or continue activities of daily living.²⁶⁷ This last RCT²⁶⁷ was a three-arm study which also compared bed rest with twice weekly hospital physiotherapy for at least 4 weeks, consisting of segmental mobilisation, exercises and hydrotherapy. Another three-arm RCT²⁵⁶ compared rest and hot packs with hot packs, massage, mobilising and isotonic strengthening exercise, and also with intermittent pelvic traction and isometric strengthening exercises. Another RCT²⁴³ compared bed rest at home with bed rest and vertical traction. A non-RCT¹⁴⁵ compared 1–2 weeks of bed rest with a sacral epidural injection of local anaesthetic.

Summary of study participants in activity restriction studies

Summary data on the included participants are presented in *Table 126*. The five studies included 551 participants with mean ages between 39 and 46 years (47–76% men). Symptom duration was acute in two studies, chronic in one and a mixture of acute and chronic in the other. Three studies included patients with recurrent symptoms, and not recorded in two. Sciatica was confirmed by imaging in one RCT.²⁶⁷ There were no patients with spinal stenosis or sequestered discs, and previous back surgery was excluded in one RCT.¹⁴

Summary of study quality for activity restriction studies

Study details are summarised in *Table 127*. Most studies were RCTs (4/5, 80%); however, the proportion that were of good quality was low (1/5, 20%). Only three had an adequate method of random number generation^{14,243,267} and none documented a secure method of allocation concealment. Two studies had good external validity.^{14,243}

ID no.	Author, year	Study design	Treatment description	Control description	
Activit	ty restriction vs exerci	se therapy			
564	Lidstrom, 1970 ²⁵⁶	RCT	Rest	Massage + mobilising and strengthening exercises	
Activit	ty restriction vs educa	tion/advice			
713	Hofstee, 2002267	RCT	Bed rest	Advised to continue activities of daily living	
658	Vroomen, 199914	RCT	Bed rest	Advice to keep active	
Activit	ty restriction vs epidu	ral/intradiscal	injection		
140	Coomes, 1961 ¹⁴⁵	Non-RCT	Bed rest at home on fracture boards	Sacral epidural injection local anaesthetic 50-60 ml procaine	
Activity restriction vs mixed treatment					
713	Hofstee, 2002 ²⁶⁷	RCT	Bed rest	Hospital physiotherapy: segmental mobilisation + exercises + hydrotherapy	
564	Lidstrom, 1970 ²⁵⁶	RCT	Rest	Traction + strengthening exercises	
Activit	ty restriction vs tractio	on			
222	Moret, 1998 ²⁴³	RCT	Bed rest	Bed rest and traction (vertical traction using patient weight), 180 minutes daily for $1-2$ weeks	

TABLE 125 Summary of the interventions used when comparing activity restriction with alternative interventions

_	
8	
E.	
ō	
ð	
L	
e	
₽	
Ъ	
f	
L L L	
ä	
Ē	
ō	
0	
<u></u>	
-	
a	
ਰੂ	
б	
Ъ.	
<u> </u>	
ŝ	
ō	
Ŧ	
ē	
Š	
te	
.⊑	
Ð	
.≥	
aj	
Ľ	
te	
ש	
Ē	
Ϊţ	
5	
Ы	
ï	
<u>0</u> .	
뇄	
ő	
5	
÷	
.≥	
ō	
0	
2	
uring	
oaring	
nparinc	
omparinç	
comparinç	
es comparinç	
dies comparinç	
udies comparinç	
studies comparinç	
or studies comparinç	
for studies comparing	
ls for studies comparinç	
ails for studies comparing	
etails for studies comparing	
details for studies comparing	
on details for studies comparing	
tion details for studies comparing	
lation details for studies comparing	
oulation details for studies comparing	
opulation details for studies comparing	
population details for studies comparing	
ty population details for studies comparing	
udy population details for studies comparing	
study population details for studies comparing	
d study population details for studies comparing	
ind study population details for studies comparing	
and study population details for studies comparing	
ce and study population details for studies comparing	
type and study population details for studies comparing	
a type and study population details for studies comparing	
ica type and study population details for studies comparing	
atica type and study population details for studies comparing	
ciatica type and study population details for studies comparing	
sciatica type and study population details for studies comparing	
of sciatica type and study population details for studies comparing	
y of sciatica type and study population details for studies comparing	
ary of sciatica type and study population details for studies comparing	
mary of sciatica type and study population details for studies comparing	
mmary of sciatica type and study population details for studies comparing	
summary of sciatica type and study population details for studies comparing	
Summary of sciatica type and study population details for studies comparing	
26 Summary of sciatica type and study population details for studies comparing	
126 Summary of sciatica type and study population details for studies comparing	or)
.E 126 Summary of sciatica type and study population details for studies comparing	(thor)

TABLE by auth	126 Sumr ior)	mary of scia	tica type	and study popu	ulation deta	ails for studies	comparing a	ctivity restricti	ion with alter	native intervent	ions (grouped b	y comparator th	ien ordered
										Included	Included patients with sequestered	Any previous	Any previous
ID no.	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	patients with stenosis?ª	disc (or extruded)?ª	treatment for sciatica?	back surgery for sciatica?
Activit	v restriction	vs education,	'advice										
713	Hofstee, 2002 ²⁶⁷	RCT	250	Mean 39 (SD 10)	150 (60)	Mean 2 weeks	Nerve root pain and referred pain	Yes	Recurrent	No	No	NR	Yes
658	Vroomen, 1999 ¹⁴	RCT	183	Mean 46 (SD 12)	103 (56)	Median 16 days	Nerve root pain	No	Recurrent and first episode	No	No	R	No
Activit	y restriction	vs epidural											
140	Coomes, 1961 ¹⁴⁵	Non-RCT	40	Mean 43 (range 16–70)	26 (65)	Mean of 34 days	Nerve root pain	No	NR	No	No	Yes	R
Activit	y restriction	vs exercise ti	herapy										
564	Lidstrom, 1970 ²⁵⁶	RCT	62	Range 21–61	29 (47)	>1 year 52%	Nerve root pain and referred pain	No	R	No	No	R	NR
Activit	y restriction	vs mixed treć	ntments										
713	Hofstee, 2002 ²⁶⁷	RCT	250	Mean 39 (SD 10)	150 (60)	Mean 2 weeks	Nerve root pain and referred pain	Yes	Recurrent	No	N	NR	Yes
564	Lidstrom, 1970 ²⁵⁶	RCT	62	Range 21–61	29 (47)	>1 year 52%	Nerve root pain and referred pain	No	R	No	No	N	NR
Activit	v restriction	vs traction											
222	Moret, 1998 ²⁴³	RCT	16	Mean 41.9 (SD 8.7)	12 (75)	Acute symptoms 50%	Nerve root pain	No	Recurrent and first episode	No	NR	Yes	Yes
NR, not a Mar	t reported. Ked yes if pat	ient populatior	1 or inclusion	n criteria specifically	/ reported tha	it patient with sequ	Jestered disc, ex	truded disc or ste	enosis were incl	uded; otherwise rep	orted as no.		

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 127 Summary of the study details for studies comparing activity restriction with alternative interventions

D no.	Author, year	Study size	Overall follow-up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
Activity	restriction vs education/advice									
713	Hofstee, 2002 ²⁶⁷	250	6 months	RCT	Yes	No	80-100	No	Moderate	Moderate
658	Vroomen, 199914	183	12 weeks	RCT	Yes	No	80-100	Yes	Moderate	Strong
Activity	restriction vs epidural/intradisca	ıl injection								
140	Coomes, 1961 ¹⁴⁵	40	9 weeks	Non-RCT	No	No	80-100	No	Weak	Weak
Activity	restriction vs exercise therapy									
564	Lidstrom, 1970 ²⁵⁶	62	1 month	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Activity	restriction vs mixed treatments									
713	Hofstee, 2002 ²⁶⁷	250	6 months	RCT	Yes	No	80-100	No	Moderate	Moderate
564	Lidstrom, 1970 ²⁵⁶	62	1 month	RCT	Unclear	Unclear	80-100	Unclear	Weak	Weak
Activity	restriction vs traction									
222	Moret, 1998 ²⁴³	16	3 weeks	RCT	Yes	Partial	80-100	No	Moderate	Strong

÷.

Activity restriction results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 128* and the accompanying forest plot (*Figure 85*). There was no significant difference between bed rest and advice to keep active in two RCTs.^{14,267} There was no significant difference between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department,²⁶⁷ between rest and spinal manipulation with exercises, pelvic traction and exercises,¹³⁷ or between bed rest and bed rest with vertical traction.²⁴³

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 129* and the accompanying forest plot (*Figure 86*). There was a significant improvement in pain intensity in the bed rest group compared with advice to keep active in one RCT,¹⁴ but no significant difference in another RCT,²⁶⁷ and none when these results were combined in a meta-analysis. There was no significant difference in pain intensity between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department.²⁶⁷ There was a significant improvement in pain intensity in the bed rest with vertical traction group compared with the group treated with bed rest alone.²⁴³

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 130* and the accompanying forest plot (*Figure 87*). There was a significant improvement in CSOMs with advice to keep active compared with bed rest when the two RCTs were combined in a meta-analysis.^{14,267} There was a significant improvement in CSOMs in the group receiving mobilisation with exercises carried out in a hospital physiotherapy department compared with the bed rest group in one RCT.²⁶⁷ There was no significant difference in CSOMs in the bed rest with vertical traction group compared with the group treated with bed rest alone.²⁴³

ID no.	Author, year	Study design		OR (95% Cl)	%) weight
Active	PT/exercise therapy	,			
564	Lidstrom, 1970 ²⁵⁶	RCT		◆ 2.20 (0.63 to	7.66) 100.00
Educati	ion/advice				
713	Hofstee, 2002 ²⁶⁷	RCT		• 1.23 (0.36 to	4.20) 20.24
658	Vroomen, 199914	RCT		• 1.24 (0.67 to	2.30) 79.76
Subtota	ll ($l^2 = 0.0\%$, $p = 0.99$	2)	<	> 1.24 (0.71 to	2.15) 100.00
Mixed t	reatments				
713	Hofstee, 2002 ²⁶⁷	RCT		0.39 (0.07 to	2.07) 51.50
564	Lidstrom, 1970 ²⁵⁶	RCT —	•	- 0.22 (0.04 to	1.24) 48.50
Subtota	l ($l^2 = 0.0\%$, $p = 0.64$.5)		0.30 (0.09 to	0.98) 100.00
Tractio	n				
222	Moret, 1998 ²⁴³	RCT	•	1.00 (0.14 to	7.10) 100.00
		0.039	8 1	25.1	
			Favours control	Favours activity restriction	

FIGURE 85 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

	S
	<u> </u>
	0
-	Ē
	5
	Ψ
	2
	e
	Ξ
•	-
	Φ
	>
-	₽.
	ğ
	F
	Ð
	<u> </u>
	б
	~
-	₽
•	⋝
	~
	0
-	₽.
	2
	₽
	ŝ
	Ψ,
	-
	≏
	5
	≓
	Ö
	g
	Ē
	2
	ŧ
	ສົ
	ŏ
	Ē
	ö.
	0
	S
	Φ
-	5
	ĭ.
	÷.
	0)
	≻
	2
	_
	S)
	ž.
	Ϋ́
	Ψ
	>
	co:
(0
•	0 VI
	9 (≥0 0
	9≥) dn
	9≥) dn-
	9≥) dn-w
	9≥) dn-wo
:	9≥) dn-wolld
:	tollow-up (≤6
:	i tollow-up (≤6
	m tollow-up (≤6
:	erm tollow-up (≤6
	term tollow-up (≤6
	t-term tollow-up (≤6
	ort-term tollow-up (≤6
	ort-term tollow-up (≤6
	short-term tollow-up (≤6
	short-term tollow-up (≤6
•	at short-term tollow-up (≤6
	: at short-term tollow-up (≤6
	ct at short-term tollow-up (≤6
	ect at short-term tollow-up (≤6
	ttect at short-term tollow-up (≤6
	effect at short-term tollow-up (≤6
	al effect at short-term tollow-up (≤6
	al effect at short-term tollow-up (≤6
	obal effect at short-term tollow-up (≤6
	ilobal effect at short-term tollow-up (≤6
	global effect at short-term tollow-up (≤6
	e global eftect at short-term follow-up (≤6
	he global eftect at short-term tollow-up (≤6
	the global effect at short-term tollow-up (≤6
	of the global effect at short-term follow-up (≤6
	of the global effect at short-term tollow-up (≤6
	is of the global effect at short-term follow-up (≤6
	igs of the global effect at short-term tollow-up (≤6
	ings of the global effect at short-term tollow-up (≤6
	dings of the global effect at short-term tollow-up (≤6
	ndings of the global effect at short-term follow-up (≤6
	tindings of the global effect at short-term tollow-up (≤6
	e tindings of the global effect at short-term tollow-up (≤6
	he tindings of the global effect at short-term follow-up (≤ 6
	the findings of the global effect at short-term follow-up (≤ 6
	of the findings of the global effect at short-term follow-up (≤ 6
	of the findings of the global effect at short-term follow-up (≤ 6
	y of the findings of the global effect at short-term follow-up (≤ 6
	ary of the findings of the global effect at short-term follow-up (≤ 6
	nary of the findings of the global effect at short-term follow-up (≤ 6
	imary of the findings of the global effect at short-term follow-up (≤ 6
	mmary of the findings of the global effect at short-term follow-up (≤ 6
	ummary of the findings of the global effect at short-term follow-up (≤ 6
	Summary of the tindings of the global effect at short-term follow-up (≤ 6
	Summary of the findings of the global effect at short-term follow-up (≤6
	Summary of the findings of the global effect at short-term follow-up (≤ 6
	28 Summary of the findings of the global effect at short-term follow-up (≤6
	128 Summary of the findings of the global effect at short-term follow-up (≤6
	E 128 Summary of the findings of the global effect at short-term follow-up (≤6
	LE 128 Summary of the findings of the global effect at short-term follow-up (≤6

TABLE	: 128 Summ	ary of the find	dings of th	ie global eff∈	ect at short-term follow-up (≤6	weeks) for stı	udies cor	nparing act	ivity restrictior	n with alt	ernative int	erventions	
							Interven	tion		Control			
Ωġ	Author, year	Chronicity	Study design	Follow- up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% CI)
Activii	ty restriction v	s education/adv	rice										
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Treatment failure. Opposite extracted	Physician	84	62	0.00	83	77	0.00	1.23 (0.36 to 4.20)
658	Vroomen, 1999 ¹⁴	A	RCT	2 weeks	Assessment of improvement	Patient	92	64	0.00	91	59	0.00	1.24 (0.67 to 2.30)
Activiì	ty restriction vs	s exercise ther:	Лa										
564	Lidstrom, 1970 ²⁵⁶	A+C	RCT	1 month	Patient's ability to function socially was a decisive factor for both evaluations (no change or worse)	Patient	21	14	0.00	21	10	0.00	2.20 (0.63 to 7.66)
Activiì	ty restriction v	s mixed treatm	ents										
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Treatment failure. Opposite extracted	Physician	84	79	0.00	83	81	0.00	0.39 (0.07 to 2.07)
564	Lidstrom, 1970 ²⁵⁶	A+C	RCT	1 month	Patient's ability to function socially was a decisive factor for both evaluations (no change or worse)	Patient	21	14	00.00	20	18	0.00	0.22 (0.04 to 1.24)
Activiì	ty restriction v	s traction											
222	Moret, 1998 ²⁴³	A	RCT	3 weeks	Leg pain: recovered or strongly improved (vs little improved, no change, little worse, much worse or worse than ever)	Patient	ω	4	0.00	ω	4	0.00	1.00 (0.14 to 7.10)

A, acute; A + C, acute and chronic.

h alternative interventions	Change course (CD)
activity restriction wit	Einel moon (CD)
or studies comparing	Baseline mean
ow-up (≤6 weeks) fc	Total (m)
ity at short-term follo	
idings of pain intens	
Summary of the fin	
TABLE 129	

							Total (<i>n</i>	(Baseline (SD)	mean	Final mea	n (SD)	Change s	cores (SD)		
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵	
Activii	y restriction vs ea	lucation/advice														1
713	Hofstee, 2002 ²⁶⁷	٨	RCT	1 month	Leg	VAS (0-100)	82	83	65.5 (18.5)	60.7 (21.4)			-25.9 (29.16)	-23.4 (29.16)	-2.50 (-11.40 to 6.40)	
658	Vroomen, 199914	A	RCT	2 weeks	Leg	VAS (0-100)	92	91	62 (22)	68 (21)	36 (28)	44 (27)			-8.00 (-15.97 to -0.03)	
Activii	y restriction vs m	ixed treatment														
713	Hofstee, 2002 ²⁶⁷ (manipulation + exercise therapy	A	RCT	1 month	Leg	VAS (0-100)	82	80	65.5 (18.5)	60.9 (20.1)			–25.9 (29.16)	–24.2 (29.31)	-1.70 (-10.70 to 7.30)	
Activii	y restriction vs tra	Iction														
222	Moret, 1998 ²⁴³	A	RCT	3 weeks	Leg	NRS (0-10)	80	ω	73 (10.0)	74 (12.0)	63 (10)	44 (12)	-10.0	-30.0	19.00 (8.18 to 29.82)	
A, acui a The b Bas	te. tesults have been ed on final means c	converted to a sca or change scores (ale of 0–10C (with a prefe) for comparabili erence given to c	ty. hange scores)											I Contraction of the second seco

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.



FIGURE 86 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				SMD (95% CI)	% weight
Educat	ion/advice						
713	Hofstee, 2002 ²⁶⁷	RCT				0.39 (0.08 to 0.70)	47.32
658	Vroomen, 1999 ¹⁴	RCT	_			0.16 (-0.13 to 0.45)	52.68
Subtota	al ($l^2 = 10.0\%$, $p = 0.2$	292)		\bigcirc		0.27 (0.04 to 0.49)	100.00
Mixed t	treatments						
713	Hofstee, 2002 ²⁶⁷	RCT				0.47 (0.16 to 0.78)	100.00
Tractio	n						
222	Moret, 1998 ²⁴³	RCT		•	\longrightarrow	0.50 (-0.49 to 1.50)	100.00
		.5	(0	1.5		
	Fa	vours activity	restriction	Favours contro	l		

FIGURE 87 Summary of the findings of CSOMs at short-term follow-up (<6 weeks) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

Activity restriction results at long-term follow-up Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 131* and the accompanying forest plot (*Figure 88*). There was no significant difference between bed rest and advice to keep active in two RCTs.^{14,267} There was no significant difference in one RCT between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department.²⁶⁷ There was a significant improvement in global effect for epidural injections compared with bed rest in one RCT.¹⁴⁵

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 132* and the accompanying forest plot (*Figure 89*). There was no significant difference between bed rest and

ŗ	
rati	
ра	
ы	
2	
d D	
bē	
DO	
ē	
suc	
ntic	
Ve Ve	
Itel	
ē	
ativ	
ŝrn	
alte	
ith	
≥	
ior	
rict	
est	
Σ	
tivii	
ac	
ng	
bari	
Ĕ	
ö	
lies	
tuo	
s	
ي و	
eks	
Ň	
9	
₽	
 -	
N	
l fo	
srm	
t-t	
þ	
lt s	
S S	
N	
Š	
ď	
gs	
din	
fin	
the	
of 1	,
ΥE	õ
Ĩ	aut
Sun	à
0	eq
ų 1	der
Щ	Š
H	e
2	2

						Total (r	(Baseline (SD)	mean	Final me	an (SD)	Change s (SD)	cores		
e ë	Author, year	Chronicity	Study design	Follow- up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)ª	Comment/conversion ^b
Activ	ty restriction	1 vs educatio	n/advice												
713	Hofstee, 2002 ²⁸⁷	A	RCT	1 month	GDS	82	83	58.6 (14.6)	57.4 (16.3)	47.2 (14.6)	41.2 (16.3)	-11.4 (18.84)	-16.2 (18.84)	0.39 (0.08 to 0.70)	Final means calculated from change scores Distribution at follow-up reported to be skewed ITT used (incorporating treatment compliance and dropouts), but dropouts excluded the results reported
658	Vroomen, 1999 ¹⁴	<	RCT	3 weeks	Revised RMDQ	92	91	5.5 (3.9)	5.2 (3.8)	14.8 (6.2)	13.8 (6.3)	-2.7	-4.0	0.16 (-0.13 to 0.45) <i>Adjusted mean</i> <i>difference -1.6</i> (95% CI -3.7 to 0.4)	Uropouls: Intervention 2/64, control 0/63 ITT used For baseline and mean, high score = good outcome; sign of change score altered so that negative indicates improvement Adjusted difference between groups not based on change scores
Activi	ty restriction	n vs traction													
222	Moret, 1998 ²⁴³	A	RCT	3 weeks	RMDQ	ω	8	18.5 (2.1)	18.1 (1.8)	17.1 (6.2)	14.5 (3.87)	-1. 4.	-3.6	0.50 (1.50 to –0.49)	Final mean based on change score with SD imputed from weighted average
Activi	ty restriction	ז vs mixed tr	eatment												
713	Hofstee, 2002 ⁸⁶⁷	<	RCT	1 month	QDS	83	80	58.6 (14.6)	56 (17.6)	47.2 (14.6)	40.3 (14.6)	-11.4 (18.84)	-45.7 (18.89)	0.47 (0.16 to 0.78)	Final means calculated from change scores Distribution at follow-up reported to be skewed ITT used (incorporating treatment compliance and dropouts), but dropouts eccluded in the results reported Dropouts: intervention 2/84, control 3/83
A, act a Ba b Th	rte; QDS, Que sed on final n e term 'dropo	thec Disability neans or chan uts' has been	Scale. ge scores (v used for mi	with a prefer ssing data, l	rence given	to change ne exclusio	 scores); ons and p 	; results as , patients lost	reported by to follow-up	study in itali 	cs.				

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 131 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing activity restriction with alternative interventions

							Intervei	ntion		Control			
Ωġ	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% CI)
Activi	ty restriction vs	s education/adv	vice										
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Treatment failure. Opposite extracted	Physician	84	63	0.00	83	69	0.00	0.16 (0.29 to 1.30)
658	Vroomen, 1999 ¹⁴	٨	RCT	12 weeks	Assessment of improvement	Patient	92	80	0.00	91	79	0.00	1.01 (0.43 to 2.39)
Activi	ty restriction vs	s epidural/intra	discal injection										
140	Coomes, 1961 ¹⁴⁵	۲	Non-RCT	9 weeks	Neurological state: completely relieved or improved (vs not changed or worse)	Physician	20	IJ	0.00	20	12	0.00	0.22 (0.06 to 0.86)
Activi	ty restriction vs	s mixed treatmu	ents										
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Treatment failure. Opposite extracted	Physician	84	63	0.00	83	64	0.00	0.89 (0.44 to 1.81)
A, acu	te.												

ID no.	Author, year	Study design			OR (9	5% CI)	% weight
Educat	ion/advice						
713	Hofstee, 2002 ²⁶⁷	RCT			— 0.61 (0.29 to 1.30)	56.21
658	Vroomen, 1999 ¹⁴	RCT			1.01 (i	0.43 to 2.39)	43.79
Subtota	$I (l^2 = 0.0\%, p = 0.38)$	34)		\sim	> 0.76 (0.43 to 1.34)	100.00
Epidura	al/intradiscal injection	on					
140	Coomes, 1961 ¹⁴⁵	Non-RCT	\leftarrow	•	0.22 (0.06 to 0.86)	100.00
Mixed 1	treatments						
713	Hofstee, 2002 ²⁶⁷	RCT		•		0.44 to 1.81)	100.00
			0.0576	1	17.	4	
				Favours control	Favours activity restriction	n	

FIGURE 88 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Educati	ion/advice					
713	Hofstee, 2002 ²⁶⁷	RCT			0.40 (-9.67 to 8.87)	37.96
658	Vroomen, 199914	RCT		•	— 2.00 (–5.25 to 9.25)	62.04
Subtota	$l (l^2 = 0.0\%, p = 0.68)$	39)			1.09 (-4.62 to 6.80)	100.00
Mixed t	reatment					
713	Hofstee, 2002 ²⁶⁷	RCT	•		-1.40 (-10.33 to 7.53)	100.00
			1			
		-1	0.3	0	10.3	
			Favours activity restriction	Favours control		

FIGURE 89 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

advice to keep active in two RCTs.^{14,267} There was no significant difference in one RCT between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department.²⁶⁷

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 133* and the accompanying forest plot (*Figure 90*). There was no significant difference between bed rest and advice to keep active in two RCTs.^{14,267} There was no significant difference in one RCT between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department.²⁶⁷

Activity restriction results at long-term follow-up (>6 months)

No long-term outcomes were reported for global effect, pain intensity or CSOMs.

Adverse effects

The total number of adverse effects are presented in *Table 134* and the accompanying forest plot (*Figure 91*). There was no significant difference between bed rest and advice to keep active in two

319

vity restriction with alternative interventions	
TABLE 132 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing a	Baseline mean

							Total (<i>r</i>	((D)		Final mea	an (SD)	Change sco	ores (SD)	
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵
Activi	ity restriction vs eu	ducation/advice													
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Leg	VAS	78	75	65.5	60.7			-48.2	-47.8	-0.40
						(0-100)			(18.5)	(21.4)			(27.92)	(30.45)	(-9.67 to 8.87)
658	Vroomen, 19991 ¹	4 A	RCT	12 weeks	Leg	VAS	92	91	62 (22)	68 (21)	16 (26)	14 (24)			2.00
						(0-100)									(- 5.25 to 9.25)
Activi	ity restriction vs m	iixed treatment													
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Leg	VAS	78	72	65.5	60.9			-48.2	-46.8	-1.40
						(0-100)			(18.5)	(20.1)			(27.92)	(27.83)	(-10.33 to 7.53)
	с +														

A, acute. a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores).

ABLE 133 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing activity restriction with alternative interventions	Baseline mean Total (<i>n</i>) (SD) Final mean (SD) Change scores (SD)	Ca Interve Ca Interve Ca Interve
--	---	---

Comment/conversion ^b			ITT used For baseline and mean, high score = good outcome; sign of change score altered so that negative indicates improvement in our analysis			
Mean difference (95% Cl)ª		0.25 (-0.07 to 0.57)	0.07 (–0.22 to 0.36) Adjusted mean difference –0.5 (95% CI –2.6 to 1.6)		0.28 (-0.04 to 0.60)	
Control		–35.4 (23.66)	-10.5		–34.6 (23.9)	
Intervention		–32.7 (23.66)	7.6-		–32.7 (23.66)	
Control		22 (16.3)	7.3 (7)		21.4 (17.6)	
Intervention		25.9 (14.6)	7.8 (7)		25.9 (14.6)	n italics.
Control		57.4 (16.3)	5.2 (3.8)		56 (17.6)	d by study i wv-up.
Intervention		58.6 (14.6)	5.5 (3.9)		58.6 (14.6)	as reported lost to follo
Control		75	91		75); results patients
Intervention		78	92		78	ge scores sions and
Scale		QDS	RMDQ		QDS	given to chan aseline exclu
Follow- up		6 months	12 weeks		6 months	a preference g data, post-t
Study design	dvice	RCT	RCT	nent	RCT	le. scores (with a id for missing
Chronicity	vs education/a	A	A	vs mixed treatr	A	ec Disability Sca ans or change ts' has been use
Author, year	restriction	Hofstee, 2002 ²⁶⁷	Vroomen, 1999 ¹⁴	restriction v	Hofstee, 2002 ²⁶⁷	s; QDS, Quebe ad on final me term 'dropout
<u> </u>	Activity	713	658	Activity	713	A, acuté a Basé b The

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Educat	ion/advice					
713	Hofstee, 2002 ²⁶⁷	RCT -			0.25 (-0.07 to 0.57)	45.34
658	Vroomen, 1999 ¹⁴	RCT ——			0.07 (-0.22 to 0.36)	54.66
Subtota	$l (l^2 = 0.0\%, p = 0.4\%)$	10) -			0.15 (-0.06 to 0.37)	100.00
Mixed t	reatments					
713	Hofstee, 2002 ²⁶⁷	RCT			0.28 (-0.04 to 0.60)	100.00
	-	0.597	Ó	0.597		
		Favours activity restriction	Favours control			

FIGURE 90 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design					OR (95% CI)	% weight
Epidura	I/intradiscal injecti	on						
140	Coomes, 1961 ¹⁴⁵	Non-RCT			•		0.32 (0.01 to 8.26)	100.00
Tractio	n							
222	Moret, 1998 ²⁴³	RCT		•			0.02 (0.00 to 0.56)	100.00
Educati	on/advice							
658	Vroomen, 199914	RCT					0.48 (0.09 to 2.71)	64.65
713	Hofstee, 2002 ²⁶⁷	RCT				•	5.06 (0.24 to 107.02)	35.35
Subtota	l (l ² = 43.3%, p = 0. ⁻	184)			<	>	1.11 (0.12 to 10.25)	100.00
							+	
		0	.00092	stivity re	1 Interior	Equation control	1088	
			i avours ac	Juvity re	SUICION	i avours control		

FIGURE 91 Summary of the findings of any adverse effect for studies comparing activity restriction with alternative interventions. Note: weights are from random effects analysis.

RCTs,^{14,267} or between bed rest and epidural injection.¹⁴⁵ However, there were significantly fewer adverse effects in the bed rest group compared with the traction group in one RCT.²⁴³

SUMMARY OF OVERALL FINDINGS FOR ACTIVITY RESTRICTION COMPARED WITH ALTERNATIVE INTERVENTIONS

Five studies,^{14,145,243,256,267} four of which were RCTs,^{14,243,256,267} compared the use of activity restriction with other interventions. Four RCTs restricted inclusion to patients with acute sciatica (*Table 135*).^{14,243,256,267}

There was no significant difference between bed rest and advice to keep active, or between bed rest and mobilisation with exercises carried out in a hospital physiotherapy department, in terms of global effect or pain intensity at short- and medium-term follow-up. However, CSOMs at short-term follow-up were significantly better in the active groups, although there TABLE 134 Summary of the findings of any adverse effect for studies comparing activity restriction with alternative interventions

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Activit	y restriction vs educ	ation/advice					
658	Vroomen, 199914	RCT	2	92	4	91	
713	Hofstee, 2002 ²⁶⁷	RCT	2	84	0	83	0.20 (0.01 to 4.18)
Activit 140	y restriction vs epid Coomes, 1961 ¹⁴⁵	<i>ıral</i> Non-RCT	0	20	1	20	0.32 (0.01 to 8.33)
Activit	y restriction vs exerc	cise therapy					
564	Lidstrom, 1970 ²⁵⁶	RCT	NR	NR	NR	NR	
Activit	y restriction vs mixe	d treatment					
564	Lidstrom, 1970 ²⁵⁶	RCT	NR	NR	NR	NR	
713	Hofstee, 2002267	RCT	2	84	0	83	0.20 (0.01 to 4.18)
Activit	y restriction vs tract	ion					
222	Moret, 1998243	RCT	0	8	6	8	0.02 (0.00 to 0.56)

NR, not reported.

was no significant difference at medium-term follow-up. There was no significant difference between rest and spinal manipulation with exercises, or between pelvic traction and exercises, in terms of global effect or pain intensity at short-term follow-up. Nor was there a significant difference between bed rest and bed rest with vertical traction, in terms of short-term global effect or CSOMs, but there was a significant reduction in pain intensity in the short term in the traction group. There was a significant improvement in medium-term global effect following epidural injections compared with bed rest, with a significantly greater number of adverse effects (*Table 135*).

Proportion reductionof studies tationsProportion of studiesof studies tationsProportion of studiesof studies tationsProportion of studiesof studies tationsProportion tationsof studies tationsAction tationsof studies tationsAction t							Proportion			Proportion	Proportion	of studies that	of studies that
Proportion of studiesof studies istudiesProportion of studiesof studies istudiesProportion of studiesof studies istudiesthat were 					Proportion	Proportion of studies	of studies that	Proportion of studies that	Proportion of	of studies that included	of studies that only	included patients	included patients
No. of studiesSample staticesthat were redian)demed good qualityacute sciaticawith nerve by imagingpatients with stanoissequestered (%)with first stanoisControl category atudiesarms)(mod ian)(%)(%)(%)(%)(%)(%)(%)(%)(%)Activity restriction vis acute2 (10)0/2 (0)0/2 (0)2/2 (100)0/2 (0)0/2 (0)0/2 (0)0/2 (0)0/2 (0)Activity restriction vis polutur/Intradiscal injection1 (1)40 (40)0/1 (0)0/1 (10)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vis polutur/Intradiscal1 (1)62 (62)1/1 (100)0/1 (10)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vis mised treatment2 (1)1 (100)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vis mised treatment2 (10)1/2 (50)2/2 (100)1/2 (50)0/2 (0)0/2 (0)0/2 (0)Activity restriction vis traction2 (1)1/1 (100)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vis mised treatment1 (1)1 (1)0/1 (0)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vis traction1 (1)1 (1)1 (1)0/1 (0)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activi				Proportion of studies	of studies that were	that only included	included patients	reported diagnosis	studies that included	patients with extruded/	included patients	who had received	who had received
Control category (arms) (median) (%) <th></th> <th>No. of studies</th> <th>Sample size range</th> <th>that were RCTs</th> <th>deemed good quality</th> <th>acute sciatica</th> <th>with nerve root pain</th> <th>confirmed by imaging</th> <th>patients with stenosis</th> <th>sequestered discs</th> <th>with first episode</th> <th>previous treatment</th> <th>previous surgery</th>		No. of studies	Sample size range	that were RCTs	deemed good quality	acute sciatica	with nerve root pain	confirmed by imaging	patients with stenosis	sequestered discs	with first episode	previous treatment	previous surgery
Activity restriction vs ducation/advice $2(2)$ $183-250$ $2/2$ (100) $0/2$ (0) $0/2$ (0) $0/2$ (0) $0/2$ (0) $0/2$ (0) $0/2$ (0)Activity restriction vs injection $1(1)$ 40 (40) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs injection $1(1)$ 40 (40) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs inted treatment $1(1)$ 62 (62) $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs inted treatment $2(2)$ $183-250$ $2/2$ (100) $0/2$ (0) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1(1)$ $1/1$ (100) $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1(1)$ $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1(1)$ $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1(1)$ $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1/1$ $1/1$ (100) $1/1$ (100) $1/1$ (100) $0/1$ (0) $0/1$ (0) $0/1$ (0)Activity restriction vs traction $1/1$ <	Control category	(arms)	(median)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
Activity restriction vs polarad/intradiscal1 (1)40 (40)0/1 (0)0/1 (0)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs exercise therapy1 (1)62 (62)1/1 (100)0/1 (0)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs exercise therapy1 (1)62 (62)1/1 (100)0/1 (0)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs mixed treatment2 (2)183–2502/2 (100)0/2 (0)1/2 (50)2/2 (100)1/2 (50)0/2 (0)0/1 (0)Activity restriction vs intraction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs traction <td>Activity restriction vs education/advice</td> <td>2 (2)</td> <td>183–250 (217)</td> <td>2/2 (100)</td> <td>0/2 (0)</td> <td>2/2 (100)</td> <td>2/2 (100)</td> <td>1/2 (50)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> <td>1/2 (50)</td>	Activity restriction vs education/advice	2 (2)	183–250 (217)	2/2 (100)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)
Activity restriction vs1 (1) $62 (62)$ $1/1 (100)$ $0/1 (0)$ $1/1 (100)$ $1/1 (100)$ $0/1 (0)$ <	Activity restriction vs epidural/intradiscal injection	1 (1)	40 (40)	(0) 1/0	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	0) 1/0	1/1 (100)	0/1 (0)
Activity restriction vs2 (2)183-2502/2 (100)0/2 (0)1/2 (50)2/2 (100)1/2 (50)0/2 (0)0/2 (0)0/2 (0)mixed treatment(217)(217)(217)(111)(16)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Activity restriction vs1 (1)16 (16)1/1 (100)1/1 (100)1/1 (100)0/1 (0)0/1 (0)0/1 (0)0/1 (0)Total (for activity5 (7)16-2504/5 (80)1/5 (20)4/5 (80)5/5 (100)1/5 (20)0/5 (0)0/5 (0)0/5 (0)Total (for activity6(2)(62)(62)(62)(62)0/5 (0)0/5 (0)0/5 (0)0/5 (0)0/5 (0)	Activity restriction vs exercise therapy	1 (1)	62 (62)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0	0/1 (0)	0/1 (0)
Activity restriction vs 1 (1) 16 (16) 1/1 (100) 1/1 (100) 1/1 (100) 1/1 (100) 0/1 (0) 0/1 (0) 0/1 (0) 0/1 (0) traction traction Total (for activity 5 (7) 16–250 4/5 (80) 1/5 (20) 4/5 (80) 5/5 (100) 1/5 (20) 0/5 (0) 0/5 (0) 0/5 (0) restriction studies) ^a (62) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)	Activity restriction vs mixed treatment	2 (2)	183–250 (217)	2/2 (100)	0/2 (0)	1/2 (50)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)
Total (for activity 5 (7) 16–250 4/5 (80) 1/5 (20) 4/5 (80) 5/5 (100) 1/5 (20) $0/5$ (0) $0/5$ (0) $0/5$ (0) restriction studies) ^a (62)	Activity restriction vs traction	1 (1)	16 (16)	1/1 (100)	1/1 (100)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	(0) 1/0	1/1 (100)	1/1 (100)
	Total (for activity restriction studies) ^a	5 (7)	16–250 (62)	4/5 (80)	1/5 (20)	4/5 (80)	5/5 (100)	1/5 (20)	0/5 (0)	0/5 (0)	0/5 (0)	2/5 (40)	2/5 (40)

TABLE 135 Summary of activity restriction results

This table shows only studies that reported outcomes for global effect, pain intensity or CSOMs. a These numbers are based on number of studies not number of arms as above (e.g. study 713 includes two comparators, but has been counted only once here).

Proportion Proportion

Description of opioid studies

Summary of interventions

Three studies compared opioids with alternative types of intervention for sciatica.^{214,229,230} Summary data of the interventions used are presented in *Table 136*. One three-arm RCT²²⁹ compared 10-day courses of intramuscular injections of a moderate-strength opioid tramadol with two oral antidepressants: imipramine or fluvoxamine. One RCT²³⁰ compared a 7-day course of oral tramadol with a tapering dose of the oral corticosteroid dexamethasone. The third was a four-arm crossover trial²¹⁴ comparing 7-week courses of a potent opioid (morphine), an antidepressant (nortriptyline), a combination of morphine and nortriptyline and a placebo (benztropine).

Summary of study participants in opioid studies

The three RCTs^{214,229,230} included 168 participants with mean ages ranging from 43 to 53 years, a majority of men, acute and chronic symptom duration and all included recurrent episodes. Sciatica was confirmed by imaging in two out of three studies. One RCT included patients with spinal stenosis. Previous back surgery was either excluded or not reported (*Table 137*).

Summary of study quality for opioid studies

Study details are summarised in *Table 138*. The full results of the quality assessment are presented in the appendices. None of the RCTs was of good quality, but one²¹⁴ had an adequate method of random number generation, a secure method of allocation concealment and good external validity.

ID no.	Author, year	Study design	Treatment description	Control description
Opioia	ls vs inactive control			
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	Sustained-release morphine plus inert placebo (oral, \leq 90 mg/day for 8.5 weeks)	Benztropine (active placebo) plus inert placebo (oral, 0.25–1.00 mg/day for 8.5 weeks)
Opioia	ls vs mixed treatment	ts (opioids and	non-opioids)	
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	Sustained-release morphine plus inert placebo (oral, \leq 90 mg/day for 8.5 weeks)	Morphine plus nortriptyline (oral morphine, \leq 90 mg/day for 8.5 weeks; oral nortriptyline, \leq 100 mg/day for 7.5 weeks)
Opioia	ls vs non-opioids			
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	Sustained-release morphine plus inert placebo (oral, \leq 90 mg/day for 8.5 weeks)	Nortriptyline plus inert placebo (oral, $\leq 100 \text{ mg/day}$ for 7.5 weeks)
547	Kwasucki, 1993 ²³⁰ (Polish language)	RCT	Tramadol. First 5 days of 100 mg twice daily; sixth and seventh days 100 mg once daily	Dexamethasone. First and second days 24 mg (16 mg at 7 _{AM} , 8 mg at 7 _{PM}); third day 8 mg twice daily; fourth and fifth days 4 mg twice daily; sixth and seventh days 4 mg once daily
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	Tramadol (100 mg intramuscular injection)	Fluvoxamine (10 mg oral)
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	Tramadol (100 mg intramuscular injection)	Imipramine (25 mg oral)

 TABLE 136
 Summary of the interventions used when comparing opioids with alternative interventions

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

th alternative interventions
iw spioids wi
dies comparir
details for stu
/ population o
ica and study
mary of sciat
E 137 Sum
TAB

Ωġ	Author, year	Study design	No. of patients	Age (years)	No. of men (%)	Symptom duration	Type of sciatica	Confirmed by imaging?	Recurrent episode	Included patients with stenosis?ª	Included patients with sequestered disc (or extruded)? ^a	Any previous treatment for sciatica?	Any previous back surgery for sciatica?
Opioic	Is vs inactive contro	F											
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	55	Median 53 (range 19–65)	30 (55)	Median 5 years (range 0.3–37 years)	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	N
Opioic	ls vs mixed treatme.	nts (opioids ar	nd non-opioi	ids)									
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	55	Median 53 (range 19–65)	30 (55)	Median 5 years (range 0.3–37 years)	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	No
Opioic	ls vs non-opioids												
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	55	Median 53 (range 19–65)	30 (55)	Median 5 years (range 0.3–37 years)	Nerve root pain	Yes	Recurrent and first episode	No	No	Yes	No
368	Kwasucki, 2002 ²²⁹ (Polish language)	RCT	20	Mean 42.8 (range 23–68)	51 (73)	Range 1 week–8 months	Nerve root pain	Yes	Recurrent and first episode	Yes	No	Yes	No
547	Kwasucki, 1993 ²³⁰ (Polish language)	RCT	43	Mean 43.2 (range 27–69)	37 (86)	Mean 6.3 weeks (range 1 week-8 months)	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	NR	R
NR no	t ranortad												

NH, not reported. a Marked yes if patient population or inclusion criteria specifically reported that patient with sequestered disc, extruded disc or stenosis were included; otherwise reported as no.

suc
entic
nterv
ive i
rnat
alte
with
oids
opic
ring
mpa
s co
ndie
or sti
ls fo
detai
udy
e st
of th
ary .
mm
Su
138
Ë
TAE

Author, year Study size Overall follow	Study size Overall follow	Overall follow	dn-	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
vs macuve control Khoromi, 2007 ²¹⁴ 55 36 weeks RCT (c.	55 36 weeks RCT (c.	36 weeks RCT (c.	RCT (c.	rossover)	Yes	Yes	<60	Yes	Moderate	Strong
vs mixed treatment (opioids and non-opioids) Khoromi, 2007 ²¹⁴ 55 36 weeks RCT (cr	and non-opioids) 55 36 weeks RCT (cr	36 weeks RCT (cr	RCT (cn	ossover)	Yes	Yes	< 60	Yes	Moderate	Strong
vs non-opioids										
Khoromi, 2007 ²¹⁴ 55 36 weeks RCT (crr	55 36 weeks RCT (cro	36 weeks RCT (cro	RCT (cro	(Javoso	Yes	Yes	<60	Yes	Moderate	Strong
Kwasucki, 2002 ²²⁹ 70 19 days RCT (Polish language)	70 19 days RCT	19 days RCT	RCT		Unclear	Unclear	80-100	Unclear	Weak	Weak
Kwasucki, 1993 ²³⁰ 43 2 weeks RCT (Polish language)	43 2 weeks RCT	2 weeks RCT	RCT		Unclear	Unclear	80-100	Unclear	Wear	Weak

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

Opioid results at short-term follow-up (≤6 weeks) Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 139* and the accompanying forest plot (*Figure 92*). Short courses of opioids were compared with short courses of antidepressants or oral corticosteroids. One poor-quality RCT²²⁹ found that a course of intramuscular injections of tramadol was not significantly different from oral antidepressants, and one poor-quality RCT²³⁰ found that oral tramadol was significantly worse than a course of oral corticosteroid.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 140* and the accompanying forest plot (*Figure 93*). Short courses of opioids were compared with short courses of antidepressants or oral corticosteroids. One poor-quality RCT²²⁹ found that a course of intramuscular injections of tramadol was not significantly different from oral antidepressants, and one moderate-quality RCT²³⁰ found that oral tramadol was significantly worse than a course of oral corticosteroid.

Condition-specific outcome measures at short-term follow-up There were no CSOMs at short-term follow-up.

Opioid results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 141* and the accompanying forest plot (*Figure 94*). One moderate-quality, four-arm crossover RCT²¹⁴ found that a 7-week course of oral morphine had similar effects to 7-week courses of oral nortriptyline, a combination of morphine and nortriptyline or a placebo (benztropine).

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 142* and the accompanying forest plot (*Figure 95*). One moderate-quality, four-arm crossover RCT²¹⁴ found that a 7-week course of oral morphine had similar effects to 7-week courses of oral nortriptyline, a combination of morphine and nortriptyline or a placebo (benztropine).

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 143* and the accompanying forest plot (*Figure 96*). One moderate-quality, four-arm crossover RCT²¹⁴ found that a 7-week course of oral morphine had similar effects to 7-week courses of oral nortriptyline, a combination of morphine and nortriptyline or a placebo (benztropine).

ID no.	Author, year	Study design				OR (95% CI)	% weight
Non-op	ioids						
547	Kwasucki, 1993 ²³⁰	RCT				0.18 (0.05 to 0.67)	49.88
368	Kwasucki, 2002229	RCT				1.70 (0.46 to 6.30)	50.12
Subtota	l (<i>I</i> ² = 82.2%, <i>p</i> = 0.01	18)				0.55 (0.06 to 5.03)	100.00
			0.0472		1	01.1	
			0.0473 Eavour	c control	Envoure opioide	21.1	

FIGURE 92 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

S
0
÷
ç
é
2
e
Ξ
-=
Φ
.≥
Ξ
2
Φ
브
ъ
-
Ξ
>
_
0
<u>.</u>
ō
÷.
×
0
σ
1
8
7
Ľ
ō
õ
8
. <u> </u>
0
Ę
ST.
Š.
ō
Ψ
5
あ
۳.
ž
>
9
VI
÷
Q
4
≽
- NO
-wolle
follow-
follow-
m follow-
erm follow-
term follow-
t-term follow-
irt-term follow-
ort-term follow-
short-term follow-
short-term follow-
it short-term follow-
at short-term follow-
st at short-term follow-
ect at short-term follow-
fect at short-term follow-
effect at short-term follow-
l effect at short-term follow-
al effect at short-term follow-
bal effect at short-term follow-
obal effect at short-term follow-
global effect at short-term follow-
global effect at short-term follow-
e global effect at short-term follow-
the global effect at short-term follow-
f the global effect at short-term follow-
of the global effect at short-term follow-
s of the global effect at short-term follow-
ys of the global effect at short-term follow-
ugs of the global effect at short-term follow-
lings of the global effect at short-term follow-
dings of the global effect at short-term follow-
indings of the global effect at short-term follow-
findings of the global effect at short-term follow-
e findings of the global effect at short-term follow-
he findings of the global effect at short-term follow-
the findings of the global effect at short-term follow-
of the findings of the global effect at short-term follow-
of the findings of the global effect at short-term follow-
y of the findings of the global effect at short-term follow-
ary of the findings of the global effect at short-term follow-
nary of the findings of the global effect at short-term follow-
mary of the findings of the global effect at short-term follow-
mmary of the findings of the global effect at short-term follow-
ummary of the findings of the global effect at short-term follow-
Summary of the findings of the global effect at short-term follow-
Summary of the findings of the global effect at short-term follow-
9 Summary of the findings of the global effect at short-term follow-
39 Summary of the findings of the global effect at short-term follow-
139 Summary of the findings of the global effect at short-term follow-
: 139 Summary of the findings of the global effect at short-term follow-
.E 139 Summary of the findings of the global effect at short-term follow-
SLE 139 Summary of the findings of the global effect at short-term follow-
BLE 139 Summary of the findings of the global effect at short-term follow-
ABLE 139 Summary of the findings of the global effect at short-term follow-

							Intervei	ntion		Control				
₽ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (n)	Outcome (n)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)	Comments
Opioic	ts vs non-opioids													
547	Kwasucki, 1993 ²³⁰ (Polish language)	A + C	RCT	2 weeks	Improvement in pain: cessation of symptoms or clear improvement (vs no improvement)		22	ω	0.00	21	16	0.00	22.50 (10.48 to 34.52)	Data extracted from histograms of raw pain scores
368	Kwasucki, 2002 ²²⁹ (Polish language) (i)ª (fluvoxamine)	A + C	RCT	19 days (end of treatment)	Overall improvement: complete relief or improvement (vs no improvement)	Patient	22	17	0.00	24	18	00.00	20.00 (6.84 to 33.16)	
368	Kwasucki, 2002 ²²⁹ (Polish language) (ii) ^a (imipramine)	A+C	RCT	19 days (end of treatment)	Overall improvement: complete relief or improvement (vs no improvement)	Patient	22	17	0.00	24	16	0.00	21.36 (12.49 to 30.24)	
A + C, a Kwi the	acute and chronic. asucki <i>et al.</i> ²²⁹ includ last two treatment gr	ed three treatmo oups have been	ent groups: f included in	luvoxamine (10) the meta-analys	mg oral) (i), imipramine (2 sis (see <i>Figure 92</i>).	5 mg oral) (ii) an	d tramado	ol (100 mg in:	tramuscular inje	ction) (iii)	. In order to p	revent using the	e same compara	ator twice, only

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ŝ
~
5
Ę
ē
Š
Ę
.⊆
è
÷
Ja
EL I
Ĕ
ő
÷
≥
S
. <u>Ö</u> .
.ĕ
ð
D
.⊑
ar
þ
n
ŏ
ŝ
Ξie
Ы
st
۲
5
ŝ
쏫
ě
3
ů,
Ľ
đ
ĩ
Š
¥
ç
Е
B
Ť
-
F
hor
shor
at shor
ty at shor
sity at shor
ensity at shor
ntensity at shor
intensity at shor
ain intensity at shor
pain intensity at shor
of pain intensity at shor
s of pain intensity at shor
gs of pain intensity at shor
ings of pain intensity at shor
ndings of pain intensity at shor
findings of pain intensity at shor
ne findings of pain intensity at shor
the findings of pain intensity at shor
of the findings of pain intensity at shor
y of the findings of pain intensity at shor
ary of the findings of pain intensity at shor
mary of the findings of pain intensity at shor
mmary of the findings of pain intensity at shor
Summary of the findings of pain intensity at shor
Summary of the findings of pain intensity at shor
40 Summary of the findings of pain intensity at shor
140 Summary of the findings of pain intensity at shor
E 140 Summary of the findings of pain intensity at shor
3LE 140 Summary of the findings of pain intensity at shor
ABLE 140 Summary of the findings of pain intensity at shor

							Total (r	((SD)		Final mea	u (SD)	(SD)		
ID no.	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Control Intervention	Mean (95%	difference CI)⁰
Opioids	vs non-opioids														
547	Kwasucki, 1993 ²³⁰	A+C	RCT	2 weeks	Overall	NRS (0-4)	22	21	77.5	77.5	50.0	27.5		22.50	
	(Polish language)								(15)	(12.5)	(22.5)	(17.5)		(10.48	to 34.52)
368	Kwasucki, 2002 ²²⁹	A+C	RCT	19 days	Overall	NRS (0-4)	22	24	70	67.5	50.0	30 (20)		20.00	
	(Polish language) (i) ^c (fluvoxamine)								(17.5)	(15)	(25.0)			(6.84	io 33.16)
368	Kwasucki, 2002 ²²⁹	A+C	RCT	19 days	Overall	NRS (0-4)	22	24	70	75 (25)	50.0	37.5		12.50	
	(Polish language) (ii) ^c (imipramine)								(17.5)		(25.0)	(25.0)		(-1.9	i to 26.96)
<															

A + C, acute and chronic; NRS, numerical rating scale. a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores). c Kwasucki *et al.*²²⁹ included three treatment groups: fluvoxamine (10 mg oral) (i), impramine (25 mg oral) (ii) and tramadol (100 mg intramuscular injection) (ii). In order to prevent using the same comparator twice, only the last two treatment groups have been included in the meta-analysis (see *Figure 93*).

Change scores

Baseline mean

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Non-opic	pids					
547	Kwasucki, 1993 ²³⁰	RCT			22.50 (10.48 to 34.52)	58.43
368	Kwasucki, 2002 ²²⁹	RCT	+	*	12.50 (-1.96 to 26.96)	41.57
Subtotal	(l ² = 8.0%, p = 0.297)			\bigcirc	18.34 (8.68 to 28.00)	100.00
		-34.5	0		34.5	

Favours opioids Favours control

FIGURE 93 Summary of the findings of pain intensity at short-term follow-up (≤ 6 weeks) for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			OR (95% CI)	% weight
Inactive	e control					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		•	1.37 (0.50 to 3.76)	100.00
Non-op	ioids					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		•	1.08 (0.39 to 2.97)	100.00
Mixed t	reatment					
534	Khoromi, 2007 ²¹⁴	RCT (crossover) —			0.38 (0.13 to 1.08)	100.00
		0.133		1	7.49	
			Favours control	Favours opioid	S	

FIGURE 94 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

Opioid results at long-term follow-up (>6 months)

No studies with long-term global effect, pain intensity or CSOMs were identified.

Adverse effects

Adverse effects were very poorly reported in most studies. *Table 144* and the accompanying forest plot (*Figure 97*) present the overall number of any adverse event that occurred. More detailed description of these are presented in the appendices. There was evidence from one RCT²¹⁴ that opioids had more adverse effects than placebo, but there was conflicting evidence from two RCTs^{229,214} about the number of adverse effects associated with placebo compared with antidepressants.

SUMMARY OF OVERALL FINDINGS FOR OPIOIDS COMPARED WITH ALTERNATIVE INTERVENTIONS

Three RCTs compared the use of opioids with other interventions (Table 145).^{214,229,230}

At short-term follow-up opioids were more efficacious than placebo in one moderate-quality crossover RCT²¹⁴ in terms of global effect, but not pain intensity. There was no significant difference in effectiveness compared with antidepressants in terms of the global effect or pain intensity at short-term and medium-term follow-up in two moderate- or poor-quality RCTs.^{229,214}

S	
\subseteq	
0	
÷÷	
Ū	
2	
Ъ.	
Ĕ	
⊒.	
-	
é	
.∠	
Ħ	
2	
Ð	
÷	
g	
_	
누	
5	
ŝ	
ň	
· ¥	
0	
ō	
5	
<u> </u>	
0	
⊇.	
Ξ.	
ğ	
9	
5	
ō	
ŏ	
~	
ŝ	
<u>.</u> Θ	
σ	
ź	
Ť.	
U)	
۲	
Q	
-	
ŝ	
Ë	
Ŧ	
5	
õ	
3	
-	
9	
VI	
-	
0	
<u>ب</u>	
S	
ž	
ð	
é	
<	
-	
5	
õ	
202	
(> 0	
p (> 6 \	
np (> 6 \	
∿ 9<) dn-,	
v-np (>6 v	
∿ 9<) dn-mc	
ow-up (>6	
ollow-up (>6 v	
follow-up (>6 \	
n follow-up (>6 v	
. m follow-up (>6	
rm follow-up (>6 √	
term follow-up (>6 \	
-term follow-up (>6 \	
n-term follow-up (>6 \	
im-term follow-up (>6 \	
ium-term follow-up (>6 \	
dium-term follow-up (>6 \	
edium-term follow-up (>6 \	
nedium-term follow-up (>6 \	
medium-term follow-up (>6 \	
t medium-term follow-up (>6 v	
at medium-term follow-up (>6 \	
t at medium-term follow-up (>6 \	
ict at medium-term follow-up (>6 v	
fect at medium-term follow-up (>6 v	
ffect at medium-term follow-up (>6 v	
effect at medium-term follow-up (>6 v	
tl effect at medium-term follow-up (>6 v	
val effect at medium-term follow-up (>6 v	
bal effect at medium-term follow-up (>6 v	
lobal effect at medium-term follow-up (>6 \	
global effect at medium-term follow-up (>6 \	
global effect at medium-term follow-up (>6 v	
le global effect at medium-term follow-up (>6 v	
the global effect at medium-term follow-up (>6 v	
f the global effect at medium-term follow-up (>6 $^{\circ}$	
of the global effect at medium-term follow-up (>6 v	
of the global effect at medium-term follow-up (>6 v	
is of the global effect at medium-term follow-up (>6 v	
igs of the global effect at medium-term follow-up (>6 $^{\circ}$	
ings of the global effect at medium-term follow-up (>6 v	
dings of the global effect at medium-term follow-up (>6 $^{\circ}$	
ndings of the global effect at medium-term follow-up (>6 \	
findings of the global effect at medium-term follow-up (>6 \	
\mathfrak{S} findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
he findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
the findings of the global effect at medium-term follow-up (>6 $^{\circ}$	
f the findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
of the findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
\prime of the findings of the global effect at medium-term follow-up (>6 \prime	
ry of the findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
ary of the findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
nary of the findings of the global effect at medium-term follow-up (>6 $^{\circ}$	
mary of the findings of the global effect at medium-term follow-up (>6 $^{\prime}$	
mmary of the findings of the global effect at medium-term follow-up (>6 $^{\circ}$	
ummary of the findings of the global effect at medium-term follow-up (>6 $^{\circ}$	
Summary of the findings of the global effect at medium-term follow-up (>6 $^{\circ}$	
Summary of the findings of the global effect at medium-term follow-up (>6 \	
1 Summary of the findings of the global effect at medium-term follow-up (>6 \	
41 Summary of the findings of the global effect at medium-term follow-up (>6 \	
141 Summary of the findings of the global effect at medium-term follow-up (>6 \	
: 141 Summary of the findings of the global effect at medium-term follow-up (>6 \	
.E 141 Summary of the findings of the global effect at medium-term follow-up (>6 \	
$LE 141$ Summary of the findings of the global effect at medium-term follow-up (> 6 $^{\circ}$	
BLE 141 Summary of the findings of the global effect at medium-term follow-up (>6 \	
ABLE 141 Summary of the findings of the global effect at medium-term follow-up (>6 \	
TABLE 141 Summary of the findings of the global effect at medium-term follow-up (>6 \	

	Comments		Pain reported only for 28/50 patients (56%) who completed study (all treatments)		Pain reported only for 28/50 patients (56%) who completed study (all treatments)		Pain reported only for 28/50 patients (56%) who completed study (all treatments)
	OR (95% CI)		1.37 (0.50 to 3.76)		1.08 (0.39 to 2.97)		0.38 (0.13 to 1.08)
	Withdrawal rate		0.40		0.44		0.49
0	Outcome (<i>n</i>)		=		12		1 8
Contro	Total (<i>n</i>)		33		31		28
	Withdrawal rate		0.42		0.42		0.42
ention	Outcome (<i>n</i>)		13		6		13
Interv	Total (<i>n</i>)		32		32		32
	Perspective						
	Outcome measure		Global pain relief (GPR): worse pain, no pain relief		Global pain relief (GPR): worse pain, no pain relief		Global pain relief (GPR): worse pain, no pain relief
	Follow- up		9 weeks (end of treatment)		9 weeks (end of treatment)	ds)	9 weeks (end of treatment)
	Study design		RCT (crossover)		RCT (crossover)	and non-opioi	RCT (crossover)
	Chronicity	ntrol	O	5	U	tment (opioids	U
	Author, year	ls vs inactive con	Khoromi, 2007 ²¹⁴	ls vs non-opioids	Khoromi, 2007 ²¹⁴	ls vs mixed treat	Khoromi, 2007 ²¹⁴ (opioids + non- opioids)
	₽ë	Opioia	534	Opioia	534	Opioia	534

C, chronic.

Ъ
int
tive
rna.
alte
ith
s ≥
ioid
do
ing
par
Com
es
ipn
r st
() 20
ths
nor
9
vi Q
ks.
vee
ہُو م
⊳ ⊳
n-n
n fo
terr
Ę
ediu
Ĕ
y at
Jsit
nter
in i
f pa
soi
ling
finc
he
of t
ary
шu
Sur
42
Ť
BL
₽

							Total (<i>i</i>	(Baseline (SD)	mean	Final me	an (SD)	Change (SD)	scores		
<u> </u>	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	Comment/conversion ^e
Opioit	ds vs inactive co.	introl														
534	Khoromi, 2007 ²¹⁴	0	RCT (crossover)	9 weeks (end of treatment)	Leg	NRS (0-10)	28	28	49 (24.3)	49 (24.3)	34 (28)	37.0 (27)			-3.00 (-17.41 to 11.41)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Opioiu	ds vs non-opioid	~														
534	Khoromi, 2007 ²¹⁴	0	RCT (crossover)	9 weeks (end of treatment)	Leg	NRS (0-10)	28	28	49 (24.3)	49 (24.3)	34 (28)	30.0 (27)			4.00 (–10.41 to 18.41)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
Opioit	ds vs mixed trea	tment (c	pioids and non	1-opioids)												
534	Khoromi, 2007 ²¹⁴	0	RCT (crossover)	9 weeks (end of treatment)	Leg	NRS (0-10)	28	28	49 (24.3)	49 (24.3)	34 (28)	38.0 (24)			-4.00 (-17.66 to 9.66)	Pain reported only for 28/50 patients (56%) who completed study (all treatments)
C, chri a Thi b Ba	onic; NRS, numer. e results have bee sed on final mean	ical ratin en conve is or chai	g scale. rted to a scale of ne scores (with	f 0-100 for con a preference d	nparability. iven to chano	e scores).										

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design			WMD (95% CI)	% weight
Inactive	e control					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)			-3.00 (-17.41 to 11.41)	100.00
Non-op	ioids					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)		•	4.00 (-10.41 to 18.41)	100.00
Mixed t	reatment					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)			-4.00 (-17.66 to 9.66)	100.00
		-18	3.4	l 0	18.4	
			Favours opioids	Favours control		

FIGURE 95 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to \leq 6 months) for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design			SMD (95% CI)	% weight
Inactive	e control					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	*		-0.18 (-0.71 to 0.34)	100.0
Mixed t	reatment					
534	Khoromi, 2007 ²¹⁴	RCT (crossover)			0.01 (-0.52 to 0.53)	100.0
Non-op	ioids					
534	Khoromi, 2007 ²¹⁴	RCT (crossover) -			-0.11 (-0.63 to 0.42)	100.0
		-0.709		0	0.709	
			Favours opioids	Favours control		

FIGURE 96 Summary of the findings of CSOMs at medium-term follow-up (>6 weeks to \leq 6 months) for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

Opioids were significantly less effective than a course of corticosteroids in one moderate-quality RCT.²³⁰ Opioids had more adverse effects than placebo in one RCT, but there was conflicting evidence from two RCTs about the number of adverse effects associated with placebo compared with antidepressants.

_
þ
Ξ
jē,
ŝ
Ť
.= 0
.≝
at
E
lte
g
ith
≥
ŝ
ij.
ē
0
g
ari
ğ
E
8
ŝ
÷
Ĕ
õ
ē
Ű,
ŝ
Ţ
Ĕ
ů
Ň
0
ŝ
÷.
ě
5
~
5
5
n-n
low-up
follow-up
n follow-up
erm follow-up
-term follow-up
m-term follow-up
lium-term follow-up
edium-term follow-up
medium-term follow-up
at medium-term follow-up
ls at medium-term follow-u
Ms at medium-term follow-up
SOMs at medium-term follow-up
CSOMs at medium-term follow-u
of CSOMs at medium-term follow-up
s of CSOMs at medium-term follow-u
ngs of CSOMs at medium-term follow-up
dings of CSOMs at medium-term follow-u
findings of CSOMs at medium-term follow-u
e findings of CSOMs at medium-term follow-u
the findings of CSOMs at medium-term follow-up
of the findings of CSOMs at medium-term follow-u
y of the findings of CSOMs at medium-term follow-u
lary of the findings of CSOMs at medium-term follow-up
mary of the findings of CSOMs at medium-term follow-up
ummary of the findings of CSOMs at medium-term follow-up
Summary of the findings of CSOMs at medium-term follow-up
3 Summary of the findings of CSOMs at medium-term follow-up
143 Summary of the findings of CSOMs at medium-term follow-up
E 143 Summary of the findings of CSOMs at medium-term follow-up
ILE 143 Summary of the findings of CSOMs at medium-term follow-up
ABLE 143 Summary of the findings of CSOMs at medium-term follow-up

	ب ت		ted only for ients (56%) leted study ents)		ted only for ients (56%) leted study ents)		ted only for ients (56%) leted study ents)	
	Comment conversio		Pain repor 28/50 pati who comp (all treatm		Pain repor 28/50 pati who comp (all treatme		Pain repor 28/50 pati who comp (all treatme	
	Mean difference (95% Cl) ^a		-0.18 (-0.71 to 0.35)		0.01 (-0.52 to 0.53)		-0.11 (-0.63 to 0.42)	
nge scores (SD)	Control							
Cha	Intervention							
an (SD)	Control		30.5 (15.9)		27.5 (16.7)		27.4 (15.4)	
Final me	Intervention		27.5 (16.7)		25.7 (16.5)		27.5 (16.7)	
mean	Control		30 (15)		30 (15)		30 (15)	
Baseline (SD)	Intervention		30 (15)		30 (15)		30 (15)	to follow-up
(u)	Control		28		28		28	ttients lost
Total	Intervention		28		28		28	scores). Is and pa
	Scale		NRS (0-10)		NRS (0-10)		NRS (0-10)	to change sine exclusion
	Follow-up		9 weeks (end of treatment)		9 weeks (end of treatment)	ioids)	9 weeks (end of treatment)	rreference giver lata, post-basel
	Study design		RCT (crossover)		RCT (crossover)	ds and non-op	RCT (crossover)	ale. scores (with a p d for missing d
	Chronicity	control	C	id	сı	eatment (opioiu	U	lerical rating sca ans or change s s' has been use
	Author, year	s vs inactive	Khoromi, 2007 ²¹⁴	s vs non-opic	Khoromi, 2007 ²¹⁴	s vs mixed tr _i	Khoromi, 2007 ²¹⁴	nic; NRS, num ed on final me term 'dropout
	D e	Opioid	534	Opioid.	534	Opioid	534	C, chro a Bas b The

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Opioid	s vs inactive control						
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	51	55	28	55	12.29 (3.91 to 38.7)
Opioid	s vs mixed treatment	(opioids and non-	-opioids)				
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	51	55	49	55	1.56 (0.42 to 5.87)
Opioid	s vs non-opioids						
534	Khoromi, 2007 ²¹⁴	RCT (crossover)	51	55	37	55	6.20 (1.94 to 19.85)
547	Kwasucki, 1993230	RCT	NR	NR	NR	NR	
368	Kwasucki, 2002 ²²⁹ (fluvoxamine)	RCT	1	22	2	24	0.52 (0.04 to 6.22)
368	Kwasucki, 2002 ²²⁹ (imipramine)	RCT	1	22	12	24	0.05 (0.01 to 0.41)

TABLE 144 Summary of the findings of any adverse effect for studies comparing opioids with alternative interventions

NR, not reported.

ID no.	Author, year	Study design			OR (95% CI)	% weight
Inactive	e control					
534	Khoromi, 2007 ²¹⁴	Crossover RCT			12.29 (3.91 to 38.70)	100.00
Mixed t	reatment					
534	Khoromi, 2007 ²¹⁴	Crossover RCT			1.56 (0.42 to 5.87)	100.00
Non-op	ioids					
534	Khoromi, 2007 ²¹⁴	Crossover RCT			6.20 (1.94 to 19.85)	51.71
368	Kwasucki, 2002 ²²⁹	RCT	•		0.05 (0.01 to 0.41)	48.29
Subtota	l (l² = 93.8%, p = 0.00)))			0.59 (0.00 to 80.16)	100.00
_					1	
		0.00	435 Favours opioids	1 Favours control	230	

FIGURE 97 Summary of the findings of any adverse effect for studies comparing opioids with alternative interventions. Note: weights are from random effects analysis.

studies
^c opioid
Summary of
TABLE 145

						Proportion	Proportion		Proportion of studies	Proportion	Proportion of studies	Proportion of studies
			9	Proportion of studies	Proportion of studies that	of studies that included	of studies that reported	Proportion of studies	that included patients with	of studies that only	that included patients who	that included patients who
Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	triat were deemed good quality (%)	only included acute sciatica (%)	pauents with nerve root pain (%)	alagnosis confirmed by imaging (%)	unat included patients with stenosis (%)	extruaea/ sequestered discs (%)	inciuaea patients with first episode (%)	nad received previous treatment (%)	nad received previous surgery (%)
Opioids vs inactive control	1 (1)	55 (55)	1/1 (100)	1/1 (100)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)
Opioids vs mixed treatment	1 (1)	55 (55)	1/1 (100)	0/1 (0)	0/1 (0)	1/1 (100)	1/1 (100)	0/1 (0)	0/1 (0)	0/1 (0)	1/1 (100)	0/1 (0)
Opioids vs non- opioids	3 (4)	43–70 (55)	2/3 (67)	1/3 (33)	0/3 (0)	3/3 (100)	2/3 (67)	1/3 (33)	0/3 (0)	0/3 (0)	2/3 (67)	0/3 (0)
Total (for opioid studies)ª	3 (6)	43–70 (55)	3/3 (100)	1/3 (33)	0/3 (0)	3/3 (100)	2/3 (67)	1/3 (33)	0/3 (0)	0/3 (0)	2/3 (67)	0/3 (0)
This table shows or a These numbers	nly studies th are based or	nat reported outor	omes for global e lies not number o	ffect, pain intensity f arms as above (e	or CSOMs. .g. study 534 incli	udes three compa	rators, but has be	en counted only c	once here).			

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

Education/advice

Description of education/advice studies

Summary of interventions

Three studies compared educational interventions or advice with alternative treatments.^{14,169,267} Summary data for the interventions are presented in *Table 146*. One RCT¹⁴ compared advice to keep active with bed rest for 2 weeks. One three-arm RCT²⁶⁷ compared bed rest for 7 days with advice to continue activities of daily living, or with hospital physiotherapy twice weekly for at least 4 weeks. Another three-arm pilot study¹⁶⁹ compared two 60-minute educational sessions about postural advice and an educational booklet with a course of chiropractic spinal manipulation or three epidural injections of corticosteroid. This pilot RCT¹⁶⁹ did not compare outcome measures between groups.

Summary of study participants in education/advice studies

The two RCTs that compared outcomes included 433 participants with mean ages between 39 and 46 years, mostly men, with acute symptom duration, and including recurrent symptoms. Sciatica was confirmed by imaging in one RCT.²⁶⁷ There were no patients with spinal stenosis or sequestered discs and previous back surgery was excluded in one RCT (*Table 147*).¹⁴

Summary of study quality for education/advice studies

Study details are summarised in *Table 148*. The full results of the quality assessment are presented in the appendices. All of the studies were RCTs and one was of good quality.¹⁴ Two had used an adequate method of random number generation,^{14,267} but none had a secure method of allocation concealment, and only one had good external validity.¹⁴

Education/advice results at short-term follow-up (≤6 weeks)

Global effect at short-term follow-up

The results for the global effect at short-term follow-up are presented in *Table 149* and the accompanying forest plot (*Figure 98*). There was no significant difference between advice to keep active and bed rest in two moderate- or good-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one RCT.²⁶⁷

ID no.	Author, year	Study design	Treatment description	Control description
Educat	ion/advice vs activity i	restriction		
713	Hofstee, 2002 ²⁶⁷	RCT	Advised to continue activities of daily living (ADL)	Bed rest (BR)
658	Vroomen, 199914	RCT	Advice to keep active	Bed rest
Educat	tion/advice vs epidural	/intradiscal	injection	
722	Bronfort, 2004169	RCT	Self-care education	Three ESIs over 12 weeks
Educat	ion/advice vs manipul	ation		
722	Bronfort, 2004169	RCT	Self-care education	Chiropractic spinal manipulation
Educat	ion/advice vs mixed tr	eatments		
713	Hofstee, 2002 ²⁶⁷	RCT	Advised to continue activities of daily living (ADL)	Hospital physiotherapy (Ph) – manipulation + exercises

TABLE 146 Summary of the interventions used when comparing education/advice with alternative interventions

	Author,	Study	No. of		No. of	Symptom	Type of	Confirmed by	Recurrent	Included patients with	Included patients with sequestered disc (or	Any previous treatment	Any previous back surgery
Ou	year	design	patients	Age	men (%)	duration	sciatica	imaging?	episode	stenosis? ^a	extruded)?ª	for sciatica?	for sciatica?
Educi	ation/advice	vs activity	restriction										
713	Hofstee, 2002 ²⁶⁷	RCT	250	Mean 39 (SD 10)	150 (60)	Mean 2 weeks	Nerve root pain and referred pain	Yes	Recurrent	No	N	NR	Yes
658	Vroomen, 1999 ¹⁴	RCT	183	Mean 46 (SD 12)	103 (56)	Median 16 days	Nerve root pain	No	Recurrent and first episode	No	No	NR	No
Educa	ation/advice	vs epidura	\/intradisca	l injection									
722	Bronfort, 2004 ¹⁶⁹	RCT	32	Mean 49.0 (SD 9.1)	18 (56)	1–3 months 19%, 4–6 months 6%, 7–12 months 9%, >12 months 66%	Nerve root pain and referred pain	No	Recurrent and first episode	No	No	R	No
Educa	ation/advice	vs manipu	lation										
722	Bronfort, 2004 ¹⁶⁹	RCT	32	Mean 49.0 (SD 9.1)	18 (56)	1–3 months 19%, 4–6 months 6%, 7–12 months 9%, >12 months 66%	Nerve root pain and referred pain	No	Recurrent and first episode	N	No	R	No
Educa	ation/advice	vs mixed t	reatments										
713	Hofstee, 2002 ²⁶⁷	RCT	250	Mean 39 (SD 10)	150 (60)	Mean 2 weeks	Nerve root pain and referred pain	Yes	Recurrent	No	No	R	Yes
NR, nc a Ma	ot reported. Irked ves if pa	atient populs	ation or inclu	usion criteria specifi	cally reported	that patient with seque	estered disc. extruc	ded disc or stenos	sis were included; of	therwise reported a	as no.		

TABLE 147 Summary of sciatica type and study population details for studies comparing education/advice with alternative interventions

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ventions
inter
ative
altern
with a
idvice
tion/a
educa
aring e
comp
udies
for st
etails
ndy d
ne sti
y of t
Summar
148
ABLE
F

ID no.	Author, year	Study size	Overall follow- up	Study design	Adequate randomisation?	Allocation concealment?	Follow-up (%)	Blind outcome assessment?	Overall quality rating	Overall external validity rating
			-	•					5	
Educatio	n/advice vs activity restriction									
658	Vroomen, 199914	183	12 weeks	RCT	Yes	No	80-100	Yes	Moderate	Strong
713	Hofstee, 2002 ²⁶⁷	250	6 months	RCT	Yes	No	80–100	No	Moderate	Moderate
Educatio	n/advice vs epidural/intradiscal	injection								
722	Bronfort, 2004 ¹⁶⁹	32	52 weeks	RCT	Unclear	Partial	80-100	Unclear	Weak	Weak
Educatio	n/advice vs manipulation									
722	Bronfort, 2004 ¹⁶⁹	32	52 weeks	RCT	Unclear	Partial	80-100	Unclear	Weak	Weak
Educatio	n/advice vs mixed treatments									
713	Hofstee, 2002 ²⁶⁷	250	6 months	RCT	Yes	No	80-100	No	Moderate	Moderate

TABLE 149 Summary of the findings of the global effect at short-term follow-up (≤6 weeks) for studies comparing education/advice with alternative interventions

							Interve	ntion		Control			
⊡ ë	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	0R (95% CI)
Educa	tion/advice v.	s activity restric	tion										
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Treatment failure Opposite extracted	Physician	83	77	0.00	84	79	0.00	0.81 (0.24 to 2.77)
658	Vroomen, 1999 ¹⁴	A	RCT	2 weeks	Assessment of improvement	Patient	91	59	0.00	92	64	00.0	0.81 (0.43 to 1.50)
Educa	tion/advice v.	s mixed treatme	ents										
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Treatment failure Opposite extracted	Physician	83	77	0.00	83	81	00.0	0.32 (0.06 to 1.62)

A, acute.

ID no.	Author, year	Study design			OR	(95% CI)	% weight
Activity	restriction						
713	Hofstee, 2002 ²⁶⁷	RCT			0.8	1 (0.24 to 2.77)	20.24
658	Vroomen, 1999 ¹⁴	RCT			0.8	1 (0.43 to 1.50)	79.76
Subtota	l (l ² = 0.0%, p = 0.99	92)		\langle	0.8	1 (0.46 to 1.40)	100.00
Mixed t	reatments						
713	Hofstee, 2002 ²⁶⁷	RCT	<i>(</i>		0.32	2 (0.06 to 1.62)	100.00
			0.0621		1	16.1	

FIGURE 98 Summary of the findings of the global effect at short-term follow-up (≤ 6 weeks) for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.

Pain intensity at short-term follow-up

The results for pain intensity at short-term follow-up are presented in *Table 150* and the accompanying forest plot (*Figure 99*). There was no significant difference between advice to keep active and bed rest in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one moderate-quality RCT.²⁶⁷

Condition-specific outcome measures at short-term follow-up

The results for CSOMs at short-term follow-up are presented in *Table 151* and the accompanying forest plot (*Figure 100*). There was no significant difference between advice to keep active and bed rest in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one moderate-quality RCT.²⁶⁷

Education/advice results at medium-term follow-up (>6 weeks to ≤6 months) Global effect at medium-term follow-up

The results for the global effect at medium-term follow-up are presented in *Table 152* and the accompanying forest plot (*Figure 101*). There was no significant difference between advice to keep active and bed rest in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one moderate-quality RCT.²⁶⁷

Pain intensity at medium-term follow-up

The results for pain intensity at medium-term follow-up are presented in *Table 153* and the accompanying forest plot (*Figure 102*). There was no significant difference between advice to keep active and bed rest in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one moderate-quality RCT.²⁶⁷

Condition-specific outcome measures at medium-term follow-up

The results for CSOMs at medium-term follow-up are presented in *Table 154* and the accompanying forest plot (*Figure 103*). There was no significant difference between advice to keep active and bed rest in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in one moderate-quality RCT.²⁶⁷

TABLE 150 Summary of the findings of pain intensity at short-term follow-up (≤6 weeks) for studies comparing education/advice with alternative interventions

							Total (I	(L	Baseline (SD)	mean	Final me	an (SD)	Change sc	ores (SD)	
e ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range)ª	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl)⁵
Educa	tion/advice vs	activity restric	tion												
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Leg	VAS (0-100)	83	82	60.7 (21.4)	65.5 (18.5)			-23.4 (29.16)	-25.9 (29.16)	2.50 (–6.40 to 11.40)
658	Vroomen, 1999 ¹⁴	A	RCT	2 weeks	Leg	VAS (0-100)	91	92	68 (21)	62 (22)	44 (27)	36 (28)			8.00 (0.03 to 15.97)
Educa	tion/advice vs	mixed treatme	'nt												
713	Hofstee, 2002 ²⁶⁷	A	RCT	1 month	Leg	VAS (0-100)	83	80	60.7 (21.4)	60.9 (20.1)			–23.4 (29.31)	–24.2 (29.31)	0.80 (- 8.20 to 9.80)
	t P														

A, acute. a The results have been converted to a scale of 0–100 for comparability. b Based on final means or change scores (with a preference given to change scores).

ID no.	Author, year	Study design	I			WMD (95% CI)	% weight
Activity	restriction						
713	Hofstee, 2002 ²⁶⁷	RCT				2.50 (-6.40 to 11.40)	44.51
658	Vroomen, 1999 ¹⁴	RCT		•		8.00 (0.03 to 15.97)	55.49
Subtota	al ($l^2 = 0.0\%$, $p = 0.36$	67)			>	5.55 (-0.38 to 11.49)	100.00
Mixed t	treatments						
713	Hofstee, 2002 ²⁶⁷	RCT		•		0.80 (-8.20 to 9.80)	100.00
		-16		0	16		
			Favours education	Favours cor	ntrol		

FIGURE 99 Summary of the findings of pain intensity at short-term follow-up (<6 weeks) for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.

	uesign				SMD (95% CI)	weight
estriction						
Hofstee, 2002 ²⁶⁷	RCT				0.00 (-0.31 to 0.31)	47.49
Vroomen, 1999 ¹⁴	RCT		•		-0.16 (-0.45 to 0.13)	52.51
$p^2 = 0.0\%, p = 0.45$	57)				-0.08 (-0.29 to 0.13)	100.00
eatments						
Hofstee, 2002 ²⁶⁷	RCT				0.00 (-0.31 to 0.31)	100.00
		-0.45)	0.45	
	estriction Hofstee, 2002 ²⁶⁷ Vroomen, 1999 ¹⁴ $J^2 = 0.0\%, p = 0.45$ eatments Hofstee, 2002 ²⁶⁷	estriction Hofstee, 2002 ²⁶⁷ RCT Vroomen, 1999 ¹⁴ RCT $l^2 = 0.0\%, p = 0.457$) eatments Hofstee, 2002 ²⁶⁷ RCT	estriction Hofstee, 2002 ²⁶⁷ RCT Vroomen, 1999 ¹⁴ RCT — $l^2 = 0.0\%, p = 0.457$) eatments Hofstee, 2002 ²⁶⁷ RCT	estriction Hofstee, 2002^{267} Vroomen, 1999^{14} RCT $l^2 = 0.0\%, p = 0.457$) estiments Hofstee, 2002^{267} RCT	estriction Hofstee, 2002^{267} RCT Vroomen, 1999^{14} RCT $l^2 = 0.0\%, p = 0.457$) estiments Hofstee, 2002^{267} RCT -0.45 Eavours education Eavours control	estriction 0.00 (-0.31 to 0.31) Hofstee, 2002^{267} RCT Vroomen, 1999^{14} RCT $q^2 = 0.0\%, p = 0.457$) -0.16 (-0.45 to 0.13) estments -0.08 (-0.29 to 0.13) Hofstee, 2002^{267} RCT RCT -0.00 (-0.31 to 0.31) -0.45 0.00 (-0.31 to 0.31) -0.45 0.00 (-0.31 to 0.31)

FIGURE 100 Summary of the findings of CSOMs at short-term follow-up (≤6 weeks) for studies comparing education/ advice with alternative interventions. Note: weights are from random effects analysis.

Education/advice at long-term follow-up (>6 months)

No long-term outcomes were reported for global effect, pain intensity or CSOMs.

Adverse effects

Adverse effects were very poorly reported in most studies. *Table 155* and the accompanying forest plot (*Figure 104*) present the overall number of any adverse event that occurred. More detailed descriptions of these are presented in the appendices. Education or advice interventions were associated with significantly fewer adverse events, in single RCTs, than epidural injections or spinal manipulation. There was no significant difference between the number of adverse events associated with education or advice compared with activity restriction in two RCTs.

SUMMARY OF OVERALL FINDINGS FOR EDUCATION/ADVICE COMPARED WITH ALTERNATIVE INTERVENTIONS

Two moderate- or good-quality RCTs compared the use of opioids with other interventions (*Table 156*).^{14,267}
TABLE 151 Summary of the findings of CSOMs at short-term follow-up (≤ 6 weeks) for studies comparing education/advice with alternative interventions

						Total (<i>i</i>	(L	Baseline (SD)	mean	Final mean	(CS) I	Change sc	ores (SD)		
						Interve	C	Interve	C	Interve	C	Interve	C		
₽ë	Author, year	Chronicity	Study design	Follow- up	Scale	ention	ontrol	ention	ontrol	ention	ontrol	ention	ontrol	Mean difference (95% Cl)ª	Comment/conversion ^b
Educa	tion/advice	vs activity resti	riction												
713	Hofstee, 2002 ²⁶⁷	٩	RCT	1 month	QDS	83	82	57.4 (16.3)	58.6 (14.6)	41.2 (16.3)	41.2 (16.3)	-16.2 (18.84)	-16.2 (18.84)	0.00 (-0.3 to 0.31)	Final means calculated from change scores Distribution at follow-up reported to
															be skewed ITT analyses reported (incorporating treatment compliance and dropouts), but dropouts excluded the results
															reputed Number randomised: BR 84, Ph 83, ADL (control) 83
658	Vroomen, 1999 ¹⁴	A	RCT	3 weeks	Revised RMDQ	10	92	5.2 (3.8)	5.5 (3.9)	9.2 (6.3)	9.2 (6.3)	4	4	-0.16 (-0.43 to 0.13) Adjusted mean difference 1.6 (95% C/-0.4 to 3.7)	ITT used For baseline and mean, high score = good outcome; sign of change score altered so that negative indicates improvement Adjusted difference between groups not based change scores
Educa	tion/advice	vs mixed treati	nents												
713	Hofstee, 2002 ⁸⁸⁷	ح	RCT	1 month	SQD	83	80	57.4 (16.3)	56 (17.6)	41.2 (16.3)	41.2 (16.3)	-16.2 (18.89)	-16.2 (18.89)	0.00 (-0.31 to 0.31)	Final means calculated from change scores Distribution at follow-up reported to be skewed ITT analyses reported (incorporating treatment compliance and dropouts), but dropouts excluded the results reported Number randomised: BR 84, Ph 83, ADL (control) 83
A, acut a Bas b The	e; ADL, activ. ed on final m term 'dropou	ities of daily livin neans or change uts' has been us	ng; BR, bed scores (wit ted for miss	rest; Ph, ph) h a preferen ing data, po;	ysiotherapy; tce given to st-baseline e	QDS, Qu change s exclusion	ebec Dis scores); ri is and pa	ability Scale esults as re trients lost t	e. sported by s o follow-up	tudy in italics					

Review of clinical effectiveness: results

TABLE 152 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing education/advice with alternative interventions

							Interve	ntion		Control			
ÐË	Author, year	Chronicity	Study design	Follow-up	Outcome measure	Perspective	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	Total (<i>n</i>)	Outcome (<i>n</i>)	Withdrawal rate	OR (95% CI)
Educ.	ation/advice v	vs activity restri	ction										
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Treatment failure. Opposite extracted	Physician	83	69	0.00	84	63	0.00	1.46 (0.77 to 3.50)
658	Vroomen, 1999 ¹⁴	٨	RCT	12 weeks	Assessment of improvement	Patient	91	79	0.00	92	80	0.00	0.99 (0.42 to 2.33)
Educ	ation/advice v	vs mixed treatm	ents										
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Treatment failure. Opposite extracted	Physician	83	69	0.00	83	64	0.00	1.46 (0.68 to 3.16)
A, acı	ıte.												

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Activity	restriction						
713	Hofstee, 2002 ²⁶⁷	RCT				1.64 (0.77 to 3.50)	56.21
658	Vroomen, 1999 ¹⁴	RCT				0.99 (0.42 to 2.33)	43.79
Subtota	$l (l^2 = 0.0\%, p = 0.38)$	34)	<			1.31 (0.74 to 2.32)	100.00
Mixed t	reatments						
713	Hofstee, 2002 ²⁶⁷	RCT		•		1.46 (0.68 to 3.16)	100.00
		0.285	- Favoura control	1 Environ advantion	3.5		

FIGURE 101 Summary of the findings of the global effect at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.



FIGURE 102 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤ 6 months) for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.

In two moderate- or good-quality RCTs there was no significant difference between advice to keep active and bed rest, in terms of the global effect, pain intensity and CSOMs at short- and medium-term follow-up, in two good- or moderate-quality RCTs.^{14,267} There was no significant difference between advice to keep active and mobilisation with exercises carried out in a hospital physiotherapy department in terms of the global effect, pain intensity and CSOMs at short- and medium-term follow-up in a moderate-quality RCT.²⁶⁷

TABLE 153 Summary of the findings of pain intensity at medium-term follow-up (>6 weeks to ≤6 months) for studies comparing education/advice with alternative interventions

							Total (<i>i</i>	(Baseline r (SD)	mean	Final mea	n (SD)	Change si (SD)	cores		
<u>e</u> ë	Author, year	Chronicity	Study design	Follow-up	Location	Scale (range) ^a	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% Cl) ^b	
Educ	ation/advice vs act.	vity restriction														1
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Leg	VAS (0-100)	75	78	60.7 (21.4)	65.5 (18.5)			-47.8 (30.45)	-48.2 (27.92)	0.40 (–8.87 to 9.67)	
658	Vroomen, 1999 ¹⁴	A	RCT	12 weeks	Leg	VAS (0-100)	91	92	68 (21)	62 (22)	14 (24)	16 (26)			-2.00 (-9.25 to 5.25)	
Educ	ation/advice vs mix	xed treatment														
713	Hofstee, 2002 ²⁶⁷	A	RCT	6 months	Leg	VAS (0-100)	75	72	60.7 (21.4)	60.9 (20.1)			-47.8 (29.99)	—46.8 (27.83)	-1.00 (-10.35 to 8.35)	
A, ac b Bi Ti	ute. 1e results have been 3sed on final means c	converted to a so or change scores	cale of 0–100 for c (with a preference	omparability. given to chang	e scores).											I

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

S
_
5
<u>.o</u>
Ħ
Ð
2
e
Ē
-
Ϋ́
÷
g
Ľ
Ð
Ē
Ë
È
Σ
5
ŏ
·5
Ó
à
ç
<u>0</u> .
ъ
ö
õ
-
p
÷
ā
đ
Ε
õ
0
ŝ
lίe
ğ
Ę
S
Ъ
Ψ
d
, i
Ś
б
=
5
Ë
퓓
Ъ
≤
9
Е
.6 m
≤6 m
to ≤6 m
s to ≤6 m
ks to ≤6 m
eks to ≤6 m
veeks to ≤6 m
weeks to ≤6 m
.6 weeks to ≤6 m
(>6 weeks to ≤6 m
ר (>6 weeks to ≤6 m
rm (>6 weeks to ≤6 m
erm (>6 weeks to ≤6 m
-term (>6 weeks to ≤6 m
m-term (>6 weeks to ≤6 m
um-term (>6 weeks to ≤6 m
dium-term (>6 weeks to ≤6 m
nedium-term (>6 weeks to ≤6 m
medium-term (>6 weeks to ≤6 m
tt medium-term (>6 weeks to ≤6 m
: at medium-term (>6 weeks to ≤6 m
4s at medium-term (>6 weeks to ≤6 m
Ms at medium-term (>6 weeks to ≤ 6 m
OMs at medium-term (>6 weeks to ≤ 6 m
SOMs at medium-term (>6 weeks to ≤6 m
CSOMs at medium-term (>6 weeks to ≤6 m
of CSOMs at medium-term (>6 weeks to ≤6 m
s of CSOMs at medium-term (>6 weeks to ≤ 6 m
gs of CSOMs at medium-term (>6 weeks to ≤6 m
ings of CSOMs at medium-term (>6 weeks to ≤6 m
dings of CSOMs at medium-term (>6 weeks to ≤ 6 m
indings of CSOMs at medium-term (>6 weeks to ≤6 m
i findings of CSOMs at medium-term (>6 weeks to <6 m
ne findings of CSOMs at medium-term (>6 weeks to ≤6 m
the findings of CSOMs at medium-term (>6 weeks to ≤ 6 m
of the findings of CSOMs at medium-term (>6 weeks to \leq 6 m
$^{\prime}$ of the findings of CSOMs at medium-term (>6 weeks to ≤6 m
iry of the findings of CSOMs at medium-term (>6 weeks to ≤6 m
ary of the findings of CSOMs at medium-term (>6 weeks to ≤6 m
imary of the findings of CSOMs at medium-term (>6 weeks to \leq 6 m
mmary of the findings of CSOMs at medium-term (>6 weeks to \leq 6 m
$\mathfrak{S}_{\mathfrak{m}}$ summary of the findings of CSOMs at medium-term (>6 weeks to \leq 6 m
Summary of the findings of CSOMs at medium-term (>6 weeks to ≤ 6 m
4 Summary of the findings of CSOMs at medium-term (>6 weeks to ≤ 6 m
54 Summary of the findings of CSOMs at medium-term (>6 weeks to ≤6 m
$^{+}154$ Summary of the findings of CSOMs at medium-term (>6 weeks to \leq 6 m
.E 154 Summary of the findings of CSOMs at medium-term (>6 weeks to ≤ 6 m

						Total (Ē	Baseline (SD)	mean	Final me	an (SD)	Change s (SD)	scores		
ID Yeî Yeî	lthor, ar	Chronicity	Study design	Follow-up	Scale	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Mean difference (95% CI)ª	Comment/conversion ^b
Education	1/advice	vs activity resi	triction												
713 Ho 20	ifstee, 102 ²⁶⁷	۲	RCT	2 months	QDS	75	78	57.4 (16.3)	58.6 (14.6)	22 (16.3)	25.9 (14.6)	-35.4 (23.66)	–32.7 (23.66)	-0.25 (-0.57 to 0.07)	Final means calculated from change scores Distribution at follow-up reported to be skewed ITT analyses reported (incorporating treatment compliance and dropouts), but dropouts excluded the
															results reported Number randomised: BR 84, Ph 83, ADL. (control) 83
658 Vrc 19	oomen, 19914	ح	RCT	12 weeks	Revised RMDQ	91	92	5.2 (3.8)	5.5 (3.9)	7.3 (7)	7.8 (7)	-10.5	2.6-	-0.07 (-0.36 to 0.22) Adjusted mean difference 0.5 (95% CI -1.6 to 2.6)	For baseline and mean, high score = good outcome; sign of change score altered so that negative indicates improvement ITT used, method not stated
Education	<i>\\advice</i>	vs mixed treat	tment												
713 Ho 200	lo2 ²⁶⁷ 102 ²⁶⁷	ح	RCT	2 months	QDS	75	75	57.4 (16.3)	56 (17.6)	22 (16.3)	21.4 (17.6)	-35.4 (23.9)	–34.6 (23.9)	0.04 (0.28 to 0.36)	Final means calculated from change scores Distribution at follow-up reported to be skewed ITT analyses reported (incorporating treatment compliance and dropouts), but dropouts excluded the results reported Number randomised: BR 84, Ph 83, ADL (control) 83
A, acute; A a Based (b The terr	ADL, advi: on final n	sed to continue neans or change	activities of (e scores (with	daily living; BR, h a preference (ing data post-b	bed rest; PI given to che	1, physio inge scol	therapy; res); res	dDS, Que ults as rep	bec Disabil orted by stu	ity Scale. Jdy in italic:	ú				

% CI) wei	weight
57 to 0.07) 45	45.34
36 to 0.22) 54	54.66
37 to 0.06) 100	100.00
28 to 0.36) 100	100.00
	36 to 0.22) 37 to 0.06) 28 to 0.36)

FIGURE 103 Summary of the findings of CSOMs at medium-term (>6 weeks to \leq 6 months) follow-up for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.

ID no.	Author, year	Study design				OR (95% CI)	% weight
Epidura	al/intradiscal injecti	on					
722	Bronfort, 2004 ¹⁶⁹	RCT	←	•		0.00 (0.00 to 0.13)	100.00
Manipu	lation						
722	Bronfort, 2004 ¹⁶⁹	RCT			_	0.04 (0.00 to 0.86)	100.00
Mixed t	reatment						
713	Hofstee, 2002 ²⁶⁷	RCT				(Excluded)	0.00
Activity	restriction						
713	Hofstee, 2002 ²⁶⁷	RCT				0.20 (0.01 to 4.18)	35.35
658	Vroomen, 1999 ¹⁴	RCT		-		2.07 (0.37 to 11.59)	64.65
Subtota	$ (l^2 = 43.3\%, p = 0.7) = 0.7$	184)		<	\rightarrow	0.90 (0.10 to 8.34)	100.00
			0.000041		1	24,373	
				Favours education	Favours control		

FIGURE 104 Summary of the findings of any adverse effect for studies comparing education/advice with alternative interventions. Note: weights are from random effects analysis.

TABLE 155 Summary of the findings of any adverse effect for studies comparing education/advice with alternative interventions

ID no.	Author, year	Study design	No. of events in intervention group	No. of participants in intervention group	No. of events in control group	No. of participants in control group	OR (95% CI)
Educa	ation/advice vs activity r	estriction					
713	Hofstee, 2002267	RCT	0	83	2	84	0.20 (0.00 to 4.18)
658	Vroomen, 199914	RCT	4	91	2	92	2.07 (0.37 to 11.59)
Educa	ation/advice vs epidural						
722	Bronfort, 2004 ¹⁶⁹	RCT	0	10	10	10	0.00 (0.00 to 0.13)
Educa	ation/advice vs manipula	ation					
722	Bronfort, 2004 ¹⁶⁹	RCT	0	10	6	11	0.04 (0.00 to 0.86)
<i>Educa</i> 713	ation/advice vs mixed tra Hofstee, 2002 ²⁶⁷	<i>eatment</i> RCT	0	83	0	83	

Control category	No. of studies (arms)	Sample size range (median)	Proportion of studies that were RCTs (%)	Proportion of studies that were deemed good quality (%)	Proportion of studies that only included acute sciatica (%)	Proportion of studies that included patients vith nerve root pain (%)	Proportion of studies that reported diagnosis by imaging (%)	Proportion of studies that included patients with stenosis (%)	Proportion of studies that included patients with extruded/ sequestered discs (%)	Proportion of studies that only included patients with first episode (%)	Proportion of studies that included patients who had received previous treatment (%)	Proportion of studies that included patients who had received previous surgery (%)
Education/advice vs activity restriction	2 (2)	183–250 (217)	2/2 (100)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)
Education/advice vs mixed treatment	1 (1)	250 (250)	1/1 (100)	(0) 1/0	1/1 (100)	1/1 (100)	1/1 (100)	(0) 1/0	0/1 (0)	0/1 (0)	(0) 1/0	1/1 (100)
Total (for education/ advice studies) ^a	2 (3)	183–250 (217)	2/2 (100)	0/2 (0)	2/2 (100)	2/2 (100)	1/2 (50)	0/2 (0)	0/2 (0)	0/2 (0)	0/2 (0)	1/2 (50)

	ce here).
	no VIr
	nted or
	in coui
	as bee
	but h
	arators,
	compa
	es two
	include
	t al. ²⁶⁷
OMs.	stee e
or CS	.g. Hot
tensity	ove (e
pain in	s as at
effect,	of arm
global e	Imber
es for g	not nu
utcome	tudies
inted o	oer of s
at repc	unut
dies th	ised or
ly stud	are ba
IO SWO	mbers
able sh	ese nu
This to	a Th

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 156 Summary of education/advice studies

Chapter 7

Mixed treatment comparisons: results

Description of mixed treatment comparison models

The network for studies reporting the outcome global effect is presented in *Figure 105*. In total, six MTC analyses were conducted for the three types of outcome (global effect, pain intensity and CSOMs) for all study designs and for RCTs and Q-RCTs only. The network diagrams for pain intensity and CSOMs are presented in *Appendix 6*, as well as the network diagram for global effect that only includes RCTs and Q-RCTs.

The MTC analyses rely on the key assumption that the relative treatment effect of one treatment versus another is the same across the entire set of studies.^{273,274} We used a random effects model, which means that we assumed that the common distribution of effects is the same across all sets of studies. A further assumption that was made in the analyses was that the relative efficacy of different treatments is the same at different stages in the care pathway.

Convergence was assessed using the Gelman–Rubin statistic (R) monitored over iteration–time. (R = B/W, where B represents the within-chain variability and W the between-chain variability.) Convergence occurred at around 6000–8000 iterations for all three outcome measures (global effect, pain intensity and CSOMs), as demonstrated in the random selection of plots presented in *Appendix 7*. The auto-correlation and history plots also showed good convergence. The goodness of fit of the models to the data, measured by the residual deviance, was found to be high (data presented in *Appendix 8*).

The results of the evaluation of between-study heterogeneity, presented in *Appendix 8*, showed a moderate-to-high level of statistical heterogeneity for many of the pair-wise comparisons, as well as across all studies as a whole.

The mean pain scores (scale 0-100) at baseline for each treatment category, according to the studies included in the MTC, were fairly similar and are presented in *Table 157*. With the exception of biological agents, most ranged from 60 to 69.

The MTC method enables us to estimate the probability that each treatment category is best (or most effective), the findings of which are presented in *Tables 159–164*, along with the summary effect estimates for comparisons of each intervention category with inactive control. The credible intervals (or the CIs presented in *Figures 106–111*) provide an indication of the uncertainty surrounding the effect sizes, which needs to be taken into account. For example, for global effect the estimates of the medians for biological agents and alternative therapy are associated with a great deal of uncertainty. Although they had the highest probability of being the best interventions, their 95% credible intervals were very wide and included unity, so were not statistically significant. Although the estimates of the median effect size for disc surgery and epidural injections were smaller, the 95% credible intervals were narrower and their findings were statistically significant (the direction of benefit in the forest plot is different for pain and CSOM is different from the direction for global effect).



FIGURE 105 Mixed treatment comparison network for global effect, including all studies.

The indirect comparison, as part of the MTC analysis, provides a full set of comparisons for all treatment groups. The summary estimates of effect (with 95% credible intervals) for each treatment comparison in the network for the analysis of global effect, which included all study designs is presented in *Table 158*. The results of each treatment comparison in the MTC analyses for all the networks are also presented in *Appendix 9*. The MTC findings can be directly compared with summaries of the pair-wise meta-analysis (with 95% CIs) derived from STATA, which are also presented in the same matrices (top right-hand corner). For example, when

Treatment category	No. of studies (no. of RCTs/Q-RCTs)	Mean baseline pain
Alternative/non-traditional	Not reported	
Intraoperative interventions	7 (7)	59.8
Active PT/exercise therapy	2 (2)	60.0
Chemonucleolysis	5 (3)	60.2
Education/advice	1 (1)	60.7
Inactive control	18 (17)	63.3
Opioids	2 (2)	63.3
Non-opioids	12 (10)	64.4
Usual/conventional care	4 (3)	65.8
Activity restriction	3 (3)	66.8
Epidural/intradiscal injection	11 (11)	67.6
Traction	4 (4)	68.0
Passive PT	3 (3)	68.3
Disc surgery	15 (11)	68.7
Biological agents	2 (1)	76.5

TABLE 157 Mean baseline pain for each treatment category (based on arm level data for studies included in the MTC analyses)

considering all study types, pair-wise data from nine studies show epidural to be significantly better than the inactive control for global effect (OR 2.58; 95% CI 1.25 to 5.29), and the indirect data show a similar result (OR 3.10; 95% credible interval 1.79 to 5.46). An example of where there is no direct comparison of interventions is that between disc surgery and epidural injections for global effect, but the indirect comparison shows a non-statistically significant finding in favour of surgery (OR 1.11; 95% credible interval 0.55 to 2.25).

The results of the mixed treatment comparison of each intervention category with inactive control

Comparisons of the findings of the pair-wise meta-analysis for each intervention category with inactive control are presented in *Tables 159–164* and *Figures 106–111*. When these direct comparisons are compared with those obtained from the MTC analysis, it can be seen that there is a broad agreement for the global effect, but there are more discrepancies for pain intensity and for CSOMs. These discrepancies are greatest for comparisons for which there is very little direct evidence, such as biological agents versus inactive control (one study²⁷¹).

For global effect, interventions that resulted in a statistically significant improvement compared with inactive control were, in order of effect size, intraoperative interventions, epidural injections, disc surgery, non-opioids and chemonucleolysis. For pain intensity these included alternative, biological agents and epidural. Opioids were found to be significantly less effective than inactive control for reducing pain. For CSOMs, biological agents resulted in statistically significant improvement compared with inactive control. When the analyses were limited to RCTs/Q-RCTs, the only interventions that remained significantly better than inactive control were intraoperative interventions, epidural injections, disc surgery and non-opioids for global effect and epidural for pain intensity.

Results when observational studies were excluded were broadly similar.

			<i>n</i> =1, 1.13 (0.4 to 3.6)						
	<i>n</i> =1, 1.37 (0.5 to 3.8)					<i>n</i> =2, 0.55 (0.1 to 5.0)			
				<i>n</i> =1, 0.22 (0.1 to 0.9)				<i>n</i> =1, 1.00 (0.1 to 7.0)	
	<i>n</i> =1, 10.0 (0.7 to 167)								
	<i>n</i> =2, 1.57 (0.2 to 11.3)			<i>n</i> =1, 0.20 (0.1 to 0.6)				<i>n</i> = 1, 0.93 (0.5 to 1.9)	
		<i>n</i> =1, 1.45 (0.7 to 3.0)	<i>n</i> =1, 0.77 (0.2 to 3.2)					<i>n</i> =1, 0.88 (0.3 to 2.7)	
						<i>n</i> =1, 3.27 (0.8 to 13.8)			
š	<i>n</i> =1, 4.71 (2.0 to 11.4)								_
8100 mon	<i>n</i> =2 to 1.11 (0.6 to 2.1)	<i>n</i> =1, 1.53 (0.6 to 4.2)						τ	4.06 (0.5 to 33.8)
			<i>n</i> =7, 1.49 (1.0 to 2.2)				J	0.26 (0.1 to 1.0)	1.03 (0.1 to 9.1)
	<i>n</i> = 10, 2.16 (1.1 to 4.5)		<i>n</i> =1, 6.72 (0.8 to 58.8)	<i>n</i> =1, 0.45 (0.2 to 1.4)		ш	1.85 (0.6 to 6.1)	0.47 (0.2 to 1.4)	1.91 (0.3 to 14.0)
	<i>n</i> =5, 2.56 (1.6 to 4.1)		<i>n</i> =23, 0.65 (0.5 to 0.9)	<i>n</i> =4, 1.13 (0.4 to 3.6)	ш	1.27 (0.6 to 2.9)	2.35 (1.0 to 5.8)	0.60 (0.2 to 1.7)	2.45 (0.3 to 18.3)
	<i>n</i> =9, 2.58 (1.3 to 5.3)	<i>n</i> =3, 5.46 (0.8 to 38.5)		Ω	0.65 (0.3 to 1.2)	0.82 (0.4 to 1.8)	1.52 (0.5 to 4.5)	0.39 (0.1 to 1.1)	1.57 (0.2 to 11.4)
		<i>n</i> =5, 2.60 (1.6 to 4.3)	O	1.11 (0.6 to 2.3)	0.72 (0.5 to 1.1)	0.92 (0.4 to 2.2)	1.70 (0.8 to 3.9)	0.44 (0.2 to 1.2)	1.76 (0.2 to 13.4)
		ш	3.37 (1.7 to 6.8)	3.75 (1.7 to 8.4)	2.42 (1.2 to 5.1)	3.09 (1.2 to 8.4)	5.72 (2.0 to 16.8)	1.46 (0.5 to 4.2)	5.91 (0.7 to 47.1)
	A	0.83 (0.4 to 1.9)	2.78 (1.4 to 5.6)	3.10 (1.8 to 5.5)	2.00 (1.1 to 3.8)	2.55 (1.4 to 4.7)	4.73 (1.6 to 14.0)	1.20 (0.5 to 3.1)	4.88 (0.7 to 33.2)

TABLE 158 Results of MTC analysis for all comparative studies reporting global effect

Health	Technology	Assessmen	t 2011; Vo

							Ø	val "
				<i>n</i> =2, 1.32 (0.8 to 2.3)		۵.	1.97 (0.1 to 34.8)	l; K, active PT; 6 credible inter
					0	1.02 (0.1 to 10.2)	2.0 (0.2 to 23.5)	non-traditiona ratio plus 95%
	<i>n</i> =1, 2.2 (0.6 to 7.7)			z	1.26 (0.2 to 8.7)	1.28 (0.3 to 4.9)	2.54 (0.2 to 31.9)	J, alternative/ meta-analysis. nalyses (odds
			≥	0.08 (0.0 to 2.9)	0.10 (0.0 to 3.3)	0.10 (0.0 to 4.9)	0.19 (0.0 to 10.1)	nanipulation; nal pair-wise r of the MTC a
		_	14.03 (0.5 to 974)	1.12 (0.2 to 6.0)	1.41 (0.3 to 6.8)	1.43 (0.2 to 12.5)	2.80 (0.3 to 28.9)	H, traction; I, r in conventior of the results
	¥	1.04 (0.2 to 4.7)	14.6 (0.4 to 1085)	1.16 (0.3 to 5.1)	1.46 (0.3 to 8.3)	1.48 (0.2 to 10.9)	2.90 (0.3 to 30.8)	terventions; H dies included nd triangle ar
۔	0.12 (0.0 to 1.6)	0.13 (0.0 to 1.5)	1.75 (0.0 to 180)	0.14 (0.0 to 2.0)	0.17 (0.0 to 2.1)	0.17 (0.0 to 3.5)	0.34 (0.0 to 8.0)	raoperative in number of stu e top right-ha
1.91 (0.1 to 41.7)	0.22 (0.0 to 2.2)	0.23 (0.0 to 2.0)	3.36 (0.1 to 306)	0.26 (0.0 to 2.9)	0.33 (0.0 to 3.3)	0.33 (0.0 to 5.3)	0.65 (0.0 to 12.2)	opioids; G, int imulation; n_i reported in th
7.73 (0.7 to 102)	0.90 (0.3 to 3.2)	0.94 (0.3 to 3.1)	13.2 (0.4 to 943)	1.05 (0.2 to 4.7)	1.33 (0.3 to 6.2)	1.35 (0.2 to 10.0)	2.66 (0.3 to 26.0)	olysis; F, non- spinal cord st al place) are
1.98 (0.2 to 27.5)	0.23 (0.1 to 1.0)	0.24 (0.1 to 1.0)	3.38 (0.1 to 249)	0.27 (0.1 to 1.5)	0.34 (0.1 to 1.7)	0.34 (0.0 to 3.0)	0.67 (0.1 to 5.9)	chemonucler on/advice; Q, to one decim Jle.
3.65 (0.4 to 38.0)	0.43 (0.1 to 1.6)	0.45 (0.1 to 1.4)	6.19 (0.2 to 409)	0.50 (0.1 to 2.4)	0.63 (0.2 to 2.0)	0.64 (0.1 to 5.0)	1.25 (0.1 to 11.6)	erve block; E, 3s; P, educati % Cl rounded ft-hand triang ading.
4.64 (0.4 to 56.2)	0.55 (0.2 to 1.9)	0.57 (0.2 to 1.8)	7.90 (0.3 to 545)	0.64 (0.1 to 2.8)	0.80 (0.2 to 3.1)	0.81 (0.1 to 6.0)	1.59 (0.2 to 12.8)	D, epidural/n tition; O, opioi s (OR plus 95' the bottom le thed using shi trol.
2.99 (0.3 to 35.6)	0.35 (0.1 to 1.2)	0.37 (0.1 to 1.1)	5.10 (0.2 to 335)	0.41 (0.1 to 1.7)	0.52 (0.1 to 1.9)	0.53 (0.1 to 3.7)	1.03 (0.1 to 8.9)	disc surgery; activity restric meta-analysec e reported in the highligh ared with con
3.35 (0.3 to 40.9)	0.40 (0.1 to 1.3)	0.41 (0.1 to 1.3)	5.68 (0.2 to 396)	0.46 (0.1 to 2.0)	0.58 (0.2 to 2.3)	0.59 (0.1 to 4.3)	1.14 (0.2 to 8.9)	Isual care; C, al agents; N, ard pairwise r findings have vention comp
11.27 (1.0 to 144.5)	1.33 (0.4 to 4.4)	1.38 (0.4 to 4.7)	19.26 (0.7 to 1357)	1.54 (0.3 to 7.1)	1.95 (0.5 to 8.4)	1.98 (0.3 to 14.7)	3.84 (0.4 to 33.7)	e control; B, I ¹ ; M, biologic f direct stand: up to one dec Ily significant favours inter
9.32 (1.0 to 104.5)	1.10 (0.3 to 3.8)	1.14 (0.4 to 3.2)	15.77 (0.6 to 1002)	1.28 (0.3 to 5.5)	1.60 (0.5 to 5.4)	1.63 (0.2 to 12.1)	3.19 (0.4 to 27.6)	A, inactiv. passive P Results or rounded t Statistical OR > 1.0

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 159 Odds ratios for global effect of the different treatment categories for all studies compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Probability of	Madian OR (OF% aradible	Results of standa	ard pair-wise meta-analysis
Treatment category	Code	(mean)	interval)	No. of studies	ORs (95% CI)
Biological agents	М	0.5062	15.77 (0.61 to 1002.00)	1	10.00 (0.65 to 100.00)
Alternative/non-traditional	J	0.2764	9.32 (0.95 to 104.50)		
Manipulation	I	0.0990	4.88 (0.73 to 33.20)	1	4.76 (11.11 to 1.96)
Spinal cord stimulation	Q	0.0604	3.19 (0.36 to 27.57)		
Intraoperative interventions	G	0.0389	4.72 (1.61 to 13.99)		
Education/advice	Р	0.0142	1.63 (0.22 to 12.05)		
Opioids	0	0.0018	1.60 (0.48 to 5.41)	1	1.37 (0.50 to 3.70)
Epidural/nerve block	D	0.0017	3.09 (1.79 to 5.46)	9	2.63 (1.27 to 5.56)
Usual care	В	0.0000	0.83 (0.35 to 1.91)		
Chemonucleolysis	E	0.0000	2.00 (1.05 to 3.82)	5	2.56 (1.59 to 4.17)
Activity restriction	Ν	7.2×10 ⁻⁴	1.28 (0.29 to 5.51)		
Non-opioids	F	4.4×10^{-4}	2.55 (1.42 to 4.65)	10	2.71 (1.05 to 4.55)
Disc surgery	С	2.4×10^{-4}	2.78 (1.37 to 5.59)		
Active PT	К	1.4×10^{-4}	1.09 (0.32 to 3.78)		
Passive PT	L	1.0×10^{-4}	1.14 (0.41 to 3.17)	2	1.56 (0.22 to 11.11)
Traction	Н	4.0×10^{-5}	1.20 (0.47 to 3.07)	2	1.11 (0.60 to 2.04)
Inactive control	А	0.0000			



FIGURE 106 Odds ratios for the global effect of the different treatment categories for all studies compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

Effect size (95% CI)

TABLE 160 Odds ratios for the global effect of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Probability of	Madian OD (050/ aradible	Results of stand	ard meta-analysis
Treatment category	Code	(mean)	interval)	No. of studies	ORs (95% CI)
Biological agents	М	0.4847	16.04 (0.60 to 1138.00)	1	10.00 (0.65 to 100.00)
Intraoperative interventions	G	0.3930	4.99 (1.50 to 17.47)		
Alternative/non-traditional	J	0.2568	9.25 (0.90 to 107.70)		
Manipulation	I	0.0882	4.90 (0.70 to 34.48)	1	4.76 (1.96 to 11.11)
Education/advice	Р	0.0593	3.12 (0.29 to 34.36)		
Spinal cord stimulation	Q	0.0582	3.30 (0.34 to 32.70)		
Activity restriction	Ν	0.00944	2.43 (0.35 to 17.52)		
Epidural/nerve block	D	0.00164	3.14 (1.77 to 5.65)	9	2.63 (1.27 to 5.56)
Opioids	0	0.00112	1.62 (0.46 to 5.66)	1	1.37 (0.50 to 3.70)
Traction	Н	1.0×10^{-4}	1.36 (0.47 to 3.94)	2	1.12 (0.60 to 2.04)
Non-opioids	F	2.6×10^{-4}	2.59 (1.37 to 4.96)	9	2.56 (1.16 to 5.26)
Disc surgery	С	3.0×10^{-4}	2.94 (1.18 to 7.49)		
Usual care	В	4.0×10^{-5}	1.14 (0.38 to 3.46)		
Active PT	К	4.2×10^{-4}	1.46 (0.38 to 5.75)		
Chemonucleolysis	Е	6.0×10^{-5}	2.38 (1.19 to 4.81)	5	2.56 (1.59 to 4.17)
Passive PT	L	6.0×10^{-6}	1.19 (0.42 to 3.42)	2	1.56 (0.22 to 11.11)
Inactive control	А	0.0000			

Treatment category

Usual care 1.15 (0.38 to 3.43) 2.95 (1.18 to 7.39) Disc surgery Epidural/nerve block 3.15 (1.77 to 5.61) Chemonucleolysis 2.38 (1.19 to 4.78) Non-opioids 2.59 (1.37 to 4.92) 5.02 (1.47 to 17.15) Intraoperative interventions Traction 1.36 (0.47 to 3.91) 4.90 (0.71 to 33.92) Manipulation 9.45 (0.87 to 102.44) Alternative/non-traditional Active PT 1.47 (0.38 to 5.67) Passive PT 1.19 (0.42 to 3.38) **Biological agents** 18.08 (0.42 to 771.50) Activity restriction 2.43 (0.34 to 17.14) Opioids 1.61 (0.46 to 5.66) Education/advice 3.13 (0.30 to 33.24) Spinal cord stimulation 3.31 (0.34 to 32.12) 10 100 1000 0.1 0.512 Favours inactive control Favours intervention

FIGURE 107 Odds ratios for the global effect of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 161 Weighted mean difference for pain intensity of the different treatment categories for all studies compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Duckshillty of		Results o	f standard meta-analysis
Treatment category	Code	being 'best' (mean)	Median of the posterior (95% credible interval)	No. of studies	WMD (95% CI)
Alternative/non-traditional	J	0.4397	-26.08 (-46.65 to -6.06)	1	-25.00 (-41.75 to -8.24)
Biological agents	М	0.2344	-21.80 (-35.95 to -7.95)	2	-9.91 (-43.23 to 23.41)
Manipulation	I	0.1474	-11.72 (-44.97 to 21.59)		
Intraoperative interventions	G	0.0688	-14.88 (-34.05 to 4.02)		
Chemonucleolysis	Е	0.01566	-11.24 (-29.76 to 7.20)	1	-5.40 (-23.66 to 12.86)
Active PT	К	0.014	-3.04 (-27.35 to 20.94)		
Education/advice	Р	0.0083	17.04 (-20.80 to 54.62)		
Traction	Н	0.00716	-1.21 (-22.07 to 20.04)	1	3.36 (-14.49 to 21.21)
Passive PT	L	0.0039	-0.40 (-19.33 to 19.00)	1	-7.00 (-13.58 to -0.42)
Epidural/nerve block	D	0.00306	-12.85 (-20.91 to -5.14)	8	-12.31 (-23.90 to -0.72)
Radiofrequency lesioning	S	0.00222	12.94 (-13.38 to 39.01)	1	13.00 (2.04 to 23.96)
Activity restriction	Ν	0.0015	18.00 (-15.57 to 51.16)		
Disc surgery	С	0.0011	-9.78 (-26.51 to 6.81)		
Usual care	В	7.2×10 ⁻⁴	-3.184 (-19.45 to 13.18)		
Non-opioids	F	8×10 ⁻⁵	-4.07 (-13.57 to 5.11)	5	-10.70 (-21.21 to -0.19)
Opioids	0	6×10 ⁻⁵	9.34 (-9.15 to 27.40)		. ,
Inactive control	А	0.0	. ,		

Treatment category



Effect size (95% CI)

FIGURE 108 Weighted mean difference for pain intensity of the different treatment categories for all studies compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

TABLE 162 Weighted mean difference for pain intensity of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Probability of		Results of stand	ard meta-analysis
Treatment category	Code	(mean)	(95% credible interval)	No. of studies	WMD (95% CI)
Alternative/non-traditional	J	0.4945	-24.89 (-55.67 to 5.35)	1	-25.00 (-41.75 to -8.24)
Manipulation	I	0.1859	-12.79 (-50.28 to 24.55)		
Intraoperative interventions	G	0.1016	-13.94 (-39.47 to 11.56)		
Biological agents	Μ	0.07186	-11.18 (-30.77 to 8.83)	1	7.00 (-5.25 to 19.25)
Chemonucleolysis	E	0.04438	-12.28 (-35.85 to 11.38)	1	-5.40 (-23.66 to 12.89)
Epidural/nerve block	D	0.02446	-12.66 (-21.47 to -4.11)	8	-12.31 (-23.90 to -0.72)
Active PT	K	0.02244	-3.39 (-30.69 to 23.94)		
Traction	Н	0.01374	-1.32 (-23.17 to 20.91)	1	3.36 (-14.49 to 21.21)
Education/advice	Р	0.0115	16.62 (-22.42 to 26.93)		
Passive PT	L	0.00792	-0.23 (-20.29 to 20.33)	1	-7.00 (-13.58 to -0.42)
Disc surgery	С	0.00516	-8.87 (-32.27 to 14.47)		
Usual care	В	0.00464	-4.45 (-23.49 to 14.63)		
Radiofrequency lesioning	S	0.00408	13.01 (-14.41 to 40.77)	1	13.00 (2.04 to 23.96)
Non-opioids	F	0.00408	-5.84 (-16.65 to 4.47)	5	-10.70 (-20.21 to -0.19)
Activity restriction	Ν	0.0025	17.44 (16.86 to 52.78)		
Opioids	0	0.00122	7.41 (-12.54 to 26.94)		
Inactive control	А	0.0			

Treatment category

Effect size (95% CI)



FIGURE 109 Weighted mean difference for pain intensity of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 163 Standardised mean difference for CSOMs of the different treatment categories for all studies compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Probability of	Madian CMD (05%	Results of stand	ard meta-analysis
Treatment category	Code	(mean)	credible interval)	No. of studies	SMD (95% CI)
Activity restriction	N	0.3223	-0.82 (-2.58 to 0.74)		
Biological agents	Μ	0.2393	-0.67 (-1.27 to -0.08)	3	-0.90 (-1.52 to -0.18)
Education/advice	Р	0.1741	-0.66 (-2.59 to 1.00)		
Passive PT	L	0.1186	-0.47 (-1.36 to 0.43)		
Intraoperative interventions	G	0.05489	-0.06 (-1.38 to 1.29)		
Active PT	K	0.0393	0.18 (-1.26 to 1.61)		
Traction	Н	0.03458	-0.35 (-1.21 to 0.46)	1	0.08 (-0.31 to 0.47)
Chemonucleolysis	E	0.00496	0.38 (-0.99 to 1.80)		
Usual care	В	0.00365	0.16 (-1.07 to 1.42)		
Disc surgery	С	0.00341	0.10 (-1.17 to 1.39)		
Epidural/nerve block	D	0.00324	-0.16 (-0.53 to 0.20)	5	0.34 (-0.81 to 0.13)
Non-opioids	F	0.00162	0.08 (-0.48 to 0.66)	2	0.30 (-0.14 to 0.74)
Inactive control	А	9.0×10^{5}			

Treatment category

Usual care 0.15 (-1.17 to 1.48) Disc surgery 0.09 (-1.27 to 1.45) Epidural/nerve block -0.16 (-0.53 to 0.20) Chemonucleolysis 0.36 (-1.09 to 1.82) Non-opioids 0.08 (-0.47 to 0.63) Intraoperative interventions -0.05 (-1.44 to 1.33) -0.37 (-1.21 to 0.47) Traction Active PT 0.16 (-1.37 to 1.70) Passive PT -0.48 (-1.39 to 0.44) **Biological agents** -0.69 (-1.28 to -0.09) Activity restriction -0.84 (-2.52 to 0.85) Education/advice -0.67 (-2.48 to 1.14) -2 -1.5 -1 -0.5 0 0.5 1.5 2 1 Favours inactive control Favours intervention

FIGURE 110 Standardised mean difference for CSOMs of the different treatment categories for all studies compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

Effect size (95% CI)

Effect size (95% CI)

TABLE 164 Standardised mean difference for CSOMs of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis and standard pair-wise meta-analyses (treatments ordered according to the probability of being the best)

		Probability of	Madian CMD (05%)	Results of stand	ard meta-analysis
Treatment category	Code	(mean)	credible interval)	No. of studies	SMD (95% CI)
Activity restriction	Ν	0.3562	-0.75 (-2.47 to 1.03)		
Education/advice	Р	0.1825	-0.61 (-2.40 to 1.31)		
Biological agents	М	0.1786	-0.41 (-1.18 to 0.37)	2	-1.07 (-2.64 to 0.50)
Passive PT	L	0.1285	-0.34 (-1.26 to 0.57)		
Intraoperative interventions	G	0.05476	0.15 (-1.29 to 1.58)		
Traction	Н	0.05209	-0.30 (-1.15 to 0.54)	1	0.08 (-0.31 to 0.47)
Active PT	Κ	0.01826	0.39 (-1.05 to 1.87)		
Non-opioids	F	0.01192	0.08 (-0.49 to 0.66)	2	0.30 (-0.141 to 0.74)
Usual care	В	0.00661	0.35 (-0.94 to 1.62)		
Chemonucleolysis	E	0.00341	0.62 (-0.86 to 2.13)		
Disc surgery	С	0.00326	0.29 (-1.07 to 1.70)		
Epidural/nerve block	D	0.00165	0.04 (-0.35 to 0.43)	4	-0.03 (-0.18 to 0.13)
Inactive control	А	0.00222			

Treatment category



FIGURE 111 Standardised mean difference for CSOMs of the different treatment categories for RCTs and Q-RCTs compared with the inactive control from the MTC analysis. Note: weights are from random effects analysis.

Results of the mixed treatment comparison comparing all interventions that formed a connected network

The following is a summary of the remaining results without the inactive control, for global effect, pain intensity or CSOMs, according to whether or not there was a statistically significant difference between the intervention groups.

For disc surgery, the MTC analysis that included all study types showed a significant improvement in global effect when compared with usual care (OR 3.4, 95% credible interval 1.7 to 6.8). Following intra-operative intervention there was also significant improvement in the global effect for the comparison with usual care (OR 5.7, 95% credible interval 2.0 to 16.8). These comparisons remained statistically significant when the observational studies were excluded from the MTC analyses.

For epidural injection, the MTC analysis that included all study types found a significant improvement in global effect for the comparison with usual care (OR 3.8, 95% credible interval 1.7 to 8.4), and for pain intensity when compared with opioid medication (WMD –22.2, 95% credible interval –3.3 to –41.1). When observational studies were excluded from the MTC analysis there was no longer a significant difference for either of these outcomes.

For chemonucleolysis, the MTC analysis that included all study types found a significant improvement in the global effect compared with usual care (OR 2.4, 95% credible interval 1.2 to 5.1). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For non-opioid medication, the MTC analysis that included all study types found a significant improvement in the global effect compared with usual care (OR 3.1, 95% credible interval 1.2 to 8.4). There was a significantly worse result in pain intensity compared with alternative therapy (mainly acupuncture) (WMD 22.1, 95% credible interval 0.1 to 43.8) or biological agents (OR 17.8, 95% credible interval 2.5 to 33.0). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For alternative therapies (mainly acupuncture), the MTC analysis that included all study types found a significant improvement in pain intensity compared with activity restriction (WMD –44.1, 95% credible interval –82.9 to –4.9), opioids (WMD –35.5, 95% credible interval –62.3 to –8.3), non-opioid medication (WMD –22.1, 95% credible interval –43.8 to –0.1), or education/ advice (WMD –44.2, 95% credible interval –85.5 to –0.2). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For passive PT, the MTC analysis that included all study types found a significantly worse result in pain intensity for the comparison with biological agents (WMD 21.3, 95% credible interval 1.9 to 45.5). This finding was no longer a significant when observational studies were excluded from the MTC analysis.

For biological agents, the MTC analysis that included all study types found a significant improvement in pain intensity compared with activity restriction (WMD –39.7, 95% credible interval –75.8 to –3.6), opioids (WMD –31.2, 95% credible interval –53.0 to –9.2), non-opioid medication (WMD –17.8, 95% credible interval –2.46 to –33.0), or passive PT (WMD –21.3, 95% credible interval –45.5 to –1.9), and CSOMs compared with non-opioid medication (SMD –0.8, 95% credible interval –1.5 to –0.0). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For activity restriction, the MTC analysis that included all study types found a significantly worse result in pain intensity compared with biological agents (WMD 39.7, 95% credible interval 3.6 to 75.8) or alternative therapies (WMD 44.1, 95% credible interval 4.9 to 82.9). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For opioid medication, the MTC analysis that included all study types found a significantly worse result in terms of pain intensity compared with epidural injections (WMD 22.2, 95% credible interval 3.3 to 41.1), alternative therapy (mainly acupuncture) (WMD 35.5, 95% credible interval 8.3 to 62.3) or biological agents (WMD 31.2, 95% credible interval 9.2 to 53.0). When observational studies were excluded from the MTC analysis these findings were no longer significant.

For education/advice, the MTC analysis that included all study types found a significantly worse result in terms of pain intensity compared with alternative therapy (WMD 43.2, 95% credible interval 0.2 to 85.5). This finding was no longer significant when observational studies were excluded from the MTC analysis.

Chapter 8

Review of existing economic evaluations: results

Introduction

It was anticipated that the existing evidence relating to the cost-effectiveness of treatments would have a number of limitations that would make it insufficient to inform decision-making regarding the most appropriate management strategy for patients with sciatica. The findings from this review, alongside the review of clinical effectiveness, are intended to assist in informing the basis for the economic model.

Summary of results

Twelve studies were reviewed, data extracted and appraised.^{62,100,173,275-283} A brief summary of these studies is presented in *Table 164*. A full summary is presented in *Appendix 10*. Studies evaluated the cost-effectiveness of single interventions for the treatment of sciatica (i.e. pair-wise comparisons) rather than mixed treatment effects. There was significant variation in the quality of studies presented as economic evaluations.

The majority of studies (9/12) were conducted primarily from a health-care or payer perspective. Several studies considered employment-related losses related to work days lost owing to sciatica; with three studies conducted from a societal perspective. The studies covered a diverse range of population settings, with some variation in age range and gender within the studies. Most studies considered a relatively short time horizon. One of the limitations of all studies was the lack of data relating to the longer-term outcome of sciatica. There was little distinction made in most studies between acute and chronic sciatica.

With the exception of one earlier study which employed a decision tree to represent potential pathways, all studies were based on individual patient data derived from RCTs and observational studies. As the majority of identified studies focused on intermediate or surgical interventions, resource utilisation and costs were commonly evaluated with respect to secondary care contacts and associated resource usage. Only one study focused specifically on primary care. Outcomes varied across studies, but the majority considered a global outcome and condition-specific or health-related quality of life (HRQoL). The measures used varied considerably from instruments designed specifically for the study to the use of established generic measures.

Of considerable importance to the review was the quality and robustness of the cost-effectiveness analysis (CEA). Only five studies were considered as full economic evaluations, i.e. reported incremental cost-effectiveness ratios (ICERs), when reviewed against established guidelines.^{29,31} The other seven studies reported costs per adjusted outcome,⁶² unsuccessful outcome,²⁸¹ cost per response²⁷⁶ or costs per extra success,²⁷⁵ with no ICERs presented. One study, published 16 years previously,²⁷⁷ reported a decision-analytic model to compare chemonucleolysis with surgical disctectomy. Again, this study did not present ICERs.

mmary of cost-effectiveness studies
Sun
165
ABLE
-

Intervention and comparator(s)	spective Source Intervention Control Outcomes ICER	Ith provider Prospective cohort Surgical macrodiscectomy Nucleotomy Marginal cost per extra success choosing surgery as primary outcome	etal Prospective cohort Disc surgery Conservative treatment Cost per QALY	th provider RCT Methylprednisolone- Saline Cost per response bupivacaine	th provider Published studies + Chemonucleolysis Surgical discectomy Cost per QALY prospective survey	etal RCT PT+GP care GP care Cost per global Direct costs: ϵ 837 (95% Cl perceived effect gain $-\epsilon$ 732 to ϵ 3186)	Total costs: €6224 (95% Cl -€10,419 to €27,551)	Ith purchaser RCT, published Lumbar discectomy Conservative management Cost per QALY Non discounted: US\$29,200 pective studies 5% discounted: US\$33,900 Based on HMO data: US\$12,000	th-care RCT Spinal cord stimulation + non Non-surgical conservative Costs and HRQoL ider (Canada surgical conservative medical medical management outcomes considered
Ē	Source In	Prospective cohort SI	Prospective cohort Di	RCT M	Published studies + Cl prospective survey	RCT P		RCT, published Lu studies	RCT SI
	Perspective	Health provider	Societal	Health provider	Health provider	Societal		Health purchaser perspective	Health-care provider (Canada
	Country	Norway	Sweden	Finland	France	Netherlands		USA	Canada, UK and Europe
	Study	Dullerud, 1999 ²⁷⁵	Hansson, 2007 ¹⁰⁰	Karppinen, 2001 ²⁷⁶	Launois, 1994 ²⁷⁷	Luijsterburg, 2007 ²⁷⁸		Malter, 1996 ²⁷⁹	Manca, 2008 ²⁸⁰
	No.		2	ŝ	4	£		9	7

I

					Intervention and comparator(s)		
No.	Study	Country	Perspective	Source	Intervention	Control	Outcomes	ICER
ω	Price, 2005 ¹⁷³	¥	Health provider and purchaser (NHS)	RCT	Epidural steroid (ESI) + local anaesthetic	Normal saline (placebo)	Cost per QALY	Provider: £44,701 Purchaser: £354,171 <i>If only one ESI</i> Provider: £25,745 Purchaser: £167,145
6	Shvartzman, 1992 ⁶²	NSA	Health payer (insurance)	Retrospective chart review	Surgery	Conservative treatment	Cost per adjusted outcome	
10	Stevenson, 1995 ²⁸¹	Я	Health provider	RCT	Automated percutaneous disctectomy	Microdistectomy	Costs per successful outcome	
1	Tosteson, 2008 ²⁸²	USA	Societal	RCT + observational cohort	Standard open aminectomy/ laminectomy with removal of herniation + examination of involved nerve route	Non-operative (usual care decided by physician and patient)	Cost per QALY	US\$69,404 (95% CI US\$49,523 to US\$94,999) using general adult surgery costs US\$34,355 (95% CI US\$20,419 to US\$52,512) using Medicare costs
12	van den Hout, 2008 ²⁸³	Netherlands	Health-care and societal perspective	RCT	6 months of prolonged conservative care	Early surgery	Cost per QALY	Health-care perspective: €41,000 (95% CI €14,000 to €430,000) Societal: −€12 (95% CI −€4029 to €4006)
	and a second	Continue in Crucia	and and official	too wotio (o a loozootoo				

HIMO, health maintenance organisation; ICER, incremental cost-effectiveness ratio (e.g. incremental cost per QALY gained).

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

Economic evaluation conducted alongside trials, modelling studies and analyses of administrative databases were included if they compared two or more treatments, and considered both costs and consequences (including cost-effectiveness, cost-utility, cost-benefit and costconsequences analysis). Some comparative studies included in the effectiveness section of the review also reported cost data, but the data on costs and consequences were not combined. Although not conforming to a full economic evaluation under our definition, two studies warrant specific attention as providing useful information on the cost-utility of interventions for sciatica.

Hansson and Hansson¹⁰⁰ undertook a cost–utility analysis (CUA) of 92 individuals who underwent surgery for lumbar disc herniation in a cohort of 1822 individuals aged between 18 and 59 years and selected consecutively in five regions of Sweden between 1994 and 1995. All participants had been off work for at least 28 days as a result of either low back pain or neck problems. The intervention was surgery with conservative treatment as the comparator. Outcome measures were HRQoL using European Quality of Life-5 Dimensions (EQ-5D); functional restrictions because of back problems using the Hannover Activities of Daily Living questionnaire; and pain experienced during the previous 6 months using the Von Korff pain scale. Medical costs for back pain were estimated (appointments, admission, examination and treatment) over a 2-year study period. Cost of work absenteeism was also estimated. A 5% discount rate and an assumed annual increase in productivity of 1.5% were used to convert future years' production loss to present values. Costs of illness, HRQoL and cost–utility (presented as difference in utility between 28 days and 2 years) were used as the gain in QALY.

The findings showed that the total cost of surgical treatment of lumbar disc herniation during a 2-year period was lower than the cost of non-surgical treatment. The direct cost of surgery was much higher than the direct cost of non-surgical treatment, whereas the indirect cost was lower. Lower indirect costs were the effect of lower rates of recurrence of work absence episodes and permanent disability benefits. Surgery reduced pain and improved back function and HRQoL to a greater extent than non-surgical treatments. The effects on HRQoL in combination with lower costs for surgery resulted in a better cost–utility for surgical treatment. The authors concluded that surgery for lumbar disc herniation is quite cost-effective.

Patients were drawn from a cohort study¹⁰⁰ with explicit selection criteria in place, although the well-reported difficulties of selecting appropriate controls was acknowledged. The EQ-5D was used with utility values derived from a time trade-off (TTO) method, although a UK (rather than Swedish) population was used. Resource costs appear limited and methods to collect cost information were not fully described. Discounting was applied, but not at comparable NHS rates. Costs of illness were reported based on mean costs over 2 years (no CIs were presented). Cost per QALY were then calculated by calculating the difference between 28 days and 2 years. It is not clear why baseline values were not used. In addition, no ICERs were presented to explore QALY gain/loss over a longer time period. No sensitivity analysis was presented, with the authors stating that the Swedish cohort had a lower frequency of disc surgery within the starting 3 months than other national cohorts.

Manca *et al.*²⁸⁰ reported HRQoL, resource consumption and costs of spinal cord stimulation compared with conventional medical management in 100 patients aged \geq 18 years participating in the PROCESS (prospective, randomised controlled multicentre study of patients with failed back surgery syndrome) trial. Conservative medical management included oral medications, nerve blocks, epidural corticosteroids, physical and psychological rehabilitative therapy, or chiropractic care. HRQoL using the Short Form questionnaire-36 items (SF-36) and EQ-5D was measured at baseline and 3 months and 6 months after initiation of treatment. Unit costs were calculated using UK and Canadian figures. Health resource-data were prospective and

collected over a comprehensive range of resources. Because of the time line, discounting was not performed.

The 6-month mean total costs were significantly higher (£15,081) in the spinal cord stimulation group than in the conservative management group (£3573), with a statistically significant adjusted differential mean cost of £11,373. However, the gain in HRQoL with spinal cord stimulation over the same period was considerably greater in this group, with a mean EQ-5D score difference of 0.25 (p < 0.001) and 0.21 (p < 0.001), respectively, at 3 and 6 months after adjustment for baseline characteristics. The authors concluded that the addition of spinal cord stimulation to conservative medical management in patients resulted in higher costs to health-care systems, but generated important improvements in patients EQ-5D over the same period.

Resource data were collected in detail and unit costs were undertaken using Canadian and UK figures, although patient resource data were derived from eight countries participating in the study. However, analysis of 'country effect' suggested that the differences in the total cost for UK and Canada did not appear to be statistically significantly different from the trial overall mean. The study did not take into account the patients' perspective in the economic evaluation. EQ-5D data were collected and utilities were derived from a UK sample. The analysis of cost and HRQoL were presented separately. The limited follow-up period was the main limitation of this study and the authors acknowledged that a full CEA would need to consider how costs and HRQoL difference developed beyond the 6-month period.

With significant heterogeneity across these studies, it was difficult for any reliable conclusions from the results to be drawn from the existing economic evaluation evidence base.

A summary of the main issues identified include:

- studies were undertaken across different countries
- variability in the population settings across studies
- lack of information on the clinical management pathways with many studies not indicating the previous treatment strategies or the timing of the intervention since diagnosis (e.g. patients who received conservative management for longer periods may be less likely to receive surgery which could lead to differences in costs and QALYs)
- different perspectives were adopted (a significant limitation; of particular relevance for this review was the lack of a NHS and personal social services perspective in the studies)
- unclear distinctions between acute and chronic sciatica
- different comparators were used across studies
- usual care was often poorly defined and variable across studies
- short time horizons for studies with little consideration for the longer-term outcomes of sciatica
- lack of discounting
- the difficulty in blinding patients in the RCTs reported (patients' preferences for treatment may have influenced the reported utilities and costs)
- different approaches to measuring resource utilisation and unit costs
- different outcome measures used across studies
- limited data (particularly in earlier studies) of preference-based valuations
- lack of information on the overall duration of symptoms and how these varied across different patient groups and treatments in order to adjust for these durations in any estimation of QALYs
- the potential for crossover between interventions and additional co-interventions (e.g. owing to recurring or worsening symptoms/relapse/complications over time) has been overlooked in the majority of economic evaluations

- variability in the CEA presented, with nearly 60% of studies not presenting an ICER
- lack of sensitivity analysis in these evaluations (where sensitivity analysis is performed, there
 was considerable variability in the parameters used for changing the base-case analysis).

A recognised limitation in reporting this review is the relevance of these studies and data to current decision-making in the UK NHS. However, even with the significant heterogeneity precluding any formal comparison or conclusions from the results, the ICER estimates reported in *Table 165* suggest marked differences between treatments. The approaches, assumptions and results of these five studies are reviewed in detail to identify possible key differences and issues in order to assist in the development of the new model. Five studies were reviewed. One study compared PT with GP care,²⁷⁸ one study compared an intermediate intervention (ESI with placebo)¹⁷³ and three studies compared surgery with conservative treatment,²⁸³ usual care²⁸² or chemonucleolysis.²⁷⁹

Review of full economic evaluations

Primary care

Luijsterburg et al.

Luijsterburg *et al.*²⁷⁸ undertook an economic evaluation as part of an RCT with 112 GPs in Rotterdam. One hundred and thirty-five patients aged between 18 and 65 years with duration of symptoms of < 6 weeks were randomised to PT and GP care compared with GP care alone. PT consisted of exercise therapy with information and advice provided by physical therapists. Passive therapies were not allowed. GP care was defined as care according to GP clinical guidelines and included information, advice and, if necessary, prescribed analgesia. A societal perspective was taken to the economic evaluation.

Source of effectiveness data

The primary outcome measure was global perceived effect (GPE) measured on a seven-point scale, dichotomised to improved and much improved versus not improved. GPE was rated as the percentage of patients who reported improvement. The EQ-5D was a secondary outcome measure that measured health utilities in order to calculate QALYs. Outcome measures and costs were assessed at baseline and at 3, 6, 12 and 52 weeks. Longer time horizons were not examined and discounting was not applied.

Source of cost data

Direct health-care costs included the costs of PT, GP care, medication, additional visits to other health-care providers and hospitalisations. Prices were obtained from Dutch guidelines²⁸⁴ or from the Professional Association.²⁸⁵ The currency was euros (€), but the year was not reported. Indirect costs outside the health-care system included the costs of production losses caused by absence from work. Costs for paid work were calculated by using the friction cost approach (period 154 days) based on the overall mean income of the Dutch population.

Summary of cost-effectiveness analysis

Analysis was undertaken using the ITT principle. Difference in resource utilisation between the two groups was assessed using non-parametric methods because of the skewed nature of the cost data. For the CEA, GPE and EQ-5D were used to calculate benefits. Utilities derived from the EQ-5D allowed a CUA to be performed, although this was not reported. ICERs were constructed and CIs were calculated using Fieller's methods using bootstrapping methods with the construction of cost-effectiveness acceptability curves. No sensitivity analysis was undertaken

Summary of the findings

Total costs (direct and indirect) at 3, 6, 12 and 52 weeks consisted mainly of production losses with significant differences between groups for PT visits in favour of the control groups. Total direct costs were also significantly different at the four follow-up time points in favour of the control group. At baseline and 6 and 12 weeks, the mean utility score was higher in the control group (0.41, 0.70 and 0.73 compared with 0.39, 0.34 and 0.65), but the difference was statistically significant only at 6 weeks. At 52 weeks, the utility in the intervention group was higher (0.76 compared with 0.73).

The ICERs were: for direct costs €837 (95% CI –€732 to €3186) per improved patient gained and for total costs €6224 (95% CI €10,419 to €27,551) per patient improvement gained. The ICERs and CIs estimated by bootstrap and Fieller's methods were similar. The cost-effectiveness acceptability curve constructed for direct costs showed, for a threshold of €600 per patient improved, an ICER acceptable with 35% certainty and, for a threshold of €1200 per patient improved, an ICER acceptable with 69% certainty. For total costs, the curve showed, for a threshold of €4000 per patient improved, an ICER acceptable at 37%, and for a threshold of €12,000 per patient improved, an ICER acceptable at 68%.

The authors concluded that treatment of patients with lumbar radicular syndrome (LRS) with PT and GP care was not more cost-effective than GP care alone.

Critique of Luijsterburg et al.

The study research question was justified because there was a lack of knowledge concerning the cost-effectiveness of PT in sciatica. The economic evaluation has been conducted alongside a RCT which appeared to have good internal validity.

However, some clear issues were identified. The data collection methods used to collect resource utilisation and cost data were not well explained and the reliability of this information could be questioned. For example, the authors recognised that some aspects that may have affected absence from work and productivity costs (e.g. waiting times) were ignore . The authors conceded that future studies should pay more attention to analysing the effect of these factors on absence from work and costs. Costs were cumulative so recall bias from patients may have occurred, but the authors did state that differences between the groups would be minimised by the randomisation process. The authors did not clarify why only a 1-year time horizon was considered, apart from the implicit reason of length of follow-up for the RCT. The collection of outcome measures was also highlighted as a possible limitation, with the EQ-5D criticised as not being sensitive enough to capture the health effects of the additional PT, but no information was given about how benefits were valued. A CUA was not undertaken as there was no effect on QoL between the two groups with higher costs for the intervention group, and in the case of no effect the authors suggested that interventions with the lowest cost were the preferred option. However, despite no significant differences reported, the authors could have estimated an ICER based on best information available, and this highlights the continued criticism that few studies are adequately powered to detect a difference in QoL outcomes.

The issue of uncertainty around the ICER was assessed using the bootstrap method. However, although this allowed CIs to be estimated, and reliability confirmed by comparison with the results of the parametric Fieller's method, it did not allow changes in the base-case assumptions to be explicitly examined (e.g. to take into account increased waiting time).

Surgery

Malter and Weinstein

Malter *et al.*²⁸⁶ undertook a review of published studies and estimated the cost-effectiveness of lumbar discectomy for herniated intervertral disc. The study was of 126 patients randomly assigned to medical or surgical treatment for radicular pain unresponsive to conservative therapy and was supplemented by data from a second trial to account for early surgery. Estimates of effectiveness were derived from a survey of 42 surgeons. This US-based study took the perspective of the health payer.

Source of effectiveness data

Effectiveness was defined as the number of QALYs gained with surgical treatment versus medical treatment. The comparator was chemonucleolysis. To determine effectiveness, results from the two trials were adjusted by QoL values obtained in a separate study of 83 subjects reporting an episode of severe back pain. A TTO utility measure was administered to estimate QoL. Mean TTO values were calculated and self-assessed outcomes reported in the trials were weighted by corresponding QoL values. For discectomy, a 2-week postoperative period was included in the base-case model. Benefits were discounted by an annual 5% rate.

Source of resource utilisation and costs

Rates of service utilisations were obtained, from a commercially available database, using data from 2175 patients diagnosed with a herniated disc. Demographic details of these patients were reported as similar to the trial participants. From this database, patients operated within 6 weeks of treatment were defined as surgically treated. Those patients who never underwent surgery and those operated on after 6 weeks were categorised as medically treated. Operation costs for medical patients requiring late surgery were counted as costs of initially choosing medical treatment. Direct costs were not discounted. Direct costs reflected costs for all services related to disc herniation (patient visits, diagnostic tests, procedures and hospitalisations). The quantity–cost boundary adopted was that of the hospital. The estimation of quantities and costs was based on actual data. Costs and rates of service utilisation were derived from MEDSTAT (January 1987–December 1989) and data on 78 patients diagnosed at a health maintenance organisation (HMO). Costs were adjusted to 1993 prices using the medical component of the Consumer Price Index and presented in US dollars (\$). A 10-year time horizon was undertaken.

Summary of cost-effectiveness analysis

A model-based cost-effectiveness analysis was undertaken. Sensitivity analyses were conducted on efficacy ($\pm 25\%$), QoL ($\pm 50\%$) and costs. Additional estimates were obtained from a survey of spine surgeons, who were presented with case scenarios and asked to estimate the probabilities of excellent to poor outcome after surgical or medical treatment. However, these estimates were not reported, but were available on request from the authors. Additional cost estimates were undertaken from 78 patients diagnosed at a HMO. The authors stated that these were designed to estimate the true resource cost and may have reflected the actual costs more accurately than those used in the base-case analysis.

Summary of the findings

Patients treated with surgical discectomy or chemonucleolysis experienced faster improvement than patients treated medically. The probability of a good outcome varied between 0.36 and 0.56 after medical treatment and between 0.64 and 0.70 after discectomy. For a poor outcome, the probability varied between 0.06 and 0.20 after medical treatment and between 0.07 and 0.14 after discectomy. QoL values associated with a good outcome were 0.95, with a fair outcome 0.77, with a poor outcome 0.62 and with a bad outcome 0.5.

During the 10 years after surgery the average surgical patient experienced 8.7 QALYs whereas the average medical patient experienced 8.27 QALYs, with the difference of 0.43 representing the non-discounted improvement in QALYs associated with surgery. Total costs for the 18-month period beginning 6 months before diagnosis, were \$17,020 for the surgical group compared with \$4470 for the medical group. The non-discounted cost-effectiveness ratio of surgical over medical therapy was \$29,200 per QALY. The discounted cost-effectiveness was \$33,900 per QALY. Cost-effectiveness of discectomy remained <\$100,000 as long as surgery produced an incremental quality-adjusted benefit of at least 0.125 years. The authors concluded that, for carefully selected patients with herniated discs, surgical discectomy was a cost-effective treatment with favourable cost-effectiveness results obtained from its effect on QoL coupled with moderate costs.

Critique of Malter and Weinstein

There are key limitations of Malter and Weinstein's study which limit its relevance to current practice. It is a US study, involving a comparator not currently available to the UK NHS. In addition, the effectiveness data were from the 1970s and 1980s; improvements in surgical management may be important, so caution would be needed if attempting to generalise these findings to current management.

Although not reported in accordance with accepted current guidelines, the paper reasonably reported the economic evaluation undertaken. One possible issue was the robustness of the review undertaken, with effectiveness estimates derived from a qualitative synthesis. Effectiveness data were collected from different subjects, combined, then the estimation of benefits was modelled. The reporting of this process was limited; however, the TTO method used to derive the measure of benefits appears to be appropriate.

All costs relevant to the perspective adopted appeared to have been included in the analysis. The authors were unable to assess costs incurred more than 1-year after diagnosis from the MEDSTAT database. A sensitivity analysis was conducted on prices, but not on costs. The authors did make appropriate comparisons of their findings with those from other studies at the time of publication.

van den Hout et al.

van den Hout *et al.*²⁸³ examined the cost-effectiveness of early surgery compared with 6 months of prolonged conservative care, for patients aged 18–65 years with sciatica for 6–12 weeks because of lumbar disc herniation. Economic evaluation was conducted alongside a RCT.

Source of effectiveness data

The source of clinical effectiveness data was a RCT undertaken in nine hospitals in the Netherlands.⁸⁷ Two hundred and eighty-three patients were randomised with 142 patients (mean age 43 ± 10 years; 68% men). Patients were followed up in the trial for 12 months. A CUA was undertaken from the perspectives of the health-care system and society.

Source of resource utilisation and cost data

Costs included the costs of hospital stay, visits to health-care professionals, home care, paid domestic help, informal care, drugs and aids, out-of-pocket expenses as a result of the disc hernia (e.g. swimming) and hours of absenteeism from work. Resource-use data were collected using patient-completed diaries and collected at several time-points over the study period. Nine per cent of patients who did not return resource diaries were equally distributed across the two comparator groups and less likely to have undergone surgery. Correction for selected nonresponse was made by multiple imputation of data on costs from patients in the same group with same surgical status who returned diaries. This did not substantially change the results compared with excluding these patients. For patients who did return cost diaries, the diaries covered 97%, 91%, 83% and 84% at 3, 6, 9 and 12 months respectively. For periods that were not covered, data were imputed from the closest available diary from the same patient.

Hospital costs were obtained following diagnosis using treatment prices available from 75 different centres, excluding the two highest and two lowest prices. Other health-care costs were based on Dutch standard prices. The costs of absenteeism were valued using the human capital approach. All costs were presented in euros and at 2008 Dutch consumer index prices. As a 1-year time horizon was used, costs were not discounted.

Summary of cost-effectiveness analysis

Utilities were obtained from the same patients participating in the RCT, through the administration of the EQ-5D (US and UK), the SF-6D (derived from the SF-36) and the VAS. Utilities were derived at several time points from baselines to 52 weeks after randomisation. Missing data were present in 4%, 5% and 5% of the EQ-5D, SF-36 and VAS, respectively, and inputted using the rounded average within the same randomisation group at the same time. QALYs were derived, using the area under the curve (AUC) method, for each separate quarter of the year after randomisation and during the entire year as the summary benefit measure.

Uncertainty was addressed by calculating CIs around the cost–utility ratios. Cost-effective acceptability curves were presented. Sensitivity analysis was carried out on the different utility measures and on the included cost categories using a health-care or societal perspective.

Summary of the findings

Over 12 months, the differences in QALYs and all four utility measures during all four quarters were consistently more favourable after early surgery. The differences in QALYs reported according to the utility measure used were UK EQ-5D 0.044 (95% CI 0.0005 to 0.083), US EQ-5D 0.032 (95% CI 0.005 to 0.059), SF-6D 0.024 (95% CI 0.003 to 0.046) and VAS 0.032 (95% CI –0.003 to 0.066).

From the perspective of the health-care system, total health-care costs remained significantly higher than the costs of prolonged conservative care, with a difference in costs of \in 1819 (95% CI \in 842 to \in 2790) per patient. Total societal costs were $-\in$ 12 (95% CI $-\in$ 4029 to \in 4006): slightly in favour of early surgery. The probability that early surgery is cost-effective compared with conservative care varies with willingness to pay. From a societal perspective it was 76% at \in 40,000 per QALY and was 87% at \in 80,000 per QALY. Smaller differences were seen with other utility measures.

From the health-care perspective, according to the UK EQ-5D and US EQ-5D, the incremental cost per QALY gained with early surgery was estimated at €41,000 (95% CI €14,000 to €430,000) and €57,000 (95% CI €19,000 to €436,000), respectively.

The authors concluded that faster recovery from sciatica makes early surgery more cost-effective than prolonged conservative care. The estimated differences in health-care costs were acceptable and were compensated for by the difference in absenteeism from work. For a 'willingness-to-pay' ceiling ratio of €40,000 or more per QALY, early surgery need not be withheld for economic reasons.

Critique of van den Hout et al.

The source of economic data, methodology and interpretation of findings from this study were generally of good quality in this well-presented paper.

The economic evaluation was performed alongside a RCT, so selection bias was unlikely with comparable clinical, demographic and economic characteristics at baseline. The comparators were well defined and justified on the basis that prolonged conservative care is often advocated with no evidence available on the optimal timing of disc surgery.

There were clear inclusion criteria, robust power calculation and analysis undertaken using ITT principles. The internal validity of the study underpinning the economic evaluation was good. One of the strengths of the paper was the considered approach taken to the instruments used to derive utilities. In the absence of a condition-specific measure of health utility, three different generic instruments were used to measure patient preferences, which were compared in a sensitivity analysis.

Costs were considered within the two perspectives. Although there are inherent difficulties associated with the collection of resource data using patient diaries, adherence was high and, where necessary, appropriate analysis was undertaken to account for missing data. A detailed breakdown of costs was presented in the paper including sources of data, price year and statistical analysis. A limitation of the paper, which was clearly acknowledged by the authors, was the considerable variation depending on the method used for assigning costs.

Cost and benefits were appropriately analysed using an ICER. These were clearly presented. Uncertainty was addressed by calculating CIs; however, these were extremely wide. The authors did caution about the limitation of this study owing to the particular characteristics of the Dutch health-care system, citing a high rate of surgery, quicker waiting times and legislation which protects employees resulting in higher absenteeism, but not necessarily lower productivity.

Other limitations acknowledged were the 1-year time horizon for the study; a longer time horizon would have reduced statistical power and the clinical evaluation showed no differences after year 1. Another limitation was that patients were inevitably aware of the randomised group they were in; their reported utilities and costs may have been influenced by their preference for treatment. A final limitation identified was that 40% of patients randomised to receive prolonged conservative care underwent disc surgery at some time, although this was similar to other reported studies. The authors stated that this was an expected clinical consequence, as the study compared two different management strategies and that persistent or increasing symptoms that caused some patients to cross over should be part of the economic evaluation.

Tosteson et al.

Tosteson *et al.*²⁸² reported a cost-effectiveness analysis based on data derived from the pooled analysis of the SPORT randomised and observational cohorts, based in the USA. The interventions compared were standard open laminectomy, laminectomy with removal of herniation and examination of the involved nerve root, and non-operative treatment, defined as usual care chosen individually by patients and physicians. Participants were aged \geq 18 years, diagnosed with herniated intervertebral disc and confirmed as surgical candidates with a symptom history of at least 6 weeks.

Source of effectiveness data

Cost-effectiveness analysis was based on data from 1191 participants, including 775 who underwent surgery and 416 who were treated non-operatively for the entire follow-up period of 2 years. Clinical effectiveness was evaluated using QALYs at baseline, 6 weeks and 3, 6, 12 and 24 months. Health-utility values were obtained using the EQ-5D with US scoring. Time-weighted sums of EQ-5D values, adjusted to the overall mean baseline health-state value, provided the estimate of QALYs for each treatment group. CEA was based on the perspective of the health insurer and society. At baseline, differences in patient demographic and clinical status were noted. Surgical patients were significantly younger, more likely to work full-time and to receive or be in receipt of social security compensation. Clinically, surgical patients were more likely to have L5–S1 (lumbar segment 5 to sacral segment 1) herniation, worse bodily pain, physical function, mental health and ODI and EQ-5D scores compared with non-operative patients.

Source of resource utilisation and cost data

Costs were collected on health-care costs (visits to health-care professionals, diagnostic tests, other health-care services, medications and surgery, including repeat surgery costs). Other costs included lost productivity, measured as missed work, unpaid caregiving time and missed housekeeping. Resource-use data were collected at each follow-up visit for health-care costs. A nurse-administered survey collected detail on medication usage. Recall time for self-reports of resource utilisation and time away from work/usual activities were 6 weeks for the 6-week and 3-month visits. For all other times a 1-month recall was used. Participants were provided with a diary to assist in tracking resource utilisation and missed work/housekeeping days.

Direct medical costs were estimated by multiplying patient-reported medical resource use by unit costs for each cost component. These were presented in the paper. Unit costs for office visits, hospitalisation, diagnostic test and procedures are based on 2004 Medicare national allowable payment amounts and medication prices on 2004 Red Book prices.²⁸⁷ Costs were adjusted for inflation, expressed in 2004 US dollars with a 3% annual discount rate used in the analysis of costs and QALYs. The differences in surgical costs were considered in terms of the procedure performed and the cost of intraoperative complications, which determined their diagnostic-related group (DRG). This was handled in the following manner: (1) a cost approximating the value paid by non-Medicare insurers was estimated to be 70% of the mean amount billed to Medicare in 2004; and (2) the observed 2004 Medicare mean total DRG price was used to reflect hospital-related surgery costs population aged >65 years. Surgeons' costs were based on 2004 Medicare amounts; anaesthesiology costs were estimated using operative time with a fixed amount added if an intraoperative complications occurred. For non-spine-related hospitalisations, costs were based on the DRG and priced using mean observed Medicare prices in 2004 for each admission.

Loss of productivity costs due to spine-related problems were calculated by recording missed days of work (for those employed) and missed homemaking days. Use of unpaid caregivers (including spousal care given) were obtained and costs were estimated using the standard human capital approach; for work days lost this was estimated by multiplying change in hours worked by the gross of tax wage rate on self-reported wages at study entry. For homemaking and caregiving these were valued using the average wage plus non-health benefits for individuals aged \leq 35 years.

Summary of cost-effectiveness

Owing to the high rates of non-adherence in the original randomised and observational cohorts, the two cohorts were combined and analysed according to treatment received using regression modelling of longitudinal data via generalised estimating equations. Separate models were fitted for EQ-5D and 30-day cost rates; measured at 6 weeks and 3, 6, 12 and 24 months. Cost rates were based on reported utilisation rates at each time period taking into account the recall period used.

Outcomes were assigned to the surgical group with follow-up times measured from the surgery date. To take into account the windows for scheduled visits and crossover, the actual time of the outcome assessment varied. This was included as adjusting variables in the longitudinal variables. To adjust for potential confounding baselines, variables associated with missing data or treatment received were included as covariates.

Based on the adjusted mean differences in EQ-5D from the longitudinal regression, an AUC/ time-weighted average was undertaken to estimate QALY differences between surgical and non-operative costs, adjusted to a common baseline value. ICER CIs were estimated using bootstrapping methods. Sensitivity analyses were undertaken to consider the impact of limiting costs included in the analysis to direct medical cost or direct medical costs plus costs of work loss for those employed.

Summary of the findings

Mean health scores improved over time for both groups of patients. Total mean discounted QALYs were 1.64 (95% CI 1.62 to 1.67) for surgical patients and 1.44 (95% CI 1.40 to 1.47) for non-operative patients, a difference of 0.21 (95% CI 0.16 to 0.25).

Ninety-six per cent of surgical procedures were back and neck without complications (DRG 500) with a mean cost of \$12,754 (95% CI \$12,740 to \$12,760). Three per cent had complications (DRG 499) with mean costs estimated at \$19,063 (95% CI \$18,960 to \$19,160). Repeat surgery occurred in 6.8% of surgical patients with a mean cost of \$28,019 (95% CI \$19,950 to \$26,730).* Total mean costs were \$27,273 (95% CI \$26,009 to \$28,644) for surgical patients and \$13,135 (95% CI \$11,244 to \$14,902) for non-operative patients. Total direct costs were \$20,237 (95% CI \$19,314 to \$21,160) for surgery and \$5804 (95% CI \$4639 to \$6969) for non-operative patients. Total loss of productivity costs were \$7089 (95% CI \$6155 to \$8022) for surgical patients and \$7399 (95% CI \$6221 to \$8577) for non-operative costs. Over the 2-year period, indirect costs were highest following the first 6 weeks among those undergoing surgery. Mean indirect costs for non-operative patients were higher over time than for surgically treated patients.

When all costs were considered, the cost per QALY gained for surgical treatment relative to non-operative care in the general population was \$69,403 (95% CI \$4923 to \$94,999). For those aged \geq 65 years, the cost per QALY gained decreased to \$34,355 (95% CI \$20,419 to \$25,512).* Limiting costs to direct costs alone for general population (\$72,181, 95% CI \$56,473 to \$92,394) and Medicare (\$37,285, 95% CI \$28,364 to \$48,993) or direct costs with lost work days (general population \$77,300, 95% CI \$60,009 to \$99,544) or Medicare (\$42,111, 95% CI \$30,976 to \$56,284) had little change. This also had little impact on the ICER, which was estimated at \$33,176 (95% CI \$18,348 to \$54,157) under Medicare pricing.

The authors concluded that surgery for intervertabral disc herniation was moderately costeffective over 2 years, but expressed caution about the different values for surgery according to the method used for assigning surgical costs.

*There was obviously an error in the published paper for the figures, but no erratum could be found; therefore, we do not know whether it is the mean estimate or the CI that is correct.

Critique of Tosteson et al.

The approach and interpretation of the data and findings in the paper appeared to be of good quality. Efforts were made by the authors to capture the different resource costs associated with different surgery, and also indirect costs. The justifications for taking into account the high non-adherence rates and the variations encountered during follow-up (e.g. missed visits, delaying surgery, timing of assessment and confounding variables) were well explained.

The rationale for the study is based upon critiquing the findings from Malter and Weinstein's study.²⁸⁶ In this paper, the comparators could be better described. The type of surgical technique
was not controlled for. There is also little description of what constituted non-operative care beyond 'usual care chosen individually by patients and physicians'.

The data were derived from two cohorts of patients: randomised and observational. The demographics of the cohorts showed significant differences. Although these were considered in the analysis, there was little interpretation beyond a descriptive analysis of these differences. Possible reasons for the decision to have surgery (e.g. surgical patients were younger, less likely to be working full-time or to be receiving or have applied for compensation, and generally had worse clinical signs and symptoms) may have resulted in worse outcomes, which in turn influenced QALYs.

The authors considered resource usage. However, the limitations of using patients' self-reporting of resource use are referred to. The paper mentions the data collection approaches to obtain patient-reported data, but provides little information on how reliable or valid the data were. Recall bias is a potential concern, and the authors attempted to minimise this by limiting the recall window to 6 weeks after early visits and 1 month after annual visits. The authors expressed reasonable confidence that chronic problems were captured as they incurred ongoing costs, and that large costs including hospitalisation and repeat surgery were not limited by the recall period. However, some acute costs could have been missed and the small but important biases when reporting indirect costs may be a factor to take into account. However, it would seem likely this bias was applicable to both groups. The authors considered better ways of capturing resource costs, e.g. linking with electronic billing records, but this would have been likely to have biased cost ascertainment with near-complete capture of surgery compared with non-operative care.

Epidural steroids

Price et al.

Price *et al.*¹⁷³ undertook a multicentre, double-blinded RCT of ESIs versus placebo in 228 patients with clinically diagnosed unilateral sciatica aged between 18 and 70 years who had duration of symptoms between 4 weeks and 18 months. The justification for the study was that, although 45,938 ESIs were performed in the NHS in 2002–3, there was a lack of evidence of their benefit, with safety and cost-effectiveness not previously evaluated.

Source of effectiveness data

The intervention was up to three ESIs compared with normal saline. The primary outcome was the ODI with measures of pain, physical and psychological function collected alongside objective measures of sciatic root irritation, neurological deficit and procedural side effects. QoL was determined using the SF-36.

Source of resource utilisation and cost data

A pilot was undertaken to inform the data collection method. Resource-use data were collected using an instrument completed by all clinical staff which recorded their time spent on patient consultation, aiding the patient before or after the consultation, the time associated with patient administration for all patients presenting with sciatica not included in the trial, pathology tests and imaging. Data were collected across all three centres during July–October 2000. Costs of initial radiology and pathology, if not already performed by the referring centre, were included. Analgesic costs were examined and assumed not to differ between the two groups, so were not considered in the economic analysis.

Cost data were used to calculate a cost per patient for treating sciatica with epidural injections from the perspective of health provider and purchaser. An average cost per patient was based on two management practices. Under each management practice it was assumed that patients had an

initial consultation and follow-up. Owing to the short time horizon when costs and benefits were incurred, discounting was not performed.

Summary of cost-effectiveness analysis

Cost-effectiveness was undertaken from the perspective of the health provider and purchaser (NHS).

QALYS were derived from SF-6D health-utility scores using SF-36 raw data by the Brazier *et al.*²⁸⁸ technique. CUA was undertaken using the standard gamble (SG) method to derive incremental cost per QALY ratios for managing a patient with an ESI. Sensitivity analysis was undertaken to explore how cost estimates changed, given the assumptions that underlay resources, resource-base costs were relaxed. Sensitivity analysis was not undertaken for purchaser costs.

Summary of the findings

The study found ESIs conferred a short-term benefit only. The resource savings could be substantial even with a modest change to treatment. For example (from the purchasers' perspective), the saving from moving from an assumed model of current pragmatic practice (maximum of three ESIs) to a patient management strategy suggested by the trial (one ESI) would represent a saving of £16,505,700 in the sector.

The estimated average cost per patient treated from the provider's perspective was £265.30 per patient for the trial protocol and £152.80 per patient assuming a management strategy based on trial costs. Using NHS recharge cost from the purchaser's perspective, the estimated average cost was £2102 per patient to deliver treatment based on the trial protocol and £992 per patient for one epidural injection, based on the trial results.

The incremental analysis is shown in *Table 166*.

To obtain an improvement at 3 weeks in one patient based on the trial protocol is $\pounds 16,816-23,963$ [depending on number needed to treat (NNT) assumed (8–11.4)], or one epidural to improvement in one patient at 3 weeks is $\pounds 936-11,306$.

In the sensitivity analysis, relaxation of the base-case assumptions of labour time, using the maximum recorded time for nurses and clinicians, more than doubled the average patient cost under each management strategy. Changing from day case to overnight stay also increased average patient costs. Assuming that QALYs remain unchanged, the effect would be to increase the cost–utility ratio further. The authors concluded that although ESIs are relatively safe, they confer only transient benefits in symptoms and self-reported function in a small group of patients

Perspective	Trial protocol (up to three ESIs)	Strategy based on trial results (one ESI)			
Provider					
Incremental cost (£)	265.30	152.80			
Incremental QALY	0.0059350	25,745.68			
Cost per benefit gain (£)	44,701.11				
Purchaser					
Incremental cost (£)	2102	992			
Cost per benefit gain (£)	354,171.65	167,144.76			

TABLE 166 Incremental analysis from Price et al.¹⁷³

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

with sciatica at substantial costs. ESIs failed the QALY threshold recommended by NICE and do not represent good value for money if NICE recommendations are followed.

Critique of Price et al.

Reporting of the economic evaluation conforms to accepted guidelines and is presented in detail. The authors recognised the limitations of the pragmatic study design and attempted to overcome this through their recruitment strategy. The intention was to compare epidural corticosteroid injections with placebo. The duration of symptoms varied from 4 weeks to 18 months, with patients who had previous back surgery excluded. There was a clear acknowledgement that the intention was to consider only patients who presented with sciatica at the point of referral to secondary care, and for the economic analysis a standard package of care was assumed. Costs associated with this package were not considered, as it was assumed that these would be incurred regardless of whether or not the patient received an epidural. Costs of health-service utilisation after week 52 were not included as no significant difference was found. There was a variability in resource usage across the three centres, reflecting the persistent limitation of a lack of clinical consensus in the management of sciatica.

The perspective taken in the economic evaluation was clearly defined and resource data appeared to have been systematically collected across the three centres. Direct costs were appropriately collected based on the perspective chosen. Indirect costs were not obtained, as it was argued that inclusion of indirect costs could overstate potential costs savings and that such savings were not relevant to resource allocation decisions. The authors clearly stated that resource data did not reflect resources expended in the trial per se, but represented the costs to normal practice.

Where differences occurred, these have been highlighted in the study. One of the most notable differences was the difference in clinicians' and nurses' time across the three centres, which probably reflected differences in practice and culture rather than marked differences in the quality of patient care. Although the justification of staff costs were made explicit, several resource costs appeared to have been generalised across several categories.

Cost–utility analysis was clearly presented. SF-6D scores were derived from the SF-36 using an established technique with SG scores calculated, assuming the trial protocol of three injections. The authors note the variability in the number in each sample, so average SG score were derived for patients with observations for all visits up to week 12 to correct for possible sample bias. One of the possible issues was the lack of sensitivity of this generic measure to detect small but important changes that may have affected the findings of limited changes in QoL. QALYs were derived and benefits were appropriately analysed using an incremental analysis.

Cost per QALY gained to the provider using a patient management strategy administering only one epidural injection. These results assumed that gain in QALY calculated would approximate that under a patient management strategy based on the trial results (one ESI). This was not considered an unreasonable assumption by the authors as change in SG score after week 3 was lower in the active group than the placebo group. However, only 21 patients received one injection to confirm this from the clinical data. Costs derived using NNT recognised the fact that ESI was compared with placebo and may therefore increase NNT and subsequent costs.

Sensitivity analysis was appropriately carried out to take into account how costs would change if base-case assumptions were relaxed. These examined changes in variation of clinical labour practices and resource use. The base-case assumption had implied that patients would be treated as day cases, so this assumption was changed. However, in practice this was felt to be too extreme, as in reality there was more likely to be a mix of day-case care and inpatient stay. In both cases, the cost increases. Assuming that QALYs remained unchanged, the effect of this would be to increase the cost–utility ratio further.

As noted by the authors, indirect costs and return to work were not considered. This was justified in terms of the recognised difficulties in using such an outcome measure owing to its definition and collection in a population of mixed age, gender and socioeconomic groups, and that there are many risk factors associated with chronic work disability apart from the level of pain. The study clearly acknowledges that the UK NHS charges differ from the actual resource used. In addition, some strategies for sciatica can be purchased from the private sector. Although these are not true resource costs (in terms of a UK NHS perspective), these may still have an opportunity cost attached. Such costs are substantial for a short period of pain relief. The lack of an individual perspective might limit the interpretation of findings, as a small chance of short-term pain relief (1 in 8 to 1 in 11) based on NNT might be welcomed by some patients. As would be expected, these findings cannot be translated into private clinical practice.

Summary

Although some economic evaluations identified in the systematic review were of reasonable to good quality, they were not able to fully address our research question. Although individual studies raised a number of important issues, it was difficult to draw meaningful conclusions across these studies because of their heterogeneity. Although there was some indication of favourable benefit such as with disc surgery, robust findings could not be reliably drawn. Although an evidence base is emerging, there remains a lack of well-designed economic evaluations. The majority of evaluations were undertaken in conjunction with clinical trials, with a lack of published decisions models. There was considerable variation with each of the studies to the management of patients with sciatica, thus limiting the lessons that can be drawn from current evidence in order to understand the relative cost-effectiveness of current management strategies that reflect current practice. Of particular note is the relevance of these studies to the UK NHS setting.

Chapter 9

Economic evaluation

Introduction

The aim of the economic evaluation was to determine the relative cost-effectiveness of the treatment regimens for managing patients with sciatica. The existing evidence relating to the cost-effectiveness of treatments had a number of limitations, which made it insufficient to inform decision-making regarding the most appropriate management strategy for patients with sciatica. The majority of evaluations were undertaken in conjunction with clinical trials with a lack of published decisions models. There was considerable variation with each of the studies to the management of patients with sciatica, thus limiting the lessons that can be drawn from current evidence in order to understand the relative cost-effectiveness of current management strategies that reflect current practice. Hence, it was necessary to construct a decision-analytic model to address a number of these issues more formally. The model provided a framework for the synthesis of data from the clinical effectiveness, economic reviews and other relevant sources. It was developed to estimate costs from the perspective of the UK NHS^{289,290} and health outcomes in terms of successful treatment and utility gain for all the relevant treatment strategies.

Development of the economic model

The limitations associated with the economic evaluation studies reviewed resulted in a decisionanalytic model being developed to estimate the relative cost-effectiveness of management strategies for patients with sciatica. The heterogeneous nature of the condition, the lack of recognised guidelines for the management of patients with sciatica and considerable variation within practice all made it extremely difficult to develop a model that reflected current practice. Further, the considerable levels of uncertainty surrounding the outcomes from the MTCs restricted the development of a probabilistic model and, therefore, a deterministic model structure was constructed based on information from some of the studies reviewed, the findings from the review of effectiveness and MTCs undertaken, published sources of unit costs and expert opinion from clinicians and other health-care professionals. The decision tree model, highlighted in Figure 112, was used to estimate the expected costs and number of successful treatments over a 12-month period. The perspective employed was that of the UK NHS and out-of-pocket expenditures on over-the-counter (OTC) medications and alternative therapies, for example, have not been included. This has important ramifications as it is assumed that ultimate treatment failures will resort to alternative therapies outside the conventional health-care system, at zero cost to the NHS.

The number of appropriate and relevant health states was informed by the results of the service provider survey (see *Chapter 10, Summary of economic evaluation*), the literature review and from advice within the research team. The cost of managing patients within each state was reflected in the model, although it was not envisaged that patient progression will be seamless, or indeed linear and uni-directional. The structure of the model will reflect this and the probability of movement between health states will be based on the evidence from the literature review, including the distribution around the point estimates. In addition, a sensitivity analysis was





used to assess the impact of 'changes' in the variable estimates, and identify potential areas for future research.

Telephone survey of service providers

A panel of service providers known to the advisory group members were contacted by telephone to determine their usual clinical practice, the usual treatment pathways and whether or not they use a stepped-care approach. This information was used to inform which sequence of treatments to include in the economic model.

Recruitment and access for the telephone survey was undertaken between June 2009 and September 2009. Three local health boards in Wales and six primary care trusts and hospital trusts in England were contacted. As required under the Research Governance Frameworks for England and Wales, permission was sought from each relevant research and development department prior to seeking and recruiting a range of service providers (e.g. spinal surgeons, physiotherapists, service commissioners). The response rate was poor from England, with only three contacts established, predominantly because of difficulty in locating the suitable person with research governance responsibility (e.g. web-based contacts out of date, lack of clarity of specific research governance procedures in primary care trusts). Of these three, two primary care trusts request evidence of NHS Ethical Committee review, despite confirmation from Cardiff University Research Governance Officer that this was deemed audit/service evaluation.

Preliminary informal interviews were conducted with four service providers. However, these generated wide disparities in services (e.g. whether or not an intermediate care service was provided) and interventions offered (e.g. biologicals were not licensed for use and so would not

be considered), resulting in difficulty in using individual service providers to contextualise a generic 'sequence of treatments' in relation to the findings emerging from the systematic review for the purposes of developing the structure for the economic model base case. On review of these difficulties, the economic team felt that the provider survey would be better placed once the MTC analysis was completed in order to 'validate' the interventions/care approaches drawn from the review findings. However, owing to time constraints, these initial interviews were used along with input from the steering group (clinicians on the review team) to build up a staged treatment approach through the assumption of patient progression through primary, intermediate and specialist care.

Previously conducted systematic reviews were used to generate a list of potential treatments for sciatica. During the telephone interviews, clinicians were asked initially what treatments (including combination and sequence of treatments) they usually use, and, afterwards, if prominent treatments identified from previous reviews were not mentioned, they were asked if they have ever considered using these.

Model description

The model was constructed on the assumption that patients presenting with sciatica would be managed through one of three pathways, with alternative treatments within each of the pathways. The first pathway would involve management within primary care and revolve around what might be termed usual care, with use of analgesics and other medications if considered appropriate, to attempt to secure symptom resolution. The treatments included within this pathway therefore include:

- usual care
- education/advice
- activity restriction
- non-opioids
- opioids.

The second pathway would involve a stepped approach and include the use of intermediate treatments – offered in addition to the initial treatments provided within primary care – and provided in secondary care outpatients by multidisciplinary teams including physiotherapists, musculoskeletal physicians, etc. The treatments here include:

- manipulation
- traction
- passive PT
- active PT
- alternative treatments
- biological agents

followed by more invasive treatment (epidural followed by disc surgery if there was no symptom resolution).

The third pathway would involve immediate referral for surgery to alleviate symptoms.

There does not appear to be any data to determine the proportion of patients managed through each pathway and therefore the treatment pathways represent the decision choices available

for GPs and their patients on presentation. Each of the pathways and the treatment variations available within them were compared with 'inactive control', which, according to the findings from the MTC, had a non-zero probability of symptom resolution, but was assumed to cost £0 in the baseline model.

The decision tree model comprised the three treatment pathways: initial treatments, initial treatments followed by intermediate treatments and invasive treatments, and initial treatments followed by disc surgery. The treatment options available within each of the pathways are shown in *Table 167*.

The focus was on the binary outcomes used in the global effect measure from the MTC, representing successful or unsuccessful symptom resolution and with results expressed as incremental cost per patient with symptoms successfully resolved. Analysis also included utility gain associated with symptom resolution, with results expressed as incremental cost per utility gain (over a 12-month period). The heterogeneity of duration effect and not evidence of relapse and recurrence, made it difficult to extend the analysis beyond this time period, with the assumption made that the utility gained following successful treatment would continue for this period.

Dealing with uncertainty

A series of one-way sensitivity analyses were used to address uncertainty in the model. The baseline estimates were based around the best-case scenarios identified for cost and then adjusted to reflect what was regarded as worst-case scenarios. Similarly, the probabilities of success were those determined from the WINBUGS output from the MTC in the baseline model and then adjusted to assess the impact on baseline findings. The utility values for symptoms and symptom remission were also adjusted to determine impact on baseline findings.

Pathways	Treatments
Initial treatments	Inactive control
	Usual care
	Education/advice
	Activity restriction
	Alternative/non-traditional
	Non-opioids
	Opioids
	Biological agents
	Intraoperative interventions
	Spinal cord stimulation
Intermediate treatments	Manipulation
	Traction
	Passive PT
	Active PT
Surgery	Epidural/nerve block
	Disc surgery

 TABLE 167
 Treatments available within pathways

Data sources

The probabilities of success for each treatment were derived from the WINBUGS output from the MTC. The WINBUGS output provides a summary output of the posterior distributions of the relevant parameters. The probability of success is the median value of the posterior distribution of the global effect measure.

The probabilities of success are shown in Table 168.

The costs associated with managing patients with sciatica were based on clinical opinion and derived from published cost sources (and based on 2008–9 prices), as shown in *Table 169*.

Drug treatments were costed according to *British National Formulary* (BNF)²⁹² list prices at the time and calculated based on the dosage and durations in line with documented indications for use. Where required, it was assumed that dosage was based on an adult male of 65 kg. It was also assumed that paracetamol and ibuprofen were OTC medication, NSAIDs and opioids would be prescribed as slow-release tablets. Where multiple products were available, the least expense option was assumed.

It was assumed that each prescription required a GP consultation and that analgesics would be prescribed in accordance with the WHO analgesic ladder; therefore, a stepped approach would be taken to analgesia prescription and consultations would be separate. For non-opioid analgesia, two GP consultations were assumed with three consultations for opioid analgesia. Unit costs of GP consultations were taken from Curtis.²⁹¹ The base-case analysis assumed that analgesics were prescribed separately. NSAIDs and opioids were costed based on single treatment for base-case analysis and multiple analgesics in the sensitivity analysis.

Intermediate care interventions reflected treatments provided in secondary care outpatient settings and included non-traditional and alternative therapies. Unit costs were taken from published *NHS reference costs 2008–2009*.²⁹³ It was assumed that an initial consultant

Pathways	Treatments	Probability of success	Probability of failure
Inactive control		0.3828	0.6172
Initial treatments	Usual care	0.3393	0.6607
	Education/advice	0.5025	0.4975
	Activity restriction	0.4411	0.5589
	Non-opioids	0.6129	0.3871
	Opioids	0.4985	0.5015
Intermediate treatments	Alternative/non-traditional treatments	0.8523	0.1477
	Biological agents	0.9074	0.0926
	Manipulation	0.7518	0.2482
	Traction	0.4277	0.5723
	Passive PT	0.4147	0.5853
	Active PT	0.4043	0.5957
Invasive therapies	Epidural/nerve block	0.6577	0.3423
	Disc surgery	0.6330	0.3670
	Intraoperative interventions	0.7454	0.2546
	Spinal cord stimulation	0.6643	0.3357

TABLE 168 Probabilities of success

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 169 Derivation of costs

Description		Unit cost (£)	Cost (£)	Cost (£)		Source of data	
Primary care							
GP consultation for all patients (within 6 weeks)		35	Average two consultation and three) £70	Average two consultations (varies between one and three) $\pounds70$			
GP consultation for patients referred to intermediate care/surgery (± 6 weeks)		35	Referral usually trigger consultation £105	Referral usually triggered after three consultation £105			
GP contact following di intermediate care/surg	scharge from ery	35	Typically one follow-up analgesia/sick note	to GP for post-operative	Curtis, 2009 ²⁹¹		
Other primary HP conta only)	act (surgery patients	10	Typically one intervention practice nurse	Typically one intervention to remove suture by practice nurse			
Drugs	Description	Dose	Cost (£)	Continuing therapy	Source of data		
Prescriptions							
Paracetamol and/or ibuprofen	Likely to be OTC and patient self- management for all patients, but GP would start as initial/	Paracetamol: dosage 4 g per 24 hours at 6 week prescription = approximately 336 tablets	£3.57 (based on 16 tablets = £0.17)	sed on 16 1 week cost £0.60 BNF N 20.17)			
	continuing therapy in first 6 weeks	lbuprofen: dosage 1600 mg per 24 hours at 6 week prescription = approximately 168 tables (if 400 mg tablets)	£3.74 (based on 84 400 mg tablets = £1.87)	1 week cost £0.62			
Mild opioids (codeine phosphate)	Prescribed if initial analgesia is not working	240 mg per 24 hours at 6 weeks = 168 tablets (if 60 mg tablets)	6-week prescription = $\pounds 1.98$ $\pounds 11.88$ (28 60 mg tablets = $\pounds 1.98$)		BNF No. 59 ²⁹²		
		If added in at second visit – 4 weeks prescription	4 weeks = £7.92				
Other NSAIDs (naproxen)	Prescribed if initial analgesia is not working and/or with mild opioid	1250 mg per 24 hours at 6 weeks = 210 tablets	6 weeks = $\pounds 10.65$ $\pounds 1.78$ (based on 250 mg 28 tablets)		BNF No. 59 ²⁹²		
		4 weeks = 140 tablets	4 weeks = £7.10				
Strong opioids (morphine) –	Often in combination with co-analgesic		£9.61 (MST 30 mg day) for 2 weeks	£4.81	BNF No. 59292		
considered only after no success with mild	amitriptyline or gabapentin		£1.04 (25 mg per day) for 2 weeks	£0.52			
opioids/combinations with NSAIDs			£7.88 for 2 weeks (based on titrating dose from 900 mg towards maximum dose)	£5.52 (based on maximum dose of 3.6 g as maintenance)			
Diazepam	For muscle spasm	6 mg per 24 hours but p.r.n.		£1.96	BNF No. 59292		

assessment would be undertaken with one follow-up, with routine pathology and haematology blood tests and magnetic resonance imaging (MRI) (one area post contrast) performed for diagnosis. Passive and physical active therapies, manipulation and traction were assumed to be a physiotherapist-administered interventions. Biological therapies are unlicensed for use in patients with sciatica in the NHS. Therefore, we assumed a similar dosage and duration in line with documented indications for other spinal conditions such as ankylosing spondylitis. For, the

Intervention	Description	Cost (£)	Source of data
Intermediate care			
Initial consultation	First attendance consultant led (110N)	124 (94–147) – skill mix can vary	NHS reference costs 2008–2009 ²⁹³
	First physiotherapy contact (650A)	55 (53–53)	NHS reference costs 2008–2009 ²⁹³
MRI	RA027b– one area post contrast	195 (142–239)	NHS reference costs 2008–2009 ²⁹³
Pathology	Haematology	3 (2–4)	NHS reference costs
	Biochemistry	1 (1–2)	2008–2009 ²⁹³
Follow-up	Consultant led (110N)	86 (64–99)	NHS reference costs 2008–2009 ²⁹³
	Follow-up physiotherapy	19 (19–19)	NHS reference costs 2008–2009 ²⁹³
Biological therapies	Unlicensed for use in patients with sciatica in the NHS. Therefore, assumed similar dosage and duration in line with documented indications for other spinal conditions such as ankylosing spondylitis		BNF No. 59; ²⁹² NHS reference costs 2008–2009 ²⁹³
	For adalimumab, it was assumed to be a 12-week course with subcutaneous injection by a practice nurse	1647	
	For influximab (worst case), it was assumed to be an i.v. administration in an outpatient setting with prophylactic antihistamine	2219	
Epidural steroids	Outpatient Intermediate pain procedure (AB05Z)	190 (125–205) – up to 3	NHS reference costs 2008–2009 ²⁹³
Procedure		Cost (£)	Source of data
Surgery			
Day-case extradural spinal minor (1) without CC (HCO6c)		980 (570–954)	NHS reference costs 2008–2009 ²⁹³
Inpatient extradural spinal minor (1) without CC (HCO6c), average stay 1.9 days		1657 (1956–2314)	NHS reference costs 2008–2009 ²⁹³
Inpatient extradural spir 3.33 days	nal minor (2) without CC (HCO6c), average stay	2858 (1699–3184)	NHS reference costs 2008–2009 ²⁹³
Follow-up consultant-le	d appointment	86 (64–99)	NHS reference costs 2008–2009 ²⁹³

TABLE 169 Derivation of costs (continued)

BNF, *British National Formulary*, CC, complications and comorbidities; HP, health professional; i.v., intravenous; MST, modified release 12 hourly preparation (morphine salt); p.r.n., as needed.

base-case analysis, it was assumed that a 12-week course of adalimumab would be prescribed for subcutaneous injection by a practice nurse. The sensitivity analysis assumed an intravenous (i.v.) administration of infliximab in an outpatient setting with prophylactic antihistamine.

Intraoperative interventions are extra interventions during disc surgery (e.g. introduction of steroid around exposed nerve root, fat graft covering nerve root, exposed nerve root covered with a gel or membrane to reduce fibrosis, etc.) and are not routinely carried out in the UK NHS and have therefore been excluded. Spinal cord stimulation involves implantation of an electrode and is used only if disc surgery has failed and has therefore also been excluded from the model.

Epidural steroids were assumed to be a consultant outpatient intervention, with one treatment being used in the base-case and three treatments in the sensitivity analysis. Surgical unit costs

were taken from *NHS reference costs 2008–2009.*²⁹³ It was assumed that an initial consultant assessment would be undertaken with one follow-up, with routine pathology and haematology blood tests and MRI (one area post contrast) performed for diagnosis. A follow-up consultant appointment was assumed with one GP follow-up and practice nurse intervention for removal of sutures. Surgery was costed on inpatient extradural spinal minor, (1) with an average length of stay of 1.9 days for base-case and inpatient extradural spinal minor and (2) with an average length of stay of 3.33 days for sensitivity analysis.

The resultant costs are shown in Table 170.

The utility values used in the model for symptoms and symptom resolution were derived from the review of studies. However, the lack of specific utility values for sciatica symptoms pre-intervention and following symptom resolution was problematic. The baseline values were derived from those in van den Hout *et al.*,²⁸³ where the utility value at point of randomisation was 0.37 and the best value obtained was 0.83. The values were adjusted within the sensitivity analysis to compensate for the lack of consensus within the literature.

Cost-effectiveness results

The purpose of the cost-effectiveness assessment was to determine whether or not the additional costs required to increase likelihood of success, over and above usual care, can be regarded as representing value for money. The comparator chosen for this analysis was that of 'inactive control', which counterintuitively is more effective than usual care. Similarly, ultimate failures were assumed to have zero cost to NHS, although the extent to which this is reflected in practice is subject to some debate.

Treatments	Base case (£)	Sensitivity analysis (£)
Initial treatments		
Inactive control	0.00	0.00
Usual care	73.74	80.68
Education/advice	81.00	81.00
Activity restriction	70.00	70.00
Alternative/non-traditional	70.00	70.00
Chemonucleolysis	Not included	Not included
Non-opioids	122.23	129.33
Opioids	130.26	152.71
Biological agents	1646.74	3467.24
Intraoperative interventions (not routine)	1462.74	2218.71
Spinal cord stimulation	1462.74	2218.71
Intermediate treatments		
Manipulation	349.00	578.00
Traction	349.00	578.00
Passive PT	349.00	578.00
Active PT	349.00	578.00
Surgery		
Epidural/nerve block	602.76	990.28
Disc surgery	1433.66	3794.71

TABLE 170 Cost summary

A series of 100 + independent scenarios were considered in which each initial treatment was considered in relation to inactive control; combined with each intermediate treatment followed by epidural/nerve block and then disc surgery; or following an initial treatment, patients were immediately referred for disc surgery. The number of successful outcomes of each treatment regime was combined with the utility of success (0.83) and failure (0.37) to give a total utility measure for each treatment regime. It was assumed that there was no reduction in utility for previous unsuccessful interventions, so a successful outcome was deemed to have utility 0.83 in baseline, regardless of how many interventions were required to achieve success.

The model demonstrated that none of the treatment regimes resulted in 100% success. In terms of initial treatments to alleviate symptoms and wait for symptom resolution, the most successful regime in the first treatment pathway was non-opioids, with a probability of success of 0.613, with treatment being unsuccessful in 39 of every 100 patients treated. When the second treatment pathway was considered, the most successful strategy was non-opioids, followed by biological agents, followed by epidural/nerve block and disc surgery, with a probability of success of 0.996, that is treatment was unsuccessful in three out of every 1000 patients treated.

A conventional approach to examining the cost-effectiveness of the treatment regimes was employed. Firstly, it was determined whether or not any of the regimes was dominated by others with both lower costs and greater probability of success and, secondly, whether or not any of the treatments were subject to extended dominance, with a more expensive treatment regime strategy having a lower ICE than the less expensive regime. This process generated the 'efficiency frontier' of increasingly more costly and more effective regimes for the management of patients with sciatica.

Table 171 highlights the mean cost, probability of success and 12-month utility gain for all possible treatment strategies.

The majority of treatment strategies were excluded on the grounds of strict dominance (the next regime was both more effective and less costly) or extended dominance (a regime has an ICER that is higher than the next more effective regime). The regimes that represent the efficiency frontier are those based on non-opioids and are highlighted in *Table 172*.

In terms of net benefit, four of the five strategies would be regarded as cost-effective if the ceiling ratio for an additional unit of utility gain over a 12-month period was <£5100, and if the ceiling ratio for each additional success was <£2500.

Sensitivity analysis

The use of the highest cost estimates results in a similar overall picture and, although the cost per QALY estimates are higher, the stepped approaches based on non-opioids remain the most cost-effective strategies, as shown in *Table 173*.

When the highest cost scenarios are employed, four of the five strategies are cost-effective if the ceiling ratio for an additional success is $< \pounds 6000$ and $< \pounds 13,100$ for an additional unit of utility gain.

In order for the third pathway – immediate referral for surgery – to feature on the efficiency frontier, the costs associated with the treatment regimen following initial treatment with non-opioids, would have to fall by 49% or the likelihood of success would have to increase by 10 percentage points to 0.95.

TABLE 171 Mean cost, probability of success and utility gain (1000 patients)

inaction 0 383 176 Usual care and ractive PT 334,324 006 279 Usual care and ractive PT 304,324 013 282 Usual care and ractive PT 304,324 622 286 Usual care and manipulation 304,324 636 365 Usual care and manipulation 304,324 602 286 Usual care and manipulation 304,324 602 415 Usual care and manipulation and epidural 537,416 685 398 Usual care and tarenaltweithor traditional treatments and epidural 532,239 671 400 Usual care and anternaltweithor traditional treatments and epidural 1198,618 979 450 Usual care and anternaltweithor traditional treatments and epidural 1198,618 979 450 Usual care and tarenal epidural and disc surgery 721,662 952 438 Usual care and tarenal epidural and surgery 412,055 989 454 Usual care and tarenal epidural and surgery 1,98,718 981 454 Usual care and tarenand epidural	Treatments	Mean cost (£)	No. of successes	Utility gain																																																																																																									
Lesal care 73,740 883 156 Usual care and passive PT 304,324 666 279 Usual care and passive PT 304,324 672 286 Usual care and manipulation 304,324 672 485 Usual care and manipulation 304,324 836 385 Usual care and alternative/non traditional treatments 304,324 836 398 Usual care and manipulation and solural 537,416 688 399 Usual care and manipulation and solural 537,416 688 399 Usual care and manipulation and solural 363,145 967 445 Usual care and manipulation and solural 363,145 967 445 Usual care and anternative/non-traditional treatments and epidural 738,621 952 438 Usual care and alternative/non-traditional treatments and epidural and surgery 721,562 952 456 Usual care and tarenative/non-traditional treatments and epidural and surgery 1292,551 992 456 Usual care and tarenative/non-traditional treatments 990,665 667 307	Inactive control	0	383	176																																																																																																									
Usual care and active PT 304,324 606 279 Usual care and traction 304,324 613 282 Usual care and traction 304,324 636 385 Usual care and traction raditional tradments 304,324 636 385 Usual care and active PT and epidural 541,558 666 398 Usual care and active PT and epidural 537,416 666 399 Usual care and traction and epidural 633,168 644 444 Usual care and traction and epidural 633,168 647 445 Usual care and traction and epidural and disc surgery 731,053 651 438 Usual care and traction and epidural and disc surgery 721,562 652 438 Usual care and traction and epidural and surgery 721,562 652 438 Usual care and traction and epidural and surgery 721,562 652 438 Usual care and traction and epidural and surgery 721,562 652 438 Usual care and traction and epidural and surgery 721,565 667 307 Actively	Usual care	73,740	383	156																																																																																																									
Listal care and passibe P1 304,324 613 282 Usual care and manipulation 304,324 662 286 Usual care and manipulation 304,324 902 415 Usual care and manipulation tratiments 304,324 902 415 Usual care and school PT and epidural 651,614 686 398 Usual care and school PT and epidural 537,416 686 399 Usual care and manipulation and epidural 532,433 871 446 Usual care and manipulation and epidural 333,145 667 445 Usual care and manipulation and epidural 338,145 667 445 Usual care and active PT and epidural and disc surgery 731,033 951 438 Usual care and aneipulation and epidural and surgery 727,562 952 451 Usual care and manipulation and epidural and surgery 12,29,571 952 451 Usual care and manipulation and epidural and surgery 12,29,571 952 456 Usual care and antenative/non-traditional treatments and epidural and surgery 12,29,571 952 45	Usual care and active PT	304,324	606	279																																																																																																									
Issail care and traction 304.324 622 286 Usual care and manipulation 304.324 892 415 Usual care and thermathy-hon-inditional treatments 304.324 892 415 Usual care and ather PT and epidural 541.558 898 398 Usual care and pather PT and epidural 532,239 871 400 Usual care and manipulation and epidural 303,158 944 434 Usual care and manipulation and epidural 303,158 947 445 Usual care and taction and epidural 1,196,618 979 450 Usual care and atsive PT and epidural and disc surgery 738,621 951 433 Usual care and atsive PT and epidural and surgery 721,562 952 438 Usual care and taction and epidural and surgery 1,220,251 992 456 Usual care and taction and epidural and surgery 1,220,251 992 456 Usual care and atterathy-hon-incatitonal treatments and epidural and surgery 1,220,251 992 456 Usual care and atterathy-hon-incatitonand surgery 1,220,251 992 <td>Usual care and passive PT</td> <td>304,324</td> <td>613</td> <td>282</td>	Usual care and passive PT	304,324	613	282																																																																																																									
Lead care and alternative/non-traditional treatments 304,324 806 385 Lauci care and biological agents 314,324 909 432 Lisual care and biological agents 531,558 865 338 Lisual care and passive PT and epidural 537,416 866 399 Lisual care and traction and epidural 532,239 871 400 Lisual care and traction and epidural 403,168 944 434 Usual care and traction and epidural 363,145 967 445 Lisual care and traction and epidural end disc surgery 733,039 951 437 Lisual care and traction and epidural and disc surgery 721,552 952 458 Lisual care and traction and epidural and surgery 422,055 979 451 Lisual care and alternative/hon-tradtional reatments and epidural and surgery 412,005 988 454 Lisual care and distersurgery 1,280,178 982 456 Lisual care and distersurgery 1,280,178 982 456 Lisual care and distersurgery 1,280,178 982 456 <	Usual care and traction	304,324	622	286																																																																																																									
Usual care and biological agents 304,324 902 415 Usual care and biological agents 1,161,741 933 432 Usual care and active PT and epidural 537,416 868 399 Usual care and traction and epidural 532,239 871 400 Usual care and manipulation and epidural 403,168 944 443 Usual care and manipulation and epidural 1,98,618 979 450 Usual care and biological agents and epidural 1,98,618 979 450 Usual care and peidural and disc surgery 731,039 951 437 Usual care and peidural and surgery 721,562 952 438 Usual care and traction and epidural and surgery 1,282,251 992 466 Usual care and disc surgery 1,202,251 992 466 Usual care and biological agents and epidural and surgery 1,282,261 932 466 Usual care and disc surgery 1,203,251 992 466 Usual care and biological agents and epidural 412,0172 758 348 Activity rest	Usual care and manipulation	304,324	836	385																																																																																																									
Usual care and active PT and epidural 541,558 686 399 Usual care and active PT and epidural 543,416 686 399 Usual care and manipulation and epidural 532,416 866 399 Usual care and manipulation and epidural 403,168 947 445 Usual care and traction and epidural 403,168 979 450 Usual care and traction and epidural and dics surgery 731,621 951 437 Usual care and traction and epidural and dics surgery 731,622 952 438 Usual care and manipulation and epidural and surgery 721,562 952 438 Usual care and manipulation and epidural and surgery 428,575 979 451 Usual care and biological agents and epidural and surgery 1,282,81 992 456 Usual care and biological agents and epidural and surgery 1,282,81 992 456 Usual care and biological agents and epidural and surgery 1,282,81 992 456 Usual care and biological agents and epidural and surgery 1,282,81 992 456 Usual care and agent epidural and surge	Usual care and alternative/non-traditional treatments	304,324	902	415																																																																																																									
Usual care and active PT and epidural 541,658 865 389 Usual care and passive PT and epidural 537,416 868 399 Usual care and traction and epidural 532,239 871 440 Usual care and traction and epidural 403,168 944 434 Usual care and atternative/non-traditional treatments and epidural 1,198,618 979 450 Usual care and atternative/non-traditional treatments and epidural and surgery 738,821 951 433 Usual care and atternative/non-traditional treatments and epidural and surgery 721,562 948 454 Usual care and intraction and epidural and surgery 412,005 988 454 Usual care and disc surgery 1,040,172 758 348 Activity restriction and active PT 265,056 667 307 Activity restriction and active PT 265,056 667 313 Activity restriction and active PT 265,056 680 313 Activity restriction and active PT 265,056 801 396 Activity restriction and active PT 265,056 801	Usual care and biological agents	1,161,741	939	432																																																																																																									
Usual care and passive PT and epidural 537,416 668 399 Usual care and traction and epidural 433,168 944 444 Usual care and mainpluation and epidural 363,145 967 445 Usual care and hological aponts and epidural 1,198,618 979 450 Usual care and active PT and epidural and disc surgery 731,622 952 438 Usual care and mainpluation and epidural and surgery 721,562 952 438 Usual care and mainpluation and epidural and surgery 12,202,251 992 456 Usual care and disc surgery 1,204,0172 758 348 Activity restriction 70,000 441 203 Activity restriction and disc surgery 1,040,172 758 348 Activity restriction and tartentive/non-traditional treatments 265,056 667 307 Activity restriction and passive PT 265,056 667 307 Activity restriction and tartentive/non-traditional treatments 265,056 661 398 Activity restriction and tartentive/non-traditional treatments 265,056 <t< td=""><td>Usual care and active PT and epidural</td><td>541,558</td><td>865</td><td>398</td></t<>	Usual care and active PT and epidural	541,558	865	398																																																																																																									
Usual care and traction and epidural532,239671400Usual care and manipulation and epidural403,168944434Usual care and theological agents and epidural1,196,6189794450Usual care and achve PT and epidural and disc surgery731,039951437Usual care and achve PT and epidural and surgery721,626952438Usual care and traction and epidural and surgery721,626952438Usual care and traction and epidural and surgery122,92519924561Usual care and alternative/non-traditional treatments and epidural and surgery1,040,172758348Activity restriction70,0004412034561Usual care and disc surgery1,040,172758348Activity restriction and active PT265,056667310Activity restriction and traction265,056667310Activity restriction and traction265,056667310Activity restriction and traction265,056617310Activity restriction and traction265,056617310Activity restriction and alternative/non-traditional treatments286,056917422Activity restriction and alternative/non-traditional treatments900,363948436Activity restriction and agents348,670953438Activity restriction and alternative/non-traditional treatments and epidural348,670953438Activity restriction and agents349,614452,237<	Usual care and passive PT and epidural	537,416	868	399																																																																																																									
Usual care and manipulation and epidural 403,168 944 434 Usual care and biological agents and epidural 363,145 967 445 Usual care and biological agents and epidural and disc surgery 731,039 951 438 Usual care and manipulation and epidural and disc surgery 731,039 951 438 Usual care and manipulation and epidural and surgery 412,005 988 454 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and biological agents 0,000 441 203 265,056 667 307 Activity restriction and bassive PT 265,056 667 307 265,056 861 366 Activity restriction and manipulation 265,056 861 366 361 366 Activ	Usual care and traction and epidural	532,239	871	400																																																																																																									
Usual care and alternative/non-traditional treatments and epidural 363,145 967 445 Usual care and biological agents and epidural 1,198,618 979 450 Usual care and active PT and epidural and dice surgery 731,039 951 433 Usual care and passive PT and epidural and surgery 721,562 952 438 Usual care and manipulation and epidural and surgery 425,275 979 451 Usual care and alternative/non-traditional treatments and epidural and surgery 1,220,55 978 451 Usual care and disc surgery 1,040,172 758 348 Activity restriction 70,000 441 203 Activity restriction and passive PT 265,056 667 310 Activity restriction and traction 265,056 6861 396 Activity restriction and traction and pasive PT 265,056 6861 396 Activity restriction and basive PT 265,056 861 396 Activity restriction and basive PT and epidural 465,737 886 408 Activity restriction and pasive PT and epidural 465,737	Usual care and manipulation and epidural	403,168	944	434																																																																																																									
Usual care and biological agents and epidural 1,198,618 979 450 Usual care and active PT and epidural and lisc surgery 733,621 951 433 Usual care and taction and epidural and surgery 721,562 952 433 Usual care and traction and epidural and surgery 485,275 979 451 Usual care and alternative/non-traditional treatments and epidural and surgery 1,229,251 992 456 Usual care and disc surgery 1,040,172 758 348 Activity restriction and pasive PT 265,056 667 307 Activity restriction and tactive PT 265,056 668 313 Activity restriction and treatments 265,056 667 307 Activity restriction and manipulation 265,056 861 396 Activity restriction and alternative/non-traditional treatments 265,056 917	Usual care and alternative/non-traditional treatments and epidural	363,145	967	445																																																																																																									
Usual care and active PT and epidural and disc surgery 738,621 951 437 Usual care and passive PT and epidural and disc surgery 721,522 952 438 Usual care and manipulation and epidural and surgery 485,275 979 451 Usual care and alternative/non-traditional treatments and epidural and surgery 1,223,251 992 456 Usual care and alternative/non-traditional treatments and epidural and surgery 1,243,251 992 456 Usual care and disc surgery 1,265,056 667 307 Activity restriction and active PT 265,056 861 396 Activity restriction and active PT and epidural 465,737 886 408 Activity restriction and active PT and epidural 465,737 896 </td <td>Usual care and biological agents and epidural</td> <td>1,198,618</td> <td>979</td> <td>450</td>	Usual care and biological agents and epidural	1,198,618	979	450																																																																																																									
Usual care and passive PT and epidural and disc surgery 731,039 951 438 Usual care and traction and epidural and surgery 721,562 952 438 Usual care and manipulation and epidural and surgery 412,005 998 454 Usual care and altemative/non-traditional treatments and epidural and surgery 1,229,251 992 456 Usual care and disc surgery 1,040,172 758 348 Activity restriction 70,000 441 203 Activity restriction and passive PT 266,056 667 307 Activity restriction and manipulation 266,056 680 313 Activity restriction and manipulation 266,056 681 396 Activity restriction and active PT 266,056 811 396 Activity restriction and abesive PT 266,056 917 422 Activity restriction and abesive PT 266,056 811 396 Activity restriction and abesive PT and epidural 462,737 886 408 Activity restriction and abesive PT and epidural 457,854 891 410 <td>Usual care and active PT and epidural and disc surgery</td> <td>738,621</td> <td>951</td> <td>437</td>	Usual care and active PT and epidural and disc surgery	738,621	951	437																																																																																																									
Usual care and traction and epidural and surgery 721,562 952 438 Usual care and manipulation and epidural and surgery 485,275 979 451 Usual care and alternative/non-traditional treatments and epidural and surgery 1,229,251 992 456 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and disc surgery 1,040,172 758 348 Activity restriction and dactive PT 265,056 667 307 Activity restriction and traction 265,056 661 396 Activity restriction and manipulation 265,056 861 396 Activity restriction and thermative/non-traditional treatments 265,056 817 422 Activity restriction and alternative/non-traditional treatments 265,056 917 422 Activity restriction and alternative/non-traditional treatments 265,056 861 396 Activity restriction and alternative/non-traditional treatments 265,056 917 422 Activity restriction and alternative/non-traditional treatments 960,333 488 408 <	Usual care and passive PT and epidural and disc surgery	731,039	951	438																																																																																																									
Usual care and manipulation and epidural and surgery 485,275 979 451 Usual care and alternative/non-traditional treatments and epidural and surgery 1,229,251 992 456 Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and disc surgery 1,040,172 758 348 Activity restriction and active PT 265,056 667 307 Activity restriction and traction 265,056 667 310 Activity restriction and traction 265,056 673 310 Activity restriction and traction 265,056 861 396 Activity restriction and toilogical agents 265,056 811 396 Activity restriction and toilogical agents 265,056 811 396 Activity restriction and traction 265,056 811 396 Activity restriction and traction 265,056 811 396 Activity restriction and basive PT and epidural 465,737 886 408 Activity restriction and manipulation and epidural and disc surgery 632,437	Usual care and traction and epidural and surgery	721,562	952	438																																																																																																									
Usual care and alternative/non-traditional treatments and epidural and surgery412,005988454Usual care and biological agents and epidural and surgery1,229,251992456Usual care and disc surgery1,040,172758348Activity restriction and othe PT265,056667307Activity restriction and passive PT265,0566680313Activity restriction and manipulation265,056861396Activity restriction and alternative/non-traditional treatments265,056861396Activity restriction and alternative/non-traditional treatments265,056861396Activity restriction and alternative/non-traditional treatments265,056871422Activity restriction and alternative/non-traditional treatments265,056871422Activity restriction and alternative/non-traditional treatments265,056917422Activity restriction and alternative/non-traditional treatments265,056811396Activity restriction and alternative/non-traditional treatments and epidural462,233888408Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and therative/non-traditional treatments and epidural1,021,558946442Activity restriction and alternative/non-traditional treatments and epidural1,021,558959441Activity re	Usual care and manipulation and epidural and surgery	485,275	979	451																																																																																																									
Usual care and biological agents and epidural and surgery 1,229,251 992 456 Usual care and disc surgery 1,040,172 758 348 Activity restriction 70,000 441 203 Activity restriction and active PT 265,056 667 307 Activity restriction and tactive PT 265,056 680 313 Activity restriction and manipulation 265,056 861 396 Activity restriction and active PT and epidural 465,737 886 408 Activity restriction and passive PT and epidural 465,737 886 408 Activity restriction and passive PT and epidural 465,737 886 408 Activity restriction and tactive PT and epidural 465,737 886 408 Activity restriction and talternative/non-traditional treatments and epidural 314,814 972 447 Activity restriction and active PT and epidural 1,021,558 982 452 Activity restriction and active PT and epidural and disc surgery 618,006 960 442 Activity restriction and active PT and epidural and surgery	Usual care and alternative/non-traditional treatments and epidural and surgery	412,005	988	454																																																																																																									
Usual care and disc surgery 1,040,172 758 348 Activity restriction 70,000 441 203 Activity restriction and active PT 265,056 667 307 Activity restriction and passive PT 265,056 6680 313 Activity restriction and manipulation 265,056 680 313 Activity restriction and traction 265,056 861 396 Activity restriction and traction and apeldural treatments 265,056 917 422 Activity restriction and cepidural agents 990,363 948 436 Activity restriction and pejdural 465,737 886 408 Activity restriction and pejdural 465,737 886 408 Activity restriction and terative/non-traditional treatments and epidural 348,870 953 438 Activity restriction and alternative/non-traditional treatments and epidural 1,021,558 982 452 Activity restriction and alternative/non-traditional treatments and epidural 1,021,558 984 441 Activity restriction and alternative/non-traditional treatments and epidural	Usual care and biological agents and epidural and surgery	1,229,251	992	456																																																																																																									
Activity restriction 70,000 441 203 Activity restriction and active PT 265,056 667 307 Activity restriction and passive PT 265,056 673 310 Activity restriction and traction 265,056 680 313 Activity restriction and traction and alternative/non-traditional treatments 265,056 861 396 Activity restriction and alternative/non-traditional treatments 265,056 917 422 Activity restriction and active PT and epidural 465,737 886 408 Activity restriction and passive PT and epidural 465,737 886 408 Activity restriction and manipulation and epidural 457,854 891 410 Activity restriction and manipulation and epidural 457,854 891 410 Activity restriction and manipulation and epidural 1,021,558 962 452 Activity restriction and alternative/non-traditional treatments and epidural 1,021,558 962 452 Activity restriction and passive PT and epidural and disc surgery 626,023 959 441 Activity restriction and alternative/non-traditional treatments and epidural and surgery 418,126	Usual care and disc surgery	1,040,172	758	348																																																																																																									
Activity restriction and active PT 265,056 667 307 Activity restriction and passive PT 265,056 673 310 Activity restriction and traction 265,056 680 313 Activity restriction and manipulation 265,056 861 396 Activity restriction and alternative/non-traditional treatments 265,056 917 422 Activity restriction and biological agents 990,363 948 436 Activity restriction and biological agents 990,363 948 408 Activity restriction and passive PT and epidural 465,737 886 408 Activity restriction and alternative/non-traditional treatments and epidural 348,670 953 433 Activity restriction and alternative/non-traditional treatments and epidural 1,021,558 982 452 Activity restriction and active PT and epidural and disc surgery 626,023 959 441 Activity restriction and manipulation and epidural and surgery 618,006 946 452 Activity restriction and alternative/non-traditional treatments and epidural and surgery 362,146 990 455	Activity restriction	70,000	441	203																																																																																																									
Activity restriction and passive PT 265,056 673 310 Activity restriction and traction 265,056 680 313 Activity restriction and manipulation 265,056 861 396 Activity restriction and alternative/non-traditional treatments 265,056 917 422 Activity restriction and biological agents 990,363 948 436 Activity restriction and active PT and epidural 465,737 886 408 Activity restriction and active PT and epidural 466,737 886 408 Activity restriction and raction and epidural 466,737 886 408 Activity restriction and traction and epidural 466,737 886 408 Activity restriction and traction and epidural 314,810 972 447 Activity restriction and alternative/non-traditional treatments and epidural 1,021,558 982 452 Activity restriction and manipulation and epidural and surgery 626,023 959 441 Activity restriction and manipulation and epidural and surgery 618,006 960 442 Activity restriction and manipulational reatments and epidural and surgery 366,146 990	Activity restriction and active PT	265,056	667	307																																																																																																									
Activity restriction and raction265,056680313Activity restriction and manipulation265,056861396Activity restriction and alternative/non-traditional treatments265,056917422Activity restriction and biological agents990,363948436Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and antipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and apassive PT and epidural and disc surgery618,006960442Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and and epidural and surgery356,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery305,284701323Opioids130,260499229290290290290290Opioids and active PT305,284706325326326326326326Opioids and passive PT305,284701323328326326326326326326326326326 <td>Activity restriction and passive PT</td> <td>265,056</td> <td>673</td> <td>310</td>	Activity restriction and passive PT	265,056	673	310																																																																																																									
Activity restriction and manipulation265,056861396Activity restriction and alternative/non-traditional treatments265,056917422Activity restriction and biological agents990,363948436Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and passive PT and epidural457,854891410Activity restriction and traction and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and passive PT and epidural and surgery418,126983452Activity restriction and passive PT and epidural and surgery366,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery366,146990455Activity restriction and alternative/non-traditional treatments305,284701323Opioids305,284701323323Opioids and active PT305,284706325Opioids and active PT305,284706325Opioids and passive PT305,284<	Activity restriction and traction	265,056	680	313																																																																																																									
Activity restriction and alternative/non-traditional treatments265,056917422Activity restriction and biological agents990,363948436Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and passive PT and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery36,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery130,260499229Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and passive PT305,284713328Opioids and manipulation305,284713328Opioids and manipulation3	Activity restriction and manipulation	265,056	861	396																																																																																																									
Activity restriction and biological agents990,363948436Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and passive PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and passive PT305,284713328Opioids and manipulation305,284766403Opioids and manipulation305,284761429 <tr <tr="">Opioids and manipulation<t< td=""><td>Activity restriction and alternative/non-traditional treatments</td><td>265.056</td><td>917</td><td>422</td></t<></tr> <tr><td>Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and raction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and biological agents and epidural and surgery305,284701323Opioids305,2847063250pioids305,284713328Opioids and passive PT305,2847133280pioids and traction305,284713328Opioids and manipulation305,284713328</td><td>Activity restriction and biological agents</td><td>990,363</td><td>948</td><td>436</td></tr> <tr><td>Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and manipulation and epidural and surgery618,006960442Activity restriction and and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery366,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and disc surgery130,260499229229Opioids130,260499229229305,284701323Opioids and passive PT305,284706325325Opioids and passive PT305,284713328Opioids and traction305,284713328Opioids and traction305,284876403Opioids and traction305,284876403Opioids and treative/non-traditional treatment</td><td>Activity restriction and active PT and epidural</td><td>465.737</td><td>886</td><td>408</td></tr> <tr><td>Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,021,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and manipulation305,284876403Opioids and anternative/non-traditional treatments305,284876403Opioids and traction305,284876403Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926<t< td=""><td>Activity restriction and passive PT and epidural</td><td>462.233</td><td>888</td><td>408</td></t<></td></tr> <tr><td>Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments96,100964429</td><td>Activity restriction and traction and epidural</td><td>457.854</td><td>891</td><td>410</td></tr> <tr><td>Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and hiological agents926</td><td>Activity restriction and manipulation and epidural</td><td>348.670</td><td>953</td><td>438</td></tr> <tr><td>Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and passive PT305,284706325Opioids and passive PT305,284713328Opioids and manipulation305,284713328Opioids and manipulation305,284713328Opioids and alternative/non-traditional treatments966100954Opioids and alternative/non-traditional treatments965100954</td><td>Activity restriction and alternative/non-traditional treatments and epidural</td><td>314.814</td><td>972</td><td>447</td></tr> <tr><td>Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and passive PT305,284926426Opioids and passive Area305,284926426Opioids and traction305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Activity restriction and biological agents and epidural</td><td>1.021.558</td><td>982</td><td>452</td></tr> <tr><td>Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and passive PT305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426</td><td>Activity restriction and active PT and epidural and disc surgery</td><td>632.437</td><td>958</td><td>441</td></tr> <tr><td>Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and pagents956,100954430</td><td>Activity restriction and passive PT and epidural and disc surgery</td><td>626.023</td><td>959</td><td>441</td></tr> <tr><td>Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Activity restriction and traction and epidural and surgery</td><td>618.006</td><td>960</td><td>442</td></tr> <tr><td>Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Activity restriction and manipulation and epidural and surgery</td><td>418.126</td><td>983</td><td>452</td></tr> <tr><td>Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Activity restriction and alternative/non-traditional treatments and epidural and surgery</td><td>356.146</td><td>990</td><td>455</td></tr> <tr><td>Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and historical agents956,100954430</td><td>Activity restriction and biological agents and epidural and surgery</td><td>1.047.471</td><td>993</td><td>457</td></tr> <tr><td>Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Activity restriction and disc surgery</td><td>887.525</td><td>795</td><td>366</td></tr> <tr><td>Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Onioids</td><td>130,260</td><td>499</td><td>229</td></tr> <tr><td>Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Opioids and active PT</td><td>305,284</td><td>701</td><td>323</td></tr> <tr><td>Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430</td><td>Opioids and passive PT</td><td>305,284</td><td>706</td><td>325</td></tr> <tr><td>Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954439</td><td>Opioids and traction</td><td>305,284</td><td>713</td><td>328</td></tr> <tr><td>Opioids and alternative/non-traditional treatments 305,284 926 426 Opioids and biological agents 956,100 954 439</td><td>Onioids and manipulation</td><td>305 284</td><td>876</td><td>403</td></tr> <tr><td>Opioide and alconautorino 000,204 020 420 Onioids and biological agents 056 100 054 420</td><td>Onioids and alternative/non-traditional treatments</td><td>305 284</td><td>926</td><td>426</td></tr> <tr><td></td><td>Onioids and biological agents</td><td>956 100</td><td>954</td><td>439</td></tr>	Activity restriction and alternative/non-traditional treatments	265.056	917	422	Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and raction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and biological agents and epidural and surgery305,284701323Opioids305,2847063250pioids305,284713328Opioids and passive PT305,2847133280pioids and traction305,284713328Opioids and manipulation305,284713328	Activity restriction and biological agents	990,363	948	436	Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and manipulation and epidural and surgery618,006960442Activity restriction and and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery366,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and disc surgery130,260499229229Opioids130,260499229229305,284701323Opioids and passive PT305,284706325325Opioids and passive PT305,284713328Opioids and traction305,284713328Opioids and traction305,284876403Opioids and traction305,284876403Opioids and treative/non-traditional treatment	Activity restriction and active PT and epidural	465.737	886	408	Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,021,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and manipulation305,284876403Opioids and anternative/non-traditional treatments305,284876403Opioids and traction305,284876403Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926 <t< td=""><td>Activity restriction and passive PT and epidural</td><td>462.233</td><td>888</td><td>408</td></t<>	Activity restriction and passive PT and epidural	462.233	888	408	Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments96,100964429	Activity restriction and traction and epidural	457.854	891	410	Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and hiological agents926	Activity restriction and manipulation and epidural	348.670	953	438	Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and passive PT305,284706325Opioids and passive PT305,284713328Opioids and manipulation305,284713328Opioids and manipulation305,284713328Opioids and alternative/non-traditional treatments966100954Opioids and alternative/non-traditional treatments965100954	Activity restriction and alternative/non-traditional treatments and epidural	314.814	972	447	Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and passive PT305,284926426Opioids and passive Area305,284926426Opioids and traction305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and biological agents and epidural	1.021.558	982	452	Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and passive PT305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426	Activity restriction and active PT and epidural and disc surgery	632.437	958	441	Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and pagents956,100954430	Activity restriction and passive PT and epidural and disc surgery	626.023	959	441	Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and traction and epidural and surgery	618.006	960	442	Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and manipulation and epidural and surgery	418.126	983	452	Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and alternative/non-traditional treatments and epidural and surgery	356.146	990	455	Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and historical agents956,100954430	Activity restriction and biological agents and epidural and surgery	1.047.471	993	457	Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and disc surgery	887.525	795	366	Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Onioids	130,260	499	229	Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Opioids and active PT	305,284	701	323	Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Opioids and passive PT	305,284	706	325	Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954439	Opioids and traction	305,284	713	328	Opioids and alternative/non-traditional treatments 305,284 926 426 Opioids and biological agents 956,100 954 439	Onioids and manipulation	305 284	876	403	Opioide and alconautorino 000,204 020 420 Onioids and biological agents 056 100 054 420	Onioids and alternative/non-traditional treatments	305 284	926	426		Onioids and biological agents	956 100	954	439
Activity restriction and alternative/non-traditional treatments	265.056	917	422																																																																																																										
Activity restriction and active PT and epidural465,737886408Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and raction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and biological agents and epidural and surgery305,284701323Opioids305,2847063250pioids305,284713328Opioids and passive PT305,2847133280pioids and traction305,284713328Opioids and manipulation305,284713328	Activity restriction and biological agents	990,363	948	436																																																																																																									
Activity restriction and passive PT and epidural462,233888408Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and alternative/non-traditional treatments and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and manipulation and epidural and surgery618,006960442Activity restriction and and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery366,146990455Activity restriction and alternative/non-traditional treatments and epidural and surgery1,047,471993457Activity restriction and disc surgery130,260499229229Opioids130,260499229229305,284701323Opioids and passive PT305,284706325325Opioids and passive PT305,284713328Opioids and traction305,284713328Opioids and traction305,284876403Opioids and traction305,284876403Opioids and treative/non-traditional treatment	Activity restriction and active PT and epidural	465.737	886	408																																																																																																									
Activity restriction and traction and epidural457,854891410Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,047,471993457Activity restriction and disc surgery1,021,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and manipulation305,284876403Opioids and anternative/non-traditional treatments305,284876403Opioids and traction305,284876403Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926 <t< td=""><td>Activity restriction and passive PT and epidural</td><td>462.233</td><td>888</td><td>408</td></t<>	Activity restriction and passive PT and epidural	462.233	888	408																																																																																																									
Activity restriction and manipulation and epidural348,670953438Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments96,100964429	Activity restriction and traction and epidural	457.854	891	410																																																																																																									
Activity restriction and alternative/non-traditional treatments and epidural314,814972447Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and hiological agents926	Activity restriction and manipulation and epidural	348.670	953	438																																																																																																									
Activity restriction and biological agents and epidural1,021,558982452Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and passive PT and epidural and surgery618,006960442Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and passive PT305,284706325Opioids and passive PT305,284713328Opioids and manipulation305,284713328Opioids and manipulation305,284713328Opioids and alternative/non-traditional treatments966100954Opioids and alternative/non-traditional treatments965100954	Activity restriction and alternative/non-traditional treatments and epidural	314.814	972	447																																																																																																									
Activity restriction and active PT and epidural and disc surgery632,437958441Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and passive PT305,284926426Opioids and passive Area305,284926426Opioids and traction305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and biological agents and epidural	1.021.558	982	452																																																																																																									
Activity restriction and passive PT and epidural and disc surgery626,023959441Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and passive PT305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426	Activity restriction and active PT and epidural and disc surgery	632.437	958	441																																																																																																									
Activity restriction and traction and epidural and surgery618,006960442Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926426Opioids and alternative/non-traditional treatments305,284926426Opioids and pagents956,100954430	Activity restriction and passive PT and epidural and disc surgery	626.023	959	441																																																																																																									
Activity restriction and manipulation and epidural and surgery418,126983452Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284713328Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and traction and epidural and surgery	618.006	960	442																																																																																																									
Activity restriction and alternative/non-traditional treatments and epidural and surgery356,146990455Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and manipulation and epidural and surgery	418.126	983	452																																																																																																									
Activity restriction and biological agents and epidural and surgery1,047,471993457Activity restriction and biological agents and epidural and surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and alternative/non-traditional treatments and epidural and surgery	356.146	990	455																																																																																																									
Activity restriction and disc surgery887,525795366Opioids130,260499229Opioids and active PT305,284701323Opioids and traction305,284706325Opioids and traction305,284713328Opioids and alternative/non-traditional treatments305,284926403Opioids and historical agents956,100954430	Activity restriction and biological agents and epidural and surgery	1.047.471	993	457																																																																																																									
Opioids130,260499229Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and traction305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Activity restriction and disc surgery	887.525	795	366																																																																																																									
Opioids and active PT305,284701323Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Onioids	130,260	499	229																																																																																																									
Opioids and passive PT305,284706325Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Opioids and active PT	305,284	701	323																																																																																																									
Opioids and traction305,284713328Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954430	Opioids and passive PT	305,284	706	325																																																																																																									
Opioids and manipulation305,284876403Opioids and alternative/non-traditional treatments305,284926426Opioids and biological agents956,100954439	Opioids and traction	305,284	713	328																																																																																																									
Opioids and alternative/non-traditional treatments 305,284 926 426 Opioids and biological agents 956,100 954 439	Onioids and manipulation	305 284	876	403																																																																																																									
Opioide and alconautorino 000,204 020 420 Onioids and biological agents 056 100 054 420	Onioids and alternative/non-traditional treatments	305 284	926	426																																																																																																									
	Onioids and biological agents	956 100	954	439																																																																																																									

395

TABLE 171 Mean cost, probability of success and utility gain (1000 patients) (continued)

Treatments	Mean cost (£)	No. of successes	Utility gain
Opioids and active PT and epidural	485,354	898	413
Opioids and passive PT and epidural	482,210	900	414
Opioids and traction and epidural	478,281	902	415
Opioids and manipulation and epidural	380,310	957	440
Opioids and alternative/non-traditional treatments and epidural	349,931	975	448
Opioids and biological agents and epidural	984,092	984	453
Opioids and active PT and epidural and disc surgery	634,934	962	443
Opioids and passive PT and epidural and disc surgery	629,179	963	443
Opioids and traction and epidural and surgery	621,985	964	443
Opioids and manipulation and epidural and surgery	442,633	984	453
Opioids and alternative/non-traditional treatments and epidural and surgery	387,018	991	456
Opioids and biological agents and epidural and surgery	1,007,343	994	457
Opioids and disc surgery	863,824	816	375
Education and advice	81,000	503	231
Education and advice and active PT	254,628	704	324
Education and advice and passive PT	254,628	709	326
Education and advice and traction	254,628	715	329
Education and advice and manipulation	254,628	877	403
Education and advice and alternative/non-traditional treatments	254,628	927	426
Education and advice and biological agents	900,253	954	439
Education and advice and active PT and epidural	433,262	899	413
Education and advice and passive PT and epidural	430,143	900	414
Education and advice and traction and epidural	426,245	903	415
Education and advice and manipulation and epidural	329,056	958	441
Education and advice and alternative/non-traditional treatments and epidural	298,919	975	448
Education and advice and biological agents and epidural	928,021	984	453
Education and advice and active PT and epidural and disc surgery	581,649	963	443
Education and advice and passive PT and epidural and disc surgery	575,939	963	443
Education and advice and traction and epidural and surgery	568,803	964	444
Education and advice and manipulation and epidural and surgery	390,882	984	453
Education and advice and alternative/non-traditional treatments and epidural and surgery	335,710	991	456
Education and advice and biological agents and epidural and surgery	951,088	994	457
Education and advice and disc surgery	808,713	817	376
Non-opioids	122,230	613	282
Non-opioids and active PT	257,328	769	354
Non-opioids and passive PT	257,328	773	356
Non-opioids and traction	257,328	778	358
Non-opioids and manipulation	257,328	904	416
Non-opioids and alternative/non-traditional treatments	257,328	943	434
Non-opioids and biological agents	759,683	964	444
Non-opioids and active PT and epidural	396,322	921	424
Non-opioids and passive PT and epidural	393,895	922	424
Non-opioids and traction and epidural	390,862	924	425
Non-opioids and manipulation and epidural	315,240	967	445
Non-opioids and alternative/non-traditional treatments and epidural	291,791	980	451
Non-opioids and biological agents and epidural	781,289	988	454
Non-opioids and active PT and epidural and disc surgery	594,629	915	421

continued

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 171 Mean cost, probability of success and utility gain (1000 patients) (continued)

Treatments	Mean cost (£)	No. of successes	Utility gain
Non-opioids and passive PT and epidural and disc surgery	588,740	917	422
Non-opioids and traction and epidural and surgery	581,379	919	423
Non-opioids and manipulation and epidural and surgery	397,865	965	444
Non-opioids and alternative/non-traditional treatments and epidural and surgery	340,960	979	450
Non-opioids and biological agents and epidural and surgery	812,116	987	454
Non-opioids and disc surgery	688,457	858	395

TABLE 172 Cost-effectiveness acceptability efficiency frontier

Treatment	Cost (£)	Probability of success	Utility gain	Incremental cost (£)	Incremental success	ICER	Incremental utility gain	ICER
Inactive control	0	383	176					
Non-opioids and alternative/non- traditional treatments	257,328	943	434	257,328	560	459	258	999
Non-opioids, alternative/non- traditional treatments and epidural	291,791	980	451	34,463	38	916	17	1992
Non-opioids, alternative/non- traditional treatments, epidural and disc surgery	320,418	993	457	28,627	12	2311	6	5023
Non-opioids, biological therapies, epidural and disc surgery	799,237	995	458	478,819	3	178,700	1.23	388,478

TABLE 173 Switching treatments using highest cost scenarios

Treatment	Cost (£)	Utility gain	Success	Incremental cost (£)	Incremental success	ICER	Incremental utility	ICER
Inactive control	0	176	383					
Non-opioids	129,330	282	613	129,330	230	562	106	1222
Non-opioids and alternative/non- traditional treatments	353,074	434	943	223,744	330	678	152	1474
Non-opioids and alternative/non- traditional treatments and epidural	409,693	451	980	56,619	38	1506	17	3273
Non-opioids and alternative/non- traditional treatments and epidural and surgery	483,959	457	993	74,266	12	5995	6	13,032
Non-opioids and biological agents and epidural and surgery	1,553,556	458	995	1,069,598	3	399,184	1	867,791

Adjusting utility values and probability of success had limited effect on baseline findings, and would need to be increased outside the bounds of probability to affect the basic premise that stepped approaches are more cost-effective than direct referral for surgery following initial treatments (as the differential in effectiveness for disc surgery is not sufficient to offset the differential in cost from conducting the procedure).

397

Discussion

The economic model has demonstrated that stepped approaches based on initial treatment with non-opioids represent the most cost-effective regimens for the treatment of sciatica. The treatment regimes that constituted the efficiency frontier were inactive control; non-opioids followed by alternative/non-traditional treatments; non-opioids followed by alternative/nontraditional treatments followed by epidural; non-opioids followed by alternative/non-traditional treatments followed by epidural followed by disc surgery; and non-opioids followed by biological therapies followed by epidural and followed by disc surgery (although this last regime would not be regarded as cost-effective when measured in terms of current cost-effectiveness thresholds). Further, the extent of potential net benefit from these treatment strategies would have relatively minor impact on NHS budgets and, when a broader societal perspective is employed, the extent of such net benefits is likely to be considerably more.

The extent to which changes in parameter estimates affect baseline findings is small, with improbable reductions in cost and improvements in success rates required to suggest that direct referral to disc surgery represents a cost-effective approach to managing patients with sciatica.

However, there are a number of limitations associated with the analysis. Firstly, the nature of the evidence has meant that the time perspective is limited to an assumed 12-month duration, with no evidence available to inform the inclusion of relapse and recurrence within the model. The perspective of the NHS does not enable issues relating to work and productivity and the preferences of patients for symptom resolution and treatment duration. Further work is needed to establish patient preferences relating to time taken to achieve success and the implications of failure after a series of treatments.

Secondly, the assumption regarding ultimate failure having a zero cost to the NHS is contentious, but again lack of data and consensus has meant that it has not been possible to provide a counterview. It is highly likely that patients will resort to alternative therapies, but outside the conventional health-care system.

Thirdly, it is acknowledged that the nature of the specified model is simplistic and fails to account fully for structural and parameter uncertainty and distributions. Further work is required to consider the implications of different modelling approaches in determining the relative cost-effectiveness of treatment regimens relating to managing patients with sciatica. However, the extent to which the findings from this study are likely to change would require a dramatic change in the evidence base surrounding the range of treatments available for use within patients. The choice of the global effect as the indicator of success can also be viewed as a limitation, although it again would probably not have changed the nature of the findings significantly.

Conclusion

The stepped approaches to managing sciatica based on an initial treatment with non-opioids, represent the most cost-effective regimens relative to direct referral to disc surgery, with positive net benefits emerging if the acceptable ceiling ratio for an additional unit of success was $< \pounds 2500$ with base-case costs and $< \pounds 6000$ if higher costs were applied to the model. The strategy of referring patients who fail initial treatments directly to disc surgery is unlikely to be cost-effective, with highly improbable reductions in cost and/or rates of success being required

to elevate these regimens to the efficiency frontier. However, these findings remain tentative, and more research is required to develop the evidence base to inform more structurally appropriate economic models and to determine patient preferences regarding treatment durations and extent of invasive treatments that would be acceptable.

Chapter 10

Discussion

Summary of clinical effectiveness review

Description of studies

The number of studies evaluating each treatment category ranged from two (manipulation and education/advice) to 62 (disc surgery), with median sample sizes ranging from 55 (opioids) to 217 (education/advice). The proportion of studies that were RCTs also varied between treatment categories, with the lowest being for disc surgery (51%), anti-inflammatory biological agents (50%) and chemonucleolysis (47%).

In practice, the term sciatica is used by some clinicians for any leg pain referred from the back, whereas others prefer to restrict its use to pain originating from lumbar nerve root irritation, usually associated with disc herniation/prolapse. Most studies included patients with nerve root pain; although some included patients with referred pain, only one study of exercise therapy specifically included such patients. The presence of disc herniation was confirmed by imaging in a greater proportion of studies evaluating invasive treatments such as disc surgery (86%), epidural injections (62%) and chemonucleolysis (86%) than in studies evaluating less invasive interventions such as non-opioids (41%), traction (30%), alternative therapies (0%), exercise therapy (50%), activity restriction (20%) and education/advice (50%). The severity of herniation also varied slightly for disc surgery studies, with the proportion of studies that specifically included some patients with sequestered or extruded disc being higher (16%) than for other intervention categories. However, 17% of exercise therapy studies also included patients with sequestered or extruded discs, but the proportion of exercise therapy studies and other intervention categories will have been influenced by the small number of included studies (chemonucleolysis was 3% and all others 0%). The proportion of studies that limited inclusion to patients with acute sciatica (with the duration of symptoms being < 3 months) was much lower for invasive interventions such as surgery (6%), epidurals (7%) and chemonucleolysis (0%) than for less invasive interventions such as education (100%), activity restriction (80%), traction (50%) and exercise therapy (50%); surprisingly, this information was not reported for many studies. Five treatment categories included a small number of studies that restricted inclusion to patients experiencing their first episode (disc surgery 10%, epidural injections 3%, chemonucleolysis 8%, non-opioids 5% and biological agents 25%). The proportion of studies that included patients who had received previous treatment was higher for studies of invasive treatments such as disc surgery (65%), epidural injections (45%) and chemonucleolysis (83%) than for studies of less invasive interventions such as manipulation (0%), exercise therapy (0%) and traction (30%). However, the portion was also fairly high for opioids (67%) and activity restriction (40%) and low for biological agents (25%).

Summary of the findings comparing different interventions

An overall summary of the results for pair-wise analyses is presented in *Table 174* and for the MTC analyses in *Table 175*. The following discussion is based upon whether or not there is a statistically significant difference between the intervention groups in the direct comparison of all study types and the MTC for randomised and Q-RCTs. For the MTC analyses, only one follow-up interval (closest to 6 months) was considered. The treatment categories are compared in a set order and, once a comparison has been made, it is not discussed again, e.g. disc surgery

399

TABLE 174 Summary of the overall findings of the standard pair-wise a	nalyses
TABLE 174 Summary of the overall findings of the standard pa	lir-wise a
TABLE 174 Summary of the overall findings of the sta	andard pa
TABLE 174 Summary of the overall findings	of the sta
TABLE 174 Summary of the overall	findings
TABLE 174 Summary of th	ne overall
IABLE 174 Summ	ary of th
TABLE 174	Summ
	FABLE 17 4

	Short-term	follow-up		Medium-ter	rm follow-up		Long-term fol	low-up		
Comparison	Global effect	Pain intensity	CSOMS	Global effect	Pain intensity	CSOMs	Global effect	Pain intensity	CSOMs	Adverse effects
Disc surgery vs usual care		+	+		+	♦	+	♦	♦	I
Disc surgery vs epidural					+			\diamond		\diamond
Disc surgery vs non-opioids				\diamond	\diamond					$\stackrel{\wedge}{\lor}$
Disc surgery vs disc surgery and non-opioids		I		\diamond						
Disc surgery plus exercise therapy vs exercise therapy	\diamond	+	\diamond	\diamond	\diamond	\diamond	\diamond	\diamond	\diamond	^ V
Disc surgery vs disc surgery and acupuncture		I								
Disc surgery vs intraoperative interventions	\diamond	\diamond	\diamond		\diamond	\diamond	\diamond	I	\diamond	^ V
Disc surgery vs chemonucleolysis	\diamond	\diamond	\diamond	\diamond	\diamond	\diamond	+ (marginal)	\diamond	\diamond	^ V
Disc surgery vs disc surgery and chemonucleolysis							$\hat{\lor}$	\diamond		$\stackrel{\wedge}{\lor}$
Epidural vs inactive control	\diamond	+	+	\diamond	\diamond	\diamond	\diamond	\diamond	\diamond	\diamond
Epidural vs usual care	+	\diamond	+	\diamond	\diamond	\diamond				I
Epidural vs non-opioids		+	+	\diamond		\diamond				^ V
Epidural vs epidural and non-opioids		\diamond	\diamond		\diamond	I		I	I	\diamond
Epidural vs chemonucleolysis	\diamond			\diamond			I			I
Epidural vs passive PT				+	\diamond	\diamond	+	\diamond	+	I
Epidural vs activity restriction				+						\diamond
Epidural vs acupuncture			\diamond		\diamond					
Epidural vs biological agents			\diamond		\diamond					\diamond
Physiotherapy vs physiotherapy and epidural	I									
Chemonucleolysis vs inactive control	\diamond	\diamond		+	\diamond		\diamond			\diamond
Chemonucleolysis vs manipulation		\diamond	\diamond			\diamond		\diamond		^ V
Non-opioids vs inactive control	+	+	\diamond	\diamond	+	\diamond				I
Non-opioids vs opioids	\diamond	+								$\stackrel{\wedge}{\lor}$
Non-opioids vs acupuncture		+					\diamond			
Non-opioids vs biological agents		I	I							
Traction vs inactive control	\diamond	\diamond	\diamond	\diamond	\diamond					\diamond
Traction vs usual care	\diamond									\Diamond
Traction vs exercise therapy	\diamond									

	Short-tern	i follow-up		Medium-te	erm follow-up		Long-term	follow-up		
	Global	Pain	00000	Global	Pain		Global	Pain	- MOOO	Adverse
comparison	епест	Intensity	CSUMS	епест	Intensity	CSUMS	епест	Intensity	CSUMS	errects
Traction vs passive PT	\diamond	\diamond	\diamond		\diamond	\diamond				\diamond
Exercise therapy vs exercise therapy and traction	\diamond	\diamond	\diamond		Ŷ	\diamond				
Passive PT vs passive PT and traction		\diamond								
Activity restriction vs activity restriction and traction	\diamond	I	\diamond							+
Manipulation vs inactive control	\diamond			+						
Alternative interventions vs inactive control		+								
Exercise therapy vs activity restriction	\diamond									
Exercise therapy vs usual care	\diamond		I	\diamond	\diamond	\diamond	+	\diamond	\diamond	
Exercise therapy vs inactive control		+								
Activity restriction vs manipulation and exercise therapy	\diamond		I	\diamond	\diamond	\diamond				
Passive PT vs inactive control	+	+								
Biological agents vs inactive control		+	+		\diamond	+			\diamond	\diamond
Activity restriction vs education/advice	\diamond	\diamond	I	\diamond	\diamond	\diamond				\diamond
Opioids vs inactive control				\diamond	\diamond	\diamond				I
Opioids vs opioids and non-opioids				\diamond	\diamond	\diamond				
<>, no statistically significant difference between the interventic The CIs of the OR for the meta-analysis comparing disc surgery significant.	ion groups; +, st y to chemonucle	atistically signific	ant findings in f it did not cross	avour of the int the line of no e	ervention group; ffect (OR 1.44, 9	-, statistically s 5% Cl 1.00 to 2	ignificant findin. 2.09) and was th	gs in favour of the nerefore consider	e control group ed marginally s	atistically

TABLE 175 Summary of the overall findings of the MTC analyses

Comparison (intervention vs control)ª	Global effect all studies (OR)	Pain intensity all studies (WMD)	CSOMs all studies (SMD)	Global effect RCTs/Q-RCTs (OR)	Pain intensity RCTs/Q-RCTs (WMD)	CSOMs RCTs/Q-RCTs (SMD)
Disc surgery vs inactive control	2.78	-9.78	0.10	2.94	-8.87	0.29
Disc surgery vs usual care	3.37	-6.64	-0.06	2.57	-4.43	-0.06
Chemonucleolysis vs disc surgery	0.72	-1.44	0.27	0.81	-3.37	0.34
Non-opioids vs disc surgery	0.92	5.71	-0.00	0.88	3.05	-0.20
Intraoperative interventions vs disc surgery	1.70	-5.11	-0.14	1.7	-5.07	-0.15
Traction vs disc surgery	0.44	8.52	-0.47	0.46	7.57	-0.58
Manipulation vs disc surgery	1.76	-1.94		1.67	-3.95	
Alternative/non-traditional vs disc surgery	3.35	-16.36		3.16	-15.95	
Active PT vs disc surgery	0.40	6.64	0.08	0.50	5.55	0.09
Passive PT vs disc surgery	0.41	9.34	-0.58	0.41	8.71	-0.62
Biological agents vs disc surgery	5.68	-12.09	-0.78	5.48	-2.32	-0.71
Activity restriction vs disc surgery	0.46	27.68	-0.96	0.83	26.41	-1.10
Opioids vs disc surgery	0.58	19.12		0.55	16.33	
Education/advice vs disc surgery	0.59	26.84	-0.78	1.07	25.51	-0.96
Intraoperative interventions vs inactive control	4.73	-14.88	-0.04	4.99	-13.94	0.13
Intraoperative interventions vs usual care	5.72	-11.75	-0.21	4.36	-9.51	-0.21
Intraoperative interventions vs epidural	1.52	-2.01	0.14	1.59	-1.27	0.10
Intraoperative interventions vs chemonucleolysis	2.36	-3.66	-0.42	2.10	-1.65	-0.49
Intraoperative interventions vs non- opioids	1.85	-10.81	-0.13	1.93	-8.16	0.05
Traction vs intraoperative interventions	0.26	13.62	-0.31	0.27	12.71	-0.44
Manipulation vs intraoperative interventions	1.03	3.19		0.98	1.12	
Alternative/non-traditional vs intraoperative interventions	1.98	-11.27		1.85	-10.90	
Active PT vs intraoperative interventions	0.23	11.75	0.22	0.29	10.61	0.24
Passive PT vs intraoperative interventions	0.24	14.42	-0.43	0.24	13.75	-0.47
Biological agents vs intraoperative interventions	3.38	-6.99	-0.64	3.24	2.74	-0.57
Activity restriction vs intraoperative interventions	0.27	32.82	-0.81	0.49	31.41	-0.95
Opioids vs intraoperative interventions	0.34	24.23		0.32	21.36	
Education/advice vs intraoperative interventions	0.34	31.95	-0.62	0.63	30.61	-0.81
Epidural vs inactive control	3.10	-12.85	-0.16	3.14	-12.66	0.03
Epidural vs usual care	3.75	-9.71	-0.34	2.74	-8.19	-0.32
Epidural vs disc surgery	1.11	-3.10	-0.28	1.07	-3.78	-0.26
Chemonucleolysis vs epidural	0.65	1.65	0.55	0.76	-0.40	0.60
Non-opioids vs epidural	0.82	8.78	0.24	0.82	6.80	0.06
Traction vs epidural	0.39	11.68	-0.21	0.43	11.36	-0.33
Manipulation vs epidural	1.57	1.11		1.56	-0.17	
Alternative/non-traditional vs epidural	2.99	-13.28		2.95	-12.20	
Active PT vs epidural	0.35	9.84	0.33	0.47	9.29	0.36
Passive PT vs epidural	0.37	12.48	-0.31	0.38	1240	-0.36

TABLE 175 Summary of the overall findings of the MTC analyses (continued)

• • • • • • • • • • •	Global effect all studies	Pain intensity all studies	CSOMs all studies	Global effect RCTs/Q-RCTs	Pain intensity RCTs/Q-RCTs	CSOMs RCTs/Q-RCTs
Comparison (intervention vs control) ^a	(UK)	(WMD)	(SMD)	(OR)	(WMD)	(SMD)
Biological agents vs epidural	5.10	-8.93	-0.51	5.11	1.41	-0.48
Activity restriction vs epidural	0.41	30.90	-0.70	0.77	30.08	-0.84
Opioids vs epidural	0.52	22.21		0.52	20.08	
Education/advice vs epidural	0.53	29.97	-0.50	0.99	29.19	-0.70
Chemonucleolysis vs inactive control	2.00	-11.24	0.37	2.38	-12.28	0.63
Chemonucleolysis vs usual care	2.42	-8.02	0.21	2.07	-7.86	0.28
Non-opioids vs chemonucleolysis	1.27	7.15	-0.29	1.09	6.46	-0.54
Traction vs chemonucleolysis	0.60	10.03	-0.74	0.57	11.06	-0.92
Manipulation vs chemonucleolysis	2.45	-0.48		2.05	-0.62	
Alternative/non-traditional vs chemonucleolysis	4.64	-14.89		3.89	-12.57	
Active PT vs chemonucleolysis	0.55	8.17	-0.20	0.62	8.94	-0.25
Passive PT vs chemonucleolysis	0.57	10.76	-0.85	0.50	12.09	-0.98
Biological agents vs chemonucleolysis	7.90	-10.68	-1.05	6.76	1.17	-1.05
Activity restriction vs chemonucleolysis	0.64	29.21	-1.24	1.03	29.69	-1.45
Opioids vs chemonucleolysis	0.80	20.55		0.68	19.73	
Education/advice vs chemonucleolysis	0.81	28.35	-1.06	1.32	28.78	-1.30
Non-opioids vs inactive control	2.55	-4.07	0.08	2.59	-5.84	0.09
Non-opioids vs usual care	3.09	0.92	-0.08	2.26	-1.36	-0.26
Traction vs non-opioids	0.47	-2.87	-0.46	0.52	4.58	-0.39
Manipulation vs non-opioids	1.91	-7.56		1.89	-6.98	
Alternative/non-traditional vs non- opioids	3.65	-22.05		3.59	-18.97	
Active PT vs non-opioids	0.43	-0.96	0.08	0.57	2.45	0.29
Passive PT vs non-opioids	0.45	3.66	-0.56	0.46	5.61	-0.42
Biological agents vs non-opioids	6.19	-17.79	-0.76	6.20	-5.35	-0.53
Activity restriction vs non-opioids	0.50	22.05	-0.93	0.93	23.29	-0.89
Opioids vs non-opioids	0.63	13.41		0.62	13.27	
Education/advice vs non-opioids	0.64	21.13	-0.76	1.20	22.42	-0.74
Traction vs inactive control	1.20	-1.21	-0.37	1.36	-1.32	-0.29
Traction vs usual care	1.46	1.90	-0.53	1.19	3.29	-0.65
Manipulation vs traction	4.06	-10.48		3.62	-11.54	
Alternative/non-traditional vs traction	7.73	-24.96		6.84	-23.70	
Active PT vs traction	0.90	-1.85	0.54	1.07	-2.14	0.69
Passive PT vs traction	0.94	0.75	-0.10	0.87	1.03	-0.03
Biological agents vs traction	13.2	-20.58	-0.31	11.77	-9.85	-0.15
Activity restriction vs traction	1.05	19.08	-0.46	1.78	18.75	-0.52
Opioids vs traction	1.33	10.51		1.18	8.77	
Education/advice vs traction	1.35	18.20	-0.30	2.30	17.96	-0.37
Manipulation vs inactive control	4.88	-11.72		4.90	-12.79	
Manipulation vs usual care	5.91	-8.58		4.31	-8.49	
Alternative/non-traditional vs manipulation	1.91	-14.41		1.92	-11.97	
Active PT vs manipulation	0.22	8.57		0.30	9.55	
Passive PT vs manipulation	0.23	11.19		0.24	12.56	
Biological agents vs manipulation	3.36	-10.19		3.32	1.69	
Activity restriction vs manipulation	0.26	29.50		0.50	30.31	

continued

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

TABLE 175 Summary of the overall findings of the MTC analyses (continued)

Comparison (intervention vs control) ^a	Global effect all studies (OR)	Pain intensity all studies (WMD)	CSOMs all studies (SMD)	Global effect RCTs/Q-RCTs (OR)	Pain intensity RCTs/Q-RCTs (WMD)	CSOMs RCTs/Q-RCTs (SMD)
Opioids vs manipulation	0.33	20.95		0.33	20.29	
Education/advice vs manipulation	0.33	28.75		0.64	29.32	
Alternative/non-traditional vs inactive control	9.32	-26.08		9.25	-24.89	
Alternative/non-traditional vs usual care	11.27	-23.00		8.15	-20.33	
Active PT vs alternative/non-traditional	0.12	23.14		0.16	21.63	
Passive PT vs alternative/non-traditional	0.13	25.67		0.13	24.73	
Biological agents vs alternative/non- traditional	1.75	4.24		1.76	13.73	
Activity restriction vs alternative/non- traditional	0.14	44.08		0.26	42.63	
Opioids vs alternative/non-traditional	0.17	35.48		0.17	32.34	
Education/advice vs alternative/non- traditional	0.17	43.22		0.33	41.57	
Active PT vs inactive control	1.10	-3.04	0.17	1.46	-3.39	0.39
Active PT vs usual care	1.33	0.08	0.02	1.28	1.01	0.03
Passive PT vs active PT	1.04	2.59	-0.66	0.81	3.26	-0.72
Biological agents vs active PT	14.6	-18.76	-0.83	11.04	-7.82	-0.83
Activity restriction vs active PT	1.16	21.10	-1.02	1.65	20.99	-1.21
Opioids vs active PT	1.46	12.51		1.10	10.79	
Education/advice vs active PT	1.48	20.21	-0.85	2.14	20.11	-1.06
Passive PT vs inactive control	1.14	-0.40	-0.47	1.19	-0.23	-0.32
Passive PT vs usual care	1.38	-2.72	-0.64	1.04	4.29	-0.69
Biological agents vs passive PT	14.0	-21.31	-0.20	13.54	-10.83	-0.12
Activity restriction vs passive PT	1.12	18.47	-0.37	2.04	17.77	-0.47
Opioids vs passive PT	1.41	9.82		1.35	7.69	
Education/advice vs passive PT	1.43	17.60	-0.19	2.62	16.82	-0.32
Biological agents vs inactive control	15.77	-21.80	-0.68	16.04	-11.18	-0.44
Biological agents vs usual care	19.26	-18.67	-0.85	14.11	-6.66	-0.79
Activity restriction vs biological agents	0.08	39.74	-0.18	0.15	28.68	-0.36
Opioids vs biological agents	0.10	31.20		0.10	18.63	
Education/advice vs biological agents	0.10	38.94	-0.01	0.19	27.7 0	-0.22
Activity restriction vs inactive control	1.28	18.00	-0.84	2.43	17.44	-0.80
Activity restriction vs usual care	1.54	21.18	-1.03	2.14	21.96	-1.18
Opioids vs activity restriction	1.26	-8.58		0.67	-10.05	
Education/advice vs activity restriction	1.28	-0.88	0.17	1.29	-0.86	0.15
Opioids vs inactive control	1.60	9.34		1.62	7.41	
Opioids vs usual care	1.95	12.60		1.41	11.92	
Education/advice vs opioids	1.02	7.72		1.94	9.18	
Education/advice vs inactive control	1.63	17.04	-0.66	3.12	16.62	-0.65
Education/advice vs usual care	1.98	20.22	-0.83	2.73	21.04	-1.02

a OR > 1 favours the intervention; WMD < 0 favours intervention; SMD < 0 favours intervention. Relative treatment effects that were statistically significant are shaded.

versus epidural injections medication is discussed only in the first paragraph and the comparison of epidural injections versus disc surgery is not repeated later. The term 'significantly' is used here in its statistical sense, not as a indication of effect size.

Disc surgery was found to be significantly better than usual care for reducing pain at shortand medium-term follow-up and improving back-specific function at short-term follow-up (according to one good-quality RCT). It was also found to be significantly better than conventional care in terms of overall improvement at long-term follow-up, but this finding is based on the meta-analysis of four studies, only one of which was a good-quality RCT that found no statistical difference between the groups. Two further studies that could not be included in the meta-analysis also reported on this outcome; one was a good-quality RCT that also found no significant difference between the intervention groups. Overall, disc surgery was associated with significantly more adverse effects than usual care. One poor-quality RCT reported that disc surgery was significantly better than epidural injection for reducing pain at medium-term follow-up. Intraoperative interventions (mainly involving application of corticosteroids to the affected nerve root) were better than conventional disc surgery in reducing pain at longterm follow-up (three medium-quality RCTs and one poor-quality RCT), but there was no difference for other outcome measures at any follow-up interval. Disc surgery was marginally but significantly better than chemonucleolysis in effecting global improvement at long-term follow-up, based on a meta-analysis of 18 RCTs, but, again, there was no difference for other outcome measures. One moderate-quality RCT found disc surgery plus exercise therapy to be marginally but significantly better than disc surgery alone for improving pain at short-term follow-up. According to one poor-quality RCT, disc surgery used in combination with nonopioids was also found to be significantly better than disc surgery alone for reducing pain at short-term follow-up. In the MTC analyses of disc surgery, there was a significant improvement in global effect in favour of disc surgery when compared with inactive control or usual care. There was a significantly worse result for pain intensity following disc surgery compared with disc surgery combined with intraoperative interventions. In the MTC analyses of intraoperative intervention, there was a significant improvement in global effect compared with inactive control or usual care.

Epidural injection was found to be significantly better than inactive control for reducing pain (four good- and three medium-quality RCTs) and improving back-related function (four good- and one poor-quality RCT) at short-term follow-up, but was also associated with a greater number of adverse effects. Epidural injection was superior to usual care in terms of global effect and condition-specific function at short-term follow-up, but these findings were based on one non-RCT and one moderate-quality RCT, respectively. Epidural injection was associated with more adverse effects than usual care. Epidural injection was better than non-opioids for reducing pain (two medium- and one poor-quality RCT) and improving back-related function (one medium-quality RCT) at short-term follow-up. In one medium-quality RCT, the addition of non-opioids to epidural injection resulted in significantly better outcomes for condition-specific function at medium- and long-term follow-up and greater pain reduction at long-term follow-up than epidural injection alone. In one medium-quality RCT, epidural injection was superior to passive PT for overall improvement at medium- and long-term follow-up, but not for reducing pain at long-term follow-up. One non-RCT found epidural injection to be significantly better than activity restriction in terms of overall improvement. One non-RCT found chemonucleolysis to be better than epidural injection for global effect at long-term follow-up. Epidural used in combination with physiotherapy was better than physiotherapy alone for overall improvement at short-term follow-up, according to one non-RCT. There was no significant difference between epidural injection and acupuncture or biological agents. In the MTC analyses of epidural injections, there was a significant improvement in pain intensity when compared with inactive

control or opioid medication. There was also a significant improvement in global effect when compared with inactive control or usual care.

Chemonucleolysis was superior to inactive control for overall improvement at medium-term follow-up (one medium-quality RCT, one poor-quality RCT and one Q-RCT), but not for any other outcomes at short- or medium-term intervals. There was no significant difference between chemonucleolysis and manipulation (one medium-quality RCT). In the MTC analyses of chemonucleolysis, there was a significant improvement in global effect compared with inactive control or usual care.

Non-opioid medication were better than inactive control for reducing pain at short-term follow-up (three medium-quality RCTs, one poor-quality RCT and one Q-RCT) and medium-term follow-up (one medium-quality RCT, one poor-quality RCT and one Q-RCT), but there were no difference between the interventions for other short- and medium-term outcome measures. Non-opioids, which included tricyclic antidepressants for treating neurogenic pain, were significantly superior to opioids for reducing pain at short-term follow-up, but there was no significant difference between the intervention groups for overall improvement; according to two poor-quality RCTs. Non-opioids were significantly better than acupuncture for reducing pain at short-term follow-up (one poor-quality RCT). Although a small, poor-quality HCS found biological agents to be better than non-opioids for reducing pain and improving condition-specific function at short-term follow-up, non-opioids resulted in significantly greater adverse effects than inactive control. In the MTC analyses of non-opioids, there was a significant improvement in the global effect when compared with the inactive control or usual care.

Traction was compared with the following treatment categories (mainly by one or two mediumquality RCTs) for which there were no significant findings: inactive control, usual care, exercise therapy, passive PT. According to two medium- and one poor-quality RCT, there was also no significant difference between traction used in combination with exercise therapy and exercise therapy used alone for most short-to-medium term outcomes. One medium-quality RCT found traction plus activity restriction to be significantly better than activity restriction alone for reducing pain, but there was no difference between the groups in terms of overall improvement and CSOMs at short-term follow-up. Activity restriction plus traction was associated with more adverse effects than traction alone. The MTC analyses found no significant findings.

Spinal manipulation was superior to inactive control for overall improvement at medium-term follow-up, but not short-term follow-up, according to one good-quality RCT. The MTC analysis of spinal manipulation, found no significant findings.

One moderate-quality RCT found alternative therapy (acupuncture) to be better than inactive control for the reduction of pain intensity at short-term follow-up. No other outcomes were evaluated. In the MTC analysis of alternative therapy, there was a significant improvement in pain intensity compared with inactive control, usual care, activity restriction, opioids, medication, or education/advice.

According to one medium-term crossover RCT, active PT/exercise therapy was better than inactive control for reducing pain at short-term follow-up. Exercise therapy was marginally significantly worse than usual care for condition-specific function at short-term follow-up, but significantly better in terms of overall improvement at long-term follow-up, according to one-good quality RCT. There was no significant difference for other outcomes. Exercise therapy was compared with activity restriction for the global effect at short-term follow-up by one poor-quality RCT, for which there was no significant difference between the interventions. According to a moderate-quality RCT, physiotherapy including exercise and passive PT was significantly

better than activity restriction for improving function at short-term follow-up. The MTC analysis of active PT/exercise therapy found no significant findings.

Passive PT was significantly better than inactive control in terms of overall improvement and pain reduction at short-term follow-up, according to one poor-quality crossover RCT. One non-RCT found passive PT in combination with epidural to be significantly better than passive PT alone in terms of overall improvement at short-term follow-up. In the MTC analysis of passive PT, there a significantly worse result in pain intensity compared with biological agents.

According to one non-RCT, anti-inflammatory biological agents were significantly better than inactive control for reducing pain at short-term follow-up and improving condition-specific function at short- and medium-term follow-up. However, there was no significant difference in terms of pain intensity at medium-term follow-up (one medium-quality RCT and one non-RCT) or condition-specific function at long-term follow-up (one medium-quality RCT). In the MTC analysis of biological agents, there was a significant improvement in pain intensity compared with inactive control, activity restriction, or opioids.

Activity restriction was less effective than advice to stay active in terms of CSOMs at short-term follow-up, but there was no difference between the intervention groups for other outcome measures at short- and medium-term follow-up, according to two moderate-quality RCTs. In the MTC analysis of activity restriction trials, there was a significantly worse result in pain intensity from activity restriction compared with usual care.

There was no significant difference between opioids medication and inactive control (one medium-quality RCT) or a combination of opioids and non-opioids (one medium-quality crossover RCT) in terms of global pain or CSOMs at medium-term follow-up. However, opioids were associated with more adverse effects than inactive control. In the MTC analysis of opioids, there was a significantly worse result in terms of pain intensity from opioids compared with inactive control or usual care.

Summary of cost-effectiveness review

The full economic evaluations identified in the systematic review were of reasonable to good quality, but were not able to fully address our research question. Although individual studies raised a number of important issues, it was difficult to draw meaningful conclusions across these studies because of their heterogeneity. Although there was some indication of favourable benefit, such as with disc surgery, robust findings could not be reliably drawn. While an evidence base is emerging, there remains a lack of well-designed economic evaluations. Of particular note are the lack of published decision models and the relevance of these studies to the UK NHS setting.

Summary of economic evaluation

Description of economic evaluation

A decision-analytic model from the perspective of the UK NHS was constructed on the assumption that patients presenting with sciatica would be managed through one of three pathways, with alternative treatments within each of the pathways. The first pathway would involve management within primary care and revolve around what might be termed usual care, with the use of analgesics and other medications if considered appropriate, to attempt to secure symptom resolution. The second pathway would involve a stepped approach and include the use of intermediate treatments – offered in addition to the initial treatments provided

within primary care – and provided in secondary care outpatients by multidisciplinary teams including physiotherapists, musculoskeletal physicians, etc. (the principle is one of ramping up the level of intervention if there is no timely symptom resolution following simpler, less invasive interventions). The third pathway would involve immediate referral for surgery to alleviate symptoms.

Each of the pathways and the treatment variations available were compared with 'inactive control', which, according to the findings from the MTC, has a non-zero probability of symptom resolution, but has been assumed to cost £0 in the baseline model.

A series of 100 independent scenarios were considered, with the utilities associated with success used to generate a utility score for each treatment regime and combined with costs to determine relative incremental cost/QALY ratios. Similarly, costs were combined with likelihood of success to generate ICERs.

A number of sensitivity analyses were conducted on the baseline findings.

Results of economic evaluation

The initial treatment of non-opioids followed by biological agents and epidural then disc surgery for those who have failed is the most effective strategy and has an incremental cost per QALY of £4500 compared with the option of not providing surgery. The strategy of referring patients who fail initial treatments directly to disc surgery is dominated by the stepped treatment pathway, with referral for surgery being the most expensive strategy and generally less effective than the stepped approaches. The stepped approaches remain the more cost-effective options even when the use of biological agents or alternative therapies is not included, as the differential in effectiveness for disc surgery is not sufficient to offset the differential in cost from conducting the procedure. For referral directly to disc surgery to be the cost-effective strategy the success rate for disc surgery would need to be 40% higher or the costs of surgery 30% lower.

All of the treatment strategies are within the cost per QALY threshold considered to represent value for money of £20,000–30,000 relative to inactive control. However, a number would be excluded on the grounds of being dominated by a more effective and less costly strategy. The issue of which strategy is the most cost-effective is therefore far from conclusive, and more research is required to determine patient preferences regarding treatment durations and extent of invasive treatments that would be acceptable.

Comparison with previous systematic reviews

Previous systematic reviews of sciatica have examined individual treatments or have considered non-surgical or surgical management strategies separately. Where multiple interventions have been included, they have been analysed either using a narrative synthesis or with pair-wise metaanalyses using direct comparisons of individual treatments. Indirect comparisons have not been attempted and this is the first review to use a MTC method. Previous reviews of non-surgical treatments have found either no evidence of effectiveness^{16,17} or conflicting evidence,^{294,295} or have reached different conclusions concerning the effectiveness of ESIs.^{17,23,24,294} The Cochrane systematic review of surgical management has also made direct comparisons using pair-wise meta-analyses, particularly in comparison with chemonucleolysis,²⁶ but because of study heterogeneity was unable to combine the results of four RCTs comparing discectomy with non-surgical treatment and concluded that the results suggested only a temporary benefit of disc surgery at 1-year follow-up. This review, however, justified the effectiveness of discectomy by using an indirect comparison of chemonucleolysis with placebo and chemonucleolysis with disc surgery. Chemonucleolysis was more effective than placebo and discectomy more effective than chemonucleolysis; therefore, disc surgery was superior to placebo. In our review, the same RCTs comparing chymopapain with placebo and chymopapain with surgery, were identified. Five additional RCTs, one non-RCT, 13 CCSs and one HCS comparing chymopapain with disc surgery were identified. In the MTC analysis it was possible to make a more robust comparison of disc surgery compared with placebo. The OR in terms of global effect was 2.8 (95% credible interval 1.4 to 5.6) in favour of disc surgery. The WMD in pain intensity was –9.8 (95% credible interval –26.5 to 6.8) in favour of disc surgery. The SMD in CSOMs was 0.1 (95% credible interval –1.4 to 1.5) in favour of disc surgery. Thus, disc surgery was significantly better than placebo in terms of the global effect but not pain intensity and CSOMs.

Assumptions, limitations and uncertainties

One of the strengths of this review is the extensive literature searches that were undertaken to identify published, unpublished and grey literature. Where possible, non-English language reports were translated; however, we were unable to translate a number of studies published in Chinese, which may have affected the overall findings relating to alternative therapy, particularly acupuncture. Forty-two ongoing (or not yet reported) studies were identified, the findings of which may influence our conclusions: 26 compared different treatment categories including surgery versus usual care (n=1), surgery versus mixed treatments (n=1), epidural versus inactive control (n=7), epidural versus usual care (n=1), epidural versus other (n=1), opioids versus inactive control (n=2), alternative versus mixed treatments (n=1), active PT versus mixed treatments (n=1), biological agents versus inactive control (n=4) and others versus inactive control (n=1).

Our review represents an attempt to answer the question 'Which treatment should I use for sciatica?' In order for the findings of the review to be relevant to the full spectrum of patients who suffer from sciatica, we tried to be as inclusive as possible. Observational studies and non-RCTs were included, as they are likely to have better external validity than RCTs^{296,297} and thus provide more generalisable findings. For example, participants keen to have surgery may have been less likely to accept randomisation to either surgery or usual care. Furthermore, some interventions may not have been evaluated by RCTs. The inclusion of observational studies and non-RCTs means that these interventions would not be excluded owing to lack of RCTs or, alternatively, lead to an increase in the precision of the overall findings for interventions evaluated by only a limited number of RCTs.

However, the RCT is widely regarded as the design of choice when assessing the effectiveness of health-care interventions²⁹⁸ and we acknowledge the controversy over the inclusion of nonrandomised evidence. The observed effect of an intervention may not necessarily be due to the therapeutic intervention itself, it could be due to confounding factors such as the natural course of sciatica (including variability of the disease status or the influence of different prognostic factors), extraneous factors (such as lifestyle, the use of other medication and placebo effect) and information errors (such as incorrect assessment or reporting of the outcome measure). A well-conducted RCT would provide an unbiased estimate of effect by ensuring the comparator groups are the same for these factors and only differ in terms of the intervention given. Observational studies, on the other hand, are likely to be affected by selection bias and confounding and may therefore yield estimates of association that deviate from the true underlying relationship beyond the play of chance.²⁹⁹ However, not all RCTs are well conducted, and they are generally smaller than observational studies. It is therefore unclear whether or not a poorly conducted RCT provides a better estimate of the treatment effect than a large, well-conducted observational study. When summarising the findings of the pair-wise analyses in our review, priority was given to RCTs, and the quality of the studies noted.

Poor reporting and variation in the way data were analysed in the included studies meant that imputation or substitution of missing data was necessary in order for the meta-analyses to be as inclusive as possible (increasing precision of the findings). Omitting studies with missing SDs may induce bias in the summary effect estimate,³⁰⁰ and Furukawa *et al.*³³ have shown that it is safe to borrow SDs from other studies. Where SDs were missing and could not be estimated from the published data, we imputed them using a weighted mean SD.^{33,300} This is based on the assumption that the variance is similar between studies and that the data are not skewed.²⁸ Ideally, the impact of this assumption would be assessed using sensitivity analysis. However, this was not possible in the time frame available and will be done at a later date. This will include comparing the pooled mean differences of studies that have reported SDs against the pooled estimate of the same studies based on imputed SDs to see if they converge.³³ Further sensitivity analyses are also needed to assess the impact of substituting mean values with medians.

Our review explored the use of MTC synthesis methodology²⁷⁴ to simultaneously compare all treatment modalities for sciatica, by providing estimates for all possible pair-wise comparisons, based on both the direct and indirect evidence. One of the main assumptions underpinning these methods is that included studies represent a coherent body of data whose relative treatment effects are effectively identical or at least exchangeable throughout.³⁰¹ Comparing two treatments indirectly, but in very different populations, is likely to produce misleading results if the treatments interact with population characteristics.³⁰² Our review included a diverse set of studies with a number of potential sources of heterogeneity, including the diagnostic criteria used, type and extent of herniation, severity of sciatica, duration of symptoms, previous treatment, mode of administration and dosages of treatments, study design, study quality, outcome measures and duration of follow-up. These characteristics especially varied between invasive and non-invasive treatments. The MTC methods can be used to show the degree of inconsistency in the evidence base.³⁰¹ Although we have used informal methods for comparing estimated effects from the (direct pair-wise) meta-analyses and the MTC analysis, more formal methods to assess coherence and consistency of the evidenced network using deviance information criteria³⁰² and related statistics are yet to be made.

Sciatica is a condition where, in clinical practice, a sequential stepped-care approach using different treatment modalities is considered useful, usually starting with non-invasive treatments and progressing to more invasive treatments if symptoms persist. However, primary studies tended to examine individual treatments in isolation and the clinical effectiveness of treatment strategies in our review were also compared on an equal basis, irrespective of their position in the care pathway. Owing to the novel and speculative use of MTC methods and the breadth of our review, covering such a broad condition with a large number of possible treatments, we did not incorporate a stepped-care approach in the MTC analyses. The optimum sequence of treatment modalities and what sequence is best for which patients are therefore not known. However, we plan to undertake further analyses to develop these methods, in order to derive comparative estimates of the effectiveness of the different interventions, conditional on the administration of previous interventions. Multiple treatments may also be administered sequentially in the hope of producing additive effects using combined therapy; therefore, the additive and interaction effects of multiple interventions also need to be explored.

When a stepped-care approach is used, the characteristics of the patient will vary in different parts of the clinical pathway. This means that the prognosis or baseline risk of the study population is likely to differ (inconsistently) for different interventions. For example, disc surgery

is usually offered to patients who have failed conservative treatment, which means that patients receiving surgery will differ in terms of the type, severity and duration of symptoms compared with those receiving conservative treatment. This trend was reflected in the included studies, with the method and criteria used for diagnosing sciatica (and therefore the patient population) differing according to the invasiveness of the treatment, which was likely to have affected the findings of the MTC analysis. This inconsistency is also present when making informal comparisons between treatment categories in the pair-wise meta-analyses. We plan to further explore this effect as part of the proposed analysis of sequential treatments.

Different countries appear to have a different preference for various treatment modalities, as well as the use of co-interventions. When simultaneously comparing treatment modalities for sciatica, it is important to note that the use of inactive control, usual care and co-interventions is likely to vary across treatment categories and between studies. There is also likely to be a placebo effect occurring with inactive control, which appears to vary according to the type of intervention being used, e.g. sham traction or placebo acupuncture. This is likely to account for why inactive control was shown to be more effective than usual care for global effect (but not for pain intensity) in the MTC analyses, although these findings were not statistically significant.

Implications for further research

The MTC analyses (for all studies and RCTs/Q-RCTs) showed alternative therapy and biological agents to be promising interventions for reducing pain intensity. However, only one non-RCT²⁷⁰ and one moderate-quality RCT²⁷¹ compared biological agents with inactive control, and one moderate-quality RCT²⁶¹ compared acupuncture with inactive control; two studies^{261,270} reported statistically significant findings in favour of the intervention. One small HCS found biological agents to be more effective than non-opioids and one poor-quality RCT found non-opioids to be more effective than acupuncture. Further research is needed on the use of alternative therapy and biological agents compared with interventions that are currently being used in practice, such as non-opioids and epidural injections. Four ongoing RCTs have been identified comparing the biological agent anti-TNF- α with placebo.

Interestingly, the MTC analyses showed opioids to be significantly less effective than inactive control for reducing pain intensity. In the pair-wise analysis, two small, poor-quality RCTs^{229,230} found non-opioids to be significantly more effective than opioids at reducing pain at short-term follow-up, and one medium-quality crossover RCT²¹⁴ found no statistically significant difference between opioids and inactive control for global pain and CSOMs at medium-term follow-up. Further research is needed to provide more evidence for the use of opioids and drugs used to treat neurogenic nerve pain, such as tricyclic antidepressants and gabapentin, for the treatment of sciatica. Two ongoing RCTs have been identified, one comparing opioids and the tricyclic antidepressant nortriptyline with placebo and the other comparing anticonvulsant pregabalin (Lyrica[®], Pfizer) with placebo (see *Appendix 4*).

There were more studies evaluating invasive interventions, such as surgery, epidural and chemonucleolysis than there were studies evaluating non-invasive interventions, such as education/advice, alterative therapies, manipulation and opioids. More research is needed for non-invasive treatments such as manipulation and exercise therapy. Further research is also needed to compare invasive treatments such as epidural and surgery, which was only evaluated by one poor-quality RCT.

Further research is needed to evaluate exactly which intervention within each treatment category is most effective and whether or not this differs for any subgroup of patients. We have

identified a number of studies that compared treatments within the same treatment category (e.g. microdicectomy vs open discectomy), the findings of which are not presented here, but would help answer these questions.

Further research is needed to determine patient preferences regarding treatment durations and extent of invasive treatments that would be acceptable.

Further work to consider implications of ultimate treatment failure and loss of utility is also needed.

Mixed treatment comparison methods include indirect comparisons which are made without breaking within-study comparison and, hence, fully respect the randomised structure of the evidence.³⁰³ Further research is needed to explore the potential effect of including observational and non-RCTs in MTC analyses. More sophisticated methods, such as the confidence profile method²⁹⁷ or using Bayesian statistics,²⁹⁶ could also be explored as a means of incorporating information relating to the differences in study design or internal and external validity in the meta-analyses.

Chapter 11

Conclusions

The review findings provide support for the effectiveness of currently used invasive treatments for treating sciatica, such as disc surgery and epidural corticosteroid injections; however, these were also associated with more adverse effects than usual care. They also provide support for the effectiveness of non-opioid medication for reducing pain in sciatica. Chemonucleolysis was also effective for reducing pain, but is no longer used in the UK NHS. With the exception of non-opioids, there were only a few studies evaluating each of the non-invasive treatment categories. The findings of these studies do not provide support for the effectiveness of opioid analgesia, which is widely used in this patient group. The mixed treatment analyses and limited pair-wise analyses suggest that less frequently used treatments such as acupuncture and experimental treatments such as anti-inflammatory biological agents may be effective. There was also a limited evidence base showing that spinal manipulation and exercise therapy may be effective. The findings do not support the use of activity restriction or traction.

The MTC method enabled both the simultaneous comparison of all treatment categories and the comparison of treatments that had not been directly compared in RCTs or observational studies. However, encouraging results for the interventions (e.g. biological agents) from a small number of poor-quality studies need to be treated with caution. Sciatica is generally treated using a stepped-care approach, starting with non-invasive treatments, such as non-opioid medication, and progressing, if necessary, to more invasive treatments, such as epidural injections or surgery. This means that the population of patients treated with non-invasive treatments in the MTC analyses is likely to differ from that treated with invasive treatments, which may have affected the MTC findings. However, the findings of the pair-wise and MTC analyses were broadly similar.

In terms of cost-effectiveness, the argument for stepped approaches based on an initial treatment with non-opioids, relative to direct referral for surgery, was apparent and, although there are a number of limitations associated with the economic model, this finding was shown to be relatively robust.

Further RCTs with concurrent economic evaluation are needed to evaluate the use of biological agents and acupuncture compared with interventions that are currently being used in practice, such as non-opioids and epidural injections. Four RCTs comparing biological agents with placebo that are in progress, have been identified from searches of trial registries (see *Appendix 4*). Further research is also needed comparing the use of opioids with drugs used to treat neurogenic nerve pain or other treatments currently used in practice. One RCT of oral morphine compared with nortriptyline or placebo was identified from the trial registries (see *Appendix 4*). Further work is also needed to develop alternative economic modelling approaches to assess the relative cost-effectiveness of treatment regimes in these proposed trials.

Acknowledgements

The review team would like to thank the following people for their help during the review process: Ralph Hendry, Nicola Hulley, Daniel Hodgson, Eleanor Pasterfield, Thomas France and Jacob Neal for editing and developing summary tables for the final report; Annie Williams for helping with the analyses of adverse effects; Ian Braithwaite (Consultant Surgeon) for providing clinical input at various stages of the review; and, John Belcher for statistical advice and proposal development.

Contribution of authors

Ruth Lewis (Lecturer) was co-principal investigator and lead reviewer responsible for writing the protocol and clinical effectiveness section of the review, involved in the study selection, data extraction and validity assessment, conducted the conventional pair-wise and MTC analyses and jointly co-ordinated the final report.

Nefyn Williams (Clinical Senior Lecturer and GP) was co-principal investigator with overall responsibility for the project, was involved in the study selection, data extraction and validity assessment and contributed to the analyses as well as the protocol and report writing.

Hosam Matar (Research Associate) was involved in the study selection, data extraction and validity assessment.

Nafees Din (Research Associate) carried out the literature searches and was involved in the study selection, data extraction and validity assessment.

Deb Fitzsimmons (Senior Lecturer) was responsible for conducting and writing the review of economic evaluations, conducting the service provider survey, was involved in the economic model and contributed to the protocol writing.

Ceri Phillips (Professor of Health Economics) was responsible for the development of the economic model and writing the cost-effectiveness section and contributed to the protocol writing.

Mari Jones (Postdoctoral Research Fellow) was involved in the development of the economic model.

Alex Sutton (Professor of Medical Statistics) was involved in and oversaw all aspects of the clinical effectiveness analyses, provided input at all stages and contributed to the protocol and report writing.

Kim Burton (Director of the Spinal Research Unit, University of Huddersfield) provided clinical input at various stages of the review, contributed to the analyses of adverse effects and the discussion and commented on the draft report.

Sadia Nafees (Research Assistant) was involved in the study selection and contributed to the report writing.
Maggie Hendry (Research Fellow) provided input at various stages of the review and commented on the draft report.

Ian Rickard (Patient Representative) provided input at various stages of the review and commented on the draft report.

Rob Chakraverty (Sports Physician) provided clinical input at various stages of the review and commented on the draft report.

Clare Wilkinson (Professor of General Practice and GP) provided input at various stages of the review and commented on the draft report.

References

- 1. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? *JAMA* 1992;**268**:760–5.
- 2. Clinical Standards Advisory Group. Back pain. London: HMSO; 1994.
- 3. Waddell G. The back pain revolution. Edinburgh: Churchill Livingstone; 1998.
- 4. Lawrence J. Rheumatism in populations. London: Heinemann; 1977.
- 5. Heliovaara M, Impivaara O, Sievers K, Melkas T, Knekt P, Korpi J. Lumbar disc syndromein Finland. *J Epidemiol Community Health* 1987;**41**:251–8.
- Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. *Spine* 1993;18:1433–8.
- Bush K, Cowan N, Katz DE, Gishen P. The natural history of sciatica associated with disc pathology. A prospective study with clinical and independent radiologic follow-up. *Spine* 1992;17:1205–12.
- 8. Tubach F, Beaute J, Leclerc A. Natural history and prognostic indicators of sciatica. *J Clin Epidemiol* 2004;**57**:174–9.
- 9. Furlan AD, Pennick V, Bombardier C, Van Tulder MW. 2009 updated methods guidelines for systematic reviews in the Cochrane Back Review Group. *Spine* 2009;**34**:1929–41.
- van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of back pain in the Netherlands. *Pain* 1995;62:233–40.
- 11. Mixer WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. *N Engl J Med* 1934;**211**:210–15.
- 12. Revdivik B, Brown M, Lundborg G. Pathoanatomy and pathophysiology of nerve root compression. *Spine* 1984;**9**:7–15.
- 13. Goupille P, Jayson MI, Valat JP, Freemont AJ. The role of inflammation in disc herniationassociated radiculopathy. *Semin Arthritis Rheum* 1998;**28**:60–71.
- 14. Vroomen PC, de Krom MC, Wilmink JT, Kester AD, Knottnerus JA. Lack of effectiveness of bed rest for sciatica. *N Engl J Med* 1999;**340**:418–23.
- 15. Rebain R, Baxter DG, McDonough S. A systematic review of the passive straight leg raising test as a diagnostic aid for low back pain. *Spine* 2002;**27**:E388–E395.
- 16. Hagen KB, Hilde G, Jamtvedt G, Winnem M. Best rest for acute low back pain and sciatica. *Cochrane Database Syst Rev* 2000;**2**:CD001254.
- 17. Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. *J Spinal Disord* 2000;**13**:463–9.
- 18. Li LC, Bombardier C. Physical therapy management of low back pain: an exploratory survey of therapist approaches. *Phys Ther* 2001;**81**:1018–28.
- 19. Harte AA, Gracey JH, Baxter GD. Current use of lumbar traction in the management of low back pain: results of a survey of physiotherapists in the United Kingdom. *Arch Phys Med Rehabil* 2005;**86**:1164–9.

- 20. Clarke JA, van Tulder MW, Blomberg SEI, de Vet HCW, van der Heijden GJMG, Bronfort G. Traction for low back pain with or without sciatica. *Cochrane Database Syst Rev* 2005;4:CD003010.
- 21. NHS The information centre for health and social care. *Hospital episode statistics (admitted patient care), England 2006–7.* 2007. URL: www.ic.nhs.uk/statistics-and-data-collections/ hospital-care/hospital-activity-hospital-episode-statistics--hes/hospital-episode-statistics- admitted-patient-care-england-2006-07 (accessed 29 April 2007).
- 22. Luijsterburg PA, Verhagen AP, Ostelo RW, van Os TA, Peul WC, Koes BW. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. *Eur Spine J* 2007;7:881–99.
- 23. Boswell MV, Hansen HC, Trescot AM, Hirsch JA. Epidural steroids in the management of chronic spinal pain and radiculopathy. *Pain Physician* 2003;**6**:319–34.
- 24. Abdi S, Datta S, Trescot AM, Schultz DM, Adlaka R, Atluri SL, *et al.* Epidural steroids in the management of chronic spinal pain: a systematic review. *Pain Physician* 2007;**10**:185–212.
- 25. Stevens CD, Dubois RW, Larequi-Lauber T, Vader JP. Efficacy of lumbar discectomy and percutaneous treatments for lumbar disc herniation. *Soz Praventivmed* 1997;**42**:367–79.
- 26. Gibson JNA, Waddell G. Surgical interventions for lumbar disc prolapse. *Cochrane Database Syst Rev* 2007;**2**:CD001350.
- 27. Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd edn. York: CRD; 2001.
- 28. Higgins JPT, Green S. *Cochrane handbook for systematic reviews of interventions.* 2nd edn. Chichester: John Wiley & Sons; 2009.
- 29. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. *Methods for the economic evaluation of health care programmes*. Oxford: Oxford University Press; 2005.
- van Tulder MW, Furlan A, Bombardier C, Bouter LM. Editorial board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003;28:1290–9.
- Ministry of Health and Long-Term Care, City of Hamilton Public Services. Effective Public Health Practice Project. URL: www.myhamilton.ca/myhamilton/CityandGovernment/ HealthandSocialServices/Research/EPHPP (accessed 12 May 2008).
- 32. Weinstein J, O'Brien B, Hornberger J, Jackson J, Johannesson MCM. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. *Value Health* 2003;**6**:9–17.
- Higgins JPT, Deeks JJ. Selecting studies and collecting data. In Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley & Sons; 2008.
- 34. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *J Clin Epidemiol* 2006;**59**:7–10.
- 35. Kopec JA, Esdaile JM. Functional disability scales for back pain. Spine 1995;20:1943–9.
- 36. Deyo RA, Battie M, Beurskens AJHM, Bombardier C, Croft P, Koes B, *et al.* Outcome measures for low back pain research: a proposal for standardized use. *Spine* 1998;**23**:2003–13.
- 37. Davidson M, Keating JL. A comparison of five low back disability questionnaires: reliability and responsiveness. *Phys Ther* 2002;**82**:8–24.

- Garratt AM. Rasch analysis of generic and specific measures f health outcome in low back pain. *Spine* 2003;26:71–7.
- 39. Fairbank JCT. Use and abuse of the oswesrty disability index. Spine 2007;32:2787–9.
- 40. Higgins JPT, Deeks JJ, Altman DG. Special topic in statistics. In Higgins JPT, Deeks JJ, Altman DG, editors. *Cochrane handbook for systematic reviews of interventions*. Chichester: John Wiley & Sons Ltd; 2008.
- 41. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. *Spine* 1983;**8**:141–4.
- 42. Fairbank JC, Couper J, Davies JB, O'Brien JP. The oswestry low back pain disability questionnaire. *Physiotherapy* 1980;**66**:271–3.
- 43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Clin Trials 1986;7:177–88.
- 44. Multi-parameter Evidence Synthesis Research Group. *Mixed treatment comparisons*. Bristol: Department of Community Based Medicine, University of Bristol; 2009. URL: www.bris. ac.uk/cobm/research/mpes/mtc.html (accessed 15 March 2010).
- 45. Thomas KC, Fisher CG, Boyd M, Bishop P, Wing P, Dvorak MF. Outcome evaluation of surgical and nonsurgical management of lumbar disc protrusion causing radiculopathy. *Spine* 2007;**32**:1414–22.
- 46. Krugluger J, Knahr K. Chemonucleolysis and automated percutaneous discectomy a prospective randomized comparison. *Int Orthop* 2000;**24**:167–9.
- 47. van Alphen HA, Braakman R, Bezemer PD, Broere G, Berfelo MW. Chemonucleolysis versus discectomy: a randomized multicenter trial. *J Neurosurg* 1989;**70**:869–75.
- 48. Javid MJ. Chemonucleolysis versus laminectomy a cohort comparison of effectiveness and charges. *Spine* 1995;**20**:2016–22.
- 49. Postacchini F, Lami R, Massobrio M. Chemonucleolysis versus surgery in lumbar disc herniations: correlation of the results to preoperative clinical pattern and size of the herniation. *Spine* 1987;12:87–96.
- 50. Norton WL. Chemonucleolysis versus surgical discectomy. Comparison of costs and results in workers' compensation claimants. *Spine* 1986;11:440–3.
- 51. Dabezies EJ, Brunet M. Chemonucleolysis vs laminectomy. Orthopedics 1978;1:26-9.
- 52. Stula D. Chemonucleolysis with chymopapain in intervertebral-disk hernia a randomized comparative-study of patients following surgery. *Neurochirurgie* 1990;**33**:169–72.
- Tregonning GD, Transfeldt EE, McCulloch JA, Macnab I, Nachemson A. Chymopapain versus conventional surgery for lumbar disc herniation. 10-year results of treatment. *J Bone Joint Surg Br* 1991;73:481–6.
- 54. Lagarrigue J, Lazorthes Y, Verdie JC, Richaud J. Comparative results of surgery and nucleolysis in 1085 cases of herniated lumbar disc. *Neurochirurgie* 1991;**37**:96–105.
- 55. Lavignolle B, Vital JM, Baulny D, Grenier F, Castagnera L. Comparative study of surgery and chemonucleolysis in the treatment of sciatica caused by a herniated disk. *Acta Orthop Belg* 1987;**53**:244–9.
- 56. Hoogmartens M, Van Loon L, Demedts D, Desmet L. Comparative study of the results obtained with discectomy and chemonucleolysis. *Acta Orthop Belg* 1976;**42**:134–8.

- 57. Rossi D, Munari L, Ubbiali A, Palumbo D, Fornari M, Lucarelli G, *et al.* Comparison between percutaneous discectomy according to Onik, microdiscectomy and conservative treatment. *Neuroradiology* 1993;**6**:445–52.
- 58. Zeiger HE, Jr. Comparison of chemonucleolysis and microsurgical discectomy for the treatment of herniated lumbar disc. *Spine* 1987;**12**:796–9.
- 59. Watts C, Hutchison G, Stern J, Clark K. Comparison of intervertebral disc disease treatment by chymopapain injection and open surgery. *J Neurosurg* 1975;**42**:397–400.
- 60. Crawshaw C, Frazer AM, Merriam WF, Mulholland RC, Webb JK. A comparison of surgery and chemonucleolysis in the treatment of sciatica. A prospective randomized trial. *Spine* 1984;**9**:195–8.
- 61. Bouillet R. Complications of discal hernia therapy. Comparative study regarding surgical therapy and nucleolysis by chymopapain. *Acta Orthop Belg* 1983;**49**:48–77.
- 62. Shvartzman L, Weingarten E, Sherry H, Levin S, Persaud A. Cost-effectiveness analysis of extended conservative therapy versus surgical intervention in the management of herniated lumbar intervertebral disc. *Spine* 1992;17:176–82.
- 63. Wang RR, Tronnier V. Effect of acupuncture on pain management in patients before and after lumbar disc protrusion surgery a randomized control study. *Am J Chin Med* 2000;**28**:25–33.
- 64. Aminmansour B, Khalili HA, Ahmadi J, Nourian M. Effect of high-dose intravenous dexamethasone on postlumbar discectomy pain. *Spine* 2006;**31**:2415–7.
- MacKay MA, Fischgrund JS, Herkowitz HN, Kurz LT, Hecht B, Schwartz M. The effect of interposition membrane on the outcome of lumbar laminectomy and diskectomy. *Spine* 1995;20:1793–6.
- Lundin A, Magnuson A, Axelsson K, Kogler H, Samuelsson L. The effect of perioperative corticosteroids on the outcome of microscopic lumbar disc surgery. *Eur Spine J* 2003;12:625–30.
- 67. Koranda I, Sefrna F. Effectiveness of conservative and surgical treatment of lumboischiadic syndrome. *Cas Lek Cesk* 1995;134:474–7.
- 68. Osterman H, Seitsalo S, Karppinen J, Malmivaara A. Effectiveness of microdiscectomy for lumbar disc herniation: a randomized controlled trial with 2 years of follow-up. *Spine* 2006;**31**:2409–14.
- 69. Cengiz SL, Baysefer A. Efficacy of Adcon-L gel or Healon-GV in epidural fibrosis after lumbar microdiscectomy. *Neurosciences* 2007;**12**:109–13.
- 70. Lavyne MH, Bilsky MH. Epidural steroids, postoperative morbidity, and recovery in patients undergoing microsurgical lumbar discectomy. *J Neurosurg* 1992;77:90–5.
- 71. Prestar FJ, Jollenbeck B. Experience with intra- and perioperative high-dosage steroids in microneursurgical revision operations on lumbar discs. *Schmerz* 1995;**9**:78–83.
- Atlas SJ, Deyo RA, Keller RB, Chapin AM, Patrick DL, Long JM, *et al.* The Maine Lumbar Spine Study. 1-year outcomes of surgical and nonsurgical management of sciatica. *Spine* 1996;21:1777–86.
- Kim KD, Wang JC, Robertson DP, Brodke DS, Olson EM, Duberg AC, *et al.* Reduction of radiculopathy and pain with Oxiplex/SP gel after laminectomy, laminotomy, and discectomy: a pilot clinical study. *Spine* 2003;28:1080–7.

- Bernsmann K, Kramer J, Ziozios I, Wehmeier J, Wiese M. Lumbar micro disc surgery with and without autologous fat graft – a prospective randomized trial evaluated with reference to clinical and social factors. *Arch Orthop Trauma Surg* 2001;121:476–80.
- Bonafe A, Tremoulet M, Sabatier J, Boetto S, Docco A, Richardi G, *et al.* Foraminal and lateroforaminal herniated disks – midterm results of percutaneous treatment with chemonucleolysis or nucleotomy. *Neurochirurgie* 1993;**39**:110–15.
- 76. Brown MD, Tompkins JS. Pain response post-chemonucleolysis or disc excision. *Spine* 1989;14:321–6.
- 77. Buric J. Ozone chemyonucleolysis vs microdiscectomy. Prospective controlled study with 18 months follow-up. *Rivista Italiana di Ossigeno-Ozonoterapia* 2005;4:49–54.
- 78. Debi R, Halperin N, Mirovsky Y. Local application of steroids following lumbar discectomy. *J Spinal Disord Tech* 2002;**15**:273–6.
- 79. Dei-Anang K, Weigand H, Mader U. Is the percutaneous discectomy an alternative to chemonucleolysis. *Radiologe* 1990;**30**:70–4.
- 80. Dubourg G, Rozenberg S, Fautrel B, Valls-Bellec I, Bissery A, Lang T, *et al.* A pilot study on the recovery from paresis after lumbar disc herniation. *Spine* 2002;**27**:1426–31.
- Gerszten PC, Moossy JJ, Flickinger JC, Welch WC. Low-dose radiotherapy for the inhibition of peridural fibrosis after reexploratory nerve root decompression for postlaminectomy syndrome. *J Neurosurg* 2003;99:271–7.
- 82. Glasser RS, Knego RS, Delashaw JB, Fessler RG. The perioperative use of corticosteroids and bupivacaine in the management of lumbar disc disease. *J Neurosurg* 1993;**78**:383–7.
- 83. Jensen TT, Asmussen K, Berg-Hansen EM, Lauritsen B, Manniche C, Vinterberg H, et al. First-time operation for lumbar disc herniation with or without free fat transplantation. Prospective triple-blind randomized study with reference to clinical factors and enhanced computed tomographic scan 1 year after operation. Spine 1996;21:1072–6.
- 84. Langmayr JJ, Obwegeser AA, Schwarz AB, Laimer I, Ulmer H, Ortler M. Intrathecals to reduce pain after lumbar disc surgery a double-blind, placebo-controlled prospective-study. *Pain* 1995;**62**:357–61.
- 85. Muralikuttan KP, Hamilton A, Kernohan WG, Mollan RA, Adair IV. A prospective randomized trial of chemonucleolysis and conventional disc surgery in single level lumbar disc herniation. *Spine* 1992;**17**:381–7.
- North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. *Neurosurgery* 2005;56:98–106.
- 87. Peul WC, Van Houwelingen HC, van den Hout WB, Brand R, Eekhof JAH, Tans JTJ, *et al.* Surgery versus prolonged conservative treatment for sciatica. *N Engl J Med* 2007;**356**:2245–56.
- Revel M, Payan C, Vallee C, Laredo JD, Lassale B, Roux C, *et al.* Automated percutaneous lumbar discectomy versus chemonucleolysis in the treatment of sciatica – a randomized multicenter trial. *Spine* 1993;18:1–7.
- 89. Richter HP, Kast E, Tomczak R, Besenfelder W, Gaus W. Results of applying ADCON-L gel after lumbar discectomy: the German ADCON-L study. *J Neurosurg* 2001;**95**:179–89.
- Steffen R. Laser discotomy/chemonucleolysis ini the therapy of displaced lumbal intervertebral disc – prospective randomised comparison. *Hefte zur der Unfallchirurg* 1999;271:215–21.

421

- 91. Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. *Spine* 1983;**8**:131–40.
- Weinstein J, Spratt KF, Lehmann T, McNeill T, Hejna W. Lumbar disc herniation. A comparison of the results of chemonucleolysis and open discectomy after ten years. *J Bone Joint Surg Am* 1986;68:43–54.
- Starkweather A, Witek-Janusek L, Nockels R. The impact of psychological and immune factors in sciatic pain: a randomized controlled trial among herniated disc patients. *Nurs Health SCI* 2006:23(3).
- 94. Alaranta H, Hurme M, Einola S, Falck B, Kallio V, Knuts LR, *et al.* A prospective study of patients with sciatica. A comparison between conservatively treated patients and patients who have undergone operation, part II: results after one year follow-up. *Spine* 1990;**15**:1345–9.
- 95. Buttermann GR. Treatment of lumbar disc herniation: epidural steroid injection compared with discectomy: s prospective, randomized study. *J Bone Joint Surg Am* 2004;**86**:670–9.
- 96. Ejeskar A, Nachemson A, Herberts P, Lysell E, Andersson G, Irstam L, *et al.* Surgery versus chemonucleolysis for herniated lumbar discs. A prospective study with random assignment. *Clin Orthop Relat Res* 1983;**174**:236–42.
- Hoogland T, Schubert M, Miklitz B, Ramirez A. Transforaminal posterolateral endoscopic discectomy with or without the combination of a low-dose chymopapain: a prospective randomized study in 280 consecutive cases. *Spine* 2006;**31**:E890–7.
- Weinstein JN, Lurie JD, Tosteson TD, Skinner JS, Hanscom B, Tosteson ANA, *et al.* Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. *JAMA* 2006;**296**:2451–9.
- Weinstein JN, Tosteson TD, Lurie JD, Tosteson ANA, Hanscom B, Skinner JS, *et al.* Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. *JAMA* 2006;**296**:2441–50.
- 100. Hansson E, Hansson T. The cost-utility of lumbar disc herniation surgery. *Eur Spine J* 2007;**16**:329–37.
- 101. Rasmussen S, Krum-Moller DS, Lauridsen LR, Jensen SEH, Mandoe H, Gerlif C, *et al.* Epidural steroid following discectomy for herniated lumbar disc reduces neurological impairment and enhances recovery: a randomized study with two-year follow-up. *Spine* 2008;**33**:2028–33.
- 102. Ronnberg K, Lind B, Zoega B, Gadeholt-Gothlin G, Halldin K, Gellerstedt M, *et al.* Peridural scar and its relation to clinical outcome: a randomised study on surgically treated lumbar disc herniation patients. *Eur Spine J* 2008;17:1714–20.
- 103. Alexander AH, Burkus JK, Mitchell JB, Ayers WV. Chymopapain chemonucleolysis versus surgical discectomy in a military population. *Clin Orthop Relat Res* 1989:158–65.
- 104. Lee SH, Lee SJ, Park KH, Lee IM, Sung KH, Kim JS, *et al.* Comparison of percutaneous manual and endoscopic laser diskectomy with chemonucleolysis and automated nucleotomy. *Orthopade* 1996;25:49–55.
- 105. Watters WC, Mirkovic S, Boss J. Treatment of the isolated lumbar intervertebral disc herniation: microdiscectomy versus chemonucleolysis. *Spine* 1988;13:360–2.
- 106. Jirarattanaphochai K, Jung S, Thienthong S, Krisanaprakornkit W, Sumananont C. Peridural methylprednisolone and wound infiltration with bupivacaine for postoperative pain control

after posterior lumbar spine surgery – a randomized double-blinded placebo-controlled trial. *Spine* 2007;**32**:609–16.

- 107. de Tribolet N, Porchet F, Lutz TW, Gratzl O, Brotchi J, van Alphen HA, *et al.* Clinical assessment of a novel antiadhesion barrier gel: prospective, randomized, multicenter, clinical trial of ADCON-L to inhibit postoperative peridural fibrosis and related symptoms after lumbar discectomy. *Am J Orthop* 1998;27:111–20.
- Barlocher CB, Krauss JK, Seiler RW. Central lumbar disc herniation. *Acta Neurochir* 2000;142:1369–74.
- 109. Takeshima T, Kambara K, Miyata S, Ueda Y, Tamai S. Clinical and radiographic evaluation of disc excision for lumbar disc herniation with and without posterolateral fusion. *Spine* 2000;**25**:450–6.
- 110. Aydn Y, Ziyal IM, Duman H, Turkmen CS, Basak M, Ahin Y. Clinical and radiological results of lumbar microdiskectomy technique with preserving of ligamentum flavum comparing to the standard microdiskectomy technique. *Surg Neurol* 2002;**57**:5–13.
- 111. Lee SH, Chung SE, Ahn Y, Kim TH, Park JY, Shin SW. Comparative radiologic evaluation of percutaneous endoscopic lumbar discectomy and open microdiscectomy: a matched cohort analysis. *Mt Sinai J Med* 2006;**73**:795–801.
- 112. Lagarrigue J, Chaynes P. Comparative study of lumbar discectomy with or without microscope. A prospective analyse of 80 cases. *Neurochirurgie* 1994;**40**:116–20.
- Kho HC, Steudel WI. Comparison between lumbar microdiscectomy and standard discectomy in lumbar-disk herniations – a retrospective analysis of 267 cases. *Neurochirurgie* 1986;29:181–5.
- Righesso O, Falavigna A, Avanzi O. Comparison of open discectomy with microendoscopic discectomy in lumbar disc herniations: results of a randomized controlled trial. *Neurosurgery* 2007;61:545–9.
- 115. Tassi GP. Comparison of results of 500 microdiscectomies and 500 percutaneous laser disc decompression procedures for lumbar disc herniation. *Photomed Laser Surg* 2006;**24**:694–7.
- 116. Katayama Y, Matsuyama Y, Yoshihara H, Sakai Y, Nakamura H, Nakashima S, *et al.* Comparison of surgical outcomes between macro discectomy and micro discectomy for lumbar disc herniation: a prospective randomized study with surgery performed by the same spine surgeon. *J Spinal Disord Tech* 2006;**19**:344–7.
- 117. Gonzalez-Castro A, Shetty A, Nagendar K, Greenough CG. Day-case conventional discectomy: a randomised controlled trial. *Eur Spine J* 2002;**11**:67–70.
- Tullberg T, Isacson J, Weidenhielm L. Does microscopic removal of lumbar disc herniation lead to better results than the standard procedure? Results of a one-year randomized study. *Spine* 1993;18:24–7.
- 119. Shin DA, Kim KN, Shin HC, Yoon DH. The efficacy of microendoscopic discectomy in reducing iatrogenic muscle injury. *J Neurosurg Spine* 2008;**8**:39–43.
- 120. Carragee EJ, Spinnickie AO, Alamin TF, Paragioudakis S. A prospective controlled study of limited versus subtotal posterior discectomy: short-term outcomes in patients with herniated lumbar intervertebral discs and large posterior anular defect. *Spine* 2006;**31**:653–7.
- 121. Ruetten S, Komp M, Merk H, Godolias G. Full-endoscopic interlaminar and transforaminal lumbar discectomy versus conventional microsurgical technique a prospective, randomized, controlled study. *Spine* 2008;**33**:931–9.

- 122. Ryang Y-M, Oertel MF, Mayfrank L, Gilsbach JM, Rohde V. Standard open microdiscectomy versus minimal access trocar microdiscectomy: results of a prospective randomized study. *Neurosurgery* 2008;**62**:174–81.
- 123. Wu X, Zhuang S, Mao Z, Chen H. Microendoscopic discectomy for lumbar disc herniation: surgical technique and outcome in 873 consecutive cases. *Spine* 2006;**31**:2689–94.
- 124. Balderston RA, Gilyard GG, Jones AA, Wiesel SW, Spengler DM, Bigos SJ, *et al.* The treatment of lumbar disc herniation: simple fragment excision versus disc space curettage. *J Spinal Disord* 1991;4:22–5.
- 125. Barrios C, Ahmed M, Arrotegui J, Bjornsson A, Gillstrom P. Microsurgery versus standard removal of the herniated lumbar disc. A 3-year comparison in 150 cases. *Acta Orthop* 1990;**61**:399–403.
- 126. Chao Z, Yue Z, Tong-wei C, Jian W, Yong H, Yong P. Microendoscopic discectomy, a less traumatic procedure for lumbar disk herniation. *Chin J Traumatol* 2007;**10**:311–4.
- 127. Chatterjee S, Foy PM, Findlay GF. Report of a controlled clinical trial comparing automated percutaneous lumbar discectomy and microdiscectomy in the treatment of contained lumbar disc herniation. *Spine* 1995;**20**:734–8.
- 128. Hagen R, Engesaeter LB. Unilateral and bilateral partial laminectomy in lumbar disc prolapse. A follow-up study of 156 patients. *Acta Orthop* 1977;**48**:41–6.
- Kahanovitz N, Viola K, Muculloch J. Limited surgical discectomy and microdiscectomy. A clinical comparison. Spine 1989;14:79–81.
- Kim M-J, Lee S-H, Jung E-S, Son B-G, Choi E-S, Shin J-H, *et al.* Targeted percutaneous transforaminal endoscopic diskectomy in 295 patients: comparison with results of microscopic diskectomy. *Surg Neurol* 2007;68:623–31.
- 131. Mayer HM, Brock M. Percutaneous endoscopic discectomy surgical technique and preliminary-results compared to microsurgical discectomy. *J Neurosurg* 1993;**78**:216–25.
- 132. Schizas C, Tsiridis E, Saksena J. Microendoscopic discectomy compared with standard microsurgical discectomy for treatment of uncontained or large contained disc herniations. *Neurosurgery* 2005;**57**:357–60.
- Striffeler H, Groger U, Reulen HJ. "Standard" microsurgical lumbar discectomy vs. "conservative" microsurgical discectomy. A preliminary study. *Acta Neurochir* 1991;112:62–4.
- 134. Thome C, Barth M, Scharf J, Schmiedek P. Outcome after lumbar sequestrectomy compared with microdiscectomy: a prospective randomized study. *J Neurosurg Spine* 2005;**2**:271–8.
- 135. Toyone T, Tanaka T, Kato D, Kaneyama R. Low-back pain following surgery for lumbar disc herniation. A prospective study. *J Bone Joint Surg Am* 2004;**86**:893–6.
- 136. Tria AJ, Jr, Williams JM, Harwood D, Zawadsky JP. Laminectomy with and without spinal fusion. *Clin Orthop Relat Res* 1987:134–7.
- Tureyen K. One-level one-sided lumbar disc surgery with and without microscopic assistance: 1-year outcome in 114 consecutive patients. J Neurosurg 2003;99:247–50.
- 138. White AH, von Rogov P, Zucherman J, Heiden D. Lumbar laminectomy for herniated disc: a prospective controlled comparison with internal fixation fusion. *Spine* 1987;**12**:305–7.
- 139. Wilson DH, Harbaugh R. Microsurgical and standard removal of the protruded lumbar disc: a comparative study. *Neurosurgery* 1981;**8**:422–7.

- 425
- 140. Yang J, Du F, Zhao DQ, Zheng YB, Li JG, Shao YG. Two different intervention measures in recovery of lumbar function of patients who underwent lumbar discectomy. *Chin J Clin Rehabil* 2005;**9**:268–9.
- 141. Mastronardi L, Pappagallo M, Puzzilli F, Tatta C. Efficacy of the morphine-Adcon-L compound in the management of postoperative pain after lumbar microdiscectomy. *Neurosurgery* 2002;**50**:518–24.
- 142. Saberski LR. A retrospective analysis of spinal canal endoscopy and laminectomy outcomes data. *Pain Physician* 2000;**3**:193–6.
- 143. Dincer U, Kiralp MZ, Cakar E, Yasar E, Dursan H. Caudal epidural injection versus nonsteroidal anti-inflammatory drugs in the treatment of low back pain accompanied with radicular pain. *Joint Bone Spine* 2007;**74**:467–71.
- 144. Graham CE. Chemonucleolysis: a double blind study comparing chemonucleolysis with intra discal hydrocortisone: in the treatment of backache and sciatica. *Clin Orthop Relat Res* 1976:179–92.
- 145. Coomes EN. Comparison between epidural anaesthesia and bed rest in sciatica. *Br Med J* 1961;1:20–4.
- 146. Yates DW. A comparison of the types of epidural injection commonly used in the treatment of low back pain and sciatica. *Rheumatol Rehabil* 1978;17:181–6.
- 147. Bush K, Hillier S. A controlled study of caudal epidural injections of triamcinolone plus procaine for the management of intractable sciatica. *Spine* 1991;**16**:572–5.
- 148. Snoek W, Weber H, Jorgensen B. Double-blind evaluation of extradural methyl prednisolone for herniated lumbar discs. *Acta Orthop* 1977;**48**:635–41.
- 149. Becker C, Heidersdorf S, Drewlo S, de Rodriguez SZ, Kramer J, Willburger RE. Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. *Spine* 2007;**32**:1803–8.
- 150. Pirbudak L, Karakurum G, Oner U, Gulec A, Karadasli H. Epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy. *Pain Clinic* 2003;**15**:247–53.
- 151. Buchner M, Zeifang F, Brocai DR, Schiltenwolf M. Epidural corticosteroid injection in the conservative management of sciatica. *Clin Orthop Relat Res* 2000;**375**:149–56.
- 152. Carette S, Leclaire R, Marcoux S, Morin F, Blaise GA, St Pierre A, *et al.* Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. *N Engl J Med* 1997;**336**:1634–40.
- 153. Valat JP, Giraudeau B, Rozenberg S, Goupille P, Bourgeois P, Micheau-Beaugendre V, *et al.* Epidural corticosteroid injections for sciatica: a randomised, double blind, controlled clinical trial. *Ann Rheum Dis* 2003;**62**:639–43.
- 154. Popiolek A, Domanik A, Mazurkiewicz G. Epidural injections of steroids in the treatment of patients with chronic sciatica in discopathy. *Neurol Neurochir Pol* 1991;**25**:640–6.
- 155. Veihelmann A, Devens C, Trouillier H, Birkenmaier C, Gerdesmeyer L, Refior HJ. Epidural neuroplasty versus physiotherapy to relieve pain in patients with sciatica: a prospective randomized blinded clinical trial. *J Orthop Sci* 2006;**11**:365–9.
- 156. Wilson-MacDonald J, Burt G, Griffin D, Glynn C. Epidural steroid injection for nerve root compression a randomized, controlled trial. *J Bone Joint Surg Bm* 2005;**87**:352–5.

- 157. Dilke TF, Burry HC, Grahame R. Extradural corticosteroid injection in management of lumbar nerve root compression. *Br Med J* 1973;2:635–7.
- 158. Vad VB, Bhat AL, Lutz GE, Cammisa F. Transforaminal epidural steroid injections in lumbosacral radiculopathy: a prospective randomized study. *Spine* 2002;**27**:11–16.
- 159. Blonna D, Calvi V, Collo G, Marmotti A, Castoldi F. Gabapentin in the conservative treatment of radiculopathy. *Minerva Ortopedica e Traumatologica* 2004;**55**:15–22.
- 160. Bourgeois P, Benoist M, Palazzo E, Belmatoug N, Folinais D, Frot B, *et al.* Multicenter, randomized and double-blind study of triamcinolone hexacetonide versus chymopapain in the treatment of lumbar sciatica. Preliminary results at six months. *Rev Rhum Mal Osteo Articulaires* 1988:767–9.
- 161. Bronfort G, Evans RL, Anderson AV, Schellhas KP, Garvey TA, Marks RA, *et al.* Nonoperative treatments for sciatica: a pilot study for a randomized clinical trial. *J Manipulative Physiol Ther* 2000;**23**:536–44.
- 162. Helliwell M, Robertson JC, Ellis RM. Outpatient treatment of low pack pain and sciatica by a single extradural corticosteroid injection. *Br J Clin Pract* 1985;**39**:228–31.
- Klenerman L, Greenwood R, Davenport HT, White DC, Peskett S. Lumbar epidural injections in the treatment of sciatica. *Rheumatology* 1984;23:35–8.
- 164. Matyjek J, Lubinski I. Treatment of sciatica with injection of hydrocortisone into the sacral hiatus. *Neurol Neurochir Pol* 1986;**20**:218–21.
- 165. Ridley MG, Kingsley GH, Gibson T, Grahame R. Outpatient lumbar epidural corticosteroid injection in the management of sciatica. *Rheumatology* 1988;**27**:295–9.
- 166. Styczynski T, Parnarauskiene R, Zarski S, Kaubrys G, Klezys V, Krzeminska-Dabrowska I, *et al.* The assessment of therapeutic effectiveness of paravertebral blockades in patients with painful radicular syndromes in discopathy and in lumbar spine spondylosis. *Neurol Neurochir Pol* 1997;**31**:939–49.
- 167. Wehling P, Reinecke J. Acupuncture together with cytokine depressing herbs in comparison to injection therapy with steroids in sciatic pain. *Schmerz* 1997;11:180–4.
- 168. Bontoux D, Alcalay M, Debiais F, Garrouste O, Ingrand P, Azais I, *et al.* Treatment of lumbardisk herniation with intradiscal injection of chymopapain or triamcinolone hexacetonid – a comparative-study of 80 cases. *Revue du Rhumatisme* 1990;57:327–31.
- 169. Bronfort G, Evans RL, Maiers M, Anderson AV. Spinal manipulation, epidural injections, and self-care for sciatica: a pilot study for a randomized clinical trial. *J Manipulative Physiol Ther* 2004;**27**:503–8.
- 170. Gallucci M, Limbucci N, Zugaro L, Barile A, Stavroulis E, Ricci A, *et al.* Sciatica: treatment with intradiscal and intraforaminal injections of steroid and oxygen-ozone versus steroid only. *Radiology* 2007;**242**:907–13.
- 171. Karppinen J, Malmivaara A, Kurunlahti M, Kyllonen E, Pienimaki T, Nieminen P, *et al.* Periradicular infiltration for sciatica – a randomized controlled trial. *Spine* 2001;**26**:1059–67.
- 172. Lafuma A, Bouvenot G, Cohen C, Eschwege E, Fagnani F, Vignon E. A pragmatic costeffectiveness study of routine epidural corticosteroid injections for lumbosciatic syndrome requiring inhospital management. *Revue Du Rhumatisme* 1997;**64**:549–55.
- 173. Price C, Arden N, Coglan L, Rogers P. Cost-effectiveness and safety of epidural steroids in the management of sciatica. *Health Technol Assess* 2005;**9**(33).

- 174. Laiq N, Khan MN, Iqbal MJ, Khan S. Comparison of epidural steroid injections with conservative management in patients with lumbar radiculopathy. *J Coll Physicians Surg Pak* 2009;**19**:539–43.
- 175. Murata Y, Kato Y, Miyamoto K, Takahashi K. Clinical study of low back pain and radicular pain pathways by using l2 spinal nerve root infiltration: a randomized, controlled, clinical trial. *Spine* 2009;**34**:2008–13.
- 176. Mathews JA, Mills SB, Jenkins VM, Grimes SM, Morkel MJ, Mathews W, *et al.* Back pain and sciatica: controlled trials of manipulation, traction, sclerosant and epidural injections. *Br J Rheumatol* 1987;**26**:416–23.
- 177. Beliveau P. A comparison between epidural anaesthesia with and without corticosteroid in the treatment of sciatica. *Rheumatol Phys Med* 1971;11:40–3.
- 178. Dashfield AK, Taylor MB, Cleaver JS, Farrow D. Comparison of caudal steroid epidural with targeted steroid placement during spinal endoscopy for chronic sciatica: a prospective, randomized, double-blind trial. *Br J Anaesth* 2005;**94**:514–9.
- 179. Owlia MB, Salimzadeh A, Alishiri G, Haghighi A. Comparison of two doses of corticosteroid in epidural steroid injection for lumbar radicular pain. *Singapore Med J* 2007;**48**:241–5.
- 180. Riew KD, Yin Y, Gilula L, Bridwell KH, Lenke LG, Lauryssen C, *et al.* The effect of nerveroot injections on the need for operative treatment of lumbar radicular pain. A prospective, randomized, controlled, double-blind study. *J Bone Joint Surg Am* 2000;**82**:1589–93.
- Jeong HS, Lee JW, Kim SH, Myung JS, Kim JH, Kang HS. Effectiveness of transforaminal epidural steroid injection by using a preganglionic approach: a prospective randomized controlled study. *Radiology* 2007;245:584–90.
- 182. Ng L, Chaudhary N, Sell P. The efficacy of corticosteroids in periradicular infiltration for chronic radicular pain: a randomized, double-blind, controlled trial. *Spine* 2005;**30**:857–62.
- 183. Ackerman WE, 3rd, Ahmad M. The efficacy of lumbar epidural steroid injections in patients with lumbar disc herniations. *Anesth Analg* 2007;**104**:1217–22.
- 184. Kolsi I, Delecrin J, Berthelot JM, Thomas L, Prost A, Maugars Y. Efficacy of nerve root versus interspinous injections of glucocorticoids in the treatment of disk-related sciatica. A pilot, prospective, randomized, double-blind study. *Joint Bone Spine* 2000;**67**:113–18.
- 185. Thomas E, Cyteval C, Abiad L, Picot MC, Taourel P, Blotman F. Efficacy of transforaminal versus interspinous corticosteroid injectionin discal radiculalgia a prospective, randomised, double-blind study. *Clin Rheumatol* 2003;**22**:299–304.
- 186. Rogers P, Nash T, Schiller D, Norman J. Epidural steroids for sciatica. *Pain Clinic* 1992;5:67–72.
- 187. Candido KD, Raghavendra MS, Chinthagada M, Badiee S, Trepashko DW. A prospective evaluation of iodinated contrast flow patterns with fluoroscopically guided lumbar epidural steroid injections: the lateral parasagittal interlaminar epidural approach versus the transforaminal epidural approach. *Anesth Analg* 2008;**106**:638–44.
- 188. Cuckler JM, Bernini PA, Wiesel SW, Booth RE, Rothman RH, Pickens GT. The use of epidural steroids in the treatment of lumbar radicular pain. A prospective, randomized, double-blind study. *J Bone Joint Surg Am* 1985;**67**:63–6.
- 189. Blankenbaker DG, De Smet AA, Stanczak JD, Fine JP. Lumbar radiculopathy: treatment with selective lumbar nerve blocks comparison of effectiveness of triamcinolone and betamethasone injectable suspensions. *Radiology* 2005;**237**:738–41.

- 190. Breivik H, Hesla PE, Molnar I, Lind B. Treatment of chronic low back pain and sciatica: comparison of caudal epidural injections of bupivacaine and methylprednisolone with bupivacaine followed by saline. *Adv Pain Res Ther* 1976;**1**:927–32.
- 191. Faraj AA, Mulholland RC. The value of nerve root infiltration for leg pain when used with a nerve stimulator. *Eur Spine J* 2006;15:1495–9.
- 192. Gronemeyer D, Seibel R, Schindler O, Schattauer K, Lange S, Schmidt A. Microinvasive, CT-controlled periradicular therapy in treatment of chronic intervertebral disk-induced functional disorders. *Wien Med Wochenschr* 1995;**145**:129–39.
- 193. Lee JW, Kim SH, Choi J-Y, Yeom J-S, Kim K-J, Chung S-K, *et al.* Transforaminal epidural steroid injection for lumbosacral radiculopathy: preganglionic versus conventional approach. *Korean J Radiol* 2006;7:139–44.
- 194. Schaufele MK, Hatch L, Jones W. Interlaminar versus transforaminal epidural injections for the treatment of symptomatic lumbar intervertebral disc herniations 414. *Pain Physician* 2006;**9**:361–6.
- 195. Cocelli LP, Karakurum G, Cebesoy O, Karadasli H, Oner U. Clinical comparison of effectiveness of epidural triamcinolone and betamethasone in discal radiculalgia: a prospective, randomized study. *J Muscoskel Pain* 2009;17:281–6.
- 196. Hagihara Y, Ogata S, Hirayama H, Koyama T, Watanabe E. Why use steroids in lumbar selective nerve root block? A randomized control study. *Chiba Med* 2009;85:71–6.
- 197. Lee JH, Moon J, Lee SH. Comparison of effectiveness according to different approaches of epidural steroid injection in lumbosacral herniated disk and spinal stenosis. *BMR* 2009;**22**:83–9.
- 198. Manchikanti L, Singh V, Cash KA, Pampati V, Damron KS, Boswell MV. Preliminary results of a randomized, equivalence trial of fluoroscopic caudal epidural injections in managing chronic low back pain: part 2 – disc herniation and radiculitis. *Pain Physician* 2008;**11**:801–15.
- 199. Manchikanti L, Singh V, Cash KA, Pampati V, Datta S. Preliminary results of a randomized, equivalence trial of fluoroscopic caudal epidural injections in managing chronic low back pain: part 3 post surgery syndrome. *Pain Physician* 2008;11:817–31.
- 200. Mendoza-Lattes S, Weiss A, Found E, Zimmerman B, Gao Y. Comparable effectiveness of caudal vs. trans-foraminal epidural steroid injections. *Iowa Orthop J* 2009;**29**:91–6.
- 201. Tafazal S, Ng L, Chaudhary N, Sell P. Corticosteroids in peri-radicular infiltration for radicular pain: a randomised double blind controlled trial. One year results and subgroup analysis. *Eur Spine J* 2009;**18**:1220–5.
- 202. Winnie AP, Hartman JT, Meyers HL, Jr, Ramamurthy S, Barangan V. Pain clinic. II. Intradural and extradural corticosteroids for sciatica. *Anesth Analg* 1972;**51**:990–1003.
- 203. Anwar A, Zaidah I, Rozita R. Prospective randomised single blind study of epidural steroid injection comparing triamcinalone acetonide with methylprednisolone acetate. *Int J Rheumatol* 2005;**8**:51–3.
- 204. Manchikanti L, Cash KA, McManus CD, Pampati V, Abdi S. Preliminary results of a randomized, equivalence trial of fluoroscopic caudal epidural injections in managing chronic low back pain: part 4 – spinal stenosis. *Pain Physician* 2008;11:833–48.
- 205. Gogan WJ, Fraser RD. Chymopapain a 10-year, double-blind-study. Spine 1992;17:388–94.
- 206. Schwetschenau PR, Ramirez A, Johnston J. Double blind evaluation of intradiscal chymopapain for herniated lumbar discs; early results. *J Neurosurg* 1976;45:622–7.

·

429

- 207. Feldman J, Menkes CJ, Pallardy G, Chevrot A, Horreard P, Zenny JC, *et al.* Double-blind study of the treatment of disc lumbosciatica by chemonucleolysis. *Revue du Rhumatisme et des Maladies Osteo-Articulaires* 1986;**53**:147–52.
- 208. Burton AK, Tillotson KM, Cleary J. Single-blind randomised controlled trial of chemonucleolysis and manipulation in the treatment of symptomatic lumbar disc herniation. *Eur Spine J* 2000;**9**:202–7.
- 209. Dabezies EJ, Langford K, Morris J, Shields CB, Wilkinson HA. Safety and efficacy of chymopapain (discase) in the treatment of sciatica due to a herniated nucleus pulposus. Results of a randomized, double-blind study. *Spine* 1988;13:561–5.
- 210. Javid MJ, Nordby EJ, Ford LT, Hejna WJ, Whisler WW, Burton C, *et al.* Safety and efficacy of chymopapain (chymodiactin) in herniated nucleus pulposus with sciatica. Results of a randomized, double-blind study. *JAMA* 1983;**249**:2489–94.
- 211. Wittenberg RH, Oppel S, Rubenthaler FA, Steffen R. Five-year results from chemonucleolysis with chymopapain or collagenase a prospective randomized study. *Spine* 2001;**26**:1835–41.
- 212. Benoist M, Bonneville JF, Lassale B, Runge M, Gillard C, Vazquez-Suarez J, *et al.* A randomized, double-blind study to compare low-dose with standard-dose chymopapain in the treatment of herniated lumbar intervertebral discs. *Spine* 1993;**18**:28–34.
- 213. Hedtmann A, Steffen R, Kramer J. Prospective comparative study of intradiscal high-dose and low-dose collagenase versus chymopapain. *Spine* 1987;12:388–92.
- 214. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. *Pain* 2007;**130**:66–75.
- 215. Chen M-R, Wang P, Cheng G, Guo X, Wei G-W, Cheng X-H. The warming acupuncture for treatment of sciatica in 30 cases. *J Tradit Chin Med* 2009;**29**:50–3.
- 216. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. *Ann Rheum Dis* 2004;**63**:1120–3.
- 217. Gibson T, Dilke TF, Grahame R. Chymoral in the treatment of lumbar disc prolapse. *Rheumatol Rehabil* 1975;**14**:186–90.
- 218. Goldie I. A clinical trial with indomethacin (indomee (R)) in low back pain and sciatica. *Acta Orthop* 1968;**39**:117–28.
- 219. Yildirim K, Sisecioglu M, Karatay S, Erdal A, Levent A, Ugur M, *et al.* The effectiveness of gabapentin in patients with chronic radiculopathy. *Pain Clinic* 2003;**15**:213–18.
- 220. Hedeboe J, Buhl M, Ramsing P. Effects of using dexamethasone and placebo in the treatment of prolapsed lumbar disc. *Acta Neurol Scand* 1982;65:6–10.
- 221. El-Zahaar MS. The Egyptian experience in the use of colchicine in lumbar disc disease. *J Neurol Orthop Med Surg* 1995;**16**:147–52.
- 222. Porsman O, Friis H. Prolapsed lumbar disc treated with intramuscularly administered dexamethasonephosphate. A prospectively planned, double-blind, controlled clinical trial in 52 patients. *Scand J Rheumatol* 1979;**8**:142–4.
- 223. Dreiser RL, Le Parc JM, Velicitat P, Lleu PL. Oral meloxicam is effective in acute sciatica: two randomised, double-blind trials versus placebo or diclofenac. *Inflamm Res* 2001;**50**:S17–23.
- 224. Finckh A, Zufferey P, Schurch M-A, Balague F, Waldburger M, So AKL. Short-term efficacy of intravenous pulse glucocorticoids in acute discogenic sciatica. A randomized controlled trial. *Spine* 2006;**31**:377–81.

- 225. Grevsten S, Johansson H. Phenylbutazone in treatment of acute lumbago-sciatica. *Z Rheumatol* 1975;**34**:444–7.
- 226. Jacobs JH, Grayson MF. Trial of an anti-inflammatory agent (indomethacin) in low back pain with and without radicular involvement. *Br Med J* 1968;**3**:158–60.
- 227. Herrmann WA, Geertsen MS. Efficacy and safety of lornoxicam compared with placebo and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised, double-blind, multicentre, parallel-group study. *Int J Clin Pract* 2009;**63**:1613–21.
- 228. Holve RL, Barkan H. Oral steroids in initial treatment of acute sciatica. *J Am Board Fam Med* 2008;**21**:469–74.
- 229. Kwasucki J, Stepien A, Maksymiuk G, Olbrych-Karpinska B. Evaluation of analgesic action of fluvoxamine compared with efficacy of imipramine and tramadol for treatment of sciatica open trial. *Wiad Lek* 2002;**55**:42–50.
- 230. Kwasucki J, Olbrych K, Ska B, Stepie A, Dec S, Maksymiuk G. Assessment of dexamethasone effectiveness in the treatment of ischalgia. *Neurol Neurochir Pol* 1993;27:515–22.
- 231. Schuermans Y, Rauis A. Comparative clinical trial of two injectable NSAIDs, tiaprofenic acid and alclofenac, in acute sciatica. *Drugs* 1988;35:83–5.
- 232. Blazek M, Keszthelyi B, Varhelyi M, Korosi O. Comparative study of Biarison and Voltaren in acute lumbar pain and lumbo-ischialgia. *Therapia Hungarica* 1986;**34**:163–6.
- 233. Desnuelle C, Acquaviva PC. Comparative trial of injectable Indocid 50 mg against injectable diclofenac in lumbosciatica (single-blind, multicenter, randomized trial). *Sem-Hop* 1986;**62**:2197–201.
- 234. Borms T. Comparison of injectable formulations of tiaprofenic acid and ketoprofen in acute lumbar sciatica. Single-blind randomised trial. *Drugs* 1988;**35**:85–7.
- 235. Andersen RB, Halskov O. A double-blind clinical comparison of proquazone and naproxen in the treatment of patients with symptoms of lumbar nerve root compression syndrome. *Scand J Rheumatol* 1978:18–20.
- Stevanovic L. Double-blind parallel clinical trial with tenoxicam vs. piroxicam in patients suffering from acute lumbalgia and subacute lumboischialgia. *Aktuelle Rheumatologie* 1986;11:196–203.
- 237. Kanayama M, Hashimoto T, Shigenobu K, Oha F, Yamane S. New treatment of lumbar disc herniation involving 5-hydroxytryptamine_{2A} receptor inhibitor: a randomized controlled trial. *J Neurosurg Spine* 2005;**2**:441–6.
- 238. Braun H, Huberty R. Therapy of lumbar sciatica. A comparative clinical study of a corticoid-free monosubstance and a corticoid–containing combination drug. *Medizinische Welt* 1982;**33**:490–1.
- 239. Friedman BW, Esses D, Solorzano C, Choi HK, Cole M, Davitt M, *et al.* A randomized placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. *Spine* 2008;**33**:E624–9.
- 240. Memeo A, Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. *Clin Drug Investig* 2008;**28**:495–500.
- 241. Toroudi HP, Borghei Razavi M, Razavi HB, Tabatabayi RM, Tabar YT, Yahyavi ST, *et al.* Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. *Neurol India* 2009;**57**:305–9.

- 242. Ljunggren AE, Walker L, Weber H, Amundsen T. Manual traction versus isometric exercises in patients with herniated intervertebral lumbar discs. *Physiother Theory Pract* 1992;**8**:207–13.
- 243. Moret NC, van der Stap M, Hagmeijer R, Molenaar A, Koes BW. Design and feasibility of a randomized clinical trial to evaluate the effect of vertical traction in patients with a lumbar radicular syndrome. *Man Ther* 1998;**3**:203–11.
- 244. Pal B, Mangion P, Hossain MA, Diffey BL. A controlled trial of continuous lumbar traction in the treatment of back pain and sciatica. *Rheumatology* 1986;**25**:181–3.
- 245. Rattanatharn R, Sanjaroensuttikul N, Anadirekkul P, Chaivisate R, Wannasetta W. Effectiveness of lumbar traction with routine conservative treatment in acute herniated disc syndrome. *J Med Assoc Thai* 2004;**87**:S272–7.
- 246. Larsson U, Choler U, Lidstrom A, Lind G, Nachemson A, Nilsson B, *et al.* Auto traction for treatment of lumbago sciatica a multicenter controlled investigation. *Acta Orthop* 1980;**51**:791–8.
- 247. Mathews JA, Hickling J. Lumbar traction: a double-blind controlled study for sciatica. *Rheumatol Rehabil* 1975;**14**:222–5.
- 248. Reust P, Chantraine A, Vischer TL. Treatment of lumbar sciatica with or without neurological deficit using mechanical traction. A double-blind study. *Swiss Med Wkly* 1998;**118**:271–4.
- 249. Unlu Z, Tasci S, Tarhan S, Pabuscu Y, Islak S. Comparison of 3 physical therapy modalities for acute pain in lumbar disc herniation measured by clinical evaluation and magnetic resonance imaging. *J Manipulative Physiol Ther* 2008;**31**:191–8.
- 250. Styczynski T, Zarski S, Drozdowska Z, Krzeminska-Dabrowska I, Lesiak A, Pirog A, *et al.* Clinical evaluation of the effectiveness of traction treatment of patients with herniation of lumbar intervertebral discs. *Reumatologia* 1991;**29**:275–81.
- 251. Guvenol K, Tuzun C, Peker O, Goktay Y. A comparison of inverted spinal traction and conventional traction in the treatment of lumbar disc herniations. *Physiother Theory Pract* 2000;**16**:151–60.
- 252. Ljunggren AE, Weber H, Larsen S. Autotraction vs. manual traction in patients with prolapsed lumbar intervertebral discs. *Scand J Rehabil Med* 1984;**16**:117–24.
- 253. Ozturk B, Gunduz OH, Ozoran K, Bostanoglu S. Effect of continuous lumbar traction on the size of herniated disc material in lumbar disc herniation. *Rheumatol Int* 2006;**26**:622–6.
- 254. Harte AA, Baxter GD, Gracey JH. The effectiveness of motorised lumbar traction in the management of LBP with lumbo sacral nerve root involvement: a feasibility study. *BMC Musculoskelet Disord* 2007;**8**:118.
- 255. Fritz JM, Lindsay W, Matheson JW, Brennan GP, Hunter SJ, Moffit SD, *et al.* Is there a subgroup of patients with low back pain likely to benefit from mechanical traction? Results of a randomized clinical trial and subgrouping analysis. *Spine* 2007;**32**:E793–800.
- 256. Lidstrom A, Zachrisson M. Physical therapy on low back pain and sciatica. An attempt at evaluation. *Scand J Rehabil Med* 1970;**2**:37–42.
- 257. Nykvist F, Knuts LR, Alaranta H, Hurme M, Torma T, Ronnemaa T, *et al.* Clinical, social, and psychological factors and outcome in a 5-year follow-up study of 276 patients hospitalized because of suspected lumbar disc herniation. *Int Disabil Stud* 1990;**12**:107–12.
- 258. Santilli V, Beghi E, Finucci S. Chiropractic manipulation in the treatment of acute back pain and sciatica with disc protrusion: a randomized double-blind clinical trial of active and simulated spinal manipulations. *Spine* 2006;**6**:131–7.

- 259. Brotchi J, Pirotte B, De Witte O, Levivier M. Prevention of epidural fibrosis in a prospective series of 100 primary lumbo-sacral discectomy patients: follow-up and assessment at re-operation. *Neurol Res* 1999;**21**:S47–50.
- 260. Zhang SQ, Wang Z, Wang HL. Analgesia of "three points and five methods" therapy on radiculalgia in protrusion of lumbar intervertebral disc. *Chin J Clin Rehabil* 2005;**9**:226–7.
- 261. Duplan B, Cabanel G, Piton JL, Grauer JL, Phelip X. Acupuncture and sciatica in the acute phase. Double-blind study of 30 cases. *Semaine des Hopitaux* 1983;**59**:3109–14.
- Khoromi S, Blackman MR, Kingman A, Patsalides A, Matheny LA, Adams S, *et al.* Low intensity permanent magnets in the treatment of chronic lumbar radicular pain. *J Pain Symptom Manage* 2007;**34**:434–45.
- 263. Zhi L, Jing S. Clinical comparison between scalp acupuncture combined with a single body acupoint and body acupuncture alone for the treatment of sciatica. *AJA* 1995;**23**:305–7.
- 264. Luijsterburg PAJ, Verhagen AP, Ostelo RWJG, van den Hoogen HJMM, Peul WC, Avezaat CJJ, *et al.* Physical therapy plus general practitioners' care versus general practitioners' care alone for sciatica: a randomised clinical trial with a 12-month follow-up. *Eur Spine J* 2008;**17**:509–17.
- 265. Bakhtiary AH, Safavi-Farokhi Z, Rezasoltani A. Lumbar stabilizing exercises improve activities of daily living in patients with lumbar disc herniation. *BMR* 2005;**18**:55–60.
- 266. Jaffe G. Double-blind, betweenpatient comparison of alclofenac (prinalgin) and indomethacin in treatment of low back pain and sciatica. *Curr Med Res Opin* 1974;**2**:424–9.
- 267. Hofstee DJ, Gijtenbeek JMM, Hoogland PH, van Houwelingen HC, Kloet A, Lotters F, *et al.* Westeinde sciatica trial: randomized controlled study of bed rest and physiotherapy for acute sciatica. *J Neurosurg* 2002;**96**:45–9.
- 268. Ghoname EA, White PF, Ahmed HE, Hamza MA, Craig WF, Noe CE. Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica. *Pain* 1999;**83**:193–9.
- 269. Bokonjic R. Epidural infiltration of dexa-neurobion for treatment of intervertebral disk hernia. *Medizinische Welt* 1975;**26**:302–5.
- 270. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren K-A, *et al.* Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. *Spine* 2003;**28**:750–3.
- 271. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Jarvinen S, *et al.* The treatment of disc herniation-induced sciatica with infliximab Results of a randomized, controlled, 3-month follow-up study. *Spine* 2005;**30**:2724–8.
- 272. Cohen S, Bogduk N, Dragovich A, Buckenmaier C, Griffith S, Kurihara C, *et al.* Randomized, double-blind, placebo-controlled, dose–response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. *Anesthesiology* 1116;**110**:1116–26.
- Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;331:897–900.
- 274. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;**23**:3105–24.
- 275. Dullerud R, Lie H, Magnaes B. Cost-effectiveness of percutaneous automated lumbar nucleotomy comparison with traditional macro-procedure discectomy. *Intervent Neuroradiol* 1999;5:35–41.

- 276. Karppinen J, Ohinmaa A, Malmivaara A, Kurunlahti M, Kyllonen E, Pienimaki T, *et al.* Cost effectiveness of periradicular infiltration for sciatica subgroup analysis of a randomized controlled trial. *Spine* 2001;**26**:2587–95.
- 277. Launois R, Henry B, Marty JR, Gersberg M, Lassale C, Benoist M, *et al.* Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation. *Pharmacoeconomics* 1994;**6**:453–63.
- 278. Luijsterburg PAJ, Lamers LM, Verhagen AP, Ostelo RWJG, van den Hoogen HJMM, Peul WC, *et al.* Cost-effectiveness of physical therapy and general practitioner care for sciatica. *Spine* 2007;**32**:1942–8.
- 279. Malter AD, Larson EB, Urban N, Deyo RA. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. *Spine* 1996;**21**:1048–54.
- 280. Manca A, Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, *et al.* Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). *Eur J Pain* 2008;**12**:1047–58.
- 281. Stevenson RC, McCabe CJ, Findlay AM. An economic evaluation of a clinical trial to compare automated percutaneous lumbar discectomy with microdiscectomy in the treatment of contained lumbar disc herniation. *Spine* 1995:739–42.
- 282. Tosteson ANA, Skinner JS, Tosteson TD, Lurie JD, Andersson GB, Berven S, *et al.* The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). *Spine* 2008;**33**:2108–15.
- 283. van den Hout WB, Peul WC, Koes BW, Brand R, Kievit J, Thomeer RTWM. Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial. *BMJ* 2008;**336**:1351–4.
- 284. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. *[Handbook for cost studies, methods and guidelines for economic evaluation in health Care] [Dutch]*. Netherlands: Health Care Insurance Council; 2004.
- 285. Health Council of the Netherlands. *Management of the lumbosacral radicular syndrome (sciatica)*. The Hague: Health Council of the Netherlands; 1999.
- 286. Malter AD, Larson EB, Nicole ScD, Deyo RA. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. *Spine* 1996;**21**:1048–54.
- 287. Anonymous. *RBRVS fee schedule: a plain-English guide*. Rockville, MD: Decision Health; 2004.
- 288. Brazier JE, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ* 2002;**21**:271–92.
- 289. Curtis LJ, Pennock M. Social assistance, lone parents and health: what do we know, where do we go? *Can J Public Health* 2006;**97**:S4–11.
- 290. Department of Health. *NHS reference costs 2005–06*. URL: http://webarchive. nationalarchives.gov.uk/+/dh.gov.uk/en/publicationsandstatistics/publications/ publicationspolicyandguidance/dh_062884 (accessed 29 January 2007).
- 291. Curtis L. *Unit costs of health and social care*. PSSRU, University of Kent; 2009. URL: www. pssru.ac.uk/pdf/uc/uc2009/uc2009.pdf (accessed 29 January 2009).
- 292. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59. March 2010. London: BMA and RPS; 2010.

- 293. Department of Health. *NHS reference costs 2008–2009*. URL: www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (accessed 29 January 2009).
- 294. Luijsterburg PAJ, Verhagen AP, Ostelo RWJG, van Os TAG, Peul WC, Koes BW. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. *Eur Spine J* 2007;**16**:881–99.
- 295. Clarke JA, van Tulder MW, Blomberg SEI, de Vet HCW, van der Heijden GJM, Bronfort G, *et al.* Traction for low-back pain with or without sciatica. *Cochrane Database Syst Rev* 2007.
- 296. Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG. Bias modelling in evidence synthesis. *J R Stat Soc Ser A Stat Soc* 2009;**172**:21–47.
- 297. Eddy DM, Hasselblad V, Shachter R. An introduction to bayesian methods for meta-analysis: the confidence profile method. *Med Decis Making* 1990;**10**:15–23.
- 298. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, *et al.* Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7(27).
- 299. Egger M, Smith GD, Schneider M. Systematic reviews of observational studies. In Egger M, Smith GD, editors. *Systematic reviews in health care. Meta-analysis in context*. London: Wiley-Blackwell; 2001. pp. 211–27.
- 300. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. *J Clin Epidemiol* 2006;**59**:342–53.
- 301. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. *J Clin Epidemiol* 2010;**63**:875–82.
- 302. Spiegelhalter DJ, Best NG, Carlin BP. Bayesian measures of model complexity and fit. *R Stat Soc (B)* 2002;**64**:583–616.
- 303. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison metaanalysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 2009;169:1158–65.

Health Technology Assessment programme

Director,

Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool

Prioritisation Group

Members

Chair,

Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool

Professor Imti Choonara, Professor in Child Health, Academic Division of Child Health, University of Nottingham Chair – Pharmaceuticals Panel

Dr Bob Coates, Consultant Advisor – Disease Prevention Panel

Dr Andrew Cook, Consultant Advisor – Intervention Procedures Panel

Dr Peter Davidson, Director of NETSCC, Health Technology Assessment

Dr Nick Hicks,

Consultant Adviser – Diagnostic Technologies and Screening Panel, Consultant Advisor–Psychological and Community Therapies Panel

Ms Susan Hird, Consultant Advisor, External Devices and Physical Therapies Panel

Professor Sallie Lamb, Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick Chair – HTA Clinical Evaluation and Trials Board

Professor Jonathan Michaels, Professor of Vascular Surgery, Sheffield Vascular Institute, University of Sheffield Chair – Interventional Procedures Panel Professor of Dermato-Epidemiology, Centre of Evidence-Based Dermatology, University of Nottingham

Deputy Director, Professor Hywel Williams,

Professor Ruairidh Milne, Director – External Relations

Dr John Pounsford, Consultant Physician, Directorate of Medical Services, North Bristol NHS Trust Chair – External Devices and Physical Therapies Panel

Dr Vaughan Thomas, Consultant Advisor – Pharmaceuticals Panel, Clinical Lead – Clinical Evaluation Trials Prioritisation Group

Professor Margaret Thorogood, Professor of Epidemiology, Health Sciences Research Institute, University of Warwick Chair – Disease Prevention Panel Professor Lindsay Turnbull, Professor of Radiology, Centre for the MR Investigations, University of Hull Chair – Diagnostic Technologies

Professor Scott Weich, Professor of Psychiatry, Health Sciences Research Institute, University of Warwick Chair – Psychological and Community Therapies Panel

and Screening Panel

Professor Hywel Williams, Director of Nottingham Clinical Trials Unit, Centre of Evidence-Based Dermatology, University of Nottingham Chair – HTA Commissioning Board Deputy HTA Programme Director

HTA Commissioning Board

Chair,

Professor Hywel Williams, Professor of Dermato-Epidemiology, Centre of Evidence-Based Dermatology, University of Nottingham

Members

Professor Ann Ashburn, Professor of Rehabilitation and Head of Research, Southampton General Hospital

Professor Peter Brocklehurst, Professor of Women's Health, Institute for Women's Health, University College London

Professor Jenny Donovan, Professor of Social Medicine, University of Bristol

Professor Jonathan Green, Professor and Acting Head of Department, Child and Adolescent Psychiatry, University of Manchester Medical School Professor John W Gregory, Professor in Paediatric Endocrinology, Department of

Deputy Chair,

Professor Jon Deeks,

Department of Public Health and

Epidemiology, University of Birmingham

Professor Steve Halligan, Professor of Gastrointestinal Radiology, University College Hospital, London

Child Health, Wales School of

Medicine, Cardiff University

Professor Freddie Hamdy, Professor of Urology, Head of Nuffield Department of Surgery, University of Oxford

Professor Allan House, Professor of Liaison Psychiatry, University of Leeds Dr Martin J Landray, Reader in Epidemiology, Honorary Consultant Physician, Clinical Trial Service Unit, University of Oxford

Professor Stephen Morris, Professor of Health Economics, University College London, Research Department of Epidemiology and Public Health, University College London

Professor Irwin Nazareth, Professor of Primary Care and Head of Department, Department of Primary Care and Population Sciences, University College London Professor E Andrea Nelson, Professor of Wound Healing and Director of Research, School of Healthcare, University of Leeds

Professor Tom Walley, CBE,

Liverpool

Professor of Clinical Pharmacology, Director,

NIHR HTA programme, University of

Professor John David Norrie, Chair in Clinical Trials and Biostatistics, Robertson Centre for Biostatistics, University of Glasgow

Dr Rafael Perera, Lecturer in Medical Statisitics, Department of Primary Health Care, University of Oxford

HTA Commissioning Board (continued)

Professor Barney Reeves, Professorial Research Fellow in Health Services Research, Department of Clinical Science, University of Bristol Professor Martin Underwood, Professor of Primary Care Research, Warwick Medical School, University of Warwick Professor Marion Walker, Professor in Stroke Rehabilitation, Associate Director UK Stroke Research Network, University of Nottingham Dr Duncan Young, Senior Clinical Lecturer and Consultant, Nuffield Department of Anaesthetics, University of Oxford

Programme Director,

Professor Tom Walley, CBE,

Director, NIHR HTA programme, Professor of

Clinical Pharmacology, University of Liverpool

Observers

Dr Tom Foulks, Medical Research Council Dr Kay Pattison, Senior NIHR Programme Manager, Department of Health

Deputy Chair.

University of Leeds

Professor Jenny Hewison,

Leeds Institute of Health Sciences,

Professor of the Psychology of Health Care,

HTA Clinical Evaluation and Trials Board

Chair, Professor Sallie Lamb, Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick and Professor of Rehabilitation, Nuffield Department of Orthopaedic, Rheumatology and Musculoskeletal Sciences, University of Oxford

Members

Professor Keith Abrams, Professor of Medical Statistics, Department of Health Sciences, University of Leicester

Professor Martin Bland, Professor of Health Statistics, Department of Health Sciences, University of York

Professor Jane Blazeby, Professor of Surgery and Consultant Upper GI Surgeon, Department of Social Medicine, University of Bristol

Professor Julia M Brown, Director, Clinical Trials Research Unit, University of Leeds

Professor Alistair Burns, Professor of Old Age Psychiatry, Psychiatry Research Group, School of Community-Based Medicine, The University of Manchester & National Clinical Director for Dementia, Department of Health Dr Jennifer Burr, Director, Centre for Healthcare Randomised trials (CHART), University of Aberdeen

Professor Linda Davies, Professor of Health Economics, Health Sciences Research Group, University of Manchester

Professor Simon Gilbody, Prof of Psych Medicine and Health Services Research, Department of Health Sciences, University of York

Professor Steven Goodacre, Professor and Consultant in Emergency Medicine, School of Health and Related Research, University of Sheffield

Professor Dyfrig Hughes, Professor of Pharmacoeconomics, Centre for Economics and Policy in Health, Institute of Medical and Social Care Research, Bangor University Professor Paul Jones, Professor of Respiratory Medicine, Department of Cardiac and Vascular Science, St George's Hospital Medical School, University of London

Professor Khalid Khan, Professor of Women's Health and Clinical Epidemiology, Barts and the London School of Medicine, Queen Mary, University of London

Professor Richard J McManus, Professor of Primary Care Cardiovascular Research, Primary Care Clinical Sciences Building, University of Birmingham

Professor Helen Rodgers, Professor of Stroke Care, Institute for Ageing and Health, Newcastle University

Professor Ken Stein, Professor of Public Health, Peninsula Technology Assessment Group, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth Professor Jonathan Sterne, Professor of Medical Statistics and Epidemiology, Department of Social Medicine, University of Bristol

Mr Andy Vail, Senior Lecturer, Health Sciences Research Group, University of Manchester

Professor Clare Wilkinson, Professor of General Practice and Director of Research North Wales Clinical School, Department of Primary Care and Public Health, Cardiff University

Dr Ian B Wilkinson, Senior Lecturer and Honorary Consultant, Clinical Pharmacology Unit, Department of Medicine, University of Cambridge

Observers

Ms Kate Law, Director of Clinical Trials, Cancer Research UK Dr Morven Roberts, Clinical Trials Manager, Health Services and Public Health Services Board, Medical Research Council

Diagnostic Technologies and Screening Panel

Members

Chair, Professor Lindsay Wilson

Turnbull, Scientific Director of the Centre for Magnetic Resonance Investigations and YCR Professor of Radiology, Hull Royal Infirmary

Professor Judith E Adams, Consultant Radiologist, Manchester Royal Infirmary, Central Manchester & Manchester Children's University Hospitals NHS Trust, and Professor of Diagnostic Radiology, University of Manchester

Mr Angus S Arunkalaivanan, Honorary Senior Lecturer, University of Birmingham and Consultant Urogynaecologist and Obstetrician, City Hospital, Birmingham

Dr Diana Baralle, Consultant and Senior Lecturer in Clinical Genetics, University of Southampton

Observers

Dr Tim Elliott, Team Leader, Cancer Screening, Department of Health

Dr Joanna Jenkinson, Board Secretary, Neurosciences and Mental Health Board (NMHB), Medical Research Council Dr Stephanie Dancer, Consultant Microbiologist, Hairmyres Hospital, East Kilbride

Dr Diane Eccles, Professor of Cancer Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital

Dr Trevor Friedman, Consultant Liason Psychiatrist, Brandon Unit, Leicester General Hospital

Dr Ron Gray, Consultant, National Perinatal Epidemiology Unit, Institute of Health Sciences, University of Oxford

Professor Paul D Griffiths, Professor of Radiology, Academic Unit of Radiology, University of Sheffield

Mr Martin Hooper, Public contributor

Professor Julietta Patnick,

Senior NIHR Programme

Programme, Sheffield

Dr Kay Pattison,

Director, NHS Cancer Screening

Manager, Department of Health

Professor Anthony Robert Kendrick, Associate Dean for Clinical Research and Professor of Primary Medical Care, University of Southampton

Dr Nicola Lennard, Senior Medical Officer, MHRA

Dr Anne Mackie, Director of Programmes, UK National Screening Committee, London

Mr David Mathew, Public contributor

Dr Michael Millar, Consultant Senior Lecturer in Microbiology, Department of Pathology & Microbiology, Barts and The London NHS Trust, Royal London Hospital

Mrs Una Rennard, Public contributor

Professor Tom Walley, CBE,

Pharmacology, University of

programme, Professor of Clinical

Director, NIHR HTA

Liverpool

Dr Stuart Smellie, Consultant in Clinical Pathology, Bishop Auckland General Hospital

Ms Jane Smith, Consultant Ultrasound Practitioner, Leeds Teaching Hospital NHS Trust, Leeds

Dr Allison Streetly, Programme Director, NHS Sickle Cell and Thalassaemia Screening Programme, King's College School of Medicine

Dr Matthew Thompson, Senior Clinical Scientist and GP, Department of Primary Health Care, University of Oxford

Dr Alan J Williams, Consultant Physician, General and Respiratory Medicine, The Royal Bournemouth Hospital

Dr Ursula Wells, Principal Research Officer, Policy Research Programme, Department of Health

Disease Prevention Panel

Members

Chair, Professor Margaret Thorogood, Professor of Epidemiology, University of Warwick Medical School, Coventry

Dr Robert Cook, Clinical Programmes Director, Bazian Ltd, London

Dr Colin Greaves, Senior Research Fellow, Peninsula Medical School (Primary Care)

Mr Michael Head, Public contributor

Observers

Ms Christine McGuire, Research & Development, Department of Health Professor Cathy Jackson, Professor of Primary Care Medicine, Bute Medical School, University of St Andrews

Dr Russell Jago, Senior Lecturer in Exercise, Nutrition and Health, Centre for Sport, Exercise and Health, University of Bristol

Dr Julie Mytton, Consultant in Child Public Health, NHS Bristol

Dr Kay Pattison,

Senior NIHR Programme

Manager, Department of Health

Professor Irwin Nazareth, Professor of Primary Care and Director, Department of Primary Care and Population Sciences, University College London

Dr Richard Richards, Assistant Director of Public Health, Derbyshire County

Primary Care Trust

Professor Ian Roberts, Professor of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine

Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool Dr Kenneth Robertson, Consultant Paediatrician, Royal Hospital for Sick Children, Glasgow

Dr Catherine Swann, Associate Director, Centre for Public Health Excellence, NICE

Mrs Jean Thurston, Public contributor

Professor David Weller, Head, School of Clinical Science and Community Health, University of Edinburgh

External Devices and Physical Therapies Panel

Members

Chair,	Dr Dawn Carnes,	Dr Shaheen Hamdy,	Mr Jim Reece,
Dr John Pounsford,	Senior Research Fellow, Barts and	Clinical Senior Lecturer and	Public contributor
Consultant Physician North Bristol	the London School of Medicine	of Manchester	Professor Maria Stokes,
NHS Trust	and Dentistry		Professor of Neuromusculoskeletal
Deputy Chair,	Dr Emma Clark,	Professor Christine Norton,	Rehabilitation, University of
Professor E Andrea Nelson,	Clinician Scientist Fellow & Cons.	Professor of Clinical Nursing	Southampton
Reader in Wound Healing and	Rheumatologist, University of	Innovation, Bucks New University	Dr Pippa Tyrrell,
Director of Research, University	Bristol	and Imperial College Healthcare	Senior Lecturer/Consultant,
of Leeds	Mrs Anthea De Barton-Watson,	NHS Trust	Salford Royal Foundation
Professor Bipin Bhakta,	Public contributor	Dr Lorraine Pinnigton,	Hospitals' Trust and University of
Charterhouse Professor in	Professor Nadine Foster,	Associate Professor in	Manchester
Rehabilitation Medicine,	Professor of Musculoskeletal	Rehabilitation, University of	Dr Nefyn Williams,
Jniversity of Leeds	Health in Primary Care Arthritis	Nottingham	Clinical Senior Lecturer, Cardiff
Mrs Penny Calder, Public contributor	Research, Keele University	Dr Kate Radford, Senior Lecturer (Research), University of Control Lancachira	University

Observers

Dr Kay Pattison, Senior NIHR Programme Manager, Department of Health Dr Morven Roberts, Clinical Trials Manager, Health Services and Public Health Services Board, Medical Research Council Senior Lecturer (Research), University of Central Lancashire Professor Tom Walley, CBE, Director, NIHR HTA

programme, Professor of Clinical

Pharmacology, University of

Liverpool

Dr Ursula Wells, Principal Research Officer, Policy Research Programme, Department of Health

Interventional Procedures Panel

Members

Chair, Professor Jonathan Michaels, Professor of Vascular Surgery, University of Sheffield

Deputy Chair, Mr Michael Thomas, Consultant Colorectal Surgeon, Bristol Royal Infirmary

Mrs Isabel Boyer, Public contributor

Mr Sankaran Chandra Sekharan, Consultant Surgeon, Breast Surgery, Colchester Hospital University NHS Foundation Trust

Professor Nicholas Clarke, Consultant Orthopaedic Surgeon, Southampton University Hospitals NHS Trust

Ms Leonie Cooke, Public contributor

Observers

Dr Kay Pattison, Senior NIHR Programme Manager, Department of Health Mr Seumas Eckford, Consultant in Obstetrics & Gynaecology, North Devon District Hospital

Professor Sam Eljamel, Consultant Neurosurgeon, Ninewells Hospital and Medical School, Dundee

Dr Adele Fielding, Senior Lecturer and Honorary Consultant in Haematology, University College London Medical School

Dr Matthew Hatton, Consultant in Clinical Oncology, Sheffield Teaching Hospital Foundation Trust

Dr John Holden, General Practitioner, Garswood Surgery, Wigan

Clinical Trials Manager, Health

Services Board, Medical Research

Services and Public Health

Dr Morven Roberts.

Council

Dr Fiona Lecky, Senior Lecturer/Honorary Consultant in Emergency Medicine, University of Manchester/Salford Royal Hospitals NHS Foundation Trust

Dr Nadim Malik, Consultant Cardiologist/Honorary Lecturer, University of Manchester

Mr Hisham Mehanna, Consultant & Honorary Associate Professor, University Hospitals Coventry & Warwickshire NHS Trust

Dr Jane Montgomery, Consultant in Anaesthetics and Critical Care, South Devon Healthcare NHS Foundation Trust Professor Jon Moss, Consultant Interventional Radiologist, North Glasgow Hospitals University NHS Trust

Dr Simon Padley, Consultant Radiologist, Chelsea & Westminster Hospital

Dr Ashish Paul, Medical Director, Bedfordshire PCT

Dr Sarah Purdy, Consultant Senior Lecturer, University of Bristol

Dr Matthew Wilson, Consultant Anaesthetist, Sheffield Teaching Hospitals NHS Foundation Trust

Professor Yit Chiun Yang, Consultant Ophthalmologist, Royal Wolverhampton Hospitals NHS Trust

Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool Dr Ursula Wells, Principal Research Officer, Policy Research Programme, Department of Health

Pharmaceuticals Panel

Members

Chair, Professor Imti Choonara, Professor in Child Health, University of Nottingham

Deputy Chair, Dr Yoon K Loke, Senior Lecturer in Clinical Pharmacology, University of East Anglia

Dr Martin Ashton-Key, Medical Advisor, National Commissioning Group, NHS London

Dr Peter Elton, Director of Public Health, Bury Primary Care Trust

Dr Ben Goldacre, Research Fellow, Epidemiology London School of Hygiene and Tropical Medicine

Observers

Dr Kay Pattison, Senior NIHR Programme Manager, Department of Health

Mr Simon Reeve, Head of Clinical and Cost-Effectiveness, Medicines, Pharmacy and Industry Group, Department of Health Dr James Gray, Consultant Microbiologist, Department of Microbiology, Birmingham Children's Hospital NHS Foundation Trust

Dr Jurjees Hasan, Consultant in Medical Oncology, The Christie, Manchester

Dr Carl Heneghan, Deputy Director Centre for Evidence-Based Medicine and Clinical Lecturer, Department of Primary Health Care, University of Oxford

Dr Dyfrig Hughes, Reader in Pharmacoeconomics and Deputy Director, Centre for Economics and Policy in Health, IMSCaR, Bangor University Dr Maria Kouimtzi, Pharmacy and Informatics Director, Global Clinical Solutions, Wiley-Blackwell

Professor Femi Oyebode, Consultant Psychiatrist and Head of Department, University of Birmingham

Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician and Gynaecologist, The Rosie Hospital, University of Cambridge

Ms Amanda Roberts, Public contributor

Dr Gillian Shepherd, Director, Health and Clinical Excellence, Merck Serono Ltd Assistant Director New Medicines, National Prescribing Centre, Liverpool

Mrs Katrina Simister,

Professor Donald Singer, Professor of Clinical Pharmacology and Therapeutics, Clinical Sciences Research Institute, CSB, University of Warwick Medical School

Mr David Symes, Public contributor

Dr Arnold Zermansky, General Practitioner, Senior Research Fellow, Pharmacy Practice and Medicines Management Group, Leeds University

Dr Heike Weber, Programme Manager, Medical Research Council

Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool Dr Ursula Wells, Principal Research Officer, Policy Research Programme, Department of Health

Psychological and Community Therapies Panel

Members

Chair,

Professor Scott Weich, Professor of Psychiatry, University of Warwick, Coventry

Deputy Chair,

Dr Howard Ring, Consultant & University Lecturer in Psychiatry, University of Cambridge

Professor Jane Barlow, Professor of Public Health in the Early Years, Health Sciences Research Institute, Warwick Medical School

Dr Sabyasachi Bhaumik, Consultant Psychiatrist, Leicestershire Partnership NHS Trust Mrs Val Carlill, Public contributor

Dr Steve Cunningham, Consultant Respiratory Paediatrician, Lothian Health Board

Dr Anne Hesketh, Senior Clinical Lecturer in Speech and Language Therapy, University of Manchester

Dr Peter Langdon, Senior Clinical Lecturer, School of Medicine, Health Policy and Practice, University of East Anglia

Dr Yann Lefeuvre, GP Partner, Burrage Road Surgery, London Dr Jeremy J Murphy, Consultant Physician and Cardiologist, County Durham and Darlington Foundation Trust

Dr Richard Neal, Clinical Senior Lecturer in General Practice, Cardiff University

Mr John Needham, Public contributor Ms Mary Nettle.

Mental Health User Consultant

Professor John Potter, Professor of Ageing and Stroke Medicine, University of East Anglia

Dr Greta Rait, Senior Clinical Lecturer and General Practitioner, University College London Dr Paul Ramchandani, Senior Research Fellow/Cons. Child Psychiatrist, University of Oxford

Dr Karen Roberts, Nurse/Consultant, Dunston Hill Hospital, Tyne and Wear

Dr Karim Saad, Consultant in Old Age Psychiatry, Coventry and Warwickshire Partnership Trust

Dr Lesley Stockton, Lecturer, School of Health Sciences, University of Liverpool

Dr Simon Wright, GP Partner, Walkden Medical Centre, Manchester

Observers

Dr Kay Pattison, Senior NIHR Programme Manager, Department of Health Dr Morven Roberts, Clinical Trials Manager, Health Services and Public Health Services Board, Medical Research Council Professor Tom Walley, CBE, Director, NIHR HTA programme, Professor of Clinical Pharmacology, University of Liverpool Dr Ursula Wells, Principal Research Officer, Policy Research Programme, Department of Health

© Queen's Printer and Controller of HMSO 2011. This work was produced by Lewis *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health.

Expert Advisory Network

Members

Professor Douglas Altman, Professor of Statistics in Medicine, Centre for Statistics in Medicine, University of Oxford

Professor John Bond, Professor of Social Gerontology & Health Services Research, University of Newcastle upon Tyne

Professor Andrew Bradbury, Professor of Vascular Surgery, Solihull Hospital, Birmingham

Mr Shaun Brogan, Chief Executive, Ridgeway Primary Care Group, Aylesbury

Mrs Stella Burnside OBE, Chief Executive, Regulation and Improvement Authority, Belfast

Ms Tracy Bury, Project Manager, World Confederation of Physical Therapy, London

Professor Iain T Cameron, Professor of Obstetrics and Gynaecology and Head of the School of Medicine, University of Southampton

Professor Bruce Campbell, Consultant Vascular & General Surgeon, Royal Devon & Exeter Hospital, Wonford

Dr Christine Clark, Medical Writer and Consultant Pharmacist, Rossendale

Professor Collette Clifford, Professor of Nursing and Head of Research, The Medical School, University of Birmingham

Professor Barry Cookson, Director, Laboratory of Hospital Infection, Public Health Laboratory Service, London

Dr Carl Counsell, Clinical Senior Lecturer in Neurology, University of Aberdeen

Professor Howard Cuckle, Professor of Reproductive Epidemiology, Department of Paediatrics, Obstetrics & Gynaecology, University of Leeds

Professor Carol Dezateux, Professor of Paediatric Epidemiology, Institute of Child Health, London

Mr John Dunning, Consultant Cardiothoracic Surgeon, Papworth Hospital NHS Trust, Cambridge

Mr Jonothan Earnshaw, Consultant Vascular Surgeon, Gloucestershire Royal Hospital, Gloucester Professor Martin Eccles, Professor of Clinical Effectiveness, Centre for Health Services Research, University of Newcastle upon Tyne

Professor Pam Enderby, Dean of Faculty of Medicine, Institute of General Practice and Primary Care, University of Sheffield

Professor Gene Feder, Professor of Primary Care Research & Development, Centre for Health Sciences, Barts and The London School of Medicine and Dentistry

Mr Leonard R Fenwick, Chief Executive, Freeman Hospital, Newcastle upon Tyne

Mrs Gillian Fletcher, Antenatal Teacher and Tutor and President, National Childbirth Trust, Henfield

Professor Jayne Franklyn, Professor of Medicine, University of Birmingham

Mr Tam Fry, Honorary Chairman, Child Growth Foundation, London

Professor Fiona Gilbert, Consultant Radiologist and NCRN Member, University of Aberdeen

Professor Paul Gregg, Professor of Orthopaedic Surgical Science, South Tees Hospital NHS Trust

Bec Hanley, Co-director, TwoCan Associates, West Sussex

Dr Maryann L Hardy, Senior Lecturer, University of Bradford

Mrs Sharon Hart, Healthcare Management Consultant, Reading

Professor Robert E Hawkins, CRC Professor and Director of Medical Oncology, Christie CRC Research Centre, Christie Hospital NHS Trust, Manchester

Professor Richard Hobbs, Head of Department of Primary Care & General Practice, University of Birmingham

Professor Alan Horwich, Dean and Section Chairman, The Institute of Cancer Research, London

Professor Allen Hutchinson, Director of Public Health and Deputy Dean of ScHARR, University of Sheffield Professor Peter Jones, Professor of Psychiatry, University of Cambridge, Cambridge

Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology, Royal Marsden Hospital and Institute of Cancer Research, Surrey

Dr Duncan Keeley, General Practitioner (Dr Burch & Ptnrs), The Health Centre, Thame

Dr Donna Lamping, Research Degrees Programme Director and Reader in Psychology, Health Services Research Unit, London School of Hygiene and Tropical Medicine, London

Professor James Lindesay, Professor of Psychiatry for the Elderly, University of Leicester

Professor Julian Little, Professor of Human Genome Epidemiology, University of Ottawa

Professor Alistaire McGuire, Professor of Health Economics, London School of Economics

Professor Neill McIntosh, Edward Clark Professor of Child Life and Health, University of Edinburgh

Professor Rajan Madhok, Consultant in Public Health, South Manchester Primary Care Trust

Professor Sir Alexander Markham, Director, Molecular Medicine Unit, St James's University Hospital, Leeds

Dr Peter Moore, Freelance Science Writer, Ashtead

Dr Andrew Mortimore, Public Health Director, Southampton City Primary Care Trust

Dr Sue Moss, Associate Director, Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton

Professor Miranda Mugford, Professor of Health Economics and Group Co-ordinator, University of East Anglia

Professor Jim Neilson, Head of School of Reproductive & Developmental Medicine and Professor of Obstetrics and Gynaecology, University of Liverpool Mrs Julietta Patnick, Director, NHS Cancer Screening Programmes, Sheffield

Professor Robert Peveler, Professor of Liaison Psychiatry, Royal South Hants Hospital, Southampton

Professor Chris Price, Director of Clinical Research, Bayer Diagnostics Europe, Stoke Poges

Professor William Rosenberg, Professor of Hepatology and Consultant Physician, University of Southampton

Professor Peter Sandercock, Professor of Medical Neurology, Department of Clinical Neurosciences, University of Edinburgh

Dr Philip Shackley, Senior Lecturer in Health Economics, Sheffield Vascular Institute, University of Sheffield

Dr Eamonn Sheridan, Consultant in Clinical Genetics, St James's University Hospital, Leeds

Dr Margaret Somerville, Director of Public Health Learning, Peninsula Medical School, University of Plymouth

Professor Sarah Stewart-Brown, Professor of Public Health, Division of Health in the Community, University of Warwick, Coventry

Dr Nick Summerton, GP Appraiser and Codirector, Research Network, Yorkshire Clinical Consultant, Primary Care and Public Health, University of Oxford

Professor Ala Szczepura, Professor of Health Service Research, Centre for Health Services Studies, University of Warwick, Coventry

Dr Ross Taylor, Senior Lecturer, University of Aberdeen

Dr Richard Tiner, Medical Director, Medical Department, Association of the British Pharmaceutical Industry

Mrs Joan Webster, Consumer Member, Southern Derbyshire Community Health Council

Professor Martin Whittle, Clinical Co-director, National Co-ordinating Centre for Women's and Children's Health, Lymington This version of the monograph does not include the appendices. This is to save download time from the HTA website.

The printed version also excludes the appendices.

View/download the appendices

Feedback

The HTA programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

We look forward to hearing from you.

NETSCC, Health Technology Assessment Alpha House University of Southampton Science Park Southampton SO16 7NS, UK Email: hta@hta.ac.uk www.hta.ac.uk